false chemical chemical Pharmacokinetic properties of entity1begin abacavir entity1end were not altered by the addition of either entity2begin lamivudine entity2end or zidovudine or the combination of lamivudine and zidovudine . 
false chemical chemical Pharmacokinetic properties of entity1begin abacavir entity1end were not altered by the addition of either lamivudine or entity2begin zidovudine entity2end or the combination of lamivudine and zidovudine . 
false chemical chemical Pharmacokinetic properties of entity1begin abacavir entity1end were not altered by the addition of either lamivudine or zidovudine or the combination of entity2begin lamivudine entity2end and zidovudine . 
false chemical chemical Pharmacokinetic properties of entity1begin abacavir entity1end were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and entity2begin zidovudine entity2end . 
false chemical chemical Pharmacokinetic properties of abacavir were not altered by the addition of either entity1begin lamivudine entity1end or entity2begin zidovudine entity2end or the combination of lamivudine and zidovudine . 
false chemical chemical Pharmacokinetic properties of abacavir were not altered by the addition of either entity1begin lamivudine entity1end or zidovudine or the combination of entity2begin lamivudine entity2end and zidovudine . 
false chemical chemical Pharmacokinetic properties of abacavir were not altered by the addition of either entity1begin lamivudine entity1end or zidovudine or the combination of lamivudine and entity2begin zidovudine entity2end . 
false chemical chemical Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or entity1begin zidovudine entity1end or the combination of entity2begin lamivudine entity2end and zidovudine . 
false chemical chemical Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or entity1begin zidovudine entity1end or the combination of lamivudine and entity2begin zidovudine entity2end . 
false chemical chemical Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of entity1begin lamivudine entity1end and entity2begin zidovudine entity2end . 
false chemical chemical No clinically significant changes to entity1begin lamivudine entity1end or entity2begin zidovudine entity2end pharmacokinetics were observed following concomitant administration of abacavir . 
false chemical chemical No clinically significant changes to entity1begin lamivudine entity1end or zidovudine pharmacokinetics were observed following concomitant administration of entity2begin abacavir entity2end . 
false chemical chemical No clinically significant changes to lamivudine or entity1begin zidovudine entity1end pharmacokinetics were observed following concomitant administration of entity2begin abacavir entity2end . 
false chemical chemical entity1begin Abacavir entity1end has no effect on the pharmacokinetic properties of entity2begin ethanol entity2end . 
true chemical chemical entity1begin Ethanol entity1end decreases the elimination of entity2begin abacavir entity2end causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir . 
false chemical chemical entity1begin Ethanol entity1end decreases the elimination of abacavir causing an increase in overall exposure . The addition of entity2begin methadone entity2end has no clinically significant effect on the pharmacokinetic properties of abacavir . 
false chemical chemical entity1begin Ethanol entity1end decreases the elimination of abacavir causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of entity2begin abacavir entity2end . 
false chemical chemical Ethanol decreases the elimination of entity1begin abacavir entity1end causing an increase in overall exposure . The addition of entity2begin methadone entity2end has no clinically significant effect on the pharmacokinetic properties of abacavir . 
false chemical chemical Ethanol decreases the elimination of entity1begin abacavir entity1end causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of entity2begin abacavir entity2end . 
false chemical chemical Ethanol decreases the elimination of abacavir causing an increase in overall exposure . The addition of entity1begin methadone entity1end has no clinically significant effect on the pharmacokinetic properties of entity2begin abacavir entity2end . 
true chemical chemical In a study of 11 HIV - infected patients receiving entity1begin methadone entity1end - maintenance therapy ( 40 mg and 90 mg daily ) with 600 mg of entity2begin ZIAGEN entity2end twice daily ( twice the currently recommended dose ) , oral methadone clearance increased 22 % ( 90 % CI 6 % to 42 % ) . 
false chemical chemical In a study of 11 HIV - infected patients receiving entity1begin methadone entity1end - maintenance therapy ( 40 mg and 90 mg daily ) with 600 mg of ZIAGEN twice daily ( twice the currently recommended dose ) , oral entity2begin methadone entity2end clearance increased 22 % ( 90 % CI 6 % to 42 % ) . 
false chemical chemical In a study of 11 HIV - infected patients receiving methadone - maintenance therapy ( 40 mg and 90 mg daily ) with 600 mg of entity1begin ZIAGEN entity1end twice daily ( twice the currently recommended dose ) , oral entity2begin methadone entity2end clearance increased 22 % ( 90 % CI 6 % to 42 % ) . 
false chemical chemical entity1begin Cholestyramine entity1end : Concomitant entity2begin cholestyramine entity2end administration decreased the mean AUC of total ezetimibe approximately 55 % . 
false chemical chemical entity1begin Cholestyramine entity1end : Concomitant cholestyramine administration decreased the mean AUC of total entity2begin ezetimibe entity2end approximately 55 % . 
true chemical chemical Cholestyramine : Concomitant entity1begin cholestyramine entity1end administration decreased the mean AUC of total entity2begin ezetimibe entity2end approximately 55 % . 
true chemical chemical The incremental LDL - C reduction due to adding entity1begin ezetimibe entity1end to entity2begin cholestyramine entity2end may be reduced by this interaction . 
false chemical chemical entity1begin Fibrates entity1end : The safety and effectiveness of entity2begin ezetimibe entity2end administered with fibrates have not been established . 
false chemical chemical entity1begin Fibrates entity1end : The safety and effectiveness of ezetimibe administered with entity2begin fibrates entity2end have not been established . 
false chemical chemical Fibrates : The safety and effectiveness of entity1begin ezetimibe entity1end administered with entity2begin fibrates entity2end have not been established . 
true chemical chemical Co - administration of entity1begin ZETIA entity1end with entity2begin fibrates entity2end is not recommended until use in patients is studied . 
false chemical chemical entity1begin Fenofibrate entity1end : In a pharmacokinetic study , concomitant entity2begin fenofibrate entity2end administration increased total ezetimibe concentrations approximately 1.5 - fold . 
false chemical chemical entity1begin Fenofibrate entity1end : In a pharmacokinetic study , concomitant fenofibrate administration increased total entity2begin ezetimibe entity2end concentrations approximately 1.5 - fold . 
true chemical chemical Fenofibrate : In a pharmacokinetic study , concomitant entity1begin fenofibrate entity1end administration increased total entity2begin ezetimibe entity2end concentrations approximately 1.5 - fold . 
false chemical chemical entity1begin Gemfibrozil entity1end : In a pharmacokinetic study , concomitant entity2begin gemfibrozil entity2end administration increased total ezetimibe concentrations approximately 1.7 - fold . 
false chemical chemical entity1begin Gemfibrozil entity1end : In a pharmacokinetic study , concomitant gemfibrozil administration increased total entity2begin ezetimibe entity2end concentrations approximately 1.7 - fold . 
false chemical chemical Gemfibrozil : In a pharmacokinetic study , concomitant entity1begin gemfibrozil entity1end administration increased total entity2begin ezetimibe entity2end concentrations approximately 1.7 - fold . 
false chemical chemical entity1begin HMG - CoA reductase inhibitors entity1end : No clinically significant pharmacokinetic interactions were seen when entity2begin ezetimibe entity2end was co - administered with atorvastatin , simvastatin , pravastatin , lovastatin , or fluvastatin . 
false chemical chemical entity1begin HMG - CoA reductase inhibitors entity1end : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co - administered with entity2begin atorvastatin entity2end , simvastatin , pravastatin , lovastatin , or fluvastatin . 
false chemical chemical entity1begin HMG - CoA reductase inhibitors entity1end : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co - administered with atorvastatin , entity2begin simvastatin entity2end , pravastatin , lovastatin , or fluvastatin . 
false chemical chemical entity1begin HMG - CoA reductase inhibitors entity1end : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co - administered with atorvastatin , simvastatin , entity2begin pravastatin entity2end , lovastatin , or fluvastatin . 
false chemical chemical entity1begin HMG - CoA reductase inhibitors entity1end : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co - administered with atorvastatin , simvastatin , pravastatin , entity2begin lovastatin entity2end , or fluvastatin . 
false chemical chemical entity1begin HMG - CoA reductase inhibitors entity1end : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co - administered with atorvastatin , simvastatin , pravastatin , lovastatin , or entity2begin fluvastatin entity2end . 
false chemical chemical HMG - CoA reductase inhibitors : No clinically significant pharmacokinetic interactions were seen when entity1begin ezetimibe entity1end was co - administered with entity2begin atorvastatin entity2end , simvastatin , pravastatin , lovastatin , or fluvastatin . 
false chemical chemical HMG - CoA reductase inhibitors : No clinically significant pharmacokinetic interactions were seen when entity1begin ezetimibe entity1end was co - administered with atorvastatin , entity2begin simvastatin entity2end , pravastatin , lovastatin , or fluvastatin . 
false chemical chemical HMG - CoA reductase inhibitors : No clinically significant pharmacokinetic interactions were seen when entity1begin ezetimibe entity1end was co - administered with atorvastatin , simvastatin , entity2begin pravastatin entity2end , lovastatin , or fluvastatin . 
false chemical chemical HMG - CoA reductase inhibitors : No clinically significant pharmacokinetic interactions were seen when entity1begin ezetimibe entity1end was co - administered with atorvastatin , simvastatin , pravastatin , entity2begin lovastatin entity2end , or fluvastatin . 
false chemical chemical HMG - CoA reductase inhibitors : No clinically significant pharmacokinetic interactions were seen when entity1begin ezetimibe entity1end was co - administered with atorvastatin , simvastatin , pravastatin , lovastatin , or entity2begin fluvastatin entity2end . 
false chemical chemical HMG - CoA reductase inhibitors : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co - administered with entity1begin atorvastatin entity1end , entity2begin simvastatin entity2end , pravastatin , lovastatin , or fluvastatin . 
false chemical chemical HMG - CoA reductase inhibitors : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co - administered with entity1begin atorvastatin entity1end , simvastatin , entity2begin pravastatin entity2end , lovastatin , or fluvastatin . 
false chemical chemical HMG - CoA reductase inhibitors : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co - administered with entity1begin atorvastatin entity1end , simvastatin , pravastatin , entity2begin lovastatin entity2end , or fluvastatin . 
false chemical chemical HMG - CoA reductase inhibitors : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co - administered with entity1begin atorvastatin entity1end , simvastatin , pravastatin , lovastatin , or entity2begin fluvastatin entity2end . 
false chemical chemical HMG - CoA reductase inhibitors : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co - administered with atorvastatin , entity1begin simvastatin entity1end , entity2begin pravastatin entity2end , lovastatin , or fluvastatin . 
false chemical chemical HMG - CoA reductase inhibitors : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co - administered with atorvastatin , entity1begin simvastatin entity1end , pravastatin , entity2begin lovastatin entity2end , or fluvastatin . 
false chemical chemical HMG - CoA reductase inhibitors : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co - administered with atorvastatin , entity1begin simvastatin entity1end , pravastatin , lovastatin , or entity2begin fluvastatin entity2end . 
false chemical chemical HMG - CoA reductase inhibitors : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co - administered with atorvastatin , simvastatin , entity1begin pravastatin entity1end , entity2begin lovastatin entity2end , or fluvastatin . 
false chemical chemical HMG - CoA reductase inhibitors : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co - administered with atorvastatin , simvastatin , entity1begin pravastatin entity1end , lovastatin , or entity2begin fluvastatin entity2end . 
false chemical chemical HMG - CoA reductase inhibitors : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co - administered with atorvastatin , simvastatin , pravastatin , entity1begin lovastatin entity1end , or entity2begin fluvastatin entity2end . 
false chemical chemical entity1begin Cyclosporine entity1end : The total entity2begin ezetimibe entity2end level increased 12 - fold in one renal transplant patient receiving multiple medications , including cyclosporine . 
false chemical chemical entity1begin Cyclosporine entity1end : The total ezetimibe level increased 12 - fold in one renal transplant patient receiving multiple medications , including entity2begin cyclosporine entity2end . 
true chemical chemical Cyclosporine : The total entity1begin ezetimibe entity1end level increased 12 - fold in one renal transplant patient receiving multiple medications , including entity2begin cyclosporine entity2end . 
true chemical chemical Patients who take both entity1begin ezetimibe entity1end and entity2begin cyclosporine entity2end should be carefully monitored . 
false chemical chemical Carcinogenesis , Mutagenesis , Impairment of Fertility A 104 - week dietary carcinogenicity study with entity1begin ezetimibe entity1end was conducted in rats at doses up to 1500 mg / kg / day ( males ) and 500 mg / kg / day ( females ) ( ~ 20 times the human exposure at 10 mg daily based on AUC0 - 24hr for total entity2begin ezetimibe entity2end ) . 
false chemical chemical A 104 - week dietary carcinogenicity study with entity1begin ezetimibe entity1end was also conducted in mice at doses up to 500 mg / kg / day ( > 150 times the human exposure at 10 mg daily based on AUC0 - 24hr for total entity2begin ezetimibe entity2end ) . 
false chemical chemical In oral ( gavage ) fertility studies of entity1begin ezetimibe entity1end conducted in rats , there was no evidence of reproductive toxicity at doses up to 1000 mg / kg / day in male or female rats ( ~ 7 times the human exposure at 10 mg daily based on AUC0 - 24hr for total entity2begin ezetimibe entity2end ) . 
false chemical chemical In rabbits treated with entity1begin ezetimibe entity1end , an increased incidence of extra thoracic ribs was observed at 1000 mg / kg / day ( 150 times the human exposure at 10 mg daily based on AUC0 - 24hr for total entity2begin ezetimibe entity2end ) . 
false chemical chemical Multiple dose studies of entity1begin ezetimibe entity1end given in combination with entity2begin HMG - CoA reductase inhibitors entity2end ( statins ) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures . 
false chemical chemical Multiple dose studies of entity1begin ezetimibe entity1end given in combination with HMG - CoA reductase inhibitors ( entity2begin statins entity2end ) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures . 
false chemical chemical Multiple dose studies of entity1begin ezetimibe entity1end given in combination with HMG - CoA reductase inhibitors ( statins ) in rats and rabbits during organogenesis result in higher entity2begin ezetimibe entity2end and statin exposures . 
false chemical chemical Multiple dose studies of ezetimibe given in combination with entity1begin HMG - CoA reductase inhibitors entity1end ( entity2begin statins entity2end ) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures . 
false chemical chemical Multiple dose studies of ezetimibe given in combination with entity1begin HMG - CoA reductase inhibitors entity1end ( statins ) in rats and rabbits during organogenesis result in higher entity2begin ezetimibe entity2end and statin exposures . 
false chemical chemical Multiple dose studies of ezetimibe given in combination with HMG - CoA reductase inhibitors ( entity1begin statins entity1end ) in rats and rabbits during organogenesis result in higher entity2begin ezetimibe entity2end and statin exposures . 
false chemical chemical When entity1begin ZETIA entity1end is administered with an entity2begin HMG - CoA reductase inhibitor entity2end in a woman of childbearing potential , refer to the pregnancy category and package labeling for the HMG - CoA reductase inhibitor . 
false chemical chemical When entity1begin ZETIA entity1end is administered with an HMG - CoA reductase inhibitor in a woman of childbearing potential , refer to the pregnancy category and package labeling for the entity2begin HMG - CoA reductase inhibitor entity2end . 
false chemical chemical When ZETIA is administered with an entity1begin HMG - CoA reductase inhibitor entity1end in a woman of childbearing potential , refer to the pregnancy category and package labeling for the entity2begin HMG - CoA reductase inhibitor entity2end . 
false chemical chemical These are described in greater detail below : Oral entity1begin hypoglycemics entity1end , entity2begin Coumarin - type anticoagulants entity2end , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral entity1begin hypoglycemics entity1end , Coumarin - type anticoagulants , entity2begin Phenytoin entity2end , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral entity1begin hypoglycemics entity1end , Coumarin - type anticoagulants , Phenytoin , entity2begin Cyclosporine entity2end , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral entity1begin hypoglycemics entity1end , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , entity2begin Rifampin entity2end , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral entity1begin hypoglycemics entity1end , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , entity2begin Theophylline entity2end , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral entity1begin hypoglycemics entity1end , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , entity2begin Terfenadine entity2end , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral entity1begin hypoglycemics entity1end , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , entity2begin Cisapride entity2end , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral entity1begin hypoglycemics entity1end , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , entity2begin Astemizole entity2end , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral entity1begin hypoglycemics entity1end , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , entity2begin Rifabutin entity2end , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral entity1begin hypoglycemics entity1end , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , entity2begin Tacrolimus entity2end , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral entity1begin hypoglycemics entity1end , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , entity2begin Short - acting benzodiazepines entity2end , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral entity1begin hypoglycemics entity1end , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral entity2begin hypoglycemics entity2end : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral entity1begin hypoglycemics entity1end , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of entity2begin DIFLUCAN entity2end with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral entity1begin hypoglycemics entity1end , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral entity2begin hypoglycemic agents entity2end ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , entity1begin Coumarin - type anticoagulants entity1end , entity2begin Phenytoin entity2end , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , entity1begin Coumarin - type anticoagulants entity1end , Phenytoin , entity2begin Cyclosporine entity2end , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , entity1begin Coumarin - type anticoagulants entity1end , Phenytoin , Cyclosporine , entity2begin Rifampin entity2end , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , entity1begin Coumarin - type anticoagulants entity1end , Phenytoin , Cyclosporine , Rifampin , entity2begin Theophylline entity2end , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , entity1begin Coumarin - type anticoagulants entity1end , Phenytoin , Cyclosporine , Rifampin , Theophylline , entity2begin Terfenadine entity2end , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , entity1begin Coumarin - type anticoagulants entity1end , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , entity2begin Cisapride entity2end , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , entity1begin Coumarin - type anticoagulants entity1end , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , entity2begin Astemizole entity2end , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , entity1begin Coumarin - type anticoagulants entity1end , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , entity2begin Rifabutin entity2end , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , entity1begin Coumarin - type anticoagulants entity1end , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , entity2begin Tacrolimus entity2end , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , entity1begin Coumarin - type anticoagulants entity1end , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , entity2begin Short - acting benzodiazepines entity2end , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , entity1begin Coumarin - type anticoagulants entity1end , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral entity2begin hypoglycemics entity2end : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , entity1begin Coumarin - type anticoagulants entity1end , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of entity2begin DIFLUCAN entity2end with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , entity1begin Coumarin - type anticoagulants entity1end , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral entity2begin hypoglycemic agents entity2end ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , entity1begin Phenytoin entity1end , entity2begin Cyclosporine entity2end , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , entity1begin Phenytoin entity1end , Cyclosporine , entity2begin Rifampin entity2end , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , entity1begin Phenytoin entity1end , Cyclosporine , Rifampin , entity2begin Theophylline entity2end , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , entity1begin Phenytoin entity1end , Cyclosporine , Rifampin , Theophylline , entity2begin Terfenadine entity2end , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , entity1begin Phenytoin entity1end , Cyclosporine , Rifampin , Theophylline , Terfenadine , entity2begin Cisapride entity2end , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , entity1begin Phenytoin entity1end , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , entity2begin Astemizole entity2end , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , entity1begin Phenytoin entity1end , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , entity2begin Rifabutin entity2end , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , entity1begin Phenytoin entity1end , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , entity2begin Tacrolimus entity2end , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , entity1begin Phenytoin entity1end , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , entity2begin Short - acting benzodiazepines entity2end , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , entity1begin Phenytoin entity1end , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral entity2begin hypoglycemics entity2end : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , entity1begin Phenytoin entity1end , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of entity2begin DIFLUCAN entity2end with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , entity1begin Phenytoin entity1end , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral entity2begin hypoglycemic agents entity2end ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , entity1begin Cyclosporine entity1end , entity2begin Rifampin entity2end , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , entity1begin Cyclosporine entity1end , Rifampin , entity2begin Theophylline entity2end , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , entity1begin Cyclosporine entity1end , Rifampin , Theophylline , entity2begin Terfenadine entity2end , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , entity1begin Cyclosporine entity1end , Rifampin , Theophylline , Terfenadine , entity2begin Cisapride entity2end , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , entity1begin Cyclosporine entity1end , Rifampin , Theophylline , Terfenadine , Cisapride , entity2begin Astemizole entity2end , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , entity1begin Cyclosporine entity1end , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , entity2begin Rifabutin entity2end , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , entity1begin Cyclosporine entity1end , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , entity2begin Tacrolimus entity2end , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , entity1begin Cyclosporine entity1end , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , entity2begin Short - acting benzodiazepines entity2end , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , entity1begin Cyclosporine entity1end , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral entity2begin hypoglycemics entity2end : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , entity1begin Cyclosporine entity1end , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of entity2begin DIFLUCAN entity2end with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , entity1begin Cyclosporine entity1end , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral entity2begin hypoglycemic agents entity2end ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , entity1begin Rifampin entity1end , entity2begin Theophylline entity2end , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , entity1begin Rifampin entity1end , Theophylline , entity2begin Terfenadine entity2end , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , entity1begin Rifampin entity1end , Theophylline , Terfenadine , entity2begin Cisapride entity2end , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , entity1begin Rifampin entity1end , Theophylline , Terfenadine , Cisapride , entity2begin Astemizole entity2end , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , entity1begin Rifampin entity1end , Theophylline , Terfenadine , Cisapride , Astemizole , entity2begin Rifabutin entity2end , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , entity1begin Rifampin entity1end , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , entity2begin Tacrolimus entity2end , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , entity1begin Rifampin entity1end , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , entity2begin Short - acting benzodiazepines entity2end , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , entity1begin Rifampin entity1end , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral entity2begin hypoglycemics entity2end : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , entity1begin Rifampin entity1end , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of entity2begin DIFLUCAN entity2end with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , entity1begin Rifampin entity1end , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral entity2begin hypoglycemic agents entity2end ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , entity1begin Theophylline entity1end , entity2begin Terfenadine entity2end , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , entity1begin Theophylline entity1end , Terfenadine , entity2begin Cisapride entity2end , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , entity1begin Theophylline entity1end , Terfenadine , Cisapride , entity2begin Astemizole entity2end , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , entity1begin Theophylline entity1end , Terfenadine , Cisapride , Astemizole , entity2begin Rifabutin entity2end , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , entity1begin Theophylline entity1end , Terfenadine , Cisapride , Astemizole , Rifabutin , entity2begin Tacrolimus entity2end , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , entity1begin Theophylline entity1end , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , entity2begin Short - acting benzodiazepines entity2end , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , entity1begin Theophylline entity1end , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral entity2begin hypoglycemics entity2end : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , entity1begin Theophylline entity1end , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of entity2begin DIFLUCAN entity2end with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , entity1begin Theophylline entity1end , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral entity2begin hypoglycemic agents entity2end ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , entity1begin Terfenadine entity1end , entity2begin Cisapride entity2end , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , entity1begin Terfenadine entity1end , Cisapride , entity2begin Astemizole entity2end , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , entity1begin Terfenadine entity1end , Cisapride , Astemizole , entity2begin Rifabutin entity2end , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , entity1begin Terfenadine entity1end , Cisapride , Astemizole , Rifabutin , entity2begin Tacrolimus entity2end , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , entity1begin Terfenadine entity1end , Cisapride , Astemizole , Rifabutin , Tacrolimus , entity2begin Short - acting benzodiazepines entity2end , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , entity1begin Terfenadine entity1end , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral entity2begin hypoglycemics entity2end : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , entity1begin Terfenadine entity1end , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of entity2begin DIFLUCAN entity2end with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , entity1begin Terfenadine entity1end , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral entity2begin hypoglycemic agents entity2end ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , entity1begin Cisapride entity1end , entity2begin Astemizole entity2end , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , entity1begin Cisapride entity1end , Astemizole , entity2begin Rifabutin entity2end , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , entity1begin Cisapride entity1end , Astemizole , Rifabutin , entity2begin Tacrolimus entity2end , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , entity1begin Cisapride entity1end , Astemizole , Rifabutin , Tacrolimus , entity2begin Short - acting benzodiazepines entity2end , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , entity1begin Cisapride entity1end , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral entity2begin hypoglycemics entity2end : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , entity1begin Cisapride entity1end , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of entity2begin DIFLUCAN entity2end with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , entity1begin Cisapride entity1end , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral entity2begin hypoglycemic agents entity2end ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , entity1begin Astemizole entity1end , entity2begin Rifabutin entity2end , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , entity1begin Astemizole entity1end , Rifabutin , entity2begin Tacrolimus entity2end , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , entity1begin Astemizole entity1end , Rifabutin , Tacrolimus , entity2begin Short - acting benzodiazepines entity2end , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , entity1begin Astemizole entity1end , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral entity2begin hypoglycemics entity2end : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , entity1begin Astemizole entity1end , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of entity2begin DIFLUCAN entity2end with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , entity1begin Astemizole entity1end , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral entity2begin hypoglycemic agents entity2end ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , entity1begin Rifabutin entity1end , entity2begin Tacrolimus entity2end , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , entity1begin Rifabutin entity1end , Tacrolimus , entity2begin Short - acting benzodiazepines entity2end , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , entity1begin Rifabutin entity1end , Tacrolimus , Short - acting benzodiazepines , Oral entity2begin hypoglycemics entity2end : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , entity1begin Rifabutin entity1end , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of entity2begin DIFLUCAN entity2end with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , entity1begin Rifabutin entity1end , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral entity2begin hypoglycemic agents entity2end ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , entity1begin Tacrolimus entity1end , entity2begin Short - acting benzodiazepines entity2end , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , entity1begin Tacrolimus entity1end , Short - acting benzodiazepines , Oral entity2begin hypoglycemics entity2end : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , entity1begin Tacrolimus entity1end , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of entity2begin DIFLUCAN entity2end with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , entity1begin Tacrolimus entity1end , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral entity2begin hypoglycemic agents entity2end ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , entity1begin Short - acting benzodiazepines entity1end , Oral entity2begin hypoglycemics entity2end : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , entity1begin Short - acting benzodiazepines entity1end , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of entity2begin DIFLUCAN entity2end with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , entity1begin Short - acting benzodiazepines entity1end , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral entity2begin hypoglycemic agents entity2end ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral entity1begin hypoglycemics entity1end : Clinically significant hypoglycemia may be precipitated by the use of entity2begin DIFLUCAN entity2end with oral hypoglycemic agents ; 
false chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral entity1begin hypoglycemics entity1end : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral entity2begin hypoglycemic agents entity2end ; 
true chemical chemical These are described in greater detail below : Oral hypoglycemics , Coumarin - type anticoagulants , Phenytoin , Cyclosporine , Rifampin , Theophylline , Terfenadine , Cisapride , Astemizole , Rifabutin , Tacrolimus , Short - acting benzodiazepines , Oral hypoglycemics : Clinically significant hypoglycemia may be precipitated by the use of entity1begin DIFLUCAN entity1end with oral entity2begin hypoglycemic agents entity2end ; 
true chemical chemical one fatality has been reported from hypoglycemia in association with combined entity1begin DIFLUCAN entity1end and entity2begin glyburide entity2end use . 
true chemical chemical entity1begin DIFLUCAN entity1end reduces the metabolism of entity2begin tolbutamide entity2end , glyburide , and glipizide and increases the plasma concentration of these agents . 
true chemical chemical entity1begin DIFLUCAN entity1end reduces the metabolism of tolbutamide , entity2begin glyburide entity2end , and glipizide and increases the plasma concentration of these agents . 
true chemical chemical entity1begin DIFLUCAN entity1end reduces the metabolism of tolbutamide , glyburide , and entity2begin glipizide entity2end and increases the plasma concentration of these agents . 
false chemical chemical DIFLUCAN reduces the metabolism of entity1begin tolbutamide entity1end , entity2begin glyburide entity2end , and glipizide and increases the plasma concentration of these agents . 
false chemical chemical DIFLUCAN reduces the metabolism of entity1begin tolbutamide entity1end , glyburide , and entity2begin glipizide entity2end and increases the plasma concentration of these agents . 
false chemical chemical DIFLUCAN reduces the metabolism of tolbutamide , entity1begin glyburide entity1end , and entity2begin glipizide entity2end and increases the plasma concentration of these agents . 
true chemical chemical When entity1begin DIFLUCAN entity1end is used concomitantly with these or other entity2begin sulfonylurea oral hypoglycemic agents entity2end , blood glucose concentrations should be carefully monitored and the dose of the sulfonylurea should be adjusted as necessary . 
false chemical chemical When entity1begin DIFLUCAN entity1end is used concomitantly with these or other sulfonylurea oral hypoglycemic agents , blood glucose concentrations should be carefully monitored and the dose of the entity2begin sulfonylurea entity2end should be adjusted as necessary . 
false chemical chemical When DIFLUCAN is used concomitantly with these or other entity1begin sulfonylurea oral hypoglycemic agents entity1end , blood glucose concentrations should be carefully monitored and the dose of the entity2begin sulfonylurea entity2end should be adjusted as necessary . 
false chemical chemical entity1begin Coumarin - type anticoagulants entity1end : Prothrombin time may be increased in patients receiving concomitant entity2begin DIFLUCAN entity2end and coumarin - type anticoagulants . 
false chemical chemical entity1begin Coumarin - type anticoagulants entity1end : Prothrombin time may be increased in patients receiving concomitant DIFLUCAN and entity2begin coumarin - type anticoagulants entity2end . 
true chemical chemical Coumarin - type anticoagulants : Prothrombin time may be increased in patients receiving concomitant entity1begin DIFLUCAN entity1end and entity2begin coumarin - type anticoagulants entity2end . 
false chemical chemical In post - marketing experience , as with other entity1begin azole antifungals entity1end , bleeding events ( bruising , epistaxis , gastrointestinal bleeding , hematuria , and melena ) have been reported in association with increases in prothrombin time in patients receiving entity2begin fluconazole entity2end concurrently with warfarin . 
false chemical chemical In post - marketing experience , as with other entity1begin azole antifungals entity1end , bleeding events ( bruising , epistaxis , gastrointestinal bleeding , hematuria , and melena ) have been reported in association with increases in prothrombin time in patients receiving fluconazole concurrently with entity2begin warfarin entity2end . 
true chemical chemical In post - marketing experience , as with other azole antifungals , bleeding events ( bruising , epistaxis , gastrointestinal bleeding , hematuria , and melena ) have been reported in association with increases in prothrombin time in patients receiving entity1begin fluconazole entity1end concurrently with entity2begin warfarin entity2end . 
true chemical chemical Careful monitoring of prothrombin time in patients receiving entity1begin DIFLUCAN entity1end and entity2begin coumarin - type anticoagulants entity2end is recommended . 
false chemical chemical entity1begin Phenytoin entity1end : entity2begin DIFLUCAN entity2end increases the plasma concentrations of phenytoin . 
false chemical chemical entity1begin Phenytoin entity1end : DIFLUCAN increases the plasma concentrations of entity2begin phenytoin entity2end . 
true chemical chemical Phenytoin : entity1begin DIFLUCAN entity1end increases the plasma concentrations of entity2begin phenytoin entity2end . 
false chemical chemical Careful monitoring of entity1begin phenytoin entity1end concentrations in patients receiving entity2begin DIFLUCAN entity2end and phenytoin is recommended . 
false chemical chemical Careful monitoring of entity1begin phenytoin entity1end concentrations in patients receiving DIFLUCAN and entity2begin phenytoin entity2end is recommended . 
true chemical chemical Careful monitoring of phenytoin concentrations in patients receiving entity1begin DIFLUCAN entity1end and entity2begin phenytoin entity2end is recommended . 
false chemical chemical entity1begin Cyclosporine entity1end : entity2begin DIFLUCAN entity2end may significantly increase cyclosporine levels in renal transplant patients with or without renal impairment . 
false chemical chemical entity1begin Cyclosporine entity1end : DIFLUCAN may significantly increase entity2begin cyclosporine entity2end levels in renal transplant patients with or without renal impairment . 
true chemical chemical Cyclosporine : entity1begin DIFLUCAN entity1end may significantly increase entity2begin cyclosporine entity2end levels in renal transplant patients with or without renal impairment . 
false chemical chemical Careful monitoring of entity1begin cyclosporine entity1end concentrations and serum creatinine is recommended in patients receiving entity2begin DIFLUCAN entity2end and cyclosporine . 
false chemical chemical Careful monitoring of entity1begin cyclosporine entity1end concentrations and serum creatinine is recommended in patients receiving DIFLUCAN and entity2begin cyclosporine entity2end . 
true chemical chemical Careful monitoring of cyclosporine concentrations and serum creatinine is recommended in patients receiving entity1begin DIFLUCAN entity1end and entity2begin cyclosporine entity2end . 
false chemical chemical entity1begin Rifampin entity1end : entity2begin Rifampin entity2end enhances the metabolism of concurrently administered DIFLUCAN . 
false chemical chemical entity1begin Rifampin entity1end : Rifampin enhances the metabolism of concurrently administered entity2begin DIFLUCAN entity2end . 
true chemical chemical Rifampin : entity1begin Rifampin entity1end enhances the metabolism of concurrently administered entity2begin DIFLUCAN entity2end . 
true chemical chemical Depending on clinical circumstances , consideration should be given to increasing the dose of entity1begin DIFLUCAN entity1end when it is administered with entity2begin rifampin entity2end . 
false chemical chemical entity1begin Theophylline entity1end : entity2begin DIFLUCAN entity2end increases the serum concentrations of theophylline . 
false chemical chemical entity1begin Theophylline entity1end : DIFLUCAN increases the serum concentrations of entity2begin theophylline entity2end . 
true chemical chemical Theophylline : entity1begin DIFLUCAN entity1end increases the serum concentrations of entity2begin theophylline entity2end . 
false chemical chemical Careful monitoring of serum entity1begin theophylline entity1end concentrations in patients receiving entity2begin DIFLUCAN entity2end and theophylline is recommended . 
false chemical chemical Careful monitoring of serum entity1begin theophylline entity1end concentrations in patients receiving DIFLUCAN and entity2begin theophylline entity2end is recommended . 
true chemical chemical Careful monitoring of serum theophylline concentrations in patients receiving entity1begin DIFLUCAN entity1end and entity2begin theophylline entity2end is recommended . 
false chemical chemical entity1begin Terfenadine entity1end : Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving entity2begin azole antifungals entity2end in conjunction with terfenadine , interaction studies have been performed . 
false chemical chemical entity1begin Terfenadine entity1end : Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving azole antifungals in conjunction with entity2begin terfenadine entity2end , interaction studies have been performed . 
true chemical chemical Terfenadine : Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving entity1begin azole antifungals entity1end in conjunction with entity2begin terfenadine entity2end , interaction studies have been performed . 
false chemical chemical Another study at a 400 - mg and 800 - mg daily dose of entity1begin fluconazole entity1end demonstrated that entity2begin DIFLUCAN entity2end taken in doses of 400 mg per day or greater significantly increases plasma levels of terfenadine when taken concomitantly . 
false chemical chemical Another study at a 400 - mg and 800 - mg daily dose of entity1begin fluconazole entity1end demonstrated that DIFLUCAN taken in doses of 400 mg per day or greater significantly increases plasma levels of entity2begin terfenadine entity2end when taken concomitantly . 
true chemical chemical Another study at a 400 - mg and 800 - mg daily dose of fluconazole demonstrated that entity1begin DIFLUCAN entity1end taken in doses of 400 mg per day or greater significantly increases plasma levels of entity2begin terfenadine entity2end when taken concomitantly . 
true chemical chemical The combined use of entity1begin fluconazole entity1end at doses of 400 mg or greater with entity2begin terfenadine entity2end is contraindicated . 
true chemical chemical The coadministration of entity1begin fluconazole entity1end at doses lower than 400 mg / day with entity2begin terfenadine entity2end should be carefully monitored . 
false chemical chemical entity1begin Cisapride entity1end : There have been reports of cardiac events , including torsade de pointes in patients to whom entity2begin fluconazole entity2end and cisapride were coadministered . 
false chemical chemical entity1begin Cisapride entity1end : There have been reports of cardiac events , including torsade de pointes in patients to whom fluconazole and entity2begin cisapride entity2end were coadministered . 
true chemical chemical Cisapride : There have been reports of cardiac events , including torsade de pointes in patients to whom entity1begin fluconazole entity1end and entity2begin cisapride entity2end were coadministered . 
true chemical chemical A controlled study found that concomitant entity1begin fluconazole entity1end 200 mg once daily and entity2begin cisapride entity2end 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval . 
false chemical chemical A controlled study found that concomitant entity1begin fluconazole entity1end 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in entity2begin cisapride entity2end plasma levels and prolongation of QTc interval . 
false chemical chemical A controlled study found that concomitant fluconazole 200 mg once daily and entity1begin cisapride entity1end 20 mg four times a day yielded a significant increase in entity2begin cisapride entity2end plasma levels and prolongation of QTc interval . 
true chemical chemical The combined use of entity1begin fluconazole entity1end with entity2begin cisapride entity2end is contraindicated . 
false chemical chemical entity1begin Astemizole entity1end : The use of entity2begin fluconazole entity2end in patients concurrently taking astemizole or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs . 
false chemical chemical entity1begin Astemizole entity1end : The use of fluconazole in patients concurrently taking entity2begin astemizole entity2end or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs . 
true chemical chemical Astemizole : The use of entity1begin fluconazole entity1end in patients concurrently taking entity2begin astemizole entity2end or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs . 
false chemical chemical entity1begin Rifabutin entity1end : There have been reports of uveitis in patients to whom entity2begin fluconazole entity2end and rifabutin were coadministered . 
false chemical chemical entity1begin Rifabutin entity1end : There have been reports of uveitis in patients to whom fluconazole and entity2begin rifabutin entity2end were coadministered . 
true chemical chemical Rifabutin : There have been reports of uveitis in patients to whom entity1begin fluconazole entity1end and entity2begin rifabutin entity2end were coadministered . 
true chemical chemical Patients receiving entity1begin rifabutin entity1end and entity2begin fluconazole entity2end concomitantly should be carefully monitored . 
false chemical chemical entity1begin Tacrolimus entity1end : There have been reports of nephrotoxicity in patients to whom entity2begin fluconazole entity2end and tacrolimus were coadministered . 
false chemical chemical entity1begin Tacrolimus entity1end : There have been reports of nephrotoxicity in patients to whom fluconazole and entity2begin tacrolimus entity2end were coadministered . 
true chemical chemical Tacrolimus : There have been reports of nephrotoxicity in patients to whom entity1begin fluconazole entity1end and entity2begin tacrolimus entity2end were coadministered . 
true chemical chemical Patients receiving entity1begin tacrolimus entity1end and entity2begin fluconazole entity2end concomitantly should be carefully monitored . 
false chemical chemical entity1begin Short - acting Benzodiazepines entity1end : Following oral administration of entity2begin midazolam entity2end , fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects . 
false chemical chemical entity1begin Short - acting Benzodiazepines entity1end : Following oral administration of midazolam , entity2begin fluconazole entity2end resulted in substantial increases in midazolam concentrations and psychomotor effects . 
false chemical chemical entity1begin Short - acting Benzodiazepines entity1end : Following oral administration of midazolam , fluconazole resulted in substantial increases in entity2begin midazolam entity2end concentrations and psychomotor effects . 
true chemical chemical Short - acting Benzodiazepines : Following oral administration of entity1begin midazolam entity1end , entity2begin fluconazole entity2end resulted in substantial increases in midazolam concentrations and psychomotor effects . 
false chemical chemical Short - acting Benzodiazepines : Following oral administration of entity1begin midazolam entity1end , fluconazole resulted in substantial increases in entity2begin midazolam entity2end concentrations and psychomotor effects . 
false chemical chemical Short - acting Benzodiazepines : Following oral administration of midazolam , entity1begin fluconazole entity1end resulted in substantial increases in entity2begin midazolam entity2end concentrations and psychomotor effects . 
true chemical chemical This effect on entity1begin midazolam entity1end appears to be more pronounced following oral administration of entity2begin fluconazole entity2end than with fluconazole administered intravenously . 
false chemical chemical This effect on entity1begin midazolam entity1end appears to be more pronounced following oral administration of fluconazole than with entity2begin fluconazole entity2end administered intravenously . 
false chemical chemical This effect on midazolam appears to be more pronounced following oral administration of entity1begin fluconazole entity1end than with entity2begin fluconazole entity2end administered intravenously . 
true chemical chemical If entity1begin short - acting benzodiazepines entity1end , which are metabolized by the cytochrome P450 system , are concomitantly administered with entity2begin fluconazole entity2end , consideration should be given to decreasing the benzodiazepine dosage , and the patients should be appropriately monitored . 
false chemical chemical If entity1begin short - acting benzodiazepines entity1end , which are metabolized by the cytochrome P450 system , are concomitantly administered with fluconazole , consideration should be given to decreasing the entity2begin benzodiazepine entity2end dosage , and the patients should be appropriately monitored . 
false chemical chemical If short - acting benzodiazepines , which are metabolized by the cytochrome P450 system , are concomitantly administered with entity1begin fluconazole entity1end , consideration should be given to decreasing the entity2begin benzodiazepine entity2end dosage , and the patients should be appropriately monitored . 
true chemical chemical entity1begin Fluconazole entity1end tablets coadministered with entity2begin ethinyl estradiol entity2end - and levonorgestrel - containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels ; 
true chemical chemical entity1begin Fluconazole entity1end tablets coadministered with ethinyl estradiol - and entity2begin levonorgestrel entity2end - containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels ; 
false chemical chemical entity1begin Fluconazole entity1end tablets coadministered with ethinyl estradiol - and levonorgestrel - containing oral entity2begin contraceptives entity2end produced an overall mean increase in ethinyl estradiol and levonorgestrel levels ; 
false chemical chemical entity1begin Fluconazole entity1end tablets coadministered with ethinyl estradiol - and levonorgestrel - containing oral contraceptives produced an overall mean increase in entity2begin ethinyl estradiol entity2end and levonorgestrel levels ; 
false chemical chemical entity1begin Fluconazole entity1end tablets coadministered with ethinyl estradiol - and levonorgestrel - containing oral contraceptives produced an overall mean increase in ethinyl estradiol and entity2begin levonorgestrel entity2end levels ; 
false chemical chemical Fluconazole tablets coadministered with entity1begin ethinyl estradiol entity1end - and entity2begin levonorgestrel entity2end - containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels ; 
false chemical chemical Fluconazole tablets coadministered with entity1begin ethinyl estradiol entity1end - and levonorgestrel - containing oral entity2begin contraceptives entity2end produced an overall mean increase in ethinyl estradiol and levonorgestrel levels ; 
false chemical chemical Fluconazole tablets coadministered with entity1begin ethinyl estradiol entity1end - and levonorgestrel - containing oral contraceptives produced an overall mean increase in entity2begin ethinyl estradiol entity2end and levonorgestrel levels ; 
false chemical chemical Fluconazole tablets coadministered with entity1begin ethinyl estradiol entity1end - and levonorgestrel - containing oral contraceptives produced an overall mean increase in ethinyl estradiol and entity2begin levonorgestrel entity2end levels ; 
false chemical chemical Fluconazole tablets coadministered with ethinyl estradiol - and entity1begin levonorgestrel entity1end - containing oral entity2begin contraceptives entity2end produced an overall mean increase in ethinyl estradiol and levonorgestrel levels ; 
false chemical chemical Fluconazole tablets coadministered with ethinyl estradiol - and entity1begin levonorgestrel entity1end - containing oral contraceptives produced an overall mean increase in entity2begin ethinyl estradiol entity2end and levonorgestrel levels ; 
false chemical chemical Fluconazole tablets coadministered with ethinyl estradiol - and entity1begin levonorgestrel entity1end - containing oral contraceptives produced an overall mean increase in ethinyl estradiol and entity2begin levonorgestrel entity2end levels ; 
false chemical chemical Fluconazole tablets coadministered with ethinyl estradiol - and levonorgestrel - containing oral entity1begin contraceptives entity1end produced an overall mean increase in entity2begin ethinyl estradiol entity2end and levonorgestrel levels ; 
false chemical chemical Fluconazole tablets coadministered with ethinyl estradiol - and levonorgestrel - containing oral entity1begin contraceptives entity1end produced an overall mean increase in ethinyl estradiol and entity2begin levonorgestrel entity2end levels ; 
false chemical chemical Fluconazole tablets coadministered with ethinyl estradiol - and levonorgestrel - containing oral contraceptives produced an overall mean increase in entity1begin ethinyl estradiol entity1end and entity2begin levonorgestrel entity2end levels ; 
false chemical chemical however , in some patients there were decreases up to 47 % and 33 % of entity1begin ethinyl estradiol entity1end and entity2begin levonorgestrel entity2end levels . 
false chemical chemical The data presently available indicate that the decreases in some individual entity1begin ethinyl estradiol entity1end and entity2begin levonorgestrel entity2end AUC values with fluconazole treatment are likely the result of random variation . 
false chemical chemical The data presently available indicate that the decreases in some individual entity1begin ethinyl estradiol entity1end and levonorgestrel AUC values with entity2begin fluconazole entity2end treatment are likely the result of random variation . 
false chemical chemical The data presently available indicate that the decreases in some individual ethinyl estradiol and entity1begin levonorgestrel entity1end AUC values with entity2begin fluconazole entity2end treatment are likely the result of random variation . 
true chemical chemical While there is evidence that entity1begin fluconazole entity1end can inhibit the metabolism of entity2begin ethinyl estradiol entity2end and levonorgestrel , there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism . 
true chemical chemical While there is evidence that entity1begin fluconazole entity1end can inhibit the metabolism of ethinyl estradiol and entity2begin levonorgestrel entity2end , there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism . 
false chemical chemical While there is evidence that entity1begin fluconazole entity1end can inhibit the metabolism of ethinyl estradiol and levonorgestrel , there is no evidence that entity2begin fluconazole entity2end is a net inducer of ethinyl estradiol or levonorgestrel metabolism . 
false chemical chemical While there is evidence that entity1begin fluconazole entity1end can inhibit the metabolism of ethinyl estradiol and levonorgestrel , there is no evidence that fluconazole is a net inducer of entity2begin ethinyl estradiol entity2end or levonorgestrel metabolism . 
false chemical chemical While there is evidence that entity1begin fluconazole entity1end can inhibit the metabolism of ethinyl estradiol and levonorgestrel , there is no evidence that fluconazole is a net inducer of ethinyl estradiol or entity2begin levonorgestrel entity2end metabolism . 
false chemical chemical While there is evidence that fluconazole can inhibit the metabolism of entity1begin ethinyl estradiol entity1end and entity2begin levonorgestrel entity2end , there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism . 
false chemical chemical While there is evidence that fluconazole can inhibit the metabolism of entity1begin ethinyl estradiol entity1end and levonorgestrel , there is no evidence that entity2begin fluconazole entity2end is a net inducer of ethinyl estradiol or levonorgestrel metabolism . 
false chemical chemical While there is evidence that fluconazole can inhibit the metabolism of entity1begin ethinyl estradiol entity1end and levonorgestrel , there is no evidence that fluconazole is a net inducer of entity2begin ethinyl estradiol entity2end or levonorgestrel metabolism . 
false chemical chemical While there is evidence that fluconazole can inhibit the metabolism of entity1begin ethinyl estradiol entity1end and levonorgestrel , there is no evidence that fluconazole is a net inducer of ethinyl estradiol or entity2begin levonorgestrel entity2end metabolism . 
false chemical chemical While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and entity1begin levonorgestrel entity1end , there is no evidence that entity2begin fluconazole entity2end is a net inducer of ethinyl estradiol or levonorgestrel metabolism . 
false chemical chemical While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and entity1begin levonorgestrel entity1end , there is no evidence that fluconazole is a net inducer of entity2begin ethinyl estradiol entity2end or levonorgestrel metabolism . 
false chemical chemical While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and entity1begin levonorgestrel entity1end , there is no evidence that fluconazole is a net inducer of ethinyl estradiol or entity2begin levonorgestrel entity2end metabolism . 
false chemical chemical While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel , there is no evidence that entity1begin fluconazole entity1end is a net inducer of entity2begin ethinyl estradiol entity2end or levonorgestrel metabolism . 
false chemical chemical While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel , there is no evidence that entity1begin fluconazole entity1end is a net inducer of ethinyl estradiol or entity2begin levonorgestrel entity2end metabolism . 
false chemical chemical While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel , there is no evidence that fluconazole is a net inducer of entity1begin ethinyl estradiol entity1end or entity2begin levonorgestrel entity2end metabolism . 
true chemical chemical You cannot take entity1begin mazindol entity1end if you have taken a entity2begin monoamine oxidase inhibitor entity2end ( MAOI ) such as isocarboxazid ( Marplan ) , tranylcypromine ( Parnate ) , or phenelzine ( Nardil ) in the last 14 days . 
true chemical chemical You cannot take entity1begin mazindol entity1end if you have taken a monoamine oxidase inhibitor ( entity2begin MAOI entity2end ) such as isocarboxazid ( Marplan ) , tranylcypromine ( Parnate ) , or phenelzine ( Nardil ) in the last 14 days . 
true chemical chemical You cannot take entity1begin mazindol entity1end if you have taken a monoamine oxidase inhibitor ( MAOI ) such as entity2begin isocarboxazid entity2end ( Marplan ) , tranylcypromine ( Parnate ) , or phenelzine ( Nardil ) in the last 14 days . 
true chemical chemical You cannot take entity1begin mazindol entity1end if you have taken a monoamine oxidase inhibitor ( MAOI ) such as isocarboxazid ( entity2begin Marplan entity2end ) , tranylcypromine ( Parnate ) , or phenelzine ( Nardil ) in the last 14 days . 
true chemical chemical You cannot take entity1begin mazindol entity1end if you have taken a monoamine oxidase inhibitor ( MAOI ) such as isocarboxazid ( Marplan ) , entity2begin tranylcypromine entity2end ( Parnate ) , or phenelzine ( Nardil ) in the last 14 days . 
true chemical chemical You cannot take entity1begin mazindol entity1end if you have taken a monoamine oxidase inhibitor ( MAOI ) such as isocarboxazid ( Marplan ) , tranylcypromine ( entity2begin Parnate entity2end ) , or phenelzine ( Nardil ) in the last 14 days . 
true chemical chemical You cannot take entity1begin mazindol entity1end if you have taken a monoamine oxidase inhibitor ( MAOI ) such as isocarboxazid ( Marplan ) , tranylcypromine ( Parnate ) , or entity2begin phenelzine entity2end ( Nardil ) in the last 14 days . 
true chemical chemical You cannot take entity1begin mazindol entity1end if you have taken a monoamine oxidase inhibitor ( MAOI ) such as isocarboxazid ( Marplan ) , tranylcypromine ( Parnate ) , or phenelzine ( entity2begin Nardil entity2end ) in the last 14 days . 
false chemical chemical You cannot take mazindol if you have taken a entity1begin monoamine oxidase inhibitor entity1end ( entity2begin MAOI entity2end ) such as isocarboxazid ( Marplan ) , tranylcypromine ( Parnate ) , or phenelzine ( Nardil ) in the last 14 days . 
false chemical chemical You cannot take mazindol if you have taken a entity1begin monoamine oxidase inhibitor entity1end ( MAOI ) such as entity2begin isocarboxazid entity2end ( Marplan ) , tranylcypromine ( Parnate ) , or phenelzine ( Nardil ) in the last 14 days . 
false chemical chemical You cannot take mazindol if you have taken a entity1begin monoamine oxidase inhibitor entity1end ( MAOI ) such as isocarboxazid ( entity2begin Marplan entity2end ) , tranylcypromine ( Parnate ) , or phenelzine ( Nardil ) in the last 14 days . 
false chemical chemical You cannot take mazindol if you have taken a entity1begin monoamine oxidase inhibitor entity1end ( MAOI ) such as isocarboxazid ( Marplan ) , entity2begin tranylcypromine entity2end ( Parnate ) , or phenelzine ( Nardil ) in the last 14 days . 
false chemical chemical You cannot take mazindol if you have taken a entity1begin monoamine oxidase inhibitor entity1end ( MAOI ) such as isocarboxazid ( Marplan ) , tranylcypromine ( entity2begin Parnate entity2end ) , or phenelzine ( Nardil ) in the last 14 days . 
false chemical chemical You cannot take mazindol if you have taken a entity1begin monoamine oxidase inhibitor entity1end ( MAOI ) such as isocarboxazid ( Marplan ) , tranylcypromine ( Parnate ) , or entity2begin phenelzine entity2end ( Nardil ) in the last 14 days . 
false chemical chemical You cannot take mazindol if you have taken a entity1begin monoamine oxidase inhibitor entity1end ( MAOI ) such as isocarboxazid ( Marplan ) , tranylcypromine ( Parnate ) , or phenelzine ( entity2begin Nardil entity2end ) in the last 14 days . 
false chemical chemical You cannot take mazindol if you have taken a monoamine oxidase inhibitor ( entity1begin MAOI entity1end ) such as entity2begin isocarboxazid entity2end ( Marplan ) , tranylcypromine ( Parnate ) , or phenelzine ( Nardil ) in the last 14 days . 
false chemical chemical You cannot take mazindol if you have taken a monoamine oxidase inhibitor ( entity1begin MAOI entity1end ) such as isocarboxazid ( entity2begin Marplan entity2end ) , tranylcypromine ( Parnate ) , or phenelzine ( Nardil ) in the last 14 days . 
false chemical chemical You cannot take mazindol if you have taken a monoamine oxidase inhibitor ( entity1begin MAOI entity1end ) such as isocarboxazid ( Marplan ) , entity2begin tranylcypromine entity2end ( Parnate ) , or phenelzine ( Nardil ) in the last 14 days . 
false chemical chemical You cannot take mazindol if you have taken a monoamine oxidase inhibitor ( entity1begin MAOI entity1end ) such as isocarboxazid ( Marplan ) , tranylcypromine ( entity2begin Parnate entity2end ) , or phenelzine ( Nardil ) in the last 14 days . 
false chemical chemical You cannot take mazindol if you have taken a monoamine oxidase inhibitor ( entity1begin MAOI entity1end ) such as isocarboxazid ( Marplan ) , tranylcypromine ( Parnate ) , or entity2begin phenelzine entity2end ( Nardil ) in the last 14 days . 
false chemical chemical You cannot take mazindol if you have taken a monoamine oxidase inhibitor ( entity1begin MAOI entity1end ) such as isocarboxazid ( Marplan ) , tranylcypromine ( Parnate ) , or phenelzine ( entity2begin Nardil entity2end ) in the last 14 days . 
false chemical chemical You cannot take mazindol if you have taken a monoamine oxidase inhibitor ( MAOI ) such as entity1begin isocarboxazid entity1end ( entity2begin Marplan entity2end ) , tranylcypromine ( Parnate ) , or phenelzine ( Nardil ) in the last 14 days . 
false chemical chemical You cannot take mazindol if you have taken a monoamine oxidase inhibitor ( MAOI ) such as entity1begin isocarboxazid entity1end ( Marplan ) , entity2begin tranylcypromine entity2end ( Parnate ) , or phenelzine ( Nardil ) in the last 14 days . 
false chemical chemical You cannot take mazindol if you have taken a monoamine oxidase inhibitor ( MAOI ) such as entity1begin isocarboxazid entity1end ( Marplan ) , tranylcypromine ( entity2begin Parnate entity2end ) , or phenelzine ( Nardil ) in the last 14 days . 
false chemical chemical You cannot take mazindol if you have taken a monoamine oxidase inhibitor ( MAOI ) such as entity1begin isocarboxazid entity1end ( Marplan ) , tranylcypromine ( Parnate ) , or entity2begin phenelzine entity2end ( Nardil ) in the last 14 days . 
false chemical chemical You cannot take mazindol if you have taken a monoamine oxidase inhibitor ( MAOI ) such as entity1begin isocarboxazid entity1end ( Marplan ) , tranylcypromine ( Parnate ) , or phenelzine ( entity2begin Nardil entity2end ) in the last 14 days . 
false chemical chemical You cannot take mazindol if you have taken a monoamine oxidase inhibitor ( MAOI ) such as isocarboxazid ( entity1begin Marplan entity1end ) , entity2begin tranylcypromine entity2end ( Parnate ) , or phenelzine ( Nardil ) in the last 14 days . 
false chemical chemical You cannot take mazindol if you have taken a monoamine oxidase inhibitor ( MAOI ) such as isocarboxazid ( entity1begin Marplan entity1end ) , tranylcypromine ( entity2begin Parnate entity2end ) , or phenelzine ( Nardil ) in the last 14 days . 
false chemical chemical You cannot take mazindol if you have taken a monoamine oxidase inhibitor ( MAOI ) such as isocarboxazid ( entity1begin Marplan entity1end ) , tranylcypromine ( Parnate ) , or entity2begin phenelzine entity2end ( Nardil ) in the last 14 days . 
false chemical chemical You cannot take mazindol if you have taken a monoamine oxidase inhibitor ( MAOI ) such as isocarboxazid ( entity1begin Marplan entity1end ) , tranylcypromine ( Parnate ) , or phenelzine ( entity2begin Nardil entity2end ) in the last 14 days . 
false chemical chemical You cannot take mazindol if you have taken a monoamine oxidase inhibitor ( MAOI ) such as isocarboxazid ( Marplan ) , entity1begin tranylcypromine entity1end ( entity2begin Parnate entity2end ) , or phenelzine ( Nardil ) in the last 14 days . 
false chemical chemical You cannot take mazindol if you have taken a monoamine oxidase inhibitor ( MAOI ) such as isocarboxazid ( Marplan ) , entity1begin tranylcypromine entity1end ( Parnate ) , or entity2begin phenelzine entity2end ( Nardil ) in the last 14 days . 
false chemical chemical You cannot take mazindol if you have taken a monoamine oxidase inhibitor ( MAOI ) such as isocarboxazid ( Marplan ) , entity1begin tranylcypromine entity1end ( Parnate ) , or phenelzine ( entity2begin Nardil entity2end ) in the last 14 days . 
false chemical chemical You cannot take mazindol if you have taken a monoamine oxidase inhibitor ( MAOI ) such as isocarboxazid ( Marplan ) , tranylcypromine ( entity1begin Parnate entity1end ) , or entity2begin phenelzine entity2end ( Nardil ) in the last 14 days . 
false chemical chemical You cannot take mazindol if you have taken a monoamine oxidase inhibitor ( MAOI ) such as isocarboxazid ( Marplan ) , tranylcypromine ( entity1begin Parnate entity1end ) , or phenelzine ( entity2begin Nardil entity2end ) in the last 14 days . 
false chemical chemical You cannot take mazindol if you have taken a monoamine oxidase inhibitor ( MAOI ) such as isocarboxazid ( Marplan ) , tranylcypromine ( Parnate ) , or entity1begin phenelzine entity1end ( entity2begin Nardil entity2end ) in the last 14 days . 
true chemical chemical Changes in entity1begin insulin entity1end and other diabetes drug therapies may be necessary during treatment with entity2begin mazindol entity2end . 
true chemical chemical entity1begin Mazindol entity1end may reduce the effects of entity2begin guanethidine entity2end ( Ismelin ) . 
true chemical chemical entity1begin Mazindol entity1end may reduce the effects of guanethidine ( entity2begin Ismelin entity2end ) . 
false chemical chemical Mazindol may reduce the effects of entity1begin guanethidine entity1end ( entity2begin Ismelin entity2end ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a entity1begin tricyclic antidepressant entity1end such as entity2begin amitriptyline entity2end ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a entity1begin tricyclic antidepressant entity1end such as amitriptyline ( entity2begin Elavil entity2end ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a entity1begin tricyclic antidepressant entity1end such as amitriptyline ( Elavil ) , entity2begin amoxapine entity2end ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a entity1begin tricyclic antidepressant entity1end such as amitriptyline ( Elavil ) , amoxapine ( entity2begin Asendin entity2end ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a entity1begin tricyclic antidepressant entity1end such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , entity2begin doxepin entity2end ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a entity1begin tricyclic antidepressant entity1end such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( entity2begin Sinequan entity2end ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a entity1begin tricyclic antidepressant entity1end such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , entity2begin nortriptyline entity2end ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a entity1begin tricyclic antidepressant entity1end such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( entity2begin Pamelor entity2end ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a entity1begin tricyclic antidepressant entity1end such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , entity2begin imipramine entity2end ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a entity1begin tricyclic antidepressant entity1end such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( entity2begin Tofranil entity2end ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a entity1begin tricyclic antidepressant entity1end such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , entity2begin clomipramine entity2end ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a entity1begin tricyclic antidepressant entity1end such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( entity2begin Anafranil entity2end ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a entity1begin tricyclic antidepressant entity1end such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , entity2begin protriptyline entity2end ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a entity1begin tricyclic antidepressant entity1end such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( entity2begin Vivactil entity2end ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a entity1begin tricyclic antidepressant entity1end such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or entity2begin desipramine entity2end ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a entity1begin tricyclic antidepressant entity1end such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( entity2begin Norpramin entity2end ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as entity1begin amitriptyline entity1end ( entity2begin Elavil entity2end ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as entity1begin amitriptyline entity1end ( Elavil ) , entity2begin amoxapine entity2end ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as entity1begin amitriptyline entity1end ( Elavil ) , amoxapine ( entity2begin Asendin entity2end ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as entity1begin amitriptyline entity1end ( Elavil ) , amoxapine ( Asendin ) , entity2begin doxepin entity2end ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as entity1begin amitriptyline entity1end ( Elavil ) , amoxapine ( Asendin ) , doxepin ( entity2begin Sinequan entity2end ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as entity1begin amitriptyline entity1end ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , entity2begin nortriptyline entity2end ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as entity1begin amitriptyline entity1end ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( entity2begin Pamelor entity2end ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as entity1begin amitriptyline entity1end ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , entity2begin imipramine entity2end ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as entity1begin amitriptyline entity1end ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( entity2begin Tofranil entity2end ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as entity1begin amitriptyline entity1end ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , entity2begin clomipramine entity2end ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as entity1begin amitriptyline entity1end ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( entity2begin Anafranil entity2end ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as entity1begin amitriptyline entity1end ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , entity2begin protriptyline entity2end ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as entity1begin amitriptyline entity1end ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( entity2begin Vivactil entity2end ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as entity1begin amitriptyline entity1end ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or entity2begin desipramine entity2end ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as entity1begin amitriptyline entity1end ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( entity2begin Norpramin entity2end ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( entity1begin Elavil entity1end ) , entity2begin amoxapine entity2end ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( entity1begin Elavil entity1end ) , amoxapine ( entity2begin Asendin entity2end ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( entity1begin Elavil entity1end ) , amoxapine ( Asendin ) , entity2begin doxepin entity2end ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( entity1begin Elavil entity1end ) , amoxapine ( Asendin ) , doxepin ( entity2begin Sinequan entity2end ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( entity1begin Elavil entity1end ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , entity2begin nortriptyline entity2end ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( entity1begin Elavil entity1end ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( entity2begin Pamelor entity2end ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( entity1begin Elavil entity1end ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , entity2begin imipramine entity2end ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( entity1begin Elavil entity1end ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( entity2begin Tofranil entity2end ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( entity1begin Elavil entity1end ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , entity2begin clomipramine entity2end ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( entity1begin Elavil entity1end ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( entity2begin Anafranil entity2end ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( entity1begin Elavil entity1end ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , entity2begin protriptyline entity2end ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( entity1begin Elavil entity1end ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( entity2begin Vivactil entity2end ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( entity1begin Elavil entity1end ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or entity2begin desipramine entity2end ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( entity1begin Elavil entity1end ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( entity2begin Norpramin entity2end ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , entity1begin amoxapine entity1end ( entity2begin Asendin entity2end ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , entity1begin amoxapine entity1end ( Asendin ) , entity2begin doxepin entity2end ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , entity1begin amoxapine entity1end ( Asendin ) , doxepin ( entity2begin Sinequan entity2end ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , entity1begin amoxapine entity1end ( Asendin ) , doxepin ( Sinequan ) , entity2begin nortriptyline entity2end ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , entity1begin amoxapine entity1end ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( entity2begin Pamelor entity2end ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , entity1begin amoxapine entity1end ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , entity2begin imipramine entity2end ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , entity1begin amoxapine entity1end ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( entity2begin Tofranil entity2end ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , entity1begin amoxapine entity1end ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , entity2begin clomipramine entity2end ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , entity1begin amoxapine entity1end ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( entity2begin Anafranil entity2end ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , entity1begin amoxapine entity1end ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , entity2begin protriptyline entity2end ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , entity1begin amoxapine entity1end ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( entity2begin Vivactil entity2end ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , entity1begin amoxapine entity1end ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or entity2begin desipramine entity2end ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , entity1begin amoxapine entity1end ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( entity2begin Norpramin entity2end ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( entity1begin Asendin entity1end ) , entity2begin doxepin entity2end ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( entity1begin Asendin entity1end ) , doxepin ( entity2begin Sinequan entity2end ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( entity1begin Asendin entity1end ) , doxepin ( Sinequan ) , entity2begin nortriptyline entity2end ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( entity1begin Asendin entity1end ) , doxepin ( Sinequan ) , nortriptyline ( entity2begin Pamelor entity2end ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( entity1begin Asendin entity1end ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , entity2begin imipramine entity2end ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( entity1begin Asendin entity1end ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( entity2begin Tofranil entity2end ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( entity1begin Asendin entity1end ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , entity2begin clomipramine entity2end ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( entity1begin Asendin entity1end ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( entity2begin Anafranil entity2end ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( entity1begin Asendin entity1end ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , entity2begin protriptyline entity2end ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( entity1begin Asendin entity1end ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( entity2begin Vivactil entity2end ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( entity1begin Asendin entity1end ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or entity2begin desipramine entity2end ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( entity1begin Asendin entity1end ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( entity2begin Norpramin entity2end ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , entity1begin doxepin entity1end ( entity2begin Sinequan entity2end ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , entity1begin doxepin entity1end ( Sinequan ) , entity2begin nortriptyline entity2end ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , entity1begin doxepin entity1end ( Sinequan ) , nortriptyline ( entity2begin Pamelor entity2end ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , entity1begin doxepin entity1end ( Sinequan ) , nortriptyline ( Pamelor ) , entity2begin imipramine entity2end ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , entity1begin doxepin entity1end ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( entity2begin Tofranil entity2end ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , entity1begin doxepin entity1end ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , entity2begin clomipramine entity2end ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , entity1begin doxepin entity1end ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( entity2begin Anafranil entity2end ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , entity1begin doxepin entity1end ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , entity2begin protriptyline entity2end ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , entity1begin doxepin entity1end ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( entity2begin Vivactil entity2end ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , entity1begin doxepin entity1end ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or entity2begin desipramine entity2end ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , entity1begin doxepin entity1end ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( entity2begin Norpramin entity2end ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( entity1begin Sinequan entity1end ) , entity2begin nortriptyline entity2end ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( entity1begin Sinequan entity1end ) , nortriptyline ( entity2begin Pamelor entity2end ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( entity1begin Sinequan entity1end ) , nortriptyline ( Pamelor ) , entity2begin imipramine entity2end ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( entity1begin Sinequan entity1end ) , nortriptyline ( Pamelor ) , imipramine ( entity2begin Tofranil entity2end ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( entity1begin Sinequan entity1end ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , entity2begin clomipramine entity2end ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( entity1begin Sinequan entity1end ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( entity2begin Anafranil entity2end ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( entity1begin Sinequan entity1end ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , entity2begin protriptyline entity2end ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( entity1begin Sinequan entity1end ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( entity2begin Vivactil entity2end ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( entity1begin Sinequan entity1end ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or entity2begin desipramine entity2end ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( entity1begin Sinequan entity1end ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( entity2begin Norpramin entity2end ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , entity1begin nortriptyline entity1end ( entity2begin Pamelor entity2end ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , entity1begin nortriptyline entity1end ( Pamelor ) , entity2begin imipramine entity2end ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , entity1begin nortriptyline entity1end ( Pamelor ) , imipramine ( entity2begin Tofranil entity2end ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , entity1begin nortriptyline entity1end ( Pamelor ) , imipramine ( Tofranil ) , entity2begin clomipramine entity2end ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , entity1begin nortriptyline entity1end ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( entity2begin Anafranil entity2end ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , entity1begin nortriptyline entity1end ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , entity2begin protriptyline entity2end ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , entity1begin nortriptyline entity1end ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( entity2begin Vivactil entity2end ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , entity1begin nortriptyline entity1end ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or entity2begin desipramine entity2end ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , entity1begin nortriptyline entity1end ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( entity2begin Norpramin entity2end ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( entity1begin Pamelor entity1end ) , entity2begin imipramine entity2end ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( entity1begin Pamelor entity1end ) , imipramine ( entity2begin Tofranil entity2end ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( entity1begin Pamelor entity1end ) , imipramine ( Tofranil ) , entity2begin clomipramine entity2end ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( entity1begin Pamelor entity1end ) , imipramine ( Tofranil ) , clomipramine ( entity2begin Anafranil entity2end ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( entity1begin Pamelor entity1end ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , entity2begin protriptyline entity2end ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( entity1begin Pamelor entity1end ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( entity2begin Vivactil entity2end ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( entity1begin Pamelor entity1end ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or entity2begin desipramine entity2end ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( entity1begin Pamelor entity1end ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( entity2begin Norpramin entity2end ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , entity1begin imipramine entity1end ( entity2begin Tofranil entity2end ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , entity1begin imipramine entity1end ( Tofranil ) , entity2begin clomipramine entity2end ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , entity1begin imipramine entity1end ( Tofranil ) , clomipramine ( entity2begin Anafranil entity2end ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , entity1begin imipramine entity1end ( Tofranil ) , clomipramine ( Anafranil ) , entity2begin protriptyline entity2end ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , entity1begin imipramine entity1end ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( entity2begin Vivactil entity2end ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , entity1begin imipramine entity1end ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or entity2begin desipramine entity2end ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , entity1begin imipramine entity1end ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( entity2begin Norpramin entity2end ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( entity1begin Tofranil entity1end ) , entity2begin clomipramine entity2end ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( entity1begin Tofranil entity1end ) , clomipramine ( entity2begin Anafranil entity2end ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( entity1begin Tofranil entity1end ) , clomipramine ( Anafranil ) , entity2begin protriptyline entity2end ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( entity1begin Tofranil entity1end ) , clomipramine ( Anafranil ) , protriptyline ( entity2begin Vivactil entity2end ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( entity1begin Tofranil entity1end ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or entity2begin desipramine entity2end ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( entity1begin Tofranil entity1end ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( entity2begin Norpramin entity2end ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , entity1begin clomipramine entity1end ( entity2begin Anafranil entity2end ) , protriptyline ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , entity1begin clomipramine entity1end ( Anafranil ) , entity2begin protriptyline entity2end ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , entity1begin clomipramine entity1end ( Anafranil ) , protriptyline ( entity2begin Vivactil entity2end ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , entity1begin clomipramine entity1end ( Anafranil ) , protriptyline ( Vivactil ) , or entity2begin desipramine entity2end ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , entity1begin clomipramine entity1end ( Anafranil ) , protriptyline ( Vivactil ) , or desipramine ( entity2begin Norpramin entity2end ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( entity1begin Anafranil entity1end ) , entity2begin protriptyline entity2end ( Vivactil ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( entity1begin Anafranil entity1end ) , protriptyline ( entity2begin Vivactil entity2end ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( entity1begin Anafranil entity1end ) , protriptyline ( Vivactil ) , or entity2begin desipramine entity2end ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( entity1begin Anafranil entity1end ) , protriptyline ( Vivactil ) , or desipramine ( entity2begin Norpramin entity2end ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , entity1begin protriptyline entity1end ( entity2begin Vivactil entity2end ) , or desipramine ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , entity1begin protriptyline entity1end ( Vivactil ) , or entity2begin desipramine entity2end ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , entity1begin protriptyline entity1end ( Vivactil ) , or desipramine ( entity2begin Norpramin entity2end ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( entity1begin Vivactil entity1end ) , or entity2begin desipramine entity2end ( Norpramin ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( entity1begin Vivactil entity1end ) , or desipramine ( entity2begin Norpramin entity2end ) . 
false chemical chemical Before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( Elavil ) , amoxapine ( Asendin ) , doxepin ( Sinequan ) , nortriptyline ( Pamelor ) , imipramine ( Tofranil ) , clomipramine ( Anafranil ) , protriptyline ( Vivactil ) , or entity1begin desipramine entity1end ( entity2begin Norpramin entity2end ) . 
true chemical chemical Preliminary evidence suggests that entity1begin cimetidine entity1end inhibits entity2begin mebendazole entity2end metabolism and may result in an increase in plasma concentrations of mebendazole . 
false chemical chemical Preliminary evidence suggests that entity1begin cimetidine entity1end inhibits mebendazole metabolism and may result in an increase in plasma concentrations of entity2begin mebendazole entity2end . 
false chemical chemical Preliminary evidence suggests that cimetidine inhibits entity1begin mebendazole entity1end metabolism and may result in an increase in plasma concentrations of entity2begin mebendazole entity2end . 
false chemical chemical Patients receiving entity1begin antibiotics entity1end and entity2begin sulfonamides entity2end generally should not be treated with ganglion blockers . 
true chemical chemical Patients receiving entity1begin antibiotics entity1end and sulfonamides generally should not be treated with entity2begin ganglion blockers entity2end . 
true chemical chemical Patients receiving antibiotics and entity1begin sulfonamides entity1end generally should not be treated with entity2begin ganglion blockers entity2end . 
true chemical chemical The action of entity1begin Mecamylamine entity1end may be potentiated by anesthesia , other entity2begin antihypertensive drugs entity2end and alcohol . 
true chemical chemical The action of entity1begin Mecamylamine entity1end may be potentiated by anesthesia , other antihypertensive drugs and entity2begin alcohol entity2end . 
false chemical chemical The action of Mecamylamine may be potentiated by anesthesia , other entity1begin antihypertensive drugs entity1end and entity2begin alcohol entity2end . 
true chemical chemical entity1begin Aminoglutethimide entity1end administered concomitantly with entity2begin depo - subQ provera 104 entity2end may significantly decrease the serum concentrations of MPA . 
false chemical chemical entity1begin Aminoglutethimide entity1end administered concomitantly with depo - subQ provera 104 may significantly decrease the serum concentrations of entity2begin MPA entity2end . 
false chemical chemical Aminoglutethimide administered concomitantly with entity1begin depo - subQ provera 104 entity1end may significantly decrease the serum concentrations of entity2begin MPA entity2end . 
false chemical chemical Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of entity1begin zidovudine entity1end or entity2begin rifabutin entity2end to warrant dosage adjustment when megestrol acetate is administered with these drugs . 
false chemical chemical Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of entity1begin zidovudine entity1end or rifabutin to warrant dosage adjustment when entity2begin megestrol acetate entity2end is administered with these drugs . 
false chemical chemical Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of zidovudine or entity1begin rifabutin entity1end to warrant dosage adjustment when entity2begin megestrol acetate entity2end is administered with these drugs . 
true chemical chemical A pharmacokinetic study demonstrated that coadministration of entity1begin megestrol acetate entity1end and entity2begin indinavir entity2end results in a significant decrease in the pharmacokinetic parameters ( ~ 36 % for Cmax and ~ 28 % for AUC ) of indinavir . 
false chemical chemical A pharmacokinetic study demonstrated that coadministration of entity1begin megestrol acetate entity1end and indinavir results in a significant decrease in the pharmacokinetic parameters ( ~ 36 % for Cmax and ~ 28 % for AUC ) of entity2begin indinavir entity2end . 
false chemical chemical A pharmacokinetic study demonstrated that coadministration of megestrol acetate and entity1begin indinavir entity1end results in a significant decrease in the pharmacokinetic parameters ( ~ 36 % for Cmax and ~ 28 % for AUC ) of entity2begin indinavir entity2end . 
true chemical chemical Administration of a higher dose of entity1begin indinavir entity1end should be considered when coadministering with entity2begin megestrol acetate entity2end . 
false chemical chemical The effects of entity1begin indinavir entity1end , entity2begin zidovudine entity2end or rifabutin on the pharmacokinetics of megestrol acetate were not studied . 
false chemical chemical The effects of entity1begin indinavir entity1end , zidovudine or entity2begin rifabutin entity2end on the pharmacokinetics of megestrol acetate were not studied . 
false chemical chemical The effects of entity1begin indinavir entity1end , zidovudine or rifabutin on the pharmacokinetics of entity2begin megestrol acetate entity2end were not studied . 
false chemical chemical The effects of indinavir , entity1begin zidovudine entity1end or entity2begin rifabutin entity2end on the pharmacokinetics of megestrol acetate were not studied . 
false chemical chemical The effects of indinavir , entity1begin zidovudine entity1end or rifabutin on the pharmacokinetics of entity2begin megestrol acetate entity2end were not studied . 
false chemical chemical The effects of indinavir , zidovudine or entity1begin rifabutin entity1end on the pharmacokinetics of entity2begin megestrol acetate entity2end were not studied . 
true chemical chemical entity1begin Melatonin entity1end may interact with the following drugs : entity2begin aspirin entity2end and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
true chemical chemical entity1begin Melatonin entity1end may interact with the following drugs : aspirin and other entity2begin NSAIDs entity2end ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical entity1begin Melatonin entity1end may interact with the following drugs : aspirin and other NSAIDs ( may lower entity2begin melatonin entity2end levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
true chemical chemical entity1begin Melatonin entity1end may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , entity2begin fluvoxamine entity2end ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical entity1begin Melatonin entity1end may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral entity2begin melatonin entity2end is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
true chemical chemical entity1begin Melatonin entity1end may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , entity2begin beta blockers entity2end ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical entity1begin Melatonin entity1end may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease entity2begin melatonin entity2end levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
true chemical chemical entity1begin Melatonin entity1end may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , entity2begin fluoxetine entity2end ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
true chemical chemical entity1begin Melatonin entity1end may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , entity2begin progestin entity2end ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical entity1begin Melatonin entity1end may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of entity2begin melatonin entity2end with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical entity1begin Melatonin entity1end may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with entity2begin progestin entity2end can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
true chemical chemical entity1begin Melatonin entity1end may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , entity2begin benzodiazepenes entity2end and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
true chemical chemical entity1begin Melatonin entity1end may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and entity2begin corticosteroids entity2end ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical entity1begin Melatonin entity1end may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of entity2begin melatonin entity2end and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical entity1begin Melatonin entity1end may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and entity2begin corticosteroids entity2end may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical entity1begin Melatonin entity1end may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the entity2begin corticosteroids entity2end ) . 
false chemical chemical Melatonin may interact with the following drugs : entity1begin aspirin entity1end and other entity2begin NSAIDs entity2end ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : entity1begin aspirin entity1end and other NSAIDs ( may lower entity2begin melatonin entity2end levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : entity1begin aspirin entity1end and other NSAIDs ( may lower melatonin levels ) , entity2begin fluvoxamine entity2end ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : entity1begin aspirin entity1end and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral entity2begin melatonin entity2end is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : entity1begin aspirin entity1end and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , entity2begin beta blockers entity2end ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : entity1begin aspirin entity1end and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease entity2begin melatonin entity2end levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : entity1begin aspirin entity1end and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , entity2begin fluoxetine entity2end ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : entity1begin aspirin entity1end and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , entity2begin progestin entity2end ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : entity1begin aspirin entity1end and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of entity2begin melatonin entity2end with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : entity1begin aspirin entity1end and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with entity2begin progestin entity2end can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : entity1begin aspirin entity1end and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , entity2begin benzodiazepenes entity2end and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : entity1begin aspirin entity1end and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and entity2begin corticosteroids entity2end ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : entity1begin aspirin entity1end and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of entity2begin melatonin entity2end and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : entity1begin aspirin entity1end and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and entity2begin corticosteroids entity2end may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : entity1begin aspirin entity1end and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the entity2begin corticosteroids entity2end ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other entity1begin NSAIDs entity1end ( may lower entity2begin melatonin entity2end levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other entity1begin NSAIDs entity1end ( may lower melatonin levels ) , entity2begin fluvoxamine entity2end ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other entity1begin NSAIDs entity1end ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral entity2begin melatonin entity2end is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other entity1begin NSAIDs entity1end ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , entity2begin beta blockers entity2end ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other entity1begin NSAIDs entity1end ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease entity2begin melatonin entity2end levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other entity1begin NSAIDs entity1end ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , entity2begin fluoxetine entity2end ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other entity1begin NSAIDs entity1end ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , entity2begin progestin entity2end ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other entity1begin NSAIDs entity1end ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of entity2begin melatonin entity2end with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other entity1begin NSAIDs entity1end ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with entity2begin progestin entity2end can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other entity1begin NSAIDs entity1end ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , entity2begin benzodiazepenes entity2end and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other entity1begin NSAIDs entity1end ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and entity2begin corticosteroids entity2end ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other entity1begin NSAIDs entity1end ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of entity2begin melatonin entity2end and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other entity1begin NSAIDs entity1end ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and entity2begin corticosteroids entity2end may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other entity1begin NSAIDs entity1end ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the entity2begin corticosteroids entity2end ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower entity1begin melatonin entity1end levels ) , entity2begin fluvoxamine entity2end ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower entity1begin melatonin entity1end levels ) , fluvoxamine ( bioavailability of oral entity2begin melatonin entity2end is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower entity1begin melatonin entity1end levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , entity2begin beta blockers entity2end ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower entity1begin melatonin entity1end levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease entity2begin melatonin entity2end levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower entity1begin melatonin entity1end levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , entity2begin fluoxetine entity2end ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower entity1begin melatonin entity1end levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , entity2begin progestin entity2end ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower entity1begin melatonin entity1end levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of entity2begin melatonin entity2end with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower entity1begin melatonin entity1end levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with entity2begin progestin entity2end can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower entity1begin melatonin entity1end levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , entity2begin benzodiazepenes entity2end and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower entity1begin melatonin entity1end levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and entity2begin corticosteroids entity2end ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower entity1begin melatonin entity1end levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of entity2begin melatonin entity2end and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower entity1begin melatonin entity1end levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and entity2begin corticosteroids entity2end may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower entity1begin melatonin entity1end levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the entity2begin corticosteroids entity2end ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , entity1begin fluvoxamine entity1end ( bioavailability of oral entity2begin melatonin entity2end is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , entity1begin fluvoxamine entity1end ( bioavailability of oral melatonin is increased with coadministration ) , entity2begin beta blockers entity2end ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , entity1begin fluvoxamine entity1end ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease entity2begin melatonin entity2end levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , entity1begin fluvoxamine entity1end ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , entity2begin fluoxetine entity2end ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , entity1begin fluvoxamine entity1end ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , entity2begin progestin entity2end ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , entity1begin fluvoxamine entity1end ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of entity2begin melatonin entity2end with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , entity1begin fluvoxamine entity1end ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with entity2begin progestin entity2end can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , entity1begin fluvoxamine entity1end ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , entity2begin benzodiazepenes entity2end and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , entity1begin fluvoxamine entity1end ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and entity2begin corticosteroids entity2end ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , entity1begin fluvoxamine entity1end ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of entity2begin melatonin entity2end and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , entity1begin fluvoxamine entity1end ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and entity2begin corticosteroids entity2end may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , entity1begin fluvoxamine entity1end ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the entity2begin corticosteroids entity2end ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral entity1begin melatonin entity1end is increased with coadministration ) , entity2begin beta blockers entity2end ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral entity1begin melatonin entity1end is increased with coadministration ) , beta blockers ( may decrease entity2begin melatonin entity2end levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral entity1begin melatonin entity1end is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , entity2begin fluoxetine entity2end ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral entity1begin melatonin entity1end is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , entity2begin progestin entity2end ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral entity1begin melatonin entity1end is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of entity2begin melatonin entity2end with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral entity1begin melatonin entity1end is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with entity2begin progestin entity2end can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral entity1begin melatonin entity1end is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , entity2begin benzodiazepenes entity2end and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral entity1begin melatonin entity1end is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and entity2begin corticosteroids entity2end ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral entity1begin melatonin entity1end is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of entity2begin melatonin entity2end and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral entity1begin melatonin entity1end is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and entity2begin corticosteroids entity2end may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral entity1begin melatonin entity1end is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the entity2begin corticosteroids entity2end ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , entity1begin beta blockers entity1end ( may decrease entity2begin melatonin entity2end levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , entity1begin beta blockers entity1end ( may decrease melatonin levels ) , entity2begin fluoxetine entity2end ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , entity1begin beta blockers entity1end ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , entity2begin progestin entity2end ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , entity1begin beta blockers entity1end ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of entity2begin melatonin entity2end with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , entity1begin beta blockers entity1end ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with entity2begin progestin entity2end can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , entity1begin beta blockers entity1end ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , entity2begin benzodiazepenes entity2end and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , entity1begin beta blockers entity1end ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and entity2begin corticosteroids entity2end ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , entity1begin beta blockers entity1end ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of entity2begin melatonin entity2end and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , entity1begin beta blockers entity1end ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and entity2begin corticosteroids entity2end may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , entity1begin beta blockers entity1end ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the entity2begin corticosteroids entity2end ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease entity1begin melatonin entity1end levels ) , entity2begin fluoxetine entity2end ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease entity1begin melatonin entity1end levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , entity2begin progestin entity2end ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease entity1begin melatonin entity1end levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of entity2begin melatonin entity2end with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease entity1begin melatonin entity1end levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with entity2begin progestin entity2end can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease entity1begin melatonin entity1end levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , entity2begin benzodiazepenes entity2end and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease entity1begin melatonin entity1end levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and entity2begin corticosteroids entity2end ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease entity1begin melatonin entity1end levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of entity2begin melatonin entity2end and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease entity1begin melatonin entity1end levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and entity2begin corticosteroids entity2end may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease entity1begin melatonin entity1end levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the entity2begin corticosteroids entity2end ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , entity1begin fluoxetine entity1end ( reports of psychotic episodes when coadministered ) , entity2begin progestin entity2end ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , entity1begin fluoxetine entity1end ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of entity2begin melatonin entity2end with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , entity1begin fluoxetine entity1end ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with entity2begin progestin entity2end can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , entity1begin fluoxetine entity1end ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , entity2begin benzodiazepenes entity2end and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , entity1begin fluoxetine entity1end ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and entity2begin corticosteroids entity2end ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , entity1begin fluoxetine entity1end ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of entity2begin melatonin entity2end and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , entity1begin fluoxetine entity1end ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and entity2begin corticosteroids entity2end may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , entity1begin fluoxetine entity1end ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the entity2begin corticosteroids entity2end ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , entity1begin progestin entity1end ( coadministration of entity2begin melatonin entity2end with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , entity1begin progestin entity1end ( coadministration of melatonin with entity2begin progestin entity2end can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , entity1begin progestin entity1end ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , entity2begin benzodiazepenes entity2end and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , entity1begin progestin entity1end ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and entity2begin corticosteroids entity2end ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , entity1begin progestin entity1end ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of entity2begin melatonin entity2end and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , entity1begin progestin entity1end ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and entity2begin corticosteroids entity2end may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , entity1begin progestin entity1end ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the entity2begin corticosteroids entity2end ) . 
true chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of entity1begin melatonin entity1end with entity2begin progestin entity2end can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of entity1begin melatonin entity1end with progestin can inhibit ovarian function in women ) , entity2begin benzodiazepenes entity2end and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of entity1begin melatonin entity1end with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and entity2begin corticosteroids entity2end ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of entity1begin melatonin entity1end with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of entity2begin melatonin entity2end and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of entity1begin melatonin entity1end with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and entity2begin corticosteroids entity2end may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of entity1begin melatonin entity1end with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the entity2begin corticosteroids entity2end ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with entity1begin progestin entity1end can inhibit ovarian function in women ) , entity2begin benzodiazepenes entity2end and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with entity1begin progestin entity1end can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and entity2begin corticosteroids entity2end ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with entity1begin progestin entity1end can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of entity2begin melatonin entity2end and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with entity1begin progestin entity1end can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and entity2begin corticosteroids entity2end may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with entity1begin progestin entity1end can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the entity2begin corticosteroids entity2end ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , entity1begin benzodiazepenes entity1end and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and entity2begin corticosteroids entity2end ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , entity1begin benzodiazepenes entity1end and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of entity2begin melatonin entity2end and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , entity1begin benzodiazepenes entity1end and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and entity2begin corticosteroids entity2end may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , entity1begin benzodiazepenes entity1end and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the entity2begin corticosteroids entity2end ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and entity1begin corticosteroids entity1end ( coadministration of entity2begin melatonin entity2end and corticosteroids may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and entity1begin corticosteroids entity1end ( coadministration of melatonin and entity2begin corticosteroids entity2end may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and entity1begin corticosteroids entity1end ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the entity2begin corticosteroids entity2end ) . 
true chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of entity1begin melatonin entity1end and entity2begin corticosteroids entity2end may interfere with the efficacy of the corticosteroids ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of entity1begin melatonin entity1end and corticosteroids may interfere with the efficacy of the entity2begin corticosteroids entity2end ) . 
false chemical chemical Melatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and entity1begin corticosteroids entity1end may interfere with the efficacy of the entity2begin corticosteroids entity2end ) . 
false chemical chemical entity1begin ACE inhibitors entity1end Reports suggest that entity2begin NSAIDs entity2end may diminish the antihypertensive effect of angiotensin - converting enzyme ( ACE ) inhibitors . 
false chemical chemical entity1begin ACE inhibitors entity1end Reports suggest that NSAIDs may diminish the antihypertensive effect of entity2begin angiotensin - converting enzyme ( ACE ) inhibitors entity2end . 
true chemical chemical ACE inhibitors Reports suggest that entity1begin NSAIDs entity1end may diminish the antihypertensive effect of entity2begin angiotensin - converting enzyme ( ACE ) inhibitors entity2end . 
true chemical chemical This interaction should be given consideration in patients taking entity1begin NSAIDs entity1end concomitantly with entity2begin ACE inhibitors entity2end . 
false chemical chemical entity1begin Aspirin entity1end : Concomitant administration of entity2begin aspirin entity2end ( 1000 mg TID ) to healthy volunteers tended to increase the AUC ( 10 % ) and Cmax ( 24 % ) of meloxicam . 
false chemical chemical entity1begin Aspirin entity1end : Concomitant administration of aspirin ( 1000 mg TID ) to healthy volunteers tended to increase the AUC ( 10 % ) and Cmax ( 24 % ) of entity2begin meloxicam entity2end . 
true chemical chemical Aspirin : Concomitant administration of entity1begin aspirin entity1end ( 1000 mg TID ) to healthy volunteers tended to increase the AUC ( 10 % ) and Cmax ( 24 % ) of entity2begin meloxicam entity2end . 
false chemical chemical however , as with other entity1begin NSAIDs entity1end , concomitant administration of entity2begin meloxicam entity2end and aspirin is not generally recommended because of the potential for increased adverse effects . 
true chemical chemical however , as with other entity1begin NSAIDs entity1end , concomitant administration of meloxicam and entity2begin aspirin entity2end is not generally recommended because of the potential for increased adverse effects . 
true chemical chemical however , as with other NSAIDs , concomitant administration of entity1begin meloxicam entity1end and entity2begin aspirin entity2end is not generally recommended because of the potential for increased adverse effects . 
true chemical chemical Concomitant administration of low - dose entity1begin aspirin entity1end with entity2begin MOBIC entity2end may result in an increased rate of GI ulceration or other complications , compared to use of MOBIC alone . 
false chemical chemical Concomitant administration of low - dose entity1begin aspirin entity1end with MOBIC may result in an increased rate of GI ulceration or other complications , compared to use of entity2begin MOBIC entity2end alone . 
false chemical chemical Concomitant administration of low - dose aspirin with entity1begin MOBIC entity1end may result in an increased rate of GI ulceration or other complications , compared to use of entity2begin MOBIC entity2end alone . 
false chemical chemical entity1begin MOBIC entity1end is not a substitute for entity2begin aspirin entity2end for cardiovascular prophylaxis . 
false chemical chemical entity1begin Cholestyramine entity1end : Pretreatment for four days with entity2begin cholestyramine entity2end significantly increased the clearance of meloxicam by 50 % . 
false chemical chemical entity1begin Cholestyramine entity1end : Pretreatment for four days with cholestyramine significantly increased the clearance of entity2begin meloxicam entity2end by 50 % . 
true chemical chemical Cholestyramine : Pretreatment for four days with entity1begin cholestyramine entity1end significantly increased the clearance of entity2begin meloxicam entity2end by 50 % . 
false chemical chemical entity1begin Cimetidine entity1end : Concomitant administration of 200 mg entity2begin cimetidine entity2end QID did not alter the single - dose pharmacokinetics of 30 mg meloxicam . 
false chemical chemical entity1begin Cimetidine entity1end : Concomitant administration of 200 mg cimetidine QID did not alter the single - dose pharmacokinetics of 30 mg entity2begin meloxicam entity2end . 
false chemical chemical Cimetidine : Concomitant administration of 200 mg entity1begin cimetidine entity1end QID did not alter the single - dose pharmacokinetics of 30 mg entity2begin meloxicam entity2end . 
false chemical chemical entity1begin Digoxin entity1end : entity2begin Meloxicam entity2end 15 mg once daily for 7 days did not alter the plasma concentration profile of digoxin after b - acetyldigoxin administration for 7 days at clinical doses . 
false chemical chemical entity1begin Digoxin entity1end : Meloxicam 15 mg once daily for 7 days did not alter the plasma concentration profile of entity2begin digoxin entity2end after b - acetyldigoxin administration for 7 days at clinical doses . 
false chemical chemical Digoxin : entity1begin Meloxicam entity1end 15 mg once daily for 7 days did not alter the plasma concentration profile of entity2begin digoxin entity2end after b - acetyldigoxin administration for 7 days at clinical doses . 
false chemical chemical In vitro testing found no protein binding drug interaction between entity1begin digoxin entity1end and entity2begin meloxicam entity2end . 
false chemical chemical entity1begin Furosemide entity1end : Clinical studies , as well as post - marketing observations , have shown that entity2begin NSAIDs entity2end can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients . 
false chemical chemical entity1begin Furosemide entity1end : Clinical studies , as well as post - marketing observations , have shown that NSAIDs can reduce the natriuretic effect of entity2begin furosemide entity2end and thiazide diuretics in some patients . 
false chemical chemical entity1begin Furosemide entity1end : Clinical studies , as well as post - marketing observations , have shown that NSAIDs can reduce the natriuretic effect of furosemide and entity2begin thiazide diuretics entity2end in some patients . 
true chemical chemical Furosemide : Clinical studies , as well as post - marketing observations , have shown that entity1begin NSAIDs entity1end can reduce the natriuretic effect of entity2begin furosemide entity2end and thiazide diuretics in some patients . 
true chemical chemical Furosemide : Clinical studies , as well as post - marketing observations , have shown that entity1begin NSAIDs entity1end can reduce the natriuretic effect of furosemide and entity2begin thiazide diuretics entity2end in some patients . 
false chemical chemical Furosemide : Clinical studies , as well as post - marketing observations , have shown that NSAIDs can reduce the natriuretic effect of entity1begin furosemide entity1end and entity2begin thiazide diuretics entity2end in some patients . 
false chemical chemical Studies with entity1begin furosemide entity1end agents and entity2begin meloxicam entity2end have not demonstrated a reduction in natriuretic effect . 
false chemical chemical entity1begin Furosemide entity1end : single and multiple dose pharmacodynamics and pharmacokinetics are not affected by multiple doses of entity2begin meloxicam entity2end . 
true chemical chemical Nevertheless , during concomitant therapy with entity1begin furosemide entity1end and entity2begin MOBIC entity2end , patients should be observed closely for signs of declining renal function , as well as to assure diuretic efficacy . 
false chemical chemical entity1begin Lithium entity1end : In clinical trials , entity2begin NSAIDs entity2end have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance . 
false chemical chemical entity1begin Lithium entity1end : In clinical trials , NSAIDs have produced an elevation of plasma entity2begin lithium entity2end levels and a reduction in renal lithium clearance . 
false chemical chemical entity1begin Lithium entity1end : In clinical trials , NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal entity2begin lithium entity2end clearance . 
true chemical chemical Lithium : In clinical trials , entity1begin NSAIDs entity1end have produced an elevation of plasma entity2begin lithium entity2end levels and a reduction in renal lithium clearance . 
false chemical chemical Lithium : In clinical trials , entity1begin NSAIDs entity1end have produced an elevation of plasma lithium levels and a reduction in renal entity2begin lithium entity2end clearance . 
false chemical chemical Lithium : In clinical trials , NSAIDs have produced an elevation of plasma entity1begin lithium entity1end levels and a reduction in renal entity2begin lithium entity2end clearance . 
false chemical chemical In a study conducted in healthy subjects , mean pre - dose entity1begin lithium entity1end concentration and AUC were increased by 21 % in subjects receiving entity2begin lithium entity2end doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving lithium alone . 
false chemical chemical In a study conducted in healthy subjects , mean pre - dose entity1begin lithium entity1end concentration and AUC were increased by 21 % in subjects receiving lithium doses ranging from 804 to 1072 mg BID with entity2begin meloxicam entity2end 15 mg QD as compared to subjects receiving lithium alone . 
false chemical chemical In a study conducted in healthy subjects , mean pre - dose entity1begin lithium entity1end concentration and AUC were increased by 21 % in subjects receiving lithium doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving entity2begin lithium entity2end alone . 
true chemical chemical In a study conducted in healthy subjects , mean pre - dose lithium concentration and AUC were increased by 21 % in subjects receiving entity1begin lithium entity1end doses ranging from 804 to 1072 mg BID with entity2begin meloxicam entity2end 15 mg QD as compared to subjects receiving lithium alone . 
false chemical chemical In a study conducted in healthy subjects , mean pre - dose lithium concentration and AUC were increased by 21 % in subjects receiving entity1begin lithium entity1end doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving entity2begin lithium entity2end alone . 
false chemical chemical In a study conducted in healthy subjects , mean pre - dose lithium concentration and AUC were increased by 21 % in subjects receiving lithium doses ranging from 804 to 1072 mg BID with entity1begin meloxicam entity1end 15 mg QD as compared to subjects receiving entity2begin lithium entity2end alone . 
true chemical chemical Patients on entity1begin lithium entity1end treatment should be closely monitored when entity2begin MOBIC entity2end is introduced or withdrawn . 
false chemical chemical entity1begin Methotrexate entity1end : A study in 13 rheumatoid arthritis ( RA ) patients evaluated the effects of multiple doses of entity2begin meloxicam entity2end on the pharmacokinetics of methotrexate taken once weekly . 
false chemical chemical entity1begin Methotrexate entity1end : A study in 13 rheumatoid arthritis ( RA ) patients evaluated the effects of multiple doses of meloxicam on the pharmacokinetics of entity2begin methotrexate entity2end taken once weekly . 
false chemical chemical Methotrexate : A study in 13 rheumatoid arthritis ( RA ) patients evaluated the effects of multiple doses of entity1begin meloxicam entity1end on the pharmacokinetics of entity2begin methotrexate entity2end taken once weekly . 
false chemical chemical entity1begin Meloxicam entity1end did not have a significant effect on the pharmacokinetics of single doses of entity2begin methotrexate entity2end . 
false chemical chemical In vitro , entity1begin methotrexate entity1end did not displace entity2begin meloxicam entity2end from its human serum binding sites . 
false chemical chemical entity1begin Warfarin entity1end : Anticoagulant activity should be monitored , particularly in the first few days after initiating or changing entity2begin MOBIC entity2end therapy in patients receiving warfarin or similar agents , since these patients are at an increased risk of bleeding . 
false chemical chemical entity1begin Warfarin entity1end : Anticoagulant activity should be monitored , particularly in the first few days after initiating or changing MOBIC therapy in patients receiving entity2begin warfarin entity2end or similar agents , since these patients are at an increased risk of bleeding . 
true chemical chemical Warfarin : Anticoagulant activity should be monitored , particularly in the first few days after initiating or changing entity1begin MOBIC entity1end therapy in patients receiving entity2begin warfarin entity2end or similar agents , since these patients are at an increased risk of bleeding . 
false chemical chemical The effect of entity1begin meloxicam entity1end on the anticoagulant effect of entity2begin warfarin entity2end was studied in a group of healthy subjects receiving daily doses of warfarin that produced an INR ( International Normalized Ratio ) between 1.2 and 1.8 . 
false chemical chemical The effect of entity1begin meloxicam entity1end on the anticoagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of entity2begin warfarin entity2end that produced an INR ( International Normalized Ratio ) between 1.2 and 1.8 . 
false chemical chemical The effect of meloxicam on the anticoagulant effect of entity1begin warfarin entity1end was studied in a group of healthy subjects receiving daily doses of entity2begin warfarin entity2end that produced an INR ( International Normalized Ratio ) between 1.2 and 1.8 . 
false chemical chemical In these subjects , entity1begin meloxicam entity1end did not alter entity2begin warfarin entity2end pharmacokinetics and the average anticoagulant effect of warfarin as determined by prothrombin time . 
false chemical chemical In these subjects , entity1begin meloxicam entity1end did not alter warfarin pharmacokinetics and the average anticoagulant effect of entity2begin warfarin entity2end as determined by prothrombin time . 
false chemical chemical In these subjects , meloxicam did not alter entity1begin warfarin entity1end pharmacokinetics and the average anticoagulant effect of entity2begin warfarin entity2end as determined by prothrombin time . 
true chemical chemical Caution should be used when administering entity1begin MOBIC entity1end with entity2begin warfarin entity2end since patients on warfarin may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced . 
false chemical chemical Caution should be used when administering entity1begin MOBIC entity1end with warfarin since patients on entity2begin warfarin entity2end may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced . 
false chemical chemical Caution should be used when administering MOBIC with entity1begin warfarin entity1end since patients on entity2begin warfarin entity2end may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced . 
false chemical chemical DRUG INTERACTIONS There are no known drug / drug interactions with oral entity1begin ALKERAN entity1end Vaccinations with entity2begin live organism vaccines entity2end are not recommended in immunocompromised individuals Nalidixic acid together with high - dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis . 
false chemical chemical DRUG INTERACTIONS There are no known drug / drug interactions with oral entity1begin ALKERAN entity1end Vaccinations with live organism vaccines are not recommended in immunocompromised individuals entity2begin Nalidixic acid entity2end together with high - dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis . 
false chemical chemical DRUG INTERACTIONS There are no known drug / drug interactions with oral entity1begin ALKERAN entity1end Vaccinations with live organism vaccines are not recommended in immunocompromised individuals Nalidixic acid together with high - dose intravenous entity2begin melphalan entity2end has caused deaths in children due to haemorrhagic enterocolitis . 
false chemical chemical DRUG INTERACTIONS There are no known drug / drug interactions with oral ALKERAN Vaccinations with entity1begin live organism vaccines entity1end are not recommended in immunocompromised individuals entity2begin Nalidixic acid entity2end together with high - dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis . 
false chemical chemical DRUG INTERACTIONS There are no known drug / drug interactions with oral ALKERAN Vaccinations with entity1begin live organism vaccines entity1end are not recommended in immunocompromised individuals Nalidixic acid together with high - dose intravenous entity2begin melphalan entity2end has caused deaths in children due to haemorrhagic enterocolitis . 
true chemical chemical DRUG INTERACTIONS There are no known drug / drug interactions with oral ALKERAN Vaccinations with live organism vaccines are not recommended in immunocompromised individuals entity1begin Nalidixic acid entity1end together with high - dose intravenous entity2begin melphalan entity2end has caused deaths in children due to haemorrhagic enterocolitis . 
true chemical chemical Impaired renal function has been described in bone marrow transplant patients who were conditioned with high - dose intravenous entity1begin melphalan entity1end and who subsequently received entity2begin cyclosporin entity2end to prevent graft - versus - host disease 
true chemical chemical The following agents may increase certain actions or side effects of entity1begin anticholinergic drugs entity1end : entity2begin amantadine entity2end , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
true chemical chemical The following agents may increase certain actions or side effects of entity1begin anticholinergic drugs entity1end : amantadine , entity2begin antiarrhythmic agents of class I entity2end ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
true chemical chemical The following agents may increase certain actions or side effects of entity1begin anticholinergic drugs entity1end : amantadine , antiarrhythmic agents of class I ( e.g. , entity2begin quinidine entity2end ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
true chemical chemical The following agents may increase certain actions or side effects of entity1begin anticholinergic drugs entity1end : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , entity2begin antihistamines entity2end , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
true chemical chemical The following agents may increase certain actions or side effects of entity1begin anticholinergic drugs entity1end : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , entity2begin antipsychotic agents entity2end ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
true chemical chemical The following agents may increase certain actions or side effects of entity1begin anticholinergic drugs entity1end : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , entity2begin phenothiazines entity2end ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
true chemical chemical The following agents may increase certain actions or side effects of entity1begin anticholinergic drugs entity1end : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , entity2begin benzodiazepines entity2end , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
true chemical chemical The following agents may increase certain actions or side effects of entity1begin anticholinergic drugs entity1end : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , entity2begin MAO inhibitors entity2end , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
true chemical chemical The following agents may increase certain actions or side effects of entity1begin anticholinergic drugs entity1end : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , entity2begin narcotic analgesics entity2end ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
true chemical chemical The following agents may increase certain actions or side effects of entity1begin anticholinergic drugs entity1end : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , entity2begin meperidine entity2end ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
true chemical chemical The following agents may increase certain actions or side effects of entity1begin anticholinergic drugs entity1end : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , entity2begin nitrates entity2end and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
true chemical chemical The following agents may increase certain actions or side effects of entity1begin anticholinergic drugs entity1end : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and entity2begin nitrites entity2end , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
true chemical chemical The following agents may increase certain actions or side effects of entity1begin anticholinergic drugs entity1end : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , entity2begin sympathomimetic agents entity2end , tricyclic antidepressants , and other drugs having anticholinergic activity . 
true chemical chemical The following agents may increase certain actions or side effects of entity1begin anticholinergic drugs entity1end : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , entity2begin tricyclic antidepressants entity2end , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : entity1begin amantadine entity1end , entity2begin antiarrhythmic agents of class I entity2end ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : entity1begin amantadine entity1end , antiarrhythmic agents of class I ( e.g. , entity2begin quinidine entity2end ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : entity1begin amantadine entity1end , antiarrhythmic agents of class I ( e.g. , quinidine ) , entity2begin antihistamines entity2end , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : entity1begin amantadine entity1end , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , entity2begin antipsychotic agents entity2end ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : entity1begin amantadine entity1end , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , entity2begin phenothiazines entity2end ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : entity1begin amantadine entity1end , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , entity2begin benzodiazepines entity2end , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : entity1begin amantadine entity1end , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , entity2begin MAO inhibitors entity2end , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : entity1begin amantadine entity1end , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , entity2begin narcotic analgesics entity2end ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : entity1begin amantadine entity1end , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , entity2begin meperidine entity2end ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : entity1begin amantadine entity1end , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , entity2begin nitrates entity2end and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : entity1begin amantadine entity1end , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and entity2begin nitrites entity2end , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : entity1begin amantadine entity1end , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , entity2begin sympathomimetic agents entity2end , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : entity1begin amantadine entity1end , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , entity2begin tricyclic antidepressants entity2end , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , entity1begin antiarrhythmic agents of class I entity1end ( e.g. , entity2begin quinidine entity2end ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , entity1begin antiarrhythmic agents of class I entity1end ( e.g. , quinidine ) , entity2begin antihistamines entity2end , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , entity1begin antiarrhythmic agents of class I entity1end ( e.g. , quinidine ) , antihistamines , entity2begin antipsychotic agents entity2end ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , entity1begin antiarrhythmic agents of class I entity1end ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , entity2begin phenothiazines entity2end ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , entity1begin antiarrhythmic agents of class I entity1end ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , entity2begin benzodiazepines entity2end , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , entity1begin antiarrhythmic agents of class I entity1end ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , entity2begin MAO inhibitors entity2end , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , entity1begin antiarrhythmic agents of class I entity1end ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , entity2begin narcotic analgesics entity2end ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , entity1begin antiarrhythmic agents of class I entity1end ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , entity2begin meperidine entity2end ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , entity1begin antiarrhythmic agents of class I entity1end ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , entity2begin nitrates entity2end and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , entity1begin antiarrhythmic agents of class I entity1end ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and entity2begin nitrites entity2end , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , entity1begin antiarrhythmic agents of class I entity1end ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , entity2begin sympathomimetic agents entity2end , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , entity1begin antiarrhythmic agents of class I entity1end ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , entity2begin tricyclic antidepressants entity2end , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , entity1begin quinidine entity1end ) , entity2begin antihistamines entity2end , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , entity1begin quinidine entity1end ) , antihistamines , entity2begin antipsychotic agents entity2end ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , entity1begin quinidine entity1end ) , antihistamines , antipsychotic agents ( e.g. , entity2begin phenothiazines entity2end ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , entity1begin quinidine entity1end ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , entity2begin benzodiazepines entity2end , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , entity1begin quinidine entity1end ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , entity2begin MAO inhibitors entity2end , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , entity1begin quinidine entity1end ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , entity2begin narcotic analgesics entity2end ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , entity1begin quinidine entity1end ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , entity2begin meperidine entity2end ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , entity1begin quinidine entity1end ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , entity2begin nitrates entity2end and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , entity1begin quinidine entity1end ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and entity2begin nitrites entity2end , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , entity1begin quinidine entity1end ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , entity2begin sympathomimetic agents entity2end , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , entity1begin quinidine entity1end ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , entity2begin tricyclic antidepressants entity2end , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , entity1begin antihistamines entity1end , entity2begin antipsychotic agents entity2end ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , entity1begin antihistamines entity1end , antipsychotic agents ( e.g. , entity2begin phenothiazines entity2end ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , entity1begin antihistamines entity1end , antipsychotic agents ( e.g. , phenothiazines ) , entity2begin benzodiazepines entity2end , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , entity1begin antihistamines entity1end , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , entity2begin MAO inhibitors entity2end , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , entity1begin antihistamines entity1end , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , entity2begin narcotic analgesics entity2end ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , entity1begin antihistamines entity1end , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , entity2begin meperidine entity2end ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , entity1begin antihistamines entity1end , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , entity2begin nitrates entity2end and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , entity1begin antihistamines entity1end , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and entity2begin nitrites entity2end , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , entity1begin antihistamines entity1end , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , entity2begin sympathomimetic agents entity2end , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , entity1begin antihistamines entity1end , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , entity2begin tricyclic antidepressants entity2end , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , entity1begin antipsychotic agents entity1end ( e.g. , entity2begin phenothiazines entity2end ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , entity1begin antipsychotic agents entity1end ( e.g. , phenothiazines ) , entity2begin benzodiazepines entity2end , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , entity1begin antipsychotic agents entity1end ( e.g. , phenothiazines ) , benzodiazepines , entity2begin MAO inhibitors entity2end , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , entity1begin antipsychotic agents entity1end ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , entity2begin narcotic analgesics entity2end ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , entity1begin antipsychotic agents entity1end ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , entity2begin meperidine entity2end ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , entity1begin antipsychotic agents entity1end ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , entity2begin nitrates entity2end and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , entity1begin antipsychotic agents entity1end ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and entity2begin nitrites entity2end , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , entity1begin antipsychotic agents entity1end ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , entity2begin sympathomimetic agents entity2end , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , entity1begin antipsychotic agents entity1end ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , entity2begin tricyclic antidepressants entity2end , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , entity1begin phenothiazines entity1end ) , entity2begin benzodiazepines entity2end , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , entity1begin phenothiazines entity1end ) , benzodiazepines , entity2begin MAO inhibitors entity2end , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , entity1begin phenothiazines entity1end ) , benzodiazepines , MAO inhibitors , entity2begin narcotic analgesics entity2end ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , entity1begin phenothiazines entity1end ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , entity2begin meperidine entity2end ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , entity1begin phenothiazines entity1end ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , entity2begin nitrates entity2end and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , entity1begin phenothiazines entity1end ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and entity2begin nitrites entity2end , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , entity1begin phenothiazines entity1end ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , entity2begin sympathomimetic agents entity2end , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , entity1begin phenothiazines entity1end ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , entity2begin tricyclic antidepressants entity2end , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , entity1begin benzodiazepines entity1end , entity2begin MAO inhibitors entity2end , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , entity1begin benzodiazepines entity1end , MAO inhibitors , entity2begin narcotic analgesics entity2end ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , entity1begin benzodiazepines entity1end , MAO inhibitors , narcotic analgesics ( e.g. , entity2begin meperidine entity2end ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , entity1begin benzodiazepines entity1end , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , entity2begin nitrates entity2end and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , entity1begin benzodiazepines entity1end , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and entity2begin nitrites entity2end , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , entity1begin benzodiazepines entity1end , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , entity2begin sympathomimetic agents entity2end , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , entity1begin benzodiazepines entity1end , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , entity2begin tricyclic antidepressants entity2end , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , entity1begin MAO inhibitors entity1end , entity2begin narcotic analgesics entity2end ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , entity1begin MAO inhibitors entity1end , narcotic analgesics ( e.g. , entity2begin meperidine entity2end ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , entity1begin MAO inhibitors entity1end , narcotic analgesics ( e.g. , meperidine ) , entity2begin nitrates entity2end and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , entity1begin MAO inhibitors entity1end , narcotic analgesics ( e.g. , meperidine ) , nitrates and entity2begin nitrites entity2end , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , entity1begin MAO inhibitors entity1end , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , entity2begin sympathomimetic agents entity2end , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , entity1begin MAO inhibitors entity1end , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , entity2begin tricyclic antidepressants entity2end , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , entity1begin narcotic analgesics entity1end ( e.g. , entity2begin meperidine entity2end ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , entity1begin narcotic analgesics entity1end ( e.g. , meperidine ) , entity2begin nitrates entity2end and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , entity1begin narcotic analgesics entity1end ( e.g. , meperidine ) , nitrates and entity2begin nitrites entity2end , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , entity1begin narcotic analgesics entity1end ( e.g. , meperidine ) , nitrates and nitrites , entity2begin sympathomimetic agents entity2end , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , entity1begin narcotic analgesics entity1end ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , entity2begin tricyclic antidepressants entity2end , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , entity1begin meperidine entity1end ) , entity2begin nitrates entity2end and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , entity1begin meperidine entity1end ) , nitrates and entity2begin nitrites entity2end , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , entity1begin meperidine entity1end ) , nitrates and nitrites , entity2begin sympathomimetic agents entity2end , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , entity1begin meperidine entity1end ) , nitrates and nitrites , sympathomimetic agents , entity2begin tricyclic antidepressants entity2end , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , entity1begin nitrates entity1end and entity2begin nitrites entity2end , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , entity1begin nitrates entity1end and nitrites , entity2begin sympathomimetic agents entity2end , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , entity1begin nitrates entity1end and nitrites , sympathomimetic agents , entity2begin tricyclic antidepressants entity2end , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and entity1begin nitrites entity1end , entity2begin sympathomimetic agents entity2end , tricyclic antidepressants , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and entity1begin nitrites entity1end , sympathomimetic agents , entity2begin tricyclic antidepressants entity2end , and other drugs having anticholinergic activity . 
false chemical chemical The following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class I ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , MAO inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , entity1begin sympathomimetic agents entity1end , entity2begin tricyclic antidepressants entity2end , and other drugs having anticholinergic activity . 
true chemical chemical entity1begin Anticholinergics entity1end antagonize the effects of entity2begin antiglaucoma agents entity2end . 
true chemical chemical entity1begin Anticholinergic drugs entity1end in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as entity2begin corticosteroids entity2end . 
true chemical chemical entity1begin Anticholinergic agents entity1end may affect gastrointestinal absorption of various drugs , such as slowly dissolving dosage forms of entity2begin digoxin entity2end ; 
true chemical chemical entity1begin Anticholinergic drugs entity1end may antagonize the effects of drugs that alter gastrointestinal motility , such as entity2begin metoclopramide entity2end . 
true chemical chemical Because entity1begin antacids entity1end may interfere with the absorption of entity2begin anticholinergic agents entity2end , simultaneous use of these drugs should be avoided . 
false chemical chemical Interaction with Other entity1begin Central Nervous System Depressants entity1end : entity2begin MEPERIDINE entity2end SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE - HYPNOTICS ( INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS ( INCLUDING ALCOHOL ) . 
false chemical chemical Interaction with Other entity1begin Central Nervous System Depressants entity1end : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER entity2begin NARCOTIC ANALGESICS entity2end , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE - HYPNOTICS ( INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS ( INCLUDING ALCOHOL ) . 
false chemical chemical Interaction with Other entity1begin Central Nervous System Depressants entity1end : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL entity2begin ANESTHETICS entity2end , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE - HYPNOTICS ( INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS ( INCLUDING ALCOHOL ) . 
false chemical chemical Interaction with Other entity1begin Central Nervous System Depressants entity1end : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , entity2begin PHENOTHIAZINES entity2end , OTHER TRANQUILIZERS , SEDATIVE - HYPNOTICS ( INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS ( INCLUDING ALCOHOL ) . 
false chemical chemical Interaction with Other entity1begin Central Nervous System Depressants entity1end : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER entity2begin TRANQUILIZERS entity2end , SEDATIVE - HYPNOTICS ( INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS ( INCLUDING ALCOHOL ) . 
false chemical chemical Interaction with Other entity1begin Central Nervous System Depressants entity1end : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , entity2begin SEDATIVE - HYPNOTICS entity2end ( INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS ( INCLUDING ALCOHOL ) . 
false chemical chemical Interaction with Other entity1begin Central Nervous System Depressants entity1end : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE - HYPNOTICS ( INCLUDING entity2begin BARBITURATES entity2end ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS ( INCLUDING ALCOHOL ) . 
false chemical chemical Interaction with Other entity1begin Central Nervous System Depressants entity1end : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE - HYPNOTICS ( INCLUDING BARBITURATES ) , entity2begin TRICYCLIC ANTIDEPRESSANTS entity2end AND OTHER CNS DEPRESSANTS ( INCLUDING ALCOHOL ) . 
false chemical chemical Interaction with Other entity1begin Central Nervous System Depressants entity1end : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE - HYPNOTICS ( INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER entity2begin CNS DEPRESSANTS entity2end ( INCLUDING ALCOHOL ) . 
false chemical chemical Interaction with Other entity1begin Central Nervous System Depressants entity1end : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE - HYPNOTICS ( INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS ( INCLUDING entity2begin ALCOHOL entity2end ) . 
true chemical chemical Interaction with Other Central Nervous System Depressants : entity1begin MEPERIDINE entity1end SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER entity2begin NARCOTIC ANALGESICS entity2end , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE - HYPNOTICS ( INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS ( INCLUDING ALCOHOL ) . 
true chemical chemical Interaction with Other Central Nervous System Depressants : entity1begin MEPERIDINE entity1end SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL entity2begin ANESTHETICS entity2end , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE - HYPNOTICS ( INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS ( INCLUDING ALCOHOL ) . 
true chemical chemical Interaction with Other Central Nervous System Depressants : entity1begin MEPERIDINE entity1end SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , entity2begin PHENOTHIAZINES entity2end , OTHER TRANQUILIZERS , SEDATIVE - HYPNOTICS ( INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS ( INCLUDING ALCOHOL ) . 
true chemical chemical Interaction with Other Central Nervous System Depressants : entity1begin MEPERIDINE entity1end SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER entity2begin TRANQUILIZERS entity2end , SEDATIVE - HYPNOTICS ( INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS ( INCLUDING ALCOHOL ) . 
true chemical chemical Interaction with Other Central Nervous System Depressants : entity1begin MEPERIDINE entity1end SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , entity2begin SEDATIVE - HYPNOTICS entity2end ( INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS ( INCLUDING ALCOHOL ) . 
true chemical chemical Interaction with Other Central Nervous System Depressants : entity1begin MEPERIDINE entity1end SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE - HYPNOTICS ( INCLUDING entity2begin BARBITURATES entity2end ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS ( INCLUDING ALCOHOL ) . 
true chemical chemical Interaction with Other Central Nervous System Depressants : entity1begin MEPERIDINE entity1end SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE - HYPNOTICS ( INCLUDING BARBITURATES ) , entity2begin TRICYCLIC ANTIDEPRESSANTS entity2end AND OTHER CNS DEPRESSANTS ( INCLUDING ALCOHOL ) . 
true chemical chemical Interaction with Other Central Nervous System Depressants : entity1begin MEPERIDINE entity1end SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE - HYPNOTICS ( INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER entity2begin CNS DEPRESSANTS entity2end ( INCLUDING ALCOHOL ) . 
true chemical chemical Interaction with Other Central Nervous System Depressants : entity1begin MEPERIDINE entity1end SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE - HYPNOTICS ( INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS ( INCLUDING entity2begin ALCOHOL entity2end ) . 
false chemical chemical Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER entity1begin NARCOTIC ANALGESICS entity1end , GENERAL entity2begin ANESTHETICS entity2end , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE - HYPNOTICS ( INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS ( INCLUDING ALCOHOL ) . 
false chemical chemical Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER entity1begin NARCOTIC ANALGESICS entity1end , GENERAL ANESTHETICS , entity2begin PHENOTHIAZINES entity2end , OTHER TRANQUILIZERS , SEDATIVE - HYPNOTICS ( INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS ( INCLUDING ALCOHOL ) . 
false chemical chemical Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER entity1begin NARCOTIC ANALGESICS entity1end , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER entity2begin TRANQUILIZERS entity2end , SEDATIVE - HYPNOTICS ( INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS ( INCLUDING ALCOHOL ) . 
false chemical chemical Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER entity1begin NARCOTIC ANALGESICS entity1end , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , entity2begin SEDATIVE - HYPNOTICS entity2end ( INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS ( INCLUDING ALCOHOL ) . 
false chemical chemical Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER entity1begin NARCOTIC ANALGESICS entity1end , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE - HYPNOTICS ( INCLUDING entity2begin BARBITURATES entity2end ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS ( INCLUDING ALCOHOL ) . 
false chemical chemical Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER entity1begin NARCOTIC ANALGESICS entity1end , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE - HYPNOTICS ( INCLUDING BARBITURATES ) , entity2begin TRICYCLIC ANTIDEPRESSANTS entity2end AND OTHER CNS DEPRESSANTS ( INCLUDING ALCOHOL ) . 
false chemical chemical Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER entity1begin NARCOTIC ANALGESICS entity1end , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE - HYPNOTICS ( INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER entity2begin CNS DEPRESSANTS entity2end ( INCLUDING ALCOHOL ) . 
false chemical chemical Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER entity1begin NARCOTIC ANALGESICS entity1end , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE - HYPNOTICS ( INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS ( INCLUDING entity2begin ALCOHOL entity2end ) . 
false chemical chemical Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL entity1begin ANESTHETICS entity1end , entity2begin PHENOTHIAZINES entity2end , OTHER TRANQUILIZERS , SEDATIVE - HYPNOTICS ( INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS ( INCLUDING ALCOHOL ) . 
false chemical chemical Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL entity1begin ANESTHETICS entity1end , PHENOTHIAZINES , OTHER entity2begin TRANQUILIZERS entity2end , SEDATIVE - HYPNOTICS ( INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS ( INCLUDING ALCOHOL ) . 
false chemical chemical Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL entity1begin ANESTHETICS entity1end , PHENOTHIAZINES , OTHER TRANQUILIZERS , entity2begin SEDATIVE - HYPNOTICS entity2end ( INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS ( INCLUDING ALCOHOL ) . 
false chemical chemical Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL entity1begin ANESTHETICS entity1end , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE - HYPNOTICS ( INCLUDING entity2begin BARBITURATES entity2end ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS ( INCLUDING ALCOHOL ) . 
false chemical chemical Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL entity1begin ANESTHETICS entity1end , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE - HYPNOTICS ( INCLUDING BARBITURATES ) , entity2begin TRICYCLIC ANTIDEPRESSANTS entity2end AND OTHER CNS DEPRESSANTS ( INCLUDING ALCOHOL ) . 
false chemical chemical Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL entity1begin ANESTHETICS entity1end , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE - HYPNOTICS ( INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER entity2begin CNS DEPRESSANTS entity2end ( INCLUDING ALCOHOL ) . 
false chemical chemical Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL entity1begin ANESTHETICS entity1end , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE - HYPNOTICS ( INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS ( INCLUDING entity2begin ALCOHOL entity2end ) . 
false chemical chemical Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , entity1begin PHENOTHIAZINES entity1end , OTHER entity2begin TRANQUILIZERS entity2end , SEDATIVE - HYPNOTICS ( INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS ( INCLUDING ALCOHOL ) . 
false chemical chemical Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , entity1begin PHENOTHIAZINES entity1end , OTHER TRANQUILIZERS , entity2begin SEDATIVE - HYPNOTICS entity2end ( INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS ( INCLUDING ALCOHOL ) . 
false chemical chemical Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , entity1begin PHENOTHIAZINES entity1end , OTHER TRANQUILIZERS , SEDATIVE - HYPNOTICS ( INCLUDING entity2begin BARBITURATES entity2end ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS ( INCLUDING ALCOHOL ) . 
false chemical chemical Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , entity1begin PHENOTHIAZINES entity1end , OTHER TRANQUILIZERS , SEDATIVE - HYPNOTICS ( INCLUDING BARBITURATES ) , entity2begin TRICYCLIC ANTIDEPRESSANTS entity2end AND OTHER CNS DEPRESSANTS ( INCLUDING ALCOHOL ) . 
false chemical chemical Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , entity1begin PHENOTHIAZINES entity1end , OTHER TRANQUILIZERS , SEDATIVE - HYPNOTICS ( INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER entity2begin CNS DEPRESSANTS entity2end ( INCLUDING ALCOHOL ) . 
false chemical chemical Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , entity1begin PHENOTHIAZINES entity1end , OTHER TRANQUILIZERS , SEDATIVE - HYPNOTICS ( INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS ( INCLUDING entity2begin ALCOHOL entity2end ) . 
false chemical chemical Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER entity1begin TRANQUILIZERS entity1end , entity2begin SEDATIVE - HYPNOTICS entity2end ( INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS ( INCLUDING ALCOHOL ) . 
false chemical chemical Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER entity1begin TRANQUILIZERS entity1end , SEDATIVE - HYPNOTICS ( INCLUDING entity2begin BARBITURATES entity2end ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS ( INCLUDING ALCOHOL ) . 
false chemical chemical Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER entity1begin TRANQUILIZERS entity1end , SEDATIVE - HYPNOTICS ( INCLUDING BARBITURATES ) , entity2begin TRICYCLIC ANTIDEPRESSANTS entity2end AND OTHER CNS DEPRESSANTS ( INCLUDING ALCOHOL ) . 
false chemical chemical Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER entity1begin TRANQUILIZERS entity1end , SEDATIVE - HYPNOTICS ( INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER entity2begin CNS DEPRESSANTS entity2end ( INCLUDING ALCOHOL ) . 
false chemical chemical Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER entity1begin TRANQUILIZERS entity1end , SEDATIVE - HYPNOTICS ( INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS ( INCLUDING entity2begin ALCOHOL entity2end ) . 
false chemical chemical Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , entity1begin SEDATIVE - HYPNOTICS entity1end ( INCLUDING entity2begin BARBITURATES entity2end ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS ( INCLUDING ALCOHOL ) . 
false chemical chemical Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , entity1begin SEDATIVE - HYPNOTICS entity1end ( INCLUDING BARBITURATES ) , entity2begin TRICYCLIC ANTIDEPRESSANTS entity2end AND OTHER CNS DEPRESSANTS ( INCLUDING ALCOHOL ) . 
false chemical chemical Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , entity1begin SEDATIVE - HYPNOTICS entity1end ( INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER entity2begin CNS DEPRESSANTS entity2end ( INCLUDING ALCOHOL ) . 
false chemical chemical Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , entity1begin SEDATIVE - HYPNOTICS entity1end ( INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS ( INCLUDING entity2begin ALCOHOL entity2end ) . 
false chemical chemical Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE - HYPNOTICS ( INCLUDING entity1begin BARBITURATES entity1end ) , entity2begin TRICYCLIC ANTIDEPRESSANTS entity2end AND OTHER CNS DEPRESSANTS ( INCLUDING ALCOHOL ) . 
false chemical chemical Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE - HYPNOTICS ( INCLUDING entity1begin BARBITURATES entity1end ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER entity2begin CNS DEPRESSANTS entity2end ( INCLUDING ALCOHOL ) . 
false chemical chemical Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE - HYPNOTICS ( INCLUDING entity1begin BARBITURATES entity1end ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS ( INCLUDING entity2begin ALCOHOL entity2end ) . 
false chemical chemical Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE - HYPNOTICS ( INCLUDING BARBITURATES ) , entity1begin TRICYCLIC ANTIDEPRESSANTS entity1end AND OTHER entity2begin CNS DEPRESSANTS entity2end ( INCLUDING ALCOHOL ) . 
false chemical chemical Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE - HYPNOTICS ( INCLUDING BARBITURATES ) , entity1begin TRICYCLIC ANTIDEPRESSANTS entity1end AND OTHER CNS DEPRESSANTS ( INCLUDING entity2begin ALCOHOL entity2end ) . 
false chemical chemical Interaction with Other Central Nervous System Depressants : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS , GENERAL ANESTHETICS , PHENOTHIAZINES , OTHER TRANQUILIZERS , SEDATIVE - HYPNOTICS ( INCLUDING BARBITURATES ) , TRICYCLIC ANTIDEPRESSANTS AND OTHER entity1begin CNS DEPRESSANTS entity1end ( INCLUDING entity2begin ALCOHOL entity2end ) . 
true chemical chemical Some entity1begin anticonvulsants entity1end may interact with entity2begin Mephenytoin entity2end . 
false chemical chemical Those entity1begin anticonvulsants entity1end include entity2begin divalproex sodium entity2end , valproic acid , and phenobarbital . 
false chemical chemical Those entity1begin anticonvulsants entity1end include divalproex sodium , entity2begin valproic acid entity2end , and phenobarbital . 
false chemical chemical Those entity1begin anticonvulsants entity1end include divalproex sodium , valproic acid , and entity2begin phenobarbital entity2end . 
false chemical chemical Those anticonvulsants include entity1begin divalproex sodium entity1end , entity2begin valproic acid entity2end , and phenobarbital . 
false chemical chemical Those anticonvulsants include entity1begin divalproex sodium entity1end , valproic acid , and entity2begin phenobarbital entity2end . 
false chemical chemical Those anticonvulsants include divalproex sodium , entity1begin valproic acid entity1end , and entity2begin phenobarbital entity2end . 
true chemical chemical entity1begin Mephenytoin entity1end may also affect the effects of other drugs , which include some entity2begin steroid medications entity2end , warfarin , certain heart medicines , birth control pills , anti - infective medicines , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here . 
true chemical chemical entity1begin Mephenytoin entity1end may also affect the effects of other drugs , which include some steroid medications , entity2begin warfarin entity2end , certain heart medicines , birth control pills , anti - infective medicines , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here . 
true chemical chemical entity1begin Mephenytoin entity1end may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , entity2begin anti - infective medicines entity2end , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here . 
true chemical chemical entity1begin Mephenytoin entity1end may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti - infective medicines , entity2begin furosemide entity2end and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here . 
true chemical chemical entity1begin Mephenytoin entity1end may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti - infective medicines , furosemide and entity2begin theophylline entity2end Please note that Mephenytoin may interact with other drugs that are not listed here . 
false chemical chemical entity1begin Mephenytoin entity1end may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti - infective medicines , furosemide and theophylline Please note that entity2begin Mephenytoin entity2end may interact with other drugs that are not listed here . 
false chemical chemical Mephenytoin may also affect the effects of other drugs , which include some entity1begin steroid medications entity1end , entity2begin warfarin entity2end , certain heart medicines , birth control pills , anti - infective medicines , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here . 
false chemical chemical Mephenytoin may also affect the effects of other drugs , which include some entity1begin steroid medications entity1end , warfarin , certain heart medicines , birth control pills , entity2begin anti - infective medicines entity2end , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here . 
false chemical chemical Mephenytoin may also affect the effects of other drugs , which include some entity1begin steroid medications entity1end , warfarin , certain heart medicines , birth control pills , anti - infective medicines , entity2begin furosemide entity2end and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here . 
false chemical chemical Mephenytoin may also affect the effects of other drugs , which include some entity1begin steroid medications entity1end , warfarin , certain heart medicines , birth control pills , anti - infective medicines , furosemide and entity2begin theophylline entity2end Please note that Mephenytoin may interact with other drugs that are not listed here . 
false chemical chemical Mephenytoin may also affect the effects of other drugs , which include some entity1begin steroid medications entity1end , warfarin , certain heart medicines , birth control pills , anti - infective medicines , furosemide and theophylline Please note that entity2begin Mephenytoin entity2end may interact with other drugs that are not listed here . 
false chemical chemical Mephenytoin may also affect the effects of other drugs , which include some steroid medications , entity1begin warfarin entity1end , certain heart medicines , birth control pills , entity2begin anti - infective medicines entity2end , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here . 
false chemical chemical Mephenytoin may also affect the effects of other drugs , which include some steroid medications , entity1begin warfarin entity1end , certain heart medicines , birth control pills , anti - infective medicines , entity2begin furosemide entity2end and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here . 
false chemical chemical Mephenytoin may also affect the effects of other drugs , which include some steroid medications , entity1begin warfarin entity1end , certain heart medicines , birth control pills , anti - infective medicines , furosemide and entity2begin theophylline entity2end Please note that Mephenytoin may interact with other drugs that are not listed here . 
false chemical chemical Mephenytoin may also affect the effects of other drugs , which include some steroid medications , entity1begin warfarin entity1end , certain heart medicines , birth control pills , anti - infective medicines , furosemide and theophylline Please note that entity2begin Mephenytoin entity2end may interact with other drugs that are not listed here . 
false chemical chemical Mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , entity1begin anti - infective medicines entity1end , entity2begin furosemide entity2end and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here . 
false chemical chemical Mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , entity1begin anti - infective medicines entity1end , furosemide and entity2begin theophylline entity2end Please note that Mephenytoin may interact with other drugs that are not listed here . 
false chemical chemical Mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , entity1begin anti - infective medicines entity1end , furosemide and theophylline Please note that entity2begin Mephenytoin entity2end may interact with other drugs that are not listed here . 
false chemical chemical Mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti - infective medicines , entity1begin furosemide entity1end and entity2begin theophylline entity2end Please note that Mephenytoin may interact with other drugs that are not listed here . 
false chemical chemical Mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti - infective medicines , entity1begin furosemide entity1end and theophylline Please note that entity2begin Mephenytoin entity2end may interact with other drugs that are not listed here . 
false chemical chemical Mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti - infective medicines , furosemide and entity1begin theophylline entity1end Please note that entity2begin Mephenytoin entity2end may interact with other drugs that are not listed here . 
true chemical chemical entity1begin Mequitazine entity1end can interact with entity2begin CNS depressant entity2end , antichlolinergic , TCA , MAOIs , and alcohol . 
true chemical chemical entity1begin Mequitazine entity1end can interact with CNS depressant , entity2begin antichlolinergic entity2end , TCA , MAOIs , and alcohol . 
true chemical chemical entity1begin Mequitazine entity1end can interact with CNS depressant , antichlolinergic , entity2begin TCA entity2end , MAOIs , and alcohol . 
true chemical chemical entity1begin Mequitazine entity1end can interact with CNS depressant , antichlolinergic , TCA , entity2begin MAOIs entity2end , and alcohol . 
true chemical chemical entity1begin Mequitazine entity1end can interact with CNS depressant , antichlolinergic , TCA , MAOIs , and entity2begin alcohol entity2end . 
false chemical chemical Mequitazine can interact with entity1begin CNS depressant entity1end , entity2begin antichlolinergic entity2end , TCA , MAOIs , and alcohol . 
false chemical chemical Mequitazine can interact with entity1begin CNS depressant entity1end , antichlolinergic , entity2begin TCA entity2end , MAOIs , and alcohol . 
false chemical chemical Mequitazine can interact with entity1begin CNS depressant entity1end , antichlolinergic , TCA , entity2begin MAOIs entity2end , and alcohol . 
false chemical chemical Mequitazine can interact with entity1begin CNS depressant entity1end , antichlolinergic , TCA , MAOIs , and entity2begin alcohol entity2end . 
false chemical chemical Mequitazine can interact with CNS depressant , entity1begin antichlolinergic entity1end , entity2begin TCA entity2end , MAOIs , and alcohol . 
false chemical chemical Mequitazine can interact with CNS depressant , entity1begin antichlolinergic entity1end , TCA , entity2begin MAOIs entity2end , and alcohol . 
false chemical chemical Mequitazine can interact with CNS depressant , entity1begin antichlolinergic entity1end , TCA , MAOIs , and entity2begin alcohol entity2end . 
false chemical chemical Mequitazine can interact with CNS depressant , antichlolinergic , entity1begin TCA entity1end , entity2begin MAOIs entity2end , and alcohol . 
false chemical chemical Mequitazine can interact with CNS depressant , antichlolinergic , entity1begin TCA entity1end , MAOIs , and entity2begin alcohol entity2end . 
false chemical chemical Mequitazine can interact with CNS depressant , antichlolinergic , TCA , entity1begin MAOIs entity1end , and entity2begin alcohol entity2end . 
true chemical chemical entity1begin Probenecid entity1end competes with entity2begin meropenem entity2end for active tubular secretion and thus inhibits the renal excretion of meropenem . 
false chemical chemical entity1begin Probenecid entity1end competes with meropenem for active tubular secretion and thus inhibits the renal excretion of entity2begin meropenem entity2end . 
false chemical chemical Probenecid competes with entity1begin meropenem entity1end for active tubular secretion and thus inhibits the renal excretion of entity2begin meropenem entity2end . 
true chemical chemical Therefore , the coadministration of entity1begin probenecid entity1end with entity2begin meropenem entity2end is not recommended . 
true chemical chemical There is evidence that entity1begin meropenem entity1end may reduce serum levels of entity2begin valproic acid entity2end to subtherapeutic levels ( therapeutic range considered to be 50 to 100 g / mL total valproate ) . 
false chemical chemical There is evidence that entity1begin meropenem entity1end may reduce serum levels of valproic acid to subtherapeutic levels ( therapeutic range considered to be 50 to 100 g / mL total entity2begin valproate entity2end ) . 
false chemical chemical There is evidence that meropenem may reduce serum levels of entity1begin valproic acid entity1end to subtherapeutic levels ( therapeutic range considered to be 50 to 100 g / mL total entity2begin valproate entity2end ) . 
false chemical chemical entity1begin ARAMINE entity1end should be used with caution in digitalized patients , since the combination of entity2begin digitalis entity2end and sympathomimetic amines may cause ectopic arrhythmias . 
false chemical chemical entity1begin ARAMINE entity1end should be used with caution in digitalized patients , since the combination of digitalis and entity2begin sympathomimetic amines entity2end may cause ectopic arrhythmias . 
true chemical chemical ARAMINE should be used with caution in digitalized patients , since the combination of entity1begin digitalis entity1end and entity2begin sympathomimetic amines entity2end may cause ectopic arrhythmias . 
false chemical chemical entity1begin Monoamine oxidase inhibitors entity1end or entity2begin tricyclic antidepressants entity2end may potentiate the action of sympathomimetic amines . 
true chemical chemical entity1begin Monoamine oxidase inhibitors entity1end or tricyclic antidepressants may potentiate the action of entity2begin sympathomimetic amines entity2end . 
true chemical chemical Monoamine oxidase inhibitors or entity1begin tricyclic antidepressants entity1end may potentiate the action of entity2begin sympathomimetic amines entity2end . 
true chemical chemical entity1begin SKELAXIN entity1end may enhance the effects of entity2begin alcohol entity2end , barbiturates and other CNS depressants . 
true chemical chemical entity1begin SKELAXIN entity1end may enhance the effects of alcohol , entity2begin barbiturates entity2end and other CNS depressants . 
true chemical chemical entity1begin SKELAXIN entity1end may enhance the effects of alcohol , barbiturates and other entity2begin CNS depressants entity2end . 
false chemical chemical SKELAXIN may enhance the effects of entity1begin alcohol entity1end , entity2begin barbiturates entity2end and other CNS depressants . 
false chemical chemical SKELAXIN may enhance the effects of entity1begin alcohol entity1end , barbiturates and other entity2begin CNS depressants entity2end . 
false chemical chemical SKELAXIN may enhance the effects of alcohol , entity1begin barbiturates entity1end and other entity2begin CNS depressants entity2end . 
true chemical chemical Caution is advised for patients receiving high - dose entity1begin aspirin entity1end and entity2begin methazolamide entity2end concomitantly , as anorexia , tachypnea , lethargy , coma and death have been reported with concomitant use of high - dose aspirin and carbonic anhydrase inhibitors . 
false chemical chemical Caution is advised for patients receiving high - dose entity1begin aspirin entity1end and methazolamide concomitantly , as anorexia , tachypnea , lethargy , coma and death have been reported with concomitant use of high - dose entity2begin aspirin entity2end and carbonic anhydrase inhibitors . 
false chemical chemical Caution is advised for patients receiving high - dose entity1begin aspirin entity1end and methazolamide concomitantly , as anorexia , tachypnea , lethargy , coma and death have been reported with concomitant use of high - dose aspirin and entity2begin carbonic anhydrase inhibitors entity2end . 
false chemical chemical Caution is advised for patients receiving high - dose aspirin and entity1begin methazolamide entity1end concomitantly , as anorexia , tachypnea , lethargy , coma and death have been reported with concomitant use of high - dose entity2begin aspirin entity2end and carbonic anhydrase inhibitors . 
false chemical chemical Caution is advised for patients receiving high - dose aspirin and entity1begin methazolamide entity1end concomitantly , as anorexia , tachypnea , lethargy , coma and death have been reported with concomitant use of high - dose aspirin and entity2begin carbonic anhydrase inhibitors entity2end . 
true chemical chemical Caution is advised for patients receiving high - dose aspirin and methazolamide concomitantly , as anorexia , tachypnea , lethargy , coma and death have been reported with concomitant use of high - dose entity1begin aspirin entity1end and entity2begin carbonic anhydrase inhibitors entity2end . 
false chemical chemical entity1begin Anticoagulants entity1end ( oral ) : The activity of oral entity2begin anticoagulants entity2end may be potentiated by anti - vitamin - K activity attributed to methimazole . 
false chemical chemical entity1begin Anticoagulants entity1end ( oral ) : The activity of oral anticoagulants may be potentiated by anti - vitamin - K activity attributed to entity2begin methimazole entity2end . 
true chemical chemical Anticoagulants ( oral ) : The activity of oral entity1begin anticoagulants entity1end may be potentiated by anti - vitamin - K activity attributed to entity2begin methimazole entity2end . 
false chemical chemical entity1begin Digitalis glycosides entity1end : Serum digitalis levels may be increased when hyperthyroid patients on a stable entity2begin digitalis glycoside entity2end regimen become euthyroid ; 
false chemical chemical entity1begin Theophylline entity1end : entity2begin Theophylline entity2end clearance may decrease when hyperthyroid patients on a stable theophylline regimen become euthyroid ; 
false chemical chemical entity1begin Theophylline entity1end : Theophylline clearance may decrease when hyperthyroid patients on a stable entity2begin theophylline entity2end regimen become euthyroid ; 
false chemical chemical Theophylline : entity1begin Theophylline entity1end clearance may decrease when hyperthyroid patients on a stable entity2begin theophylline entity2end regimen become euthyroid ; 
true chemical chemical Dosages of concomitantly administered entity1begin opioids entity1end should be reduced by approximately half , because entity2begin levomepromazine entity2end amplifies the therapeutic actions and side - effects of opioids . 
false chemical chemical Dosages of concomitantly administered entity1begin opioids entity1end should be reduced by approximately half , because levomepromazine amplifies the therapeutic actions and side - effects of entity2begin opioids entity2end . 
true chemical chemical Dosages of concomitantly administered opioids should be reduced by approximately half , because entity1begin levomepromazine entity1end amplifies the therapeutic actions and side - effects of entity2begin opioids entity2end . 
false chemical chemical Combination with entity1begin tramadol entity1end ( entity2begin Ultram entity2end ) is associated with increased risk of seizures . 
true chemical chemical Additive sedative effects and confusional states may emerge if entity1begin levomepromazine entity1end is given with entity2begin benzodiazepines entity2end or barbiturates . 
true chemical chemical Additive sedative effects and confusional states may emerge if entity1begin levomepromazine entity1end is given with benzodiazepines or entity2begin barbiturates entity2end . 
false chemical chemical Additive sedative effects and confusional states may emerge if levomepromazine is given with entity1begin benzodiazepines entity1end or entity2begin barbiturates entity2end . 
true chemical chemical Exert particular caution in combining entity1begin levomepromazine entity1end with other entity2begin anticholinergic drugs entity2end ( tricyclic antidepressants and antiparkinsonian - agents ) : Particularly the elderly may develop delirium , high fever , severe obstipation , even ileus and glaucoma . 
true chemical chemical Exert particular caution in combining entity1begin levomepromazine entity1end with other anticholinergic drugs ( entity2begin tricyclic antidepressants entity2end and antiparkinsonian - agents ) : Particularly the elderly may develop delirium , high fever , severe obstipation , even ileus and glaucoma . 
true chemical chemical Exert particular caution in combining entity1begin levomepromazine entity1end with other anticholinergic drugs ( tricyclic antidepressants and entity2begin antiparkinsonian - agents entity2end ) : Particularly the elderly may develop delirium , high fever , severe obstipation , even ileus and glaucoma . 
false chemical chemical Exert particular caution in combining levomepromazine with other entity1begin anticholinergic drugs entity1end ( entity2begin tricyclic antidepressants entity2end and antiparkinsonian - agents ) : Particularly the elderly may develop delirium , high fever , severe obstipation , even ileus and glaucoma . 
false chemical chemical Exert particular caution in combining levomepromazine with other entity1begin anticholinergic drugs entity1end ( tricyclic antidepressants and entity2begin antiparkinsonian - agents entity2end ) : Particularly the elderly may develop delirium , high fever , severe obstipation , even ileus and glaucoma . 
false chemical chemical Exert particular caution in combining levomepromazine with other anticholinergic drugs ( entity1begin tricyclic antidepressants entity1end and entity2begin antiparkinsonian - agents entity2end ) : Particularly the elderly may develop delirium , high fever , severe obstipation , even ileus and glaucoma . 
false chemical chemical entity1begin Caffeine entity1end and / or stimulantes of the entity2begin ephedrine entity2end / amphetamine type may counteract the specific actions of levomepromazine . 
false chemical chemical entity1begin Caffeine entity1end and / or stimulantes of the ephedrine / entity2begin amphetamine entity2end type may counteract the specific actions of levomepromazine . 
true chemical chemical entity1begin Caffeine entity1end and / or stimulantes of the ephedrine / amphetamine type may counteract the specific actions of entity2begin levomepromazine entity2end . 
false chemical chemical Caffeine and / or stimulantes of the entity1begin ephedrine entity1end / entity2begin amphetamine entity2end type may counteract the specific actions of levomepromazine . 
true chemical chemical Caffeine and / or stimulantes of the entity1begin ephedrine entity1end / amphetamine type may counteract the specific actions of entity2begin levomepromazine entity2end . 
true chemical chemical Caffeine and / or stimulantes of the ephedrine / entity1begin amphetamine entity1end type may counteract the specific actions of entity2begin levomepromazine entity2end . 
false chemical chemical Since entity1begin Celontin entity1end ( entity2begin methsuximide entity2end ) may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary ( eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital ) . 
true chemical chemical Since entity1begin Celontin entity1end ( methsuximide ) may interact with concurrently administered entity2begin antiepileptic drugs entity2end , periodic serum level determinations of these drugs may be necessary ( eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital ) . 
false chemical chemical Since entity1begin Celontin entity1end ( methsuximide ) may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary ( eg entity2begin methsuximide entity2end may increase the plasma concentrations of phenytoin and phenobarbital ) . 
false chemical chemical Since entity1begin Celontin entity1end ( methsuximide ) may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary ( eg methsuximide may increase the plasma concentrations of entity2begin phenytoin entity2end and phenobarbital ) . 
false chemical chemical Since entity1begin Celontin entity1end ( methsuximide ) may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary ( eg methsuximide may increase the plasma concentrations of phenytoin and entity2begin phenobarbital entity2end ) . 
true chemical chemical Since Celontin ( entity1begin methsuximide entity1end ) may interact with concurrently administered entity2begin antiepileptic drugs entity2end , periodic serum level determinations of these drugs may be necessary ( eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital ) . 
false chemical chemical Since Celontin ( entity1begin methsuximide entity1end ) may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary ( eg entity2begin methsuximide entity2end may increase the plasma concentrations of phenytoin and phenobarbital ) . 
false chemical chemical Since Celontin ( entity1begin methsuximide entity1end ) may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary ( eg methsuximide may increase the plasma concentrations of entity2begin phenytoin entity2end and phenobarbital ) . 
false chemical chemical Since Celontin ( entity1begin methsuximide entity1end ) may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary ( eg methsuximide may increase the plasma concentrations of phenytoin and entity2begin phenobarbital entity2end ) . 
false chemical chemical Since Celontin ( methsuximide ) may interact with concurrently administered entity1begin antiepileptic drugs entity1end , periodic serum level determinations of these drugs may be necessary ( eg entity2begin methsuximide entity2end may increase the plasma concentrations of phenytoin and phenobarbital ) . 
false chemical chemical Since Celontin ( methsuximide ) may interact with concurrently administered entity1begin antiepileptic drugs entity1end , periodic serum level determinations of these drugs may be necessary ( eg methsuximide may increase the plasma concentrations of entity2begin phenytoin entity2end and phenobarbital ) . 
false chemical chemical Since Celontin ( methsuximide ) may interact with concurrently administered entity1begin antiepileptic drugs entity1end , periodic serum level determinations of these drugs may be necessary ( eg methsuximide may increase the plasma concentrations of phenytoin and entity2begin phenobarbital entity2end ) . 
true chemical chemical Since Celontin ( methsuximide ) may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary ( eg entity1begin methsuximide entity1end may increase the plasma concentrations of entity2begin phenytoin entity2end and phenobarbital ) . 
true chemical chemical Since Celontin ( methsuximide ) may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary ( eg entity1begin methsuximide entity1end may increase the plasma concentrations of phenytoin and entity2begin phenobarbital entity2end ) . 
false chemical chemical Since Celontin ( methsuximide ) may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary ( eg methsuximide may increase the plasma concentrations of entity1begin phenytoin entity1end and entity2begin phenobarbital entity2end ) . 
false chemical chemical Hypokalemia may develop during concomitant use of entity1begin steroids entity1end or entity2begin ACTH entity2end . 
true chemical chemical entity1begin Thiazides entity1end may decrease arterial responsiveness to entity2begin norepinephrine entity2end . 
true chemical chemical entity1begin Thiazide drugs entity1end may increase the responsiveness of entity2begin tubocurarine entity2end . 
true chemical chemical entity1begin Lithium entity1end renal clearance is reduced by entity2begin thiazides entity2end , increasing the risk of lithium toxicity . 
false chemical chemical entity1begin Lithium entity1end renal clearance is reduced by thiazides , increasing the risk of entity2begin lithium entity2end toxicity . 
false chemical chemical Lithium renal clearance is reduced by entity1begin thiazides entity1end , increasing the risk of entity2begin lithium entity2end toxicity . 
true chemical chemical entity1begin Thiazides entity1end may add to or potentiate the action of other entity2begin antihypertensive drugs entity2end . 
true chemical chemical When entity1begin methyldopa entity1end is used with other entity2begin antihypertensive drugs entity2end , potentiation of antihypertensive effect may occur . 
true chemical chemical Patients may require reduced doses of entity1begin anesthetics entity1end when on entity2begin methyldopa entity2end . 
true chemical chemical When entity1begin methyldopa entity1end and entity2begin lithium entity2end are given concomitantly the patient should be carefully monitored for symptoms of lithium toxicity . 
false chemical chemical When entity1begin methyldopa entity1end and lithium are given concomitantly the patient should be carefully monitored for symptoms of entity2begin lithium entity2end toxicity . 
false chemical chemical When methyldopa and entity1begin lithium entity1end are given concomitantly the patient should be carefully monitored for symptoms of entity2begin lithium entity2end toxicity . 
true chemical chemical Several studies demonstrate a decrease in the bioavailability of entity1begin methyldopa entity1end when it is ingested with entity2begin ferrous sulfate entity2end or ferrous gluconate . 
true chemical chemical Several studies demonstrate a decrease in the bioavailability of entity1begin methyldopa entity1end when it is ingested with ferrous sulfate or entity2begin ferrous gluconate entity2end . 
false chemical chemical Several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with entity1begin ferrous sulfate entity1end or entity2begin ferrous gluconate entity2end . 
true chemical chemical Coadministration of entity1begin methyldopa entity1end with entity2begin ferrous sulfate entity2end or ferrous gluconate is not recommended . 
true chemical chemical Coadministration of entity1begin methyldopa entity1end with ferrous sulfate or entity2begin ferrous gluconate entity2end is not recommended . 
false chemical chemical Coadministration of methyldopa with entity1begin ferrous sulfate entity1end or entity2begin ferrous gluconate entity2end is not recommended . 
false chemical chemical entity1begin Methyldopa entity1end does not interfere with measurement of entity2begin VMA entity2end ( vanillylmandelic acid ) , a test for pheochromocytoma , by those methods which convert VMA to vanillin . 
false chemical chemical entity1begin Methyldopa entity1end does not interfere with measurement of VMA ( entity2begin vanillylmandelic acid entity2end ) , a test for pheochromocytoma , by those methods which convert VMA to vanillin . 
false chemical chemical entity1begin Methyldopa entity1end does not interfere with measurement of VMA ( vanillylmandelic acid ) , a test for pheochromocytoma , by those methods which convert entity2begin VMA entity2end to vanillin . 
false chemical chemical entity1begin Methyldopa entity1end does not interfere with measurement of VMA ( vanillylmandelic acid ) , a test for pheochromocytoma , by those methods which convert VMA to entity2begin vanillin entity2end . 
false chemical chemical Methyldopa does not interfere with measurement of entity1begin VMA entity1end ( entity2begin vanillylmandelic acid entity2end ) , a test for pheochromocytoma , by those methods which convert VMA to vanillin . 
false chemical chemical Methyldopa does not interfere with measurement of entity1begin VMA entity1end ( vanillylmandelic acid ) , a test for pheochromocytoma , by those methods which convert entity2begin VMA entity2end to vanillin . 
false chemical chemical Methyldopa does not interfere with measurement of entity1begin VMA entity1end ( vanillylmandelic acid ) , a test for pheochromocytoma , by those methods which convert VMA to entity2begin vanillin entity2end . 
false chemical chemical Methyldopa does not interfere with measurement of VMA ( entity1begin vanillylmandelic acid entity1end ) , a test for pheochromocytoma , by those methods which convert entity2begin VMA entity2end to vanillin . 
false chemical chemical Methyldopa does not interfere with measurement of VMA ( entity1begin vanillylmandelic acid entity1end ) , a test for pheochromocytoma , by those methods which convert VMA to entity2begin vanillin entity2end . 
false chemical chemical Methyldopa does not interfere with measurement of VMA ( vanillylmandelic acid ) , a test for pheochromocytoma , by those methods which convert entity1begin VMA entity1end to entity2begin vanillin entity2end . 
false chemical chemical CYP 3A4 Inhibitors ( e.g. entity1begin Macrolide Antibiotics entity1end and entity2begin Protease Inhibitors entity2end ) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs ( e.g. dihydroergotamine and ergotamine ) and potent CYP 3A4 inhibitors , resulting in vasospasm leading to cerebral ischemia and / or ischemia of the extremities . 
false chemical chemical CYP 3A4 Inhibitors ( e.g. entity1begin Macrolide Antibiotics entity1end and Protease Inhibitors ) There have been rare reports of serious adverse events in connection with the coadministration of certain entity2begin ergot alkaloid drugs entity2end ( e.g. dihydroergotamine and ergotamine ) and potent CYP 3A4 inhibitors , resulting in vasospasm leading to cerebral ischemia and / or ischemia of the extremities . 
false chemical chemical CYP 3A4 Inhibitors ( e.g. entity1begin Macrolide Antibiotics entity1end and Protease Inhibitors ) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs ( e.g. entity2begin dihydroergotamine entity2end and ergotamine ) and potent CYP 3A4 inhibitors , resulting in vasospasm leading to cerebral ischemia and / or ischemia of the extremities . 
false chemical chemical CYP 3A4 Inhibitors ( e.g. entity1begin Macrolide Antibiotics entity1end and Protease Inhibitors ) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs ( e.g. dihydroergotamine and entity2begin ergotamine entity2end ) and potent CYP 3A4 inhibitors , resulting in vasospasm leading to cerebral ischemia and / or ischemia of the extremities . 
false chemical chemical CYP 3A4 Inhibitors ( e.g. Macrolide Antibiotics and entity1begin Protease Inhibitors entity1end ) There have been rare reports of serious adverse events in connection with the coadministration of certain entity2begin ergot alkaloid drugs entity2end ( e.g. dihydroergotamine and ergotamine ) and potent CYP 3A4 inhibitors , resulting in vasospasm leading to cerebral ischemia and / or ischemia of the extremities . 
false chemical chemical CYP 3A4 Inhibitors ( e.g. Macrolide Antibiotics and entity1begin Protease Inhibitors entity1end ) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs ( e.g. entity2begin dihydroergotamine entity2end and ergotamine ) and potent CYP 3A4 inhibitors , resulting in vasospasm leading to cerebral ischemia and / or ischemia of the extremities . 
false chemical chemical CYP 3A4 Inhibitors ( e.g. Macrolide Antibiotics and entity1begin Protease Inhibitors entity1end ) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs ( e.g. dihydroergotamine and entity2begin ergotamine entity2end ) and potent CYP 3A4 inhibitors , resulting in vasospasm leading to cerebral ischemia and / or ischemia of the extremities . 
false chemical chemical CYP 3A4 Inhibitors ( e.g. Macrolide Antibiotics and Protease Inhibitors ) There have been rare reports of serious adverse events in connection with the coadministration of certain entity1begin ergot alkaloid drugs entity1end ( e.g. entity2begin dihydroergotamine entity2end and ergotamine ) and potent CYP 3A4 inhibitors , resulting in vasospasm leading to cerebral ischemia and / or ischemia of the extremities . 
false chemical chemical CYP 3A4 Inhibitors ( e.g. Macrolide Antibiotics and Protease Inhibitors ) There have been rare reports of serious adverse events in connection with the coadministration of certain entity1begin ergot alkaloid drugs entity1end ( e.g. dihydroergotamine and entity2begin ergotamine entity2end ) and potent CYP 3A4 inhibitors , resulting in vasospasm leading to cerebral ischemia and / or ischemia of the extremities . 
false chemical chemical CYP 3A4 Inhibitors ( e.g. Macrolide Antibiotics and Protease Inhibitors ) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs ( e.g. entity1begin dihydroergotamine entity1end and entity2begin ergotamine entity2end ) and potent CYP 3A4 inhibitors , resulting in vasospasm leading to cerebral ischemia and / or ischemia of the extremities . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include entity1begin macrolide antibiotics entity1end ( e.g. , entity2begin erythromycin entity2end , troleandomycin , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include entity1begin macrolide antibiotics entity1end ( e.g. , erythromycin , entity2begin troleandomycin entity2end , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include entity1begin macrolide antibiotics entity1end ( e.g. , erythromycin , troleandomycin , entity2begin clarithromycin entity2end ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include entity1begin macrolide antibiotics entity1end ( e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease or entity2begin reverse transcriptase inhibitors entity2end ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include entity1begin macrolide antibiotics entity1end ( e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , entity2begin ritonavir entity2end , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include entity1begin macrolide antibiotics entity1end ( e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , entity2begin indinavir entity2end , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include entity1begin macrolide antibiotics entity1end ( e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , entity2begin nelfinavir entity2end , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include entity1begin macrolide antibiotics entity1end ( e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , entity2begin delavirdine entity2end ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include entity1begin macrolide antibiotics entity1end ( e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or entity2begin azole antifungals entity2end ( e.g. , ketoconazole , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include entity1begin macrolide antibiotics entity1end ( e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , entity2begin ketoconazole entity2end , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include entity1begin macrolide antibiotics entity1end ( e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , entity2begin itraconazole entity2end , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include entity1begin macrolide antibiotics entity1end ( e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , entity2begin voriconazole entity2end ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , entity1begin erythromycin entity1end , entity2begin troleandomycin entity2end , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , entity1begin erythromycin entity1end , troleandomycin , entity2begin clarithromycin entity2end ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , entity1begin erythromycin entity1end , troleandomycin , clarithromycin ) , HIV protease or entity2begin reverse transcriptase inhibitors entity2end ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , entity1begin erythromycin entity1end , troleandomycin , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , entity2begin ritonavir entity2end , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , entity1begin erythromycin entity1end , troleandomycin , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , entity2begin indinavir entity2end , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , entity1begin erythromycin entity1end , troleandomycin , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , entity2begin nelfinavir entity2end , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , entity1begin erythromycin entity1end , troleandomycin , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , entity2begin delavirdine entity2end ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , entity1begin erythromycin entity1end , troleandomycin , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or entity2begin azole antifungals entity2end ( e.g. , ketoconazole , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , entity1begin erythromycin entity1end , troleandomycin , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , entity2begin ketoconazole entity2end , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , entity1begin erythromycin entity1end , troleandomycin , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , entity2begin itraconazole entity2end , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , entity1begin erythromycin entity1end , troleandomycin , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , entity2begin voriconazole entity2end ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , entity1begin troleandomycin entity1end , entity2begin clarithromycin entity2end ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , entity1begin troleandomycin entity1end , clarithromycin ) , HIV protease or entity2begin reverse transcriptase inhibitors entity2end ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , entity1begin troleandomycin entity1end , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , entity2begin ritonavir entity2end , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , entity1begin troleandomycin entity1end , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , entity2begin indinavir entity2end , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , entity1begin troleandomycin entity1end , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , entity2begin nelfinavir entity2end , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , entity1begin troleandomycin entity1end , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , entity2begin delavirdine entity2end ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , entity1begin troleandomycin entity1end , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or entity2begin azole antifungals entity2end ( e.g. , ketoconazole , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , entity1begin troleandomycin entity1end , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , entity2begin ketoconazole entity2end , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , entity1begin troleandomycin entity1end , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , entity2begin itraconazole entity2end , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , entity1begin troleandomycin entity1end , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , entity2begin voriconazole entity2end ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , entity1begin clarithromycin entity1end ) , HIV protease or entity2begin reverse transcriptase inhibitors entity2end ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , entity1begin clarithromycin entity1end ) , HIV protease or reverse transcriptase inhibitors ( e.g. , entity2begin ritonavir entity2end , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , entity1begin clarithromycin entity1end ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , entity2begin indinavir entity2end , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , entity1begin clarithromycin entity1end ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , entity2begin nelfinavir entity2end , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , entity1begin clarithromycin entity1end ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , entity2begin delavirdine entity2end ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , entity1begin clarithromycin entity1end ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or entity2begin azole antifungals entity2end ( e.g. , ketoconazole , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , entity1begin clarithromycin entity1end ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , entity2begin ketoconazole entity2end , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , entity1begin clarithromycin entity1end ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , entity2begin itraconazole entity2end , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , entity1begin clarithromycin entity1end ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , entity2begin voriconazole entity2end ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease or entity1begin reverse transcriptase inhibitors entity1end ( e.g. , entity2begin ritonavir entity2end , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease or entity1begin reverse transcriptase inhibitors entity1end ( e.g. , ritonavir , entity2begin indinavir entity2end , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease or entity1begin reverse transcriptase inhibitors entity1end ( e.g. , ritonavir , indinavir , entity2begin nelfinavir entity2end , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease or entity1begin reverse transcriptase inhibitors entity1end ( e.g. , ritonavir , indinavir , nelfinavir , entity2begin delavirdine entity2end ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease or entity1begin reverse transcriptase inhibitors entity1end ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or entity2begin azole antifungals entity2end ( e.g. , ketoconazole , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease or entity1begin reverse transcriptase inhibitors entity1end ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , entity2begin ketoconazole entity2end , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease or entity1begin reverse transcriptase inhibitors entity1end ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , entity2begin itraconazole entity2end , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease or entity1begin reverse transcriptase inhibitors entity1end ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , entity2begin voriconazole entity2end ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , entity1begin ritonavir entity1end , entity2begin indinavir entity2end , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , entity1begin ritonavir entity1end , indinavir , entity2begin nelfinavir entity2end , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , entity1begin ritonavir entity1end , indinavir , nelfinavir , entity2begin delavirdine entity2end ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , entity1begin ritonavir entity1end , indinavir , nelfinavir , delavirdine ) or entity2begin azole antifungals entity2end ( e.g. , ketoconazole , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , entity1begin ritonavir entity1end , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , entity2begin ketoconazole entity2end , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , entity1begin ritonavir entity1end , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , entity2begin itraconazole entity2end , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , entity1begin ritonavir entity1end , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , entity2begin voriconazole entity2end ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , entity1begin indinavir entity1end , entity2begin nelfinavir entity2end , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , entity1begin indinavir entity1end , nelfinavir , entity2begin delavirdine entity2end ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , entity1begin indinavir entity1end , nelfinavir , delavirdine ) or entity2begin azole antifungals entity2end ( e.g. , ketoconazole , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , entity1begin indinavir entity1end , nelfinavir , delavirdine ) or azole antifungals ( e.g. , entity2begin ketoconazole entity2end , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , entity1begin indinavir entity1end , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , entity2begin itraconazole entity2end , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , entity1begin indinavir entity1end , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , entity2begin voriconazole entity2end ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , entity1begin nelfinavir entity1end , entity2begin delavirdine entity2end ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , entity1begin nelfinavir entity1end , delavirdine ) or entity2begin azole antifungals entity2end ( e.g. , ketoconazole , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , entity1begin nelfinavir entity1end , delavirdine ) or azole antifungals ( e.g. , entity2begin ketoconazole entity2end , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , entity1begin nelfinavir entity1end , delavirdine ) or azole antifungals ( e.g. , ketoconazole , entity2begin itraconazole entity2end , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , entity1begin nelfinavir entity1end , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , entity2begin voriconazole entity2end ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , entity1begin delavirdine entity1end ) or entity2begin azole antifungals entity2end ( e.g. , ketoconazole , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , entity1begin delavirdine entity1end ) or azole antifungals ( e.g. , entity2begin ketoconazole entity2end , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , entity1begin delavirdine entity1end ) or azole antifungals ( e.g. , ketoconazole , entity2begin itraconazole entity2end , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , entity1begin delavirdine entity1end ) or azole antifungals ( e.g. , ketoconazole , itraconazole , entity2begin voriconazole entity2end ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or entity1begin azole antifungals entity1end ( e.g. , entity2begin ketoconazole entity2end , itraconazole , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or entity1begin azole antifungals entity1end ( e.g. , ketoconazole , entity2begin itraconazole entity2end , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or entity1begin azole antifungals entity1end ( e.g. , ketoconazole , itraconazole , entity2begin voriconazole entity2end ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , entity1begin ketoconazole entity1end , entity2begin itraconazole entity2end , voriconazole ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , entity1begin ketoconazole entity1end , itraconazole , entity2begin voriconazole entity2end ) . 
false chemical chemical Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , HIV protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , entity1begin itraconazole entity1end , entity2begin voriconazole entity2end ) . 
false chemical chemical Less potent inhibitors include entity1begin saquinavir entity1end , entity2begin nefazodone entity2end , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole . 
false chemical chemical Less potent inhibitors include entity1begin saquinavir entity1end , nefazodone , entity2begin fluconazole entity2end , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole . 
false chemical chemical Less potent inhibitors include entity1begin saquinavir entity1end , nefazodone , fluconazole , grapefruit juice , entity2begin fluoxetine entity2end , fluvoxamine , zileuton , and clotrimazole . 
false chemical chemical Less potent inhibitors include entity1begin saquinavir entity1end , nefazodone , fluconazole , grapefruit juice , fluoxetine , entity2begin fluvoxamine entity2end , zileuton , and clotrimazole . 
false chemical chemical Less potent inhibitors include entity1begin saquinavir entity1end , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , entity2begin zileuton entity2end , and clotrimazole . 
false chemical chemical Less potent inhibitors include entity1begin saquinavir entity1end , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and entity2begin clotrimazole entity2end . 
false chemical chemical Less potent inhibitors include saquinavir , entity1begin nefazodone entity1end , entity2begin fluconazole entity2end , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole . 
false chemical chemical Less potent inhibitors include saquinavir , entity1begin nefazodone entity1end , fluconazole , grapefruit juice , entity2begin fluoxetine entity2end , fluvoxamine , zileuton , and clotrimazole . 
false chemical chemical Less potent inhibitors include saquinavir , entity1begin nefazodone entity1end , fluconazole , grapefruit juice , fluoxetine , entity2begin fluvoxamine entity2end , zileuton , and clotrimazole . 
false chemical chemical Less potent inhibitors include saquinavir , entity1begin nefazodone entity1end , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , entity2begin zileuton entity2end , and clotrimazole . 
false chemical chemical Less potent inhibitors include saquinavir , entity1begin nefazodone entity1end , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and entity2begin clotrimazole entity2end . 
false chemical chemical Less potent inhibitors include saquinavir , nefazodone , entity1begin fluconazole entity1end , grapefruit juice , entity2begin fluoxetine entity2end , fluvoxamine , zileuton , and clotrimazole . 
false chemical chemical Less potent inhibitors include saquinavir , nefazodone , entity1begin fluconazole entity1end , grapefruit juice , fluoxetine , entity2begin fluvoxamine entity2end , zileuton , and clotrimazole . 
false chemical chemical Less potent inhibitors include saquinavir , nefazodone , entity1begin fluconazole entity1end , grapefruit juice , fluoxetine , fluvoxamine , entity2begin zileuton entity2end , and clotrimazole . 
false chemical chemical Less potent inhibitors include saquinavir , nefazodone , entity1begin fluconazole entity1end , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and entity2begin clotrimazole entity2end . 
false chemical chemical Less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , entity1begin fluoxetine entity1end , entity2begin fluvoxamine entity2end , zileuton , and clotrimazole . 
false chemical chemical Less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , entity1begin fluoxetine entity1end , fluvoxamine , entity2begin zileuton entity2end , and clotrimazole . 
false chemical chemical Less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , entity1begin fluoxetine entity1end , fluvoxamine , zileuton , and entity2begin clotrimazole entity2end . 
false chemical chemical Less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , entity1begin fluvoxamine entity1end , entity2begin zileuton entity2end , and clotrimazole . 
false chemical chemical Less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , entity1begin fluvoxamine entity1end , zileuton , and entity2begin clotrimazole entity2end . 
false chemical chemical Less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , entity1begin zileuton entity1end , and entity2begin clotrimazole entity2end . 
false chemical chemical Caution should be exercised when entity1begin Methergine entity1end ( entity2begin methylergonovine maleate entity2end ) is used concurrently with other vasoconstrictors or ergot alkaloids . 
true chemical chemical Caution should be exercised when entity1begin Methergine entity1end ( methylergonovine maleate ) is used concurrently with other entity2begin vasoconstrictors entity2end or ergot alkaloids . 
true chemical chemical Caution should be exercised when entity1begin Methergine entity1end ( methylergonovine maleate ) is used concurrently with other vasoconstrictors or entity2begin ergot alkaloids entity2end . 
true chemical chemical Caution should be exercised when Methergine ( entity1begin methylergonovine maleate entity1end ) is used concurrently with other entity2begin vasoconstrictors entity2end or ergot alkaloids . 
false chemical chemical Caution should be exercised when Methergine ( entity1begin methylergonovine maleate entity1end ) is used concurrently with other vasoconstrictors or entity2begin ergot alkaloids entity2end . 
false chemical chemical Caution should be exercised when Methergine ( methylergonovine maleate ) is used concurrently with other entity1begin vasoconstrictors entity1end or entity2begin ergot alkaloids entity2end . 
true chemical chemical entity1begin Ritalin entity1end may decrease the hypotensive effect of entity2begin guanethidine entity2end . 
true chemical chemical Human pharmacologic studies have shown that entity1begin Ritalin entity1end may inhibit the metabolism of entity2begin coumarin anticoagulants entity2end , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) . 
true chemical chemical Human pharmacologic studies have shown that entity1begin Ritalin entity1end may inhibit the metabolism of coumarin anticoagulants , entity2begin anticonvulsants entity2end ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) . 
true chemical chemical Human pharmacologic studies have shown that entity1begin Ritalin entity1end may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( entity2begin phenobarbital entity2end , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) . 
true chemical chemical Human pharmacologic studies have shown that entity1begin Ritalin entity1end may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , entity2begin diphenylhydantoin entity2end , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) . 
true chemical chemical Human pharmacologic studies have shown that entity1begin Ritalin entity1end may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , entity2begin primidone entity2end ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) . 
true chemical chemical Human pharmacologic studies have shown that entity1begin Ritalin entity1end may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , entity2begin phenylbutazone entity2end , and tricyclic drugs ( imipramine , clomipramine , desipramine ) . 
true chemical chemical Human pharmacologic studies have shown that entity1begin Ritalin entity1end may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and entity2begin tricyclic drugs entity2end ( imipramine , clomipramine , desipramine ) . 
true chemical chemical Human pharmacologic studies have shown that entity1begin Ritalin entity1end may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( entity2begin imipramine entity2end , clomipramine , desipramine ) . 
true chemical chemical Human pharmacologic studies have shown that entity1begin Ritalin entity1end may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , entity2begin clomipramine entity2end , desipramine ) . 
true chemical chemical Human pharmacologic studies have shown that entity1begin Ritalin entity1end may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , entity2begin desipramine entity2end ) . 
false chemical chemical Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of entity1begin coumarin anticoagulants entity1end , entity2begin anticonvulsants entity2end ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) . 
false chemical chemical Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of entity1begin coumarin anticoagulants entity1end , anticonvulsants ( entity2begin phenobarbital entity2end , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) . 
false chemical chemical Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of entity1begin coumarin anticoagulants entity1end , anticonvulsants ( phenobarbital , entity2begin diphenylhydantoin entity2end , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) . 
false chemical chemical Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of entity1begin coumarin anticoagulants entity1end , anticonvulsants ( phenobarbital , diphenylhydantoin , entity2begin primidone entity2end ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) . 
false chemical chemical Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of entity1begin coumarin anticoagulants entity1end , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , entity2begin phenylbutazone entity2end , and tricyclic drugs ( imipramine , clomipramine , desipramine ) . 
false chemical chemical Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of entity1begin coumarin anticoagulants entity1end , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and entity2begin tricyclic drugs entity2end ( imipramine , clomipramine , desipramine ) . 
false chemical chemical Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of entity1begin coumarin anticoagulants entity1end , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( entity2begin imipramine entity2end , clomipramine , desipramine ) . 
false chemical chemical Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of entity1begin coumarin anticoagulants entity1end , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , entity2begin clomipramine entity2end , desipramine ) . 
false chemical chemical Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of entity1begin coumarin anticoagulants entity1end , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , entity2begin desipramine entity2end ) . 
false chemical chemical Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , entity1begin anticonvulsants entity1end ( entity2begin phenobarbital entity2end , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) . 
false chemical chemical Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , entity1begin anticonvulsants entity1end ( phenobarbital , entity2begin diphenylhydantoin entity2end , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) . 
false chemical chemical Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , entity1begin anticonvulsants entity1end ( phenobarbital , diphenylhydantoin , entity2begin primidone entity2end ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) . 
false chemical chemical Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , entity1begin anticonvulsants entity1end ( phenobarbital , diphenylhydantoin , primidone ) , entity2begin phenylbutazone entity2end , and tricyclic drugs ( imipramine , clomipramine , desipramine ) . 
false chemical chemical Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , entity1begin anticonvulsants entity1end ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and entity2begin tricyclic drugs entity2end ( imipramine , clomipramine , desipramine ) . 
false chemical chemical Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , entity1begin anticonvulsants entity1end ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( entity2begin imipramine entity2end , clomipramine , desipramine ) . 
false chemical chemical Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , entity1begin anticonvulsants entity1end ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , entity2begin clomipramine entity2end , desipramine ) . 
false chemical chemical Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , entity1begin anticonvulsants entity1end ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , entity2begin desipramine entity2end ) . 
false chemical chemical Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( entity1begin phenobarbital entity1end , entity2begin diphenylhydantoin entity2end , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) . 
false chemical chemical Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( entity1begin phenobarbital entity1end , diphenylhydantoin , entity2begin primidone entity2end ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) . 
false chemical chemical Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( entity1begin phenobarbital entity1end , diphenylhydantoin , primidone ) , entity2begin phenylbutazone entity2end , and tricyclic drugs ( imipramine , clomipramine , desipramine ) . 
false chemical chemical Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( entity1begin phenobarbital entity1end , diphenylhydantoin , primidone ) , phenylbutazone , and entity2begin tricyclic drugs entity2end ( imipramine , clomipramine , desipramine ) . 
false chemical chemical Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( entity1begin phenobarbital entity1end , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( entity2begin imipramine entity2end , clomipramine , desipramine ) . 
false chemical chemical Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( entity1begin phenobarbital entity1end , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , entity2begin clomipramine entity2end , desipramine ) . 
false chemical chemical Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( entity1begin phenobarbital entity1end , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , entity2begin desipramine entity2end ) . 
false chemical chemical Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , entity1begin diphenylhydantoin entity1end , entity2begin primidone entity2end ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) . 
false chemical chemical Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , entity1begin diphenylhydantoin entity1end , primidone ) , entity2begin phenylbutazone entity2end , and tricyclic drugs ( imipramine , clomipramine , desipramine ) . 
false chemical chemical Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , entity1begin diphenylhydantoin entity1end , primidone ) , phenylbutazone , and entity2begin tricyclic drugs entity2end ( imipramine , clomipramine , desipramine ) . 
false chemical chemical Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , entity1begin diphenylhydantoin entity1end , primidone ) , phenylbutazone , and tricyclic drugs ( entity2begin imipramine entity2end , clomipramine , desipramine ) . 
false chemical chemical Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , entity1begin diphenylhydantoin entity1end , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , entity2begin clomipramine entity2end , desipramine ) . 
false chemical chemical Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , entity1begin diphenylhydantoin entity1end , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , entity2begin desipramine entity2end ) . 
false chemical chemical Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , entity1begin primidone entity1end ) , entity2begin phenylbutazone entity2end , and tricyclic drugs ( imipramine , clomipramine , desipramine ) . 
false chemical chemical Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , entity1begin primidone entity1end ) , phenylbutazone , and entity2begin tricyclic drugs entity2end ( imipramine , clomipramine , desipramine ) . 
false chemical chemical Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , entity1begin primidone entity1end ) , phenylbutazone , and tricyclic drugs ( entity2begin imipramine entity2end , clomipramine , desipramine ) . 
false chemical chemical Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , entity1begin primidone entity1end ) , phenylbutazone , and tricyclic drugs ( imipramine , entity2begin clomipramine entity2end , desipramine ) . 
false chemical chemical Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , entity1begin primidone entity1end ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , entity2begin desipramine entity2end ) . 
false chemical chemical Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , entity1begin phenylbutazone entity1end , and entity2begin tricyclic drugs entity2end ( imipramine , clomipramine , desipramine ) . 
false chemical chemical Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , entity1begin phenylbutazone entity1end , and tricyclic drugs ( entity2begin imipramine entity2end , clomipramine , desipramine ) . 
false chemical chemical Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , entity1begin phenylbutazone entity1end , and tricyclic drugs ( imipramine , entity2begin clomipramine entity2end , desipramine ) . 
false chemical chemical Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , entity1begin phenylbutazone entity1end , and tricyclic drugs ( imipramine , clomipramine , entity2begin desipramine entity2end ) . 
false chemical chemical Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and entity1begin tricyclic drugs entity1end ( entity2begin imipramine entity2end , clomipramine , desipramine ) . 
false chemical chemical Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and entity1begin tricyclic drugs entity1end ( imipramine , entity2begin clomipramine entity2end , desipramine ) . 
false chemical chemical Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and entity1begin tricyclic drugs entity1end ( imipramine , clomipramine , entity2begin desipramine entity2end ) . 
false chemical chemical Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( entity1begin imipramine entity1end , entity2begin clomipramine entity2end , desipramine ) . 
false chemical chemical Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( entity1begin imipramine entity1end , clomipramine , entity2begin desipramine entity2end ) . 
false chemical chemical Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , entity1begin clomipramine entity1end , entity2begin desipramine entity2end ) . 
false chemical chemical The safety of using entity1begin methylphenidate entity1end in combination with entity2begin clonidine entity2end or other centrally acting alpha - 2 agonists has not been systemically evaluated . 
false chemical chemical The safety of using entity1begin methylphenidate entity1end in combination with clonidine or other centrally acting entity2begin alpha - 2 agonists entity2end has not been systemically evaluated . 
false chemical chemical The safety of using methylphenidate in combination with entity1begin clonidine entity1end or other centrally acting entity2begin alpha - 2 agonists entity2end has not been systemically evaluated . 
true chemical chemical Mutual inhibition of metabolism occurs with concurrent use of entity1begin cyclosporin entity1end and entity2begin methylprednisolone entity2end ; 
true chemical chemical convulsions have been reported with concurrent use of entity1begin methylprednisolone entity1end and entity2begin cyclosporin entity2end . 
false chemical chemical Drugs that induce hepatic enzymes such as entity1begin phenobarbital entity1end , entity2begin phenytoin entity2end , and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response . 
false chemical chemical Drugs that induce hepatic enzymes such as entity1begin phenobarbital entity1end , phenytoin , and entity2begin rifampin entity2end may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response . 
true chemical chemical Drugs that induce hepatic enzymes such as entity1begin phenobarbital entity1end , phenytoin , and rifampin may increase the clearance of entity2begin methylprednisolone entity2end and may require increased in methylprednisolone dose to achieve the desired response . 
true chemical chemical Drugs that induce hepatic enzymes such as entity1begin phenobarbital entity1end , phenytoin , and rifampin may increase the clearance of methylprednisolone and may require increased in entity2begin methylprednisolone entity2end dose to achieve the desired response . 
false chemical chemical Drugs that induce hepatic enzymes such as phenobarbital , entity1begin phenytoin entity1end , and entity2begin rifampin entity2end may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response . 
true chemical chemical Drugs that induce hepatic enzymes such as phenobarbital , entity1begin phenytoin entity1end , and rifampin may increase the clearance of entity2begin methylprednisolone entity2end and may require increased in methylprednisolone dose to achieve the desired response . 
true chemical chemical Drugs that induce hepatic enzymes such as phenobarbital , entity1begin phenytoin entity1end , and rifampin may increase the clearance of methylprednisolone and may require increased in entity2begin methylprednisolone entity2end dose to achieve the desired response . 
true chemical chemical Drugs that induce hepatic enzymes such as phenobarbital , phenytoin , and entity1begin rifampin entity1end may increase the clearance of entity2begin methylprednisolone entity2end and may require increased in methylprednisolone dose to achieve the desired response . 
true chemical chemical Drugs that induce hepatic enzymes such as phenobarbital , phenytoin , and entity1begin rifampin entity1end may increase the clearance of methylprednisolone and may require increased in entity2begin methylprednisolone entity2end dose to achieve the desired response . 
false chemical chemical Drugs that induce hepatic enzymes such as phenobarbital , phenytoin , and rifampin may increase the clearance of entity1begin methylprednisolone entity1end and may require increased in entity2begin methylprednisolone entity2end dose to achieve the desired response . 
false chemical chemical Drugs such as entity1begin troleandomycin entity1end and entity2begin ketoconazole entity2end may inhibit the metabolism of methylprednisolone and thus decrease its clearance . 
true chemical chemical Drugs such as entity1begin troleandomycin entity1end and ketoconazole may inhibit the metabolism of entity2begin methylprednisolone entity2end and thus decrease its clearance . 
true chemical chemical Drugs such as troleandomycin and entity1begin ketoconazole entity1end may inhibit the metabolism of entity2begin methylprednisolone entity2end and thus decrease its clearance . 
true chemical chemical entity1begin Methylprednisolone entity1end may increase the clearance of chronic high dose entity2begin aspirin entity2end . 
false chemical chemical This could lead to decreased entity1begin salicylate entity1end serum levels or increase the risk of entity2begin salicylate entity2end toxicity when methylprednisolone is withdrawn . 
false chemical chemical This could lead to decreased entity1begin salicylate entity1end serum levels or increase the risk of salicylate toxicity when entity2begin methylprednisolone entity2end is withdrawn . 
true chemical chemical This could lead to decreased salicylate serum levels or increase the risk of entity1begin salicylate entity1end toxicity when entity2begin methylprednisolone entity2end is withdrawn . 
true chemical chemical entity1begin Aspirin entity1end should be used cautiously in conjunction with entity2begin corticosteroids entity2end in patients suffering from hypoprothrombinemia . 
false chemical chemical The effect of entity1begin methylprednisolone entity1end on oral entity2begin anticoagulants entity2end is variable . 
true chemical chemical There are reports of enhanced as well as diminished effects of entity1begin anticoagulant entity1end when given concurrently with entity2begin corticosteroids entity2end . 
false chemical chemical entity1begin Methscopolamine entity1end may interact with entity2begin antidepressants entity2end ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
true chemical chemical entity1begin Methscopolamine entity1end may interact with antidepressants ( entity2begin tricyclic entity2end type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
true chemical chemical entity1begin Methscopolamine entity1end may interact with antidepressants ( tricyclic type ) , entity2begin MAO inhibitors entity2end ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
true chemical chemical entity1begin Methscopolamine entity1end may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , entity2begin phenelzine entity2end , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
true chemical chemical entity1begin Methscopolamine entity1end may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , entity2begin linezolid entity2end , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
true chemical chemical entity1begin Methscopolamine entity1end may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , entity2begin tranylcypromine entity2end , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
true chemical chemical entity1begin Methscopolamine entity1end may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , entity2begin isocarboxazid entity2end , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
true chemical chemical entity1begin Methscopolamine entity1end may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , entity2begin selegiline entity2end , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
true chemical chemical entity1begin Methscopolamine entity1end may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , entity2begin furazolidone entity2end ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
true chemical chemical entity1begin Methscopolamine entity1end may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , entity2begin quinidine entity2end , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
true chemical chemical entity1begin Methscopolamine entity1end may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , entity2begin amantadine entity2end , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
true chemical chemical entity1begin Methscopolamine entity1end may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , entity2begin antihistamines entity2end ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
true chemical chemical entity1begin Methscopolamine entity1end may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , entity2begin diphenhydramine entity2end ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
true chemical chemical entity1begin Methscopolamine entity1end may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other entity2begin anticholinergics entity2end , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
true chemical chemical entity1begin Methscopolamine entity1end may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , entity2begin potassium chloride entity2end supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
true chemical chemical entity1begin Methscopolamine entity1end may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , entity2begin antacids entity2end , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
true chemical chemical entity1begin Methscopolamine entity1end may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , entity2begin absorbent - type anti - diarrhea medicines entity2end ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
true chemical chemical entity1begin Methscopolamine entity1end may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , entity2begin kaolin entity2end - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
true chemical chemical entity1begin Methscopolamine entity1end may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - entity2begin pectin entity2end ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
true chemical chemical entity1begin Methscopolamine entity1end may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , entity2begin phenothiazines entity2end ( e.g. , chlorpromazine , promethazine ) . 
true chemical chemical entity1begin Methscopolamine entity1end may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , entity2begin chlorpromazine entity2end , promethazine ) . 
true chemical chemical entity1begin Methscopolamine entity1end may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , entity2begin promethazine entity2end ) . 
false chemical chemical Methscopolamine may interact with entity1begin antidepressants entity1end ( entity2begin tricyclic entity2end type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with entity1begin antidepressants entity1end ( tricyclic type ) , entity2begin MAO inhibitors entity2end ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with entity1begin antidepressants entity1end ( tricyclic type ) , MAO inhibitors ( e.g. , entity2begin phenelzine entity2end , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with entity1begin antidepressants entity1end ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , entity2begin linezolid entity2end , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with entity1begin antidepressants entity1end ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , entity2begin tranylcypromine entity2end , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with entity1begin antidepressants entity1end ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , entity2begin isocarboxazid entity2end , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with entity1begin antidepressants entity1end ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , entity2begin selegiline entity2end , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with entity1begin antidepressants entity1end ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , entity2begin furazolidone entity2end ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with entity1begin antidepressants entity1end ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , entity2begin quinidine entity2end , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with entity1begin antidepressants entity1end ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , entity2begin amantadine entity2end , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with entity1begin antidepressants entity1end ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , entity2begin antihistamines entity2end ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with entity1begin antidepressants entity1end ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , entity2begin diphenhydramine entity2end ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with entity1begin antidepressants entity1end ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other entity2begin anticholinergics entity2end , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with entity1begin antidepressants entity1end ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , entity2begin potassium chloride entity2end supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with entity1begin antidepressants entity1end ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , entity2begin antacids entity2end , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with entity1begin antidepressants entity1end ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , entity2begin absorbent - type anti - diarrhea medicines entity2end ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with entity1begin antidepressants entity1end ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , entity2begin kaolin entity2end - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with entity1begin antidepressants entity1end ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - entity2begin pectin entity2end ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with entity1begin antidepressants entity1end ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , entity2begin phenothiazines entity2end ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with entity1begin antidepressants entity1end ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , entity2begin chlorpromazine entity2end , promethazine ) . 
false chemical chemical Methscopolamine may interact with entity1begin antidepressants entity1end ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , entity2begin promethazine entity2end ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( entity1begin tricyclic entity1end type ) , entity2begin MAO inhibitors entity2end ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( entity1begin tricyclic entity1end type ) , MAO inhibitors ( e.g. , entity2begin phenelzine entity2end , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( entity1begin tricyclic entity1end type ) , MAO inhibitors ( e.g. , phenelzine , entity2begin linezolid entity2end , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( entity1begin tricyclic entity1end type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , entity2begin tranylcypromine entity2end , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( entity1begin tricyclic entity1end type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , entity2begin isocarboxazid entity2end , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( entity1begin tricyclic entity1end type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , entity2begin selegiline entity2end , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( entity1begin tricyclic entity1end type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , entity2begin furazolidone entity2end ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( entity1begin tricyclic entity1end type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , entity2begin quinidine entity2end , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( entity1begin tricyclic entity1end type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , entity2begin amantadine entity2end , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( entity1begin tricyclic entity1end type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , entity2begin antihistamines entity2end ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( entity1begin tricyclic entity1end type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , entity2begin diphenhydramine entity2end ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( entity1begin tricyclic entity1end type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other entity2begin anticholinergics entity2end , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( entity1begin tricyclic entity1end type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , entity2begin potassium chloride entity2end supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( entity1begin tricyclic entity1end type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , entity2begin antacids entity2end , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( entity1begin tricyclic entity1end type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , entity2begin absorbent - type anti - diarrhea medicines entity2end ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( entity1begin tricyclic entity1end type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , entity2begin kaolin entity2end - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( entity1begin tricyclic entity1end type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - entity2begin pectin entity2end ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( entity1begin tricyclic entity1end type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , entity2begin phenothiazines entity2end ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( entity1begin tricyclic entity1end type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , entity2begin chlorpromazine entity2end , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( entity1begin tricyclic entity1end type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , entity2begin promethazine entity2end ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , entity1begin MAO inhibitors entity1end ( e.g. , entity2begin phenelzine entity2end , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , entity1begin MAO inhibitors entity1end ( e.g. , phenelzine , entity2begin linezolid entity2end , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , entity1begin MAO inhibitors entity1end ( e.g. , phenelzine , linezolid , entity2begin tranylcypromine entity2end , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , entity1begin MAO inhibitors entity1end ( e.g. , phenelzine , linezolid , tranylcypromine , entity2begin isocarboxazid entity2end , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , entity1begin MAO inhibitors entity1end ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , entity2begin selegiline entity2end , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , entity1begin MAO inhibitors entity1end ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , entity2begin furazolidone entity2end ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , entity1begin MAO inhibitors entity1end ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , entity2begin quinidine entity2end , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , entity1begin MAO inhibitors entity1end ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , entity2begin amantadine entity2end , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , entity1begin MAO inhibitors entity1end ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , entity2begin antihistamines entity2end ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , entity1begin MAO inhibitors entity1end ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , entity2begin diphenhydramine entity2end ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , entity1begin MAO inhibitors entity1end ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other entity2begin anticholinergics entity2end , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , entity1begin MAO inhibitors entity1end ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , entity2begin potassium chloride entity2end supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , entity1begin MAO inhibitors entity1end ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , entity2begin antacids entity2end , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , entity1begin MAO inhibitors entity1end ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , entity2begin absorbent - type anti - diarrhea medicines entity2end ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , entity1begin MAO inhibitors entity1end ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , entity2begin kaolin entity2end - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , entity1begin MAO inhibitors entity1end ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - entity2begin pectin entity2end ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , entity1begin MAO inhibitors entity1end ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , entity2begin phenothiazines entity2end ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , entity1begin MAO inhibitors entity1end ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , entity2begin chlorpromazine entity2end , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , entity1begin MAO inhibitors entity1end ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , entity2begin promethazine entity2end ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , entity1begin phenelzine entity1end , entity2begin linezolid entity2end , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , entity1begin phenelzine entity1end , linezolid , entity2begin tranylcypromine entity2end , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , entity1begin phenelzine entity1end , linezolid , tranylcypromine , entity2begin isocarboxazid entity2end , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , entity1begin phenelzine entity1end , linezolid , tranylcypromine , isocarboxazid , entity2begin selegiline entity2end , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , entity1begin phenelzine entity1end , linezolid , tranylcypromine , isocarboxazid , selegiline , entity2begin furazolidone entity2end ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , entity1begin phenelzine entity1end , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , entity2begin quinidine entity2end , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , entity1begin phenelzine entity1end , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , entity2begin amantadine entity2end , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , entity1begin phenelzine entity1end , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , entity2begin antihistamines entity2end ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , entity1begin phenelzine entity1end , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , entity2begin diphenhydramine entity2end ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , entity1begin phenelzine entity1end , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other entity2begin anticholinergics entity2end , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , entity1begin phenelzine entity1end , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , entity2begin potassium chloride entity2end supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , entity1begin phenelzine entity1end , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , entity2begin antacids entity2end , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , entity1begin phenelzine entity1end , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , entity2begin absorbent - type anti - diarrhea medicines entity2end ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , entity1begin phenelzine entity1end , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , entity2begin kaolin entity2end - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , entity1begin phenelzine entity1end , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - entity2begin pectin entity2end ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , entity1begin phenelzine entity1end , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , entity2begin phenothiazines entity2end ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , entity1begin phenelzine entity1end , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , entity2begin chlorpromazine entity2end , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , entity1begin phenelzine entity1end , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , entity2begin promethazine entity2end ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , entity1begin linezolid entity1end , entity2begin tranylcypromine entity2end , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , entity1begin linezolid entity1end , tranylcypromine , entity2begin isocarboxazid entity2end , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , entity1begin linezolid entity1end , tranylcypromine , isocarboxazid , entity2begin selegiline entity2end , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , entity1begin linezolid entity1end , tranylcypromine , isocarboxazid , selegiline , entity2begin furazolidone entity2end ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , entity1begin linezolid entity1end , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , entity2begin quinidine entity2end , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , entity1begin linezolid entity1end , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , entity2begin amantadine entity2end , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , entity1begin linezolid entity1end , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , entity2begin antihistamines entity2end ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , entity1begin linezolid entity1end , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , entity2begin diphenhydramine entity2end ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , entity1begin linezolid entity1end , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other entity2begin anticholinergics entity2end , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , entity1begin linezolid entity1end , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , entity2begin potassium chloride entity2end supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , entity1begin linezolid entity1end , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , entity2begin antacids entity2end , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , entity1begin linezolid entity1end , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , entity2begin absorbent - type anti - diarrhea medicines entity2end ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , entity1begin linezolid entity1end , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , entity2begin kaolin entity2end - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , entity1begin linezolid entity1end , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - entity2begin pectin entity2end ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , entity1begin linezolid entity1end , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , entity2begin phenothiazines entity2end ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , entity1begin linezolid entity1end , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , entity2begin chlorpromazine entity2end , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , entity1begin linezolid entity1end , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , entity2begin promethazine entity2end ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , entity1begin tranylcypromine entity1end , entity2begin isocarboxazid entity2end , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , entity1begin tranylcypromine entity1end , isocarboxazid , entity2begin selegiline entity2end , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , entity1begin tranylcypromine entity1end , isocarboxazid , selegiline , entity2begin furazolidone entity2end ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , entity1begin tranylcypromine entity1end , isocarboxazid , selegiline , furazolidone ) , entity2begin quinidine entity2end , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , entity1begin tranylcypromine entity1end , isocarboxazid , selegiline , furazolidone ) , quinidine , entity2begin amantadine entity2end , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , entity1begin tranylcypromine entity1end , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , entity2begin antihistamines entity2end ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , entity1begin tranylcypromine entity1end , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , entity2begin diphenhydramine entity2end ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , entity1begin tranylcypromine entity1end , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other entity2begin anticholinergics entity2end , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , entity1begin tranylcypromine entity1end , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , entity2begin potassium chloride entity2end supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , entity1begin tranylcypromine entity1end , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , entity2begin antacids entity2end , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , entity1begin tranylcypromine entity1end , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , entity2begin absorbent - type anti - diarrhea medicines entity2end ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , entity1begin tranylcypromine entity1end , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , entity2begin kaolin entity2end - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , entity1begin tranylcypromine entity1end , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - entity2begin pectin entity2end ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , entity1begin tranylcypromine entity1end , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , entity2begin phenothiazines entity2end ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , entity1begin tranylcypromine entity1end , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , entity2begin chlorpromazine entity2end , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , entity1begin tranylcypromine entity1end , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , entity2begin promethazine entity2end ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , entity1begin isocarboxazid entity1end , entity2begin selegiline entity2end , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , entity1begin isocarboxazid entity1end , selegiline , entity2begin furazolidone entity2end ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , entity1begin isocarboxazid entity1end , selegiline , furazolidone ) , entity2begin quinidine entity2end , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , entity1begin isocarboxazid entity1end , selegiline , furazolidone ) , quinidine , entity2begin amantadine entity2end , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , entity1begin isocarboxazid entity1end , selegiline , furazolidone ) , quinidine , amantadine , entity2begin antihistamines entity2end ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , entity1begin isocarboxazid entity1end , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , entity2begin diphenhydramine entity2end ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , entity1begin isocarboxazid entity1end , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other entity2begin anticholinergics entity2end , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , entity1begin isocarboxazid entity1end , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , entity2begin potassium chloride entity2end supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , entity1begin isocarboxazid entity1end , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , entity2begin antacids entity2end , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , entity1begin isocarboxazid entity1end , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , entity2begin absorbent - type anti - diarrhea medicines entity2end ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , entity1begin isocarboxazid entity1end , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , entity2begin kaolin entity2end - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , entity1begin isocarboxazid entity1end , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - entity2begin pectin entity2end ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , entity1begin isocarboxazid entity1end , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , entity2begin phenothiazines entity2end ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , entity1begin isocarboxazid entity1end , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , entity2begin chlorpromazine entity2end , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , entity1begin isocarboxazid entity1end , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , entity2begin promethazine entity2end ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , entity1begin selegiline entity1end , entity2begin furazolidone entity2end ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , entity1begin selegiline entity1end , furazolidone ) , entity2begin quinidine entity2end , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , entity1begin selegiline entity1end , furazolidone ) , quinidine , entity2begin amantadine entity2end , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , entity1begin selegiline entity1end , furazolidone ) , quinidine , amantadine , entity2begin antihistamines entity2end ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , entity1begin selegiline entity1end , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , entity2begin diphenhydramine entity2end ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , entity1begin selegiline entity1end , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other entity2begin anticholinergics entity2end , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , entity1begin selegiline entity1end , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , entity2begin potassium chloride entity2end supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , entity1begin selegiline entity1end , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , entity2begin antacids entity2end , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , entity1begin selegiline entity1end , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , entity2begin absorbent - type anti - diarrhea medicines entity2end ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , entity1begin selegiline entity1end , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , entity2begin kaolin entity2end - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , entity1begin selegiline entity1end , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - entity2begin pectin entity2end ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , entity1begin selegiline entity1end , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , entity2begin phenothiazines entity2end ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , entity1begin selegiline entity1end , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , entity2begin chlorpromazine entity2end , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , entity1begin selegiline entity1end , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , entity2begin promethazine entity2end ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , entity1begin furazolidone entity1end ) , entity2begin quinidine entity2end , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , entity1begin furazolidone entity1end ) , quinidine , entity2begin amantadine entity2end , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , entity1begin furazolidone entity1end ) , quinidine , amantadine , entity2begin antihistamines entity2end ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , entity1begin furazolidone entity1end ) , quinidine , amantadine , antihistamines ( e.g. , entity2begin diphenhydramine entity2end ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , entity1begin furazolidone entity1end ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other entity2begin anticholinergics entity2end , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , entity1begin furazolidone entity1end ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , entity2begin potassium chloride entity2end supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , entity1begin furazolidone entity1end ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , entity2begin antacids entity2end , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , entity1begin furazolidone entity1end ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , entity2begin absorbent - type anti - diarrhea medicines entity2end ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , entity1begin furazolidone entity1end ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , entity2begin kaolin entity2end - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , entity1begin furazolidone entity1end ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - entity2begin pectin entity2end ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , entity1begin furazolidone entity1end ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , entity2begin phenothiazines entity2end ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , entity1begin furazolidone entity1end ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , entity2begin chlorpromazine entity2end , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , entity1begin furazolidone entity1end ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , entity2begin promethazine entity2end ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , entity1begin quinidine entity1end , entity2begin amantadine entity2end , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , entity1begin quinidine entity1end , amantadine , entity2begin antihistamines entity2end ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , entity1begin quinidine entity1end , amantadine , antihistamines ( e.g. , entity2begin diphenhydramine entity2end ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , entity1begin quinidine entity1end , amantadine , antihistamines ( e.g. , diphenhydramine ) , other entity2begin anticholinergics entity2end , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , entity1begin quinidine entity1end , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , entity2begin potassium chloride entity2end supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , entity1begin quinidine entity1end , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , entity2begin antacids entity2end , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , entity1begin quinidine entity1end , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , entity2begin absorbent - type anti - diarrhea medicines entity2end ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , entity1begin quinidine entity1end , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , entity2begin kaolin entity2end - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , entity1begin quinidine entity1end , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - entity2begin pectin entity2end ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , entity1begin quinidine entity1end , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , entity2begin phenothiazines entity2end ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , entity1begin quinidine entity1end , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , entity2begin chlorpromazine entity2end , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , entity1begin quinidine entity1end , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , entity2begin promethazine entity2end ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , entity1begin amantadine entity1end , entity2begin antihistamines entity2end ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , entity1begin amantadine entity1end , antihistamines ( e.g. , entity2begin diphenhydramine entity2end ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , entity1begin amantadine entity1end , antihistamines ( e.g. , diphenhydramine ) , other entity2begin anticholinergics entity2end , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , entity1begin amantadine entity1end , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , entity2begin potassium chloride entity2end supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , entity1begin amantadine entity1end , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , entity2begin antacids entity2end , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , entity1begin amantadine entity1end , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , entity2begin absorbent - type anti - diarrhea medicines entity2end ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , entity1begin amantadine entity1end , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , entity2begin kaolin entity2end - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , entity1begin amantadine entity1end , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - entity2begin pectin entity2end ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , entity1begin amantadine entity1end , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , entity2begin phenothiazines entity2end ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , entity1begin amantadine entity1end , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , entity2begin chlorpromazine entity2end , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , entity1begin amantadine entity1end , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , entity2begin promethazine entity2end ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , entity1begin antihistamines entity1end ( e.g. , entity2begin diphenhydramine entity2end ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , entity1begin antihistamines entity1end ( e.g. , diphenhydramine ) , other entity2begin anticholinergics entity2end , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , entity1begin antihistamines entity1end ( e.g. , diphenhydramine ) , other anticholinergics , entity2begin potassium chloride entity2end supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , entity1begin antihistamines entity1end ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , entity2begin antacids entity2end , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , entity1begin antihistamines entity1end ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , entity2begin absorbent - type anti - diarrhea medicines entity2end ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , entity1begin antihistamines entity1end ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , entity2begin kaolin entity2end - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , entity1begin antihistamines entity1end ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - entity2begin pectin entity2end ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , entity1begin antihistamines entity1end ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , entity2begin phenothiazines entity2end ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , entity1begin antihistamines entity1end ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , entity2begin chlorpromazine entity2end , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , entity1begin antihistamines entity1end ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , entity2begin promethazine entity2end ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , entity1begin diphenhydramine entity1end ) , other entity2begin anticholinergics entity2end , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , entity1begin diphenhydramine entity1end ) , other anticholinergics , entity2begin potassium chloride entity2end supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , entity1begin diphenhydramine entity1end ) , other anticholinergics , potassium chloride supplements , entity2begin antacids entity2end , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , entity1begin diphenhydramine entity1end ) , other anticholinergics , potassium chloride supplements , antacids , entity2begin absorbent - type anti - diarrhea medicines entity2end ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , entity1begin diphenhydramine entity1end ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , entity2begin kaolin entity2end - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , entity1begin diphenhydramine entity1end ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - entity2begin pectin entity2end ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , entity1begin diphenhydramine entity1end ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , entity2begin phenothiazines entity2end ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , entity1begin diphenhydramine entity1end ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , entity2begin chlorpromazine entity2end , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , entity1begin diphenhydramine entity1end ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , entity2begin promethazine entity2end ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other entity1begin anticholinergics entity1end , entity2begin potassium chloride entity2end supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other entity1begin anticholinergics entity1end , potassium chloride supplements , entity2begin antacids entity2end , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other entity1begin anticholinergics entity1end , potassium chloride supplements , antacids , entity2begin absorbent - type anti - diarrhea medicines entity2end ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other entity1begin anticholinergics entity1end , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , entity2begin kaolin entity2end - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other entity1begin anticholinergics entity1end , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - entity2begin pectin entity2end ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other entity1begin anticholinergics entity1end , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , entity2begin phenothiazines entity2end ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other entity1begin anticholinergics entity1end , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , entity2begin chlorpromazine entity2end , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other entity1begin anticholinergics entity1end , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , entity2begin promethazine entity2end ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , entity1begin potassium chloride entity1end supplements , entity2begin antacids entity2end , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , entity1begin potassium chloride entity1end supplements , antacids , entity2begin absorbent - type anti - diarrhea medicines entity2end ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , entity1begin potassium chloride entity1end supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , entity2begin kaolin entity2end - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , entity1begin potassium chloride entity1end supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - entity2begin pectin entity2end ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , entity1begin potassium chloride entity1end supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , entity2begin phenothiazines entity2end ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , entity1begin potassium chloride entity1end supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , entity2begin chlorpromazine entity2end , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , entity1begin potassium chloride entity1end supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , entity2begin promethazine entity2end ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , entity1begin antacids entity1end , entity2begin absorbent - type anti - diarrhea medicines entity2end ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , entity1begin antacids entity1end , absorbent - type anti - diarrhea medicines ( e.g. , entity2begin kaolin entity2end - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , entity1begin antacids entity1end , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - entity2begin pectin entity2end ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , entity1begin antacids entity1end , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , entity2begin phenothiazines entity2end ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , entity1begin antacids entity1end , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , entity2begin chlorpromazine entity2end , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , entity1begin antacids entity1end , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , entity2begin promethazine entity2end ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , entity1begin absorbent - type anti - diarrhea medicines entity1end ( e.g. , entity2begin kaolin entity2end - pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , entity1begin absorbent - type anti - diarrhea medicines entity1end ( e.g. , kaolin - entity2begin pectin entity2end ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , entity1begin absorbent - type anti - diarrhea medicines entity1end ( e.g. , kaolin - pectin ) , entity2begin phenothiazines entity2end ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , entity1begin absorbent - type anti - diarrhea medicines entity1end ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , entity2begin chlorpromazine entity2end , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , entity1begin absorbent - type anti - diarrhea medicines entity1end ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , chlorpromazine , entity2begin promethazine entity2end ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , entity1begin kaolin entity1end - entity2begin pectin entity2end ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , entity1begin kaolin entity1end - pectin ) , entity2begin phenothiazines entity2end ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , entity1begin kaolin entity1end - pectin ) , phenothiazines ( e.g. , entity2begin chlorpromazine entity2end , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , entity1begin kaolin entity1end - pectin ) , phenothiazines ( e.g. , chlorpromazine , entity2begin promethazine entity2end ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - entity1begin pectin entity1end ) , entity2begin phenothiazines entity2end ( e.g. , chlorpromazine , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - entity1begin pectin entity1end ) , phenothiazines ( e.g. , entity2begin chlorpromazine entity2end , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - entity1begin pectin entity1end ) , phenothiazines ( e.g. , chlorpromazine , entity2begin promethazine entity2end ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , entity1begin phenothiazines entity1end ( e.g. , entity2begin chlorpromazine entity2end , promethazine ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , entity1begin phenothiazines entity1end ( e.g. , chlorpromazine , entity2begin promethazine entity2end ) . 
false chemical chemical Methscopolamine may interact with antidepressants ( tricyclic type ) , MAO inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent - type anti - diarrhea medicines ( e.g. , kaolin - pectin ) , phenothiazines ( e.g. , entity1begin chlorpromazine entity1end , entity2begin promethazine entity2end ) . 
false chemical chemical Concurrent use of entity1begin alcohol entity1end and other entity2begin CNS depression - producing drugs entity2end may increase the CNS depressant effects of methyprylon or these other medications . 
true chemical chemical Concurrent use of entity1begin alcohol entity1end and other CNS depression - producing drugs may increase the CNS depressant effects of entity2begin methyprylon entity2end or these other medications . 
true chemical chemical Concurrent use of alcohol and other entity1begin CNS depression - producing drugs entity1end may increase the CNS depressant effects of entity2begin methyprylon entity2end or these other medications . 
true chemical chemical entity1begin Methysergide entity1end may reverse the analgesic activity of entity2begin narcotic analgesics entity2end . 
false chemical chemical Concurrent use with entity1begin vasoconstrictor agents entity1end including entity2begin ergot alkaloids entity2end , sumatriptan , and nicotine ( e.g. smoking ) may result in enhanced vasoconstriction . 
false chemical chemical Concurrent use with entity1begin vasoconstrictor agents entity1end including ergot alkaloids , entity2begin sumatriptan entity2end , and nicotine ( e.g. smoking ) may result in enhanced vasoconstriction . 
false chemical chemical Concurrent use with entity1begin vasoconstrictor agents entity1end including ergot alkaloids , sumatriptan , and entity2begin nicotine entity2end ( e.g. smoking ) may result in enhanced vasoconstriction . 
false chemical chemical Concurrent use with vasoconstrictor agents including entity1begin ergot alkaloids entity1end , entity2begin sumatriptan entity2end , and nicotine ( e.g. smoking ) may result in enhanced vasoconstriction . 
false chemical chemical Concurrent use with vasoconstrictor agents including entity1begin ergot alkaloids entity1end , sumatriptan , and entity2begin nicotine entity2end ( e.g. smoking ) may result in enhanced vasoconstriction . 
false chemical chemical Concurrent use with vasoconstrictor agents including ergot alkaloids , entity1begin sumatriptan entity1end , and entity2begin nicotine entity2end ( e.g. smoking ) may result in enhanced vasoconstriction . 
true chemical chemical The effects of entity1begin metoclopramide entity1end on gastrointestinal motility are antagonized by entity2begin anticholinergic drugs entity2end and narcotic analgesics . 
true chemical chemical The effects of entity1begin metoclopramide entity1end on gastrointestinal motility are antagonized by anticholinergic drugs and entity2begin narcotic analgesics entity2end . 
false chemical chemical The effects of metoclopramide on gastrointestinal motility are antagonized by entity1begin anticholinergic drugs entity1end and entity2begin narcotic analgesics entity2end . 
true chemical chemical Additive sedative effects can occur when entity1begin metoclopramide entity1end is given with entity2begin alcohol entity2end , sedatives , hypnotics , narcotics , or tranquilizers . 
true chemical chemical Additive sedative effects can occur when entity1begin metoclopramide entity1end is given with alcohol , entity2begin sedatives entity2end , hypnotics , narcotics , or tranquilizers . 
true chemical chemical Additive sedative effects can occur when entity1begin metoclopramide entity1end is given with alcohol , sedatives , entity2begin hypnotics entity2end , narcotics , or tranquilizers . 
true chemical chemical Additive sedative effects can occur when entity1begin metoclopramide entity1end is given with alcohol , sedatives , hypnotics , entity2begin narcotics entity2end , or tranquilizers . 
true chemical chemical Additive sedative effects can occur when entity1begin metoclopramide entity1end is given with alcohol , sedatives , hypnotics , narcotics , or entity2begin tranquilizers entity2end . 
false chemical chemical Additive sedative effects can occur when metoclopramide is given with entity1begin alcohol entity1end , entity2begin sedatives entity2end , hypnotics , narcotics , or tranquilizers . 
false chemical chemical Additive sedative effects can occur when metoclopramide is given with entity1begin alcohol entity1end , sedatives , entity2begin hypnotics entity2end , narcotics , or tranquilizers . 
false chemical chemical Additive sedative effects can occur when metoclopramide is given with entity1begin alcohol entity1end , sedatives , hypnotics , entity2begin narcotics entity2end , or tranquilizers . 
false chemical chemical Additive sedative effects can occur when metoclopramide is given with entity1begin alcohol entity1end , sedatives , hypnotics , narcotics , or entity2begin tranquilizers entity2end . 
false chemical chemical Additive sedative effects can occur when metoclopramide is given with alcohol , entity1begin sedatives entity1end , entity2begin hypnotics entity2end , narcotics , or tranquilizers . 
false chemical chemical Additive sedative effects can occur when metoclopramide is given with alcohol , entity1begin sedatives entity1end , hypnotics , entity2begin narcotics entity2end , or tranquilizers . 
false chemical chemical Additive sedative effects can occur when metoclopramide is given with alcohol , entity1begin sedatives entity1end , hypnotics , narcotics , or entity2begin tranquilizers entity2end . 
false chemical chemical Additive sedative effects can occur when metoclopramide is given with alcohol , sedatives , entity1begin hypnotics entity1end , entity2begin narcotics entity2end , or tranquilizers . 
false chemical chemical Additive sedative effects can occur when metoclopramide is given with alcohol , sedatives , entity1begin hypnotics entity1end , narcotics , or entity2begin tranquilizers entity2end . 
false chemical chemical Additive sedative effects can occur when metoclopramide is given with alcohol , sedatives , hypnotics , entity1begin narcotics entity1end , or entity2begin tranquilizers entity2end . 
true chemical chemical The finding that entity1begin metoclopramide entity1end releases catecholamines in patients with essential hypertension suggests that it should be used cautiously , if at all , in patients receiving entity2begin monoamine oxi - dase inhibitors entity2end . 
true chemical chemical Absorption of drugs from the stomach may be diminished ( e.g. , entity1begin digoxin entity1end ) by entity2begin metoclopramide entity2end , whereas the rate and / or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , tetracycline , levodopa , ethanol , cyclosporine ) . 
false chemical chemical Absorption of drugs from the stomach may be diminished ( e.g. , entity1begin digoxin entity1end ) by metoclopramide , whereas the rate and / or extent of absorption of drugs from the small bowel may be increased ( e.g. , entity2begin acetaminophen entity2end , tetracycline , levodopa , ethanol , cyclosporine ) . 
false chemical chemical Absorption of drugs from the stomach may be diminished ( e.g. , entity1begin digoxin entity1end ) by metoclopramide , whereas the rate and / or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , entity2begin tetracycline entity2end , levodopa , ethanol , cyclosporine ) . 
false chemical chemical Absorption of drugs from the stomach may be diminished ( e.g. , entity1begin digoxin entity1end ) by metoclopramide , whereas the rate and / or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , tetracycline , entity2begin levodopa entity2end , ethanol , cyclosporine ) . 
false chemical chemical Absorption of drugs from the stomach may be diminished ( e.g. , entity1begin digoxin entity1end ) by metoclopramide , whereas the rate and / or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , tetracycline , levodopa , entity2begin ethanol entity2end , cyclosporine ) . 
false chemical chemical Absorption of drugs from the stomach may be diminished ( e.g. , entity1begin digoxin entity1end ) by metoclopramide , whereas the rate and / or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , tetracycline , levodopa , ethanol , entity2begin cyclosporine entity2end ) . 
true chemical chemical Absorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by entity1begin metoclopramide entity1end , whereas the rate and / or extent of absorption of drugs from the small bowel may be increased ( e.g. , entity2begin acetaminophen entity2end , tetracycline , levodopa , ethanol , cyclosporine ) . 
false chemical chemical Absorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by entity1begin metoclopramide entity1end , whereas the rate and / or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , entity2begin tetracycline entity2end , levodopa , ethanol , cyclosporine ) . 
false chemical chemical Absorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by entity1begin metoclopramide entity1end , whereas the rate and / or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , tetracycline , entity2begin levodopa entity2end , ethanol , cyclosporine ) . 
false chemical chemical Absorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by entity1begin metoclopramide entity1end , whereas the rate and / or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , tetracycline , levodopa , entity2begin ethanol entity2end , cyclosporine ) . 
false chemical chemical Absorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by entity1begin metoclopramide entity1end , whereas the rate and / or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , tetracycline , levodopa , ethanol , entity2begin cyclosporine entity2end ) . 
false chemical chemical Absorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by metoclopramide , whereas the rate and / or extent of absorption of drugs from the small bowel may be increased ( e.g. , entity1begin acetaminophen entity1end , entity2begin tetracycline entity2end , levodopa , ethanol , cyclosporine ) . 
false chemical chemical Absorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by metoclopramide , whereas the rate and / or extent of absorption of drugs from the small bowel may be increased ( e.g. , entity1begin acetaminophen entity1end , tetracycline , entity2begin levodopa entity2end , ethanol , cyclosporine ) . 
false chemical chemical Absorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by metoclopramide , whereas the rate and / or extent of absorption of drugs from the small bowel may be increased ( e.g. , entity1begin acetaminophen entity1end , tetracycline , levodopa , entity2begin ethanol entity2end , cyclosporine ) . 
false chemical chemical Absorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by metoclopramide , whereas the rate and / or extent of absorption of drugs from the small bowel may be increased ( e.g. , entity1begin acetaminophen entity1end , tetracycline , levodopa , ethanol , entity2begin cyclosporine entity2end ) . 
false chemical chemical Absorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by metoclopramide , whereas the rate and / or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , entity1begin tetracycline entity1end , entity2begin levodopa entity2end , ethanol , cyclosporine ) . 
false chemical chemical Absorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by metoclopramide , whereas the rate and / or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , entity1begin tetracycline entity1end , levodopa , entity2begin ethanol entity2end , cyclosporine ) . 
false chemical chemical Absorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by metoclopramide , whereas the rate and / or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , entity1begin tetracycline entity1end , levodopa , ethanol , entity2begin cyclosporine entity2end ) . 
false chemical chemical Absorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by metoclopramide , whereas the rate and / or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , tetracycline , entity1begin levodopa entity1end , entity2begin ethanol entity2end , cyclosporine ) . 
false chemical chemical Absorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by metoclopramide , whereas the rate and / or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , tetracycline , entity1begin levodopa entity1end , ethanol , entity2begin cyclosporine entity2end ) . 
false chemical chemical Absorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by metoclopramide , whereas the rate and / or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , tetracycline , levodopa , entity1begin ethanol entity1end , entity2begin cyclosporine entity2end ) . 
true chemical chemical Because the action of entity1begin metoclopramide entity1end will influence the delivery of food to the intestines and thus the rate of absorption , entity2begin insulin entity2end dosage or timing of dosage may require adjustment . 
false chemical chemical entity1begin Diuretics entity1end : entity2begin Furosemide entity2end and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes . 
false chemical chemical entity1begin Diuretics entity1end : Furosemide and probably other entity2begin loop diuretics entity2end given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes . 
false chemical chemical entity1begin Diuretics entity1end : Furosemide and probably other loop diuretics given concomitantly with entity2begin metolazone entity2end can cause unusually large or prolonged losses of fluid and electrolytes . 
false chemical chemical Diuretics : entity1begin Furosemide entity1end and probably other entity2begin loop diuretics entity2end given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes . 
true chemical chemical Diuretics : entity1begin Furosemide entity1end and probably other loop diuretics given concomitantly with entity2begin metolazone entity2end can cause unusually large or prolonged losses of fluid and electrolytes . 
true chemical chemical Diuretics : Furosemide and probably other entity1begin loop diuretics entity1end given concomitantly with entity2begin metolazone entity2end can cause unusually large or prolonged losses of fluid and electrolytes . 
false chemical chemical Other entity1begin Antihypertensives entity1end : When entity2begin MYKROX entity2end Tablets are used with other antihypertensive drugs , care must be taken , especially during initial therapy . 
false chemical chemical Other entity1begin Antihypertensives entity1end : When MYKROX Tablets are used with other entity2begin antihypertensive drugs entity2end , care must be taken , especially during initial therapy . 
true chemical chemical Other Antihypertensives : When entity1begin MYKROX entity1end Tablets are used with other entity2begin antihypertensive drugs entity2end , care must be taken , especially during initial therapy . 
false chemical chemical entity1begin Alcohol entity1end , entity2begin Barbiturates entity2end , and Narcotics : The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy . 
false chemical chemical entity1begin Alcohol entity1end , Barbiturates , and entity2begin Narcotics entity2end : The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy . 
false chemical chemical entity1begin Alcohol entity1end , Barbiturates , and Narcotics : The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with entity2begin metolazone entity2end therapy . 
false chemical chemical Alcohol , entity1begin Barbiturates entity1end , and entity2begin Narcotics entity2end : The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy . 
false chemical chemical Alcohol , entity1begin Barbiturates entity1end , and Narcotics : The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with entity2begin metolazone entity2end therapy . 
false chemical chemical Alcohol , Barbiturates , and entity1begin Narcotics entity1end : The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with entity2begin metolazone entity2end therapy . 
false chemical chemical entity1begin Digitalis Glycosides entity1end : entity2begin Diuretic entity2end - induced hypokalemia can increase the sensitivity of the myocardium to digitalis . 
false chemical chemical entity1begin Digitalis Glycosides entity1end : Diuretic - induced hypokalemia can increase the sensitivity of the myocardium to entity2begin digitalis entity2end . 
true chemical chemical Digitalis Glycosides : entity1begin Diuretic entity1end - induced hypokalemia can increase the sensitivity of the myocardium to entity2begin digitalis entity2end . 
false chemical chemical entity1begin Corticosteroids entity1end or entity2begin ACTH entity2end : May increase the risk of hypokalemia and increase salt and water retention . 
false chemical chemical entity1begin Lithium entity1end : Serum entity2begin lithium entity2end levels may increase . 
false chemical chemical entity1begin Curariform Drugs entity1end : entity2begin Diuretic entity2end - induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs ( such as tubocurarine ) the most serious effect would be respiratory depression which could proceed to apnea . 
false chemical chemical entity1begin Curariform Drugs entity1end : Diuretic - induced hypokalemia may enhance neuromuscular blocking effects of entity2begin curariform drugs entity2end ( such as tubocurarine ) the most serious effect would be respiratory depression which could proceed to apnea . 
false chemical chemical entity1begin Curariform Drugs entity1end : Diuretic - induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs ( such as entity2begin tubocurarine entity2end ) the most serious effect would be respiratory depression which could proceed to apnea . 
true chemical chemical Curariform Drugs : entity1begin Diuretic entity1end - induced hypokalemia may enhance neuromuscular blocking effects of entity2begin curariform drugs entity2end ( such as tubocurarine ) the most serious effect would be respiratory depression which could proceed to apnea . 
true chemical chemical Curariform Drugs : entity1begin Diuretic entity1end - induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs ( such as entity2begin tubocurarine entity2end ) the most serious effect would be respiratory depression which could proceed to apnea . 
false chemical chemical Curariform Drugs : Diuretic - induced hypokalemia may enhance neuromuscular blocking effects of entity1begin curariform drugs entity1end ( such as entity2begin tubocurarine entity2end ) the most serious effect would be respiratory depression which could proceed to apnea . 
false chemical chemical entity1begin Salicylates entity1end and Other entity2begin Non - Steroidal Anti - Inflammatory Drugs entity2end : May decrease the antihypertensive effects of MYKROX Tablets . 
true chemical chemical entity1begin Salicylates entity1end and Other Non - Steroidal Anti - Inflammatory Drugs : May decrease the antihypertensive effects of entity2begin MYKROX entity2end Tablets . 
true chemical chemical Salicylates and Other entity1begin Non - Steroidal Anti - Inflammatory Drugs entity1end : May decrease the antihypertensive effects of entity2begin MYKROX entity2end Tablets . 
false chemical chemical entity1begin Sympathomimetics entity1end : entity2begin Metolazone entity2end may decrease arterial responsiveness to norepinephrine , but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use . 
false chemical chemical entity1begin Sympathomimetics entity1end : Metolazone may decrease arterial responsiveness to entity2begin norepinephrine entity2end , but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use . 
true chemical chemical Sympathomimetics : entity1begin Metolazone entity1end may decrease arterial responsiveness to entity2begin norepinephrine entity2end , but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use . 
true chemical chemical entity1begin Methenamine entity1end : Efficacy may be decreased due to urinary alkalizing effect of entity2begin metolazone entity2end . 
false chemical chemical entity1begin Anticoagulants entity1end : entity2begin Metolazone entity2end , as well as other thiazide - like diuretics , may affect the hypoprothrombinemic response to anticoagulants ; 
false chemical chemical entity1begin Anticoagulants entity1end : Metolazone , as well as other entity2begin thiazide - like diuretics entity2end , may affect the hypoprothrombinemic response to anticoagulants ; 
false chemical chemical entity1begin Anticoagulants entity1end : Metolazone , as well as other thiazide - like diuretics , may affect the hypoprothrombinemic response to entity2begin anticoagulants entity2end ; 
false chemical chemical Anticoagulants : entity1begin Metolazone entity1end , as well as other entity2begin thiazide - like diuretics entity2end , may affect the hypoprothrombinemic response to anticoagulants ; 
true chemical chemical Anticoagulants : entity1begin Metolazone entity1end , as well as other thiazide - like diuretics , may affect the hypoprothrombinemic response to entity2begin anticoagulants entity2end ; 
false chemical chemical Anticoagulants : Metolazone , as well as other entity1begin thiazide - like diuretics entity1end , may affect the hypoprothrombinemic response to entity2begin anticoagulants entity2end ; 
true chemical chemical Catecholamine - depleting drugs ( e.g. , entity1begin reserpine entity1end ) may have an additive effect when given with entity2begin beta - blocking agents entity2end . 
true chemical chemical Oral entity1begin metronidazole entity1end has been reported to potentiate the anticoagulant effect of entity2begin coumarin entity2end and warfarin , resulting in a prolongation of prothrombin time . 
true chemical chemical Oral entity1begin metronidazole entity1end has been reported to potentiate the anticoagulant effect of coumarin and entity2begin warfarin entity2end , resulting in a prolongation of prothrombin time . 
false chemical chemical Oral metronidazole has been reported to potentiate the anticoagulant effect of entity1begin coumarin entity1end and entity2begin warfarin entity2end , resulting in a prolongation of prothrombin time . 
false chemical chemical Drug interactions should be kept in mind when entity1begin METROGEL entity1end ( entity2begin metronidazole entity2end gel ) , 1 % is prescribed for patients who are receiving anticoagulant treatment , although they are less likely to occur with topical metronidazole administration because of low absorption . 
false chemical chemical Drug interactions should be kept in mind when entity1begin METROGEL entity1end ( metronidazole gel ) , 1 % is prescribed for patients who are receiving anticoagulant treatment , although they are less likely to occur with topical entity2begin metronidazole entity2end administration because of low absorption . 
false chemical chemical Drug interactions should be kept in mind when METROGEL ( entity1begin metronidazole entity1end gel ) , 1 % is prescribed for patients who are receiving anticoagulant treatment , although they are less likely to occur with topical entity2begin metronidazole entity2end administration because of low absorption . 
true chemical chemical The metabolism of entity1begin Metopirone entity1end is accelerated by entity2begin phenytoin entity2end ; 
true chemical chemical entity1begin Metopirone entity1end inhibits the glucuronidation of entity2begin acetaminophen entity2end and could possibly potentiate acetaminophen toxicity . 
true chemical chemical entity1begin Metopirone entity1end inhibits the glucuronidation of acetaminophen and could possibly potentiate entity2begin acetaminophen entity2end toxicity . 
false chemical chemical Metopirone inhibits the glucuronidation of entity1begin acetaminophen entity1end and could possibly potentiate entity2begin acetaminophen entity2end toxicity . 
true chemical chemical Caution should be observed in administering entity1begin DEMSER entity1end to patients receiving entity2begin phenothiazines entity2end or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis . 
true chemical chemical Caution should be observed in administering entity1begin DEMSER entity1end to patients receiving phenothiazines or entity2begin haloperidol entity2end because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis . 
false chemical chemical Caution should be observed in administering DEMSER to patients receiving entity1begin phenothiazines entity1end or entity2begin haloperidol entity2end because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis . 
true chemical chemical Concurrent use of entity1begin DEMSER entity1end with entity2begin alcohol entity2end or other CNS depressants can increase their sedative effects . 
true chemical chemical Concurrent use of entity1begin DEMSER entity1end with alcohol or other entity2begin CNS depressants entity2end can increase their sedative effects . 
false chemical chemical Concurrent use of DEMSER with entity1begin alcohol entity1end or other entity2begin CNS depressants entity2end can increase their sedative effects . 
false chemical chemical Since entity1begin MEXITIL entity1end is a substrate for the metabolic pathways involving CYP2D6 and CYP1A2 enzymes , inhibition or induction of either of these enzymes would be expected to alter entity2begin mexiletine entity2end plasma concentrations . 
true chemical chemical In a formal , single - dose interaction study ( n = 6 males ) the clearance of entity1begin mexiletine entity1end was decreased by 38 % following the coadministration of entity2begin fluvoxamine entity2end , an inhibitor of CYP1A2 . 
false chemical chemical In another formal study ( n = 8 extensive and n = 7 poor metabolizers of CYP2D6 ) , coadministration of entity1begin propafenone entity1end did not alter the kinetics of entity2begin mexiletine entity2end in the poor CYP2D6 metabolizer group . 
false chemical chemical In this crossover steady state study , the pharmacokinetics of entity1begin propafenone entity1end were unaffected in either phenotype by the coadministration of entity2begin mexiletine entity2end . 
false chemical chemical Addition of entity1begin mexiletine entity1end to entity2begin propafenone entity2end did not lead to further electrocardiographic parameters changes of QRS , QTc , RR , and PR intervals than propafenone alone . 
false chemical chemical Addition of entity1begin mexiletine entity1end to propafenone did not lead to further electrocardiographic parameters changes of QRS , QTc , RR , and PR intervals than entity2begin propafenone entity2end alone . 
false chemical chemical Addition of mexiletine to entity1begin propafenone entity1end did not lead to further electrocardiographic parameters changes of QRS , QTc , RR , and PR intervals than entity2begin propafenone entity2end alone . 
false chemical chemical When concomitant administration of either of these two drugs with entity1begin mexiletine entity1end is initiated , the dose of entity2begin mexiletine entity2end should be slowly titrated to desired effect . 
false chemical chemical In a large compassionate use program entity1begin Mexitil entity1end has been used concurrently with commonly employed antianginal , entity2begin antihypertensive entity2end , and anticoagulant drugs without observed interactions . 
false chemical chemical In a large compassionate use program entity1begin Mexitil entity1end has been used concurrently with commonly employed antianginal , antihypertensive , and entity2begin anticoagulant drugs entity2end without observed interactions . 
false chemical chemical In a large compassionate use program Mexitil has been used concurrently with commonly employed antianginal , entity1begin antihypertensive entity1end , and entity2begin anticoagulant drugs entity2end without observed interactions . 
false chemical chemical A variety of entity1begin antiarrhythmics entity1end such as entity2begin quinidine entity2end or propranolol were also added , sometimes with improved control of ventricular ectopy . 
false chemical chemical A variety of entity1begin antiarrhythmics entity1end such as quinidine or entity2begin propranolol entity2end were also added , sometimes with improved control of ventricular ectopy . 
false chemical chemical A variety of antiarrhythmics such as entity1begin quinidine entity1end or entity2begin propranolol entity2end were also added , sometimes with improved control of ventricular ectopy . 
false chemical chemical When entity1begin phenytoin entity1end or other hepatic enzyme inducers such as entity2begin rifampin entity2end and phenobarbital have been taken concurrently with Mexitil , lowered Mexitil plasma levels have been reported . 
false chemical chemical When entity1begin phenytoin entity1end or other hepatic enzyme inducers such as rifampin and entity2begin phenobarbital entity2end have been taken concurrently with Mexitil , lowered Mexitil plasma levels have been reported . 
true chemical chemical When entity1begin phenytoin entity1end or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with entity2begin Mexitil entity2end , lowered Mexitil plasma levels have been reported . 
false chemical chemical When entity1begin phenytoin entity1end or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil , lowered entity2begin Mexitil entity2end plasma levels have been reported . 
false chemical chemical When phenytoin or other hepatic enzyme inducers such as entity1begin rifampin entity1end and entity2begin phenobarbital entity2end have been taken concurrently with Mexitil , lowered Mexitil plasma levels have been reported . 
true chemical chemical When phenytoin or other hepatic enzyme inducers such as entity1begin rifampin entity1end and phenobarbital have been taken concurrently with entity2begin Mexitil entity2end , lowered Mexitil plasma levels have been reported . 
false chemical chemical When phenytoin or other hepatic enzyme inducers such as entity1begin rifampin entity1end and phenobarbital have been taken concurrently with Mexitil , lowered entity2begin Mexitil entity2end plasma levels have been reported . 
true chemical chemical When phenytoin or other hepatic enzyme inducers such as rifampin and entity1begin phenobarbital entity1end have been taken concurrently with entity2begin Mexitil entity2end , lowered Mexitil plasma levels have been reported . 
false chemical chemical When phenytoin or other hepatic enzyme inducers such as rifampin and entity1begin phenobarbital entity1end have been taken concurrently with Mexitil , lowered entity2begin Mexitil entity2end plasma levels have been reported . 
false chemical chemical When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with entity1begin Mexitil entity1end , lowered entity2begin Mexitil entity2end plasma levels have been reported . 
false chemical chemical In a formal study , entity1begin benzodiazepines entity1end were shown not to affect entity2begin Mexitil entity2end plasma concentrations . 
false chemical chemical ECG intervals ( PR , QRS , and QT ) were not affected by concurrent entity1begin Mexitil entity1end and entity2begin digoxin entity2end , diuretics , or propranolol . 
false chemical chemical ECG intervals ( PR , QRS , and QT ) were not affected by concurrent entity1begin Mexitil entity1end and digoxin , entity2begin diuretics entity2end , or propranolol . 
false chemical chemical ECG intervals ( PR , QRS , and QT ) were not affected by concurrent entity1begin Mexitil entity1end and digoxin , diuretics , or entity2begin propranolol entity2end . 
false chemical chemical ECG intervals ( PR , QRS , and QT ) were not affected by concurrent Mexitil and entity1begin digoxin entity1end , entity2begin diuretics entity2end , or propranolol . 
false chemical chemical ECG intervals ( PR , QRS , and QT ) were not affected by concurrent Mexitil and entity1begin digoxin entity1end , diuretics , or entity2begin propranolol entity2end . 
false chemical chemical ECG intervals ( PR , QRS , and QT ) were not affected by concurrent Mexitil and digoxin , entity1begin diuretics entity1end , or entity2begin propranolol entity2end . 
true chemical chemical Concurrent administration of entity1begin cimetidine entity1end and entity2begin Mexitil entity2end has been reported to increase , decrease , or leave unchanged Mexitil plasma levels ; 
false chemical chemical Concurrent administration of entity1begin cimetidine entity1end and Mexitil has been reported to increase , decrease , or leave unchanged entity2begin Mexitil entity2end plasma levels ; 
false chemical chemical Concurrent administration of cimetidine and entity1begin Mexitil entity1end has been reported to increase , decrease , or leave unchanged entity2begin Mexitil entity2end plasma levels ; 
false chemical chemical entity1begin Mexitil entity1end does not alter serum entity2begin digoxin entity2end levels but magnesium - aluminum hydroxide , when used to treat gastrointestinal symptoms due to Mexitil , has been reported to lower serum digoxin levels . 
false chemical chemical entity1begin Mexitil entity1end does not alter serum digoxin levels but entity2begin magnesium - aluminum hydroxide entity2end , when used to treat gastrointestinal symptoms due to Mexitil , has been reported to lower serum digoxin levels . 
false chemical chemical entity1begin Mexitil entity1end does not alter serum digoxin levels but magnesium - aluminum hydroxide , when used to treat gastrointestinal symptoms due to entity2begin Mexitil entity2end , has been reported to lower serum digoxin levels . 
false chemical chemical entity1begin Mexitil entity1end does not alter serum digoxin levels but magnesium - aluminum hydroxide , when used to treat gastrointestinal symptoms due to Mexitil , has been reported to lower serum entity2begin digoxin entity2end levels . 
false chemical chemical Mexitil does not alter serum entity1begin digoxin entity1end levels but entity2begin magnesium - aluminum hydroxide entity2end , when used to treat gastrointestinal symptoms due to Mexitil , has been reported to lower serum digoxin levels . 
false chemical chemical Mexitil does not alter serum entity1begin digoxin entity1end levels but magnesium - aluminum hydroxide , when used to treat gastrointestinal symptoms due to entity2begin Mexitil entity2end , has been reported to lower serum digoxin levels . 
false chemical chemical Mexitil does not alter serum entity1begin digoxin entity1end levels but magnesium - aluminum hydroxide , when used to treat gastrointestinal symptoms due to Mexitil , has been reported to lower serum entity2begin digoxin entity2end levels . 
false chemical chemical Mexitil does not alter serum digoxin levels but entity1begin magnesium - aluminum hydroxide entity1end , when used to treat gastrointestinal symptoms due to entity2begin Mexitil entity2end , has been reported to lower serum digoxin levels . 
true chemical chemical Mexitil does not alter serum digoxin levels but entity1begin magnesium - aluminum hydroxide entity1end , when used to treat gastrointestinal symptoms due to Mexitil , has been reported to lower serum entity2begin digoxin entity2end levels . 
false chemical chemical Mexitil does not alter serum digoxin levels but magnesium - aluminum hydroxide , when used to treat gastrointestinal symptoms due to entity1begin Mexitil entity1end , has been reported to lower serum entity2begin digoxin entity2end levels . 
true chemical chemical Concurrent use of entity1begin Mexitil entity1end and entity2begin theophylline entity2end may lead to increased plasma theophylline levels . 
false chemical chemical Concurrent use of entity1begin Mexitil entity1end and theophylline may lead to increased plasma entity2begin theophylline entity2end levels . 
false chemical chemical Concurrent use of Mexitil and entity1begin theophylline entity1end may lead to increased plasma entity2begin theophylline entity2end levels . 
false chemical chemical This increase was observed at the first test point which was the second day after starting entity1begin Mexitil entity1end . entity2begin Theophylline entity2end plasma levels returned to pre - Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 
false chemical chemical This increase was observed at the first test point which was the second day after starting entity1begin Mexitil entity1end . Theophylline plasma levels returned to pre - entity2begin Mexitil entity2end values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 
false chemical chemical This increase was observed at the first test point which was the second day after starting entity1begin Mexitil entity1end . Theophylline plasma levels returned to pre - Mexitil values within 48 hours after discontinuing entity2begin Mexitil entity2end . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 
false chemical chemical This increase was observed at the first test point which was the second day after starting entity1begin Mexitil entity1end . Theophylline plasma levels returned to pre - Mexitil values within 48 hours after discontinuing Mexitil . If entity2begin Mexitil entity2end and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 
false chemical chemical This increase was observed at the first test point which was the second day after starting entity1begin Mexitil entity1end . Theophylline plasma levels returned to pre - Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and entity2begin theophylline entity2end are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 
false chemical chemical This increase was observed at the first test point which was the second day after starting entity1begin Mexitil entity1end . Theophylline plasma levels returned to pre - Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , entity2begin theophylline entity2end blood levels should be monitored , particularly when the Mexitil dose is changed . 
false chemical chemical This increase was observed at the first test point which was the second day after starting entity1begin Mexitil entity1end . Theophylline plasma levels returned to pre - Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the entity2begin Mexitil entity2end dose is changed . 
false chemical chemical This increase was observed at the first test point which was the second day after starting Mexitil . entity1begin Theophylline entity1end plasma levels returned to pre - entity2begin Mexitil entity2end values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 
true chemical chemical This increase was observed at the first test point which was the second day after starting Mexitil . entity1begin Theophylline entity1end plasma levels returned to pre - Mexitil values within 48 hours after discontinuing entity2begin Mexitil entity2end . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 
false chemical chemical This increase was observed at the first test point which was the second day after starting Mexitil . entity1begin Theophylline entity1end plasma levels returned to pre - Mexitil values within 48 hours after discontinuing Mexitil . If entity2begin Mexitil entity2end and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 
false chemical chemical This increase was observed at the first test point which was the second day after starting Mexitil . entity1begin Theophylline entity1end plasma levels returned to pre - Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and entity2begin theophylline entity2end are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 
false chemical chemical This increase was observed at the first test point which was the second day after starting Mexitil . entity1begin Theophylline entity1end plasma levels returned to pre - Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , entity2begin theophylline entity2end blood levels should be monitored , particularly when the Mexitil dose is changed . 
false chemical chemical This increase was observed at the first test point which was the second day after starting Mexitil . entity1begin Theophylline entity1end plasma levels returned to pre - Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the entity2begin Mexitil entity2end dose is changed . 
false chemical chemical This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre - entity1begin Mexitil entity1end values within 48 hours after discontinuing entity2begin Mexitil entity2end . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 
false chemical chemical This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre - entity1begin Mexitil entity1end values within 48 hours after discontinuing Mexitil . If entity2begin Mexitil entity2end and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 
false chemical chemical This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre - entity1begin Mexitil entity1end values within 48 hours after discontinuing Mexitil . If Mexitil and entity2begin theophylline entity2end are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 
false chemical chemical This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre - entity1begin Mexitil entity1end values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , entity2begin theophylline entity2end blood levels should be monitored , particularly when the Mexitil dose is changed . 
false chemical chemical This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre - entity1begin Mexitil entity1end values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the entity2begin Mexitil entity2end dose is changed . 
false chemical chemical This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre - Mexitil values within 48 hours after discontinuing entity1begin Mexitil entity1end . If entity2begin Mexitil entity2end and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 
false chemical chemical This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre - Mexitil values within 48 hours after discontinuing entity1begin Mexitil entity1end . If Mexitil and entity2begin theophylline entity2end are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 
false chemical chemical This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre - Mexitil values within 48 hours after discontinuing entity1begin Mexitil entity1end . If Mexitil and theophylline are to be used concurrently , entity2begin theophylline entity2end blood levels should be monitored , particularly when the Mexitil dose is changed . 
false chemical chemical This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre - Mexitil values within 48 hours after discontinuing entity1begin Mexitil entity1end . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the entity2begin Mexitil entity2end dose is changed . 
true chemical chemical This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre - Mexitil values within 48 hours after discontinuing Mexitil . If entity1begin Mexitil entity1end and entity2begin theophylline entity2end are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . 
false chemical chemical This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre - Mexitil values within 48 hours after discontinuing Mexitil . If entity1begin Mexitil entity1end and theophylline are to be used concurrently , entity2begin theophylline entity2end blood levels should be monitored , particularly when the Mexitil dose is changed . 
false chemical chemical This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre - Mexitil values within 48 hours after discontinuing Mexitil . If entity1begin Mexitil entity1end and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the entity2begin Mexitil entity2end dose is changed . 
false chemical chemical This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre - Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and entity1begin theophylline entity1end are to be used concurrently , entity2begin theophylline entity2end blood levels should be monitored , particularly when the Mexitil dose is changed . 
false chemical chemical This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre - Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and entity1begin theophylline entity1end are to be used concurrently , theophylline blood levels should be monitored , particularly when the entity2begin Mexitil entity2end dose is changed . 
false chemical chemical This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre - Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , entity1begin theophylline entity1end blood levels should be monitored , particularly when the entity2begin Mexitil entity2end dose is changed . 
true chemical chemical Additionally , in one controlled study in five normal subjects and seven patients , the clearance of entity1begin caffeine entity1end was decreased 50 % following the administration of entity2begin Mexitil entity2end . 
true chemical chemical entity1begin Posicor entity1end inhibits some of the liver 's ability to metabolize some other drugs - entity2begin terfenadine entity2end , astemizole , cisapride , cyclosporine , and tricyclic antidepressants . 
true chemical chemical entity1begin Posicor entity1end inhibits some of the liver 's ability to metabolize some other drugs - terfenadine , entity2begin astemizole entity2end , cisapride , cyclosporine , and tricyclic antidepressants . 
true chemical chemical entity1begin Posicor entity1end inhibits some of the liver 's ability to metabolize some other drugs - terfenadine , astemizole , entity2begin cisapride entity2end , cyclosporine , and tricyclic antidepressants . 
true chemical chemical entity1begin Posicor entity1end inhibits some of the liver 's ability to metabolize some other drugs - terfenadine , astemizole , cisapride , entity2begin cyclosporine entity2end , and tricyclic antidepressants . 
true chemical chemical entity1begin Posicor entity1end inhibits some of the liver 's ability to metabolize some other drugs - terfenadine , astemizole , cisapride , cyclosporine , and entity2begin tricyclic antidepressants entity2end . 
false chemical chemical Posicor inhibits some of the liver 's ability to metabolize some other drugs - entity1begin terfenadine entity1end , entity2begin astemizole entity2end , cisapride , cyclosporine , and tricyclic antidepressants . 
false chemical chemical Posicor inhibits some of the liver 's ability to metabolize some other drugs - entity1begin terfenadine entity1end , astemizole , entity2begin cisapride entity2end , cyclosporine , and tricyclic antidepressants . 
false chemical chemical Posicor inhibits some of the liver 's ability to metabolize some other drugs - entity1begin terfenadine entity1end , astemizole , cisapride , entity2begin cyclosporine entity2end , and tricyclic antidepressants . 
false chemical chemical Posicor inhibits some of the liver 's ability to metabolize some other drugs - entity1begin terfenadine entity1end , astemizole , cisapride , cyclosporine , and entity2begin tricyclic antidepressants entity2end . 
false chemical chemical Posicor inhibits some of the liver 's ability to metabolize some other drugs - terfenadine , entity1begin astemizole entity1end , entity2begin cisapride entity2end , cyclosporine , and tricyclic antidepressants . 
false chemical chemical Posicor inhibits some of the liver 's ability to metabolize some other drugs - terfenadine , entity1begin astemizole entity1end , cisapride , entity2begin cyclosporine entity2end , and tricyclic antidepressants . 
false chemical chemical Posicor inhibits some of the liver 's ability to metabolize some other drugs - terfenadine , entity1begin astemizole entity1end , cisapride , cyclosporine , and entity2begin tricyclic antidepressants entity2end . 
false chemical chemical Posicor inhibits some of the liver 's ability to metabolize some other drugs - terfenadine , astemizole , entity1begin cisapride entity1end , entity2begin cyclosporine entity2end , and tricyclic antidepressants . 
false chemical chemical Posicor inhibits some of the liver 's ability to metabolize some other drugs - terfenadine , astemizole , entity1begin cisapride entity1end , cyclosporine , and entity2begin tricyclic antidepressants entity2end . 
false chemical chemical Posicor inhibits some of the liver 's ability to metabolize some other drugs - terfenadine , astemizole , cisapride , entity1begin cyclosporine entity1end , and entity2begin tricyclic antidepressants entity2end . 
false chemical chemical A total of 11 clinical drug - drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between entity1begin MYCAMINE entity1end and entity2begin mycophenolate mofetil entity2end , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
false chemical chemical A total of 11 clinical drug - drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between entity1begin MYCAMINE entity1end and mycophenolate mofetil , entity2begin cyclosporine entity2end , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
false chemical chemical A total of 11 clinical drug - drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between entity1begin MYCAMINE entity1end and mycophenolate mofetil , cyclosporine , entity2begin tacrolimus entity2end , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
false chemical chemical A total of 11 clinical drug - drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between entity1begin MYCAMINE entity1end and mycophenolate mofetil , cyclosporine , tacrolimus , entity2begin prednisolone entity2end , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
false chemical chemical A total of 11 clinical drug - drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between entity1begin MYCAMINE entity1end and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , entity2begin sirolimus entity2end , nifedipine , fluconazole , ritonavir , and rifampin . 
false chemical chemical A total of 11 clinical drug - drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between entity1begin MYCAMINE entity1end and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , entity2begin nifedipine entity2end , fluconazole , ritonavir , and rifampin . 
false chemical chemical A total of 11 clinical drug - drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between entity1begin MYCAMINE entity1end and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , entity2begin fluconazole entity2end , ritonavir , and rifampin . 
false chemical chemical A total of 11 clinical drug - drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between entity1begin MYCAMINE entity1end and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , entity2begin ritonavir entity2end , and rifampin . 
false chemical chemical A total of 11 clinical drug - drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between entity1begin MYCAMINE entity1end and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and entity2begin rifampin entity2end . 
false chemical chemical A total of 11 clinical drug - drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and entity1begin mycophenolate mofetil entity1end , entity2begin cyclosporine entity2end , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
false chemical chemical A total of 11 clinical drug - drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and entity1begin mycophenolate mofetil entity1end , cyclosporine , entity2begin tacrolimus entity2end , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
false chemical chemical A total of 11 clinical drug - drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and entity1begin mycophenolate mofetil entity1end , cyclosporine , tacrolimus , entity2begin prednisolone entity2end , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
false chemical chemical A total of 11 clinical drug - drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and entity1begin mycophenolate mofetil entity1end , cyclosporine , tacrolimus , prednisolone , entity2begin sirolimus entity2end , nifedipine , fluconazole , ritonavir , and rifampin . 
false chemical chemical A total of 11 clinical drug - drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and entity1begin mycophenolate mofetil entity1end , cyclosporine , tacrolimus , prednisolone , sirolimus , entity2begin nifedipine entity2end , fluconazole , ritonavir , and rifampin . 
false chemical chemical A total of 11 clinical drug - drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and entity1begin mycophenolate mofetil entity1end , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , entity2begin fluconazole entity2end , ritonavir , and rifampin . 
false chemical chemical A total of 11 clinical drug - drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and entity1begin mycophenolate mofetil entity1end , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , entity2begin ritonavir entity2end , and rifampin . 
false chemical chemical A total of 11 clinical drug - drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and entity1begin mycophenolate mofetil entity1end , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and entity2begin rifampin entity2end . 
false chemical chemical A total of 11 clinical drug - drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , entity1begin cyclosporine entity1end , entity2begin tacrolimus entity2end , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
false chemical chemical A total of 11 clinical drug - drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , entity1begin cyclosporine entity1end , tacrolimus , entity2begin prednisolone entity2end , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
false chemical chemical A total of 11 clinical drug - drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , entity1begin cyclosporine entity1end , tacrolimus , prednisolone , entity2begin sirolimus entity2end , nifedipine , fluconazole , ritonavir , and rifampin . 
false chemical chemical A total of 11 clinical drug - drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , entity1begin cyclosporine entity1end , tacrolimus , prednisolone , sirolimus , entity2begin nifedipine entity2end , fluconazole , ritonavir , and rifampin . 
false chemical chemical A total of 11 clinical drug - drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , entity1begin cyclosporine entity1end , tacrolimus , prednisolone , sirolimus , nifedipine , entity2begin fluconazole entity2end , ritonavir , and rifampin . 
false chemical chemical A total of 11 clinical drug - drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , entity1begin cyclosporine entity1end , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , entity2begin ritonavir entity2end , and rifampin . 
false chemical chemical A total of 11 clinical drug - drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , entity1begin cyclosporine entity1end , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and entity2begin rifampin entity2end . 
false chemical chemical A total of 11 clinical drug - drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , entity1begin tacrolimus entity1end , entity2begin prednisolone entity2end , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . 
false chemical chemical A total of 11 clinical drug - drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , entity1begin tacrolimus entity1end , prednisolone , entity2begin sirolimus entity2end , nifedipine , fluconazole , ritonavir , and rifampin . 
false chemical chemical A total of 11 clinical drug - drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , entity1begin tacrolimus entity1end , prednisolone , sirolimus , entity2begin nifedipine entity2end , fluconazole , ritonavir , and rifampin . 
false chemical chemical A total of 11 clinical drug - drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , entity1begin tacrolimus entity1end , prednisolone , sirolimus , nifedipine , entity2begin fluconazole entity2end , ritonavir , and rifampin . 
false chemical chemical A total of 11 clinical drug - drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , entity1begin tacrolimus entity1end , prednisolone , sirolimus , nifedipine , fluconazole , entity2begin ritonavir entity2end , and rifampin . 
false chemical chemical A total of 11 clinical drug - drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , entity1begin tacrolimus entity1end , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and entity2begin rifampin entity2end . 
false chemical chemical A total of 11 clinical drug - drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , entity1begin prednisolone entity1end , entity2begin sirolimus entity2end , nifedipine , fluconazole , ritonavir , and rifampin . 
false chemical chemical A total of 11 clinical drug - drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , entity1begin prednisolone entity1end , sirolimus , entity2begin nifedipine entity2end , fluconazole , ritonavir , and rifampin . 
false chemical chemical A total of 11 clinical drug - drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , entity1begin prednisolone entity1end , sirolimus , nifedipine , entity2begin fluconazole entity2end , ritonavir , and rifampin . 
false chemical chemical A total of 11 clinical drug - drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , entity1begin prednisolone entity1end , sirolimus , nifedipine , fluconazole , entity2begin ritonavir entity2end , and rifampin . 
false chemical chemical A total of 11 clinical drug - drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , entity1begin prednisolone entity1end , sirolimus , nifedipine , fluconazole , ritonavir , and entity2begin rifampin entity2end . 
false chemical chemical A total of 11 clinical drug - drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , entity1begin sirolimus entity1end , entity2begin nifedipine entity2end , fluconazole , ritonavir , and rifampin . 
false chemical chemical A total of 11 clinical drug - drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , entity1begin sirolimus entity1end , nifedipine , entity2begin fluconazole entity2end , ritonavir , and rifampin . 
false chemical chemical A total of 11 clinical drug - drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , entity1begin sirolimus entity1end , nifedipine , fluconazole , entity2begin ritonavir entity2end , and rifampin . 
false chemical chemical A total of 11 clinical drug - drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , entity1begin sirolimus entity1end , nifedipine , fluconazole , ritonavir , and entity2begin rifampin entity2end . 
false chemical chemical A total of 11 clinical drug - drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , entity1begin nifedipine entity1end , entity2begin fluconazole entity2end , ritonavir , and rifampin . 
false chemical chemical A total of 11 clinical drug - drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , entity1begin nifedipine entity1end , fluconazole , entity2begin ritonavir entity2end , and rifampin . 
false chemical chemical A total of 11 clinical drug - drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , entity1begin nifedipine entity1end , fluconazole , ritonavir , and entity2begin rifampin entity2end . 
false chemical chemical A total of 11 clinical drug - drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , entity1begin fluconazole entity1end , entity2begin ritonavir entity2end , and rifampin . 
false chemical chemical A total of 11 clinical drug - drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , entity1begin fluconazole entity1end , ritonavir , and entity2begin rifampin entity2end . 
false chemical chemical A total of 11 clinical drug - drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , entity1begin ritonavir entity1end , and entity2begin rifampin entity2end . 
false chemical chemical There was no effect of a single dose or multiple doses of entity1begin MYCAMINE entity1end on entity2begin mycophenolate mofetil entity2end , cyclosporine , tacrolimus , prednisolone , and fluconazole pharmacokinetics . 
false chemical chemical There was no effect of a single dose or multiple doses of entity1begin MYCAMINE entity1end on mycophenolate mofetil , entity2begin cyclosporine entity2end , tacrolimus , prednisolone , and fluconazole pharmacokinetics . 
false chemical chemical There was no effect of a single dose or multiple doses of entity1begin MYCAMINE entity1end on mycophenolate mofetil , cyclosporine , entity2begin tacrolimus entity2end , prednisolone , and fluconazole pharmacokinetics . 
false chemical chemical There was no effect of a single dose or multiple doses of entity1begin MYCAMINE entity1end on mycophenolate mofetil , cyclosporine , tacrolimus , entity2begin prednisolone entity2end , and fluconazole pharmacokinetics . 
false chemical chemical There was no effect of a single dose or multiple doses of entity1begin MYCAMINE entity1end on mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , and entity2begin fluconazole entity2end pharmacokinetics . 
false chemical chemical There was no effect of a single dose or multiple doses of MYCAMINE on entity1begin mycophenolate mofetil entity1end , entity2begin cyclosporine entity2end , tacrolimus , prednisolone , and fluconazole pharmacokinetics . 
false chemical chemical There was no effect of a single dose or multiple doses of MYCAMINE on entity1begin mycophenolate mofetil entity1end , cyclosporine , entity2begin tacrolimus entity2end , prednisolone , and fluconazole pharmacokinetics . 
false chemical chemical There was no effect of a single dose or multiple doses of MYCAMINE on entity1begin mycophenolate mofetil entity1end , cyclosporine , tacrolimus , entity2begin prednisolone entity2end , and fluconazole pharmacokinetics . 
false chemical chemical There was no effect of a single dose or multiple doses of MYCAMINE on entity1begin mycophenolate mofetil entity1end , cyclosporine , tacrolimus , prednisolone , and entity2begin fluconazole entity2end pharmacokinetics . 
false chemical chemical There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil , entity1begin cyclosporine entity1end , entity2begin tacrolimus entity2end , prednisolone , and fluconazole pharmacokinetics . 
false chemical chemical There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil , entity1begin cyclosporine entity1end , tacrolimus , entity2begin prednisolone entity2end , and fluconazole pharmacokinetics . 
false chemical chemical There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil , entity1begin cyclosporine entity1end , tacrolimus , prednisolone , and entity2begin fluconazole entity2end pharmacokinetics . 
false chemical chemical There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil , cyclosporine , entity1begin tacrolimus entity1end , entity2begin prednisolone entity2end , and fluconazole pharmacokinetics . 
false chemical chemical There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil , cyclosporine , entity1begin tacrolimus entity1end , prednisolone , and entity2begin fluconazole entity2end pharmacokinetics . 
false chemical chemical There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil , cyclosporine , tacrolimus , entity1begin prednisolone entity1end , and entity2begin fluconazole entity2end pharmacokinetics . 
true chemical chemical entity1begin Sirolimus entity1end AUC was increased by 21 % with no effect on Cmax in the presence of steady - state entity2begin MYCAMINE entity2end compared with sirolimus alone . 
false chemical chemical entity1begin Sirolimus entity1end AUC was increased by 21 % with no effect on Cmax in the presence of steady - state MYCAMINE compared with entity2begin sirolimus entity2end alone . 
false chemical chemical Sirolimus AUC was increased by 21 % with no effect on Cmax in the presence of steady - state entity1begin MYCAMINE entity1end compared with entity2begin sirolimus entity2end alone . 
true chemical chemical entity1begin Nifedipine entity1end AUC and Cmax were increased by 18 % and 42 % , respectively , in the presence of steady - state entity2begin MYCAMINE entity2end compared with nifedipine alone . 
false chemical chemical entity1begin Nifedipine entity1end AUC and Cmax were increased by 18 % and 42 % , respectively , in the presence of steady - state MYCAMINE compared with entity2begin nifedipine entity2end alone . 
false chemical chemical Nifedipine AUC and Cmax were increased by 18 % and 42 % , respectively , in the presence of steady - state entity1begin MYCAMINE entity1end compared with entity2begin nifedipine entity2end alone . 
false chemical chemical Patients receiving entity1begin sirolimus entity1end or entity2begin nifedipine entity2end in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary . 
true chemical chemical Patients receiving entity1begin sirolimus entity1end or nifedipine in combination with entity2begin MYCAMINE entity2end should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary . 
false chemical chemical Patients receiving entity1begin sirolimus entity1end or nifedipine in combination with MYCAMINE should be monitored for entity2begin sirolimus entity2end or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary . 
false chemical chemical Patients receiving entity1begin sirolimus entity1end or nifedipine in combination with MYCAMINE should be monitored for sirolimus or entity2begin nifedipine entity2end toxicity and sirolimus or nifedipine dosage should be reduced if necessary . 
false chemical chemical Patients receiving entity1begin sirolimus entity1end or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and entity2begin sirolimus entity2end or nifedipine dosage should be reduced if necessary . 
false chemical chemical Patients receiving entity1begin sirolimus entity1end or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or entity2begin nifedipine entity2end dosage should be reduced if necessary . 
true chemical chemical Patients receiving sirolimus or entity1begin nifedipine entity1end in combination with entity2begin MYCAMINE entity2end should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary . 
false chemical chemical Patients receiving sirolimus or entity1begin nifedipine entity1end in combination with MYCAMINE should be monitored for entity2begin sirolimus entity2end or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary . 
false chemical chemical Patients receiving sirolimus or entity1begin nifedipine entity1end in combination with MYCAMINE should be monitored for sirolimus or entity2begin nifedipine entity2end toxicity and sirolimus or nifedipine dosage should be reduced if necessary . 
false chemical chemical Patients receiving sirolimus or entity1begin nifedipine entity1end in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and entity2begin sirolimus entity2end or nifedipine dosage should be reduced if necessary . 
false chemical chemical Patients receiving sirolimus or entity1begin nifedipine entity1end in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or entity2begin nifedipine entity2end dosage should be reduced if necessary . 
false chemical chemical Patients receiving sirolimus or nifedipine in combination with entity1begin MYCAMINE entity1end should be monitored for entity2begin sirolimus entity2end or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary . 
false chemical chemical Patients receiving sirolimus or nifedipine in combination with entity1begin MYCAMINE entity1end should be monitored for sirolimus or entity2begin nifedipine entity2end toxicity and sirolimus or nifedipine dosage should be reduced if necessary . 
false chemical chemical Patients receiving sirolimus or nifedipine in combination with entity1begin MYCAMINE entity1end should be monitored for sirolimus or nifedipine toxicity and entity2begin sirolimus entity2end or nifedipine dosage should be reduced if necessary . 
false chemical chemical Patients receiving sirolimus or nifedipine in combination with entity1begin MYCAMINE entity1end should be monitored for sirolimus or nifedipine toxicity and sirolimus or entity2begin nifedipine entity2end dosage should be reduced if necessary . 
false chemical chemical Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for entity1begin sirolimus entity1end or entity2begin nifedipine entity2end toxicity and sirolimus or nifedipine dosage should be reduced if necessary . 
false chemical chemical Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for entity1begin sirolimus entity1end or nifedipine toxicity and entity2begin sirolimus entity2end or nifedipine dosage should be reduced if necessary . 
false chemical chemical Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for entity1begin sirolimus entity1end or nifedipine toxicity and sirolimus or entity2begin nifedipine entity2end dosage should be reduced if necessary . 
false chemical chemical Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or entity1begin nifedipine entity1end toxicity and entity2begin sirolimus entity2end or nifedipine dosage should be reduced if necessary . 
false chemical chemical Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or entity1begin nifedipine entity1end toxicity and sirolimus or entity2begin nifedipine entity2end dosage should be reduced if necessary . 
false chemical chemical Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and entity1begin sirolimus entity1end or entity2begin nifedipine entity2end dosage should be reduced if necessary . 
true chemical chemical Drug Interactions : Inhibitors of CYP3A4 Isozymes : Caution is advised when entity1begin midazolam entity1end is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system ( ie , some drugs in the drug classes of entity2begin azole antimycotics entity2end , protease inhibitors , calcium channel antagonists , and macrolide antibiotics ) . 
true chemical chemical Drug Interactions : Inhibitors of CYP3A4 Isozymes : Caution is advised when entity1begin midazolam entity1end is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system ( ie , some drugs in the drug classes of azole antimycotics , entity2begin protease inhibitors entity2end , calcium channel antagonists , and macrolide antibiotics ) . 
true chemical chemical Drug Interactions : Inhibitors of CYP3A4 Isozymes : Caution is advised when entity1begin midazolam entity1end is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system ( ie , some drugs in the drug classes of azole antimycotics , protease inhibitors , entity2begin calcium channel antagonists entity2end , and macrolide antibiotics ) . 
true chemical chemical Drug Interactions : Inhibitors of CYP3A4 Isozymes : Caution is advised when entity1begin midazolam entity1end is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system ( ie , some drugs in the drug classes of azole antimycotics , protease inhibitors , calcium channel antagonists , and entity2begin macrolide antibiotics entity2end ) . 
false chemical chemical Drug Interactions : Inhibitors of CYP3A4 Isozymes : Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system ( ie , some drugs in the drug classes of entity1begin azole antimycotics entity1end , entity2begin protease inhibitors entity2end , calcium channel antagonists , and macrolide antibiotics ) . 
false chemical chemical Drug Interactions : Inhibitors of CYP3A4 Isozymes : Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system ( ie , some drugs in the drug classes of entity1begin azole antimycotics entity1end , protease inhibitors , entity2begin calcium channel antagonists entity2end , and macrolide antibiotics ) . 
false chemical chemical Drug Interactions : Inhibitors of CYP3A4 Isozymes : Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system ( ie , some drugs in the drug classes of entity1begin azole antimycotics entity1end , protease inhibitors , calcium channel antagonists , and entity2begin macrolide antibiotics entity2end ) . 
false chemical chemical Drug Interactions : Inhibitors of CYP3A4 Isozymes : Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system ( ie , some drugs in the drug classes of azole antimycotics , entity1begin protease inhibitors entity1end , entity2begin calcium channel antagonists entity2end , and macrolide antibiotics ) . 
false chemical chemical Drug Interactions : Inhibitors of CYP3A4 Isozymes : Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system ( ie , some drugs in the drug classes of azole antimycotics , entity1begin protease inhibitors entity1end , calcium channel antagonists , and entity2begin macrolide antibiotics entity2end ) . 
false chemical chemical Drug Interactions : Inhibitors of CYP3A4 Isozymes : Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system ( ie , some drugs in the drug classes of azole antimycotics , protease inhibitors , entity1begin calcium channel antagonists entity1end , and entity2begin macrolide antibiotics entity2end ) . 
false chemical chemical Drugs such as entity1begin erythromycin entity1end , entity2begin diltiazem entity2end , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . 
false chemical chemical Drugs such as entity1begin erythromycin entity1end , diltiazem , entity2begin verapamil entity2end , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . 
false chemical chemical Drugs such as entity1begin erythromycin entity1end , diltiazem , verapamil , entity2begin ketoconazole entity2end , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . 
false chemical chemical Drugs such as entity1begin erythromycin entity1end , diltiazem , verapamil , ketoconazole , entity2begin fluconazole entity2end and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . 
false chemical chemical Drugs such as entity1begin erythromycin entity1end , diltiazem , verapamil , ketoconazole , fluconazole and entity2begin itraconazole entity2end were shown to significantly increase the C max and AUC of orally administered midazolam . 
true chemical chemical Drugs such as entity1begin erythromycin entity1end , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered entity2begin midazolam entity2end . 
false chemical chemical Drugs such as erythromycin , entity1begin diltiazem entity1end , entity2begin verapamil entity2end , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . 
false chemical chemical Drugs such as erythromycin , entity1begin diltiazem entity1end , verapamil , entity2begin ketoconazole entity2end , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . 
false chemical chemical Drugs such as erythromycin , entity1begin diltiazem entity1end , verapamil , ketoconazole , entity2begin fluconazole entity2end and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . 
false chemical chemical Drugs such as erythromycin , entity1begin diltiazem entity1end , verapamil , ketoconazole , fluconazole and entity2begin itraconazole entity2end were shown to significantly increase the C max and AUC of orally administered midazolam . 
true chemical chemical Drugs such as erythromycin , entity1begin diltiazem entity1end , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered entity2begin midazolam entity2end . 
false chemical chemical Drugs such as erythromycin , diltiazem , entity1begin verapamil entity1end , entity2begin ketoconazole entity2end , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . 
false chemical chemical Drugs such as erythromycin , diltiazem , entity1begin verapamil entity1end , ketoconazole , entity2begin fluconazole entity2end and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . 
false chemical chemical Drugs such as erythromycin , diltiazem , entity1begin verapamil entity1end , ketoconazole , fluconazole and entity2begin itraconazole entity2end were shown to significantly increase the C max and AUC of orally administered midazolam . 
true chemical chemical Drugs such as erythromycin , diltiazem , entity1begin verapamil entity1end , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered entity2begin midazolam entity2end . 
false chemical chemical Drugs such as erythromycin , diltiazem , verapamil , entity1begin ketoconazole entity1end , entity2begin fluconazole entity2end and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . 
false chemical chemical Drugs such as erythromycin , diltiazem , verapamil , entity1begin ketoconazole entity1end , fluconazole and entity2begin itraconazole entity2end were shown to significantly increase the C max and AUC of orally administered midazolam . 
true chemical chemical Drugs such as erythromycin , diltiazem , verapamil , entity1begin ketoconazole entity1end , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered entity2begin midazolam entity2end . 
false chemical chemical Drugs such as erythromycin , diltiazem , verapamil , ketoconazole , entity1begin fluconazole entity1end and entity2begin itraconazole entity2end were shown to significantly increase the C max and AUC of orally administered midazolam . 
true chemical chemical Drugs such as erythromycin , diltiazem , verapamil , ketoconazole , entity1begin fluconazole entity1end and itraconazole were shown to significantly increase the C max and AUC of orally administered entity2begin midazolam entity2end . 
true chemical chemical Drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and entity1begin itraconazole entity1end were shown to significantly increase the C max and AUC of orally administered entity2begin midazolam entity2end . 
false chemical chemical Although not studied , the potent cytochrome P450 3A4 inhibitors entity1begin ritonavir entity1end and entity2begin nelfinavir entity2end may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam . 
true chemical chemical Although not studied , the potent cytochrome P450 3A4 inhibitors entity1begin ritonavir entity1end and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of entity2begin midazolam entity2end . 
true chemical chemical Although not studied , the potent cytochrome P450 3A4 inhibitors ritonavir and entity1begin nelfinavir entity1end may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of entity2begin midazolam entity2end . 
false chemical chemical Inducers of CYP3A4 Isozymes : Cytochrome P450 inducers , such as entity1begin rifampin entity1end , entity2begin carbamazepine entity2end , and phenytoin , induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies . 
false chemical chemical Inducers of CYP3A4 Isozymes : Cytochrome P450 inducers , such as entity1begin rifampin entity1end , carbamazepine , and entity2begin phenytoin entity2end , induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies . 
true chemical chemical Inducers of CYP3A4 Isozymes : Cytochrome P450 inducers , such as entity1begin rifampin entity1end , carbamazepine , and phenytoin , induce metabolism and caused a markedly decreased C max and AUC of oral entity2begin midazolam entity2end in adult studies . 
false chemical chemical Inducers of CYP3A4 Isozymes : Cytochrome P450 inducers , such as rifampin , entity1begin carbamazepine entity1end , and entity2begin phenytoin entity2end , induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies . 
true chemical chemical Inducers of CYP3A4 Isozymes : Cytochrome P450 inducers , such as rifampin , entity1begin carbamazepine entity1end , and phenytoin , induce metabolism and caused a markedly decreased C max and AUC of oral entity2begin midazolam entity2end in adult studies . 
true chemical chemical Inducers of CYP3A4 Isozymes : Cytochrome P450 inducers , such as rifampin , carbamazepine , and entity1begin phenytoin entity1end , induce metabolism and caused a markedly decreased C max and AUC of oral entity2begin midazolam entity2end in adult studies . 
false chemical chemical The difficulty in achieving adequate sedation may have been the result of decreased absorption of the entity1begin sedatives entity1end due to both the gastrointestinal effects and stimulant effects of entity2begin methylphenidate entity2end . 
true chemical chemical The sedative effect of entity1begin VERSED Syrup entity1end is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly entity2begin narcotics entity2end ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
true chemical chemical The sedative effect of entity1begin VERSED Syrup entity1end is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , entity2begin morphine entity2end , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
true chemical chemical The sedative effect of entity1begin VERSED Syrup entity1end is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , entity2begin meperidine entity2end and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
true chemical chemical The sedative effect of entity1begin VERSED Syrup entity1end is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and entity2begin fentanyl entity2end ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
true chemical chemical The sedative effect of entity1begin VERSED Syrup entity1end is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , entity2begin propofol entity2end , ketamine , nitrous oxide , secobarbital and droperidol . 
true chemical chemical The sedative effect of entity1begin VERSED Syrup entity1end is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , entity2begin ketamine entity2end , nitrous oxide , secobarbital and droperidol . 
true chemical chemical The sedative effect of entity1begin VERSED Syrup entity1end is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , entity2begin nitrous oxide entity2end , secobarbital and droperidol . 
true chemical chemical The sedative effect of entity1begin VERSED Syrup entity1end is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , entity2begin secobarbital entity2end and droperidol . 
true chemical chemical The sedative effect of entity1begin VERSED Syrup entity1end is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and entity2begin droperidol entity2end . 
false chemical chemical The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly entity1begin narcotics entity1end ( eg , entity2begin morphine entity2end , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
false chemical chemical The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly entity1begin narcotics entity1end ( eg , morphine , entity2begin meperidine entity2end and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
false chemical chemical The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly entity1begin narcotics entity1end ( eg , morphine , meperidine and entity2begin fentanyl entity2end ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
false chemical chemical The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly entity1begin narcotics entity1end ( eg , morphine , meperidine and fentanyl ) , entity2begin propofol entity2end , ketamine , nitrous oxide , secobarbital and droperidol . 
false chemical chemical The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly entity1begin narcotics entity1end ( eg , morphine , meperidine and fentanyl ) , propofol , entity2begin ketamine entity2end , nitrous oxide , secobarbital and droperidol . 
false chemical chemical The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly entity1begin narcotics entity1end ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , entity2begin nitrous oxide entity2end , secobarbital and droperidol . 
false chemical chemical The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly entity1begin narcotics entity1end ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , entity2begin secobarbital entity2end and droperidol . 
false chemical chemical The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly entity1begin narcotics entity1end ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and entity2begin droperidol entity2end . 
false chemical chemical The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , entity1begin morphine entity1end , entity2begin meperidine entity2end and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
false chemical chemical The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , entity1begin morphine entity1end , meperidine and entity2begin fentanyl entity2end ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
false chemical chemical The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , entity1begin morphine entity1end , meperidine and fentanyl ) , entity2begin propofol entity2end , ketamine , nitrous oxide , secobarbital and droperidol . 
false chemical chemical The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , entity1begin morphine entity1end , meperidine and fentanyl ) , propofol , entity2begin ketamine entity2end , nitrous oxide , secobarbital and droperidol . 
false chemical chemical The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , entity1begin morphine entity1end , meperidine and fentanyl ) , propofol , ketamine , entity2begin nitrous oxide entity2end , secobarbital and droperidol . 
false chemical chemical The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , entity1begin morphine entity1end , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , entity2begin secobarbital entity2end and droperidol . 
false chemical chemical The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , entity1begin morphine entity1end , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and entity2begin droperidol entity2end . 
false chemical chemical The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , entity1begin meperidine entity1end and entity2begin fentanyl entity2end ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol . 
false chemical chemical The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , entity1begin meperidine entity1end and fentanyl ) , entity2begin propofol entity2end , ketamine , nitrous oxide , secobarbital and droperidol . 
false chemical chemical The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , entity1begin meperidine entity1end and fentanyl ) , propofol , entity2begin ketamine entity2end , nitrous oxide , secobarbital and droperidol . 
false chemical chemical The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , entity1begin meperidine entity1end and fentanyl ) , propofol , ketamine , entity2begin nitrous oxide entity2end , secobarbital and droperidol . 
false chemical chemical The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , entity1begin meperidine entity1end and fentanyl ) , propofol , ketamine , nitrous oxide , entity2begin secobarbital entity2end and droperidol . 
false chemical chemical The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , entity1begin meperidine entity1end and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and entity2begin droperidol entity2end . 
false chemical chemical The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and entity1begin fentanyl entity1end ) , entity2begin propofol entity2end , ketamine , nitrous oxide , secobarbital and droperidol . 
false chemical chemical The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and entity1begin fentanyl entity1end ) , propofol , entity2begin ketamine entity2end , nitrous oxide , secobarbital and droperidol . 
false chemical chemical The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and entity1begin fentanyl entity1end ) , propofol , ketamine , entity2begin nitrous oxide entity2end , secobarbital and droperidol . 
false chemical chemical The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and entity1begin fentanyl entity1end ) , propofol , ketamine , nitrous oxide , entity2begin secobarbital entity2end and droperidol . 
false chemical chemical The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and entity1begin fentanyl entity1end ) , propofol , ketamine , nitrous oxide , secobarbital and entity2begin droperidol entity2end . 
false chemical chemical The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , entity1begin propofol entity1end , entity2begin ketamine entity2end , nitrous oxide , secobarbital and droperidol . 
false chemical chemical The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , entity1begin propofol entity1end , ketamine , entity2begin nitrous oxide entity2end , secobarbital and droperidol . 
false chemical chemical The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , entity1begin propofol entity1end , ketamine , nitrous oxide , entity2begin secobarbital entity2end and droperidol . 
false chemical chemical The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , entity1begin propofol entity1end , ketamine , nitrous oxide , secobarbital and entity2begin droperidol entity2end . 
false chemical chemical The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , entity1begin ketamine entity1end , entity2begin nitrous oxide entity2end , secobarbital and droperidol . 
false chemical chemical The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , entity1begin ketamine entity1end , nitrous oxide , entity2begin secobarbital entity2end and droperidol . 
false chemical chemical The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , entity1begin ketamine entity1end , nitrous oxide , secobarbital and entity2begin droperidol entity2end . 
false chemical chemical The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , entity1begin nitrous oxide entity1end , entity2begin secobarbital entity2end and droperidol . 
false chemical chemical The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , entity1begin nitrous oxide entity1end , secobarbital and entity2begin droperidol entity2end . 
false chemical chemical The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , entity1begin secobarbital entity1end and entity2begin droperidol entity2end . 
false chemical chemical No significant adverse interactions with common premedications ( such as entity1begin atropine entity1end , entity2begin scopolamine entity2end , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants ) or local anesthetics have been observed . 
false chemical chemical No significant adverse interactions with common premedications ( such as entity1begin atropine entity1end , scopolamine , entity2begin glycopyrrolate entity2end , diazepam , hydroxyzine , and other muscle relaxants ) or local anesthetics have been observed . 
false chemical chemical No significant adverse interactions with common premedications ( such as entity1begin atropine entity1end , scopolamine , glycopyrrolate , entity2begin diazepam entity2end , hydroxyzine , and other muscle relaxants ) or local anesthetics have been observed . 
false chemical chemical No significant adverse interactions with common premedications ( such as entity1begin atropine entity1end , scopolamine , glycopyrrolate , diazepam , entity2begin hydroxyzine entity2end , and other muscle relaxants ) or local anesthetics have been observed . 
false chemical chemical No significant adverse interactions with common premedications ( such as entity1begin atropine entity1end , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other entity2begin muscle relaxants entity2end ) or local anesthetics have been observed . 
false chemical chemical No significant adverse interactions with common premedications ( such as entity1begin atropine entity1end , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants ) or local entity2begin anesthetics entity2end have been observed . 
false chemical chemical No significant adverse interactions with common premedications ( such as atropine , entity1begin scopolamine entity1end , entity2begin glycopyrrolate entity2end , diazepam , hydroxyzine , and other muscle relaxants ) or local anesthetics have been observed . 
false chemical chemical No significant adverse interactions with common premedications ( such as atropine , entity1begin scopolamine entity1end , glycopyrrolate , entity2begin diazepam entity2end , hydroxyzine , and other muscle relaxants ) or local anesthetics have been observed . 
false chemical chemical No significant adverse interactions with common premedications ( such as atropine , entity1begin scopolamine entity1end , glycopyrrolate , diazepam , entity2begin hydroxyzine entity2end , and other muscle relaxants ) or local anesthetics have been observed . 
false chemical chemical No significant adverse interactions with common premedications ( such as atropine , entity1begin scopolamine entity1end , glycopyrrolate , diazepam , hydroxyzine , and other entity2begin muscle relaxants entity2end ) or local anesthetics have been observed . 
false chemical chemical No significant adverse interactions with common premedications ( such as atropine , entity1begin scopolamine entity1end , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants ) or local entity2begin anesthetics entity2end have been observed . 
false chemical chemical No significant adverse interactions with common premedications ( such as atropine , scopolamine , entity1begin glycopyrrolate entity1end , entity2begin diazepam entity2end , hydroxyzine , and other muscle relaxants ) or local anesthetics have been observed . 
false chemical chemical No significant adverse interactions with common premedications ( such as atropine , scopolamine , entity1begin glycopyrrolate entity1end , diazepam , entity2begin hydroxyzine entity2end , and other muscle relaxants ) or local anesthetics have been observed . 
false chemical chemical No significant adverse interactions with common premedications ( such as atropine , scopolamine , entity1begin glycopyrrolate entity1end , diazepam , hydroxyzine , and other entity2begin muscle relaxants entity2end ) or local anesthetics have been observed . 
false chemical chemical No significant adverse interactions with common premedications ( such as atropine , scopolamine , entity1begin glycopyrrolate entity1end , diazepam , hydroxyzine , and other muscle relaxants ) or local entity2begin anesthetics entity2end have been observed . 
false chemical chemical No significant adverse interactions with common premedications ( such as atropine , scopolamine , glycopyrrolate , entity1begin diazepam entity1end , entity2begin hydroxyzine entity2end , and other muscle relaxants ) or local anesthetics have been observed . 
false chemical chemical No significant adverse interactions with common premedications ( such as atropine , scopolamine , glycopyrrolate , entity1begin diazepam entity1end , hydroxyzine , and other entity2begin muscle relaxants entity2end ) or local anesthetics have been observed . 
false chemical chemical No significant adverse interactions with common premedications ( such as atropine , scopolamine , glycopyrrolate , entity1begin diazepam entity1end , hydroxyzine , and other muscle relaxants ) or local entity2begin anesthetics entity2end have been observed . 
false chemical chemical No significant adverse interactions with common premedications ( such as atropine , scopolamine , glycopyrrolate , diazepam , entity1begin hydroxyzine entity1end , and other entity2begin muscle relaxants entity2end ) or local anesthetics have been observed . 
false chemical chemical No significant adverse interactions with common premedications ( such as atropine , scopolamine , glycopyrrolate , diazepam , entity1begin hydroxyzine entity1end , and other muscle relaxants ) or local entity2begin anesthetics entity2end have been observed . 
false chemical chemical No significant adverse interactions with common premedications ( such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other entity1begin muscle relaxants entity1end ) or local entity2begin anesthetics entity2end have been observed . 
true chemical chemical When administered concomitantly with entity1begin ProAmatine entity1end , entity2begin cardiac glycosides entity2end may enhance or precipitate bradycardia , A.V . 
false chemical chemical The use of drugs that stimulate alpha - adrenergic receptors ( e.g. , entity1begin phenylephrine entity1end , entity2begin pseudoephedrine entity2end , ephedrine , phenylpropanolamine or dihydroergotamine ) may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 
false chemical chemical The use of drugs that stimulate alpha - adrenergic receptors ( e.g. , entity1begin phenylephrine entity1end , pseudoephedrine , entity2begin ephedrine entity2end , phenylpropanolamine or dihydroergotamine ) may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 
false chemical chemical The use of drugs that stimulate alpha - adrenergic receptors ( e.g. , entity1begin phenylephrine entity1end , pseudoephedrine , ephedrine , entity2begin phenylpropanolamine entity2end or dihydroergotamine ) may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 
false chemical chemical The use of drugs that stimulate alpha - adrenergic receptors ( e.g. , entity1begin phenylephrine entity1end , pseudoephedrine , ephedrine , phenylpropanolamine or entity2begin dihydroergotamine entity2end ) may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 
true chemical chemical The use of drugs that stimulate alpha - adrenergic receptors ( e.g. , entity1begin phenylephrine entity1end , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine ) may enhance or potentiate the pressor effects of entity2begin ProAmatine entity2end . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 
false chemical chemical The use of drugs that stimulate alpha - adrenergic receptors ( e.g. , entity1begin phenylephrine entity1end , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine ) may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when entity2begin ProAmatine entity2end is administered concomitantly with agents that cause vasoconstriction . 
false chemical chemical The use of drugs that stimulate alpha - adrenergic receptors ( e.g. , phenylephrine , entity1begin pseudoephedrine entity1end , entity2begin ephedrine entity2end , phenylpropanolamine or dihydroergotamine ) may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 
false chemical chemical The use of drugs that stimulate alpha - adrenergic receptors ( e.g. , phenylephrine , entity1begin pseudoephedrine entity1end , ephedrine , entity2begin phenylpropanolamine entity2end or dihydroergotamine ) may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 
false chemical chemical The use of drugs that stimulate alpha - adrenergic receptors ( e.g. , phenylephrine , entity1begin pseudoephedrine entity1end , ephedrine , phenylpropanolamine or entity2begin dihydroergotamine entity2end ) may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 
true chemical chemical The use of drugs that stimulate alpha - adrenergic receptors ( e.g. , phenylephrine , entity1begin pseudoephedrine entity1end , ephedrine , phenylpropanolamine or dihydroergotamine ) may enhance or potentiate the pressor effects of entity2begin ProAmatine entity2end . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 
false chemical chemical The use of drugs that stimulate alpha - adrenergic receptors ( e.g. , phenylephrine , entity1begin pseudoephedrine entity1end , ephedrine , phenylpropanolamine or dihydroergotamine ) may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when entity2begin ProAmatine entity2end is administered concomitantly with agents that cause vasoconstriction . 
false chemical chemical The use of drugs that stimulate alpha - adrenergic receptors ( e.g. , phenylephrine , pseudoephedrine , entity1begin ephedrine entity1end , entity2begin phenylpropanolamine entity2end or dihydroergotamine ) may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 
false chemical chemical The use of drugs that stimulate alpha - adrenergic receptors ( e.g. , phenylephrine , pseudoephedrine , entity1begin ephedrine entity1end , phenylpropanolamine or entity2begin dihydroergotamine entity2end ) may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 
true chemical chemical The use of drugs that stimulate alpha - adrenergic receptors ( e.g. , phenylephrine , pseudoephedrine , entity1begin ephedrine entity1end , phenylpropanolamine or dihydroergotamine ) may enhance or potentiate the pressor effects of entity2begin ProAmatine entity2end . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 
false chemical chemical The use of drugs that stimulate alpha - adrenergic receptors ( e.g. , phenylephrine , pseudoephedrine , entity1begin ephedrine entity1end , phenylpropanolamine or dihydroergotamine ) may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when entity2begin ProAmatine entity2end is administered concomitantly with agents that cause vasoconstriction . 
false chemical chemical The use of drugs that stimulate alpha - adrenergic receptors ( e.g. , phenylephrine , pseudoephedrine , ephedrine , entity1begin phenylpropanolamine entity1end or entity2begin dihydroergotamine entity2end ) may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 
true chemical chemical The use of drugs that stimulate alpha - adrenergic receptors ( e.g. , phenylephrine , pseudoephedrine , ephedrine , entity1begin phenylpropanolamine entity1end or dihydroergotamine ) may enhance or potentiate the pressor effects of entity2begin ProAmatine entity2end . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 
false chemical chemical The use of drugs that stimulate alpha - adrenergic receptors ( e.g. , phenylephrine , pseudoephedrine , ephedrine , entity1begin phenylpropanolamine entity1end or dihydroergotamine ) may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when entity2begin ProAmatine entity2end is administered concomitantly with agents that cause vasoconstriction . 
true chemical chemical The use of drugs that stimulate alpha - adrenergic receptors ( e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or entity1begin dihydroergotamine entity1end ) may enhance or potentiate the pressor effects of entity2begin ProAmatine entity2end . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . 
false chemical chemical The use of drugs that stimulate alpha - adrenergic receptors ( e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or entity1begin dihydroergotamine entity1end ) may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when entity2begin ProAmatine entity2end is administered concomitantly with agents that cause vasoconstriction . 
false chemical chemical The use of drugs that stimulate alpha - adrenergic receptors ( e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine ) may enhance or potentiate the pressor effects of entity1begin ProAmatine entity1end . Therefore , caution should be used when entity2begin ProAmatine entity2end is administered concomitantly with agents that cause vasoconstriction . 
false chemical chemical entity1begin ProAmatine entity1end has been used in patients concomitantly treated with salt - retaining steroid therapy ( i.e. , entity2begin fludrocortisone acetate entity2end ) , with or without salt supplementation . 
false chemical chemical entity1begin ProAmatine entity1end . entity2begin Alpha - adrenergic blocking agents entity2end , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
false chemical chemical entity1begin ProAmatine entity1end . Alpha - adrenergic blocking agents , such as entity2begin prazosin entity2end , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
false chemical chemical entity1begin ProAmatine entity1end . Alpha - adrenergic blocking agents , such as prazosin , entity2begin terazosin entity2end , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
false chemical chemical entity1begin ProAmatine entity1end . Alpha - adrenergic blocking agents , such as prazosin , terazosin , and entity2begin doxazosin entity2end , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
false chemical chemical entity1begin ProAmatine entity1end . Alpha - adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of entity2begin ProAmatine entity2end . Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
false chemical chemical entity1begin ProAmatine entity1end . Alpha - adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of entity2begin desglymidodrine entity2end ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
false chemical chemical entity1begin ProAmatine entity1end . Alpha - adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as entity2begin metformin entity2end , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
false chemical chemical entity1begin ProAmatine entity1end . Alpha - adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , entity2begin cimetidine entity2end , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
false chemical chemical entity1begin ProAmatine entity1end . Alpha - adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , entity2begin ranitidine entity2end , procainamide , triamterene , flecainide , and quinidine . 
false chemical chemical entity1begin ProAmatine entity1end . Alpha - adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , entity2begin procainamide entity2end , triamterene , flecainide , and quinidine . 
false chemical chemical entity1begin ProAmatine entity1end . Alpha - adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , entity2begin triamterene entity2end , flecainide , and quinidine . 
false chemical chemical entity1begin ProAmatine entity1end . Alpha - adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , entity2begin flecainide entity2end , and quinidine . 
false chemical chemical entity1begin ProAmatine entity1end . Alpha - adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and entity2begin quinidine entity2end . 
false chemical chemical ProAmatine. entity1begin Alpha - adrenergic blocking agents entity1end , such as entity2begin prazosin entity2end , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
false chemical chemical ProAmatine. entity1begin Alpha - adrenergic blocking agents entity1end , such as prazosin , entity2begin terazosin entity2end , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
false chemical chemical ProAmatine. entity1begin Alpha - adrenergic blocking agents entity1end , such as prazosin , terazosin , and entity2begin doxazosin entity2end , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
true chemical chemical ProAmatine. entity1begin Alpha - adrenergic blocking agents entity1end , such as prazosin , terazosin , and doxazosin , can antagonize the effects of entity2begin ProAmatine entity2end . Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
false chemical chemical ProAmatine. entity1begin Alpha - adrenergic blocking agents entity1end , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of entity2begin desglymidodrine entity2end ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
false chemical chemical ProAmatine. entity1begin Alpha - adrenergic blocking agents entity1end , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as entity2begin metformin entity2end , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
false chemical chemical ProAmatine. entity1begin Alpha - adrenergic blocking agents entity1end , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , entity2begin cimetidine entity2end , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
false chemical chemical ProAmatine. entity1begin Alpha - adrenergic blocking agents entity1end , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , entity2begin ranitidine entity2end , procainamide , triamterene , flecainide , and quinidine . 
false chemical chemical ProAmatine. entity1begin Alpha - adrenergic blocking agents entity1end , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , entity2begin procainamide entity2end , triamterene , flecainide , and quinidine . 
false chemical chemical ProAmatine. entity1begin Alpha - adrenergic blocking agents entity1end , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , entity2begin triamterene entity2end , flecainide , and quinidine . 
false chemical chemical ProAmatine. entity1begin Alpha - adrenergic blocking agents entity1end , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , entity2begin flecainide entity2end , and quinidine . 
false chemical chemical ProAmatine. entity1begin Alpha - adrenergic blocking agents entity1end , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and entity2begin quinidine entity2end . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as entity1begin prazosin entity1end , entity2begin terazosin entity2end , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as entity1begin prazosin entity1end , terazosin , and entity2begin doxazosin entity2end , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
true chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as entity1begin prazosin entity1end , terazosin , and doxazosin , can antagonize the effects of entity2begin ProAmatine entity2end . Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as entity1begin prazosin entity1end , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of entity2begin desglymidodrine entity2end ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as entity1begin prazosin entity1end , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as entity2begin metformin entity2end , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as entity1begin prazosin entity1end , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , entity2begin cimetidine entity2end , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as entity1begin prazosin entity1end , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , entity2begin ranitidine entity2end , procainamide , triamterene , flecainide , and quinidine . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as entity1begin prazosin entity1end , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , entity2begin procainamide entity2end , triamterene , flecainide , and quinidine . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as entity1begin prazosin entity1end , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , entity2begin triamterene entity2end , flecainide , and quinidine . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as entity1begin prazosin entity1end , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , entity2begin flecainide entity2end , and quinidine . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as entity1begin prazosin entity1end , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and entity2begin quinidine entity2end . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , entity1begin terazosin entity1end , and entity2begin doxazosin entity2end , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
true chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , entity1begin terazosin entity1end , and doxazosin , can antagonize the effects of entity2begin ProAmatine entity2end . Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , entity1begin terazosin entity1end , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of entity2begin desglymidodrine entity2end ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , entity1begin terazosin entity1end , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as entity2begin metformin entity2end , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , entity1begin terazosin entity1end , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , entity2begin cimetidine entity2end , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , entity1begin terazosin entity1end , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , entity2begin ranitidine entity2end , procainamide , triamterene , flecainide , and quinidine . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , entity1begin terazosin entity1end , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , entity2begin procainamide entity2end , triamterene , flecainide , and quinidine . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , entity1begin terazosin entity1end , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , entity2begin triamterene entity2end , flecainide , and quinidine . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , entity1begin terazosin entity1end , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , entity2begin flecainide entity2end , and quinidine . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , entity1begin terazosin entity1end , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and entity2begin quinidine entity2end . 
true chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , terazosin , and entity1begin doxazosin entity1end , can antagonize the effects of entity2begin ProAmatine entity2end . Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , terazosin , and entity1begin doxazosin entity1end , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of entity2begin desglymidodrine entity2end ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , terazosin , and entity1begin doxazosin entity1end , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as entity2begin metformin entity2end , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , terazosin , and entity1begin doxazosin entity1end , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , entity2begin cimetidine entity2end , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , terazosin , and entity1begin doxazosin entity1end , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , entity2begin ranitidine entity2end , procainamide , triamterene , flecainide , and quinidine . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , terazosin , and entity1begin doxazosin entity1end , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , entity2begin procainamide entity2end , triamterene , flecainide , and quinidine . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , terazosin , and entity1begin doxazosin entity1end , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , entity2begin triamterene entity2end , flecainide , and quinidine . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , terazosin , and entity1begin doxazosin entity1end , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , entity2begin flecainide entity2end , and quinidine . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , terazosin , and entity1begin doxazosin entity1end , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and entity2begin quinidine entity2end . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of entity1begin ProAmatine entity1end . Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of entity2begin desglymidodrine entity2end ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of entity1begin ProAmatine entity1end . Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as entity2begin metformin entity2end , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of entity1begin ProAmatine entity1end . Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , entity2begin cimetidine entity2end , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of entity1begin ProAmatine entity1end . Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , entity2begin ranitidine entity2end , procainamide , triamterene , flecainide , and quinidine . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of entity1begin ProAmatine entity1end . Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , entity2begin procainamide entity2end , triamterene , flecainide , and quinidine . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of entity1begin ProAmatine entity1end . Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , entity2begin triamterene entity2end , flecainide , and quinidine . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of entity1begin ProAmatine entity1end . Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , entity2begin flecainide entity2end , and quinidine . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of entity1begin ProAmatine entity1end . Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and entity2begin quinidine entity2end . 
true chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of entity1begin desglymidodrine entity1end ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as entity2begin metformin entity2end , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
true chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of entity1begin desglymidodrine entity1end ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , entity2begin cimetidine entity2end , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
true chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of entity1begin desglymidodrine entity1end ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , entity2begin ranitidine entity2end , procainamide , triamterene , flecainide , and quinidine . 
true chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of entity1begin desglymidodrine entity1end ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , entity2begin procainamide entity2end , triamterene , flecainide , and quinidine . 
true chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of entity1begin desglymidodrine entity1end ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , entity2begin triamterene entity2end , flecainide , and quinidine . 
true chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of entity1begin desglymidodrine entity1end ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , entity2begin flecainide entity2end , and quinidine . 
true chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of entity1begin desglymidodrine entity1end ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and entity2begin quinidine entity2end . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as entity1begin metformin entity1end , entity2begin cimetidine entity2end , ranitidine , procainamide , triamterene , flecainide , and quinidine . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as entity1begin metformin entity1end , cimetidine , entity2begin ranitidine entity2end , procainamide , triamterene , flecainide , and quinidine . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as entity1begin metformin entity1end , cimetidine , ranitidine , entity2begin procainamide entity2end , triamterene , flecainide , and quinidine . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as entity1begin metformin entity1end , cimetidine , ranitidine , procainamide , entity2begin triamterene entity2end , flecainide , and quinidine . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as entity1begin metformin entity1end , cimetidine , ranitidine , procainamide , triamterene , entity2begin flecainide entity2end , and quinidine . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as entity1begin metformin entity1end , cimetidine , ranitidine , procainamide , triamterene , flecainide , and entity2begin quinidine entity2end . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , entity1begin cimetidine entity1end , entity2begin ranitidine entity2end , procainamide , triamterene , flecainide , and quinidine . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , entity1begin cimetidine entity1end , ranitidine , entity2begin procainamide entity2end , triamterene , flecainide , and quinidine . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , entity1begin cimetidine entity1end , ranitidine , procainamide , entity2begin triamterene entity2end , flecainide , and quinidine . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , entity1begin cimetidine entity1end , ranitidine , procainamide , triamterene , entity2begin flecainide entity2end , and quinidine . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , entity1begin cimetidine entity1end , ranitidine , procainamide , triamterene , flecainide , and entity2begin quinidine entity2end . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , entity1begin ranitidine entity1end , entity2begin procainamide entity2end , triamterene , flecainide , and quinidine . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , entity1begin ranitidine entity1end , procainamide , entity2begin triamterene entity2end , flecainide , and quinidine . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , entity1begin ranitidine entity1end , procainamide , triamterene , entity2begin flecainide entity2end , and quinidine . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , entity1begin ranitidine entity1end , procainamide , triamterene , flecainide , and entity2begin quinidine entity2end . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , entity1begin procainamide entity1end , entity2begin triamterene entity2end , flecainide , and quinidine . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , entity1begin procainamide entity1end , triamterene , entity2begin flecainide entity2end , and quinidine . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , entity1begin procainamide entity1end , triamterene , flecainide , and entity2begin quinidine entity2end . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , entity1begin triamterene entity1end , entity2begin flecainide entity2end , and quinidine . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , entity1begin triamterene entity1end , flecainide , and entity2begin quinidine entity2end . 
false chemical chemical ProAmatine. Alpha - adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of ProAmatine. Potential for Drug Interactions : It appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base - secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , entity1begin flecainide entity1end , and entity2begin quinidine entity2end . 
false chemical chemical Although specific drug or food interactions with entity1begin mifepristone entity1end have not been studied , on the basis of this drug s metabolism by CYP 3A4 , it is possible that entity2begin ketoconazole entity2end , itraconazole , erythromycin , and grapefruit juice may inhibit its metabolism ( increasing serum levels of mifepristone ) . 
false chemical chemical Although specific drug or food interactions with entity1begin mifepristone entity1end have not been studied , on the basis of this drug s metabolism by CYP 3A4 , it is possible that ketoconazole , entity2begin itraconazole entity2end , erythromycin , and grapefruit juice may inhibit its metabolism ( increasing serum levels of mifepristone ) . 
false chemical chemical Although specific drug or food interactions with entity1begin mifepristone entity1end have not been studied , on the basis of this drug s metabolism by CYP 3A4 , it is possible that ketoconazole , itraconazole , entity2begin erythromycin entity2end , and grapefruit juice may inhibit its metabolism ( increasing serum levels of mifepristone ) . 
false chemical chemical Although specific drug or food interactions with entity1begin mifepristone entity1end have not been studied , on the basis of this drug s metabolism by CYP 3A4 , it is possible that ketoconazole , itraconazole , erythromycin , and grapefruit juice may inhibit its metabolism ( increasing serum levels of entity2begin mifepristone entity2end ) . 
false chemical chemical Although specific drug or food interactions with mifepristone have not been studied , on the basis of this drug s metabolism by CYP 3A4 , it is possible that entity1begin ketoconazole entity1end , entity2begin itraconazole entity2end , erythromycin , and grapefruit juice may inhibit its metabolism ( increasing serum levels of mifepristone ) . 
false chemical chemical Although specific drug or food interactions with mifepristone have not been studied , on the basis of this drug s metabolism by CYP 3A4 , it is possible that entity1begin ketoconazole entity1end , itraconazole , entity2begin erythromycin entity2end , and grapefruit juice may inhibit its metabolism ( increasing serum levels of mifepristone ) . 
true chemical chemical Although specific drug or food interactions with mifepristone have not been studied , on the basis of this drug s metabolism by CYP 3A4 , it is possible that entity1begin ketoconazole entity1end , itraconazole , erythromycin , and grapefruit juice may inhibit its metabolism ( increasing serum levels of entity2begin mifepristone entity2end ) . 
false chemical chemical Although specific drug or food interactions with mifepristone have not been studied , on the basis of this drug s metabolism by CYP 3A4 , it is possible that ketoconazole , entity1begin itraconazole entity1end , entity2begin erythromycin entity2end , and grapefruit juice may inhibit its metabolism ( increasing serum levels of mifepristone ) . 
true chemical chemical Although specific drug or food interactions with mifepristone have not been studied , on the basis of this drug s metabolism by CYP 3A4 , it is possible that ketoconazole , entity1begin itraconazole entity1end , erythromycin , and grapefruit juice may inhibit its metabolism ( increasing serum levels of entity2begin mifepristone entity2end ) . 
true chemical chemical Although specific drug or food interactions with mifepristone have not been studied , on the basis of this drug s metabolism by CYP 3A4 , it is possible that ketoconazole , itraconazole , entity1begin erythromycin entity1end , and grapefruit juice may inhibit its metabolism ( increasing serum levels of entity2begin mifepristone entity2end ) . 
false chemical chemical Furthermore , entity1begin rifampin entity1end , entity2begin dexamethasone entity2end , St . 
false chemical chemical John s Wort , and certain entity1begin anticonvulsants entity1end ( entity2begin phenytoin entity2end , phenobarbital , carbamazepine ) may induce mifepristone metabolism ( lowering serum levels of mifepristone ) . 
false chemical chemical John s Wort , and certain entity1begin anticonvulsants entity1end ( phenytoin , entity2begin phenobarbital entity2end , carbamazepine ) may induce mifepristone metabolism ( lowering serum levels of mifepristone ) . 
false chemical chemical John s Wort , and certain entity1begin anticonvulsants entity1end ( phenytoin , phenobarbital , entity2begin carbamazepine entity2end ) may induce mifepristone metabolism ( lowering serum levels of mifepristone ) . 
true chemical chemical John s Wort , and certain entity1begin anticonvulsants entity1end ( phenytoin , phenobarbital , carbamazepine ) may induce entity2begin mifepristone entity2end metabolism ( lowering serum levels of mifepristone ) . 
false chemical chemical John s Wort , and certain entity1begin anticonvulsants entity1end ( phenytoin , phenobarbital , carbamazepine ) may induce mifepristone metabolism ( lowering serum levels of entity2begin mifepristone entity2end ) . 
false chemical chemical John s Wort , and certain anticonvulsants ( entity1begin phenytoin entity1end , entity2begin phenobarbital entity2end , carbamazepine ) may induce mifepristone metabolism ( lowering serum levels of mifepristone ) . 
false chemical chemical John s Wort , and certain anticonvulsants ( entity1begin phenytoin entity1end , phenobarbital , entity2begin carbamazepine entity2end ) may induce mifepristone metabolism ( lowering serum levels of mifepristone ) . 
true chemical chemical John s Wort , and certain anticonvulsants ( entity1begin phenytoin entity1end , phenobarbital , carbamazepine ) may induce entity2begin mifepristone entity2end metabolism ( lowering serum levels of mifepristone ) . 
false chemical chemical John s Wort , and certain anticonvulsants ( entity1begin phenytoin entity1end , phenobarbital , carbamazepine ) may induce mifepristone metabolism ( lowering serum levels of entity2begin mifepristone entity2end ) . 
false chemical chemical John s Wort , and certain anticonvulsants ( phenytoin , entity1begin phenobarbital entity1end , entity2begin carbamazepine entity2end ) may induce mifepristone metabolism ( lowering serum levels of mifepristone ) . 
true chemical chemical John s Wort , and certain anticonvulsants ( phenytoin , entity1begin phenobarbital entity1end , carbamazepine ) may induce entity2begin mifepristone entity2end metabolism ( lowering serum levels of mifepristone ) . 
false chemical chemical John s Wort , and certain anticonvulsants ( phenytoin , entity1begin phenobarbital entity1end , carbamazepine ) may induce mifepristone metabolism ( lowering serum levels of entity2begin mifepristone entity2end ) . 
true chemical chemical John s Wort , and certain anticonvulsants ( phenytoin , phenobarbital , entity1begin carbamazepine entity1end ) may induce entity2begin mifepristone entity2end metabolism ( lowering serum levels of mifepristone ) . 
false chemical chemical John s Wort , and certain anticonvulsants ( phenytoin , phenobarbital , entity1begin carbamazepine entity1end ) may induce mifepristone metabolism ( lowering serum levels of entity2begin mifepristone entity2end ) . 
false chemical chemical John s Wort , and certain anticonvulsants ( phenytoin , phenobarbital , carbamazepine ) may induce entity1begin mifepristone entity1end metabolism ( lowering serum levels of entity2begin mifepristone entity2end ) . 
true chemical chemical While co - administration of entity1begin ZAVESCA entity1end appeared to increase the clearance of entity2begin Cerezyme entity2end by 70 % , these results are not conclusive because of the small number of subjects studied and because patients took variable doses of Cerezyme . 
false chemical chemical While co - administration of entity1begin ZAVESCA entity1end appeared to increase the clearance of Cerezyme by 70 % , these results are not conclusive because of the small number of subjects studied and because patients took variable doses of entity2begin Cerezyme entity2end . 
false chemical chemical While co - administration of ZAVESCA appeared to increase the clearance of entity1begin Cerezyme entity1end by 70 % , these results are not conclusive because of the small number of subjects studied and because patients took variable doses of entity2begin Cerezyme entity2end . 
false chemical chemical Combination therapy with entity1begin Cerezyme entity1end ( entity2begin imiglucerase entity2end ) and ZAVESCA is not indicated . 
true chemical chemical Combination therapy with entity1begin Cerezyme entity1end ( imiglucerase ) and entity2begin ZAVESCA entity2end is not indicated . 
true chemical chemical Combination therapy with Cerezyme ( entity1begin imiglucerase entity1end ) and entity2begin ZAVESCA entity2end is not indicated . 
true chemical chemical Because entity1begin tetracyclines entity1end have been shown to depress plasma prothrombin activity , patients who are on entity2begin anticoagulant entity2end therapy may require downward adjustment of their anticoagulant dosage . 
false chemical chemical Because entity1begin tetracyclines entity1end have been shown to depress plasma prothrombin activity , patients who are on anticoagulant therapy may require downward adjustment of their entity2begin anticoagulant entity2end dosage . 
false chemical chemical Because tetracyclines have been shown to depress plasma prothrombin activity , patients who are on entity1begin anticoagulant entity1end therapy may require downward adjustment of their entity2begin anticoagulant entity2end dosage . 
false chemical chemical Since bacteriostatic drugs may interfere with the bactericidal action of entity1begin penicillin entity1end , it is advisable to avoid giving entity2begin tetracycline class drugs entity2end in conjunction with penicillin . 
false chemical chemical Since bacteriostatic drugs may interfere with the bactericidal action of entity1begin penicillin entity1end , it is advisable to avoid giving tetracycline class drugs in conjunction with entity2begin penicillin entity2end . 
true chemical chemical Since bacteriostatic drugs may interfere with the bactericidal action of penicillin , it is advisable to avoid giving entity1begin tetracycline class drugs entity1end in conjunction with entity2begin penicillin entity2end . 
false chemical chemical Absorption of entity1begin tetracyclines entity1end is impaired by entity2begin antacids entity2end containing aluminum , calcium or magnesium , and iron - containing preparations . 
true chemical chemical Absorption of entity1begin tetracyclines entity1end is impaired by antacids containing entity2begin aluminum entity2end , calcium or magnesium , and iron - containing preparations . 
true chemical chemical Absorption of entity1begin tetracyclines entity1end is impaired by antacids containing aluminum , entity2begin calcium entity2end or magnesium , and iron - containing preparations . 
true chemical chemical Absorption of entity1begin tetracyclines entity1end is impaired by antacids containing aluminum , calcium or entity2begin magnesium entity2end , and iron - containing preparations . 
true chemical chemical Absorption of entity1begin tetracyclines entity1end is impaired by antacids containing aluminum , calcium or magnesium , and entity2begin iron entity2end - containing preparations . 
false chemical chemical Absorption of tetracyclines is impaired by entity1begin antacids entity1end containing entity2begin aluminum entity2end , calcium or magnesium , and iron - containing preparations . 
false chemical chemical Absorption of tetracyclines is impaired by entity1begin antacids entity1end containing aluminum , entity2begin calcium entity2end or magnesium , and iron - containing preparations . 
false chemical chemical Absorption of tetracyclines is impaired by entity1begin antacids entity1end containing aluminum , calcium or entity2begin magnesium entity2end , and iron - containing preparations . 
false chemical chemical Absorption of tetracyclines is impaired by entity1begin antacids entity1end containing aluminum , calcium or magnesium , and entity2begin iron entity2end - containing preparations . 
false chemical chemical Absorption of tetracyclines is impaired by antacids containing entity1begin aluminum entity1end , entity2begin calcium entity2end or magnesium , and iron - containing preparations . 
false chemical chemical Absorption of tetracyclines is impaired by antacids containing entity1begin aluminum entity1end , calcium or entity2begin magnesium entity2end , and iron - containing preparations . 
false chemical chemical Absorption of tetracyclines is impaired by antacids containing entity1begin aluminum entity1end , calcium or magnesium , and entity2begin iron entity2end - containing preparations . 
false chemical chemical Absorption of tetracyclines is impaired by antacids containing aluminum , entity1begin calcium entity1end or entity2begin magnesium entity2end , and iron - containing preparations . 
false chemical chemical Absorption of tetracyclines is impaired by antacids containing aluminum , entity1begin calcium entity1end or magnesium , and entity2begin iron entity2end - containing preparations . 
false chemical chemical Absorption of tetracyclines is impaired by antacids containing aluminum , calcium or entity1begin magnesium entity1end , and entity2begin iron entity2end - containing preparations . 
true chemical chemical The concurrent use of entity1begin tetracycline entity1end and entity2begin methoxyflurane entity2end has been reported to result in fatal renal toxicity . 
true chemical chemical Concurrent use of entity1begin tetracyclines entity1end with oral entity2begin contraceptives entity2end may render oral contraceptives less effective . 
false chemical chemical Concurrent use of entity1begin tetracyclines entity1end with oral contraceptives may render oral entity2begin contraceptives entity2end less effective . 
false chemical chemical Concurrent use of tetracyclines with oral entity1begin contraceptives entity1end may render oral entity2begin contraceptives entity2end less effective . 
false chemical chemical Interaction with entity1begin Guanethidine entity1end : Although entity2begin minoxidil entity2end does not itself cause orthostatic hypotension , its administration to patients already receiving guanethidine can result in profound orthostatic effects . 
false chemical chemical Interaction with entity1begin Guanethidine entity1end : Although minoxidil does not itself cause orthostatic hypotension , its administration to patients already receiving entity2begin guanethidine entity2end can result in profound orthostatic effects . 
true chemical chemical Interaction with Guanethidine : Although entity1begin minoxidil entity1end does not itself cause orthostatic hypotension , its administration to patients already receiving entity2begin guanethidine entity2end can result in profound orthostatic effects . 
true chemical chemical If at all possible entity1begin guanethidine entity1end should be discontinued well before entity2begin minoxidil entity2end is begun . 
false chemical chemical Drugs Affecting Hepatic Metabolism The metabolism and pharmacokinetics of entity1begin REMERON SolTab entity1end ( entity2begin mirtazapine entity2end ) Orally Disintegrating Tablets may be affected by the induction or inhibition of drug - metab - olizing enzymes . 
false chemical chemical While in vitro studies have shown that entity1begin mirtazapine entity1end is not a potent inhibitor of any of these enzymes , an indication that entity2begin mirtazapine entity2end is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes , the concomitant use of REMERON SolTab with most other drugs metabolized by these enzymes has not been formally studied . 
false chemical chemical While in vitro studies have shown that entity1begin mirtazapine entity1end is not a potent inhibitor of any of these enzymes , an indication that mirtazapine is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes , the concomitant use of entity2begin REMERON SolTab entity2end with most other drugs metabolized by these enzymes has not been formally studied . 
false chemical chemical While in vitro studies have shown that mirtazapine is not a potent inhibitor of any of these enzymes , an indication that entity1begin mirtazapine entity1end is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes , the concomitant use of entity2begin REMERON SolTab entity2end with most other drugs metabolized by these enzymes has not been formally studied . 
false chemical chemical entity1begin Alcohol entity1end : Concomitant administration of entity2begin alcohol entity2end ( equivalent to 60 g ) had a minimal effect on plasma levels of mirtazapine ( 15 mg ) in 6 healthy male subjects . 
false chemical chemical entity1begin Alcohol entity1end : Concomitant administration of alcohol ( equivalent to 60 g ) had a minimal effect on plasma levels of entity2begin mirtazapine entity2end ( 15 mg ) in 6 healthy male subjects . 
true chemical chemical Alcohol : Concomitant administration of entity1begin alcohol entity1end ( equivalent to 60 g ) had a minimal effect on plasma levels of entity2begin mirtazapine entity2end ( 15 mg ) in 6 healthy male subjects . 
true chemical chemical However , the impairment of cognitive and motor skills produced by entity1begin REMERON entity1end were shown to be additive with those produced by entity2begin alcohol entity2end . 
true chemical chemical Accordingly , patients should be advised to avoid entity1begin alcohol entity1end while taking entity2begin REMERON SolTab entity2end . Diazepam : Concomitant administration of diazepam ( 15 mg ) had a minimal effect on plasma levels of mirtazapine ( 15 mg ) in 12 healthy subjects . 
false chemical chemical Accordingly , patients should be advised to avoid entity1begin alcohol entity1end while taking REMERON SolTab. entity2begin Diazepam entity2end : Concomitant administration of diazepam ( 15 mg ) had a minimal effect on plasma levels of mirtazapine ( 15 mg ) in 12 healthy subjects . 
false chemical chemical Accordingly , patients should be advised to avoid entity1begin alcohol entity1end while taking REMERON SolTab. Diazepam : Concomitant administration of entity2begin diazepam entity2end ( 15 mg ) had a minimal effect on plasma levels of mirtazapine ( 15 mg ) in 12 healthy subjects . 
false chemical chemical Accordingly , patients should be advised to avoid entity1begin alcohol entity1end while taking REMERON SolTab. Diazepam : Concomitant administration of diazepam ( 15 mg ) had a minimal effect on plasma levels of entity2begin mirtazapine entity2end ( 15 mg ) in 12 healthy subjects . 
false chemical chemical Accordingly , patients should be advised to avoid alcohol while taking entity1begin REMERON SolTab entity1end . entity2begin Diazepam entity2end : Concomitant administration of diazepam ( 15 mg ) had a minimal effect on plasma levels of mirtazapine ( 15 mg ) in 12 healthy subjects . 
false chemical chemical Accordingly , patients should be advised to avoid alcohol while taking entity1begin REMERON SolTab entity1end . Diazepam : Concomitant administration of entity2begin diazepam entity2end ( 15 mg ) had a minimal effect on plasma levels of mirtazapine ( 15 mg ) in 12 healthy subjects . 
false chemical chemical Accordingly , patients should be advised to avoid alcohol while taking entity1begin REMERON SolTab entity1end . Diazepam : Concomitant administration of diazepam ( 15 mg ) had a minimal effect on plasma levels of entity2begin mirtazapine entity2end ( 15 mg ) in 12 healthy subjects . 
false chemical chemical Accordingly , patients should be advised to avoid alcohol while taking REMERON SolTab. entity1begin Diazepam entity1end : Concomitant administration of entity2begin diazepam entity2end ( 15 mg ) had a minimal effect on plasma levels of mirtazapine ( 15 mg ) in 12 healthy subjects . 
false chemical chemical Accordingly , patients should be advised to avoid alcohol while taking REMERON SolTab. entity1begin Diazepam entity1end : Concomitant administration of diazepam ( 15 mg ) had a minimal effect on plasma levels of entity2begin mirtazapine entity2end ( 15 mg ) in 12 healthy subjects . 
true chemical chemical Accordingly , patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam : Concomitant administration of entity1begin diazepam entity1end ( 15 mg ) had a minimal effect on plasma levels of entity2begin mirtazapine entity2end ( 15 mg ) in 12 healthy subjects . 
true chemical chemical However , the impairment of motor skills produced by entity1begin REMERON entity1end has been shown to be additive with those caused by entity2begin diazepam entity2end . 
true chemical chemical Accordingly , patients should be advised to avoid entity1begin diazepam entity1end and other similar drugs while taking entity2begin REMERON SolTab entity2end . 
true chemical chemical entity1begin Mitotane entity1end has been reported to accelerate the metabolism of entity2begin warfarin entity2end by the mechanism of hepatic microsomal enzyme induction , leading to an increase in dosage requirements for warfarin . 
false chemical chemical entity1begin Mitotane entity1end has been reported to accelerate the metabolism of warfarin by the mechanism of hepatic microsomal enzyme induction , leading to an increase in dosage requirements for entity2begin warfarin entity2end . 
false chemical chemical Mitotane has been reported to accelerate the metabolism of entity1begin warfarin entity1end by the mechanism of hepatic microsomal enzyme induction , leading to an increase in dosage requirements for entity2begin warfarin entity2end . 
false chemical chemical Therefore , physicians should closely monitor patients for a change in entity1begin anticoagulant entity1end dosage requirements when administering entity2begin Mitotane entity2end to patients on coumarin - type anticoagulants . 
false chemical chemical Therefore , physicians should closely monitor patients for a change in entity1begin anticoagulant entity1end dosage requirements when administering Mitotane to patients on entity2begin coumarin - type anticoagulants entity2end . 
true chemical chemical Therefore , physicians should closely monitor patients for a change in anticoagulant dosage requirements when administering entity1begin Mitotane entity1end to patients on entity2begin coumarin - type anticoagulants entity2end . 
false chemical chemical Although entity1begin MIVACRON entity1end ( a mixture of three stereoisomers ) has been administered safely following succinylcholine - facilitated tracheal intubation , the interaction between entity2begin MIVACRON entity2end and succinylcholine has not been systematically studied . 
false chemical chemical Although entity1begin MIVACRON entity1end ( a mixture of three stereoisomers ) has been administered safely following succinylcholine - facilitated tracheal intubation , the interaction between MIVACRON and entity2begin succinylcholine entity2end has not been systematically studied . 
false chemical chemical Although MIVACRON ( a mixture of three stereoisomers ) has been administered safely following succinylcholine - facilitated tracheal intubation , the interaction between entity1begin MIVACRON entity1end and entity2begin succinylcholine entity2end has not been systematically studied . 
true chemical chemical Prior administration of entity1begin succinylcholine entity1end can potentiate the neuromuscular blocking effects of entity2begin nondepolarizing agents entity2end . 
true chemical chemical Evidence of spontaneous recovery from entity1begin succinylcholine entity1end should be observed before the administration of entity2begin MIVACRON entity2end . 
false chemical chemical The use of entity1begin MIVACRON entity1end before entity2begin succinylcholine entity2end to attenuate some of the side effects of succinylcholine has not been studied . 
false chemical chemical The use of entity1begin MIVACRON entity1end before succinylcholine to attenuate some of the side effects of entity2begin succinylcholine entity2end has not been studied . 
false chemical chemical The use of MIVACRON before entity1begin succinylcholine entity1end to attenuate some of the side effects of entity2begin succinylcholine entity2end has not been studied . 
false chemical chemical There are no clinical data on the use of entity1begin MIVACRON entity1end with other entity2begin nondepolarizing neuromuscular blocking agents entity2end . 
false chemical chemical entity1begin Isoflurane entity1end and entity2begin enflurane entity2end ( administered with nitrous oxide / oxygen to achieve 1.25 M.C . 
false chemical chemical entity1begin Isoflurane entity1end and enflurane ( administered with entity2begin nitrous oxide entity2end / oxygen to achieve 1.25 M.C . 
false chemical chemical entity1begin Isoflurane entity1end and enflurane ( administered with nitrous oxide / entity2begin oxygen entity2end to achieve 1.25 M.C . 
false chemical chemical Isoflurane and entity1begin enflurane entity1end ( administered with entity2begin nitrous oxide entity2end / oxygen to achieve 1.25 M.C . 
false chemical chemical Isoflurane and entity1begin enflurane entity1end ( administered with nitrous oxide / entity2begin oxygen entity2end to achieve 1.25 M.C . 
false chemical chemical Isoflurane and enflurane ( administered with entity1begin nitrous oxide entity1end / entity2begin oxygen entity2end to achieve 1.25 M.C . 
false chemical chemical A greater potentiation of the neuromuscular blocking effects of entity1begin MIVACRON entity1end may be expected with higher concentrations of entity2begin enflurane entity2end or isoflurane . 
false chemical chemical A greater potentiation of the neuromuscular blocking effects of entity1begin MIVACRON entity1end may be expected with higher concentrations of enflurane or entity2begin isoflurane entity2end . 
false chemical chemical A greater potentiation of the neuromuscular blocking effects of MIVACRON may be expected with higher concentrations of entity1begin enflurane entity1end or entity2begin isoflurane entity2end . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of entity1begin nondepolarizing agents entity1end such as entity2begin MIVACRON entity2end include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
true chemical chemical Other drugs which may enhance the neuromuscular blocking action of entity1begin nondepolarizing agents entity1end such as MIVACRON include certain entity2begin antibiotics entity2end ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
true chemical chemical Other drugs which may enhance the neuromuscular blocking action of entity1begin nondepolarizing agents entity1end such as MIVACRON include certain antibiotics ( e.g. , entity2begin aminoglycosides entity2end , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
true chemical chemical Other drugs which may enhance the neuromuscular blocking action of entity1begin nondepolarizing agents entity1end such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , entity2begin tetracyclines entity2end , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
true chemical chemical Other drugs which may enhance the neuromuscular blocking action of entity1begin nondepolarizing agents entity1end such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , entity2begin bacitracin entity2end , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
true chemical chemical Other drugs which may enhance the neuromuscular blocking action of entity1begin nondepolarizing agents entity1end such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , entity2begin polymyxins entity2end , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
true chemical chemical Other drugs which may enhance the neuromuscular blocking action of entity1begin nondepolarizing agents entity1end such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , entity2begin lincomycin entity2end , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
true chemical chemical Other drugs which may enhance the neuromuscular blocking action of entity1begin nondepolarizing agents entity1end such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , entity2begin clindamycin entity2end , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
true chemical chemical Other drugs which may enhance the neuromuscular blocking action of entity1begin nondepolarizing agents entity1end such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , entity2begin colistin entity2end , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
true chemical chemical Other drugs which may enhance the neuromuscular blocking action of entity1begin nondepolarizing agents entity1end such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and entity2begin sodium colistimethate entity2end ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
true chemical chemical Other drugs which may enhance the neuromuscular blocking action of entity1begin nondepolarizing agents entity1end such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , entity2begin magnesium entity2end salts , lithium , local anesthetics , procainamide , and quinidine . 
true chemical chemical Other drugs which may enhance the neuromuscular blocking action of entity1begin nondepolarizing agents entity1end such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , entity2begin lithium entity2end , local anesthetics , procainamide , and quinidine . 
true chemical chemical Other drugs which may enhance the neuromuscular blocking action of entity1begin nondepolarizing agents entity1end such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local entity2begin anesthetics entity2end , procainamide , and quinidine . 
true chemical chemical Other drugs which may enhance the neuromuscular blocking action of entity1begin nondepolarizing agents entity1end such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , entity2begin procainamide entity2end , and quinidine . 
true chemical chemical Other drugs which may enhance the neuromuscular blocking action of entity1begin nondepolarizing agents entity1end such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and entity2begin quinidine entity2end . 
true chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as entity1begin MIVACRON entity1end include certain entity2begin antibiotics entity2end ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
true chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as entity1begin MIVACRON entity1end include certain antibiotics ( e.g. , entity2begin aminoglycosides entity2end , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
true chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as entity1begin MIVACRON entity1end include certain antibiotics ( e.g. , aminoglycosides , entity2begin tetracyclines entity2end , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
true chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as entity1begin MIVACRON entity1end include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , entity2begin bacitracin entity2end , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
true chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as entity1begin MIVACRON entity1end include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , entity2begin polymyxins entity2end , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
true chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as entity1begin MIVACRON entity1end include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , entity2begin lincomycin entity2end , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
true chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as entity1begin MIVACRON entity1end include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , entity2begin clindamycin entity2end , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
true chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as entity1begin MIVACRON entity1end include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , entity2begin colistin entity2end , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
true chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as entity1begin MIVACRON entity1end include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and entity2begin sodium colistimethate entity2end ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
true chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as entity1begin MIVACRON entity1end include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , entity2begin magnesium entity2end salts , lithium , local anesthetics , procainamide , and quinidine . 
true chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as entity1begin MIVACRON entity1end include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , entity2begin lithium entity2end , local anesthetics , procainamide , and quinidine . 
true chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as entity1begin MIVACRON entity1end include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local entity2begin anesthetics entity2end , procainamide , and quinidine . 
true chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as entity1begin MIVACRON entity1end include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , entity2begin procainamide entity2end , and quinidine . 
true chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as entity1begin MIVACRON entity1end include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and entity2begin quinidine entity2end . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain entity1begin antibiotics entity1end ( e.g. , entity2begin aminoglycosides entity2end , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain entity1begin antibiotics entity1end ( e.g. , aminoglycosides , entity2begin tetracyclines entity2end , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain entity1begin antibiotics entity1end ( e.g. , aminoglycosides , tetracyclines , entity2begin bacitracin entity2end , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain entity1begin antibiotics entity1end ( e.g. , aminoglycosides , tetracyclines , bacitracin , entity2begin polymyxins entity2end , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain entity1begin antibiotics entity1end ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , entity2begin lincomycin entity2end , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain entity1begin antibiotics entity1end ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , entity2begin clindamycin entity2end , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain entity1begin antibiotics entity1end ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , entity2begin colistin entity2end , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain entity1begin antibiotics entity1end ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and entity2begin sodium colistimethate entity2end ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain entity1begin antibiotics entity1end ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , entity2begin magnesium entity2end salts , lithium , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain entity1begin antibiotics entity1end ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , entity2begin lithium entity2end , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain entity1begin antibiotics entity1end ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local entity2begin anesthetics entity2end , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain entity1begin antibiotics entity1end ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , entity2begin procainamide entity2end , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain entity1begin antibiotics entity1end ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and entity2begin quinidine entity2end . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , entity1begin aminoglycosides entity1end , entity2begin tetracyclines entity2end , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , entity1begin aminoglycosides entity1end , tetracyclines , entity2begin bacitracin entity2end , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , entity1begin aminoglycosides entity1end , tetracyclines , bacitracin , entity2begin polymyxins entity2end , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , entity1begin aminoglycosides entity1end , tetracyclines , bacitracin , polymyxins , entity2begin lincomycin entity2end , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , entity1begin aminoglycosides entity1end , tetracyclines , bacitracin , polymyxins , lincomycin , entity2begin clindamycin entity2end , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , entity1begin aminoglycosides entity1end , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , entity2begin colistin entity2end , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , entity1begin aminoglycosides entity1end , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and entity2begin sodium colistimethate entity2end ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , entity1begin aminoglycosides entity1end , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , entity2begin magnesium entity2end salts , lithium , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , entity1begin aminoglycosides entity1end , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , entity2begin lithium entity2end , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , entity1begin aminoglycosides entity1end , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local entity2begin anesthetics entity2end , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , entity1begin aminoglycosides entity1end , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , entity2begin procainamide entity2end , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , entity1begin aminoglycosides entity1end , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and entity2begin quinidine entity2end . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , entity1begin tetracyclines entity1end , entity2begin bacitracin entity2end , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , entity1begin tetracyclines entity1end , bacitracin , entity2begin polymyxins entity2end , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , entity1begin tetracyclines entity1end , bacitracin , polymyxins , entity2begin lincomycin entity2end , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , entity1begin tetracyclines entity1end , bacitracin , polymyxins , lincomycin , entity2begin clindamycin entity2end , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , entity1begin tetracyclines entity1end , bacitracin , polymyxins , lincomycin , clindamycin , entity2begin colistin entity2end , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , entity1begin tetracyclines entity1end , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and entity2begin sodium colistimethate entity2end ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , entity1begin tetracyclines entity1end , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , entity2begin magnesium entity2end salts , lithium , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , entity1begin tetracyclines entity1end , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , entity2begin lithium entity2end , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , entity1begin tetracyclines entity1end , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local entity2begin anesthetics entity2end , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , entity1begin tetracyclines entity1end , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , entity2begin procainamide entity2end , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , entity1begin tetracyclines entity1end , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and entity2begin quinidine entity2end . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , entity1begin bacitracin entity1end , entity2begin polymyxins entity2end , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , entity1begin bacitracin entity1end , polymyxins , entity2begin lincomycin entity2end , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , entity1begin bacitracin entity1end , polymyxins , lincomycin , entity2begin clindamycin entity2end , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , entity1begin bacitracin entity1end , polymyxins , lincomycin , clindamycin , entity2begin colistin entity2end , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , entity1begin bacitracin entity1end , polymyxins , lincomycin , clindamycin , colistin , and entity2begin sodium colistimethate entity2end ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , entity1begin bacitracin entity1end , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , entity2begin magnesium entity2end salts , lithium , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , entity1begin bacitracin entity1end , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , entity2begin lithium entity2end , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , entity1begin bacitracin entity1end , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local entity2begin anesthetics entity2end , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , entity1begin bacitracin entity1end , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , entity2begin procainamide entity2end , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , entity1begin bacitracin entity1end , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and entity2begin quinidine entity2end . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , entity1begin polymyxins entity1end , entity2begin lincomycin entity2end , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , entity1begin polymyxins entity1end , lincomycin , entity2begin clindamycin entity2end , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , entity1begin polymyxins entity1end , lincomycin , clindamycin , entity2begin colistin entity2end , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , entity1begin polymyxins entity1end , lincomycin , clindamycin , colistin , and entity2begin sodium colistimethate entity2end ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , entity1begin polymyxins entity1end , lincomycin , clindamycin , colistin , and sodium colistimethate ) , entity2begin magnesium entity2end salts , lithium , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , entity1begin polymyxins entity1end , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , entity2begin lithium entity2end , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , entity1begin polymyxins entity1end , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local entity2begin anesthetics entity2end , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , entity1begin polymyxins entity1end , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , entity2begin procainamide entity2end , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , entity1begin polymyxins entity1end , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and entity2begin quinidine entity2end . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , entity1begin lincomycin entity1end , entity2begin clindamycin entity2end , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , entity1begin lincomycin entity1end , clindamycin , entity2begin colistin entity2end , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , entity1begin lincomycin entity1end , clindamycin , colistin , and entity2begin sodium colistimethate entity2end ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , entity1begin lincomycin entity1end , clindamycin , colistin , and sodium colistimethate ) , entity2begin magnesium entity2end salts , lithium , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , entity1begin lincomycin entity1end , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , entity2begin lithium entity2end , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , entity1begin lincomycin entity1end , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local entity2begin anesthetics entity2end , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , entity1begin lincomycin entity1end , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , entity2begin procainamide entity2end , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , entity1begin lincomycin entity1end , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and entity2begin quinidine entity2end . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , entity1begin clindamycin entity1end , entity2begin colistin entity2end , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , entity1begin clindamycin entity1end , colistin , and entity2begin sodium colistimethate entity2end ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , entity1begin clindamycin entity1end , colistin , and sodium colistimethate ) , entity2begin magnesium entity2end salts , lithium , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , entity1begin clindamycin entity1end , colistin , and sodium colistimethate ) , magnesium salts , entity2begin lithium entity2end , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , entity1begin clindamycin entity1end , colistin , and sodium colistimethate ) , magnesium salts , lithium , local entity2begin anesthetics entity2end , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , entity1begin clindamycin entity1end , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , entity2begin procainamide entity2end , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , entity1begin clindamycin entity1end , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and entity2begin quinidine entity2end . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , entity1begin colistin entity1end , and entity2begin sodium colistimethate entity2end ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , entity1begin colistin entity1end , and sodium colistimethate ) , entity2begin magnesium entity2end salts , lithium , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , entity1begin colistin entity1end , and sodium colistimethate ) , magnesium salts , entity2begin lithium entity2end , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , entity1begin colistin entity1end , and sodium colistimethate ) , magnesium salts , lithium , local entity2begin anesthetics entity2end , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , entity1begin colistin entity1end , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , entity2begin procainamide entity2end , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , entity1begin colistin entity1end , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and entity2begin quinidine entity2end . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and entity1begin sodium colistimethate entity1end ) , entity2begin magnesium entity2end salts , lithium , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and entity1begin sodium colistimethate entity1end ) , magnesium salts , entity2begin lithium entity2end , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and entity1begin sodium colistimethate entity1end ) , magnesium salts , lithium , local entity2begin anesthetics entity2end , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and entity1begin sodium colistimethate entity1end ) , magnesium salts , lithium , local anesthetics , entity2begin procainamide entity2end , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and entity1begin sodium colistimethate entity1end ) , magnesium salts , lithium , local anesthetics , procainamide , and entity2begin quinidine entity2end . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , entity1begin magnesium entity1end salts , entity2begin lithium entity2end , local anesthetics , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , entity1begin magnesium entity1end salts , lithium , local entity2begin anesthetics entity2end , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , entity1begin magnesium entity1end salts , lithium , local anesthetics , entity2begin procainamide entity2end , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , entity1begin magnesium entity1end salts , lithium , local anesthetics , procainamide , and entity2begin quinidine entity2end . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , entity1begin lithium entity1end , local entity2begin anesthetics entity2end , procainamide , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , entity1begin lithium entity1end , local anesthetics , entity2begin procainamide entity2end , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , entity1begin lithium entity1end , local anesthetics , procainamide , and entity2begin quinidine entity2end . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local entity1begin anesthetics entity1end , entity2begin procainamide entity2end , and quinidine . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local entity1begin anesthetics entity1end , procainamide , and entity2begin quinidine entity2end . 
false chemical chemical Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , entity1begin procainamide entity1end , and entity2begin quinidine entity2end . 
true chemical chemical The neuromuscular blocking effect of entity1begin MIVACRON entity1end may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral entity2begin contraceptives entity2end , glucocorticoids , or certain monoamine oxidase inhibitors ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine . 
true chemical chemical The neuromuscular blocking effect of entity1begin MIVACRON entity1end may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral contraceptives , entity2begin glucocorticoids entity2end , or certain monoamine oxidase inhibitors ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine . 
true chemical chemical The neuromuscular blocking effect of entity1begin MIVACRON entity1end may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral contraceptives , glucocorticoids , or certain entity2begin monoamine oxidase inhibitors entity2end ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine . 
false chemical chemical The neuromuscular blocking effect of entity1begin MIVACRON entity1end may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing entity2begin neuromuscular blocking agents entity2end has been demonstrated in patients chronically administered phenytoin or carbamazepine . 
false chemical chemical The neuromuscular blocking effect of entity1begin MIVACRON entity1end may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered entity2begin phenytoin entity2end or carbamazepine . 
false chemical chemical The neuromuscular blocking effect of entity1begin MIVACRON entity1end may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or entity2begin carbamazepine entity2end . 
false chemical chemical The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral entity1begin contraceptives entity1end , entity2begin glucocorticoids entity2end , or certain monoamine oxidase inhibitors ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine . 
false chemical chemical The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral entity1begin contraceptives entity1end , glucocorticoids , or certain entity2begin monoamine oxidase inhibitors entity2end ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine . 
false chemical chemical The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral entity1begin contraceptives entity1end , glucocorticoids , or certain monoamine oxidase inhibitors ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing entity2begin neuromuscular blocking agents entity2end has been demonstrated in patients chronically administered phenytoin or carbamazepine . 
false chemical chemical The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral entity1begin contraceptives entity1end , glucocorticoids , or certain monoamine oxidase inhibitors ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered entity2begin phenytoin entity2end or carbamazepine . 
false chemical chemical The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral entity1begin contraceptives entity1end , glucocorticoids , or certain monoamine oxidase inhibitors ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or entity2begin carbamazepine entity2end . 
false chemical chemical The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral contraceptives , entity1begin glucocorticoids entity1end , or certain entity2begin monoamine oxidase inhibitors entity2end ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine . 
false chemical chemical The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral contraceptives , entity1begin glucocorticoids entity1end , or certain monoamine oxidase inhibitors ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing entity2begin neuromuscular blocking agents entity2end has been demonstrated in patients chronically administered phenytoin or carbamazepine . 
false chemical chemical The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral contraceptives , entity1begin glucocorticoids entity1end , or certain monoamine oxidase inhibitors ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered entity2begin phenytoin entity2end or carbamazepine . 
false chemical chemical The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral contraceptives , entity1begin glucocorticoids entity1end , or certain monoamine oxidase inhibitors ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or entity2begin carbamazepine entity2end . 
false chemical chemical The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral contraceptives , glucocorticoids , or certain entity1begin monoamine oxidase inhibitors entity1end ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing entity2begin neuromuscular blocking agents entity2end has been demonstrated in patients chronically administered phenytoin or carbamazepine . 
false chemical chemical The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral contraceptives , glucocorticoids , or certain entity1begin monoamine oxidase inhibitors entity1end ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered entity2begin phenytoin entity2end or carbamazepine . 
false chemical chemical The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral contraceptives , glucocorticoids , or certain entity1begin monoamine oxidase inhibitors entity1end ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or entity2begin carbamazepine entity2end . 
true chemical chemical The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing entity1begin neuromuscular blocking agents entity1end has been demonstrated in patients chronically administered entity2begin phenytoin entity2end or carbamazepine . 
true chemical chemical The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing entity1begin neuromuscular blocking agents entity1end has been demonstrated in patients chronically administered phenytoin or entity2begin carbamazepine entity2end . 
false chemical chemical The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered entity1begin phenytoin entity1end or entity2begin carbamazepine entity2end . 
false chemical chemical While the effects of chronic entity1begin phenytoin entity1end or entity2begin carbamazepine entity2end therapy on the action of MIVACRON are unknown , slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher . 
true chemical chemical While the effects of chronic entity1begin phenytoin entity1end or carbamazepine therapy on the action of entity2begin MIVACRON entity2end are unknown , slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher . 
true chemical chemical While the effects of chronic phenytoin or entity1begin carbamazepine entity1end therapy on the action of entity2begin MIVACRON entity2end are unknown , slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher . 
false chemical chemical Some drug interactions are : - birth control pills - entity1begin corticosteroids entity1end - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as entity2begin phenytoin entity2end or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - entity1begin corticosteroids entity1end - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or entity2begin carbamazepine entity2end - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - entity1begin corticosteroids entity1end - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain entity2begin antibiotics entity2end given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - entity1begin corticosteroids entity1end - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - entity2begin cisplatin entity2end - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - entity1begin corticosteroids entity1end - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - entity2begin edrophonium entity2end - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - entity1begin corticosteroids entity1end - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - entity2begin neostigmine entity2end - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - entity1begin corticosteroids entity1end - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - entity2begin polymyxin B entity2end or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - entity1begin corticosteroids entity1end - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or entity2begin bacitracin entity2end - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - entity1begin corticosteroids entity1end - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local entity2begin anesthetics entity2end such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - entity1begin corticosteroids entity1end - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as entity2begin procaine entity2end - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - entity1begin corticosteroids entity1end - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general entity2begin anesthetics entity2end - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - entity1begin corticosteroids entity1end - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - entity2begin succinylcholine entity2end or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - entity1begin corticosteroids entity1end - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other entity2begin muscle relaxants entity2end 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as entity1begin phenytoin entity1end or entity2begin carbamazepine entity2end - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as entity1begin phenytoin entity1end or carbamazepine - certain entity2begin antibiotics entity2end given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as entity1begin phenytoin entity1end or carbamazepine - certain antibiotics given by injection - entity2begin cisplatin entity2end - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as entity1begin phenytoin entity1end or carbamazepine - certain antibiotics given by injection - cisplatin - entity2begin edrophonium entity2end - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as entity1begin phenytoin entity1end or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - entity2begin neostigmine entity2end - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as entity1begin phenytoin entity1end or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - entity2begin polymyxin B entity2end or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as entity1begin phenytoin entity1end or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or entity2begin bacitracin entity2end - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as entity1begin phenytoin entity1end or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local entity2begin anesthetics entity2end such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as entity1begin phenytoin entity1end or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as entity2begin procaine entity2end - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as entity1begin phenytoin entity1end or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general entity2begin anesthetics entity2end - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as entity1begin phenytoin entity1end or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - entity2begin succinylcholine entity2end or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as entity1begin phenytoin entity1end or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other entity2begin muscle relaxants entity2end 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or entity1begin carbamazepine entity1end - certain entity2begin antibiotics entity2end given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or entity1begin carbamazepine entity1end - certain antibiotics given by injection - entity2begin cisplatin entity2end - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or entity1begin carbamazepine entity1end - certain antibiotics given by injection - cisplatin - entity2begin edrophonium entity2end - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or entity1begin carbamazepine entity1end - certain antibiotics given by injection - cisplatin - edrophonium - entity2begin neostigmine entity2end - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or entity1begin carbamazepine entity1end - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - entity2begin polymyxin B entity2end or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or entity1begin carbamazepine entity1end - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or entity2begin bacitracin entity2end - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or entity1begin carbamazepine entity1end - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local entity2begin anesthetics entity2end such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or entity1begin carbamazepine entity1end - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as entity2begin procaine entity2end - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or entity1begin carbamazepine entity1end - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general entity2begin anesthetics entity2end - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or entity1begin carbamazepine entity1end - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - entity2begin succinylcholine entity2end or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or entity1begin carbamazepine entity1end - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other entity2begin muscle relaxants entity2end 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain entity1begin antibiotics entity1end given by injection - entity2begin cisplatin entity2end - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain entity1begin antibiotics entity1end given by injection - cisplatin - entity2begin edrophonium entity2end - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain entity1begin antibiotics entity1end given by injection - cisplatin - edrophonium - entity2begin neostigmine entity2end - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain entity1begin antibiotics entity1end given by injection - cisplatin - edrophonium - neostigmine - entity2begin polymyxin B entity2end or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain entity1begin antibiotics entity1end given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or entity2begin bacitracin entity2end - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain entity1begin antibiotics entity1end given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local entity2begin anesthetics entity2end such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain entity1begin antibiotics entity1end given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as entity2begin procaine entity2end - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain entity1begin antibiotics entity1end given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general entity2begin anesthetics entity2end - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain entity1begin antibiotics entity1end given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - entity2begin succinylcholine entity2end or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain entity1begin antibiotics entity1end given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other entity2begin muscle relaxants entity2end 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - entity1begin cisplatin entity1end - entity2begin edrophonium entity2end - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - entity1begin cisplatin entity1end - edrophonium - entity2begin neostigmine entity2end - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - entity1begin cisplatin entity1end - edrophonium - neostigmine - entity2begin polymyxin B entity2end or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - entity1begin cisplatin entity1end - edrophonium - neostigmine - polymyxin B or entity2begin bacitracin entity2end - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - entity1begin cisplatin entity1end - edrophonium - neostigmine - polymyxin B or bacitracin - local entity2begin anesthetics entity2end such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - entity1begin cisplatin entity1end - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as entity2begin procaine entity2end - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - entity1begin cisplatin entity1end - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general entity2begin anesthetics entity2end - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - entity1begin cisplatin entity1end - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - entity2begin succinylcholine entity2end or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - entity1begin cisplatin entity1end - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other entity2begin muscle relaxants entity2end 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - entity1begin edrophonium entity1end - entity2begin neostigmine entity2end - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - entity1begin edrophonium entity1end - neostigmine - entity2begin polymyxin B entity2end or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - entity1begin edrophonium entity1end - neostigmine - polymyxin B or entity2begin bacitracin entity2end - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - entity1begin edrophonium entity1end - neostigmine - polymyxin B or bacitracin - local entity2begin anesthetics entity2end such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - entity1begin edrophonium entity1end - neostigmine - polymyxin B or bacitracin - local anesthetics such as entity2begin procaine entity2end - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - entity1begin edrophonium entity1end - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general entity2begin anesthetics entity2end - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - entity1begin edrophonium entity1end - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - entity2begin succinylcholine entity2end or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - entity1begin edrophonium entity1end - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other entity2begin muscle relaxants entity2end 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - entity1begin neostigmine entity1end - entity2begin polymyxin B entity2end or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - entity1begin neostigmine entity1end - polymyxin B or entity2begin bacitracin entity2end - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - entity1begin neostigmine entity1end - polymyxin B or bacitracin - local entity2begin anesthetics entity2end such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - entity1begin neostigmine entity1end - polymyxin B or bacitracin - local anesthetics such as entity2begin procaine entity2end - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - entity1begin neostigmine entity1end - polymyxin B or bacitracin - local anesthetics such as procaine - general entity2begin anesthetics entity2end - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - entity1begin neostigmine entity1end - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - entity2begin succinylcholine entity2end or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - entity1begin neostigmine entity1end - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other entity2begin muscle relaxants entity2end 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - entity1begin polymyxin B entity1end or entity2begin bacitracin entity2end - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - entity1begin polymyxin B entity1end or bacitracin - local entity2begin anesthetics entity2end such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - entity1begin polymyxin B entity1end or bacitracin - local anesthetics such as entity2begin procaine entity2end - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - entity1begin polymyxin B entity1end or bacitracin - local anesthetics such as procaine - general entity2begin anesthetics entity2end - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - entity1begin polymyxin B entity1end or bacitracin - local anesthetics such as procaine - general anesthetics - entity2begin succinylcholine entity2end or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - entity1begin polymyxin B entity1end or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other entity2begin muscle relaxants entity2end 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or entity1begin bacitracin entity1end - local entity2begin anesthetics entity2end such as procaine - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or entity1begin bacitracin entity1end - local anesthetics such as entity2begin procaine entity2end - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or entity1begin bacitracin entity1end - local anesthetics such as procaine - general entity2begin anesthetics entity2end - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or entity1begin bacitracin entity1end - local anesthetics such as procaine - general anesthetics - entity2begin succinylcholine entity2end or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or entity1begin bacitracin entity1end - local anesthetics such as procaine - general anesthetics - succinylcholine or other entity2begin muscle relaxants entity2end 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local entity1begin anesthetics entity1end such as entity2begin procaine entity2end - general anesthetics - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local entity1begin anesthetics entity1end such as procaine - general entity2begin anesthetics entity2end - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local entity1begin anesthetics entity1end such as procaine - general anesthetics - entity2begin succinylcholine entity2end or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local entity1begin anesthetics entity1end such as procaine - general anesthetics - succinylcholine or other entity2begin muscle relaxants entity2end 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as entity1begin procaine entity1end - general entity2begin anesthetics entity2end - succinylcholine or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as entity1begin procaine entity1end - general anesthetics - entity2begin succinylcholine entity2end or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as entity1begin procaine entity1end - general anesthetics - succinylcholine or other entity2begin muscle relaxants entity2end 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general entity1begin anesthetics entity1end - entity2begin succinylcholine entity2end or other muscle relaxants 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general entity1begin anesthetics entity1end - succinylcholine or other entity2begin muscle relaxants entity2end 
false chemical chemical Some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - entity1begin succinylcholine entity1end or other entity2begin muscle relaxants entity2end 
false chemical chemical entity1begin Diuretics entity1end : Excessive reductions in blood pressure may occur in patients on diuretic therapy when entity2begin ACE inhibitors entity2end are started . 
false chemical chemical The possibility of hypotensive effects with entity1begin UNIVASC entity1end can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with entity2begin UNIVASC entity2end . If this is not possible , the starting dose of moexpril should be reduced. . 
false chemical chemical The possibility of hypotensive effects with entity1begin UNIVASC entity1end can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with UNIVASC . If this is not possible , the starting dose of entity2begin moexpril entity2end should be reduced. . 
false chemical chemical The possibility of hypotensive effects with UNIVASC can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with entity1begin UNIVASC entity1end . If this is not possible , the starting dose of entity2begin moexpril entity2end should be reduced. . 
false chemical chemical entity1begin Potassium entity1end Supplements and entity2begin Potassium - Sparing Diuretics entity2end : UNIVASC can increase serum potassium because it decreases aldosterone secretion . 
false chemical chemical entity1begin Potassium entity1end Supplements and Potassium - Sparing Diuretics : entity2begin UNIVASC entity2end can increase serum potassium because it decreases aldosterone secretion . 
false chemical chemical Potassium Supplements and entity1begin Potassium - Sparing Diuretics entity1end : entity2begin UNIVASC entity2end can increase serum potassium because it decreases aldosterone secretion . 
false chemical chemical Use of entity1begin potassium - sparing diuretics entity1end ( entity2begin spironolactone entity2end , triamterene , amiloride ) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia . 
false chemical chemical Use of entity1begin potassium - sparing diuretics entity1end ( spironolactone , entity2begin triamterene entity2end , amiloride ) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia . 
false chemical chemical Use of entity1begin potassium - sparing diuretics entity1end ( spironolactone , triamterene , entity2begin amiloride entity2end ) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia . 
false chemical chemical Use of entity1begin potassium - sparing diuretics entity1end ( spironolactone , triamterene , amiloride ) or entity2begin potassium entity2end supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia . 
true chemical chemical Use of entity1begin potassium - sparing diuretics entity1end ( spironolactone , triamterene , amiloride ) or potassium supplements concomitantly with entity2begin ACE inhibitors entity2end can increase the risk of hyperkalemia . 
false chemical chemical Use of potassium - sparing diuretics ( entity1begin spironolactone entity1end , entity2begin triamterene entity2end , amiloride ) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia . 
false chemical chemical Use of potassium - sparing diuretics ( entity1begin spironolactone entity1end , triamterene , entity2begin amiloride entity2end ) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia . 
false chemical chemical Use of potassium - sparing diuretics ( entity1begin spironolactone entity1end , triamterene , amiloride ) or entity2begin potassium entity2end supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia . 
true chemical chemical Use of potassium - sparing diuretics ( entity1begin spironolactone entity1end , triamterene , amiloride ) or potassium supplements concomitantly with entity2begin ACE inhibitors entity2end can increase the risk of hyperkalemia . 
false chemical chemical Use of potassium - sparing diuretics ( spironolactone , entity1begin triamterene entity1end , entity2begin amiloride entity2end ) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia . 
false chemical chemical Use of potassium - sparing diuretics ( spironolactone , entity1begin triamterene entity1end , amiloride ) or entity2begin potassium entity2end supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia . 
true chemical chemical Use of potassium - sparing diuretics ( spironolactone , entity1begin triamterene entity1end , amiloride ) or potassium supplements concomitantly with entity2begin ACE inhibitors entity2end can increase the risk of hyperkalemia . 
false chemical chemical Use of potassium - sparing diuretics ( spironolactone , triamterene , entity1begin amiloride entity1end ) or entity2begin potassium entity2end supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia . 
true chemical chemical Use of potassium - sparing diuretics ( spironolactone , triamterene , entity1begin amiloride entity1end ) or potassium supplements concomitantly with entity2begin ACE inhibitors entity2end can increase the risk of hyperkalemia . 
true chemical chemical Use of potassium - sparing diuretics ( spironolactone , triamterene , amiloride ) or entity1begin potassium entity1end supplements concomitantly with entity2begin ACE inhibitors entity2end can increase the risk of hyperkalemia . 
false chemical chemical Oral entity1begin Anticoagulants entity1end : Interaction studies with entity2begin warfarin entity2end failed to identify any clinically important effect on the serum concentrations of the anticoagulant or on its anticoagulant effect . 
false chemical chemical Oral entity1begin Anticoagulants entity1end : Interaction studies with warfarin failed to identify any clinically important effect on the serum concentrations of the entity2begin anticoagulant entity2end or on its anticoagulant effect . 
false chemical chemical Oral Anticoagulants : Interaction studies with entity1begin warfarin entity1end failed to identify any clinically important effect on the serum concentrations of the entity2begin anticoagulant entity2end or on its anticoagulant effect . 
false chemical chemical entity1begin Lithium entity1end : Increased serum entity2begin lithium entity2end levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium . 
false chemical chemical entity1begin Lithium entity1end : Increased serum lithium levels and symptoms of entity2begin lithium entity2end toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium . 
false chemical chemical entity1begin Lithium entity1end : Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving entity2begin ACE inhibitors entity2end during therapy with lithium . 
false chemical chemical entity1begin Lithium entity1end : Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with entity2begin lithium entity2end . 
false chemical chemical Lithium : Increased serum entity1begin lithium entity1end levels and symptoms of entity2begin lithium entity2end toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium . 
false chemical chemical Lithium : Increased serum entity1begin lithium entity1end levels and symptoms of lithium toxicity have been reported in patients receiving entity2begin ACE inhibitors entity2end during therapy with lithium . 
false chemical chemical Lithium : Increased serum entity1begin lithium entity1end levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with entity2begin lithium entity2end . 
false chemical chemical Lithium : Increased serum lithium levels and symptoms of entity1begin lithium entity1end toxicity have been reported in patients receiving entity2begin ACE inhibitors entity2end during therapy with lithium . 
false chemical chemical Lithium : Increased serum lithium levels and symptoms of entity1begin lithium entity1end toxicity have been reported in patients receiving ACE inhibitors during therapy with entity2begin lithium entity2end . 
true chemical chemical Lithium : Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving entity1begin ACE inhibitors entity1end during therapy with entity2begin lithium entity2end . 
true chemical chemical If a entity1begin diuretic entity1end is also used , the risk of entity2begin lithium entity2end toxicity may be increased . 
false chemical chemical Other Agents : No clinically important pharmacokinetic interactions occurred when entity1begin UNIVASC entity1end was administered concomitantly with entity2begin hydrochlorothiazide entity2end , digoxin , or cimetidine . 
false chemical chemical Other Agents : No clinically important pharmacokinetic interactions occurred when entity1begin UNIVASC entity1end was administered concomitantly with hydrochlorothiazide , entity2begin digoxin entity2end , or cimetidine . 
false chemical chemical Other Agents : No clinically important pharmacokinetic interactions occurred when entity1begin UNIVASC entity1end was administered concomitantly with hydrochlorothiazide , digoxin , or entity2begin cimetidine entity2end . 
false chemical chemical Other Agents : No clinically important pharmacokinetic interactions occurred when UNIVASC was administered concomitantly with entity1begin hydrochlorothiazide entity1end , entity2begin digoxin entity2end , or cimetidine . 
false chemical chemical Other Agents : No clinically important pharmacokinetic interactions occurred when UNIVASC was administered concomitantly with entity1begin hydrochlorothiazide entity1end , digoxin , or entity2begin cimetidine entity2end . 
false chemical chemical Other Agents : No clinically important pharmacokinetic interactions occurred when UNIVASC was administered concomitantly with hydrochlorothiazide , entity1begin digoxin entity1end , or entity2begin cimetidine entity2end . 
false chemical chemical entity1begin UNIVASC entity1end has been used in clinical trials concomitantly with entity2begin calcium - channel - blocking agents entity2end , diuretics , H2 blockers , digoxin , oral hypoglycemic agents , and cholesterol - lowering agents . 
false chemical chemical entity1begin UNIVASC entity1end has been used in clinical trials concomitantly with calcium - channel - blocking agents , entity2begin diuretics entity2end , H2 blockers , digoxin , oral hypoglycemic agents , and cholesterol - lowering agents . 
false chemical chemical entity1begin UNIVASC entity1end has been used in clinical trials concomitantly with calcium - channel - blocking agents , diuretics , entity2begin H2 blockers entity2end , digoxin , oral hypoglycemic agents , and cholesterol - lowering agents . 
false chemical chemical entity1begin UNIVASC entity1end has been used in clinical trials concomitantly with calcium - channel - blocking agents , diuretics , H2 blockers , entity2begin digoxin entity2end , oral hypoglycemic agents , and cholesterol - lowering agents . 
false chemical chemical entity1begin UNIVASC entity1end has been used in clinical trials concomitantly with calcium - channel - blocking agents , diuretics , H2 blockers , digoxin , oral entity2begin hypoglycemic agents entity2end , and cholesterol - lowering agents . 
false chemical chemical UNIVASC has been used in clinical trials concomitantly with entity1begin calcium - channel - blocking agents entity1end , entity2begin diuretics entity2end , H2 blockers , digoxin , oral hypoglycemic agents , and cholesterol - lowering agents . 
false chemical chemical UNIVASC has been used in clinical trials concomitantly with entity1begin calcium - channel - blocking agents entity1end , diuretics , entity2begin H2 blockers entity2end , digoxin , oral hypoglycemic agents , and cholesterol - lowering agents . 
false chemical chemical UNIVASC has been used in clinical trials concomitantly with entity1begin calcium - channel - blocking agents entity1end , diuretics , H2 blockers , entity2begin digoxin entity2end , oral hypoglycemic agents , and cholesterol - lowering agents . 
false chemical chemical UNIVASC has been used in clinical trials concomitantly with entity1begin calcium - channel - blocking agents entity1end , diuretics , H2 blockers , digoxin , oral entity2begin hypoglycemic agents entity2end , and cholesterol - lowering agents . 
false chemical chemical UNIVASC has been used in clinical trials concomitantly with calcium - channel - blocking agents , entity1begin diuretics entity1end , entity2begin H2 blockers entity2end , digoxin , oral hypoglycemic agents , and cholesterol - lowering agents . 
false chemical chemical UNIVASC has been used in clinical trials concomitantly with calcium - channel - blocking agents , entity1begin diuretics entity1end , H2 blockers , entity2begin digoxin entity2end , oral hypoglycemic agents , and cholesterol - lowering agents . 
false chemical chemical UNIVASC has been used in clinical trials concomitantly with calcium - channel - blocking agents , entity1begin diuretics entity1end , H2 blockers , digoxin , oral entity2begin hypoglycemic agents entity2end , and cholesterol - lowering agents . 
false chemical chemical UNIVASC has been used in clinical trials concomitantly with calcium - channel - blocking agents , diuretics , entity1begin H2 blockers entity1end , entity2begin digoxin entity2end , oral hypoglycemic agents , and cholesterol - lowering agents . 
false chemical chemical UNIVASC has been used in clinical trials concomitantly with calcium - channel - blocking agents , diuretics , entity1begin H2 blockers entity1end , digoxin , oral entity2begin hypoglycemic agents entity2end , and cholesterol - lowering agents . 
false chemical chemical UNIVASC has been used in clinical trials concomitantly with calcium - channel - blocking agents , diuretics , H2 blockers , entity1begin digoxin entity1end , oral entity2begin hypoglycemic agents entity2end , and cholesterol - lowering agents . 
true chemical chemical However , entity1begin ketoconazole entity1end , a potent inhibitor of cytochrome P450 3A4 , may increase plasma levels of entity2begin mometasone furoate entity2end during concomitant dosing . 
false chemical chemical entity1begin Montelukast entity1end at a Dose of 10 mg Once Daily Dosed to Pharmacokinetic Steady State - did not cause clinically significant changes in the kinetics of a single intravenous dose of entity2begin theophylline entity2end ( predominantly a cytochrome P450 1A2 substrate ) . 
false chemical chemical - did not change the pharmacokinetic profile of entity1begin warfarin entity1end ( a substrate of cytochromes P450 2A6 and 2C9 ) or influence the effect of a single 30 - mg oral dose of entity2begin warfarin entity2end on prothrombin time or the INR ( International Normalized Ratio ) . 
false chemical chemical - did not change the plasma concentration profile of entity1begin terfenadine entity1end ( a substrate of cytochrome P450 3A4 ) or entity2begin fexofenadine entity2end , its carboxylated metabolite , and did not prolong the QTc interval following co - administration with terfenadine 60 mg twice daily . 
false chemical chemical - did not change the plasma concentration profile of entity1begin terfenadine entity1end ( a substrate of cytochrome P450 3A4 ) or fexofenadine , its carboxylated metabolite , and did not prolong the QTc interval following co - administration with entity2begin terfenadine entity2end 60 mg twice daily . 
false chemical chemical - did not change the plasma concentration profile of terfenadine ( a substrate of cytochrome P450 3A4 ) or entity1begin fexofenadine entity1end , its carboxylated metabolite , and did not prolong the QTc interval following co - administration with entity2begin terfenadine entity2end 60 mg twice daily . 
false chemical chemical entity1begin Montelukast entity1end at Doses of 100 mg Daily Dosed to Pharmacokinetic Steady State : - did not significantly alter the plasma concentrations of either component of an oral entity2begin contraceptive entity2end containing norethindrone 1 mg / ethinyl estradiol 35 mcg . 
false chemical chemical entity1begin Montelukast entity1end at Doses of 100 mg Daily Dosed to Pharmacokinetic Steady State : - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing entity2begin norethindrone entity2end 1 mg / ethinyl estradiol 35 mcg . 
false chemical chemical entity1begin Montelukast entity1end at Doses of 100 mg Daily Dosed to Pharmacokinetic Steady State : - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg / ethinyl entity2begin estradiol entity2end 35 mcg . 
false chemical chemical Montelukast at Doses of 100 mg Daily Dosed to Pharmacokinetic Steady State : - did not significantly alter the plasma concentrations of either component of an oral entity1begin contraceptive entity1end containing entity2begin norethindrone entity2end 1 mg / ethinyl estradiol 35 mcg . 
false chemical chemical Montelukast at Doses of 100 mg Daily Dosed to Pharmacokinetic Steady State : - did not significantly alter the plasma concentrations of either component of an oral entity1begin contraceptive entity1end containing norethindrone 1 mg / ethinyl entity2begin estradiol entity2end 35 mcg . 
false chemical chemical Montelukast at Doses of 100 mg Daily Dosed to Pharmacokinetic Steady State : - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing entity1begin norethindrone entity1end 1 mg / ethinyl entity2begin estradiol entity2end 35 mcg . 
false chemical chemical - did not cause any clinically significant change in plasma profiles of entity1begin prednisone entity1end or entity2begin prednisolone entity2end following administration of either oral prednisone or intravenous prednisolone . 
false chemical chemical - did not cause any clinically significant change in plasma profiles of entity1begin prednisone entity1end or prednisolone following administration of either oral entity2begin prednisone entity2end or intravenous prednisolone . 
false chemical chemical - did not cause any clinically significant change in plasma profiles of entity1begin prednisone entity1end or prednisolone following administration of either oral prednisone or intravenous entity2begin prednisolone entity2end . 
false chemical chemical - did not cause any clinically significant change in plasma profiles of prednisone or entity1begin prednisolone entity1end following administration of either oral entity2begin prednisone entity2end or intravenous prednisolone . 
false chemical chemical - did not cause any clinically significant change in plasma profiles of prednisone or entity1begin prednisolone entity1end following administration of either oral prednisone or intravenous entity2begin prednisolone entity2end . 
false chemical chemical - did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral entity1begin prednisone entity1end or intravenous entity2begin prednisolone entity2end . 
false chemical chemical entity1begin Phenobarbital entity1end , which induces hepatic metabolism , decreased the AUC of entity2begin montelukast entity2end approximately 40 % following a single 10 - mg dose of montelukast . 
false chemical chemical entity1begin Phenobarbital entity1end , which induces hepatic metabolism , decreased the AUC of montelukast approximately 40 % following a single 10 - mg dose of entity2begin montelukast entity2end . 
false chemical chemical Phenobarbital , which induces hepatic metabolism , decreased the AUC of entity1begin montelukast entity1end approximately 40 % following a single 10 - mg dose of entity2begin montelukast entity2end . 
false chemical chemical It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers , such as entity1begin phenobarbital entity1end or entity2begin rifampin entity2end , are co - administered with montelukast . 
true chemical chemical It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers , such as entity1begin phenobarbital entity1end or rifampin , are co - administered with entity2begin montelukast entity2end . 
true chemical chemical It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers , such as phenobarbital or entity1begin rifampin entity1end , are co - administered with entity2begin montelukast entity2end . 
false chemical chemical In drug - interaction studies , the recommended clinical dose of entity1begin montelukast entity1end did not have clinically important effects on the pharmacokinetics of the following drugs : entity2begin theophylline entity2end , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg / ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin . 
false chemical chemical In drug - interaction studies , the recommended clinical dose of entity1begin montelukast entity1end did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , entity2begin prednisone entity2end , prednisolone , oral contraceptives ( norethindrone 1 mg / ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin . 
false chemical chemical In drug - interaction studies , the recommended clinical dose of entity1begin montelukast entity1end did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , entity2begin prednisolone entity2end , oral contraceptives ( norethindrone 1 mg / ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin . 
false chemical chemical In drug - interaction studies , the recommended clinical dose of entity1begin montelukast entity1end did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral entity2begin contraceptives entity2end ( norethindrone 1 mg / ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin . 
false chemical chemical In drug - interaction studies , the recommended clinical dose of entity1begin montelukast entity1end did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( entity2begin norethindrone entity2end 1 mg / ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin . 
false chemical chemical In drug - interaction studies , the recommended clinical dose of entity1begin montelukast entity1end did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg / entity2begin ethinyl estradiol entity2end 35 mcg ) , terfenadine , digoxin , and warfarin . 
false chemical chemical In drug - interaction studies , the recommended clinical dose of entity1begin montelukast entity1end did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg / ethinyl estradiol 35 mcg ) , entity2begin terfenadine entity2end , digoxin , and warfarin . 
false chemical chemical In drug - interaction studies , the recommended clinical dose of entity1begin montelukast entity1end did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg / ethinyl estradiol 35 mcg ) , terfenadine , entity2begin digoxin entity2end , and warfarin . 
false chemical chemical In drug - interaction studies , the recommended clinical dose of entity1begin montelukast entity1end did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg / ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and entity2begin warfarin entity2end . 
false chemical chemical In drug - interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : entity1begin theophylline entity1end , entity2begin prednisone entity2end , prednisolone , oral contraceptives ( norethindrone 1 mg / ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin . 
false chemical chemical In drug - interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : entity1begin theophylline entity1end , prednisone , entity2begin prednisolone entity2end , oral contraceptives ( norethindrone 1 mg / ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin . 
false chemical chemical In drug - interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : entity1begin theophylline entity1end , prednisone , prednisolone , oral entity2begin contraceptives entity2end ( norethindrone 1 mg / ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin . 
false chemical chemical In drug - interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : entity1begin theophylline entity1end , prednisone , prednisolone , oral contraceptives ( entity2begin norethindrone entity2end 1 mg / ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin . 
false chemical chemical In drug - interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : entity1begin theophylline entity1end , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg / entity2begin ethinyl estradiol entity2end 35 mcg ) , terfenadine , digoxin , and warfarin . 
false chemical chemical In drug - interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : entity1begin theophylline entity1end , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg / ethinyl estradiol 35 mcg ) , entity2begin terfenadine entity2end , digoxin , and warfarin . 
false chemical chemical In drug - interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : entity1begin theophylline entity1end , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg / ethinyl estradiol 35 mcg ) , terfenadine , entity2begin digoxin entity2end , and warfarin . 
false chemical chemical In drug - interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : entity1begin theophylline entity1end , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg / ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and entity2begin warfarin entity2end . 
false chemical chemical In drug - interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , entity1begin prednisone entity1end , entity2begin prednisolone entity2end , oral contraceptives ( norethindrone 1 mg / ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin . 
false chemical chemical In drug - interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , entity1begin prednisone entity1end , prednisolone , oral entity2begin contraceptives entity2end ( norethindrone 1 mg / ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin . 
false chemical chemical In drug - interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , entity1begin prednisone entity1end , prednisolone , oral contraceptives ( entity2begin norethindrone entity2end 1 mg / ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin . 
false chemical chemical In drug - interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , entity1begin prednisone entity1end , prednisolone , oral contraceptives ( norethindrone 1 mg / entity2begin ethinyl estradiol entity2end 35 mcg ) , terfenadine , digoxin , and warfarin . 
false chemical chemical In drug - interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , entity1begin prednisone entity1end , prednisolone , oral contraceptives ( norethindrone 1 mg / ethinyl estradiol 35 mcg ) , entity2begin terfenadine entity2end , digoxin , and warfarin . 
false chemical chemical In drug - interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , entity1begin prednisone entity1end , prednisolone , oral contraceptives ( norethindrone 1 mg / ethinyl estradiol 35 mcg ) , terfenadine , entity2begin digoxin entity2end , and warfarin . 
false chemical chemical In drug - interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , entity1begin prednisone entity1end , prednisolone , oral contraceptives ( norethindrone 1 mg / ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and entity2begin warfarin entity2end . 
false chemical chemical In drug - interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , entity1begin prednisolone entity1end , oral entity2begin contraceptives entity2end ( norethindrone 1 mg / ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin . 
false chemical chemical In drug - interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , entity1begin prednisolone entity1end , oral contraceptives ( entity2begin norethindrone entity2end 1 mg / ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin . 
false chemical chemical In drug - interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , entity1begin prednisolone entity1end , oral contraceptives ( norethindrone 1 mg / entity2begin ethinyl estradiol entity2end 35 mcg ) , terfenadine , digoxin , and warfarin . 
false chemical chemical In drug - interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , entity1begin prednisolone entity1end , oral contraceptives ( norethindrone 1 mg / ethinyl estradiol 35 mcg ) , entity2begin terfenadine entity2end , digoxin , and warfarin . 
false chemical chemical In drug - interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , entity1begin prednisolone entity1end , oral contraceptives ( norethindrone 1 mg / ethinyl estradiol 35 mcg ) , terfenadine , entity2begin digoxin entity2end , and warfarin . 
false chemical chemical In drug - interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , entity1begin prednisolone entity1end , oral contraceptives ( norethindrone 1 mg / ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and entity2begin warfarin entity2end . 
false chemical chemical In drug - interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral entity1begin contraceptives entity1end ( entity2begin norethindrone entity2end 1 mg / ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin . 
false chemical chemical In drug - interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral entity1begin contraceptives entity1end ( norethindrone 1 mg / entity2begin ethinyl estradiol entity2end 35 mcg ) , terfenadine , digoxin , and warfarin . 
false chemical chemical In drug - interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral entity1begin contraceptives entity1end ( norethindrone 1 mg / ethinyl estradiol 35 mcg ) , entity2begin terfenadine entity2end , digoxin , and warfarin . 
false chemical chemical In drug - interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral entity1begin contraceptives entity1end ( norethindrone 1 mg / ethinyl estradiol 35 mcg ) , terfenadine , entity2begin digoxin entity2end , and warfarin . 
false chemical chemical In drug - interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral entity1begin contraceptives entity1end ( norethindrone 1 mg / ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and entity2begin warfarin entity2end . 
false chemical chemical In drug - interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( entity1begin norethindrone entity1end 1 mg / entity2begin ethinyl estradiol entity2end 35 mcg ) , terfenadine , digoxin , and warfarin . 
false chemical chemical In drug - interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( entity1begin norethindrone entity1end 1 mg / ethinyl estradiol 35 mcg ) , entity2begin terfenadine entity2end , digoxin , and warfarin . 
false chemical chemical In drug - interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( entity1begin norethindrone entity1end 1 mg / ethinyl estradiol 35 mcg ) , terfenadine , entity2begin digoxin entity2end , and warfarin . 
false chemical chemical In drug - interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( entity1begin norethindrone entity1end 1 mg / ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and entity2begin warfarin entity2end . 
false chemical chemical In drug - interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg / entity1begin ethinyl estradiol entity1end 35 mcg ) , entity2begin terfenadine entity2end , digoxin , and warfarin . 
false chemical chemical In drug - interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg / entity1begin ethinyl estradiol entity1end 35 mcg ) , terfenadine , entity2begin digoxin entity2end , and warfarin . 
false chemical chemical In drug - interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg / entity1begin ethinyl estradiol entity1end 35 mcg ) , terfenadine , digoxin , and entity2begin warfarin entity2end . 
false chemical chemical In drug - interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg / ethinyl estradiol 35 mcg ) , entity1begin terfenadine entity1end , entity2begin digoxin entity2end , and warfarin . 
false chemical chemical In drug - interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg / ethinyl estradiol 35 mcg ) , entity1begin terfenadine entity1end , digoxin , and entity2begin warfarin entity2end . 
false chemical chemical In drug - interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg / ethinyl estradiol 35 mcg ) , terfenadine , entity1begin digoxin entity1end , and entity2begin warfarin entity2end . 
false chemical chemical These medications included entity1begin thyroid hormones entity1end , entity2begin sedative hypnotics entity2end , non - steroidal anti - inflammatory agents , benzodiazepines , and decongestants . 
false chemical chemical These medications included entity1begin thyroid hormones entity1end , sedative hypnotics , entity2begin non - steroidal anti - inflammatory agents entity2end , benzodiazepines , and decongestants . 
false chemical chemical These medications included entity1begin thyroid hormones entity1end , sedative hypnotics , non - steroidal anti - inflammatory agents , entity2begin benzodiazepines entity2end , and decongestants . 
false chemical chemical These medications included entity1begin thyroid hormones entity1end , sedative hypnotics , non - steroidal anti - inflammatory agents , benzodiazepines , and entity2begin decongestants entity2end . 
false chemical chemical These medications included thyroid hormones , entity1begin sedative hypnotics entity1end , entity2begin non - steroidal anti - inflammatory agents entity2end , benzodiazepines , and decongestants . 
false chemical chemical These medications included thyroid hormones , entity1begin sedative hypnotics entity1end , non - steroidal anti - inflammatory agents , entity2begin benzodiazepines entity2end , and decongestants . 
false chemical chemical These medications included thyroid hormones , entity1begin sedative hypnotics entity1end , non - steroidal anti - inflammatory agents , benzodiazepines , and entity2begin decongestants entity2end . 
false chemical chemical These medications included thyroid hormones , sedative hypnotics , entity1begin non - steroidal anti - inflammatory agents entity1end , entity2begin benzodiazepines entity2end , and decongestants . 
false chemical chemical These medications included thyroid hormones , sedative hypnotics , entity1begin non - steroidal anti - inflammatory agents entity1end , benzodiazepines , and entity2begin decongestants entity2end . 
false chemical chemical These medications included thyroid hormones , sedative hypnotics , non - steroidal anti - inflammatory agents , entity1begin benzodiazepines entity1end , and entity2begin decongestants entity2end . 
false chemical chemical entity1begin Phenobarbital entity1end , which induces hepatic metabolism , decreased the AUC of entity2begin montelukast entity2end approximately 40 % following a single 10 - mg dose of montelukast . 
false chemical chemical entity1begin Phenobarbital entity1end , which induces hepatic metabolism , decreased the AUC of montelukast approximately 40 % following a single 10 - mg dose of entity2begin montelukast entity2end . 
false chemical chemical Phenobarbital , which induces hepatic metabolism , decreased the AUC of entity1begin montelukast entity1end approximately 40 % following a single 10 - mg dose of entity2begin montelukast entity2end . 
false chemical chemical It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers , such as entity1begin phenobarbital entity1end or entity2begin rifampin entity2end , are co - administered with montelukast . 
true chemical chemical It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers , such as entity1begin phenobarbital entity1end or rifampin , are co - administered with entity2begin montelukast entity2end . 
true chemical chemical It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers , such as phenobarbital or entity1begin rifampin entity1end , are co - administered with entity2begin montelukast entity2end . 
false chemical chemical Use with Other entity1begin Central Nervous System Depressants entity1end : The depressant effects of entity2begin morphine entity2end are potentiated by the presence of other CNS depressants such as alcohol , sedatives , antihistaminics , or psychotropic drugs . 
false chemical chemical Use with Other entity1begin Central Nervous System Depressants entity1end : The depressant effects of morphine are potentiated by the presence of other entity2begin CNS depressants entity2end such as alcohol , sedatives , antihistaminics , or psychotropic drugs . 
false chemical chemical Use with Other entity1begin Central Nervous System Depressants entity1end : The depressant effects of morphine are potentiated by the presence of other CNS depressants such as entity2begin alcohol entity2end , sedatives , antihistaminics , or psychotropic drugs . 
false chemical chemical Use with Other entity1begin Central Nervous System Depressants entity1end : The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol , entity2begin sedatives entity2end , antihistaminics , or psychotropic drugs . 
false chemical chemical Use with Other entity1begin Central Nervous System Depressants entity1end : The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol , sedatives , entity2begin antihistaminics entity2end , or psychotropic drugs . 
false chemical chemical Use with Other entity1begin Central Nervous System Depressants entity1end : The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol , sedatives , antihistaminics , or entity2begin psychotropic drugs entity2end . 
true chemical chemical Use with Other Central Nervous System Depressants : The depressant effects of entity1begin morphine entity1end are potentiated by the presence of other entity2begin CNS depressants entity2end such as alcohol , sedatives , antihistaminics , or psychotropic drugs . 
true chemical chemical Use with Other Central Nervous System Depressants : The depressant effects of entity1begin morphine entity1end are potentiated by the presence of other CNS depressants such as entity2begin alcohol entity2end , sedatives , antihistaminics , or psychotropic drugs . 
true chemical chemical Use with Other Central Nervous System Depressants : The depressant effects of entity1begin morphine entity1end are potentiated by the presence of other CNS depressants such as alcohol , entity2begin sedatives entity2end , antihistaminics , or psychotropic drugs . 
true chemical chemical Use with Other Central Nervous System Depressants : The depressant effects of entity1begin morphine entity1end are potentiated by the presence of other CNS depressants such as alcohol , sedatives , entity2begin antihistaminics entity2end , or psychotropic drugs . 
true chemical chemical Use with Other Central Nervous System Depressants : The depressant effects of entity1begin morphine entity1end are potentiated by the presence of other CNS depressants such as alcohol , sedatives , antihistaminics , or entity2begin psychotropic drugs entity2end . 
false chemical chemical Use with Other Central Nervous System Depressants : The depressant effects of morphine are potentiated by the presence of other entity1begin CNS depressants entity1end such as entity2begin alcohol entity2end , sedatives , antihistaminics , or psychotropic drugs . 
false chemical chemical Use with Other Central Nervous System Depressants : The depressant effects of morphine are potentiated by the presence of other entity1begin CNS depressants entity1end such as alcohol , entity2begin sedatives entity2end , antihistaminics , or psychotropic drugs . 
false chemical chemical Use with Other Central Nervous System Depressants : The depressant effects of morphine are potentiated by the presence of other entity1begin CNS depressants entity1end such as alcohol , sedatives , entity2begin antihistaminics entity2end , or psychotropic drugs . 
false chemical chemical Use with Other Central Nervous System Depressants : The depressant effects of morphine are potentiated by the presence of other entity1begin CNS depressants entity1end such as alcohol , sedatives , antihistaminics , or entity2begin psychotropic drugs entity2end . 
false chemical chemical Use with Other Central Nervous System Depressants : The depressant effects of morphine are potentiated by the presence of other CNS depressants such as entity1begin alcohol entity1end , entity2begin sedatives entity2end , antihistaminics , or psychotropic drugs . 
false chemical chemical Use with Other Central Nervous System Depressants : The depressant effects of morphine are potentiated by the presence of other CNS depressants such as entity1begin alcohol entity1end , sedatives , entity2begin antihistaminics entity2end , or psychotropic drugs . 
false chemical chemical Use with Other Central Nervous System Depressants : The depressant effects of morphine are potentiated by the presence of other CNS depressants such as entity1begin alcohol entity1end , sedatives , antihistaminics , or entity2begin psychotropic drugs entity2end . 
false chemical chemical Use with Other Central Nervous System Depressants : The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol , entity1begin sedatives entity1end , entity2begin antihistaminics entity2end , or psychotropic drugs . 
false chemical chemical Use with Other Central Nervous System Depressants : The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol , entity1begin sedatives entity1end , antihistaminics , or entity2begin psychotropic drugs entity2end . 
false chemical chemical Use with Other Central Nervous System Depressants : The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol , sedatives , entity1begin antihistaminics entity1end , or entity2begin psychotropic drugs entity2end . 
true chemical chemical Use of entity1begin neuroleptics entity1end in conjunction with oral entity2begin morphine entity2end may increase the risk of respiratory depression , hypotension and profound sedation or coma . 
false chemical chemical Interaction with entity1begin Mixed Agonist / Antagonist Opioid Analgesics entity1end : entity2begin Agonist / antagonist analgesics entity2end ( i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 
false chemical chemical Interaction with entity1begin Mixed Agonist / Antagonist Opioid Analgesics entity1end : Agonist / antagonist analgesics ( i.e. , entity2begin pentazocine entity2end , nalbuphine , butorphanol , or buprenorphine ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 
false chemical chemical Interaction with entity1begin Mixed Agonist / Antagonist Opioid Analgesics entity1end : Agonist / antagonist analgesics ( i.e. , pentazocine , entity2begin nalbuphine entity2end , butorphanol , or buprenorphine ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 
false chemical chemical Interaction with entity1begin Mixed Agonist / Antagonist Opioid Analgesics entity1end : Agonist / antagonist analgesics ( i.e. , pentazocine , nalbuphine , entity2begin butorphanol entity2end , or buprenorphine ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 
false chemical chemical Interaction with entity1begin Mixed Agonist / Antagonist Opioid Analgesics entity1end : Agonist / antagonist analgesics ( i.e. , pentazocine , nalbuphine , butorphanol , or entity2begin buprenorphine entity2end ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 
false chemical chemical Interaction with entity1begin Mixed Agonist / Antagonist Opioid Analgesics entity1end : Agonist / antagonist analgesics ( i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof entity2begin opioid agonist analgesic entity2end . 
false chemical chemical Interaction with Mixed Agonist / Antagonist Opioid Analgesics : entity1begin Agonist / antagonist analgesics entity1end ( i.e. , entity2begin pentazocine entity2end , nalbuphine , butorphanol , or buprenorphine ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 
false chemical chemical Interaction with Mixed Agonist / Antagonist Opioid Analgesics : entity1begin Agonist / antagonist analgesics entity1end ( i.e. , pentazocine , entity2begin nalbuphine entity2end , butorphanol , or buprenorphine ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 
false chemical chemical Interaction with Mixed Agonist / Antagonist Opioid Analgesics : entity1begin Agonist / antagonist analgesics entity1end ( i.e. , pentazocine , nalbuphine , entity2begin butorphanol entity2end , or buprenorphine ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 
false chemical chemical Interaction with Mixed Agonist / Antagonist Opioid Analgesics : entity1begin Agonist / antagonist analgesics entity1end ( i.e. , pentazocine , nalbuphine , butorphanol , or entity2begin buprenorphine entity2end ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 
true chemical chemical Interaction with Mixed Agonist / Antagonist Opioid Analgesics : entity1begin Agonist / antagonist analgesics entity1end ( i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof entity2begin opioid agonist analgesic entity2end . 
false chemical chemical Interaction with Mixed Agonist / Antagonist Opioid Analgesics : Agonist / antagonist analgesics ( i.e. , entity1begin pentazocine entity1end , entity2begin nalbuphine entity2end , butorphanol , or buprenorphine ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 
false chemical chemical Interaction with Mixed Agonist / Antagonist Opioid Analgesics : Agonist / antagonist analgesics ( i.e. , entity1begin pentazocine entity1end , nalbuphine , entity2begin butorphanol entity2end , or buprenorphine ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 
false chemical chemical Interaction with Mixed Agonist / Antagonist Opioid Analgesics : Agonist / antagonist analgesics ( i.e. , entity1begin pentazocine entity1end , nalbuphine , butorphanol , or entity2begin buprenorphine entity2end ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 
true chemical chemical Interaction with Mixed Agonist / Antagonist Opioid Analgesics : Agonist / antagonist analgesics ( i.e. , entity1begin pentazocine entity1end , nalbuphine , butorphanol , or buprenorphine ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof entity2begin opioid agonist analgesic entity2end . 
false chemical chemical Interaction with Mixed Agonist / Antagonist Opioid Analgesics : Agonist / antagonist analgesics ( i.e. , pentazocine , entity1begin nalbuphine entity1end , entity2begin butorphanol entity2end , or buprenorphine ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 
false chemical chemical Interaction with Mixed Agonist / Antagonist Opioid Analgesics : Agonist / antagonist analgesics ( i.e. , pentazocine , entity1begin nalbuphine entity1end , butorphanol , or entity2begin buprenorphine entity2end ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 
true chemical chemical Interaction with Mixed Agonist / Antagonist Opioid Analgesics : Agonist / antagonist analgesics ( i.e. , pentazocine , entity1begin nalbuphine entity1end , butorphanol , or buprenorphine ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof entity2begin opioid agonist analgesic entity2end . 
false chemical chemical Interaction with Mixed Agonist / Antagonist Opioid Analgesics : Agonist / antagonist analgesics ( i.e. , pentazocine , nalbuphine , entity1begin butorphanol entity1end , or entity2begin buprenorphine entity2end ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . 
true chemical chemical Interaction with Mixed Agonist / Antagonist Opioid Analgesics : Agonist / antagonist analgesics ( i.e. , pentazocine , nalbuphine , entity1begin butorphanol entity1end , or buprenorphine ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof entity2begin opioid agonist analgesic entity2end . 
true chemical chemical Interaction with Mixed Agonist / Antagonist Opioid Analgesics : Agonist / antagonist analgesics ( i.e. , pentazocine , nalbuphine , butorphanol , or entity1begin buprenorphine entity1end ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof entity2begin opioid agonist analgesic entity2end . 
false chemical chemical entity1begin Antacids entity1end : Absorption of a single dose of entity2begin Myfortic entity2end was decreased when administered to 12 stable renal transplant patients also taking magnesium - aluminum containing antacids ( 30 mL ) : the mean Cmax and AUC ( 0 - t ) values for MPA were 25 % and 37 % lower , respectively , than when Myfortic was administered alone under fasting conditions . 
false chemical chemical entity1begin Antacids entity1end : Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking entity2begin magnesium entity2end - aluminum containing antacids ( 30 mL ) : the mean Cmax and AUC ( 0 - t ) values for MPA were 25 % and 37 % lower , respectively , than when Myfortic was administered alone under fasting conditions . 
false chemical chemical entity1begin Antacids entity1end : Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium - entity2begin aluminum entity2end containing antacids ( 30 mL ) : the mean Cmax and AUC ( 0 - t ) values for MPA were 25 % and 37 % lower , respectively , than when Myfortic was administered alone under fasting conditions . 
false chemical chemical entity1begin Antacids entity1end : Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium - aluminum containing entity2begin antacids entity2end ( 30 mL ) : the mean Cmax and AUC ( 0 - t ) values for MPA were 25 % and 37 % lower , respectively , than when Myfortic was administered alone under fasting conditions . 
false chemical chemical entity1begin Antacids entity1end : Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium - aluminum containing antacids ( 30 mL ) : the mean Cmax and AUC ( 0 - t ) values for MPA were 25 % and 37 % lower , respectively , than when entity2begin Myfortic entity2end was administered alone under fasting conditions . 
true chemical chemical Antacids : Absorption of a single dose of entity1begin Myfortic entity1end was decreased when administered to 12 stable renal transplant patients also taking entity2begin magnesium entity2end - aluminum containing antacids ( 30 mL ) : the mean Cmax and AUC ( 0 - t ) values for MPA were 25 % and 37 % lower , respectively , than when Myfortic was administered alone under fasting conditions . 
true chemical chemical Antacids : Absorption of a single dose of entity1begin Myfortic entity1end was decreased when administered to 12 stable renal transplant patients also taking magnesium - entity2begin aluminum entity2end containing antacids ( 30 mL ) : the mean Cmax and AUC ( 0 - t ) values for MPA were 25 % and 37 % lower , respectively , than when Myfortic was administered alone under fasting conditions . 
false chemical chemical Antacids : Absorption of a single dose of entity1begin Myfortic entity1end was decreased when administered to 12 stable renal transplant patients also taking magnesium - aluminum containing entity2begin antacids entity2end ( 30 mL ) : the mean Cmax and AUC ( 0 - t ) values for MPA were 25 % and 37 % lower , respectively , than when Myfortic was administered alone under fasting conditions . 
false chemical chemical Antacids : Absorption of a single dose of entity1begin Myfortic entity1end was decreased when administered to 12 stable renal transplant patients also taking magnesium - aluminum containing antacids ( 30 mL ) : the mean Cmax and AUC ( 0 - t ) values for MPA were 25 % and 37 % lower , respectively , than when entity2begin Myfortic entity2end was administered alone under fasting conditions . 
false chemical chemical Antacids : Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking entity1begin magnesium entity1end - entity2begin aluminum entity2end containing antacids ( 30 mL ) : the mean Cmax and AUC ( 0 - t ) values for MPA were 25 % and 37 % lower , respectively , than when Myfortic was administered alone under fasting conditions . 
false chemical chemical Antacids : Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking entity1begin magnesium entity1end - aluminum containing entity2begin antacids entity2end ( 30 mL ) : the mean Cmax and AUC ( 0 - t ) values for MPA were 25 % and 37 % lower , respectively , than when Myfortic was administered alone under fasting conditions . 
false chemical chemical Antacids : Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking entity1begin magnesium entity1end - aluminum containing antacids ( 30 mL ) : the mean Cmax and AUC ( 0 - t ) values for MPA were 25 % and 37 % lower , respectively , than when entity2begin Myfortic entity2end was administered alone under fasting conditions . 
false chemical chemical Antacids : Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium - entity1begin aluminum entity1end containing entity2begin antacids entity2end ( 30 mL ) : the mean Cmax and AUC ( 0 - t ) values for MPA were 25 % and 37 % lower , respectively , than when Myfortic was administered alone under fasting conditions . 
false chemical chemical Antacids : Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium - entity1begin aluminum entity1end containing antacids ( 30 mL ) : the mean Cmax and AUC ( 0 - t ) values for MPA were 25 % and 37 % lower , respectively , than when entity2begin Myfortic entity2end was administered alone under fasting conditions . 
false chemical chemical Antacids : Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium - aluminum containing entity1begin antacids entity1end ( 30 mL ) : the mean Cmax and AUC ( 0 - t ) values for MPA were 25 % and 37 % lower , respectively , than when entity2begin Myfortic entity2end was administered alone under fasting conditions . 
true chemical chemical It is recommended that entity1begin Myfortic entity1end and entity2begin antacids entity2end not be administered simultaneously . 
false chemical chemical entity1begin Cyclosporine entity1end : When studied in stable renal transplant patients , entity2begin cyclosporine entity2end , USP ( MODIFIED ) pharmacokinetics were unaffected by steady state dosing of Myfortic . 
false chemical chemical entity1begin Cyclosporine entity1end : When studied in stable renal transplant patients , cyclosporine , USP ( MODIFIED ) pharmacokinetics were unaffected by steady state dosing of entity2begin Myfortic entity2end . 
false chemical chemical Cyclosporine : When studied in stable renal transplant patients , entity1begin cyclosporine entity1end , USP ( MODIFIED ) pharmacokinetics were unaffected by steady state dosing of entity2begin Myfortic entity2end . 
false chemical chemical entity1begin Acyclovir entity1end / entity2begin Ganciclovir entity2end : may be taken with Myfortic ; 
false chemical chemical entity1begin Acyclovir entity1end / Ganciclovir : may be taken with entity2begin Myfortic entity2end ; 
false chemical chemical Acyclovir / entity1begin Ganciclovir entity1end : may be taken with entity2begin Myfortic entity2end ; 
false chemical chemical Both entity1begin acyclovir entity1end / entity2begin ganciclovir entity2end and MPAG concentrations are increased in the presence of renal impairment , their coexistence may compete for tubular secretion and further increase in the concentrations of the two . 
false chemical chemical Both entity1begin acyclovir entity1end / ganciclovir and entity2begin MPAG entity2end concentrations are increased in the presence of renal impairment , their coexistence may compete for tubular secretion and further increase in the concentrations of the two . 
false chemical chemical Both acyclovir / entity1begin ganciclovir entity1end and entity2begin MPAG entity2end concentrations are increased in the presence of renal impairment , their coexistence may compete for tubular secretion and further increase in the concentrations of the two . 
false chemical chemical entity1begin Azathioprine entity1end / entity2begin Mycophenolate Mofetil entity2end : Given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil . 
false chemical chemical entity1begin Azathioprine entity1end / Mycophenolate Mofetil : Given that entity2begin azathioprine entity2end and mycophenolate mofetil inhibit purine metabolism , it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil . 
false chemical chemical entity1begin Azathioprine entity1end / Mycophenolate Mofetil : Given that azathioprine and entity2begin mycophenolate mofetil entity2end inhibit purine metabolism , it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil . 
false chemical chemical entity1begin Azathioprine entity1end / Mycophenolate Mofetil : Given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that entity2begin Myfortic entity2end not be administered concomitantly with azathioprine or mycophenolate mofetil . 
false chemical chemical entity1begin Azathioprine entity1end / Mycophenolate Mofetil : Given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that Myfortic not be administered concomitantly with entity2begin azathioprine entity2end or mycophenolate mofetil . 
false chemical chemical entity1begin Azathioprine entity1end / Mycophenolate Mofetil : Given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that Myfortic not be administered concomitantly with azathioprine or entity2begin mycophenolate mofetil entity2end . 
false chemical chemical Azathioprine / entity1begin Mycophenolate Mofetil entity1end : Given that entity2begin azathioprine entity2end and mycophenolate mofetil inhibit purine metabolism , it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil . 
false chemical chemical Azathioprine / entity1begin Mycophenolate Mofetil entity1end : Given that azathioprine and entity2begin mycophenolate mofetil entity2end inhibit purine metabolism , it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil . 
false chemical chemical Azathioprine / entity1begin Mycophenolate Mofetil entity1end : Given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that entity2begin Myfortic entity2end not be administered concomitantly with azathioprine or mycophenolate mofetil . 
false chemical chemical Azathioprine / entity1begin Mycophenolate Mofetil entity1end : Given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that Myfortic not be administered concomitantly with entity2begin azathioprine entity2end or mycophenolate mofetil . 
false chemical chemical Azathioprine / entity1begin Mycophenolate Mofetil entity1end : Given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that Myfortic not be administered concomitantly with azathioprine or entity2begin mycophenolate mofetil entity2end . 
false chemical chemical Azathioprine / Mycophenolate Mofetil : Given that entity1begin azathioprine entity1end and entity2begin mycophenolate mofetil entity2end inhibit purine metabolism , it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil . 
false chemical chemical Azathioprine / Mycophenolate Mofetil : Given that entity1begin azathioprine entity1end and mycophenolate mofetil inhibit purine metabolism , it is recommended that entity2begin Myfortic entity2end not be administered concomitantly with azathioprine or mycophenolate mofetil . 
false chemical chemical Azathioprine / Mycophenolate Mofetil : Given that entity1begin azathioprine entity1end and mycophenolate mofetil inhibit purine metabolism , it is recommended that Myfortic not be administered concomitantly with entity2begin azathioprine entity2end or mycophenolate mofetil . 
false chemical chemical Azathioprine / Mycophenolate Mofetil : Given that entity1begin azathioprine entity1end and mycophenolate mofetil inhibit purine metabolism , it is recommended that Myfortic not be administered concomitantly with azathioprine or entity2begin mycophenolate mofetil entity2end . 
false chemical chemical Azathioprine / Mycophenolate Mofetil : Given that azathioprine and entity1begin mycophenolate mofetil entity1end inhibit purine metabolism , it is recommended that entity2begin Myfortic entity2end not be administered concomitantly with azathioprine or mycophenolate mofetil . 
false chemical chemical Azathioprine / Mycophenolate Mofetil : Given that azathioprine and entity1begin mycophenolate mofetil entity1end inhibit purine metabolism , it is recommended that Myfortic not be administered concomitantly with entity2begin azathioprine entity2end or mycophenolate mofetil . 
false chemical chemical Azathioprine / Mycophenolate Mofetil : Given that azathioprine and entity1begin mycophenolate mofetil entity1end inhibit purine metabolism , it is recommended that Myfortic not be administered concomitantly with azathioprine or entity2begin mycophenolate mofetil entity2end . 
true chemical chemical Azathioprine / Mycophenolate Mofetil : Given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that entity1begin Myfortic entity1end not be administered concomitantly with entity2begin azathioprine entity2end or mycophenolate mofetil . 
true chemical chemical Azathioprine / Mycophenolate Mofetil : Given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that entity1begin Myfortic entity1end not be administered concomitantly with azathioprine or entity2begin mycophenolate mofetil entity2end . 
false chemical chemical Azathioprine / Mycophenolate Mofetil : Given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that Myfortic not be administered concomitantly with entity1begin azathioprine entity1end or entity2begin mycophenolate mofetil entity2end . 
false chemical chemical entity1begin Cholestyramine entity1end and Drugs that Bind Bile Acids : These drugs interrupt enterohepatic recirculation and reduce entity2begin MPA entity2end exposure when coadministered with mycophenolate mofetil . 
false chemical chemical entity1begin Cholestyramine entity1end and Drugs that Bind Bile Acids : These drugs interrupt enterohepatic recirculation and reduce MPA exposure when coadministered with entity2begin mycophenolate mofetil entity2end . 
false chemical chemical Cholestyramine and Drugs that Bind Bile Acids : These drugs interrupt enterohepatic recirculation and reduce entity1begin MPA entity1end exposure when coadministered with entity2begin mycophenolate mofetil entity2end . 
true chemical chemical Therefore , do not administer entity1begin Myfortic entity1end with entity2begin cholestyramine entity2end or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids , for example bile acid sequestrates or oral activated charcoal , because of the potential to reduce the efficacy of Myfortic . 
true chemical chemical Therefore , do not administer entity1begin Myfortic entity1end with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids , for example bile acid sequestrates or oral entity2begin activated charcoal entity2end , because of the potential to reduce the efficacy of Myfortic . 
false chemical chemical Therefore , do not administer entity1begin Myfortic entity1end with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids , for example bile acid sequestrates or oral activated charcoal , because of the potential to reduce the efficacy of entity2begin Myfortic entity2end . 
false chemical chemical Therefore , do not administer Myfortic with entity1begin cholestyramine entity1end or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids , for example bile acid sequestrates or oral entity2begin activated charcoal entity2end , because of the potential to reduce the efficacy of Myfortic . 
false chemical chemical Therefore , do not administer Myfortic with entity1begin cholestyramine entity1end or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids , for example bile acid sequestrates or oral activated charcoal , because of the potential to reduce the efficacy of entity2begin Myfortic entity2end . 
false chemical chemical Therefore , do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids , for example bile acid sequestrates or oral entity1begin activated charcoal entity1end , because of the potential to reduce the efficacy of entity2begin Myfortic entity2end . 
false chemical chemical Oral entity1begin Contraceptives entity1end : Given the different metabolism of entity2begin Myfortic entity2end and oral contraceptives , no drug interaction between these two classes of drug is expected . 
false chemical chemical Oral entity1begin Contraceptives entity1end : Given the different metabolism of Myfortic and oral entity2begin contraceptives entity2end , no drug interaction between these two classes of drug is expected . 
false chemical chemical Oral Contraceptives : Given the different metabolism of entity1begin Myfortic entity1end and oral entity2begin contraceptives entity2end , no drug interaction between these two classes of drug is expected . 
true chemical chemical However , in a drug - drug interaction study , mean entity1begin levonorgesterol entity1end AUC was decreased by 15 % when coadministered with entity2begin mycophenolate mofetil entity2end . 
true chemical chemical Therefore , it is recommended that oral entity1begin contraceptives entity1end are co - administered with entity2begin Myfortic entity2end with caution and additional birth control methods be considered . 
false chemical chemical entity1begin Live Vaccines entity1end : During treatment with entity2begin Myfortic entity2end , the use of live attenuated vaccines should be avoided and patients should be advised that vaccinations may be less effective . 
false chemical chemical entity1begin Live Vaccines entity1end : During treatment with Myfortic , the use of entity2begin live attenuated vaccines entity2end should be avoided and patients should be advised that vaccinations may be less effective . 
true chemical chemical Live Vaccines : During treatment with entity1begin Myfortic entity1end , the use of entity2begin live attenuated vaccines entity2end should be avoided and patients should be advised that vaccinations may be less effective . 
false chemical chemical Interference of entity1begin MPAG entity1end hydrolysis may lead to less entity2begin MPA entity2end available for absorption . 
false chemical chemical Because entity1begin ondansetron entity1end is metabolized by hepatic cytochrome P - 450 drug - metabolizing enzymes ( CYP3A4 , CYP2D6 , CYP1A2 ) , inducers or inhibitors of these enzymes may change the clearance and , hence , the half - life of entity2begin ondansetron entity2end . 
false chemical chemical entity1begin Phenytoin entity1end , entity2begin Carbamazepine entity2end , and Rifampicin : In patients treated with potent inducers of CYP3A4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 
false chemical chemical entity1begin Phenytoin entity1end , Carbamazepine , and entity2begin Rifampicin entity2end : In patients treated with potent inducers of CYP3A4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 
false chemical chemical entity1begin Phenytoin entity1end , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 ( i.e. , entity2begin phenytoin entity2end , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 
false chemical chemical entity1begin Phenytoin entity1end , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 ( i.e. , phenytoin , entity2begin carbamazepine entity2end , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 
false chemical chemical entity1begin Phenytoin entity1end , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 ( i.e. , phenytoin , carbamazepine , and entity2begin rifampicin entity2end ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 
false chemical chemical entity1begin Phenytoin entity1end , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of entity2begin ondansetron entity2end was significantly increased and ondansetron blood concentrations were decreased . 
false chemical chemical entity1begin Phenytoin entity1end , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and entity2begin ondansetron entity2end blood concentrations were decreased . 
false chemical chemical Phenytoin , entity1begin Carbamazepine entity1end , and entity2begin Rifampicin entity2end : In patients treated with potent inducers of CYP3A4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 
false chemical chemical Phenytoin , entity1begin Carbamazepine entity1end , and Rifampicin : In patients treated with potent inducers of CYP3A4 ( i.e. , entity2begin phenytoin entity2end , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 
false chemical chemical Phenytoin , entity1begin Carbamazepine entity1end , and Rifampicin : In patients treated with potent inducers of CYP3A4 ( i.e. , phenytoin , entity2begin carbamazepine entity2end , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 
false chemical chemical Phenytoin , entity1begin Carbamazepine entity1end , and Rifampicin : In patients treated with potent inducers of CYP3A4 ( i.e. , phenytoin , carbamazepine , and entity2begin rifampicin entity2end ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 
false chemical chemical Phenytoin , entity1begin Carbamazepine entity1end , and Rifampicin : In patients treated with potent inducers of CYP3A4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of entity2begin ondansetron entity2end was significantly increased and ondansetron blood concentrations were decreased . 
false chemical chemical Phenytoin , entity1begin Carbamazepine entity1end , and Rifampicin : In patients treated with potent inducers of CYP3A4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and entity2begin ondansetron entity2end blood concentrations were decreased . 
false chemical chemical Phenytoin , Carbamazepine , and entity1begin Rifampicin entity1end : In patients treated with potent inducers of CYP3A4 ( i.e. , entity2begin phenytoin entity2end , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 
false chemical chemical Phenytoin , Carbamazepine , and entity1begin Rifampicin entity1end : In patients treated with potent inducers of CYP3A4 ( i.e. , phenytoin , entity2begin carbamazepine entity2end , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 
false chemical chemical Phenytoin , Carbamazepine , and entity1begin Rifampicin entity1end : In patients treated with potent inducers of CYP3A4 ( i.e. , phenytoin , carbamazepine , and entity2begin rifampicin entity2end ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 
false chemical chemical Phenytoin , Carbamazepine , and entity1begin Rifampicin entity1end : In patients treated with potent inducers of CYP3A4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of entity2begin ondansetron entity2end was significantly increased and ondansetron blood concentrations were decreased . 
false chemical chemical Phenytoin , Carbamazepine , and entity1begin Rifampicin entity1end : In patients treated with potent inducers of CYP3A4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and entity2begin ondansetron entity2end blood concentrations were decreased . 
false chemical chemical Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 ( i.e. , entity1begin phenytoin entity1end , entity2begin carbamazepine entity2end , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 
false chemical chemical Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 ( i.e. , entity1begin phenytoin entity1end , carbamazepine , and entity2begin rifampicin entity2end ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 
true chemical chemical Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 ( i.e. , entity1begin phenytoin entity1end , carbamazepine , and rifampicin ) , the clearance of entity2begin ondansetron entity2end was significantly increased and ondansetron blood concentrations were decreased . 
true chemical chemical Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 ( i.e. , entity1begin phenytoin entity1end , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and entity2begin ondansetron entity2end blood concentrations were decreased . 
false chemical chemical Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 ( i.e. , phenytoin , entity1begin carbamazepine entity1end , and entity2begin rifampicin entity2end ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . 
true chemical chemical Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 ( i.e. , phenytoin , entity1begin carbamazepine entity1end , and rifampicin ) , the clearance of entity2begin ondansetron entity2end was significantly increased and ondansetron blood concentrations were decreased . 
true chemical chemical Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 ( i.e. , phenytoin , entity1begin carbamazepine entity1end , and rifampicin ) , the clearance of ondansetron was significantly increased and entity2begin ondansetron entity2end blood concentrations were decreased . 
true chemical chemical Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 ( i.e. , phenytoin , carbamazepine , and entity1begin rifampicin entity1end ) , the clearance of entity2begin ondansetron entity2end was significantly increased and ondansetron blood concentrations were decreased . 
true chemical chemical Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 ( i.e. , phenytoin , carbamazepine , and entity1begin rifampicin entity1end ) , the clearance of ondansetron was significantly increased and entity2begin ondansetron entity2end blood concentrations were decreased . 
false chemical chemical Phenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of entity1begin ondansetron entity1end was significantly increased and entity2begin ondansetron entity2end blood concentrations were decreased . 
false chemical chemical However , on the basis of available data , no dosage adjustment for entity1begin ondansetron entity1end is recommended for patients on these drugs.1,3 entity2begin Tramadol entity2end : Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy : Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron . 
false chemical chemical However , on the basis of available data , no dosage adjustment for entity1begin ondansetron entity1end is recommended for patients on these drugs.1,3 Tramadol : Although no pharmacokinetic drug interaction between entity2begin ondansetron entity2end and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy : Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron . 
false chemical chemical However , on the basis of available data , no dosage adjustment for entity1begin ondansetron entity1end is recommended for patients on these drugs.1,3 Tramadol : Although no pharmacokinetic drug interaction between ondansetron and entity2begin tramadol entity2end has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy : Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron . 
false chemical chemical However , on the basis of available data , no dosage adjustment for entity1begin ondansetron entity1end is recommended for patients on these drugs.1,3 Tramadol : Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that entity2begin ondansetron entity2end may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy : Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron . 
false chemical chemical However , on the basis of available data , no dosage adjustment for entity1begin ondansetron entity1end is recommended for patients on these drugs.1,3 Tramadol : Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of entity2begin tramadol entity2end .4,5 Chemotherapy : Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron . 
false chemical chemical However , on the basis of available data , no dosage adjustment for entity1begin ondansetron entity1end is recommended for patients on these drugs.1,3 Tramadol : Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy : Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by entity2begin ondansetron entity2end . 
false chemical chemical However , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 entity1begin Tramadol entity1end : Although no pharmacokinetic drug interaction between entity2begin ondansetron entity2end and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy : Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron . 
false chemical chemical However , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 entity1begin Tramadol entity1end : Although no pharmacokinetic drug interaction between ondansetron and entity2begin tramadol entity2end has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy : Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron . 
false chemical chemical However , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 entity1begin Tramadol entity1end : Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that entity2begin ondansetron entity2end may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy : Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron . 
false chemical chemical However , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 entity1begin Tramadol entity1end : Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of entity2begin tramadol entity2end .4,5 Chemotherapy : Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron . 
false chemical chemical However , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 entity1begin Tramadol entity1end : Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy : Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by entity2begin ondansetron entity2end . 
false chemical chemical However , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol : Although no pharmacokinetic drug interaction between entity1begin ondansetron entity1end and entity2begin tramadol entity2end has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy : Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron . 
false chemical chemical However , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol : Although no pharmacokinetic drug interaction between entity1begin ondansetron entity1end and tramadol has been observed , data from 2 small studies indicate that entity2begin ondansetron entity2end may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy : Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron . 
false chemical chemical However , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol : Although no pharmacokinetic drug interaction between entity1begin ondansetron entity1end and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of entity2begin tramadol entity2end .4,5 Chemotherapy : Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron . 
false chemical chemical However , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol : Although no pharmacokinetic drug interaction between entity1begin ondansetron entity1end and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy : Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by entity2begin ondansetron entity2end . 
false chemical chemical However , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol : Although no pharmacokinetic drug interaction between ondansetron and entity1begin tramadol entity1end has been observed , data from 2 small studies indicate that entity2begin ondansetron entity2end may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy : Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron . 
false chemical chemical However , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol : Although no pharmacokinetic drug interaction between ondansetron and entity1begin tramadol entity1end has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of entity2begin tramadol entity2end .4,5 Chemotherapy : Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron . 
false chemical chemical However , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol : Although no pharmacokinetic drug interaction between ondansetron and entity1begin tramadol entity1end has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy : Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by entity2begin ondansetron entity2end . 
true chemical chemical However , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol : Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that entity1begin ondansetron entity1end may be associated with an increase in patient controlled administration of entity2begin tramadol entity2end .4,5 Chemotherapy : Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron . 
false chemical chemical However , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol : Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that entity1begin ondansetron entity1end may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy : Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by entity2begin ondansetron entity2end . 
false chemical chemical However , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol : Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of entity1begin tramadol entity1end .4,5 Chemotherapy : Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by entity2begin ondansetron entity2end . 
false chemical chemical In humans , entity1begin carmustine entity1end , entity2begin etoposide entity2end , and cisplatin do not affect the pharmacokinetics of ondansetron . 
false chemical chemical In humans , entity1begin carmustine entity1end , etoposide , and entity2begin cisplatin entity2end do not affect the pharmacokinetics of ondansetron . 
false chemical chemical In humans , entity1begin carmustine entity1end , etoposide , and cisplatin do not affect the pharmacokinetics of entity2begin ondansetron entity2end . 
false chemical chemical In humans , carmustine , entity1begin etoposide entity1end , and entity2begin cisplatin entity2end do not affect the pharmacokinetics of ondansetron . 
false chemical chemical In humans , carmustine , entity1begin etoposide entity1end , and cisplatin do not affect the pharmacokinetics of entity2begin ondansetron entity2end . 
false chemical chemical In humans , carmustine , etoposide , and entity1begin cisplatin entity1end do not affect the pharmacokinetics of entity2begin ondansetron entity2end . 
false chemical chemical entity1begin ondansetron entity1end did not increase blood levels of high - dose entity2begin methotrexate entity2end . 
true chemical chemical Other entity1begin beta adrenergic aerosol bronchodilators entity1end should not be used concomitantly with entity2begin Alupent entity2end ( metaproterenol sulfate USP ) because they may have additive effects . 
true chemical chemical Other entity1begin beta adrenergic aerosol bronchodilators entity1end should not be used concomitantly with Alupent ( entity2begin metaproterenol sulfate entity2end USP ) because they may have additive effects . 
false chemical chemical Other beta adrenergic aerosol bronchodilators should not be used concomitantly with entity1begin Alupent entity1end ( entity2begin metaproterenol sulfate entity2end USP ) because they may have additive effects . 
true chemical chemical entity1begin Beta adrenergic agonists entity1end should be administered with caution to patients being treated with entity2begin monoamine oxidase inhibitors entity2end or tricyclic antidepressants , since the action of beta adrenergic agonists on the vascular system may be potentiated . 
true chemical chemical entity1begin Beta adrenergic agonists entity1end should be administered with caution to patients being treated with monoamine oxidase inhibitors or entity2begin tricyclic antidepressants entity2end , since the action of beta adrenergic agonists on the vascular system may be potentiated . 
false chemical chemical entity1begin Beta adrenergic agonists entity1end should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants , since the action of entity2begin beta adrenergic agonists entity2end on the vascular system may be potentiated . 
false chemical chemical Beta adrenergic agonists should be administered with caution to patients being treated with entity1begin monoamine oxidase inhibitors entity1end or entity2begin tricyclic antidepressants entity2end , since the action of beta adrenergic agonists on the vascular system may be potentiated . 
false chemical chemical Beta adrenergic agonists should be administered with caution to patients being treated with entity1begin monoamine oxidase inhibitors entity1end or tricyclic antidepressants , since the action of entity2begin beta adrenergic agonists entity2end on the vascular system may be potentiated . 
false chemical chemical Beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or entity1begin tricyclic antidepressants entity1end , since the action of entity2begin beta adrenergic agonists entity2end on the vascular system may be potentiated . 
false chemical chemical entity1begin Alcohol entity1end : In a multiple - dose study in 30 normal weight subjects , coadministration of entity2begin XENICAL entity2end and 40 grams of alcohol ( e.g. , approximately 3 glasses of wine ) did not result in alteration of alcohol pharmacokinetics , orlistat pharmacodynamics ( fecal fat excretion ) , or systemic exposure to orlistat . 
false chemical chemical entity1begin Alcohol entity1end : In a multiple - dose study in 30 normal weight subjects , coadministration of XENICAL and 40 grams of entity2begin alcohol entity2end ( e.g. , approximately 3 glasses of wine ) did not result in alteration of alcohol pharmacokinetics , orlistat pharmacodynamics ( fecal fat excretion ) , or systemic exposure to orlistat . 
false chemical chemical entity1begin Alcohol entity1end : In a multiple - dose study in 30 normal weight subjects , coadministration of XENICAL and 40 grams of alcohol ( e.g. , approximately 3 glasses of wine ) did not result in alteration of entity2begin alcohol entity2end pharmacokinetics , orlistat pharmacodynamics ( fecal fat excretion ) , or systemic exposure to orlistat . 
false chemical chemical entity1begin Alcohol entity1end : In a multiple - dose study in 30 normal weight subjects , coadministration of XENICAL and 40 grams of alcohol ( e.g. , approximately 3 glasses of wine ) did not result in alteration of alcohol pharmacokinetics , entity2begin orlistat entity2end pharmacodynamics ( fecal fat excretion ) , or systemic exposure to orlistat . 
false chemical chemical entity1begin Alcohol entity1end : In a multiple - dose study in 30 normal weight subjects , coadministration of XENICAL and 40 grams of alcohol ( e.g. , approximately 3 glasses of wine ) did not result in alteration of alcohol pharmacokinetics , orlistat pharmacodynamics ( fecal fat excretion ) , or systemic exposure to entity2begin orlistat entity2end . 
false chemical chemical Alcohol : In a multiple - dose study in 30 normal weight subjects , coadministration of entity1begin XENICAL entity1end and 40 grams of entity2begin alcohol entity2end ( e.g. , approximately 3 glasses of wine ) did not result in alteration of alcohol pharmacokinetics , orlistat pharmacodynamics ( fecal fat excretion ) , or systemic exposure to orlistat . 
false chemical chemical Alcohol : In a multiple - dose study in 30 normal weight subjects , coadministration of entity1begin XENICAL entity1end and 40 grams of alcohol ( e.g. , approximately 3 glasses of wine ) did not result in alteration of entity2begin alcohol entity2end pharmacokinetics , orlistat pharmacodynamics ( fecal fat excretion ) , or systemic exposure to orlistat . 
false chemical chemical Alcohol : In a multiple - dose study in 30 normal weight subjects , coadministration of entity1begin XENICAL entity1end and 40 grams of alcohol ( e.g. , approximately 3 glasses of wine ) did not result in alteration of alcohol pharmacokinetics , entity2begin orlistat entity2end pharmacodynamics ( fecal fat excretion ) , or systemic exposure to orlistat . 
false chemical chemical Alcohol : In a multiple - dose study in 30 normal weight subjects , coadministration of entity1begin XENICAL entity1end and 40 grams of alcohol ( e.g. , approximately 3 glasses of wine ) did not result in alteration of alcohol pharmacokinetics , orlistat pharmacodynamics ( fecal fat excretion ) , or systemic exposure to entity2begin orlistat entity2end . 
false chemical chemical Alcohol : In a multiple - dose study in 30 normal weight subjects , coadministration of XENICAL and 40 grams of entity1begin alcohol entity1end ( e.g. , approximately 3 glasses of wine ) did not result in alteration of entity2begin alcohol entity2end pharmacokinetics , orlistat pharmacodynamics ( fecal fat excretion ) , or systemic exposure to orlistat . 
false chemical chemical Alcohol : In a multiple - dose study in 30 normal weight subjects , coadministration of XENICAL and 40 grams of entity1begin alcohol entity1end ( e.g. , approximately 3 glasses of wine ) did not result in alteration of alcohol pharmacokinetics , entity2begin orlistat entity2end pharmacodynamics ( fecal fat excretion ) , or systemic exposure to orlistat . 
false chemical chemical Alcohol : In a multiple - dose study in 30 normal weight subjects , coadministration of XENICAL and 40 grams of entity1begin alcohol entity1end ( e.g. , approximately 3 glasses of wine ) did not result in alteration of alcohol pharmacokinetics , orlistat pharmacodynamics ( fecal fat excretion ) , or systemic exposure to entity2begin orlistat entity2end . 
false chemical chemical Alcohol : In a multiple - dose study in 30 normal weight subjects , coadministration of XENICAL and 40 grams of alcohol ( e.g. , approximately 3 glasses of wine ) did not result in alteration of entity1begin alcohol entity1end pharmacokinetics , entity2begin orlistat entity2end pharmacodynamics ( fecal fat excretion ) , or systemic exposure to orlistat . 
false chemical chemical Alcohol : In a multiple - dose study in 30 normal weight subjects , coadministration of XENICAL and 40 grams of alcohol ( e.g. , approximately 3 glasses of wine ) did not result in alteration of entity1begin alcohol entity1end pharmacokinetics , orlistat pharmacodynamics ( fecal fat excretion ) , or systemic exposure to entity2begin orlistat entity2end . 
false chemical chemical Alcohol : In a multiple - dose study in 30 normal weight subjects , coadministration of XENICAL and 40 grams of alcohol ( e.g. , approximately 3 glasses of wine ) did not result in alteration of alcohol pharmacokinetics , entity1begin orlistat entity1end pharmacodynamics ( fecal fat excretion ) , or systemic exposure to entity2begin orlistat entity2end . 
false chemical chemical entity1begin Cyclosporine entity1end : Preliminary data from a entity2begin XENICAL entity2end and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine . 
false chemical chemical entity1begin Cyclosporine entity1end : Preliminary data from a XENICAL and entity2begin cyclosporine entity2end drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine . 
false chemical chemical entity1begin Cyclosporine entity1end : Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in entity2begin cyclosporine entity2end plasma levels when XENICAL was coadministered with cyclosporine . 
false chemical chemical entity1begin Cyclosporine entity1end : Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when entity2begin XENICAL entity2end was coadministered with cyclosporine . 
false chemical chemical entity1begin Cyclosporine entity1end : Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with entity2begin cyclosporine entity2end . 
false chemical chemical Cyclosporine : Preliminary data from a entity1begin XENICAL entity1end and entity2begin cyclosporine entity2end drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine . 
false chemical chemical Cyclosporine : Preliminary data from a entity1begin XENICAL entity1end and cyclosporine drug interaction study indicate a reduction in entity2begin cyclosporine entity2end plasma levels when XENICAL was coadministered with cyclosporine . 
false chemical chemical Cyclosporine : Preliminary data from a entity1begin XENICAL entity1end and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when entity2begin XENICAL entity2end was coadministered with cyclosporine . 
false chemical chemical Cyclosporine : Preliminary data from a entity1begin XENICAL entity1end and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with entity2begin cyclosporine entity2end . 
false chemical chemical Cyclosporine : Preliminary data from a XENICAL and entity1begin cyclosporine entity1end drug interaction study indicate a reduction in entity2begin cyclosporine entity2end plasma levels when XENICAL was coadministered with cyclosporine . 
false chemical chemical Cyclosporine : Preliminary data from a XENICAL and entity1begin cyclosporine entity1end drug interaction study indicate a reduction in cyclosporine plasma levels when entity2begin XENICAL entity2end was coadministered with cyclosporine . 
false chemical chemical Cyclosporine : Preliminary data from a XENICAL and entity1begin cyclosporine entity1end drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with entity2begin cyclosporine entity2end . 
false chemical chemical Cyclosporine : Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in entity1begin cyclosporine entity1end plasma levels when entity2begin XENICAL entity2end was coadministered with cyclosporine . 
false chemical chemical Cyclosporine : Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in entity1begin cyclosporine entity1end plasma levels when XENICAL was coadministered with entity2begin cyclosporine entity2end . 
true chemical chemical Cyclosporine : Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when entity1begin XENICAL entity1end was coadministered with entity2begin cyclosporine entity2end . 
false chemical chemical entity1begin Digoxin entity1end : In 12 normal - weight subjects receiving entity2begin XENICAL entity2end 120 mg three times a day for 6 days , XENICAL did not alter the pharmacokinetics of a single dose of digoxin . 
false chemical chemical entity1begin Digoxin entity1end : In 12 normal - weight subjects receiving XENICAL 120 mg three times a day for 6 days , entity2begin XENICAL entity2end did not alter the pharmacokinetics of a single dose of digoxin . 
false chemical chemical entity1begin Digoxin entity1end : In 12 normal - weight subjects receiving XENICAL 120 mg three times a day for 6 days , XENICAL did not alter the pharmacokinetics of a single dose of entity2begin digoxin entity2end . 
false chemical chemical Digoxin : In 12 normal - weight subjects receiving entity1begin XENICAL entity1end 120 mg three times a day for 6 days , entity2begin XENICAL entity2end did not alter the pharmacokinetics of a single dose of digoxin . 
false chemical chemical Digoxin : In 12 normal - weight subjects receiving entity1begin XENICAL entity1end 120 mg three times a day for 6 days , XENICAL did not alter the pharmacokinetics of a single dose of entity2begin digoxin entity2end . 
false chemical chemical Digoxin : In 12 normal - weight subjects receiving XENICAL 120 mg three times a day for 6 days , entity1begin XENICAL entity1end did not alter the pharmacokinetics of a single dose of entity2begin digoxin entity2end . 
false chemical chemical entity1begin Fat - soluble Vitamin Supplements entity1end and Analogues : A pharmacokinetic interaction study showed a 30 % reduction in entity2begin beta - carotene entity2end supplement absorption when concomitantly administered with XENICAL . 
false chemical chemical entity1begin Fat - soluble Vitamin Supplements entity1end and Analogues : A pharmacokinetic interaction study showed a 30 % reduction in beta - carotene supplement absorption when concomitantly administered with entity2begin XENICAL entity2end . 
true chemical chemical Fat - soluble Vitamin Supplements and Analogues : A pharmacokinetic interaction study showed a 30 % reduction in entity1begin beta - carotene entity1end supplement absorption when concomitantly administered with entity2begin XENICAL entity2end . 
true chemical chemical entity1begin XENICAL entity1end inhibited absorption of a entity2begin vitamin E acetate entity2end supplement by approximately 60 % . 
false chemical chemical The effect of entity1begin orlistat entity1end on the absorption of supplemental entity2begin vitamin D entity2end , vitamin A , and nutritionally - derived vitamin K is not known at this time . 
false chemical chemical The effect of entity1begin orlistat entity1end on the absorption of supplemental vitamin D , entity2begin vitamin A entity2end , and nutritionally - derived vitamin K is not known at this time . 
false chemical chemical The effect of entity1begin orlistat entity1end on the absorption of supplemental vitamin D , vitamin A , and nutritionally - derived entity2begin vitamin K entity2end is not known at this time . 
false chemical chemical The effect of orlistat on the absorption of supplemental entity1begin vitamin D entity1end , entity2begin vitamin A entity2end , and nutritionally - derived vitamin K is not known at this time . 
false chemical chemical The effect of orlistat on the absorption of supplemental entity1begin vitamin D entity1end , vitamin A , and nutritionally - derived entity2begin vitamin K entity2end is not known at this time . 
false chemical chemical The effect of orlistat on the absorption of supplemental vitamin D , entity1begin vitamin A entity1end , and nutritionally - derived entity2begin vitamin K entity2end is not known at this time . 
false chemical chemical entity1begin Glyburide entity1end : In 12 normal - weight subjects receiving entity2begin orlistat entity2end 80 mg three times a day for 5 days , orlistat did not alter the pharmacokinetics or pharmacodynamics ( blood glucose - lowering ) of glyburide . 
false chemical chemical entity1begin Glyburide entity1end : In 12 normal - weight subjects receiving orlistat 80 mg three times a day for 5 days , entity2begin orlistat entity2end did not alter the pharmacokinetics or pharmacodynamics ( blood glucose - lowering ) of glyburide . 
false chemical chemical entity1begin Glyburide entity1end : In 12 normal - weight subjects receiving orlistat 80 mg three times a day for 5 days , orlistat did not alter the pharmacokinetics or pharmacodynamics ( blood glucose - lowering ) of entity2begin glyburide entity2end . 
false chemical chemical Glyburide : In 12 normal - weight subjects receiving entity1begin orlistat entity1end 80 mg three times a day for 5 days , entity2begin orlistat entity2end did not alter the pharmacokinetics or pharmacodynamics ( blood glucose - lowering ) of glyburide . 
false chemical chemical Glyburide : In 12 normal - weight subjects receiving entity1begin orlistat entity1end 80 mg three times a day for 5 days , orlistat did not alter the pharmacokinetics or pharmacodynamics ( blood glucose - lowering ) of entity2begin glyburide entity2end . 
false chemical chemical Glyburide : In 12 normal - weight subjects receiving orlistat 80 mg three times a day for 5 days , entity1begin orlistat entity1end did not alter the pharmacokinetics or pharmacodynamics ( blood glucose - lowering ) of entity2begin glyburide entity2end . 
false chemical chemical entity1begin Nifedipine entity1end ( extended - release tablets ) : In 17 normal - weight subjects receiving entity2begin XENICAL entity2end 120 mg three times a day for 6 days , XENICAL did not alter the bioavailability of nifedipine ( extended - release tablets ) . 
false chemical chemical entity1begin Nifedipine entity1end ( extended - release tablets ) : In 17 normal - weight subjects receiving XENICAL 120 mg three times a day for 6 days , entity2begin XENICAL entity2end did not alter the bioavailability of nifedipine ( extended - release tablets ) . 
false chemical chemical entity1begin Nifedipine entity1end ( extended - release tablets ) : In 17 normal - weight subjects receiving XENICAL 120 mg three times a day for 6 days , XENICAL did not alter the bioavailability of entity2begin nifedipine entity2end ( extended - release tablets ) . 
false chemical chemical Nifedipine ( extended - release tablets ) : In 17 normal - weight subjects receiving entity1begin XENICAL entity1end 120 mg three times a day for 6 days , entity2begin XENICAL entity2end did not alter the bioavailability of nifedipine ( extended - release tablets ) . 
false chemical chemical Nifedipine ( extended - release tablets ) : In 17 normal - weight subjects receiving entity1begin XENICAL entity1end 120 mg three times a day for 6 days , XENICAL did not alter the bioavailability of entity2begin nifedipine entity2end ( extended - release tablets ) . 
false chemical chemical Nifedipine ( extended - release tablets ) : In 17 normal - weight subjects receiving XENICAL 120 mg three times a day for 6 days , entity1begin XENICAL entity1end did not alter the bioavailability of entity2begin nifedipine entity2end ( extended - release tablets ) . 
false chemical chemical Oral entity1begin Contraceptives entity1end : In 20 normal - weight female subjects , the treatment of entity2begin XENICAL entity2end 120 mg three times a day for 23 days resulted in no changes in the ovulation - suppressing action of oral contraceptives . 
false chemical chemical Oral entity1begin Contraceptives entity1end : In 20 normal - weight female subjects , the treatment of XENICAL 120 mg three times a day for 23 days resulted in no changes in the ovulation - suppressing action of oral entity2begin contraceptives entity2end . 
false chemical chemical Oral Contraceptives : In 20 normal - weight female subjects , the treatment of entity1begin XENICAL entity1end 120 mg three times a day for 23 days resulted in no changes in the ovulation - suppressing action of oral entity2begin contraceptives entity2end . 
false chemical chemical entity1begin Phenytoin entity1end : In 12 normal - weight subjects receiving entity2begin XENICAL entity2end 120 mg three times a day for 7 days , XENICAL did not alter the pharmacokinetics of a single 300 - mg dose of phenytoin . 
false chemical chemical entity1begin Phenytoin entity1end : In 12 normal - weight subjects receiving XENICAL 120 mg three times a day for 7 days , entity2begin XENICAL entity2end did not alter the pharmacokinetics of a single 300 - mg dose of phenytoin . 
false chemical chemical entity1begin Phenytoin entity1end : In 12 normal - weight subjects receiving XENICAL 120 mg three times a day for 7 days , XENICAL did not alter the pharmacokinetics of a single 300 - mg dose of entity2begin phenytoin entity2end . 
false chemical chemical Phenytoin : In 12 normal - weight subjects receiving entity1begin XENICAL entity1end 120 mg three times a day for 7 days , entity2begin XENICAL entity2end did not alter the pharmacokinetics of a single 300 - mg dose of phenytoin . 
false chemical chemical Phenytoin : In 12 normal - weight subjects receiving entity1begin XENICAL entity1end 120 mg three times a day for 7 days , XENICAL did not alter the pharmacokinetics of a single 300 - mg dose of entity2begin phenytoin entity2end . 
false chemical chemical Phenytoin : In 12 normal - weight subjects receiving XENICAL 120 mg three times a day for 7 days , entity1begin XENICAL entity1end did not alter the pharmacokinetics of a single 300 - mg dose of entity2begin phenytoin entity2end . 
false chemical chemical entity1begin Pravastatin entity1end : In a 2 - way crossover study of 24 normal - weight , mildly hypercholesterolemic patients receiving entity2begin XENICAL entity2end 120 mg three times a day for 6 days , XENICAL did not affect the pharmacokinetics of pravastatin . 
false chemical chemical entity1begin Pravastatin entity1end : In a 2 - way crossover study of 24 normal - weight , mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days , entity2begin XENICAL entity2end did not affect the pharmacokinetics of pravastatin . 
false chemical chemical entity1begin Pravastatin entity1end : In a 2 - way crossover study of 24 normal - weight , mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days , XENICAL did not affect the pharmacokinetics of entity2begin pravastatin entity2end . 
false chemical chemical Pravastatin : In a 2 - way crossover study of 24 normal - weight , mildly hypercholesterolemic patients receiving entity1begin XENICAL entity1end 120 mg three times a day for 6 days , entity2begin XENICAL entity2end did not affect the pharmacokinetics of pravastatin . 
false chemical chemical Pravastatin : In a 2 - way crossover study of 24 normal - weight , mildly hypercholesterolemic patients receiving entity1begin XENICAL entity1end 120 mg three times a day for 6 days , XENICAL did not affect the pharmacokinetics of entity2begin pravastatin entity2end . 
false chemical chemical Pravastatin : In a 2 - way crossover study of 24 normal - weight , mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days , entity1begin XENICAL entity1end did not affect the pharmacokinetics of entity2begin pravastatin entity2end . 
false chemical chemical entity1begin Warfarin entity1end : In 12 normal - weight subjects , administration of entity2begin XENICAL entity2end 120 mg three times a day for 16 days did not result in any change in either warfarin pharmacokinetics ( both R - and S - enantiomers ) or pharmacodynamics ( prothrombin time and serum Factor VII ) . 
false chemical chemical entity1begin Warfarin entity1end : In 12 normal - weight subjects , administration of XENICAL 120 mg three times a day for 16 days did not result in any change in either entity2begin warfarin entity2end pharmacokinetics ( both R - and S - enantiomers ) or pharmacodynamics ( prothrombin time and serum Factor VII ) . 
false chemical chemical Warfarin : In 12 normal - weight subjects , administration of entity1begin XENICAL entity1end 120 mg three times a day for 16 days did not result in any change in either entity2begin warfarin entity2end pharmacokinetics ( both R - and S - enantiomers ) or pharmacodynamics ( prothrombin time and serum Factor VII ) . 
false chemical chemical Although undercarboxylated osteocalcin , a marker of vitamin K nutritional status , was unaltered with entity1begin XENICAL entity1end administration , vitamin K levels tended to decline in subjects taking entity2begin XENICAL entity2end . 
true chemical chemical Therefore , as entity1begin vitamin K entity1end absorption may be decreased with entity2begin XENICAL entity2end , patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters . 
false chemical chemical Therefore , as entity1begin vitamin K entity1end absorption may be decreased with XENICAL , patients on chronic stable doses of entity2begin warfarin entity2end who are prescribed XENICAL should be monitored closely for changes in coagulation parameters . 
false chemical chemical Therefore , as entity1begin vitamin K entity1end absorption may be decreased with XENICAL , patients on chronic stable doses of warfarin who are prescribed entity2begin XENICAL entity2end should be monitored closely for changes in coagulation parameters . 
false chemical chemical Therefore , as vitamin K absorption may be decreased with entity1begin XENICAL entity1end , patients on chronic stable doses of entity2begin warfarin entity2end who are prescribed XENICAL should be monitored closely for changes in coagulation parameters . 
false chemical chemical Therefore , as vitamin K absorption may be decreased with entity1begin XENICAL entity1end , patients on chronic stable doses of warfarin who are prescribed entity2begin XENICAL entity2end should be monitored closely for changes in coagulation parameters . 
true chemical chemical Therefore , as vitamin K absorption may be decreased with XENICAL , patients on chronic stable doses of entity1begin warfarin entity1end who are prescribed entity2begin XENICAL entity2end should be monitored closely for changes in coagulation parameters . 
false chemical chemical entity1begin Tetracycline entity1end , a bacteriostatic entity2begin antibiotic entity2end , may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided . 
true chemical chemical entity1begin Tetracycline entity1end , a bacteriostatic antibiotic , may antagonize the bactericidal effect of entity2begin penicillin entity2end and concurrent use of these drugs should be avoided . 
false chemical chemical Tetracycline , a bacteriostatic entity1begin antibiotic entity1end , may antagonize the bactericidal effect of entity2begin penicillin entity2end and concurrent use of these drugs should be avoided . 
false chemical chemical No pharmacokinetic interaction between 85 mg / m2 entity1begin ELOXATIN entity1end and infusional entity2begin 5 - FU entity2end has been observed in patients treated every 2 weeks . 
true chemical chemical Increases of entity1begin 5 - FU entity1end plasma concentrations by approximately 20 % have been observed with doses of 130 mg / m2 entity2begin ELOXATIN entity2end dosed every 3 weeks . 
false chemical chemical entity1begin Anticoagulants entity1end entity2begin Anabolic steroids entity2end may increase sensitivity to oral anticoagulants . 
false chemical chemical entity1begin Anticoagulants entity1end Anabolic steroids may increase sensitivity to oral entity2begin anticoagulants entity2end . 
true chemical chemical Anticoagulants entity1begin Anabolic steroids entity1end may increase sensitivity to oral entity2begin anticoagulants entity2end . 
false chemical chemical entity1begin Warfarin entity1end : A multidose study of entity2begin oxandrolone entity2end , given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin , resulted in a mean increase in S - warfarin half - life from 26 to 48 hours and AUC from 4.55 to 12.08 ng * hr / mL : similar increases in R - warfarin half - life and AUC were also detected . 
false chemical chemical entity1begin Warfarin entity1end : A multidose study of oxandrolone , given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with entity2begin warfarin entity2end , resulted in a mean increase in S - warfarin half - life from 26 to 48 hours and AUC from 4.55 to 12.08 ng * hr / mL : similar increases in R - warfarin half - life and AUC were also detected . 
false chemical chemical entity1begin Warfarin entity1end : A multidose study of oxandrolone , given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin , resulted in a mean increase in entity2begin S - warfarin entity2end half - life from 26 to 48 hours and AUC from 4.55 to 12.08 ng * hr / mL : similar increases in R - warfarin half - life and AUC were also detected . 
false chemical chemical entity1begin Warfarin entity1end : A multidose study of oxandrolone , given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin , resulted in a mean increase in S - warfarin half - life from 26 to 48 hours and AUC from 4.55 to 12.08 ng * hr / mL : similar increases in entity2begin R - warfarin entity2end half - life and AUC were also detected . 
true chemical chemical Warfarin : A multidose study of entity1begin oxandrolone entity1end , given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with entity2begin warfarin entity2end , resulted in a mean increase in S - warfarin half - life from 26 to 48 hours and AUC from 4.55 to 12.08 ng * hr / mL : similar increases in R - warfarin half - life and AUC were also detected . 
false chemical chemical Warfarin : A multidose study of entity1begin oxandrolone entity1end , given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin , resulted in a mean increase in entity2begin S - warfarin entity2end half - life from 26 to 48 hours and AUC from 4.55 to 12.08 ng * hr / mL : similar increases in R - warfarin half - life and AUC were also detected . 
false chemical chemical Warfarin : A multidose study of entity1begin oxandrolone entity1end , given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin , resulted in a mean increase in S - warfarin half - life from 26 to 48 hours and AUC from 4.55 to 12.08 ng * hr / mL : similar increases in entity2begin R - warfarin entity2end half - life and AUC were also detected . 
false chemical chemical Warfarin : A multidose study of oxandrolone , given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with entity1begin warfarin entity1end , resulted in a mean increase in entity2begin S - warfarin entity2end half - life from 26 to 48 hours and AUC from 4.55 to 12.08 ng * hr / mL : similar increases in R - warfarin half - life and AUC were also detected . 
false chemical chemical Warfarin : A multidose study of oxandrolone , given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with entity1begin warfarin entity1end , resulted in a mean increase in S - warfarin half - life from 26 to 48 hours and AUC from 4.55 to 12.08 ng * hr / mL : similar increases in entity2begin R - warfarin entity2end half - life and AUC were also detected . 
false chemical chemical Warfarin : A multidose study of oxandrolone , given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin , resulted in a mean increase in entity1begin S - warfarin entity1end half - life from 26 to 48 hours and AUC from 4.55 to 12.08 ng * hr / mL : similar increases in entity2begin R - warfarin entity2end half - life and AUC were also detected . 
false chemical chemical A 5.5 - fold decrease in the mean entity1begin warfarin entity1end dose from 6.13 mg / day to 1.13 mg / day ( approximately 80 - 85 % reduction of entity2begin warfarin entity2end dose ) , was necessary to maintain a target INR of 1.5 . 
true chemical chemical When entity1begin oxandrolone entity1end therapy is initiated in a patient already receiving treatment with entity2begin warfarin entity2end , the INR or prothrombin time ( PT ) should be monitored closely and the dose of warfarin adjusted as necessary until a stable target INR or PT has been achieved . 
false chemical chemical When entity1begin oxandrolone entity1end therapy is initiated in a patient already receiving treatment with warfarin , the INR or prothrombin time ( PT ) should be monitored closely and the dose of entity2begin warfarin entity2end adjusted as necessary until a stable target INR or PT has been achieved . 
false chemical chemical When oxandrolone therapy is initiated in a patient already receiving treatment with entity1begin warfarin entity1end , the INR or prothrombin time ( PT ) should be monitored closely and the dose of entity2begin warfarin entity2end adjusted as necessary until a stable target INR or PT has been achieved . 
true chemical chemical Furthermore , in patients receiving both drugs , careful monitoring of the INR or PT , and adjustment of the entity1begin warfarin entity1end dosage if indicated are recommended when the entity2begin oxandrolone entity2end dose is changed or discontinued . 
false chemical chemical Oral entity1begin hypoglycemic agents entity1end entity2begin Oxandrolone entity2end may inhibit the metabolism of oral hypoglycemic agents . 
false chemical chemical Oral entity1begin hypoglycemic agents entity1end Oxandrolone may inhibit the metabolism of oral entity2begin hypoglycemic agents entity2end . 
true chemical chemical Oral hypoglycemic agents entity1begin Oxandrolone entity1end may inhibit the metabolism of oral entity2begin hypoglycemic agents entity2end . 
false chemical chemical entity1begin Adrenal steroids entity1end or entity2begin ACTH entity2end In patients with edema , concomitant administration with adrenal cortical steroids or ACTH may increase the edema . 
false chemical chemical entity1begin Adrenal steroids entity1end or ACTH In patients with edema , concomitant administration with entity2begin adrenal cortical steroids entity2end or ACTH may increase the edema . 
false chemical chemical entity1begin Adrenal steroids entity1end or ACTH In patients with edema , concomitant administration with adrenal cortical steroids or entity2begin ACTH entity2end may increase the edema . 
false chemical chemical Adrenal steroids or entity1begin ACTH entity1end In patients with edema , concomitant administration with entity2begin adrenal cortical steroids entity2end or ACTH may increase the edema . 
false chemical chemical Adrenal steroids or entity1begin ACTH entity1end In patients with edema , concomitant administration with adrenal cortical steroids or entity2begin ACTH entity2end may increase the edema . 
false chemical chemical Adrenal steroids or ACTH In patients with edema , concomitant administration with entity1begin adrenal cortical steroids entity1end or entity2begin ACTH entity2end may increase the edema . 
true chemical chemical The concomitant use of entity1begin oxybutynin entity1end with other entity2begin anticholinergic drugs entity2end or with other agents which produce dry mouth , constipation , somnolence ( drowsiness ) , and / or other anticholinergic - like effects may increase the frequency and / or severity of such effects . 
false chemical chemical Mean entity1begin oxybutynin chloride entity1end plasma concentrations were approximately 2 fold higher when entity2begin DITROPAN XL entity2end was administered with ketoconazole , a potent CYP3A4 inhibitor . 
false chemical chemical Mean entity1begin oxybutynin chloride entity1end plasma concentrations were approximately 2 fold higher when DITROPAN XL was administered with entity2begin ketoconazole entity2end , a potent CYP3A4 inhibitor . 
true chemical chemical Mean oxybutynin chloride plasma concentrations were approximately 2 fold higher when entity1begin DITROPAN XL entity1end was administered with entity2begin ketoconazole entity2end , a potent CYP3A4 inhibitor . 
false chemical chemical Other inhibitors of the cytochrome P450 3A4 enzyme system , such as entity1begin antimycotic agents entity1end ( e.g. , entity2begin itraconazole entity2end and miconazole ) or macrolide antibiotics ( e.g. , erythromycin and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , Cmax and AUC ) . 
false chemical chemical Other inhibitors of the cytochrome P450 3A4 enzyme system , such as entity1begin antimycotic agents entity1end ( e.g. , itraconazole and entity2begin miconazole entity2end ) or macrolide antibiotics ( e.g. , erythromycin and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , Cmax and AUC ) . 
false chemical chemical Other inhibitors of the cytochrome P450 3A4 enzyme system , such as entity1begin antimycotic agents entity1end ( e.g. , itraconazole and miconazole ) or entity2begin macrolide antibiotics entity2end ( e.g. , erythromycin and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , Cmax and AUC ) . 
false chemical chemical Other inhibitors of the cytochrome P450 3A4 enzyme system , such as entity1begin antimycotic agents entity1end ( e.g. , itraconazole and miconazole ) or macrolide antibiotics ( e.g. , entity2begin erythromycin entity2end and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , Cmax and AUC ) . 
false chemical chemical Other inhibitors of the cytochrome P450 3A4 enzyme system , such as entity1begin antimycotic agents entity1end ( e.g. , itraconazole and miconazole ) or macrolide antibiotics ( e.g. , erythromycin and entity2begin clarithromycin entity2end ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , Cmax and AUC ) . 
true chemical chemical Other inhibitors of the cytochrome P450 3A4 enzyme system , such as entity1begin antimycotic agents entity1end ( e.g. , itraconazole and miconazole ) or macrolide antibiotics ( e.g. , erythromycin and clarithromycin ) , may alter entity2begin oxybutynin entity2end mean pharmacokinetic parameters ( i.e. , Cmax and AUC ) . 
false chemical chemical Other inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents ( e.g. , entity1begin itraconazole entity1end and entity2begin miconazole entity2end ) or macrolide antibiotics ( e.g. , erythromycin and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , Cmax and AUC ) . 
false chemical chemical Other inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents ( e.g. , entity1begin itraconazole entity1end and miconazole ) or entity2begin macrolide antibiotics entity2end ( e.g. , erythromycin and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , Cmax and AUC ) . 
false chemical chemical Other inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents ( e.g. , entity1begin itraconazole entity1end and miconazole ) or macrolide antibiotics ( e.g. , entity2begin erythromycin entity2end and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , Cmax and AUC ) . 
false chemical chemical Other inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents ( e.g. , entity1begin itraconazole entity1end and miconazole ) or macrolide antibiotics ( e.g. , erythromycin and entity2begin clarithromycin entity2end ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , Cmax and AUC ) . 
true chemical chemical Other inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents ( e.g. , entity1begin itraconazole entity1end and miconazole ) or macrolide antibiotics ( e.g. , erythromycin and clarithromycin ) , may alter entity2begin oxybutynin entity2end mean pharmacokinetic parameters ( i.e. , Cmax and AUC ) . 
false chemical chemical Other inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents ( e.g. , itraconazole and entity1begin miconazole entity1end ) or entity2begin macrolide antibiotics entity2end ( e.g. , erythromycin and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , Cmax and AUC ) . 
false chemical chemical Other inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents ( e.g. , itraconazole and entity1begin miconazole entity1end ) or macrolide antibiotics ( e.g. , entity2begin erythromycin entity2end and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , Cmax and AUC ) . 
false chemical chemical Other inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents ( e.g. , itraconazole and entity1begin miconazole entity1end ) or macrolide antibiotics ( e.g. , erythromycin and entity2begin clarithromycin entity2end ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , Cmax and AUC ) . 
true chemical chemical Other inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents ( e.g. , itraconazole and entity1begin miconazole entity1end ) or macrolide antibiotics ( e.g. , erythromycin and clarithromycin ) , may alter entity2begin oxybutynin entity2end mean pharmacokinetic parameters ( i.e. , Cmax and AUC ) . 
false chemical chemical Other inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents ( e.g. , itraconazole and miconazole ) or entity1begin macrolide antibiotics entity1end ( e.g. , entity2begin erythromycin entity2end and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , Cmax and AUC ) . 
false chemical chemical Other inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents ( e.g. , itraconazole and miconazole ) or entity1begin macrolide antibiotics entity1end ( e.g. , erythromycin and entity2begin clarithromycin entity2end ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , Cmax and AUC ) . 
true chemical chemical Other inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents ( e.g. , itraconazole and miconazole ) or entity1begin macrolide antibiotics entity1end ( e.g. , erythromycin and clarithromycin ) , may alter entity2begin oxybutynin entity2end mean pharmacokinetic parameters ( i.e. , Cmax and AUC ) . 
false chemical chemical Other inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents ( e.g. , itraconazole and miconazole ) or macrolide antibiotics ( e.g. , entity1begin erythromycin entity1end and entity2begin clarithromycin entity2end ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , Cmax and AUC ) . 
true chemical chemical Other inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents ( e.g. , itraconazole and miconazole ) or macrolide antibiotics ( e.g. , entity1begin erythromycin entity1end and clarithromycin ) , may alter entity2begin oxybutynin entity2end mean pharmacokinetic parameters ( i.e. , Cmax and AUC ) . 
true chemical chemical Other inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents ( e.g. , itraconazole and miconazole ) or macrolide antibiotics ( e.g. , erythromycin and entity1begin clarithromycin entity1end ) , may alter entity2begin oxybutynin entity2end mean pharmacokinetic parameters ( i.e. , Cmax and AUC ) . 
false chemical chemical Concurrent ingestion of entity1begin antacid entity1end ( 20 mL of entity2begin antacid entity2end containing aluminum hydroxide , magnesium hydroxide , and simethicone ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin . 
false chemical chemical Concurrent ingestion of entity1begin antacid entity1end ( 20 mL of antacid containing entity2begin aluminum hydroxide entity2end , magnesium hydroxide , and simethicone ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin . 
false chemical chemical Concurrent ingestion of entity1begin antacid entity1end ( 20 mL of antacid containing aluminum hydroxide , entity2begin magnesium hydroxide entity2end , and simethicone ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin . 
false chemical chemical Concurrent ingestion of entity1begin antacid entity1end ( 20 mL of antacid containing aluminum hydroxide , magnesium hydroxide , and entity2begin simethicone entity2end ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin . 
false chemical chemical Concurrent ingestion of entity1begin antacid entity1end ( 20 mL of antacid containing aluminum hydroxide , magnesium hydroxide , and simethicone ) did not significantly affect the exposure of entity2begin oxybutynin entity2end or desethyloxybutynin . 
false chemical chemical Concurrent ingestion of entity1begin antacid entity1end ( 20 mL of antacid containing aluminum hydroxide , magnesium hydroxide , and simethicone ) did not significantly affect the exposure of oxybutynin or entity2begin desethyloxybutynin entity2end . 
false chemical chemical Concurrent ingestion of antacid ( 20 mL of entity1begin antacid entity1end containing entity2begin aluminum hydroxide entity2end , magnesium hydroxide , and simethicone ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin . 
false chemical chemical Concurrent ingestion of antacid ( 20 mL of entity1begin antacid entity1end containing aluminum hydroxide , entity2begin magnesium hydroxide entity2end , and simethicone ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin . 
false chemical chemical Concurrent ingestion of antacid ( 20 mL of entity1begin antacid entity1end containing aluminum hydroxide , magnesium hydroxide , and entity2begin simethicone entity2end ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin . 
false chemical chemical Concurrent ingestion of antacid ( 20 mL of entity1begin antacid entity1end containing aluminum hydroxide , magnesium hydroxide , and simethicone ) did not significantly affect the exposure of entity2begin oxybutynin entity2end or desethyloxybutynin . 
false chemical chemical Concurrent ingestion of antacid ( 20 mL of entity1begin antacid entity1end containing aluminum hydroxide , magnesium hydroxide , and simethicone ) did not significantly affect the exposure of oxybutynin or entity2begin desethyloxybutynin entity2end . 
false chemical chemical Concurrent ingestion of antacid ( 20 mL of antacid containing entity1begin aluminum hydroxide entity1end , entity2begin magnesium hydroxide entity2end , and simethicone ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin . 
false chemical chemical Concurrent ingestion of antacid ( 20 mL of antacid containing entity1begin aluminum hydroxide entity1end , magnesium hydroxide , and entity2begin simethicone entity2end ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin . 
false chemical chemical Concurrent ingestion of antacid ( 20 mL of antacid containing entity1begin aluminum hydroxide entity1end , magnesium hydroxide , and simethicone ) did not significantly affect the exposure of entity2begin oxybutynin entity2end or desethyloxybutynin . 
false chemical chemical Concurrent ingestion of antacid ( 20 mL of antacid containing entity1begin aluminum hydroxide entity1end , magnesium hydroxide , and simethicone ) did not significantly affect the exposure of oxybutynin or entity2begin desethyloxybutynin entity2end . 
false chemical chemical Concurrent ingestion of antacid ( 20 mL of antacid containing aluminum hydroxide , entity1begin magnesium hydroxide entity1end , and entity2begin simethicone entity2end ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin . 
false chemical chemical Concurrent ingestion of antacid ( 20 mL of antacid containing aluminum hydroxide , entity1begin magnesium hydroxide entity1end , and simethicone ) did not significantly affect the exposure of entity2begin oxybutynin entity2end or desethyloxybutynin . 
false chemical chemical Concurrent ingestion of antacid ( 20 mL of antacid containing aluminum hydroxide , entity1begin magnesium hydroxide entity1end , and simethicone ) did not significantly affect the exposure of oxybutynin or entity2begin desethyloxybutynin entity2end . 
false chemical chemical Concurrent ingestion of antacid ( 20 mL of antacid containing aluminum hydroxide , magnesium hydroxide , and entity1begin simethicone entity1end ) did not significantly affect the exposure of entity2begin oxybutynin entity2end or desethyloxybutynin . 
false chemical chemical Concurrent ingestion of antacid ( 20 mL of antacid containing aluminum hydroxide , magnesium hydroxide , and entity1begin simethicone entity1end ) did not significantly affect the exposure of oxybutynin or entity2begin desethyloxybutynin entity2end . 
false chemical chemical Concurrent ingestion of antacid ( 20 mL of antacid containing aluminum hydroxide , magnesium hydroxide , and simethicone ) did not significantly affect the exposure of entity1begin oxybutynin entity1end or entity2begin desethyloxybutynin entity2end . 
true chemical chemical The CNS depressant effects of entity1begin oxycodone hydrochloride entity1end may be additive with that of other entity2begin CNS depressants entity2end . . 
false chemical chemical The concomitant use of other entity1begin CNS depressants entity1end including entity2begin sedatives entity2end , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( MAO ) inhibitors , and alcohol may produce additive CNS depressant effects . 
false chemical chemical The concomitant use of other entity1begin CNS depressants entity1end including sedatives , entity2begin hypnotics entity2end , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( MAO ) inhibitors , and alcohol may produce additive CNS depressant effects . 
false chemical chemical The concomitant use of other entity1begin CNS depressants entity1end including sedatives , hypnotics , entity2begin tranquilizers entity2end , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( MAO ) inhibitors , and alcohol may produce additive CNS depressant effects . 
false chemical chemical The concomitant use of other entity1begin CNS depressants entity1end including sedatives , hypnotics , tranquilizers , general entity2begin anesthetics entity2end , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( MAO ) inhibitors , and alcohol may produce additive CNS depressant effects . 
false chemical chemical The concomitant use of other entity1begin CNS depressants entity1end including sedatives , hypnotics , tranquilizers , general anesthetics , entity2begin phenothiazines entity2end , other opioids , tricyclic antidepressants , monoamine oxidase ( MAO ) inhibitors , and alcohol may produce additive CNS depressant effects . 
false chemical chemical The concomitant use of other entity1begin CNS depressants entity1end including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other entity2begin opioids entity2end , tricyclic antidepressants , monoamine oxidase ( MAO ) inhibitors , and alcohol may produce additive CNS depressant effects . 
false chemical chemical The concomitant use of other entity1begin CNS depressants entity1end including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , entity2begin tricyclic antidepressants entity2end , monoamine oxidase ( MAO ) inhibitors , and alcohol may produce additive CNS depressant effects . 
false chemical chemical The concomitant use of other entity1begin CNS depressants entity1end including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , entity2begin monoamine oxidase ( MAO ) inhibitors entity2end , and alcohol may produce additive CNS depressant effects . 
false chemical chemical The concomitant use of other entity1begin CNS depressants entity1end including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( MAO ) inhibitors , and entity2begin alcohol entity2end may produce additive CNS depressant effects . 
false chemical chemical The concomitant use of other CNS depressants including entity1begin sedatives entity1end , entity2begin hypnotics entity2end , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( MAO ) inhibitors , and alcohol may produce additive CNS depressant effects . 
false chemical chemical The concomitant use of other CNS depressants including entity1begin sedatives entity1end , hypnotics , entity2begin tranquilizers entity2end , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( MAO ) inhibitors , and alcohol may produce additive CNS depressant effects . 
false chemical chemical The concomitant use of other CNS depressants including entity1begin sedatives entity1end , hypnotics , tranquilizers , general entity2begin anesthetics entity2end , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( MAO ) inhibitors , and alcohol may produce additive CNS depressant effects . 
false chemical chemical The concomitant use of other CNS depressants including entity1begin sedatives entity1end , hypnotics , tranquilizers , general anesthetics , entity2begin phenothiazines entity2end , other opioids , tricyclic antidepressants , monoamine oxidase ( MAO ) inhibitors , and alcohol may produce additive CNS depressant effects . 
false chemical chemical The concomitant use of other CNS depressants including entity1begin sedatives entity1end , hypnotics , tranquilizers , general anesthetics , phenothiazines , other entity2begin opioids entity2end , tricyclic antidepressants , monoamine oxidase ( MAO ) inhibitors , and alcohol may produce additive CNS depressant effects . 
false chemical chemical The concomitant use of other CNS depressants including entity1begin sedatives entity1end , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , entity2begin tricyclic antidepressants entity2end , monoamine oxidase ( MAO ) inhibitors , and alcohol may produce additive CNS depressant effects . 
false chemical chemical The concomitant use of other CNS depressants including entity1begin sedatives entity1end , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , entity2begin monoamine oxidase ( MAO ) inhibitors entity2end , and alcohol may produce additive CNS depressant effects . 
false chemical chemical The concomitant use of other CNS depressants including entity1begin sedatives entity1end , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( MAO ) inhibitors , and entity2begin alcohol entity2end may produce additive CNS depressant effects . 
false chemical chemical The concomitant use of other CNS depressants including sedatives , entity1begin hypnotics entity1end , entity2begin tranquilizers entity2end , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( MAO ) inhibitors , and alcohol may produce additive CNS depressant effects . 
false chemical chemical The concomitant use of other CNS depressants including sedatives , entity1begin hypnotics entity1end , tranquilizers , general entity2begin anesthetics entity2end , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( MAO ) inhibitors , and alcohol may produce additive CNS depressant effects . 
false chemical chemical The concomitant use of other CNS depressants including sedatives , entity1begin hypnotics entity1end , tranquilizers , general anesthetics , entity2begin phenothiazines entity2end , other opioids , tricyclic antidepressants , monoamine oxidase ( MAO ) inhibitors , and alcohol may produce additive CNS depressant effects . 
false chemical chemical The concomitant use of other CNS depressants including sedatives , entity1begin hypnotics entity1end , tranquilizers , general anesthetics , phenothiazines , other entity2begin opioids entity2end , tricyclic antidepressants , monoamine oxidase ( MAO ) inhibitors , and alcohol may produce additive CNS depressant effects . 
false chemical chemical The concomitant use of other CNS depressants including sedatives , entity1begin hypnotics entity1end , tranquilizers , general anesthetics , phenothiazines , other opioids , entity2begin tricyclic antidepressants entity2end , monoamine oxidase ( MAO ) inhibitors , and alcohol may produce additive CNS depressant effects . 
false chemical chemical The concomitant use of other CNS depressants including sedatives , entity1begin hypnotics entity1end , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , entity2begin monoamine oxidase ( MAO ) inhibitors entity2end , and alcohol may produce additive CNS depressant effects . 
false chemical chemical The concomitant use of other CNS depressants including sedatives , entity1begin hypnotics entity1end , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( MAO ) inhibitors , and entity2begin alcohol entity2end may produce additive CNS depressant effects . 
false chemical chemical The concomitant use of other CNS depressants including sedatives , hypnotics , entity1begin tranquilizers entity1end , general entity2begin anesthetics entity2end , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( MAO ) inhibitors , and alcohol may produce additive CNS depressant effects . 
false chemical chemical The concomitant use of other CNS depressants including sedatives , hypnotics , entity1begin tranquilizers entity1end , general anesthetics , entity2begin phenothiazines entity2end , other opioids , tricyclic antidepressants , monoamine oxidase ( MAO ) inhibitors , and alcohol may produce additive CNS depressant effects . 
false chemical chemical The concomitant use of other CNS depressants including sedatives , hypnotics , entity1begin tranquilizers entity1end , general anesthetics , phenothiazines , other entity2begin opioids entity2end , tricyclic antidepressants , monoamine oxidase ( MAO ) inhibitors , and alcohol may produce additive CNS depressant effects . 
false chemical chemical The concomitant use of other CNS depressants including sedatives , hypnotics , entity1begin tranquilizers entity1end , general anesthetics , phenothiazines , other opioids , entity2begin tricyclic antidepressants entity2end , monoamine oxidase ( MAO ) inhibitors , and alcohol may produce additive CNS depressant effects . 
false chemical chemical The concomitant use of other CNS depressants including sedatives , hypnotics , entity1begin tranquilizers entity1end , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , entity2begin monoamine oxidase ( MAO ) inhibitors entity2end , and alcohol may produce additive CNS depressant effects . 
false chemical chemical The concomitant use of other CNS depressants including sedatives , hypnotics , entity1begin tranquilizers entity1end , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( MAO ) inhibitors , and entity2begin alcohol entity2end may produce additive CNS depressant effects . 
false chemical chemical The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general entity1begin anesthetics entity1end , entity2begin phenothiazines entity2end , other opioids , tricyclic antidepressants , monoamine oxidase ( MAO ) inhibitors , and alcohol may produce additive CNS depressant effects . 
false chemical chemical The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general entity1begin anesthetics entity1end , phenothiazines , other entity2begin opioids entity2end , tricyclic antidepressants , monoamine oxidase ( MAO ) inhibitors , and alcohol may produce additive CNS depressant effects . 
false chemical chemical The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general entity1begin anesthetics entity1end , phenothiazines , other opioids , entity2begin tricyclic antidepressants entity2end , monoamine oxidase ( MAO ) inhibitors , and alcohol may produce additive CNS depressant effects . 
false chemical chemical The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general entity1begin anesthetics entity1end , phenothiazines , other opioids , tricyclic antidepressants , entity2begin monoamine oxidase ( MAO ) inhibitors entity2end , and alcohol may produce additive CNS depressant effects . 
false chemical chemical The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general entity1begin anesthetics entity1end , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( MAO ) inhibitors , and entity2begin alcohol entity2end may produce additive CNS depressant effects . 
false chemical chemical The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , entity1begin phenothiazines entity1end , other entity2begin opioids entity2end , tricyclic antidepressants , monoamine oxidase ( MAO ) inhibitors , and alcohol may produce additive CNS depressant effects . 
false chemical chemical The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , entity1begin phenothiazines entity1end , other opioids , entity2begin tricyclic antidepressants entity2end , monoamine oxidase ( MAO ) inhibitors , and alcohol may produce additive CNS depressant effects . 
false chemical chemical The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , entity1begin phenothiazines entity1end , other opioids , tricyclic antidepressants , entity2begin monoamine oxidase ( MAO ) inhibitors entity2end , and alcohol may produce additive CNS depressant effects . 
false chemical chemical The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , entity1begin phenothiazines entity1end , other opioids , tricyclic antidepressants , monoamine oxidase ( MAO ) inhibitors , and entity2begin alcohol entity2end may produce additive CNS depressant effects . 
false chemical chemical The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other entity1begin opioids entity1end , entity2begin tricyclic antidepressants entity2end , monoamine oxidase ( MAO ) inhibitors , and alcohol may produce additive CNS depressant effects . 
false chemical chemical The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other entity1begin opioids entity1end , tricyclic antidepressants , entity2begin monoamine oxidase ( MAO ) inhibitors entity2end , and alcohol may produce additive CNS depressant effects . 
false chemical chemical The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other entity1begin opioids entity1end , tricyclic antidepressants , monoamine oxidase ( MAO ) inhibitors , and entity2begin alcohol entity2end may produce additive CNS depressant effects . 
false chemical chemical The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , entity1begin tricyclic antidepressants entity1end , entity2begin monoamine oxidase ( MAO ) inhibitors entity2end , and alcohol may produce additive CNS depressant effects . 
false chemical chemical The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , entity1begin tricyclic antidepressants entity1end , monoamine oxidase ( MAO ) inhibitors , and entity2begin alcohol entity2end may produce additive CNS depressant effects . 
false chemical chemical The concomitant use of other CNS depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , entity1begin monoamine oxidase ( MAO ) inhibitors entity1end , and entity2begin alcohol entity2end may produce additive CNS depressant effects . 
true chemical chemical entity1begin Anticholinergics entity1end or other medications with anticholinergic activity when used concurrently with entity2begin opioid analgesics entity2end may result in increased risk of urinary retention and / or severe constipation , which may lead to paralytic ileus . 
true chemical chemical It has been reported that the incidence of bradycardia was increased when entity1begin oxymorphone entity1end was combined with entity2begin propofol entity2end for induction of anesthesia . 
true chemical chemical In addition , CNS toxicity has been reported ( confusion , disorientation , respiratory depression , apnea , seizures ) following coadministration of entity1begin cimetidine entity1end with entity2begin opioid analgesics entity2end ; 
false chemical chemical Potential for entity1begin INVEGA entity1end to Affect Other Drugs entity2begin Paliperidone entity2end is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes . 
false chemical chemical Given the primary CNS effects of entity1begin paliperidone entity1end , entity2begin INVEGA entity2end should be used with caution in combination with other centrally acting drugs and alcohol . 
true chemical chemical Given the primary CNS effects of entity1begin paliperidone entity1end , INVEGA should be used with caution in combination with other entity2begin centrally acting drugs entity2end and alcohol . 
true chemical chemical Given the primary CNS effects of entity1begin paliperidone entity1end , INVEGA should be used with caution in combination with other centrally acting drugs and entity2begin alcohol entity2end . 
true chemical chemical Given the primary CNS effects of paliperidone , entity1begin INVEGA entity1end should be used with caution in combination with other entity2begin centrally acting drugs entity2end and alcohol . 
true chemical chemical Given the primary CNS effects of paliperidone , entity1begin INVEGA entity1end should be used with caution in combination with other centrally acting drugs and entity2begin alcohol entity2end . 
false chemical chemical Given the primary CNS effects of paliperidone , INVEGA should be used with caution in combination with other entity1begin centrally acting drugs entity1end and entity2begin alcohol entity2end . 
true chemical chemical entity1begin Paliperidone entity1end may antagonize the effect of entity2begin levodopa entity2end and other dopamine agonists . 
true chemical chemical entity1begin Paliperidone entity1end may antagonize the effect of levodopa and other entity2begin dopamine agonists entity2end . 
false chemical chemical Paliperidone may antagonize the effect of entity1begin levodopa entity1end and other entity2begin dopamine agonists entity2end . 
false chemical chemical Potential for Other Drugs to Affect entity1begin INVEGA entity1end entity2begin Paliperidone entity2end is not a substrate of CYP1A2 , CYP2A6 , CYP2C9 , and CYP2C19 , so that an interaction with inhibitors or inducers of these isozymes is unlikely . 
false chemical chemical Based on studies evaluating possible interactions of entity1begin pantoprazole entity1end with other drugs , no dosage adjustment is needed with concomitant use of the following : entity2begin theophylline entity2end , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of entity1begin pantoprazole entity1end with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , entity2begin cisapride entity2end , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of entity1begin pantoprazole entity1end with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , entity2begin antipyrine entity2end , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of entity1begin pantoprazole entity1end with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , entity2begin caffeine entity2end , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of entity1begin pantoprazole entity1end with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , entity2begin carbamazepine entity2end , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of entity1begin pantoprazole entity1end with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , entity2begin diazepam entity2end ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of entity1begin pantoprazole entity1end with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , entity2begin desmethyldiazepam entity2end ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of entity1begin pantoprazole entity1end with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , entity2begin diclofenac entity2end , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of entity1begin pantoprazole entity1end with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , entity2begin naproxen entity2end , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of entity1begin pantoprazole entity1end with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , entity2begin piroxicam entity2end , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of entity1begin pantoprazole entity1end with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , entity2begin digoxin entity2end , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of entity1begin pantoprazole entity1end with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , entity2begin ethanol entity2end , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of entity1begin pantoprazole entity1end with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , entity2begin glyburide entity2end , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of entity1begin pantoprazole entity1end with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral entity2begin contraceptive entity2end ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of entity1begin pantoprazole entity1end with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( entity2begin levonorgestrel entity2end / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of entity1begin pantoprazole entity1end with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / entity2begin ethinyl estradiol entity2end ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of entity1begin pantoprazole entity1end with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , entity2begin metoprolol entity2end , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of entity1begin pantoprazole entity1end with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , entity2begin nifedipine entity2end , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of entity1begin pantoprazole entity1end with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , entity2begin phenytoin entity2end , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of entity1begin pantoprazole entity1end with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , entity2begin warfarin entity2end , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of entity1begin pantoprazole entity1end with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , entity2begin midazolam entity2end , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of entity1begin pantoprazole entity1end with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , entity2begin clarithromycin entity2end , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of entity1begin pantoprazole entity1end with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , entity2begin metronidazole entity2end , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of entity1begin pantoprazole entity1end with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or entity2begin amoxicillin entity2end . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : entity1begin theophylline entity1end , entity2begin cisapride entity2end , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : entity1begin theophylline entity1end , cisapride , entity2begin antipyrine entity2end , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : entity1begin theophylline entity1end , cisapride , antipyrine , entity2begin caffeine entity2end , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : entity1begin theophylline entity1end , cisapride , antipyrine , caffeine , entity2begin carbamazepine entity2end , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : entity1begin theophylline entity1end , cisapride , antipyrine , caffeine , carbamazepine , entity2begin diazepam entity2end ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : entity1begin theophylline entity1end , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , entity2begin desmethyldiazepam entity2end ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : entity1begin theophylline entity1end , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , entity2begin diclofenac entity2end , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : entity1begin theophylline entity1end , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , entity2begin naproxen entity2end , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : entity1begin theophylline entity1end , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , entity2begin piroxicam entity2end , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : entity1begin theophylline entity1end , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , entity2begin digoxin entity2end , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : entity1begin theophylline entity1end , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , entity2begin ethanol entity2end , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : entity1begin theophylline entity1end , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , entity2begin glyburide entity2end , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : entity1begin theophylline entity1end , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral entity2begin contraceptive entity2end ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : entity1begin theophylline entity1end , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( entity2begin levonorgestrel entity2end / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : entity1begin theophylline entity1end , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / entity2begin ethinyl estradiol entity2end ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : entity1begin theophylline entity1end , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , entity2begin metoprolol entity2end , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : entity1begin theophylline entity1end , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , entity2begin nifedipine entity2end , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : entity1begin theophylline entity1end , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , entity2begin phenytoin entity2end , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : entity1begin theophylline entity1end , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , entity2begin warfarin entity2end , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : entity1begin theophylline entity1end , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , entity2begin midazolam entity2end , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : entity1begin theophylline entity1end , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , entity2begin clarithromycin entity2end , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : entity1begin theophylline entity1end , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , entity2begin metronidazole entity2end , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : entity1begin theophylline entity1end , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or entity2begin amoxicillin entity2end . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , entity1begin cisapride entity1end , entity2begin antipyrine entity2end , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , entity1begin cisapride entity1end , antipyrine , entity2begin caffeine entity2end , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , entity1begin cisapride entity1end , antipyrine , caffeine , entity2begin carbamazepine entity2end , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , entity1begin cisapride entity1end , antipyrine , caffeine , carbamazepine , entity2begin diazepam entity2end ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , entity1begin cisapride entity1end , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , entity2begin desmethyldiazepam entity2end ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , entity1begin cisapride entity1end , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , entity2begin diclofenac entity2end , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , entity1begin cisapride entity1end , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , entity2begin naproxen entity2end , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , entity1begin cisapride entity1end , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , entity2begin piroxicam entity2end , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , entity1begin cisapride entity1end , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , entity2begin digoxin entity2end , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , entity1begin cisapride entity1end , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , entity2begin ethanol entity2end , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , entity1begin cisapride entity1end , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , entity2begin glyburide entity2end , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , entity1begin cisapride entity1end , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral entity2begin contraceptive entity2end ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , entity1begin cisapride entity1end , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( entity2begin levonorgestrel entity2end / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , entity1begin cisapride entity1end , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / entity2begin ethinyl estradiol entity2end ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , entity1begin cisapride entity1end , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , entity2begin metoprolol entity2end , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , entity1begin cisapride entity1end , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , entity2begin nifedipine entity2end , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , entity1begin cisapride entity1end , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , entity2begin phenytoin entity2end , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , entity1begin cisapride entity1end , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , entity2begin warfarin entity2end , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , entity1begin cisapride entity1end , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , entity2begin midazolam entity2end , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , entity1begin cisapride entity1end , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , entity2begin clarithromycin entity2end , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , entity1begin cisapride entity1end , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , entity2begin metronidazole entity2end , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , entity1begin cisapride entity1end , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or entity2begin amoxicillin entity2end . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , entity1begin antipyrine entity1end , entity2begin caffeine entity2end , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , entity1begin antipyrine entity1end , caffeine , entity2begin carbamazepine entity2end , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , entity1begin antipyrine entity1end , caffeine , carbamazepine , entity2begin diazepam entity2end ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , entity1begin antipyrine entity1end , caffeine , carbamazepine , diazepam ( and its active metabolite , entity2begin desmethyldiazepam entity2end ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , entity1begin antipyrine entity1end , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , entity2begin diclofenac entity2end , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , entity1begin antipyrine entity1end , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , entity2begin naproxen entity2end , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , entity1begin antipyrine entity1end , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , entity2begin piroxicam entity2end , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , entity1begin antipyrine entity1end , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , entity2begin digoxin entity2end , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , entity1begin antipyrine entity1end , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , entity2begin ethanol entity2end , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , entity1begin antipyrine entity1end , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , entity2begin glyburide entity2end , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , entity1begin antipyrine entity1end , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral entity2begin contraceptive entity2end ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , entity1begin antipyrine entity1end , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( entity2begin levonorgestrel entity2end / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , entity1begin antipyrine entity1end , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / entity2begin ethinyl estradiol entity2end ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , entity1begin antipyrine entity1end , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , entity2begin metoprolol entity2end , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , entity1begin antipyrine entity1end , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , entity2begin nifedipine entity2end , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , entity1begin antipyrine entity1end , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , entity2begin phenytoin entity2end , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , entity1begin antipyrine entity1end , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , entity2begin warfarin entity2end , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , entity1begin antipyrine entity1end , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , entity2begin midazolam entity2end , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , entity1begin antipyrine entity1end , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , entity2begin clarithromycin entity2end , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , entity1begin antipyrine entity1end , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , entity2begin metronidazole entity2end , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , entity1begin antipyrine entity1end , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or entity2begin amoxicillin entity2end . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , entity1begin caffeine entity1end , entity2begin carbamazepine entity2end , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , entity1begin caffeine entity1end , carbamazepine , entity2begin diazepam entity2end ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , entity1begin caffeine entity1end , carbamazepine , diazepam ( and its active metabolite , entity2begin desmethyldiazepam entity2end ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , entity1begin caffeine entity1end , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , entity2begin diclofenac entity2end , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , entity1begin caffeine entity1end , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , entity2begin naproxen entity2end , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , entity1begin caffeine entity1end , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , entity2begin piroxicam entity2end , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , entity1begin caffeine entity1end , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , entity2begin digoxin entity2end , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , entity1begin caffeine entity1end , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , entity2begin ethanol entity2end , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , entity1begin caffeine entity1end , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , entity2begin glyburide entity2end , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , entity1begin caffeine entity1end , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral entity2begin contraceptive entity2end ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , entity1begin caffeine entity1end , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( entity2begin levonorgestrel entity2end / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , entity1begin caffeine entity1end , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / entity2begin ethinyl estradiol entity2end ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , entity1begin caffeine entity1end , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , entity2begin metoprolol entity2end , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , entity1begin caffeine entity1end , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , entity2begin nifedipine entity2end , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , entity1begin caffeine entity1end , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , entity2begin phenytoin entity2end , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , entity1begin caffeine entity1end , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , entity2begin warfarin entity2end , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , entity1begin caffeine entity1end , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , entity2begin midazolam entity2end , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , entity1begin caffeine entity1end , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , entity2begin clarithromycin entity2end , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , entity1begin caffeine entity1end , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , entity2begin metronidazole entity2end , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , entity1begin caffeine entity1end , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or entity2begin amoxicillin entity2end . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , entity1begin carbamazepine entity1end , entity2begin diazepam entity2end ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , entity1begin carbamazepine entity1end , diazepam ( and its active metabolite , entity2begin desmethyldiazepam entity2end ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , entity1begin carbamazepine entity1end , diazepam ( and its active metabolite , desmethyldiazepam ) , entity2begin diclofenac entity2end , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , entity1begin carbamazepine entity1end , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , entity2begin naproxen entity2end , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , entity1begin carbamazepine entity1end , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , entity2begin piroxicam entity2end , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , entity1begin carbamazepine entity1end , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , entity2begin digoxin entity2end , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , entity1begin carbamazepine entity1end , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , entity2begin ethanol entity2end , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , entity1begin carbamazepine entity1end , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , entity2begin glyburide entity2end , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , entity1begin carbamazepine entity1end , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral entity2begin contraceptive entity2end ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , entity1begin carbamazepine entity1end , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( entity2begin levonorgestrel entity2end / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , entity1begin carbamazepine entity1end , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / entity2begin ethinyl estradiol entity2end ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , entity1begin carbamazepine entity1end , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , entity2begin metoprolol entity2end , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , entity1begin carbamazepine entity1end , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , entity2begin nifedipine entity2end , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , entity1begin carbamazepine entity1end , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , entity2begin phenytoin entity2end , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , entity1begin carbamazepine entity1end , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , entity2begin warfarin entity2end , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , entity1begin carbamazepine entity1end , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , entity2begin midazolam entity2end , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , entity1begin carbamazepine entity1end , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , entity2begin clarithromycin entity2end , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , entity1begin carbamazepine entity1end , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , entity2begin metronidazole entity2end , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , entity1begin carbamazepine entity1end , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or entity2begin amoxicillin entity2end . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , entity1begin diazepam entity1end ( and its active metabolite , entity2begin desmethyldiazepam entity2end ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , entity1begin diazepam entity1end ( and its active metabolite , desmethyldiazepam ) , entity2begin diclofenac entity2end , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , entity1begin diazepam entity1end ( and its active metabolite , desmethyldiazepam ) , diclofenac , entity2begin naproxen entity2end , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , entity1begin diazepam entity1end ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , entity2begin piroxicam entity2end , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , entity1begin diazepam entity1end ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , entity2begin digoxin entity2end , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , entity1begin diazepam entity1end ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , entity2begin ethanol entity2end , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , entity1begin diazepam entity1end ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , entity2begin glyburide entity2end , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , entity1begin diazepam entity1end ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral entity2begin contraceptive entity2end ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , entity1begin diazepam entity1end ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( entity2begin levonorgestrel entity2end / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , entity1begin diazepam entity1end ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / entity2begin ethinyl estradiol entity2end ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , entity1begin diazepam entity1end ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , entity2begin metoprolol entity2end , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , entity1begin diazepam entity1end ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , entity2begin nifedipine entity2end , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , entity1begin diazepam entity1end ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , entity2begin phenytoin entity2end , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , entity1begin diazepam entity1end ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , entity2begin warfarin entity2end , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , entity1begin diazepam entity1end ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , entity2begin midazolam entity2end , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , entity1begin diazepam entity1end ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , entity2begin clarithromycin entity2end , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , entity1begin diazepam entity1end ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , entity2begin metronidazole entity2end , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , entity1begin diazepam entity1end ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or entity2begin amoxicillin entity2end . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , entity1begin desmethyldiazepam entity1end ) , entity2begin diclofenac entity2end , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , entity1begin desmethyldiazepam entity1end ) , diclofenac , entity2begin naproxen entity2end , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , entity1begin desmethyldiazepam entity1end ) , diclofenac , naproxen , entity2begin piroxicam entity2end , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , entity1begin desmethyldiazepam entity1end ) , diclofenac , naproxen , piroxicam , entity2begin digoxin entity2end , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , entity1begin desmethyldiazepam entity1end ) , diclofenac , naproxen , piroxicam , digoxin , entity2begin ethanol entity2end , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , entity1begin desmethyldiazepam entity1end ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , entity2begin glyburide entity2end , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , entity1begin desmethyldiazepam entity1end ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral entity2begin contraceptive entity2end ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , entity1begin desmethyldiazepam entity1end ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( entity2begin levonorgestrel entity2end / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , entity1begin desmethyldiazepam entity1end ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / entity2begin ethinyl estradiol entity2end ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , entity1begin desmethyldiazepam entity1end ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , entity2begin metoprolol entity2end , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , entity1begin desmethyldiazepam entity1end ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , entity2begin nifedipine entity2end , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , entity1begin desmethyldiazepam entity1end ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , entity2begin phenytoin entity2end , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , entity1begin desmethyldiazepam entity1end ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , entity2begin warfarin entity2end , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , entity1begin desmethyldiazepam entity1end ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , entity2begin midazolam entity2end , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , entity1begin desmethyldiazepam entity1end ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , entity2begin clarithromycin entity2end , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , entity1begin desmethyldiazepam entity1end ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , entity2begin metronidazole entity2end , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , entity1begin desmethyldiazepam entity1end ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or entity2begin amoxicillin entity2end . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , entity1begin diclofenac entity1end , entity2begin naproxen entity2end , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , entity1begin diclofenac entity1end , naproxen , entity2begin piroxicam entity2end , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , entity1begin diclofenac entity1end , naproxen , piroxicam , entity2begin digoxin entity2end , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , entity1begin diclofenac entity1end , naproxen , piroxicam , digoxin , entity2begin ethanol entity2end , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , entity1begin diclofenac entity1end , naproxen , piroxicam , digoxin , ethanol , entity2begin glyburide entity2end , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , entity1begin diclofenac entity1end , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral entity2begin contraceptive entity2end ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , entity1begin diclofenac entity1end , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( entity2begin levonorgestrel entity2end / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , entity1begin diclofenac entity1end , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / entity2begin ethinyl estradiol entity2end ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , entity1begin diclofenac entity1end , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , entity2begin metoprolol entity2end , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , entity1begin diclofenac entity1end , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , entity2begin nifedipine entity2end , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , entity1begin diclofenac entity1end , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , entity2begin phenytoin entity2end , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , entity1begin diclofenac entity1end , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , entity2begin warfarin entity2end , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , entity1begin diclofenac entity1end , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , entity2begin midazolam entity2end , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , entity1begin diclofenac entity1end , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , entity2begin clarithromycin entity2end , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , entity1begin diclofenac entity1end , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , entity2begin metronidazole entity2end , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , entity1begin diclofenac entity1end , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or entity2begin amoxicillin entity2end . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , entity1begin naproxen entity1end , entity2begin piroxicam entity2end , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , entity1begin naproxen entity1end , piroxicam , entity2begin digoxin entity2end , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , entity1begin naproxen entity1end , piroxicam , digoxin , entity2begin ethanol entity2end , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , entity1begin naproxen entity1end , piroxicam , digoxin , ethanol , entity2begin glyburide entity2end , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , entity1begin naproxen entity1end , piroxicam , digoxin , ethanol , glyburide , an oral entity2begin contraceptive entity2end ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , entity1begin naproxen entity1end , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( entity2begin levonorgestrel entity2end / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , entity1begin naproxen entity1end , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / entity2begin ethinyl estradiol entity2end ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , entity1begin naproxen entity1end , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , entity2begin metoprolol entity2end , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , entity1begin naproxen entity1end , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , entity2begin nifedipine entity2end , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , entity1begin naproxen entity1end , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , entity2begin phenytoin entity2end , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , entity1begin naproxen entity1end , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , entity2begin warfarin entity2end , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , entity1begin naproxen entity1end , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , entity2begin midazolam entity2end , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , entity1begin naproxen entity1end , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , entity2begin clarithromycin entity2end , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , entity1begin naproxen entity1end , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , entity2begin metronidazole entity2end , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , entity1begin naproxen entity1end , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or entity2begin amoxicillin entity2end . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , entity1begin piroxicam entity1end , entity2begin digoxin entity2end , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , entity1begin piroxicam entity1end , digoxin , entity2begin ethanol entity2end , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , entity1begin piroxicam entity1end , digoxin , ethanol , entity2begin glyburide entity2end , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , entity1begin piroxicam entity1end , digoxin , ethanol , glyburide , an oral entity2begin contraceptive entity2end ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , entity1begin piroxicam entity1end , digoxin , ethanol , glyburide , an oral contraceptive ( entity2begin levonorgestrel entity2end / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , entity1begin piroxicam entity1end , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / entity2begin ethinyl estradiol entity2end ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , entity1begin piroxicam entity1end , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , entity2begin metoprolol entity2end , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , entity1begin piroxicam entity1end , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , entity2begin nifedipine entity2end , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , entity1begin piroxicam entity1end , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , entity2begin phenytoin entity2end , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , entity1begin piroxicam entity1end , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , entity2begin warfarin entity2end , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , entity1begin piroxicam entity1end , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , entity2begin midazolam entity2end , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , entity1begin piroxicam entity1end , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , entity2begin clarithromycin entity2end , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , entity1begin piroxicam entity1end , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , entity2begin metronidazole entity2end , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , entity1begin piroxicam entity1end , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or entity2begin amoxicillin entity2end . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , entity1begin digoxin entity1end , entity2begin ethanol entity2end , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , entity1begin digoxin entity1end , ethanol , entity2begin glyburide entity2end , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , entity1begin digoxin entity1end , ethanol , glyburide , an oral entity2begin contraceptive entity2end ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , entity1begin digoxin entity1end , ethanol , glyburide , an oral contraceptive ( entity2begin levonorgestrel entity2end / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , entity1begin digoxin entity1end , ethanol , glyburide , an oral contraceptive ( levonorgestrel / entity2begin ethinyl estradiol entity2end ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , entity1begin digoxin entity1end , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , entity2begin metoprolol entity2end , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , entity1begin digoxin entity1end , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , entity2begin nifedipine entity2end , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , entity1begin digoxin entity1end , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , entity2begin phenytoin entity2end , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , entity1begin digoxin entity1end , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , entity2begin warfarin entity2end , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , entity1begin digoxin entity1end , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , entity2begin midazolam entity2end , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , entity1begin digoxin entity1end , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , entity2begin clarithromycin entity2end , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , entity1begin digoxin entity1end , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , entity2begin metronidazole entity2end , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , entity1begin digoxin entity1end , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or entity2begin amoxicillin entity2end . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , entity1begin ethanol entity1end , entity2begin glyburide entity2end , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , entity1begin ethanol entity1end , glyburide , an oral entity2begin contraceptive entity2end ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , entity1begin ethanol entity1end , glyburide , an oral contraceptive ( entity2begin levonorgestrel entity2end / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , entity1begin ethanol entity1end , glyburide , an oral contraceptive ( levonorgestrel / entity2begin ethinyl estradiol entity2end ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , entity1begin ethanol entity1end , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , entity2begin metoprolol entity2end , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , entity1begin ethanol entity1end , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , entity2begin nifedipine entity2end , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , entity1begin ethanol entity1end , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , entity2begin phenytoin entity2end , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , entity1begin ethanol entity1end , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , entity2begin warfarin entity2end , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , entity1begin ethanol entity1end , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , entity2begin midazolam entity2end , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , entity1begin ethanol entity1end , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , entity2begin clarithromycin entity2end , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , entity1begin ethanol entity1end , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , entity2begin metronidazole entity2end , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , entity1begin ethanol entity1end , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or entity2begin amoxicillin entity2end . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , entity1begin glyburide entity1end , an oral entity2begin contraceptive entity2end ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , entity1begin glyburide entity1end , an oral contraceptive ( entity2begin levonorgestrel entity2end / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , entity1begin glyburide entity1end , an oral contraceptive ( levonorgestrel / entity2begin ethinyl estradiol entity2end ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , entity1begin glyburide entity1end , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , entity2begin metoprolol entity2end , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , entity1begin glyburide entity1end , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , entity2begin nifedipine entity2end , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , entity1begin glyburide entity1end , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , entity2begin phenytoin entity2end , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , entity1begin glyburide entity1end , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , entity2begin warfarin entity2end , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , entity1begin glyburide entity1end , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , entity2begin midazolam entity2end , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , entity1begin glyburide entity1end , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , entity2begin clarithromycin entity2end , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , entity1begin glyburide entity1end , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , entity2begin metronidazole entity2end , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , entity1begin glyburide entity1end , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or entity2begin amoxicillin entity2end . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral entity1begin contraceptive entity1end ( entity2begin levonorgestrel entity2end / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral entity1begin contraceptive entity1end ( levonorgestrel / entity2begin ethinyl estradiol entity2end ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral entity1begin contraceptive entity1end ( levonorgestrel / ethinyl estradiol ) , entity2begin metoprolol entity2end , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral entity1begin contraceptive entity1end ( levonorgestrel / ethinyl estradiol ) , metoprolol , entity2begin nifedipine entity2end , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral entity1begin contraceptive entity1end ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , entity2begin phenytoin entity2end , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral entity1begin contraceptive entity1end ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , entity2begin warfarin entity2end , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral entity1begin contraceptive entity1end ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , entity2begin midazolam entity2end , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral entity1begin contraceptive entity1end ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , entity2begin clarithromycin entity2end , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral entity1begin contraceptive entity1end ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , entity2begin metronidazole entity2end , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral entity1begin contraceptive entity1end ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or entity2begin amoxicillin entity2end . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( entity1begin levonorgestrel entity1end / entity2begin ethinyl estradiol entity2end ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( entity1begin levonorgestrel entity1end / ethinyl estradiol ) , entity2begin metoprolol entity2end , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( entity1begin levonorgestrel entity1end / ethinyl estradiol ) , metoprolol , entity2begin nifedipine entity2end , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( entity1begin levonorgestrel entity1end / ethinyl estradiol ) , metoprolol , nifedipine , entity2begin phenytoin entity2end , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( entity1begin levonorgestrel entity1end / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , entity2begin warfarin entity2end , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( entity1begin levonorgestrel entity1end / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , entity2begin midazolam entity2end , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( entity1begin levonorgestrel entity1end / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , entity2begin clarithromycin entity2end , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( entity1begin levonorgestrel entity1end / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , entity2begin metronidazole entity2end , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( entity1begin levonorgestrel entity1end / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or entity2begin amoxicillin entity2end . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / entity1begin ethinyl estradiol entity1end ) , entity2begin metoprolol entity2end , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / entity1begin ethinyl estradiol entity1end ) , metoprolol , entity2begin nifedipine entity2end , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / entity1begin ethinyl estradiol entity1end ) , metoprolol , nifedipine , entity2begin phenytoin entity2end , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / entity1begin ethinyl estradiol entity1end ) , metoprolol , nifedipine , phenytoin , entity2begin warfarin entity2end , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / entity1begin ethinyl estradiol entity1end ) , metoprolol , nifedipine , phenytoin , warfarin , entity2begin midazolam entity2end , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / entity1begin ethinyl estradiol entity1end ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , entity2begin clarithromycin entity2end , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / entity1begin ethinyl estradiol entity1end ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , entity2begin metronidazole entity2end , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / entity1begin ethinyl estradiol entity1end ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or entity2begin amoxicillin entity2end . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , entity1begin metoprolol entity1end , entity2begin nifedipine entity2end , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , entity1begin metoprolol entity1end , nifedipine , entity2begin phenytoin entity2end , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , entity1begin metoprolol entity1end , nifedipine , phenytoin , entity2begin warfarin entity2end , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , entity1begin metoprolol entity1end , nifedipine , phenytoin , warfarin , entity2begin midazolam entity2end , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , entity1begin metoprolol entity1end , nifedipine , phenytoin , warfarin , midazolam , entity2begin clarithromycin entity2end , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , entity1begin metoprolol entity1end , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , entity2begin metronidazole entity2end , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , entity1begin metoprolol entity1end , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or entity2begin amoxicillin entity2end . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , entity1begin nifedipine entity1end , entity2begin phenytoin entity2end , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , entity1begin nifedipine entity1end , phenytoin , entity2begin warfarin entity2end , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , entity1begin nifedipine entity1end , phenytoin , warfarin , entity2begin midazolam entity2end , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , entity1begin nifedipine entity1end , phenytoin , warfarin , midazolam , entity2begin clarithromycin entity2end , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , entity1begin nifedipine entity1end , phenytoin , warfarin , midazolam , clarithromycin , entity2begin metronidazole entity2end , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , entity1begin nifedipine entity1end , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or entity2begin amoxicillin entity2end . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , entity1begin phenytoin entity1end , entity2begin warfarin entity2end , midazolam , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , entity1begin phenytoin entity1end , warfarin , entity2begin midazolam entity2end , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , entity1begin phenytoin entity1end , warfarin , midazolam , entity2begin clarithromycin entity2end , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , entity1begin phenytoin entity1end , warfarin , midazolam , clarithromycin , entity2begin metronidazole entity2end , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , entity1begin phenytoin entity1end , warfarin , midazolam , clarithromycin , metronidazole , or entity2begin amoxicillin entity2end . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , entity1begin warfarin entity1end , entity2begin midazolam entity2end , clarithromycin , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , entity1begin warfarin entity1end , midazolam , entity2begin clarithromycin entity2end , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , entity1begin warfarin entity1end , midazolam , clarithromycin , entity2begin metronidazole entity2end , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , entity1begin warfarin entity1end , midazolam , clarithromycin , metronidazole , or entity2begin amoxicillin entity2end . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , entity1begin midazolam entity1end , entity2begin clarithromycin entity2end , metronidazole , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , entity1begin midazolam entity1end , clarithromycin , entity2begin metronidazole entity2end , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , entity1begin midazolam entity1end , clarithromycin , metronidazole , or entity2begin amoxicillin entity2end . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , entity1begin clarithromycin entity1end , entity2begin metronidazole entity2end , or amoxicillin . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , entity1begin clarithromycin entity1end , metronidazole , or entity2begin amoxicillin entity2end . 
false chemical chemical Based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , entity1begin metronidazole entity1end , or entity2begin amoxicillin entity2end . 
false chemical chemical Therefore , when coadministered with entity1begin pantoprazole entity1end , adjustment of the dosage of entity2begin pantoprazole entity2end or of such drugs may not be necessary . 
false chemical chemical There have been postmarketing reports of increased INR and prothrombin time in patients receiving entity1begin proton pump inhibitors entity1end , including entity2begin pantoprazole entity2end , and warfarin concomitantly . 
true chemical chemical There have been postmarketing reports of increased INR and prothrombin time in patients receiving entity1begin proton pump inhibitors entity1end , including pantoprazole , and entity2begin warfarin entity2end concomitantly . 
true chemical chemical There have been postmarketing reports of increased INR and prothrombin time in patients receiving proton pump inhibitors , including entity1begin pantoprazole entity1end , and entity2begin warfarin entity2end concomitantly . 
true chemical chemical Patients treated with entity1begin proton pump inhibitors entity1end and entity2begin warfarin entity2end concomitantly should be monitored for increases in INR and prothrombin time . 
true chemical chemical Because of profound and long lasting inhibition of gastric acid secretion , entity1begin pantoprazole entity1end may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability ( eg , entity2begin ketoconazole entity2end , ampicillin esters , and iron salts ) . 
true chemical chemical Because of profound and long lasting inhibition of gastric acid secretion , entity1begin pantoprazole entity1end may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability ( eg , ketoconazole , entity2begin ampicillin entity2end esters , and iron salts ) . 
true chemical chemical Because of profound and long lasting inhibition of gastric acid secretion , entity1begin pantoprazole entity1end may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability ( eg , ketoconazole , ampicillin esters , and entity2begin iron entity2end salts ) . 
false chemical chemical Because of profound and long lasting inhibition of gastric acid secretion , pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability ( eg , entity1begin ketoconazole entity1end , entity2begin ampicillin entity2end esters , and iron salts ) . 
false chemical chemical Because of profound and long lasting inhibition of gastric acid secretion , pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability ( eg , entity1begin ketoconazole entity1end , ampicillin esters , and entity2begin iron entity2end salts ) . 
false chemical chemical Because of profound and long lasting inhibition of gastric acid secretion , pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability ( eg , ketoconazole , entity1begin ampicillin entity1end esters , and entity2begin iron entity2end salts ) . 
false chemical chemical Laboratory Tests There have been reports of false - positive urine screening tests for entity1begin tetrahydrocannabinol entity1end ( entity2begin THC entity2end ) in patients receiving most proton pump inhibitors , including pantoprazole . 
false chemical chemical Laboratory Tests There have been reports of false - positive urine screening tests for entity1begin tetrahydrocannabinol entity1end ( THC ) in patients receiving most entity2begin proton pump inhibitors entity2end , including pantoprazole . 
false chemical chemical Laboratory Tests There have been reports of false - positive urine screening tests for entity1begin tetrahydrocannabinol entity1end ( THC ) in patients receiving most proton pump inhibitors , including entity2begin pantoprazole entity2end . 
false chemical chemical Laboratory Tests There have been reports of false - positive urine screening tests for tetrahydrocannabinol ( entity1begin THC entity1end ) in patients receiving most entity2begin proton pump inhibitors entity2end , including pantoprazole . 
false chemical chemical Laboratory Tests There have been reports of false - positive urine screening tests for tetrahydrocannabinol ( entity1begin THC entity1end ) in patients receiving most proton pump inhibitors , including entity2begin pantoprazole entity2end . 
false chemical chemical Laboratory Tests There have been reports of false - positive urine screening tests for tetrahydrocannabinol ( THC ) in patients receiving most entity1begin proton pump inhibitors entity1end , including entity2begin pantoprazole entity2end . 
true chemical chemical A multiple dose drug - drug interaction study demonstrated that entity1begin ketoconazole entity1end approximately doubled entity2begin paricalcitol entity2end AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that entity1begin ketoconazole entity1end approximately doubled paricalcitol AUC0 - . Since entity2begin paricalcitol entity2end is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that entity1begin ketoconazole entity1end approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and entity2begin ketoconazole entity2end le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that entity1begin ketoconazole entity1end approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing entity2begin paricalcitol entity2end with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that entity1begin ketoconazole entity1end approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with entity2begin ketoconazole entity2end and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that entity1begin ketoconazole entity1end approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including entity2begin atazanavir entity2end , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that entity1begin ketoconazole entity1end approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , entity2begin clarithromycin entity2end , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that entity1begin ketoconazole entity1end approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , entity2begin indinavir entity2end , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that entity1begin ketoconazole entity1end approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , entity2begin itraconazole entity2end , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that entity1begin ketoconazole entity1end approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , entity2begin nefazodone entity2end , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that entity1begin ketoconazole entity1end approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , entity2begin nelfinavir entity2end , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that entity1begin ketoconazole entity1end approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , entity2begin ritonavir entity2end , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that entity1begin ketoconazole entity1end approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , entity2begin saquinavir entity2end , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that entity1begin ketoconazole entity1end approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , entity2begin telithromycin entity2end or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that entity1begin ketoconazole entity1end approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or entity2begin voriconazole entity2end . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled entity1begin paricalcitol entity1end AUC0 - . Since entity2begin paricalcitol entity2end is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled entity1begin paricalcitol entity1end AUC0 - . Since paricalcitol is partially metabolized by CYP3A and entity2begin ketoconazole entity2end le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled entity1begin paricalcitol entity1end AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing entity2begin paricalcitol entity2end with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled entity1begin paricalcitol entity1end AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with entity2begin ketoconazole entity2end and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled entity1begin paricalcitol entity1end AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including entity2begin atazanavir entity2end , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled entity1begin paricalcitol entity1end AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , entity2begin clarithromycin entity2end , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled entity1begin paricalcitol entity1end AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , entity2begin indinavir entity2end , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled entity1begin paricalcitol entity1end AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , entity2begin itraconazole entity2end , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled entity1begin paricalcitol entity1end AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , entity2begin nefazodone entity2end , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled entity1begin paricalcitol entity1end AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , entity2begin nelfinavir entity2end , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled entity1begin paricalcitol entity1end AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , entity2begin ritonavir entity2end , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled entity1begin paricalcitol entity1end AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , entity2begin saquinavir entity2end , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled entity1begin paricalcitol entity1end AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , entity2begin telithromycin entity2end or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled entity1begin paricalcitol entity1end AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or entity2begin voriconazole entity2end . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since entity1begin paricalcitol entity1end is partially metabolized by CYP3A and entity2begin ketoconazole entity2end le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since entity1begin paricalcitol entity1end is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing entity2begin paricalcitol entity2end with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since entity1begin paricalcitol entity1end is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with entity2begin ketoconazole entity2end and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since entity1begin paricalcitol entity1end is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including entity2begin atazanavir entity2end , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since entity1begin paricalcitol entity1end is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , entity2begin clarithromycin entity2end , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since entity1begin paricalcitol entity1end is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , entity2begin indinavir entity2end , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since entity1begin paricalcitol entity1end is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , entity2begin itraconazole entity2end , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since entity1begin paricalcitol entity1end is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , entity2begin nefazodone entity2end , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since entity1begin paricalcitol entity1end is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , entity2begin nelfinavir entity2end , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since entity1begin paricalcitol entity1end is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , entity2begin ritonavir entity2end , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since entity1begin paricalcitol entity1end is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , entity2begin saquinavir entity2end , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since entity1begin paricalcitol entity1end is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , entity2begin telithromycin entity2end or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since entity1begin paricalcitol entity1end is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or entity2begin voriconazole entity2end . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and entity1begin ketoconazole entity1end le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing entity2begin paricalcitol entity2end with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and entity1begin ketoconazole entity1end le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with entity2begin ketoconazole entity2end and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and entity1begin ketoconazole entity1end le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including entity2begin atazanavir entity2end , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and entity1begin ketoconazole entity1end le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , entity2begin clarithromycin entity2end , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and entity1begin ketoconazole entity1end le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , entity2begin indinavir entity2end , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and entity1begin ketoconazole entity1end le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , entity2begin itraconazole entity2end , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and entity1begin ketoconazole entity1end le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , entity2begin nefazodone entity2end , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and entity1begin ketoconazole entity1end le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , entity2begin nelfinavir entity2end , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and entity1begin ketoconazole entity1end le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , entity2begin ritonavir entity2end , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and entity1begin ketoconazole entity1end le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , entity2begin saquinavir entity2end , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and entity1begin ketoconazole entity1end le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , entity2begin telithromycin entity2end or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and entity1begin ketoconazole entity1end le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or entity2begin voriconazole entity2end . 
true chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing entity1begin paricalcitol entity1end with entity2begin ketoconazole entity2end and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
true chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing entity1begin paricalcitol entity1end with ketoconazole and other strong P450 3A inhibitors including entity2begin atazanavir entity2end , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
true chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing entity1begin paricalcitol entity1end with ketoconazole and other strong P450 3A inhibitors including atazanavir , entity2begin clarithromycin entity2end , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
true chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing entity1begin paricalcitol entity1end with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , entity2begin indinavir entity2end , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
true chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing entity1begin paricalcitol entity1end with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , entity2begin itraconazole entity2end , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
true chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing entity1begin paricalcitol entity1end with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , entity2begin nefazodone entity2end , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
true chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing entity1begin paricalcitol entity1end with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , entity2begin nelfinavir entity2end , ritonavir , saquinavir , telithromycin or voriconazole . 
true chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing entity1begin paricalcitol entity1end with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , entity2begin ritonavir entity2end , saquinavir , telithromycin or voriconazole . 
true chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing entity1begin paricalcitol entity1end with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , entity2begin saquinavir entity2end , telithromycin or voriconazole . 
true chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing entity1begin paricalcitol entity1end with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , entity2begin telithromycin entity2end or voriconazole . 
true chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing entity1begin paricalcitol entity1end with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or entity2begin voriconazole entity2end . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with entity1begin ketoconazole entity1end and other strong P450 3A inhibitors including entity2begin atazanavir entity2end , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with entity1begin ketoconazole entity1end and other strong P450 3A inhibitors including atazanavir , entity2begin clarithromycin entity2end , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with entity1begin ketoconazole entity1end and other strong P450 3A inhibitors including atazanavir , clarithromycin , entity2begin indinavir entity2end , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with entity1begin ketoconazole entity1end and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , entity2begin itraconazole entity2end , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with entity1begin ketoconazole entity1end and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , entity2begin nefazodone entity2end , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with entity1begin ketoconazole entity1end and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , entity2begin nelfinavir entity2end , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with entity1begin ketoconazole entity1end and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , entity2begin ritonavir entity2end , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with entity1begin ketoconazole entity1end and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , entity2begin saquinavir entity2end , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with entity1begin ketoconazole entity1end and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , entity2begin telithromycin entity2end or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with entity1begin ketoconazole entity1end and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or entity2begin voriconazole entity2end . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including entity1begin atazanavir entity1end , entity2begin clarithromycin entity2end , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including entity1begin atazanavir entity1end , clarithromycin , entity2begin indinavir entity2end , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including entity1begin atazanavir entity1end , clarithromycin , indinavir , entity2begin itraconazole entity2end , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including entity1begin atazanavir entity1end , clarithromycin , indinavir , itraconazole , entity2begin nefazodone entity2end , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including entity1begin atazanavir entity1end , clarithromycin , indinavir , itraconazole , nefazodone , entity2begin nelfinavir entity2end , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including entity1begin atazanavir entity1end , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , entity2begin ritonavir entity2end , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including entity1begin atazanavir entity1end , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , entity2begin saquinavir entity2end , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including entity1begin atazanavir entity1end , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , entity2begin telithromycin entity2end or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including entity1begin atazanavir entity1end , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or entity2begin voriconazole entity2end . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , entity1begin clarithromycin entity1end , entity2begin indinavir entity2end , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , entity1begin clarithromycin entity1end , indinavir , entity2begin itraconazole entity2end , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , entity1begin clarithromycin entity1end , indinavir , itraconazole , entity2begin nefazodone entity2end , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , entity1begin clarithromycin entity1end , indinavir , itraconazole , nefazodone , entity2begin nelfinavir entity2end , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , entity1begin clarithromycin entity1end , indinavir , itraconazole , nefazodone , nelfinavir , entity2begin ritonavir entity2end , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , entity1begin clarithromycin entity1end , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , entity2begin saquinavir entity2end , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , entity1begin clarithromycin entity1end , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , entity2begin telithromycin entity2end or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , entity1begin clarithromycin entity1end , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or entity2begin voriconazole entity2end . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , entity1begin indinavir entity1end , entity2begin itraconazole entity2end , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , entity1begin indinavir entity1end , itraconazole , entity2begin nefazodone entity2end , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , entity1begin indinavir entity1end , itraconazole , nefazodone , entity2begin nelfinavir entity2end , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , entity1begin indinavir entity1end , itraconazole , nefazodone , nelfinavir , entity2begin ritonavir entity2end , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , entity1begin indinavir entity1end , itraconazole , nefazodone , nelfinavir , ritonavir , entity2begin saquinavir entity2end , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , entity1begin indinavir entity1end , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , entity2begin telithromycin entity2end or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , entity1begin indinavir entity1end , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or entity2begin voriconazole entity2end . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , entity1begin itraconazole entity1end , entity2begin nefazodone entity2end , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , entity1begin itraconazole entity1end , nefazodone , entity2begin nelfinavir entity2end , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , entity1begin itraconazole entity1end , nefazodone , nelfinavir , entity2begin ritonavir entity2end , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , entity1begin itraconazole entity1end , nefazodone , nelfinavir , ritonavir , entity2begin saquinavir entity2end , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , entity1begin itraconazole entity1end , nefazodone , nelfinavir , ritonavir , saquinavir , entity2begin telithromycin entity2end or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , entity1begin itraconazole entity1end , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or entity2begin voriconazole entity2end . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , entity1begin nefazodone entity1end , entity2begin nelfinavir entity2end , ritonavir , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , entity1begin nefazodone entity1end , nelfinavir , entity2begin ritonavir entity2end , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , entity1begin nefazodone entity1end , nelfinavir , ritonavir , entity2begin saquinavir entity2end , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , entity1begin nefazodone entity1end , nelfinavir , ritonavir , saquinavir , entity2begin telithromycin entity2end or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , entity1begin nefazodone entity1end , nelfinavir , ritonavir , saquinavir , telithromycin or entity2begin voriconazole entity2end . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , entity1begin nelfinavir entity1end , entity2begin ritonavir entity2end , saquinavir , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , entity1begin nelfinavir entity1end , ritonavir , entity2begin saquinavir entity2end , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , entity1begin nelfinavir entity1end , ritonavir , saquinavir , entity2begin telithromycin entity2end or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , entity1begin nelfinavir entity1end , ritonavir , saquinavir , telithromycin or entity2begin voriconazole entity2end . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , entity1begin ritonavir entity1end , entity2begin saquinavir entity2end , telithromycin or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , entity1begin ritonavir entity1end , saquinavir , entity2begin telithromycin entity2end or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , entity1begin ritonavir entity1end , saquinavir , telithromycin or entity2begin voriconazole entity2end . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , entity1begin saquinavir entity1end , entity2begin telithromycin entity2end or voriconazole . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , entity1begin saquinavir entity1end , telithromycin or entity2begin voriconazole entity2end . 
false chemical chemical A multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0 - . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , entity1begin telithromycin entity1end or entity2begin voriconazole entity2end . 
true chemical chemical Dose adjustment of entity1begin Zemplar entity1end Capsules may be required , and iPTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor such as entity2begin ketoconazole entity2end . 
true chemical chemical Drugs that impair intestinal absorption of entity1begin fat - soluble vitamins entity1end , such as entity2begin cholestyramine entity2end , may interfere with the absorption of Zemplar Capsules . 
false chemical chemical Drugs that impair intestinal absorption of entity1begin fat - soluble vitamins entity1end , such as cholestyramine , may interfere with the absorption of entity2begin Zemplar entity2end Capsules . 
true chemical chemical Drugs that impair intestinal absorption of fat - soluble vitamins , such as entity1begin cholestyramine entity1end , may interfere with the absorption of entity2begin Zemplar entity2end Capsules . 
true chemical chemical patients receiving entity1begin lithium entity1end and entity2begin Neulasta entity2end should have more frequent monitoring of neutrophil counts . 
true chemical chemical In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving entity1begin methadone entity1end , treatment with entity2begin PEG - Intron entity2end once weekly for 4 weeks was associated with a mean increase of 16 % in methadone AUC ; 
false chemical chemical In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving entity1begin methadone entity1end , treatment with PEG - Intron once weekly for 4 weeks was associated with a mean increase of 16 % in entity2begin methadone entity2end AUC ; 
false chemical chemical In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving methadone , treatment with entity1begin PEG - Intron entity1end once weekly for 4 weeks was associated with a mean increase of 16 % in entity2begin methadone entity2end AUC ; 
false chemical chemical Acromegalic patients with diabetes mellitus being treated with entity1begin insulin entity1end and / or oral entity2begin hypoglycemic entity2end agents may require dose reductions of these therapeutic agents after the initiation of therapy with SOMAVERT . 
true chemical chemical Acromegalic patients with diabetes mellitus being treated with entity1begin insulin entity1end and / or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with entity2begin SOMAVERT entity2end . 
true chemical chemical Acromegalic patients with diabetes mellitus being treated with insulin and / or oral entity1begin hypoglycemic entity1end agents may require dose reductions of these therapeutic agents after the initiation of therapy with entity2begin SOMAVERT entity2end . 
true chemical chemical In clinical studies , patients on entity1begin opioids entity1end often needed higher serum entity2begin pegvisomant entity2end concentrations to achieve appropriate IGF - I suppression compared with patients not receiving opioids . 
false chemical chemical In clinical studies , patients on entity1begin opioids entity1end often needed higher serum pegvisomant concentrations to achieve appropriate IGF - I suppression compared with patients not receiving entity2begin opioids entity2end . 
false chemical chemical In clinical studies , patients on opioids often needed higher serum entity1begin pegvisomant entity1end concentrations to achieve appropriate IGF - I suppression compared with patients not receiving entity2begin opioids entity2end . 
true chemical chemical Concomitant administration of substances that are also tubularly secreted ( e.g. , entity1begin probenecid entity1end ) could potentially result in delayed clearance of entity2begin ALIMTA entity2end . 
false chemical chemical Although entity1begin ibuprofen entity1end ( 400 mg qid ) can be administered with entity2begin ALIMTA entity2end in patients with normal renal function ( creatinine clearance 80 mL / min ) , caution should be used when administering ibuprofen concurrently with ALIMTA to patients with mild to moderate renal insufficiency ( creatinine clearance from 45 to 79 mL / min ) . 
false chemical chemical Although entity1begin ibuprofen entity1end ( 400 mg qid ) can be administered with ALIMTA in patients with normal renal function ( creatinine clearance 80 mL / min ) , caution should be used when administering entity2begin ibuprofen entity2end concurrently with ALIMTA to patients with mild to moderate renal insufficiency ( creatinine clearance from 45 to 79 mL / min ) . 
false chemical chemical Although entity1begin ibuprofen entity1end ( 400 mg qid ) can be administered with ALIMTA in patients with normal renal function ( creatinine clearance 80 mL / min ) , caution should be used when administering ibuprofen concurrently with entity2begin ALIMTA entity2end to patients with mild to moderate renal insufficiency ( creatinine clearance from 45 to 79 mL / min ) . 
false chemical chemical Although ibuprofen ( 400 mg qid ) can be administered with entity1begin ALIMTA entity1end in patients with normal renal function ( creatinine clearance 80 mL / min ) , caution should be used when administering entity2begin ibuprofen entity2end concurrently with ALIMTA to patients with mild to moderate renal insufficiency ( creatinine clearance from 45 to 79 mL / min ) . 
false chemical chemical Although ibuprofen ( 400 mg qid ) can be administered with entity1begin ALIMTA entity1end in patients with normal renal function ( creatinine clearance 80 mL / min ) , caution should be used when administering ibuprofen concurrently with entity2begin ALIMTA entity2end to patients with mild to moderate renal insufficiency ( creatinine clearance from 45 to 79 mL / min ) . 
true chemical chemical Although ibuprofen ( 400 mg qid ) can be administered with ALIMTA in patients with normal renal function ( creatinine clearance 80 mL / min ) , caution should be used when administering entity1begin ibuprofen entity1end concurrently with entity2begin ALIMTA entity2end to patients with mild to moderate renal insufficiency ( creatinine clearance from 45 to 79 mL / min ) . 
true chemical chemical Patients with mild to moderate renal insufficiency should avoid taking entity1begin NSAIDs entity1end with short elimination half - lives for a period of 2 days before , the day of , and 2 days following administration of entity2begin ALIMTA entity2end . 
false chemical chemical In the absence of data regarding potential interaction between entity1begin ALIMTA entity1end and entity2begin NSAIDs entity2end with longer half - lives , all patients taking these NSAIDs should interrupt dosing for at least 5 days before , the day of , and 2 days following ALIMTA administration . 
false chemical chemical In the absence of data regarding potential interaction between entity1begin ALIMTA entity1end and NSAIDs with longer half - lives , all patients taking these entity2begin NSAIDs entity2end should interrupt dosing for at least 5 days before , the day of , and 2 days following ALIMTA administration . 
false chemical chemical In the absence of data regarding potential interaction between entity1begin ALIMTA entity1end and NSAIDs with longer half - lives , all patients taking these NSAIDs should interrupt dosing for at least 5 days before , the day of , and 2 days following entity2begin ALIMTA entity2end administration . 
false chemical chemical In the absence of data regarding potential interaction between ALIMTA and entity1begin NSAIDs entity1end with longer half - lives , all patients taking these entity2begin NSAIDs entity2end should interrupt dosing for at least 5 days before , the day of , and 2 days following ALIMTA administration . 
false chemical chemical In the absence of data regarding potential interaction between ALIMTA and entity1begin NSAIDs entity1end with longer half - lives , all patients taking these NSAIDs should interrupt dosing for at least 5 days before , the day of , and 2 days following entity2begin ALIMTA entity2end administration . 
true chemical chemical In the absence of data regarding potential interaction between ALIMTA and NSAIDs with longer half - lives , all patients taking these entity1begin NSAIDs entity1end should interrupt dosing for at least 5 days before , the day of , and 2 days following entity2begin ALIMTA entity2end administration . 
false chemical chemical The interaction of entity1begin CYLERT entity1end ( entity2begin pemoline entity2end ) with other drugs has not been studied in humans . 
true chemical chemical Decreased seizure threshold has been reported in patients receiving entity1begin CYLERT entity1end concomitantly with entity2begin antiepileptic medications entity2end . 
false chemical chemical Concurrent administration of entity1begin bacteriostatic antibiotics entity1end ( e.g. , entity2begin erythromycin entity2end , tetracycline ) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth . 
false chemical chemical Concurrent administration of entity1begin bacteriostatic antibiotics entity1end ( e.g. , erythromycin , entity2begin tetracycline entity2end ) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth . 
true chemical chemical Concurrent administration of entity1begin bacteriostatic antibiotics entity1end ( e.g. , erythromycin , tetracycline ) may diminish the bactericidal effects of entity2begin penicillins entity2end by slowing the rate of bacterial growth . 
false chemical chemical Concurrent administration of bacteriostatic antibiotics ( e.g. , entity1begin erythromycin entity1end , entity2begin tetracycline entity2end ) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth . 
true chemical chemical Concurrent administration of bacteriostatic antibiotics ( e.g. , entity1begin erythromycin entity1end , tetracycline ) may diminish the bactericidal effects of entity2begin penicillins entity2end by slowing the rate of bacterial growth . 
true chemical chemical Concurrent administration of bacteriostatic antibiotics ( e.g. , erythromycin , entity1begin tetracycline entity1end ) may diminish the bactericidal effects of entity2begin penicillins entity2end by slowing the rate of bacterial growth . 
true chemical chemical entity1begin Penicillin entity1end blood levels may be prolonged by concurrent administration of entity2begin probenecid entity2end which blocks the renal tubular secretion of penicillins . 
false chemical chemical entity1begin Penicillin entity1end blood levels may be prolonged by concurrent administration of probenecid which blocks the renal tubular secretion of entity2begin penicillins entity2end . 
false chemical chemical Penicillin blood levels may be prolonged by concurrent administration of entity1begin probenecid entity1end which blocks the renal tubular secretion of entity2begin penicillins entity2end . 
false chemical chemical Displacement of entity1begin penicillin entity1end from plasma protein binding sites will elevate the level of free entity2begin penicillin entity2end in the serum . 
false chemical chemical Usage with entity1begin Alcohol entity1end : Due to the potential for increased CNS depressants effects , entity2begin alcohol entity2end should be used with caution in patients who are currently receiving pentazocine . 
false chemical chemical Usage with entity1begin Alcohol entity1end : Due to the potential for increased CNS depressants effects , alcohol should be used with caution in patients who are currently receiving entity2begin pentazocine entity2end . 
true chemical chemical Usage with Alcohol : Due to the potential for increased CNS depressants effects , entity1begin alcohol entity1end should be used with caution in patients who are currently receiving entity2begin pentazocine entity2end . 
true chemical chemical Although a causal relationship has not been established , there have been reports of bleeding and / or prolonged prothrombin time in patients treated with entity1begin TRENTAL entity1end with and without entity2begin anticoagulants entity2end or platelet aggregation inhibitors . 
true chemical chemical Although a causal relationship has not been established , there have been reports of bleeding and / or prolonged prothrombin time in patients treated with entity1begin TRENTAL entity1end with and without anticoagulants or entity2begin platelet aggregation inhibitors entity2end . 
false chemical chemical Although a causal relationship has not been established , there have been reports of bleeding and / or prolonged prothrombin time in patients treated with TRENTAL with and without entity1begin anticoagulants entity1end or entity2begin platelet aggregation inhibitors entity2end . 
true chemical chemical Concomitant administration of entity1begin TRENTAL entity1end and entity2begin theophylline entity2end - containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals . 
false chemical chemical Concomitant administration of entity1begin TRENTAL entity1end and theophylline - containing drugs leads to increased entity2begin theophylline entity2end levels and theophylline toxicity in some individuals . 
false chemical chemical Concomitant administration of entity1begin TRENTAL entity1end and theophylline - containing drugs leads to increased theophylline levels and entity2begin theophylline entity2end toxicity in some individuals . 
false chemical chemical Concomitant administration of TRENTAL and entity1begin theophylline entity1end - containing drugs leads to increased entity2begin theophylline entity2end levels and theophylline toxicity in some individuals . 
false chemical chemical Concomitant administration of TRENTAL and entity1begin theophylline entity1end - containing drugs leads to increased theophylline levels and entity2begin theophylline entity2end toxicity in some individuals . 
false chemical chemical Concomitant administration of TRENTAL and theophylline - containing drugs leads to increased entity1begin theophylline entity1end levels and entity2begin theophylline entity2end toxicity in some individuals . 
false chemical chemical entity1begin TRENTAL entity1end has been used concurrently with entity2begin antihypertensive drugs entity2end , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems . 
false chemical chemical entity1begin TRENTAL entity1end has been used concurrently with antihypertensive drugs , entity2begin beta blockers entity2end , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems . 
false chemical chemical entity1begin TRENTAL entity1end has been used concurrently with antihypertensive drugs , beta blockers , entity2begin digitalis entity2end , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems . 
false chemical chemical entity1begin TRENTAL entity1end has been used concurrently with antihypertensive drugs , beta blockers , digitalis , entity2begin diuretics entity2end , antidiabetic agents , and antiarrhythmics , without observed problems . 
false chemical chemical entity1begin TRENTAL entity1end has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , entity2begin antidiabetic agents entity2end , and antiarrhythmics , without observed problems . 
false chemical chemical entity1begin TRENTAL entity1end has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and entity2begin antiarrhythmics entity2end , without observed problems . 
false chemical chemical TRENTAL has been used concurrently with entity1begin antihypertensive drugs entity1end , entity2begin beta blockers entity2end , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems . 
false chemical chemical TRENTAL has been used concurrently with entity1begin antihypertensive drugs entity1end , beta blockers , entity2begin digitalis entity2end , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems . 
false chemical chemical TRENTAL has been used concurrently with entity1begin antihypertensive drugs entity1end , beta blockers , digitalis , entity2begin diuretics entity2end , antidiabetic agents , and antiarrhythmics , without observed problems . 
false chemical chemical TRENTAL has been used concurrently with entity1begin antihypertensive drugs entity1end , beta blockers , digitalis , diuretics , entity2begin antidiabetic agents entity2end , and antiarrhythmics , without observed problems . 
false chemical chemical TRENTAL has been used concurrently with entity1begin antihypertensive drugs entity1end , beta blockers , digitalis , diuretics , antidiabetic agents , and entity2begin antiarrhythmics entity2end , without observed problems . 
false chemical chemical TRENTAL has been used concurrently with antihypertensive drugs , entity1begin beta blockers entity1end , entity2begin digitalis entity2end , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems . 
false chemical chemical TRENTAL has been used concurrently with antihypertensive drugs , entity1begin beta blockers entity1end , digitalis , entity2begin diuretics entity2end , antidiabetic agents , and antiarrhythmics , without observed problems . 
false chemical chemical TRENTAL has been used concurrently with antihypertensive drugs , entity1begin beta blockers entity1end , digitalis , diuretics , entity2begin antidiabetic agents entity2end , and antiarrhythmics , without observed problems . 
false chemical chemical TRENTAL has been used concurrently with antihypertensive drugs , entity1begin beta blockers entity1end , digitalis , diuretics , antidiabetic agents , and entity2begin antiarrhythmics entity2end , without observed problems . 
false chemical chemical TRENTAL has been used concurrently with antihypertensive drugs , beta blockers , entity1begin digitalis entity1end , entity2begin diuretics entity2end , antidiabetic agents , and antiarrhythmics , without observed problems . 
false chemical chemical TRENTAL has been used concurrently with antihypertensive drugs , beta blockers , entity1begin digitalis entity1end , diuretics , entity2begin antidiabetic agents entity2end , and antiarrhythmics , without observed problems . 
false chemical chemical TRENTAL has been used concurrently with antihypertensive drugs , beta blockers , entity1begin digitalis entity1end , diuretics , antidiabetic agents , and entity2begin antiarrhythmics entity2end , without observed problems . 
false chemical chemical TRENTAL has been used concurrently with antihypertensive drugs , beta blockers , digitalis , entity1begin diuretics entity1end , entity2begin antidiabetic agents entity2end , and antiarrhythmics , without observed problems . 
false chemical chemical TRENTAL has been used concurrently with antihypertensive drugs , beta blockers , digitalis , entity1begin diuretics entity1end , antidiabetic agents , and entity2begin antiarrhythmics entity2end , without observed problems . 
false chemical chemical TRENTAL has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , entity1begin antidiabetic agents entity1end , and entity2begin antiarrhythmics entity2end , without observed problems . 
false chemical chemical entity1begin Dopamine antagonists entity1end , such as the entity2begin neuroleptics entity2end ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with Permax ( a dopamine agonist ) ; 
false chemical chemical entity1begin Dopamine antagonists entity1end , such as the neuroleptics ( entity2begin phenothiazines entity2end , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with Permax ( a dopamine agonist ) ; 
false chemical chemical entity1begin Dopamine antagonists entity1end , such as the neuroleptics ( phenothiazines , entity2begin butyrophenones entity2end , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with Permax ( a dopamine agonist ) ; 
false chemical chemical entity1begin Dopamine antagonists entity1end , such as the neuroleptics ( phenothiazines , butyrophenones , entity2begin thioxanthines entity2end ) or metoclopramide , ordinarily should not be administered concurrently with Permax ( a dopamine agonist ) ; 
false chemical chemical entity1begin Dopamine antagonists entity1end , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or entity2begin metoclopramide entity2end , ordinarily should not be administered concurrently with Permax ( a dopamine agonist ) ; 
true chemical chemical entity1begin Dopamine antagonists entity1end , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with entity2begin Permax entity2end ( a dopamine agonist ) ; 
false chemical chemical entity1begin Dopamine antagonists entity1end , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with Permax ( a entity2begin dopamine agonist entity2end ) ; 
false chemical chemical Dopamine antagonists , such as the entity1begin neuroleptics entity1end ( entity2begin phenothiazines entity2end , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with Permax ( a dopamine agonist ) ; 
false chemical chemical Dopamine antagonists , such as the entity1begin neuroleptics entity1end ( phenothiazines , entity2begin butyrophenones entity2end , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with Permax ( a dopamine agonist ) ; 
false chemical chemical Dopamine antagonists , such as the entity1begin neuroleptics entity1end ( phenothiazines , butyrophenones , entity2begin thioxanthines entity2end ) or metoclopramide , ordinarily should not be administered concurrently with Permax ( a dopamine agonist ) ; 
false chemical chemical Dopamine antagonists , such as the entity1begin neuroleptics entity1end ( phenothiazines , butyrophenones , thioxanthines ) or entity2begin metoclopramide entity2end , ordinarily should not be administered concurrently with Permax ( a dopamine agonist ) ; 
true chemical chemical Dopamine antagonists , such as the entity1begin neuroleptics entity1end ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with entity2begin Permax entity2end ( a dopamine agonist ) ; 
false chemical chemical Dopamine antagonists , such as the entity1begin neuroleptics entity1end ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with Permax ( a entity2begin dopamine agonist entity2end ) ; 
false chemical chemical Dopamine antagonists , such as the neuroleptics ( entity1begin phenothiazines entity1end , entity2begin butyrophenones entity2end , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with Permax ( a dopamine agonist ) ; 
false chemical chemical Dopamine antagonists , such as the neuroleptics ( entity1begin phenothiazines entity1end , butyrophenones , entity2begin thioxanthines entity2end ) or metoclopramide , ordinarily should not be administered concurrently with Permax ( a dopamine agonist ) ; 
false chemical chemical Dopamine antagonists , such as the neuroleptics ( entity1begin phenothiazines entity1end , butyrophenones , thioxanthines ) or entity2begin metoclopramide entity2end , ordinarily should not be administered concurrently with Permax ( a dopamine agonist ) ; 
true chemical chemical Dopamine antagonists , such as the neuroleptics ( entity1begin phenothiazines entity1end , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with entity2begin Permax entity2end ( a dopamine agonist ) ; 
false chemical chemical Dopamine antagonists , such as the neuroleptics ( entity1begin phenothiazines entity1end , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with Permax ( a entity2begin dopamine agonist entity2end ) ; 
false chemical chemical Dopamine antagonists , such as the neuroleptics ( phenothiazines , entity1begin butyrophenones entity1end , entity2begin thioxanthines entity2end ) or metoclopramide , ordinarily should not be administered concurrently with Permax ( a dopamine agonist ) ; 
false chemical chemical Dopamine antagonists , such as the neuroleptics ( phenothiazines , entity1begin butyrophenones entity1end , thioxanthines ) or entity2begin metoclopramide entity2end , ordinarily should not be administered concurrently with Permax ( a dopamine agonist ) ; 
true chemical chemical Dopamine antagonists , such as the neuroleptics ( phenothiazines , entity1begin butyrophenones entity1end , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with entity2begin Permax entity2end ( a dopamine agonist ) ; 
false chemical chemical Dopamine antagonists , such as the neuroleptics ( phenothiazines , entity1begin butyrophenones entity1end , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with Permax ( a entity2begin dopamine agonist entity2end ) ; 
false chemical chemical Dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , entity1begin thioxanthines entity1end ) or entity2begin metoclopramide entity2end , ordinarily should not be administered concurrently with Permax ( a dopamine agonist ) ; 
true chemical chemical Dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , entity1begin thioxanthines entity1end ) or metoclopramide , ordinarily should not be administered concurrently with entity2begin Permax entity2end ( a dopamine agonist ) ; 
false chemical chemical Dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , entity1begin thioxanthines entity1end ) or metoclopramide , ordinarily should not be administered concurrently with Permax ( a entity2begin dopamine agonist entity2end ) ; 
true chemical chemical Dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or entity1begin metoclopramide entity1end , ordinarily should not be administered concurrently with entity2begin Permax entity2end ( a dopamine agonist ) ; 
false chemical chemical Dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or entity1begin metoclopramide entity1end , ordinarily should not be administered concurrently with Permax ( a entity2begin dopamine agonist entity2end ) ; 
false chemical chemical Dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with entity1begin Permax entity1end ( a entity2begin dopamine agonist entity2end ) ; 
false chemical chemical Because entity1begin pergolide mesylate entity1end is approximately 90 % bound to plasma proteins , caution should be exercised if entity2begin pergolide mesylate entity2end is coadministered with other drugs known to affect protein binding . 
false chemical chemical entity1begin Diuretics entity1end : Patients on entity2begin diuretics entity2end , and especially those started recently , may occasionally experience an excessive reduction of blood pressure after initiation of ACEON Tablets therapy . 
false chemical chemical entity1begin Diuretics entity1end : Patients on diuretics , and especially those started recently , may occasionally experience an excessive reduction of blood pressure after initiation of entity2begin ACEON entity2end Tablets therapy . 
true chemical chemical Diuretics : Patients on entity1begin diuretics entity1end , and especially those started recently , may occasionally experience an excessive reduction of blood pressure after initiation of entity2begin ACEON entity2end Tablets therapy . 
true chemical chemical The possibility of hypotensive effects can be minimized by either discontinuing the entity1begin diuretic entity1end or increasing the salt intake prior to initiation of treatment with entity2begin perindopril entity2end . 
true chemical chemical If entity1begin diuretics entity1end cannot be interrupted , close medical supervision should be provided with the first dose of entity2begin ACEON entity2end Tablets , for at least two hours and until blood pressure has stabilized for another hour . 
false chemical chemical The rate and extent of entity1begin perindopril entity1end absorption and elimination are not affected by concomitant entity2begin diuretics entity2end . 
false chemical chemical The bioavailability of entity1begin perindoprilat entity1end was reduced by entity2begin diuretics entity2end , however , and this was associated with a decrease in plasma ACE inhibition . 
false chemical chemical entity1begin Potassium entity1end Supplements and entity2begin Potassium - Sparing Diuretics entity2end : ACEON Tablets may increase serum potassium because of its potential to decrease aldosterone production . 
false chemical chemical entity1begin Potassium entity1end Supplements and Potassium - Sparing Diuretics : entity2begin ACEON entity2end Tablets may increase serum potassium because of its potential to decrease aldosterone production . 
false chemical chemical Potassium Supplements and entity1begin Potassium - Sparing Diuretics entity1end : entity2begin ACEON entity2end Tablets may increase serum potassium because of its potential to decrease aldosterone production . 
false chemical chemical Use of entity1begin potassium - sparing diuretics entity1end ( entity2begin spironolactone entity2end , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia . 
false chemical chemical Use of entity1begin potassium - sparing diuretics entity1end ( spironolactone , entity2begin amiloride entity2end , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia . 
false chemical chemical Use of entity1begin potassium - sparing diuretics entity1end ( spironolactone , amiloride , entity2begin triamterene entity2end and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia . 
false chemical chemical Use of entity1begin potassium - sparing diuretics entity1end ( spironolactone , amiloride , triamterene and others ) , entity2begin potassium entity2end supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia . 
false chemical chemical Use of entity1begin potassium - sparing diuretics entity1end ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( entity2begin indomethacin entity2end , heparin , cyclosporine and others ) can increase the risk of hyperkalemia . 
false chemical chemical Use of entity1begin potassium - sparing diuretics entity1end ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , entity2begin heparin entity2end , cyclosporine and others ) can increase the risk of hyperkalemia . 
false chemical chemical Use of entity1begin potassium - sparing diuretics entity1end ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , entity2begin cyclosporine entity2end and others ) can increase the risk of hyperkalemia . 
false chemical chemical Use of potassium - sparing diuretics ( entity1begin spironolactone entity1end , entity2begin amiloride entity2end , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia . 
false chemical chemical Use of potassium - sparing diuretics ( entity1begin spironolactone entity1end , amiloride , entity2begin triamterene entity2end and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia . 
false chemical chemical Use of potassium - sparing diuretics ( entity1begin spironolactone entity1end , amiloride , triamterene and others ) , entity2begin potassium entity2end supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia . 
false chemical chemical Use of potassium - sparing diuretics ( entity1begin spironolactone entity1end , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( entity2begin indomethacin entity2end , heparin , cyclosporine and others ) can increase the risk of hyperkalemia . 
false chemical chemical Use of potassium - sparing diuretics ( entity1begin spironolactone entity1end , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , entity2begin heparin entity2end , cyclosporine and others ) can increase the risk of hyperkalemia . 
false chemical chemical Use of potassium - sparing diuretics ( entity1begin spironolactone entity1end , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , entity2begin cyclosporine entity2end and others ) can increase the risk of hyperkalemia . 
false chemical chemical Use of potassium - sparing diuretics ( spironolactone , entity1begin amiloride entity1end , entity2begin triamterene entity2end and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia . 
false chemical chemical Use of potassium - sparing diuretics ( spironolactone , entity1begin amiloride entity1end , triamterene and others ) , entity2begin potassium entity2end supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia . 
false chemical chemical Use of potassium - sparing diuretics ( spironolactone , entity1begin amiloride entity1end , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( entity2begin indomethacin entity2end , heparin , cyclosporine and others ) can increase the risk of hyperkalemia . 
false chemical chemical Use of potassium - sparing diuretics ( spironolactone , entity1begin amiloride entity1end , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , entity2begin heparin entity2end , cyclosporine and others ) can increase the risk of hyperkalemia . 
false chemical chemical Use of potassium - sparing diuretics ( spironolactone , entity1begin amiloride entity1end , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , entity2begin cyclosporine entity2end and others ) can increase the risk of hyperkalemia . 
false chemical chemical Use of potassium - sparing diuretics ( spironolactone , amiloride , entity1begin triamterene entity1end and others ) , entity2begin potassium entity2end supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia . 
false chemical chemical Use of potassium - sparing diuretics ( spironolactone , amiloride , entity1begin triamterene entity1end and others ) , potassium supplements or other drugs capable of increasing serum potassium ( entity2begin indomethacin entity2end , heparin , cyclosporine and others ) can increase the risk of hyperkalemia . 
false chemical chemical Use of potassium - sparing diuretics ( spironolactone , amiloride , entity1begin triamterene entity1end and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , entity2begin heparin entity2end , cyclosporine and others ) can increase the risk of hyperkalemia . 
false chemical chemical Use of potassium - sparing diuretics ( spironolactone , amiloride , entity1begin triamterene entity1end and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , entity2begin cyclosporine entity2end and others ) can increase the risk of hyperkalemia . 
false chemical chemical Use of potassium - sparing diuretics ( spironolactone , amiloride , triamterene and others ) , entity1begin potassium entity1end supplements or other drugs capable of increasing serum potassium ( entity2begin indomethacin entity2end , heparin , cyclosporine and others ) can increase the risk of hyperkalemia . 
false chemical chemical Use of potassium - sparing diuretics ( spironolactone , amiloride , triamterene and others ) , entity1begin potassium entity1end supplements or other drugs capable of increasing serum potassium ( indomethacin , entity2begin heparin entity2end , cyclosporine and others ) can increase the risk of hyperkalemia . 
false chemical chemical Use of potassium - sparing diuretics ( spironolactone , amiloride , triamterene and others ) , entity1begin potassium entity1end supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , entity2begin cyclosporine entity2end and others ) can increase the risk of hyperkalemia . 
false chemical chemical Use of potassium - sparing diuretics ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( entity1begin indomethacin entity1end , entity2begin heparin entity2end , cyclosporine and others ) can increase the risk of hyperkalemia . 
false chemical chemical Use of potassium - sparing diuretics ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( entity1begin indomethacin entity1end , heparin , entity2begin cyclosporine entity2end and others ) can increase the risk of hyperkalemia . 
false chemical chemical Use of potassium - sparing diuretics ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , entity1begin heparin entity1end , entity2begin cyclosporine entity2end and others ) can increase the risk of hyperkalemia . 
false chemical chemical entity1begin Lithium entity1end : Increased serum entity2begin lithium entity2end and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy . 
false chemical chemical entity1begin Lithium entity1end : Increased serum lithium and symptoms of entity2begin lithium entity2end toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy . 
false chemical chemical entity1begin Lithium entity1end : Increased serum lithium and symptoms of lithium toxicity have been reported in patients receiving concomitant entity2begin lithium entity2end and ACE inhibitor therapy . 
false chemical chemical Lithium : Increased serum entity1begin lithium entity1end and symptoms of entity2begin lithium entity2end toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy . 
false chemical chemical Lithium : Increased serum entity1begin lithium entity1end and symptoms of lithium toxicity have been reported in patients receiving concomitant entity2begin lithium entity2end and ACE inhibitor therapy . 
false chemical chemical Lithium : Increased serum lithium and symptoms of entity1begin lithium entity1end toxicity have been reported in patients receiving concomitant entity2begin lithium entity2end and ACE inhibitor therapy . 
false chemical chemical Use of a entity1begin diuretic entity1end may further increase the risk of entity2begin lithium entity2end toxicity . 
false chemical chemical entity1begin Digoxin entity1end : A controlled pharmacokinetic study has shown no effect on plasma entity2begin digoxin entity2end concentrations when coadministered with ACEON Tablets , but an effect of digoxin on the plasma concentration of perindopril / perindoprilat has not been excluded . 
false chemical chemical entity1begin Digoxin entity1end : A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with entity2begin ACEON entity2end Tablets , but an effect of digoxin on the plasma concentration of perindopril / perindoprilat has not been excluded . 
false chemical chemical entity1begin Digoxin entity1end : A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON Tablets , but an effect of entity2begin digoxin entity2end on the plasma concentration of perindopril / perindoprilat has not been excluded . 
false chemical chemical entity1begin Digoxin entity1end : A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON Tablets , but an effect of digoxin on the plasma concentration of entity2begin perindopril entity2end / perindoprilat has not been excluded . 
false chemical chemical entity1begin Digoxin entity1end : A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON Tablets , but an effect of digoxin on the plasma concentration of perindopril / entity2begin perindoprilat entity2end has not been excluded . 
false chemical chemical Digoxin : A controlled pharmacokinetic study has shown no effect on plasma entity1begin digoxin entity1end concentrations when coadministered with entity2begin ACEON entity2end Tablets , but an effect of digoxin on the plasma concentration of perindopril / perindoprilat has not been excluded . 
false chemical chemical Digoxin : A controlled pharmacokinetic study has shown no effect on plasma entity1begin digoxin entity1end concentrations when coadministered with ACEON Tablets , but an effect of entity2begin digoxin entity2end on the plasma concentration of perindopril / perindoprilat has not been excluded . 
false chemical chemical Digoxin : A controlled pharmacokinetic study has shown no effect on plasma entity1begin digoxin entity1end concentrations when coadministered with ACEON Tablets , but an effect of digoxin on the plasma concentration of entity2begin perindopril entity2end / perindoprilat has not been excluded . 
false chemical chemical Digoxin : A controlled pharmacokinetic study has shown no effect on plasma entity1begin digoxin entity1end concentrations when coadministered with ACEON Tablets , but an effect of digoxin on the plasma concentration of perindopril / entity2begin perindoprilat entity2end has not been excluded . 
false chemical chemical Digoxin : A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with entity1begin ACEON entity1end Tablets , but an effect of entity2begin digoxin entity2end on the plasma concentration of perindopril / perindoprilat has not been excluded . 
false chemical chemical Digoxin : A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with entity1begin ACEON entity1end Tablets , but an effect of digoxin on the plasma concentration of entity2begin perindopril entity2end / perindoprilat has not been excluded . 
false chemical chemical Digoxin : A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with entity1begin ACEON entity1end Tablets , but an effect of digoxin on the plasma concentration of perindopril / entity2begin perindoprilat entity2end has not been excluded . 
true chemical chemical Digoxin : A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON Tablets , but an effect of entity1begin digoxin entity1end on the plasma concentration of entity2begin perindopril entity2end / perindoprilat has not been excluded . 
true chemical chemical Digoxin : A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON Tablets , but an effect of entity1begin digoxin entity1end on the plasma concentration of perindopril / entity2begin perindoprilat entity2end has not been excluded . 
false chemical chemical Digoxin : A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON Tablets , but an effect of digoxin on the plasma concentration of entity1begin perindopril entity1end / entity2begin perindoprilat entity2end has not been excluded . 
false chemical chemical entity1begin Gentamicin entity1end : Animal data have suggested the possibility of interaction between entity2begin perindopril entity2end and gentamicin . 
false chemical chemical entity1begin Gentamicin entity1end : Animal data have suggested the possibility of interaction between perindopril and entity2begin gentamicin entity2end . 
true chemical chemical Gentamicin : Animal data have suggested the possibility of interaction between entity1begin perindopril entity1end and entity2begin gentamicin entity2end . 
false chemical chemical Food Interaction : Oral administration of entity1begin ACEON entity1end Tablets with food does not significantly lower the rate or extent of entity2begin perindopril entity2end absorption relative to the fasted state . 
false chemical chemical However , the extent of biotransformation of entity1begin perindopril entity1end to the active metabolite , entity2begin perindoprilat entity2end , is reduced approximately 43 % , resulting in a reduction in the plasma ACE inhibition curve of approximately 20 % , probably clinically insignificant . 
true chemical chemical Concomitant use of entity1begin alcohol entity1end with entity2begin phentermine hydrochloride entity2end may result in an adverse drug interaction . 
false chemical chemical entity1begin Vasopressors entity1end , particularly entity2begin metaraminol entity2end , may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all . 
true chemical chemical entity1begin Vasopressors entity1end , particularly metaraminol , may cause serious cardiac arrhythmias during entity2begin halothane entity2end anesthesia and therefore should be used only with great caution or not at all . 
true chemical chemical Vasopressors , particularly entity1begin metaraminol entity1end , may cause serious cardiac arrhythmias during entity2begin halothane entity2end anesthesia and therefore should be used only with great caution or not at all . 
false chemical chemical entity1begin MAO Inhibitors entity1end : The pressor effect of entity2begin sympathomimetic pressor amines entity2end is markedly potentiated in patients receiving monoamine oxidase inhibitors ( MAOI ) . 
false chemical chemical entity1begin MAO Inhibitors entity1end : The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving entity2begin monoamine oxidase inhibitors entity2end ( MAOI ) . 
false chemical chemical entity1begin MAO Inhibitors entity1end : The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors ( entity2begin MAOI entity2end ) . 
true chemical chemical MAO Inhibitors : The pressor effect of entity1begin sympathomimetic pressor amines entity1end is markedly potentiated in patients receiving entity2begin monoamine oxidase inhibitors entity2end ( MAOI ) . 
true chemical chemical MAO Inhibitors : The pressor effect of entity1begin sympathomimetic pressor amines entity1end is markedly potentiated in patients receiving monoamine oxidase inhibitors ( entity2begin MAOI entity2end ) . 
false chemical chemical MAO Inhibitors : The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving entity1begin monoamine oxidase inhibitors entity1end ( entity2begin MAOI entity2end ) . 
true chemical chemical The pressor response of entity1begin adrenergic agents entity1end may also be potentiated by entity2begin tricyclic antidepressants entity2end . 
false chemical chemical entity1begin Vasopressors entity1end , particularly entity2begin metaraminol entity2end , may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all . 
true chemical chemical entity1begin Vasopressors entity1end , particularly metaraminol , may cause serious cardiac arrhythmias during entity2begin halothane entity2end anesthesia and therefore should be used only with great caution or not at all . 
true chemical chemical Vasopressors , particularly entity1begin metaraminol entity1end , may cause serious cardiac arrhythmias during entity2begin halothane entity2end anesthesia and therefore should be used only with great caution or not at all . 
false chemical chemical entity1begin MAO Inhibitors entity1end - The pressor effect of entity2begin sympathomimetic pressor amines entity2end is markedly potentiated in patients receiving monoamine oxidase inhibitors ( MAOI ) . 
false chemical chemical entity1begin MAO Inhibitors entity1end - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving entity2begin monoamine oxidase inhibitors entity2end ( MAOI ) . 
false chemical chemical entity1begin MAO Inhibitors entity1end - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors ( entity2begin MAOI entity2end ) . 
true chemical chemical MAO Inhibitors - The pressor effect of entity1begin sympathomimetic pressor amines entity1end is markedly potentiated in patients receiving entity2begin monoamine oxidase inhibitors entity2end ( MAOI ) . 
true chemical chemical MAO Inhibitors - The pressor effect of entity1begin sympathomimetic pressor amines entity1end is markedly potentiated in patients receiving monoamine oxidase inhibitors ( entity2begin MAOI entity2end ) . 
false chemical chemical MAO Inhibitors - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving entity1begin monoamine oxidase inhibitors entity1end ( entity2begin MAOI entity2end ) . 
true chemical chemical The pressor response of entity1begin adrenergic agents entity1end may also be potentiated by entity2begin tricyclic antidepressants entity2end . 
true chemical chemical entity1begin Pilocarpine entity1end should be administered with caution to patients taking entity2begin beta adrenergic antagonists entity2end because of the possibility of conduction disturbances . 
false chemical chemical These effects should be considered when anticholinergic properties may be contributing to the therapeutic effect of concomitant medication ( e.g. , entity1begin atropine entity1end , inhaled entity2begin ipratropium entity2end ) . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : entity1begin acetylsalicylic acid entity1end , artificial tears , entity2begin calcium entity2end , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : entity1begin acetylsalicylic acid entity1end , artificial tears , calcium , entity2begin conjugated estrogens entity2end , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : entity1begin acetylsalicylic acid entity1end , artificial tears , calcium , conjugated estrogens , entity2begin hydroxychloroquine sulfate entity2end , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : entity1begin acetylsalicylic acid entity1end , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , entity2begin ibuprofen entity2end , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : entity1begin acetylsalicylic acid entity1end , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , entity2begin levothyroxine sodium entity2end , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : entity1begin acetylsalicylic acid entity1end , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , entity2begin medroxyprogesterone acetate entity2end , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : entity1begin acetylsalicylic acid entity1end , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , entity2begin methotrexate entity2end , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : entity1begin acetylsalicylic acid entity1end , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , entity2begin multivitamins entity2end , naproxen , omeprazole , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : entity1begin acetylsalicylic acid entity1end , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , entity2begin naproxen entity2end , omeprazole , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : entity1begin acetylsalicylic acid entity1end , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , entity2begin omeprazole entity2end , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : entity1begin acetylsalicylic acid entity1end , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , entity2begin paracetamol entity2end , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : entity1begin acetylsalicylic acid entity1end , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and entity2begin prednisone entity2end . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , entity1begin calcium entity1end , entity2begin conjugated estrogens entity2end , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , entity1begin calcium entity1end , conjugated estrogens , entity2begin hydroxychloroquine sulfate entity2end , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , entity1begin calcium entity1end , conjugated estrogens , hydroxychloroquine sulfate , entity2begin ibuprofen entity2end , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , entity1begin calcium entity1end , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , entity2begin levothyroxine sodium entity2end , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , entity1begin calcium entity1end , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , entity2begin medroxyprogesterone acetate entity2end , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , entity1begin calcium entity1end , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , entity2begin methotrexate entity2end , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , entity1begin calcium entity1end , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , entity2begin multivitamins entity2end , naproxen , omeprazole , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , entity1begin calcium entity1end , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , entity2begin naproxen entity2end , omeprazole , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , entity1begin calcium entity1end , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , entity2begin omeprazole entity2end , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , entity1begin calcium entity1end , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , entity2begin paracetamol entity2end , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , entity1begin calcium entity1end , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and entity2begin prednisone entity2end . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , entity1begin conjugated estrogens entity1end , entity2begin hydroxychloroquine sulfate entity2end , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , entity1begin conjugated estrogens entity1end , hydroxychloroquine sulfate , entity2begin ibuprofen entity2end , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , entity1begin conjugated estrogens entity1end , hydroxychloroquine sulfate , ibuprofen , entity2begin levothyroxine sodium entity2end , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , entity1begin conjugated estrogens entity1end , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , entity2begin medroxyprogesterone acetate entity2end , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , entity1begin conjugated estrogens entity1end , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , entity2begin methotrexate entity2end , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , entity1begin conjugated estrogens entity1end , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , entity2begin multivitamins entity2end , naproxen , omeprazole , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , entity1begin conjugated estrogens entity1end , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , entity2begin naproxen entity2end , omeprazole , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , entity1begin conjugated estrogens entity1end , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , entity2begin omeprazole entity2end , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , entity1begin conjugated estrogens entity1end , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , entity2begin paracetamol entity2end , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , entity1begin conjugated estrogens entity1end , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and entity2begin prednisone entity2end . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , entity1begin hydroxychloroquine sulfate entity1end , entity2begin ibuprofen entity2end , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , entity1begin hydroxychloroquine sulfate entity1end , ibuprofen , entity2begin levothyroxine sodium entity2end , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , entity1begin hydroxychloroquine sulfate entity1end , ibuprofen , levothyroxine sodium , entity2begin medroxyprogesterone acetate entity2end , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , entity1begin hydroxychloroquine sulfate entity1end , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , entity2begin methotrexate entity2end , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , entity1begin hydroxychloroquine sulfate entity1end , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , entity2begin multivitamins entity2end , naproxen , omeprazole , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , entity1begin hydroxychloroquine sulfate entity1end , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , entity2begin naproxen entity2end , omeprazole , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , entity1begin hydroxychloroquine sulfate entity1end , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , entity2begin omeprazole entity2end , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , entity1begin hydroxychloroquine sulfate entity1end , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , entity2begin paracetamol entity2end , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , entity1begin hydroxychloroquine sulfate entity1end , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and entity2begin prednisone entity2end . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , entity1begin ibuprofen entity1end , entity2begin levothyroxine sodium entity2end , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , entity1begin ibuprofen entity1end , levothyroxine sodium , entity2begin medroxyprogesterone acetate entity2end , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , entity1begin ibuprofen entity1end , levothyroxine sodium , medroxyprogesterone acetate , entity2begin methotrexate entity2end , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , entity1begin ibuprofen entity1end , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , entity2begin multivitamins entity2end , naproxen , omeprazole , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , entity1begin ibuprofen entity1end , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , entity2begin naproxen entity2end , omeprazole , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , entity1begin ibuprofen entity1end , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , entity2begin omeprazole entity2end , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , entity1begin ibuprofen entity1end , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , entity2begin paracetamol entity2end , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , entity1begin ibuprofen entity1end , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and entity2begin prednisone entity2end . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , entity1begin levothyroxine sodium entity1end , entity2begin medroxyprogesterone acetate entity2end , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , entity1begin levothyroxine sodium entity1end , medroxyprogesterone acetate , entity2begin methotrexate entity2end , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , entity1begin levothyroxine sodium entity1end , medroxyprogesterone acetate , methotrexate , entity2begin multivitamins entity2end , naproxen , omeprazole , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , entity1begin levothyroxine sodium entity1end , medroxyprogesterone acetate , methotrexate , multivitamins , entity2begin naproxen entity2end , omeprazole , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , entity1begin levothyroxine sodium entity1end , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , entity2begin omeprazole entity2end , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , entity1begin levothyroxine sodium entity1end , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , entity2begin paracetamol entity2end , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , entity1begin levothyroxine sodium entity1end , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and entity2begin prednisone entity2end . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , entity1begin medroxyprogesterone acetate entity1end , entity2begin methotrexate entity2end , multivitamins , naproxen , omeprazole , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , entity1begin medroxyprogesterone acetate entity1end , methotrexate , entity2begin multivitamins entity2end , naproxen , omeprazole , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , entity1begin medroxyprogesterone acetate entity1end , methotrexate , multivitamins , entity2begin naproxen entity2end , omeprazole , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , entity1begin medroxyprogesterone acetate entity1end , methotrexate , multivitamins , naproxen , entity2begin omeprazole entity2end , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , entity1begin medroxyprogesterone acetate entity1end , methotrexate , multivitamins , naproxen , omeprazole , entity2begin paracetamol entity2end , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , entity1begin medroxyprogesterone acetate entity1end , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and entity2begin prednisone entity2end . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , entity1begin methotrexate entity1end , entity2begin multivitamins entity2end , naproxen , omeprazole , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , entity1begin methotrexate entity1end , multivitamins , entity2begin naproxen entity2end , omeprazole , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , entity1begin methotrexate entity1end , multivitamins , naproxen , entity2begin omeprazole entity2end , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , entity1begin methotrexate entity1end , multivitamins , naproxen , omeprazole , entity2begin paracetamol entity2end , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , entity1begin methotrexate entity1end , multivitamins , naproxen , omeprazole , paracetamol , and entity2begin prednisone entity2end . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , entity1begin multivitamins entity1end , entity2begin naproxen entity2end , omeprazole , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , entity1begin multivitamins entity1end , naproxen , entity2begin omeprazole entity2end , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , entity1begin multivitamins entity1end , naproxen , omeprazole , entity2begin paracetamol entity2end , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , entity1begin multivitamins entity1end , naproxen , omeprazole , paracetamol , and entity2begin prednisone entity2end . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , entity1begin naproxen entity1end , entity2begin omeprazole entity2end , paracetamol , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , entity1begin naproxen entity1end , omeprazole , entity2begin paracetamol entity2end , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , entity1begin naproxen entity1end , omeprazole , paracetamol , and entity2begin prednisone entity2end . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , entity1begin omeprazole entity1end , entity2begin paracetamol entity2end , and prednisone . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , entity1begin omeprazole entity1end , paracetamol , and entity2begin prednisone entity2end . 
false chemical chemical While no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both Sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , entity1begin paracetamol entity1end , and entity2begin prednisone entity2end . 
true chemical chemical Catecholamine - depleting drugs ( e.g. , entity1begin reserpine entity1end ) may have an additive effect when given with entity2begin beta - blocking agents entity2end . 
false chemical chemical entity1begin Pindolol entity1end has been used with a variety of entity2begin antihypertensive agents entity2end , including hydrochlorothiazide , hydralazine , and guanethidine without unexpected adverse interactions . 
false chemical chemical entity1begin Pindolol entity1end has been used with a variety of antihypertensive agents , including entity2begin hydrochlorothiazide entity2end , hydralazine , and guanethidine without unexpected adverse interactions . 
false chemical chemical entity1begin Pindolol entity1end has been used with a variety of antihypertensive agents , including hydrochlorothiazide , entity2begin hydralazine entity2end , and guanethidine without unexpected adverse interactions . 
false chemical chemical entity1begin Pindolol entity1end has been used with a variety of antihypertensive agents , including hydrochlorothiazide , hydralazine , and entity2begin guanethidine entity2end without unexpected adverse interactions . 
false chemical chemical Pindolol has been used with a variety of entity1begin antihypertensive agents entity1end , including entity2begin hydrochlorothiazide entity2end , hydralazine , and guanethidine without unexpected adverse interactions . 
false chemical chemical Pindolol has been used with a variety of entity1begin antihypertensive agents entity1end , including hydrochlorothiazide , entity2begin hydralazine entity2end , and guanethidine without unexpected adverse interactions . 
false chemical chemical Pindolol has been used with a variety of entity1begin antihypertensive agents entity1end , including hydrochlorothiazide , hydralazine , and entity2begin guanethidine entity2end without unexpected adverse interactions . 
false chemical chemical Pindolol has been used with a variety of antihypertensive agents , including entity1begin hydrochlorothiazide entity1end , entity2begin hydralazine entity2end , and guanethidine without unexpected adverse interactions . 
false chemical chemical Pindolol has been used with a variety of antihypertensive agents , including entity1begin hydrochlorothiazide entity1end , hydralazine , and entity2begin guanethidine entity2end without unexpected adverse interactions . 
false chemical chemical Pindolol has been used with a variety of antihypertensive agents , including hydrochlorothiazide , entity1begin hydralazine entity1end , and entity2begin guanethidine entity2end without unexpected adverse interactions . 
true chemical chemical entity1begin Pindolol entity1end has been shown to increase serum entity2begin thioridazine entity2end levels when both drugs are co - administered . 
true chemical chemical Other entity1begin short - acting beta adrenergic aerosol bronchodilators entity1end should not be used concomitantly with entity2begin MAXAIR AUTOHALER entity2end because they may have additive effects . 
false chemical chemical Although this has not occurred in in vitro studies with entity1begin coumarin - type anticoagulants entity1end , interactions with entity2begin coumarin - type anticoagulants entity2end have been reported with FELDENE since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin - type anticoagulants and other highly protein - bound drugs . 
false chemical chemical Although this has not occurred in in vitro studies with entity1begin coumarin - type anticoagulants entity1end , interactions with coumarin - type anticoagulants have been reported with entity2begin FELDENE entity2end since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin - type anticoagulants and other highly protein - bound drugs . 
false chemical chemical Although this has not occurred in in vitro studies with entity1begin coumarin - type anticoagulants entity1end , interactions with coumarin - type anticoagulants have been reported with FELDENE since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering entity2begin FELDENE entity2end to patients on coumarin - type anticoagulants and other highly protein - bound drugs . 
false chemical chemical Although this has not occurred in in vitro studies with entity1begin coumarin - type anticoagulants entity1end , interactions with coumarin - type anticoagulants have been reported with FELDENE since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on entity2begin coumarin - type anticoagulants entity2end and other highly protein - bound drugs . 
true chemical chemical Although this has not occurred in in vitro studies with coumarin - type anticoagulants , interactions with entity1begin coumarin - type anticoagulants entity1end have been reported with entity2begin FELDENE entity2end since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin - type anticoagulants and other highly protein - bound drugs . 
false chemical chemical Although this has not occurred in in vitro studies with coumarin - type anticoagulants , interactions with entity1begin coumarin - type anticoagulants entity1end have been reported with FELDENE since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering entity2begin FELDENE entity2end to patients on coumarin - type anticoagulants and other highly protein - bound drugs . 
false chemical chemical Although this has not occurred in in vitro studies with coumarin - type anticoagulants , interactions with entity1begin coumarin - type anticoagulants entity1end have been reported with FELDENE since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on entity2begin coumarin - type anticoagulants entity2end and other highly protein - bound drugs . 
false chemical chemical Although this has not occurred in in vitro studies with coumarin - type anticoagulants , interactions with coumarin - type anticoagulants have been reported with entity1begin FELDENE entity1end since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering entity2begin FELDENE entity2end to patients on coumarin - type anticoagulants and other highly protein - bound drugs . 
false chemical chemical Although this has not occurred in in vitro studies with coumarin - type anticoagulants , interactions with coumarin - type anticoagulants have been reported with entity1begin FELDENE entity1end since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on entity2begin coumarin - type anticoagulants entity2end and other highly protein - bound drugs . 
true chemical chemical Although this has not occurred in in vitro studies with coumarin - type anticoagulants , interactions with coumarin - type anticoagulants have been reported with FELDENE since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering entity1begin FELDENE entity1end to patients on entity2begin coumarin - type anticoagulants entity2end and other highly protein - bound drugs . 
false chemical chemical Plasma levels of entity1begin piroxicam entity1end are depressed to approximately 80 % of their normal values when entity2begin FELDENE entity2end is administered in conjunction with aspirin ( 3900 mg / day ) , but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti - inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . 
false chemical chemical Plasma levels of entity1begin piroxicam entity1end are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with entity2begin aspirin entity2end ( 3900 mg / day ) , but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti - inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . 
false chemical chemical Plasma levels of entity1begin piroxicam entity1end are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with aspirin ( 3900 mg / day ) , but concomitant administration of entity2begin antacids entity2end has no effect on piroxicam plasma levels . Nonsteroidal anti - inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . 
false chemical chemical Plasma levels of entity1begin piroxicam entity1end are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with aspirin ( 3900 mg / day ) , but concomitant administration of antacids has no effect on entity2begin piroxicam entity2end plasma levels . Nonsteroidal anti - inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . 
false chemical chemical Plasma levels of entity1begin piroxicam entity1end are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with aspirin ( 3900 mg / day ) , but concomitant administration of antacids has no effect on piroxicam plasma levels . entity2begin Nonsteroidal anti - inflammatory agents entity2end , including FELDENE , have been reported to increase steady state plasma lithium levels . 
false chemical chemical Plasma levels of entity1begin piroxicam entity1end are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with aspirin ( 3900 mg / day ) , but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti - inflammatory agents , including entity2begin FELDENE entity2end , have been reported to increase steady state plasma lithium levels . 
false chemical chemical Plasma levels of entity1begin piroxicam entity1end are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with aspirin ( 3900 mg / day ) , but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti - inflammatory agents , including FELDENE , have been reported to increase steady state plasma entity2begin lithium entity2end levels . 
true chemical chemical Plasma levels of piroxicam are depressed to approximately 80 % of their normal values when entity1begin FELDENE entity1end is administered in conjunction with entity2begin aspirin entity2end ( 3900 mg / day ) , but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti - inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . 
false chemical chemical Plasma levels of piroxicam are depressed to approximately 80 % of their normal values when entity1begin FELDENE entity1end is administered in conjunction with aspirin ( 3900 mg / day ) , but concomitant administration of entity2begin antacids entity2end has no effect on piroxicam plasma levels . Nonsteroidal anti - inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . 
false chemical chemical Plasma levels of piroxicam are depressed to approximately 80 % of their normal values when entity1begin FELDENE entity1end is administered in conjunction with aspirin ( 3900 mg / day ) , but concomitant administration of antacids has no effect on entity2begin piroxicam entity2end plasma levels . Nonsteroidal anti - inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . 
false chemical chemical Plasma levels of piroxicam are depressed to approximately 80 % of their normal values when entity1begin FELDENE entity1end is administered in conjunction with aspirin ( 3900 mg / day ) , but concomitant administration of antacids has no effect on piroxicam plasma levels . entity2begin Nonsteroidal anti - inflammatory agents entity2end , including FELDENE , have been reported to increase steady state plasma lithium levels . 
false chemical chemical Plasma levels of piroxicam are depressed to approximately 80 % of their normal values when entity1begin FELDENE entity1end is administered in conjunction with aspirin ( 3900 mg / day ) , but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti - inflammatory agents , including entity2begin FELDENE entity2end , have been reported to increase steady state plasma lithium levels . 
false chemical chemical Plasma levels of piroxicam are depressed to approximately 80 % of their normal values when entity1begin FELDENE entity1end is administered in conjunction with aspirin ( 3900 mg / day ) , but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti - inflammatory agents , including FELDENE , have been reported to increase steady state plasma entity2begin lithium entity2end levels . 
false chemical chemical Plasma levels of piroxicam are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with entity1begin aspirin entity1end ( 3900 mg / day ) , but concomitant administration of entity2begin antacids entity2end has no effect on piroxicam plasma levels . Nonsteroidal anti - inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . 
false chemical chemical Plasma levels of piroxicam are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with entity1begin aspirin entity1end ( 3900 mg / day ) , but concomitant administration of antacids has no effect on entity2begin piroxicam entity2end plasma levels . Nonsteroidal anti - inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . 
false chemical chemical Plasma levels of piroxicam are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with entity1begin aspirin entity1end ( 3900 mg / day ) , but concomitant administration of antacids has no effect on piroxicam plasma levels . entity2begin Nonsteroidal anti - inflammatory agents entity2end , including FELDENE , have been reported to increase steady state plasma lithium levels . 
false chemical chemical Plasma levels of piroxicam are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with entity1begin aspirin entity1end ( 3900 mg / day ) , but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti - inflammatory agents , including entity2begin FELDENE entity2end , have been reported to increase steady state plasma lithium levels . 
false chemical chemical Plasma levels of piroxicam are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with entity1begin aspirin entity1end ( 3900 mg / day ) , but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti - inflammatory agents , including FELDENE , have been reported to increase steady state plasma entity2begin lithium entity2end levels . 
false chemical chemical Plasma levels of piroxicam are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with aspirin ( 3900 mg / day ) , but concomitant administration of entity1begin antacids entity1end has no effect on entity2begin piroxicam entity2end plasma levels . Nonsteroidal anti - inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . 
false chemical chemical Plasma levels of piroxicam are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with aspirin ( 3900 mg / day ) , but concomitant administration of entity1begin antacids entity1end has no effect on piroxicam plasma levels . entity2begin Nonsteroidal anti - inflammatory agents entity2end , including FELDENE , have been reported to increase steady state plasma lithium levels . 
false chemical chemical Plasma levels of piroxicam are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with aspirin ( 3900 mg / day ) , but concomitant administration of entity1begin antacids entity1end has no effect on piroxicam plasma levels . Nonsteroidal anti - inflammatory agents , including entity2begin FELDENE entity2end , have been reported to increase steady state plasma lithium levels . 
false chemical chemical Plasma levels of piroxicam are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with aspirin ( 3900 mg / day ) , but concomitant administration of entity1begin antacids entity1end has no effect on piroxicam plasma levels . Nonsteroidal anti - inflammatory agents , including FELDENE , have been reported to increase steady state plasma entity2begin lithium entity2end levels . 
false chemical chemical Plasma levels of piroxicam are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with aspirin ( 3900 mg / day ) , but concomitant administration of antacids has no effect on entity1begin piroxicam entity1end plasma levels . entity2begin Nonsteroidal anti - inflammatory agents entity2end , including FELDENE , have been reported to increase steady state plasma lithium levels . 
false chemical chemical Plasma levels of piroxicam are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with aspirin ( 3900 mg / day ) , but concomitant administration of antacids has no effect on entity1begin piroxicam entity1end plasma levels . Nonsteroidal anti - inflammatory agents , including entity2begin FELDENE entity2end , have been reported to increase steady state plasma lithium levels . 
false chemical chemical Plasma levels of piroxicam are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with aspirin ( 3900 mg / day ) , but concomitant administration of antacids has no effect on entity1begin piroxicam entity1end plasma levels . Nonsteroidal anti - inflammatory agents , including FELDENE , have been reported to increase steady state plasma entity2begin lithium entity2end levels . 
false chemical chemical Plasma levels of piroxicam are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with aspirin ( 3900 mg / day ) , but concomitant administration of antacids has no effect on piroxicam plasma levels . entity1begin Nonsteroidal anti - inflammatory agents entity1end , including entity2begin FELDENE entity2end , have been reported to increase steady state plasma lithium levels . 
true chemical chemical Plasma levels of piroxicam are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with aspirin ( 3900 mg / day ) , but concomitant administration of antacids has no effect on piroxicam plasma levels . entity1begin Nonsteroidal anti - inflammatory agents entity1end , including FELDENE , have been reported to increase steady state plasma entity2begin lithium entity2end levels . 
true chemical chemical Plasma levels of piroxicam are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with aspirin ( 3900 mg / day ) , but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti - inflammatory agents , including entity1begin FELDENE entity1end , have been reported to increase steady state plasma entity2begin lithium entity2end levels . 
true chemical chemical It is recommended that plasma entity1begin lithium entity1end levels be monitored when initiating , adjusting and discontinuing entity2begin FELDENE entity2end . 
true chemical chemical When entity1begin atropine entity1end and entity2begin pralidoxime entity2end are used together , the signs of atropinization ( flushing , mydriasis , tachycardia , dryness of the mouth and nose ) may occur earlier than might be expected when atropine is used alone . 
false chemical chemical When entity1begin atropine entity1end and pralidoxime are used together , the signs of atropinization ( flushing , mydriasis , tachycardia , dryness of the mouth and nose ) may occur earlier than might be expected when entity2begin atropine entity2end is used alone . 
false chemical chemical When atropine and entity1begin pralidoxime entity1end are used together , the signs of atropinization ( flushing , mydriasis , tachycardia , dryness of the mouth and nose ) may occur earlier than might be expected when entity2begin atropine entity2end is used alone . 
false chemical chemical This is especially true if the total dose of entity1begin atropine entity1end has been large and the administration of entity2begin pralidoxime entity2end has been delayed . 
false chemical chemical 2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning , although they do not bear directly on the use of entity1begin pralidoxime entity1end : since entity2begin barbiturates entity2end are potentiated by the anticholinesterases , they should be used cautiously in the treatment of convulsions ; 
false chemical chemical 2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning , although they do not bear directly on the use of entity1begin pralidoxime entity1end : since barbiturates are potentiated by the entity2begin anticholinesterases entity2end , they should be used cautiously in the treatment of convulsions ; 
true chemical chemical 2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning , although they do not bear directly on the use of pralidoxime : since entity1begin barbiturates entity1end are potentiated by the entity2begin anticholinesterases entity2end , they should be used cautiously in the treatment of convulsions ; 
false chemical chemical entity1begin morphine entity1end , entity2begin theophylline entity2end , aminophylline , succinylcholine , reserpine , and phenothiazine - type tranquilizers should be avoided in patients with organophosphate poisoning . 
false chemical chemical entity1begin morphine entity1end , theophylline , entity2begin aminophylline entity2end , succinylcholine , reserpine , and phenothiazine - type tranquilizers should be avoided in patients with organophosphate poisoning . 
false chemical chemical entity1begin morphine entity1end , theophylline , aminophylline , entity2begin succinylcholine entity2end , reserpine , and phenothiazine - type tranquilizers should be avoided in patients with organophosphate poisoning . 
false chemical chemical entity1begin morphine entity1end , theophylline , aminophylline , succinylcholine , entity2begin reserpine entity2end , and phenothiazine - type tranquilizers should be avoided in patients with organophosphate poisoning . 
false chemical chemical entity1begin morphine entity1end , theophylline , aminophylline , succinylcholine , reserpine , and entity2begin phenothiazine - type tranquilizers entity2end should be avoided in patients with organophosphate poisoning . 
false chemical chemical morphine , entity1begin theophylline entity1end , entity2begin aminophylline entity2end , succinylcholine , reserpine , and phenothiazine - type tranquilizers should be avoided in patients with organophosphate poisoning . 
false chemical chemical morphine , entity1begin theophylline entity1end , aminophylline , entity2begin succinylcholine entity2end , reserpine , and phenothiazine - type tranquilizers should be avoided in patients with organophosphate poisoning . 
false chemical chemical morphine , entity1begin theophylline entity1end , aminophylline , succinylcholine , entity2begin reserpine entity2end , and phenothiazine - type tranquilizers should be avoided in patients with organophosphate poisoning . 
false chemical chemical morphine , entity1begin theophylline entity1end , aminophylline , succinylcholine , reserpine , and entity2begin phenothiazine - type tranquilizers entity2end should be avoided in patients with organophosphate poisoning . 
false chemical chemical morphine , theophylline , entity1begin aminophylline entity1end , entity2begin succinylcholine entity2end , reserpine , and phenothiazine - type tranquilizers should be avoided in patients with organophosphate poisoning . 
false chemical chemical morphine , theophylline , entity1begin aminophylline entity1end , succinylcholine , entity2begin reserpine entity2end , and phenothiazine - type tranquilizers should be avoided in patients with organophosphate poisoning . 
false chemical chemical morphine , theophylline , entity1begin aminophylline entity1end , succinylcholine , reserpine , and entity2begin phenothiazine - type tranquilizers entity2end should be avoided in patients with organophosphate poisoning . 
false chemical chemical morphine , theophylline , aminophylline , entity1begin succinylcholine entity1end , entity2begin reserpine entity2end , and phenothiazine - type tranquilizers should be avoided in patients with organophosphate poisoning . 
false chemical chemical morphine , theophylline , aminophylline , entity1begin succinylcholine entity1end , reserpine , and entity2begin phenothiazine - type tranquilizers entity2end should be avoided in patients with organophosphate poisoning . 
false chemical chemical morphine , theophylline , aminophylline , succinylcholine , entity1begin reserpine entity1end , and entity2begin phenothiazine - type tranquilizers entity2end should be avoided in patients with organophosphate poisoning . 
false chemical chemical entity1begin Carbidopa entity1end / entity2begin Levodopa entity2end : Carbidopa / Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers ( N = 10 ) . 
false chemical chemical entity1begin Carbidopa entity1end / Levodopa : entity2begin Carbidopa entity2end / Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers ( N = 10 ) . 
false chemical chemical entity1begin Carbidopa entity1end / Levodopa : Carbidopa / entity2begin Levodopa entity2end does not influence the pharmacokinetics of pramipexole in healthy volunteers ( N = 10 ) . 
false chemical chemical entity1begin Carbidopa entity1end / Levodopa : Carbidopa / Levodopa does not influence the pharmacokinetics of entity2begin pramipexole entity2end in healthy volunteers ( N = 10 ) . 
false chemical chemical Carbidopa / entity1begin Levodopa entity1end : entity2begin Carbidopa entity2end / Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers ( N = 10 ) . 
false chemical chemical Carbidopa / entity1begin Levodopa entity1end : Carbidopa / entity2begin Levodopa entity2end does not influence the pharmacokinetics of pramipexole in healthy volunteers ( N = 10 ) . 
false chemical chemical Carbidopa / entity1begin Levodopa entity1end : Carbidopa / Levodopa does not influence the pharmacokinetics of entity2begin pramipexole entity2end in healthy volunteers ( N = 10 ) . 
false chemical chemical Carbidopa / Levodopa : entity1begin Carbidopa entity1end / entity2begin Levodopa entity2end does not influence the pharmacokinetics of pramipexole in healthy volunteers ( N = 10 ) . 
false chemical chemical Carbidopa / Levodopa : entity1begin Carbidopa entity1end / Levodopa does not influence the pharmacokinetics of entity2begin pramipexole entity2end in healthy volunteers ( N = 10 ) . 
false chemical chemical Carbidopa / Levodopa : Carbidopa / entity1begin Levodopa entity1end does not influence the pharmacokinetics of entity2begin pramipexole entity2end in healthy volunteers ( N = 10 ) . 
false chemical chemical entity1begin Selegiline entity1end : In healthy volunteers ( N = 11 ) , entity2begin selegiline entity2end did not influence the pharmacokinetics of pramipexole . 
false chemical chemical entity1begin Selegiline entity1end : In healthy volunteers ( N = 11 ) , selegiline did not influence the pharmacokinetics of entity2begin pramipexole entity2end . 
false chemical chemical Selegiline : In healthy volunteers ( N = 11 ) , entity1begin selegiline entity1end did not influence the pharmacokinetics of entity2begin pramipexole entity2end . 
false chemical chemical entity1begin Amantadine entity1end : Population pharmacokinetic analysis suggests that entity2begin amantadine entity2end is unlikely to alter the oral clearance of pramipexole ( N = 54 ) . 
false chemical chemical entity1begin Amantadine entity1end : Population pharmacokinetic analysis suggests that amantadine is unlikely to alter the oral clearance of entity2begin pramipexole entity2end ( N = 54 ) . 
false chemical chemical Amantadine : Population pharmacokinetic analysis suggests that entity1begin amantadine entity1end is unlikely to alter the oral clearance of entity2begin pramipexole entity2end ( N = 54 ) . 
false chemical chemical entity1begin Cimetidine entity1end : entity2begin Cimetidine entity2end , a known inhibitor of renal tubular secretion of organic bases via the cationic transport system , caused a 50 % increase in pramipexole AUC and a 40 % increase in half - life ( N = 12 ) . 
false chemical chemical entity1begin Cimetidine entity1end : Cimetidine , a known inhibitor of renal tubular secretion of organic bases via the cationic transport system , caused a 50 % increase in entity2begin pramipexole entity2end AUC and a 40 % increase in half - life ( N = 12 ) . 
true chemical chemical Cimetidine : entity1begin Cimetidine entity1end , a known inhibitor of renal tubular secretion of organic bases via the cationic transport system , caused a 50 % increase in entity2begin pramipexole entity2end AUC and a 40 % increase in half - life ( N = 12 ) . 
false chemical chemical entity1begin Probenecid entity1end : entity2begin Probenecid entity2end , a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter , did not noticeably influence pramipexole pharmacokinetics ( N = 12 ) . 
false chemical chemical entity1begin Probenecid entity1end : Probenecid , a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter , did not noticeably influence entity2begin pramipexole entity2end pharmacokinetics ( N = 12 ) . 
false chemical chemical Probenecid : entity1begin Probenecid entity1end , a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter , did not noticeably influence entity2begin pramipexole entity2end pharmacokinetics ( N = 12 ) . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , entity1begin cimetidine entity1end , entity2begin ranitidine entity2end , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , entity1begin cimetidine entity1end , ranitidine , entity2begin diltiazem entity2end , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , entity1begin cimetidine entity1end , ranitidine , diltiazem , entity2begin triamterene entity2end , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , entity1begin cimetidine entity1end , ranitidine , diltiazem , triamterene , entity2begin verapamil entity2end , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , entity1begin cimetidine entity1end , ranitidine , diltiazem , triamterene , verapamil , entity2begin quinidine entity2end , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , entity1begin cimetidine entity1end , ranitidine , diltiazem , triamterene , verapamil , quinidine , and entity2begin quinine entity2end ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
true chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , entity1begin cimetidine entity1end , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of entity2begin pramipexole entity2end by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , entity1begin cimetidine entity1end , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , entity2begin cephalosporins entity2end , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , entity1begin cimetidine entity1end , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , entity2begin penicillins entity2end , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , entity1begin cimetidine entity1end , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , entity2begin indomethacin entity2end , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , entity1begin cimetidine entity1end , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , entity2begin hydrochlorothiazide entity2end , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , entity1begin cimetidine entity1end , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and entity2begin chlorpropamide entity2end ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , entity1begin cimetidine entity1end , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of entity2begin pramipexole entity2end . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , entity1begin ranitidine entity1end , entity2begin diltiazem entity2end , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , entity1begin ranitidine entity1end , diltiazem , entity2begin triamterene entity2end , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , entity1begin ranitidine entity1end , diltiazem , triamterene , entity2begin verapamil entity2end , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , entity1begin ranitidine entity1end , diltiazem , triamterene , verapamil , entity2begin quinidine entity2end , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , entity1begin ranitidine entity1end , diltiazem , triamterene , verapamil , quinidine , and entity2begin quinine entity2end ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
true chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , entity1begin ranitidine entity1end , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of entity2begin pramipexole entity2end by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , entity1begin ranitidine entity1end , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , entity2begin cephalosporins entity2end , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , entity1begin ranitidine entity1end , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , entity2begin penicillins entity2end , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , entity1begin ranitidine entity1end , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , entity2begin indomethacin entity2end , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , entity1begin ranitidine entity1end , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , entity2begin hydrochlorothiazide entity2end , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , entity1begin ranitidine entity1end , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and entity2begin chlorpropamide entity2end ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , entity1begin ranitidine entity1end , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of entity2begin pramipexole entity2end . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , entity1begin diltiazem entity1end , entity2begin triamterene entity2end , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , entity1begin diltiazem entity1end , triamterene , entity2begin verapamil entity2end , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , entity1begin diltiazem entity1end , triamterene , verapamil , entity2begin quinidine entity2end , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , entity1begin diltiazem entity1end , triamterene , verapamil , quinidine , and entity2begin quinine entity2end ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
true chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , entity1begin diltiazem entity1end , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of entity2begin pramipexole entity2end by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , entity1begin diltiazem entity1end , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , entity2begin cephalosporins entity2end , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , entity1begin diltiazem entity1end , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , entity2begin penicillins entity2end , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , entity1begin diltiazem entity1end , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , entity2begin indomethacin entity2end , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , entity1begin diltiazem entity1end , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , entity2begin hydrochlorothiazide entity2end , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , entity1begin diltiazem entity1end , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and entity2begin chlorpropamide entity2end ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , entity1begin diltiazem entity1end , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of entity2begin pramipexole entity2end . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , entity1begin triamterene entity1end , entity2begin verapamil entity2end , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , entity1begin triamterene entity1end , verapamil , entity2begin quinidine entity2end , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , entity1begin triamterene entity1end , verapamil , quinidine , and entity2begin quinine entity2end ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
true chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , entity1begin triamterene entity1end , verapamil , quinidine , and quinine ) decreases the oral clearance of entity2begin pramipexole entity2end by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , entity1begin triamterene entity1end , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , entity2begin cephalosporins entity2end , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , entity1begin triamterene entity1end , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , entity2begin penicillins entity2end , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , entity1begin triamterene entity1end , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , entity2begin indomethacin entity2end , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , entity1begin triamterene entity1end , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , entity2begin hydrochlorothiazide entity2end , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , entity1begin triamterene entity1end , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and entity2begin chlorpropamide entity2end ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , entity1begin triamterene entity1end , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of entity2begin pramipexole entity2end . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , entity1begin verapamil entity1end , entity2begin quinidine entity2end , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , entity1begin verapamil entity1end , quinidine , and entity2begin quinine entity2end ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
true chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , entity1begin verapamil entity1end , quinidine , and quinine ) decreases the oral clearance of entity2begin pramipexole entity2end by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , entity1begin verapamil entity1end , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , entity2begin cephalosporins entity2end , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , entity1begin verapamil entity1end , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , entity2begin penicillins entity2end , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , entity1begin verapamil entity1end , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , entity2begin indomethacin entity2end , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , entity1begin verapamil entity1end , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , entity2begin hydrochlorothiazide entity2end , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , entity1begin verapamil entity1end , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and entity2begin chlorpropamide entity2end ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , entity1begin verapamil entity1end , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of entity2begin pramipexole entity2end . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , entity1begin quinidine entity1end , and entity2begin quinine entity2end ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
true chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , entity1begin quinidine entity1end , and quinine ) decreases the oral clearance of entity2begin pramipexole entity2end by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , entity1begin quinidine entity1end , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , entity2begin cephalosporins entity2end , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , entity1begin quinidine entity1end , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , entity2begin penicillins entity2end , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , entity1begin quinidine entity1end , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , entity2begin indomethacin entity2end , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , entity1begin quinidine entity1end , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , entity2begin hydrochlorothiazide entity2end , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , entity1begin quinidine entity1end , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and entity2begin chlorpropamide entity2end ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , entity1begin quinidine entity1end , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of entity2begin pramipexole entity2end . 
true chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and entity1begin quinine entity1end ) decreases the oral clearance of entity2begin pramipexole entity2end by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and entity1begin quinine entity1end ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , entity2begin cephalosporins entity2end , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and entity1begin quinine entity1end ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , entity2begin penicillins entity2end , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and entity1begin quinine entity1end ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , entity2begin indomethacin entity2end , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and entity1begin quinine entity1end ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , entity2begin hydrochlorothiazide entity2end , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and entity1begin quinine entity1end ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and entity2begin chlorpropamide entity2end ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and entity1begin quinine entity1end ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of entity2begin pramipexole entity2end . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of entity1begin pramipexole entity1end by about 20 % , while those secreted by the anionic transport system ( e.g. , entity2begin cephalosporins entity2end , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of entity1begin pramipexole entity1end by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , entity2begin penicillins entity2end , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of entity1begin pramipexole entity1end by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , entity2begin indomethacin entity2end , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of entity1begin pramipexole entity1end by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , entity2begin hydrochlorothiazide entity2end , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of entity1begin pramipexole entity1end by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and entity2begin chlorpropamide entity2end ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of entity1begin pramipexole entity1end by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of entity2begin pramipexole entity2end . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , entity1begin cephalosporins entity1end , entity2begin penicillins entity2end , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , entity1begin cephalosporins entity1end , penicillins , entity2begin indomethacin entity2end , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , entity1begin cephalosporins entity1end , penicillins , indomethacin , entity2begin hydrochlorothiazide entity2end , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , entity1begin cephalosporins entity1end , penicillins , indomethacin , hydrochlorothiazide , and entity2begin chlorpropamide entity2end ) are likely to have little effect on the oral clearance of pramipexole . 
true chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , entity1begin cephalosporins entity1end , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of entity2begin pramipexole entity2end . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , entity1begin penicillins entity1end , entity2begin indomethacin entity2end , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , entity1begin penicillins entity1end , indomethacin , entity2begin hydrochlorothiazide entity2end , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , entity1begin penicillins entity1end , indomethacin , hydrochlorothiazide , and entity2begin chlorpropamide entity2end ) are likely to have little effect on the oral clearance of pramipexole . 
true chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , entity1begin penicillins entity1end , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of entity2begin pramipexole entity2end . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , entity1begin indomethacin entity1end , entity2begin hydrochlorothiazide entity2end , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , entity1begin indomethacin entity1end , hydrochlorothiazide , and entity2begin chlorpropamide entity2end ) are likely to have little effect on the oral clearance of pramipexole . 
true chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , entity1begin indomethacin entity1end , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of entity2begin pramipexole entity2end . 
false chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , entity1begin hydrochlorothiazide entity1end , and entity2begin chlorpropamide entity2end ) are likely to have little effect on the oral clearance of pramipexole . 
true chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , entity1begin hydrochlorothiazide entity1end , and chlorpropamide ) are likely to have little effect on the oral clearance of entity2begin pramipexole entity2end . 
true chemical chemical Other drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and entity1begin chlorpropamide entity1end ) are likely to have little effect on the oral clearance of entity2begin pramipexole entity2end . 
false chemical chemical CYP interactions : Inhibitors of cytochrome P450 enzymes would not be expected to affect entity1begin pramipexole entity1end elimination because entity2begin pramipexole entity2end is not appreciably metabolized by these enzymes in vivo or in vitro . 
false chemical chemical entity1begin Dopamine antagonists entity1end : Since entity2begin pramipexole entity2end is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of MIRAPEX . 
false chemical chemical entity1begin Dopamine antagonists entity1end : Since pramipexole is a entity2begin dopamine agonist entity2end , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of MIRAPEX . 
false chemical chemical entity1begin Dopamine antagonists entity1end : Since pramipexole is a dopamine agonist , it is possible that entity2begin dopamine antagonists entity2end , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of MIRAPEX . 
false chemical chemical entity1begin Dopamine antagonists entity1end : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the entity2begin neuroleptics entity2end ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of MIRAPEX . 
false chemical chemical entity1begin Dopamine antagonists entity1end : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( entity2begin phenothiazines entity2end , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of MIRAPEX . 
false chemical chemical entity1begin Dopamine antagonists entity1end : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , entity2begin butyrophenones entity2end , thioxanthenes ) or metoclopramide , may diminish the effectiveness of MIRAPEX . 
false chemical chemical entity1begin Dopamine antagonists entity1end : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , entity2begin thioxanthenes entity2end ) or metoclopramide , may diminish the effectiveness of MIRAPEX . 
false chemical chemical entity1begin Dopamine antagonists entity1end : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or entity2begin metoclopramide entity2end , may diminish the effectiveness of MIRAPEX . 
false chemical chemical entity1begin Dopamine antagonists entity1end : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of entity2begin MIRAPEX entity2end . 
false chemical chemical Dopamine antagonists : Since entity1begin pramipexole entity1end is a entity2begin dopamine agonist entity2end , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of MIRAPEX . 
false chemical chemical Dopamine antagonists : Since entity1begin pramipexole entity1end is a dopamine agonist , it is possible that entity2begin dopamine antagonists entity2end , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of MIRAPEX . 
false chemical chemical Dopamine antagonists : Since entity1begin pramipexole entity1end is a dopamine agonist , it is possible that dopamine antagonists , such as the entity2begin neuroleptics entity2end ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of MIRAPEX . 
false chemical chemical Dopamine antagonists : Since entity1begin pramipexole entity1end is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( entity2begin phenothiazines entity2end , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of MIRAPEX . 
false chemical chemical Dopamine antagonists : Since entity1begin pramipexole entity1end is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , entity2begin butyrophenones entity2end , thioxanthenes ) or metoclopramide , may diminish the effectiveness of MIRAPEX . 
false chemical chemical Dopamine antagonists : Since entity1begin pramipexole entity1end is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , entity2begin thioxanthenes entity2end ) or metoclopramide , may diminish the effectiveness of MIRAPEX . 
false chemical chemical Dopamine antagonists : Since entity1begin pramipexole entity1end is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or entity2begin metoclopramide entity2end , may diminish the effectiveness of MIRAPEX . 
false chemical chemical Dopamine antagonists : Since entity1begin pramipexole entity1end is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of entity2begin MIRAPEX entity2end . 
false chemical chemical Dopamine antagonists : Since pramipexole is a entity1begin dopamine agonist entity1end , it is possible that entity2begin dopamine antagonists entity2end , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of MIRAPEX . 
false chemical chemical Dopamine antagonists : Since pramipexole is a entity1begin dopamine agonist entity1end , it is possible that dopamine antagonists , such as the entity2begin neuroleptics entity2end ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of MIRAPEX . 
false chemical chemical Dopamine antagonists : Since pramipexole is a entity1begin dopamine agonist entity1end , it is possible that dopamine antagonists , such as the neuroleptics ( entity2begin phenothiazines entity2end , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of MIRAPEX . 
false chemical chemical Dopamine antagonists : Since pramipexole is a entity1begin dopamine agonist entity1end , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , entity2begin butyrophenones entity2end , thioxanthenes ) or metoclopramide , may diminish the effectiveness of MIRAPEX . 
false chemical chemical Dopamine antagonists : Since pramipexole is a entity1begin dopamine agonist entity1end , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , entity2begin thioxanthenes entity2end ) or metoclopramide , may diminish the effectiveness of MIRAPEX . 
false chemical chemical Dopamine antagonists : Since pramipexole is a entity1begin dopamine agonist entity1end , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or entity2begin metoclopramide entity2end , may diminish the effectiveness of MIRAPEX . 
false chemical chemical Dopamine antagonists : Since pramipexole is a entity1begin dopamine agonist entity1end , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of entity2begin MIRAPEX entity2end . 
false chemical chemical Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that entity1begin dopamine antagonists entity1end , such as the entity2begin neuroleptics entity2end ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of MIRAPEX . 
false chemical chemical Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that entity1begin dopamine antagonists entity1end , such as the neuroleptics ( entity2begin phenothiazines entity2end , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of MIRAPEX . 
false chemical chemical Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that entity1begin dopamine antagonists entity1end , such as the neuroleptics ( phenothiazines , entity2begin butyrophenones entity2end , thioxanthenes ) or metoclopramide , may diminish the effectiveness of MIRAPEX . 
false chemical chemical Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that entity1begin dopamine antagonists entity1end , such as the neuroleptics ( phenothiazines , butyrophenones , entity2begin thioxanthenes entity2end ) or metoclopramide , may diminish the effectiveness of MIRAPEX . 
false chemical chemical Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that entity1begin dopamine antagonists entity1end , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or entity2begin metoclopramide entity2end , may diminish the effectiveness of MIRAPEX . 
true chemical chemical Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that entity1begin dopamine antagonists entity1end , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of entity2begin MIRAPEX entity2end . 
false chemical chemical Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the entity1begin neuroleptics entity1end ( entity2begin phenothiazines entity2end , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of MIRAPEX . 
false chemical chemical Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the entity1begin neuroleptics entity1end ( phenothiazines , entity2begin butyrophenones entity2end , thioxanthenes ) or metoclopramide , may diminish the effectiveness of MIRAPEX . 
false chemical chemical Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the entity1begin neuroleptics entity1end ( phenothiazines , butyrophenones , entity2begin thioxanthenes entity2end ) or metoclopramide , may diminish the effectiveness of MIRAPEX . 
false chemical chemical Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the entity1begin neuroleptics entity1end ( phenothiazines , butyrophenones , thioxanthenes ) or entity2begin metoclopramide entity2end , may diminish the effectiveness of MIRAPEX . 
true chemical chemical Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the entity1begin neuroleptics entity1end ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of entity2begin MIRAPEX entity2end . 
false chemical chemical Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( entity1begin phenothiazines entity1end , entity2begin butyrophenones entity2end , thioxanthenes ) or metoclopramide , may diminish the effectiveness of MIRAPEX . 
false chemical chemical Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( entity1begin phenothiazines entity1end , butyrophenones , entity2begin thioxanthenes entity2end ) or metoclopramide , may diminish the effectiveness of MIRAPEX . 
false chemical chemical Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( entity1begin phenothiazines entity1end , butyrophenones , thioxanthenes ) or entity2begin metoclopramide entity2end , may diminish the effectiveness of MIRAPEX . 
true chemical chemical Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( entity1begin phenothiazines entity1end , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of entity2begin MIRAPEX entity2end . 
false chemical chemical Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , entity1begin butyrophenones entity1end , entity2begin thioxanthenes entity2end ) or metoclopramide , may diminish the effectiveness of MIRAPEX . 
false chemical chemical Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , entity1begin butyrophenones entity1end , thioxanthenes ) or entity2begin metoclopramide entity2end , may diminish the effectiveness of MIRAPEX . 
true chemical chemical Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , entity1begin butyrophenones entity1end , thioxanthenes ) or metoclopramide , may diminish the effectiveness of entity2begin MIRAPEX entity2end . 
false chemical chemical Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , entity1begin thioxanthenes entity1end ) or entity2begin metoclopramide entity2end , may diminish the effectiveness of MIRAPEX . 
true chemical chemical Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , entity1begin thioxanthenes entity1end ) or metoclopramide , may diminish the effectiveness of entity2begin MIRAPEX entity2end . 
true chemical chemical Dopamine antagonists : Since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or entity1begin metoclopramide entity1end , may diminish the effectiveness of entity2begin MIRAPEX entity2end . 
true chemical chemical Due to its effects on gastric emptying , entity1begin SYMLIN entity1end therapy should not be considered for patients taking drugs that alter gastrointestinal motility ( e.g. , entity2begin anticholinergic agents entity2end such as atropine ) and agents that slow the intestinal absorption of nutrients ( e.g. , alpha glucosidase inhibitors ) . 
true chemical chemical Due to its effects on gastric emptying , entity1begin SYMLIN entity1end therapy should not be considered for patients taking drugs that alter gastrointestinal motility ( e.g. , anticholinergic agents such as entity2begin atropine entity2end ) and agents that slow the intestinal absorption of nutrients ( e.g. , alpha glucosidase inhibitors ) . 
true chemical chemical Due to its effects on gastric emptying , entity1begin SYMLIN entity1end therapy should not be considered for patients taking drugs that alter gastrointestinal motility ( e.g. , anticholinergic agents such as atropine ) and agents that slow the intestinal absorption of nutrients ( e.g. , entity2begin alpha glucosidase inhibitors entity2end ) . 
false chemical chemical Due to its effects on gastric emptying , SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility ( e.g. , entity1begin anticholinergic agents entity1end such as entity2begin atropine entity2end ) and agents that slow the intestinal absorption of nutrients ( e.g. , alpha glucosidase inhibitors ) . 
false chemical chemical Due to its effects on gastric emptying , SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility ( e.g. , entity1begin anticholinergic agents entity1end such as atropine ) and agents that slow the intestinal absorption of nutrients ( e.g. , entity2begin alpha glucosidase inhibitors entity2end ) . 
false chemical chemical Due to its effects on gastric emptying , SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility ( e.g. , anticholinergic agents such as entity1begin atropine entity1end ) and agents that slow the intestinal absorption of nutrients ( e.g. , entity2begin alpha glucosidase inhibitors entity2end ) . 
true chemical chemical When the rapid onset of a concomitant orally administered agent is a critical determinant of effectiveness ( such as entity1begin analgesics entity1end ) , the agent should be administered at least 1 hour prior to or 2 hours after entity2begin SYMLIN entity2end injection . 
false chemical chemical In clinical trials , the concomitant use of entity1begin sulfonylureas entity1end or entity2begin biguanides entity2end did not alter the adverse event profile of SYMLIN . 
false chemical chemical In clinical trials , the concomitant use of entity1begin sulfonylureas entity1end or biguanides did not alter the adverse event profile of entity2begin SYMLIN entity2end . 
false chemical chemical In clinical trials , the concomitant use of sulfonylureas or entity1begin biguanides entity1end did not alter the adverse event profile of entity2begin SYMLIN entity2end . 
false chemical chemical No formal interaction studies have been performed to assess the effect of entity1begin SYMLIN entity1end on the kinetics of oral entity2begin antidiabetic agents entity2end . 
false chemical chemical Mixing entity1begin SYMLIN entity1end and entity2begin Insulin entity2end The pharmacokinetic parameters of SYMLIN were altered when mixed with regular , NPH , and 70 / 30 premixed formulations of recombinant human insulin immediately prior to injection . 
false chemical chemical Mixing entity1begin SYMLIN entity1end and Insulin The pharmacokinetic parameters of entity2begin SYMLIN entity2end were altered when mixed with regular , NPH , and 70 / 30 premixed formulations of recombinant human insulin immediately prior to injection . 
false chemical chemical Mixing entity1begin SYMLIN entity1end and Insulin The pharmacokinetic parameters of SYMLIN were altered when mixed with regular , NPH , and 70 / 30 premixed formulations of recombinant entity2begin human insulin entity2end immediately prior to injection . 
false chemical chemical Mixing SYMLIN and entity1begin Insulin entity1end The pharmacokinetic parameters of entity2begin SYMLIN entity2end were altered when mixed with regular , NPH , and 70 / 30 premixed formulations of recombinant human insulin immediately prior to injection . 
false chemical chemical Mixing SYMLIN and entity1begin Insulin entity1end The pharmacokinetic parameters of SYMLIN were altered when mixed with regular , NPH , and 70 / 30 premixed formulations of recombinant entity2begin human insulin entity2end immediately prior to injection . 
true chemical chemical Mixing SYMLIN and Insulin The pharmacokinetic parameters of entity1begin SYMLIN entity1end were altered when mixed with regular , NPH , and 70 / 30 premixed formulations of recombinant entity2begin human insulin entity2end immediately prior to injection . 
false chemical chemical Thus , entity1begin SYMLIN entity1end and entity2begin insulin entity2end should not be mixed and must be administered separately . 
false chemical chemical Drugs that induce hepatic enzymes such as entity1begin phenobarbital entity1end , entity2begin phenytoin entity2end and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response . 
false chemical chemical Drugs that induce hepatic enzymes such as entity1begin phenobarbital entity1end , phenytoin and entity2begin rifampin entity2end may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response . 
true chemical chemical Drugs that induce hepatic enzymes such as entity1begin phenobarbital entity1end , phenytoin and rifampin may increase the clearance of entity2begin corticosteroids entity2end and may require increases in corticosteroid dose to achieve the desired response . 
true chemical chemical Drugs that induce hepatic enzymes such as entity1begin phenobarbital entity1end , phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in entity2begin corticosteroid entity2end dose to achieve the desired response . 
false chemical chemical Drugs that induce hepatic enzymes such as phenobarbital , entity1begin phenytoin entity1end and entity2begin rifampin entity2end may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response . 
true chemical chemical Drugs that induce hepatic enzymes such as phenobarbital , entity1begin phenytoin entity1end and rifampin may increase the clearance of entity2begin corticosteroids entity2end and may require increases in corticosteroid dose to achieve the desired response . 
true chemical chemical Drugs that induce hepatic enzymes such as phenobarbital , entity1begin phenytoin entity1end and rifampin may increase the clearance of corticosteroids and may require increases in entity2begin corticosteroid entity2end dose to achieve the desired response . 
true chemical chemical Drugs that induce hepatic enzymes such as phenobarbital , phenytoin and entity1begin rifampin entity1end may increase the clearance of entity2begin corticosteroids entity2end and may require increases in corticosteroid dose to achieve the desired response . 
true chemical chemical Drugs that induce hepatic enzymes such as phenobarbital , phenytoin and entity1begin rifampin entity1end may increase the clearance of corticosteroids and may require increases in entity2begin corticosteroid entity2end dose to achieve the desired response . 
false chemical chemical Drugs that induce hepatic enzymes such as phenobarbital , phenytoin and rifampin may increase the clearance of entity1begin corticosteroids entity1end and may require increases in entity2begin corticosteroid entity2end dose to achieve the desired response . 
false chemical chemical Drugs such as entity1begin troleandomycin entity1end and entity2begin ketoconazole entity2end may inhibit the metabolism of corticosteroids and thus decrease their clearance . 
true chemical chemical Drugs such as entity1begin troleandomycin entity1end and ketoconazole may inhibit the metabolism of entity2begin corticosteroids entity2end and thus decrease their clearance . 
true chemical chemical Drugs such as troleandomycin and entity1begin ketoconazole entity1end may inhibit the metabolism of entity2begin corticosteroids entity2end and thus decrease their clearance . 
true chemical chemical entity1begin Corticosteroids entity1end may increase the clearance of chronic high dose entity2begin aspirin entity2end . 
false chemical chemical This could lead to decreased entity1begin salicylate entity1end serum levels or increase the risk of entity2begin salicylate entity2end toxicity when corticosteroid is withdrawn . 
false chemical chemical This could lead to decreased entity1begin salicylate entity1end serum levels or increase the risk of salicylate toxicity when entity2begin corticosteroid entity2end is withdrawn . 
true chemical chemical This could lead to decreased salicylate serum levels or increase the risk of entity1begin salicylate entity1end toxicity when entity2begin corticosteroid entity2end is withdrawn . 
true chemical chemical entity1begin Aspirin entity1end should be used cautiously in conjunction with entity2begin corticosteroids entity2end in patients suffering from hypoprothrombinemia . 
true chemical chemical The effect of entity1begin corticosteroids entity1end on oral entity2begin anticoagulants entity2end is variable . 
true chemical chemical There are reports of enhanced as well as diminished effects of entity1begin anticoagulants entity1end when given concurrently with entity2begin corticosteroids entity2end . 
false chemical chemical entity1begin Anticholinesterases entity1end : Concurrent use of entity2begin procaine hydrochloride entity2end and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride . 
false chemical chemical entity1begin Anticholinesterases entity1end : Concurrent use of procaine hydrochloride and entity2begin anticholinesterase agents entity2end may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride . 
false chemical chemical entity1begin Anticholinesterases entity1end : Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since entity2begin anticholinesterases entity2end inhibit the breakdown of procaine hydrochloride . 
false chemical chemical entity1begin Anticholinesterases entity1end : Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of entity2begin procaine hydrochloride entity2end . 
true chemical chemical Anticholinesterases : Concurrent use of entity1begin procaine hydrochloride entity1end and entity2begin anticholinesterase agents entity2end may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride . 
false chemical chemical Anticholinesterases : Concurrent use of entity1begin procaine hydrochloride entity1end and anticholinesterase agents may result in increased systemic toxicity since entity2begin anticholinesterases entity2end inhibit the breakdown of procaine hydrochloride . 
false chemical chemical Anticholinesterases : Concurrent use of entity1begin procaine hydrochloride entity1end and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of entity2begin procaine hydrochloride entity2end . 
false chemical chemical Anticholinesterases : Concurrent use of procaine hydrochloride and entity1begin anticholinesterase agents entity1end may result in increased systemic toxicity since entity2begin anticholinesterases entity2end inhibit the breakdown of procaine hydrochloride . 
false chemical chemical Anticholinesterases : Concurrent use of procaine hydrochloride and entity1begin anticholinesterase agents entity1end may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of entity2begin procaine hydrochloride entity2end . 
true chemical chemical Anticholinesterases : Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since entity1begin anticholinesterases entity1end inhibit the breakdown of entity2begin procaine hydrochloride entity2end . 
false chemical chemical entity1begin CNS depressant entity1end medications : Concurrent use of entity2begin procaine hydrochloride entity2end and CNS depressant medications may result in additive depressant effects . 
false chemical chemical entity1begin CNS depressant entity1end medications : Concurrent use of procaine hydrochloride and entity2begin CNS depressant medications entity2end may result in additive depressant effects . 
true chemical chemical CNS depressant medications : Concurrent use of entity1begin procaine hydrochloride entity1end and entity2begin CNS depressant medications entity2end may result in additive depressant effects . 
false chemical chemical entity1begin Hyaluronidase entity1end : entity2begin Hyaluronidase entity2end may increase the diffusion rate of procaine hydrochloride , resulting in a decreased time of onset , but an increase in systemic toxicity . 
false chemical chemical entity1begin Hyaluronidase entity1end : Hyaluronidase may increase the diffusion rate of entity2begin procaine hydrochloride entity2end , resulting in a decreased time of onset , but an increase in systemic toxicity . 
true chemical chemical Hyaluronidase : entity1begin Hyaluronidase entity1end may increase the diffusion rate of entity2begin procaine hydrochloride entity2end , resulting in a decreased time of onset , but an increase in systemic toxicity . 
false chemical chemical entity1begin Neuromuscular blocking agents entity1end ( such as entity2begin suxamethonium chloride entity2end ) : Concurrent use of procaine hydrochloride and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade . 
false chemical chemical entity1begin Neuromuscular blocking agents entity1end ( such as suxamethonium chloride ) : Concurrent use of entity2begin procaine hydrochloride entity2end and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade . 
false chemical chemical entity1begin Neuromuscular blocking agents entity1end ( such as suxamethonium chloride ) : Concurrent use of procaine hydrochloride and entity2begin neuromuscular blocking agents entity2end may result in prolongation or enhancement of the neuromuscular blockade . 
false chemical chemical Neuromuscular blocking agents ( such as entity1begin suxamethonium chloride entity1end ) : Concurrent use of entity2begin procaine hydrochloride entity2end and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade . 
false chemical chemical Neuromuscular blocking agents ( such as entity1begin suxamethonium chloride entity1end ) : Concurrent use of procaine hydrochloride and entity2begin neuromuscular blocking agents entity2end may result in prolongation or enhancement of the neuromuscular blockade . 
true chemical chemical Neuromuscular blocking agents ( such as suxamethonium chloride ) : Concurrent use of entity1begin procaine hydrochloride entity1end and entity2begin neuromuscular blocking agents entity2end may result in prolongation or enhancement of the neuromuscular blockade . 
false chemical chemical entity1begin Sulfonamides entity1end : Concurrent use of entity2begin procaine hydrochloride entity2end and sulfonamides may result in a reduction of the antibacterial action of the sulfonamide . 
false chemical chemical entity1begin Sulfonamides entity1end : Concurrent use of procaine hydrochloride and entity2begin sulfonamides entity2end may result in a reduction of the antibacterial action of the sulfonamide . 
false chemical chemical entity1begin Sulfonamides entity1end : Concurrent use of procaine hydrochloride and sulfonamides may result in a reduction of the antibacterial action of the entity2begin sulfonamide entity2end . 
true chemical chemical Sulfonamides : Concurrent use of entity1begin procaine hydrochloride entity1end and entity2begin sulfonamides entity2end may result in a reduction of the antibacterial action of the sulfonamide . 
false chemical chemical Sulfonamides : Concurrent use of entity1begin procaine hydrochloride entity1end and sulfonamides may result in a reduction of the antibacterial action of the entity2begin sulfonamide entity2end . 
false chemical chemical Sulfonamides : Concurrent use of procaine hydrochloride and entity1begin sulfonamides entity1end may result in a reduction of the antibacterial action of the entity2begin sulfonamide entity2end . 
false chemical chemical entity1begin Acetazolamide entity1end : Concurrent use of entity2begin acetazolamide entity2end and procaine hydrochloride may extend the plasma half - life of procaine . 
false chemical chemical entity1begin Acetazolamide entity1end : Concurrent use of acetazolamide and entity2begin procaine hydrochloride entity2end may extend the plasma half - life of procaine . 
false chemical chemical entity1begin Acetazolamide entity1end : Concurrent use of acetazolamide and procaine hydrochloride may extend the plasma half - life of entity2begin procaine entity2end . 
true chemical chemical Acetazolamide : Concurrent use of entity1begin acetazolamide entity1end and entity2begin procaine hydrochloride entity2end may extend the plasma half - life of procaine . 
false chemical chemical Acetazolamide : Concurrent use of entity1begin acetazolamide entity1end and procaine hydrochloride may extend the plasma half - life of entity2begin procaine entity2end . 
false chemical chemical Acetazolamide : Concurrent use of acetazolamide and entity1begin procaine hydrochloride entity1end may extend the plasma half - life of entity2begin procaine entity2end . 
false chemical chemical To minimize CNS depression and possible potentiation , entity1begin barbiturates entity1end , entity2begin antihistamines entity2end , narcotics , hypotensive agents or phenothiazines should be used with caution . 
false chemical chemical To minimize CNS depression and possible potentiation , entity1begin barbiturates entity1end , antihistamines , entity2begin narcotics entity2end , hypotensive agents or phenothiazines should be used with caution . 
false chemical chemical To minimize CNS depression and possible potentiation , entity1begin barbiturates entity1end , antihistamines , narcotics , entity2begin hypotensive agents entity2end or phenothiazines should be used with caution . 
false chemical chemical To minimize CNS depression and possible potentiation , entity1begin barbiturates entity1end , antihistamines , narcotics , hypotensive agents or entity2begin phenothiazines entity2end should be used with caution . 
false chemical chemical To minimize CNS depression and possible potentiation , barbiturates , entity1begin antihistamines entity1end , entity2begin narcotics entity2end , hypotensive agents or phenothiazines should be used with caution . 
false chemical chemical To minimize CNS depression and possible potentiation , barbiturates , entity1begin antihistamines entity1end , narcotics , entity2begin hypotensive agents entity2end or phenothiazines should be used with caution . 
false chemical chemical To minimize CNS depression and possible potentiation , barbiturates , entity1begin antihistamines entity1end , narcotics , hypotensive agents or entity2begin phenothiazines entity2end should be used with caution . 
false chemical chemical To minimize CNS depression and possible potentiation , barbiturates , antihistamines , entity1begin narcotics entity1end , entity2begin hypotensive agents entity2end or phenothiazines should be used with caution . 
false chemical chemical To minimize CNS depression and possible potentiation , barbiturates , antihistamines , entity1begin narcotics entity1end , hypotensive agents or entity2begin phenothiazines entity2end should be used with caution . 
false chemical chemical To minimize CNS depression and possible potentiation , barbiturates , antihistamines , narcotics , entity1begin hypotensive agents entity1end or entity2begin phenothiazines entity2end should be used with caution . 
true chemical chemical Because entity1begin Matulane entity1end exhibits some monoamine oxidase inhibitory activity , entity2begin sympathomimetic drugs entity2end , tricyclic antidepressant drugs ( e.g. , amitriptyline HCl , imipramine HCl ) and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided . 
true chemical chemical Because entity1begin Matulane entity1end exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , entity2begin tricyclic antidepressant entity2end drugs ( e.g. , amitriptyline HCl , imipramine HCl ) and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided . 
true chemical chemical Because entity1begin Matulane entity1end exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs ( e.g. , entity2begin amitriptyline HCl entity2end , imipramine HCl ) and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided . 
true chemical chemical Because entity1begin Matulane entity1end exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs ( e.g. , amitriptyline HCl , entity2begin imipramine HCl entity2end ) and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided . 
true chemical chemical Because entity1begin Matulane entity1end exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs ( e.g. , amitriptyline HCl , imipramine HCl ) and other drugs and foods with known high entity2begin tyramine entity2end content , such as wine , yogurt , ripe cheese and bananas , should be avoided . 
false chemical chemical Because Matulane exhibits some monoamine oxidase inhibitory activity , entity1begin sympathomimetic drugs entity1end , entity2begin tricyclic antidepressant entity2end drugs ( e.g. , amitriptyline HCl , imipramine HCl ) and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided . 
false chemical chemical Because Matulane exhibits some monoamine oxidase inhibitory activity , entity1begin sympathomimetic drugs entity1end , tricyclic antidepressant drugs ( e.g. , entity2begin amitriptyline HCl entity2end , imipramine HCl ) and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided . 
false chemical chemical Because Matulane exhibits some monoamine oxidase inhibitory activity , entity1begin sympathomimetic drugs entity1end , tricyclic antidepressant drugs ( e.g. , amitriptyline HCl , entity2begin imipramine HCl entity2end ) and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided . 
false chemical chemical Because Matulane exhibits some monoamine oxidase inhibitory activity , entity1begin sympathomimetic drugs entity1end , tricyclic antidepressant drugs ( e.g. , amitriptyline HCl , imipramine HCl ) and other drugs and foods with known high entity2begin tyramine entity2end content , such as wine , yogurt , ripe cheese and bananas , should be avoided . 
false chemical chemical Because Matulane exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , entity1begin tricyclic antidepressant entity1end drugs ( e.g. , entity2begin amitriptyline HCl entity2end , imipramine HCl ) and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided . 
false chemical chemical Because Matulane exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , entity1begin tricyclic antidepressant entity1end drugs ( e.g. , amitriptyline HCl , entity2begin imipramine HCl entity2end ) and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided . 
false chemical chemical Because Matulane exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , entity1begin tricyclic antidepressant entity1end drugs ( e.g. , amitriptyline HCl , imipramine HCl ) and other drugs and foods with known high entity2begin tyramine entity2end content , such as wine , yogurt , ripe cheese and bananas , should be avoided . 
false chemical chemical Because Matulane exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs ( e.g. , entity1begin amitriptyline HCl entity1end , entity2begin imipramine HCl entity2end ) and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided . 
false chemical chemical Because Matulane exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs ( e.g. , entity1begin amitriptyline HCl entity1end , imipramine HCl ) and other drugs and foods with known high entity2begin tyramine entity2end content , such as wine , yogurt , ripe cheese and bananas , should be avoided . 
false chemical chemical Because Matulane exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs ( e.g. , amitriptyline HCl , entity1begin imipramine HCl entity1end ) and other drugs and foods with known high entity2begin tyramine entity2end content , such as wine , yogurt , ripe cheese and bananas , should be avoided . 
false chemical chemical No cross - resistance with other entity1begin chemotherapeutic agents entity1end , radiotherapy or entity2begin steroids entity2end has been demonstrated . 
true chemical chemical entity1begin Thiazide diuretics entity1end may accentuate the orthostatic hypotension that may occur with entity2begin phenothiazines entity2end . 
true chemical chemical Antihypertensive effects of entity1begin guanethidine entity1end and related compounds may be counteracted when entity2begin phenothiazines entity2end are used concomitantly . 
true chemical chemical Concomitant administration of entity1begin propranolol entity1end with entity2begin phenothiazines entity2end results in increased plasma levels of both drugs . 
true chemical chemical The induction dose requirements of entity1begin DIPRIVAN entity1end Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with entity2begin narcotics entity2end ( eg , morphine , meperidine , and fentanyl , etc. ) 
true chemical chemical The induction dose requirements of entity1begin DIPRIVAN entity1end Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with narcotics ( eg , entity2begin morphine entity2end , meperidine , and fentanyl , etc. ) 
true chemical chemical The induction dose requirements of entity1begin DIPRIVAN entity1end Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with narcotics ( eg , morphine , entity2begin meperidine entity2end , and fentanyl , etc. ) 
true chemical chemical The induction dose requirements of entity1begin DIPRIVAN entity1end Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with narcotics ( eg , morphine , meperidine , and entity2begin fentanyl entity2end , etc. ) 
false chemical chemical The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with entity1begin narcotics entity1end ( eg , entity2begin morphine entity2end , meperidine , and fentanyl , etc. ) 
false chemical chemical The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with entity1begin narcotics entity1end ( eg , morphine , entity2begin meperidine entity2end , and fentanyl , etc. ) 
false chemical chemical The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with entity1begin narcotics entity1end ( eg , morphine , meperidine , and entity2begin fentanyl entity2end , etc. ) 
false chemical chemical The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with narcotics ( eg , entity1begin morphine entity1end , entity2begin meperidine entity2end , and fentanyl , etc. ) 
false chemical chemical The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with narcotics ( eg , entity1begin morphine entity1end , meperidine , and entity2begin fentanyl entity2end , etc. ) 
false chemical chemical The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with narcotics ( eg , morphine , entity1begin meperidine entity1end , and entity2begin fentanyl entity2end , etc. ) 
false chemical chemical and combinations of entity1begin opioids entity1end and entity2begin sedatives entity2end ( eg , benzodiazepines , barbiturates , chloral hydrate , droperidol , etc. ) . 
false chemical chemical and combinations of entity1begin opioids entity1end and sedatives ( eg , entity2begin benzodiazepines entity2end , barbiturates , chloral hydrate , droperidol , etc. ) . 
false chemical chemical and combinations of entity1begin opioids entity1end and sedatives ( eg , benzodiazepines , entity2begin barbiturates entity2end , chloral hydrate , droperidol , etc. ) . 
false chemical chemical and combinations of entity1begin opioids entity1end and sedatives ( eg , benzodiazepines , barbiturates , entity2begin chloral hydrate entity2end , droperidol , etc. ) . 
false chemical chemical and combinations of entity1begin opioids entity1end and sedatives ( eg , benzodiazepines , barbiturates , chloral hydrate , entity2begin droperidol entity2end , etc. ) . 
false chemical chemical and combinations of opioids and entity1begin sedatives entity1end ( eg , entity2begin benzodiazepines entity2end , barbiturates , chloral hydrate , droperidol , etc. ) . 
false chemical chemical and combinations of opioids and entity1begin sedatives entity1end ( eg , benzodiazepines , entity2begin barbiturates entity2end , chloral hydrate , droperidol , etc. ) . 
false chemical chemical and combinations of opioids and entity1begin sedatives entity1end ( eg , benzodiazepines , barbiturates , entity2begin chloral hydrate entity2end , droperidol , etc. ) . 
false chemical chemical and combinations of opioids and entity1begin sedatives entity1end ( eg , benzodiazepines , barbiturates , chloral hydrate , entity2begin droperidol entity2end , etc. ) . 
false chemical chemical and combinations of opioids and sedatives ( eg , entity1begin benzodiazepines entity1end , entity2begin barbiturates entity2end , chloral hydrate , droperidol , etc. ) . 
false chemical chemical and combinations of opioids and sedatives ( eg , entity1begin benzodiazepines entity1end , barbiturates , entity2begin chloral hydrate entity2end , droperidol , etc. ) . 
false chemical chemical and combinations of opioids and sedatives ( eg , entity1begin benzodiazepines entity1end , barbiturates , chloral hydrate , entity2begin droperidol entity2end , etc. ) . 
false chemical chemical and combinations of opioids and sedatives ( eg , benzodiazepines , entity1begin barbiturates entity1end , entity2begin chloral hydrate entity2end , droperidol , etc. ) . 
false chemical chemical and combinations of opioids and sedatives ( eg , benzodiazepines , entity1begin barbiturates entity1end , chloral hydrate , entity2begin droperidol entity2end , etc. ) . 
false chemical chemical and combinations of opioids and sedatives ( eg , benzodiazepines , barbiturates , entity1begin chloral hydrate entity1end , entity2begin droperidol entity2end , etc. ) . 
true chemical chemical During maintenance of anesthesia or sedation , the rate of entity1begin DIPRIVAN entity1end Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental entity2begin analgesic agents entity2end ( eg , nitrous oxide or opioids ) . 
true chemical chemical During maintenance of anesthesia or sedation , the rate of entity1begin DIPRIVAN entity1end Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents ( eg , entity2begin nitrous oxide entity2end or opioids ) . 
true chemical chemical During maintenance of anesthesia or sedation , the rate of entity1begin DIPRIVAN entity1end Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents ( eg , nitrous oxide or entity2begin opioids entity2end ) . 
false chemical chemical During maintenance of anesthesia or sedation , the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental entity1begin analgesic agents entity1end ( eg , entity2begin nitrous oxide entity2end or opioids ) . 
false chemical chemical During maintenance of anesthesia or sedation , the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental entity1begin analgesic agents entity1end ( eg , nitrous oxide or entity2begin opioids entity2end ) . 
false chemical chemical During maintenance of anesthesia or sedation , the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents ( eg , entity1begin nitrous oxide entity1end or entity2begin opioids entity2end ) . 
false chemical chemical The concurrent administration of potent inhalational agents ( eg , entity1begin isoflurane entity1end , entity2begin enflurane entity2end , and halothane ) during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated . 
false chemical chemical The concurrent administration of potent inhalational agents ( eg , entity1begin isoflurane entity1end , enflurane , and entity2begin halothane entity2end ) during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated . 
false chemical chemical The concurrent administration of potent inhalational agents ( eg , entity1begin isoflurane entity1end , enflurane , and halothane ) during maintenance with entity2begin DIPRIVAN entity2end Injectable Emulsion has not been extensively evaluated . 
false chemical chemical The concurrent administration of potent inhalational agents ( eg , isoflurane , entity1begin enflurane entity1end , and entity2begin halothane entity2end ) during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated . 
false chemical chemical The concurrent administration of potent inhalational agents ( eg , isoflurane , entity1begin enflurane entity1end , and halothane ) during maintenance with entity2begin DIPRIVAN entity2end Injectable Emulsion has not been extensively evaluated . 
false chemical chemical The concurrent administration of potent inhalational agents ( eg , isoflurane , enflurane , and entity1begin halothane entity1end ) during maintenance with entity2begin DIPRIVAN entity2end Injectable Emulsion has not been extensively evaluated . 
false chemical chemical entity1begin DIPRIVAN entity1end Injectable Emulsion does not cause a clinically significant change in onset , intensity , or duration of action of the commonly used entity2begin neuromuscular blocking agents entity2end ( eg , succinylcholine and nondepolarizing muscle relaxants ) . 
false chemical chemical entity1begin DIPRIVAN entity1end Injectable Emulsion does not cause a clinically significant change in onset , intensity , or duration of action of the commonly used neuromuscular blocking agents ( eg , entity2begin succinylcholine entity2end and nondepolarizing muscle relaxants ) . 
false chemical chemical entity1begin DIPRIVAN entity1end Injectable Emulsion does not cause a clinically significant change in onset , intensity , or duration of action of the commonly used neuromuscular blocking agents ( eg , succinylcholine and entity2begin nondepolarizing muscle relaxants entity2end ) . 
false chemical chemical DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset , intensity , or duration of action of the commonly used entity1begin neuromuscular blocking agents entity1end ( eg , entity2begin succinylcholine entity2end and nondepolarizing muscle relaxants ) . 
false chemical chemical DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset , intensity , or duration of action of the commonly used entity1begin neuromuscular blocking agents entity1end ( eg , succinylcholine and entity2begin nondepolarizing muscle relaxants entity2end ) . 
false chemical chemical DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset , intensity , or duration of action of the commonly used neuromuscular blocking agents ( eg , entity1begin succinylcholine entity1end and entity2begin nondepolarizing muscle relaxants entity2end ) . 
false chemical chemical No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation ( including a range of entity1begin muscle relaxants entity1end , inhalational agents , entity2begin analgesic agents entity2end , and local anesthetic agents ) have been observed . 
false chemical chemical No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation ( including a range of entity1begin muscle relaxants entity1end , inhalational agents , analgesic agents , and local entity2begin anesthetic agents entity2end ) have been observed . 
false chemical chemical No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation ( including a range of muscle relaxants , inhalational agents , entity1begin analgesic agents entity1end , and local entity2begin anesthetic agents entity2end ) have been observed . 
true chemical chemical The CNS - depressant effect of entity1begin propoxyphene entity1end is additive with that of other entity2begin CNS depressants entity2end , including alcohol . 
true chemical chemical The CNS - depressant effect of entity1begin propoxyphene entity1end is additive with that of other CNS depressants , including entity2begin alcohol entity2end . 
false chemical chemical The CNS - depressant effect of propoxyphene is additive with that of other entity1begin CNS depressants entity1end , including entity2begin alcohol entity2end . 
false chemical chemical Such occurrences have been reported when entity1begin propoxyphene entity1end was administered to patients on entity2begin antidepressants entity2end , anticonvulsants , or warfarin - like drugs . 
false chemical chemical Such occurrences have been reported when entity1begin propoxyphene entity1end was administered to patients on antidepressants , entity2begin anticonvulsants entity2end , or warfarin - like drugs . 
false chemical chemical Such occurrences have been reported when entity1begin propoxyphene entity1end was administered to patients on antidepressants , anticonvulsants , or entity2begin warfarin entity2end - like drugs . 
false chemical chemical Such occurrences have been reported when propoxyphene was administered to patients on entity1begin antidepressants entity1end , entity2begin anticonvulsants entity2end , or warfarin - like drugs . 
false chemical chemical Such occurrences have been reported when propoxyphene was administered to patients on entity1begin antidepressants entity1end , anticonvulsants , or entity2begin warfarin entity2end - like drugs . 
false chemical chemical Such occurrences have been reported when propoxyphene was administered to patients on antidepressants , entity1begin anticonvulsants entity1end , or entity2begin warfarin entity2end - like drugs . 
false chemical chemical entity1begin MAO inhibitors entity1end and entity2begin beta adrenergic blockers entity2end increase the effects of pseudoephedrine . 
true chemical chemical entity1begin MAO inhibitors entity1end and beta adrenergic blockers increase the effects of entity2begin pseudoephedrine entity2end . 
true chemical chemical MAO inhibitors and entity1begin beta adrenergic blockers entity1end increase the effects of entity2begin pseudoephedrine entity2end . 
true chemical chemical entity1begin Sympathomimetics entity1end may reduce the antihypertensive effects of entity2begin methyldopa entity2end , mecamylamine , reserpine and veratrum alkaloids . 
true chemical chemical entity1begin Sympathomimetics entity1end may reduce the antihypertensive effects of methyldopa , entity2begin mecamylamine entity2end , reserpine and veratrum alkaloids . 
true chemical chemical entity1begin Sympathomimetics entity1end may reduce the antihypertensive effects of methyldopa , mecamylamine , entity2begin reserpine entity2end and veratrum alkaloids . 
true chemical chemical entity1begin Sympathomimetics entity1end may reduce the antihypertensive effects of methyldopa , mecamylamine , reserpine and entity2begin veratrum alkaloids entity2end . 
false chemical chemical Sympathomimetics may reduce the antihypertensive effects of entity1begin methyldopa entity1end , entity2begin mecamylamine entity2end , reserpine and veratrum alkaloids . 
false chemical chemical Sympathomimetics may reduce the antihypertensive effects of entity1begin methyldopa entity1end , mecamylamine , entity2begin reserpine entity2end and veratrum alkaloids . 
false chemical chemical Sympathomimetics may reduce the antihypertensive effects of entity1begin methyldopa entity1end , mecamylamine , reserpine and entity2begin veratrum alkaloids entity2end . 
false chemical chemical Sympathomimetics may reduce the antihypertensive effects of methyldopa , entity1begin mecamylamine entity1end , entity2begin reserpine entity2end and veratrum alkaloids . 
false chemical chemical Sympathomimetics may reduce the antihypertensive effects of methyldopa , entity1begin mecamylamine entity1end , reserpine and entity2begin veratrum alkaloids entity2end . 
false chemical chemical Sympathomimetics may reduce the antihypertensive effects of methyldopa , mecamylamine , entity1begin reserpine entity1end and entity2begin veratrum alkaloids entity2end . 
false chemical chemical entity1begin Pyrimethamine entity1end may be used with entity2begin sulfonamides entity2end , quinine and other antimalarials , and with other antibiotics . 
false chemical chemical entity1begin Pyrimethamine entity1end may be used with sulfonamides , entity2begin quinine entity2end and other antimalarials , and with other antibiotics . 
false chemical chemical entity1begin Pyrimethamine entity1end may be used with sulfonamides , quinine and other entity2begin antimalarials entity2end , and with other antibiotics . 
false chemical chemical entity1begin Pyrimethamine entity1end may be used with sulfonamides , quinine and other antimalarials , and with other entity2begin antibiotics entity2end . 
false chemical chemical Pyrimethamine may be used with entity1begin sulfonamides entity1end , entity2begin quinine entity2end and other antimalarials , and with other antibiotics . 
false chemical chemical Pyrimethamine may be used with entity1begin sulfonamides entity1end , quinine and other entity2begin antimalarials entity2end , and with other antibiotics . 
false chemical chemical Pyrimethamine may be used with entity1begin sulfonamides entity1end , quinine and other antimalarials , and with other entity2begin antibiotics entity2end . 
false chemical chemical Pyrimethamine may be used with sulfonamides , entity1begin quinine entity1end and other entity2begin antimalarials entity2end , and with other antibiotics . 
false chemical chemical Pyrimethamine may be used with sulfonamides , entity1begin quinine entity1end and other antimalarials , and with other entity2begin antibiotics entity2end . 
false chemical chemical Pyrimethamine may be used with sulfonamides , quinine and other entity1begin antimalarials entity1end , and with other entity2begin antibiotics entity2end . 
false chemical chemical entity1begin Folinic acid entity1end ( entity2begin leucovorin entity2end ) should be administered until normal hematopoiesis is restored . 
true chemical chemical Mild hepatotoxicity has been reported in some patients when entity1begin lorazepam entity1end and entity2begin pyrimethamine entity2end were administered concomitantly . 
false chemical chemical entity1begin Cholestyramine entity1end : entity2begin Cholestyramine entity2end causes a 60 % reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA . 
false chemical chemical entity1begin Cholestyramine entity1end : Cholestyramine causes a 60 % reduction in the absorption and enterohepatic cycling of entity2begin raloxifene entity2end and should not be coadministered with EVISTA . 
false chemical chemical entity1begin Cholestyramine entity1end : Cholestyramine causes a 60 % reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with entity2begin EVISTA entity2end . 
true chemical chemical Cholestyramine : entity1begin Cholestyramine entity1end causes a 60 % reduction in the absorption and enterohepatic cycling of entity2begin raloxifene entity2end and should not be coadministered with EVISTA . 
true chemical chemical Cholestyramine : entity1begin Cholestyramine entity1end causes a 60 % reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with entity2begin EVISTA entity2end . 
false chemical chemical Cholestyramine : Cholestyramine causes a 60 % reduction in the absorption and enterohepatic cycling of entity1begin raloxifene entity1end and should not be coadministered with entity2begin EVISTA entity2end . 
false chemical chemical entity1begin Warfarin entity1end : The coadministration of entity2begin EVISTA entity2end and warfarin has not been assessed under chronic conditions . 
false chemical chemical entity1begin Warfarin entity1end : The coadministration of EVISTA and entity2begin warfarin entity2end has not been assessed under chronic conditions . 
false chemical chemical Warfarin : The coadministration of entity1begin EVISTA entity1end and entity2begin warfarin entity2end has not been assessed under chronic conditions . 
true chemical chemical If entity1begin EVISTA entity1end is given concurrently with entity2begin warfarin entity2end , prothrombin time should be monitored . 
false chemical chemical In vitro , entity1begin raloxifene entity1end did not affect the binding of entity2begin warfarin entity2end , phenytoin , or tamoxifen . 
false chemical chemical In vitro , entity1begin raloxifene entity1end did not affect the binding of warfarin , entity2begin phenytoin entity2end , or tamoxifen . 
false chemical chemical In vitro , entity1begin raloxifene entity1end did not affect the binding of warfarin , phenytoin , or entity2begin tamoxifen entity2end . 
false chemical chemical In vitro , raloxifene did not affect the binding of entity1begin warfarin entity1end , entity2begin phenytoin entity2end , or tamoxifen . 
false chemical chemical In vitro , raloxifene did not affect the binding of entity1begin warfarin entity1end , phenytoin , or entity2begin tamoxifen entity2end . 
false chemical chemical In vitro , raloxifene did not affect the binding of warfarin , entity1begin phenytoin entity1end , or entity2begin tamoxifen entity2end . 
true chemical chemical Caution should be used when entity1begin EVISTA entity1end is coadministered with other highly protein - bound drugs , such as entity2begin clofibrate entity2end , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide . 
true chemical chemical Caution should be used when entity1begin EVISTA entity1end is coadministered with other highly protein - bound drugs , such as clofibrate , entity2begin indomethacin entity2end , naproxen , ibuprofen , diazepam , and diazoxide . 
true chemical chemical Caution should be used when entity1begin EVISTA entity1end is coadministered with other highly protein - bound drugs , such as clofibrate , indomethacin , entity2begin naproxen entity2end , ibuprofen , diazepam , and diazoxide . 
true chemical chemical Caution should be used when entity1begin EVISTA entity1end is coadministered with other highly protein - bound drugs , such as clofibrate , indomethacin , naproxen , entity2begin ibuprofen entity2end , diazepam , and diazoxide . 
true chemical chemical Caution should be used when entity1begin EVISTA entity1end is coadministered with other highly protein - bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , entity2begin diazepam entity2end , and diazoxide . 
true chemical chemical Caution should be used when entity1begin EVISTA entity1end is coadministered with other highly protein - bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and entity2begin diazoxide entity2end . 
false chemical chemical Caution should be used when EVISTA is coadministered with other highly protein - bound drugs , such as entity1begin clofibrate entity1end , entity2begin indomethacin entity2end , naproxen , ibuprofen , diazepam , and diazoxide . 
false chemical chemical Caution should be used when EVISTA is coadministered with other highly protein - bound drugs , such as entity1begin clofibrate entity1end , indomethacin , entity2begin naproxen entity2end , ibuprofen , diazepam , and diazoxide . 
false chemical chemical Caution should be used when EVISTA is coadministered with other highly protein - bound drugs , such as entity1begin clofibrate entity1end , indomethacin , naproxen , entity2begin ibuprofen entity2end , diazepam , and diazoxide . 
false chemical chemical Caution should be used when EVISTA is coadministered with other highly protein - bound drugs , such as entity1begin clofibrate entity1end , indomethacin , naproxen , ibuprofen , entity2begin diazepam entity2end , and diazoxide . 
false chemical chemical Caution should be used when EVISTA is coadministered with other highly protein - bound drugs , such as entity1begin clofibrate entity1end , indomethacin , naproxen , ibuprofen , diazepam , and entity2begin diazoxide entity2end . 
false chemical chemical Caution should be used when EVISTA is coadministered with other highly protein - bound drugs , such as clofibrate , entity1begin indomethacin entity1end , entity2begin naproxen entity2end , ibuprofen , diazepam , and diazoxide . 
false chemical chemical Caution should be used when EVISTA is coadministered with other highly protein - bound drugs , such as clofibrate , entity1begin indomethacin entity1end , naproxen , entity2begin ibuprofen entity2end , diazepam , and diazoxide . 
false chemical chemical Caution should be used when EVISTA is coadministered with other highly protein - bound drugs , such as clofibrate , entity1begin indomethacin entity1end , naproxen , ibuprofen , entity2begin diazepam entity2end , and diazoxide . 
false chemical chemical Caution should be used when EVISTA is coadministered with other highly protein - bound drugs , such as clofibrate , entity1begin indomethacin entity1end , naproxen , ibuprofen , diazepam , and entity2begin diazoxide entity2end . 
false chemical chemical Caution should be used when EVISTA is coadministered with other highly protein - bound drugs , such as clofibrate , indomethacin , entity1begin naproxen entity1end , entity2begin ibuprofen entity2end , diazepam , and diazoxide . 
false chemical chemical Caution should be used when EVISTA is coadministered with other highly protein - bound drugs , such as clofibrate , indomethacin , entity1begin naproxen entity1end , ibuprofen , entity2begin diazepam entity2end , and diazoxide . 
false chemical chemical Caution should be used when EVISTA is coadministered with other highly protein - bound drugs , such as clofibrate , indomethacin , entity1begin naproxen entity1end , ibuprofen , diazepam , and entity2begin diazoxide entity2end . 
false chemical chemical Caution should be used when EVISTA is coadministered with other highly protein - bound drugs , such as clofibrate , indomethacin , naproxen , entity1begin ibuprofen entity1end , entity2begin diazepam entity2end , and diazoxide . 
false chemical chemical Caution should be used when EVISTA is coadministered with other highly protein - bound drugs , such as clofibrate , indomethacin , naproxen , entity1begin ibuprofen entity1end , diazepam , and entity2begin diazoxide entity2end . 
false chemical chemical Caution should be used when EVISTA is coadministered with other highly protein - bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , entity1begin diazepam entity1end , and entity2begin diazoxide entity2end . 
true chemical chemical Coadministration of entity1begin TRITEC entity1end with entity2begin clarithromycin entity2end resulted in increased plasma ranitidine concentrations ( 57 % ) , increased plasma bismuth trough concentrations ( 48 % ) , and increased 14 - hydroxy - clarithromycin plasma concentrations ( 31 % ) . 
false chemical chemical Coadministration of entity1begin TRITEC entity1end with clarithromycin resulted in increased plasma entity2begin ranitidine entity2end concentrations ( 57 % ) , increased plasma bismuth trough concentrations ( 48 % ) , and increased 14 - hydroxy - clarithromycin plasma concentrations ( 31 % ) . 
false chemical chemical Coadministration of entity1begin TRITEC entity1end with clarithromycin resulted in increased plasma ranitidine concentrations ( 57 % ) , increased plasma bismuth trough concentrations ( 48 % ) , and increased entity2begin 14 - hydroxy - clarithromycin entity2end plasma concentrations ( 31 % ) . 
false chemical chemical Coadministration of TRITEC with entity1begin clarithromycin entity1end resulted in increased plasma entity2begin ranitidine entity2end concentrations ( 57 % ) , increased plasma bismuth trough concentrations ( 48 % ) , and increased 14 - hydroxy - clarithromycin plasma concentrations ( 31 % ) . 
false chemical chemical Coadministration of TRITEC with entity1begin clarithromycin entity1end resulted in increased plasma ranitidine concentrations ( 57 % ) , increased plasma bismuth trough concentrations ( 48 % ) , and increased entity2begin 14 - hydroxy - clarithromycin entity2end plasma concentrations ( 31 % ) . 
false chemical chemical Coadministration of TRITEC with clarithromycin resulted in increased plasma entity1begin ranitidine entity1end concentrations ( 57 % ) , increased plasma bismuth trough concentrations ( 48 % ) , and increased entity2begin 14 - hydroxy - clarithromycin entity2end plasma concentrations ( 31 % ) . 
false chemical chemical Coadministration with entity1begin aspirin entity1end results in a slight decrease in the rate of entity2begin salicylate entity2end absorption that is clinically unimportant . 
true chemical chemical Coadministration with a high dose of entity1begin antacid entity1end ( 170 mEq ) results in a 28 % decrease in plasma concentrations of entity2begin ranitidine entity2end and may decrease plasma concentrations of bismuth from TRITEC . 
true chemical chemical Coadministration with a high dose of entity1begin antacid entity1end ( 170 mEq ) results in a 28 % decrease in plasma concentrations of ranitidine and may decrease plasma concentrations of bismuth from entity2begin TRITEC entity2end . 
false chemical chemical Coadministration with a high dose of antacid ( 170 mEq ) results in a 28 % decrease in plasma concentrations of entity1begin ranitidine entity1end and may decrease plasma concentrations of bismuth from entity2begin TRITEC entity2end . 
false chemical chemical For information on drug interactions associated with entity1begin ranitidine entity1end , refer to the entity2begin ZANTAC entity2end package insert . 
false chemical chemical Co - administration of oral entity1begin ketoconazole entity1end 200 mg twice daily increased entity2begin retapamulin entity2end geometric mean AUC ( 0 - 24 ) and Cmax by 81 % after topical application of retapamulin ointment , 1 % on the abraded skin of healthy adult males . 
true chemical chemical Co - administration of oral entity1begin ketoconazole entity1end 200 mg twice daily increased retapamulin geometric mean AUC ( 0 - 24 ) and Cmax by 81 % after topical application of entity2begin retapamulin entity2end ointment , 1 % on the abraded skin of healthy adult males . 
false chemical chemical Co - administration of oral ketoconazole 200 mg twice daily increased entity1begin retapamulin entity1end geometric mean AUC ( 0 - 24 ) and Cmax by 81 % after topical application of entity2begin retapamulin entity2end ointment , 1 % on the abraded skin of healthy adult males . 
false chemical chemical Due to low systemic exposure to entity1begin retapamulin entity1end following topical application in patients , dosage adjustments for entity2begin retapamulin entity2end are unnecessary when co - administered with CYP3A4 inhibitors , such as ketoconazole . 
false chemical chemical Due to low systemic exposure to entity1begin retapamulin entity1end following topical application in patients , dosage adjustments for retapamulin are unnecessary when co - administered with CYP3A4 inhibitors , such as entity2begin ketoconazole entity2end . 
false chemical chemical Due to low systemic exposure to retapamulin following topical application in patients , dosage adjustments for entity1begin retapamulin entity1end are unnecessary when co - administered with CYP3A4 inhibitors , such as entity2begin ketoconazole entity2end . 
false chemical chemical Based on in vitro P450 inhibition studies and the low systemic exposure observed following topical application of entity1begin ALTABAX entity1end , entity2begin retapamulin entity2end is unlikely to affect the metabolism of other P450 substrates . 
false chemical chemical In addition to bleeding associated with entity1begin heparin entity1end and entity2begin vitamin K antagonists entity2end , drugs that alter platelet function ( such as aspirin , dipyridamole , and abciximab ) may increase the risk of bleeding if administered prior to or after Retavase therapy . 
false chemical chemical In addition to bleeding associated with entity1begin heparin entity1end and vitamin K antagonists , drugs that alter platelet function ( such as entity2begin aspirin entity2end , dipyridamole , and abciximab ) may increase the risk of bleeding if administered prior to or after Retavase therapy . 
false chemical chemical In addition to bleeding associated with entity1begin heparin entity1end and vitamin K antagonists , drugs that alter platelet function ( such as aspirin , entity2begin dipyridamole entity2end , and abciximab ) may increase the risk of bleeding if administered prior to or after Retavase therapy . 
false chemical chemical In addition to bleeding associated with entity1begin heparin entity1end and vitamin K antagonists , drugs that alter platelet function ( such as aspirin , dipyridamole , and entity2begin abciximab entity2end ) may increase the risk of bleeding if administered prior to or after Retavase therapy . 
true chemical chemical In addition to bleeding associated with entity1begin heparin entity1end and vitamin K antagonists , drugs that alter platelet function ( such as aspirin , dipyridamole , and abciximab ) may increase the risk of bleeding if administered prior to or after entity2begin Retavase entity2end therapy . 
false chemical chemical In addition to bleeding associated with heparin and entity1begin vitamin K antagonists entity1end , drugs that alter platelet function ( such as entity2begin aspirin entity2end , dipyridamole , and abciximab ) may increase the risk of bleeding if administered prior to or after Retavase therapy . 
false chemical chemical In addition to bleeding associated with heparin and entity1begin vitamin K antagonists entity1end , drugs that alter platelet function ( such as aspirin , entity2begin dipyridamole entity2end , and abciximab ) may increase the risk of bleeding if administered prior to or after Retavase therapy . 
false chemical chemical In addition to bleeding associated with heparin and entity1begin vitamin K antagonists entity1end , drugs that alter platelet function ( such as aspirin , dipyridamole , and entity2begin abciximab entity2end ) may increase the risk of bleeding if administered prior to or after Retavase therapy . 
true chemical chemical In addition to bleeding associated with heparin and entity1begin vitamin K antagonists entity1end , drugs that alter platelet function ( such as aspirin , dipyridamole , and abciximab ) may increase the risk of bleeding if administered prior to or after entity2begin Retavase entity2end therapy . 
false chemical chemical In addition to bleeding associated with heparin and vitamin K antagonists , drugs that alter platelet function ( such as entity1begin aspirin entity1end , entity2begin dipyridamole entity2end , and abciximab ) may increase the risk of bleeding if administered prior to or after Retavase therapy . 
false chemical chemical In addition to bleeding associated with heparin and vitamin K antagonists , drugs that alter platelet function ( such as entity1begin aspirin entity1end , dipyridamole , and entity2begin abciximab entity2end ) may increase the risk of bleeding if administered prior to or after Retavase therapy . 
true chemical chemical In addition to bleeding associated with heparin and vitamin K antagonists , drugs that alter platelet function ( such as entity1begin aspirin entity1end , dipyridamole , and abciximab ) may increase the risk of bleeding if administered prior to or after entity2begin Retavase entity2end therapy . 
false chemical chemical In addition to bleeding associated with heparin and vitamin K antagonists , drugs that alter platelet function ( such as aspirin , entity1begin dipyridamole entity1end , and entity2begin abciximab entity2end ) may increase the risk of bleeding if administered prior to or after Retavase therapy . 
true chemical chemical In addition to bleeding associated with heparin and vitamin K antagonists , drugs that alter platelet function ( such as aspirin , entity1begin dipyridamole entity1end , and abciximab ) may increase the risk of bleeding if administered prior to or after entity2begin Retavase entity2end therapy . 
true chemical chemical In addition to bleeding associated with heparin and vitamin K antagonists , drugs that alter platelet function ( such as aspirin , dipyridamole , and entity1begin abciximab entity1end ) may increase the risk of bleeding if administered prior to or after entity2begin Retavase entity2end therapy . 
false chemical chemical Interactions for entity1begin Vitamin B2 entity1end ( entity2begin Riboflavin entity2end ) : Alcohol - impairs the intestinal absorption of riboflavin 
false chemical chemical Interactions for entity1begin Vitamin B2 entity1end ( Riboflavin ) : entity2begin Alcohol entity2end - impairs the intestinal absorption of riboflavin 
false chemical chemical Interactions for entity1begin Vitamin B2 entity1end ( Riboflavin ) : Alcohol - impairs the intestinal absorption of entity2begin riboflavin entity2end 
false chemical chemical Interactions for Vitamin B2 ( entity1begin Riboflavin entity1end ) : entity2begin Alcohol entity2end - impairs the intestinal absorption of riboflavin 
false chemical chemical Interactions for Vitamin B2 ( entity1begin Riboflavin entity1end ) : Alcohol - impairs the intestinal absorption of entity2begin riboflavin entity2end 
true chemical chemical Interactions for Vitamin B2 ( Riboflavin ) : entity1begin Alcohol entity1end - impairs the intestinal absorption of entity2begin riboflavin entity2end 
true chemical chemical entity1begin Probenecid entity1end - concurrent use decreases gastrointestinal absorption of entity2begin riboflavin entity2end ; 
true chemical chemical requirements for entity1begin riboflavin entity1end may be increased in patients receiving entity2begin probenecid entity2end . 
false chemical chemical entity1begin Cimetidine entity1end : The effects of chronic entity2begin cimetidine entity2end use on the metabolism of rimantadine are not known . 
false chemical chemical entity1begin Cimetidine entity1end : The effects of chronic cimetidine use on the metabolism of entity2begin rimantadine entity2end are not known . 
false chemical chemical Cimetidine : The effects of chronic entity1begin cimetidine entity1end use on the metabolism of entity2begin rimantadine entity2end are not known . 
true chemical chemical When a single 100 mg dose of entity1begin rimantadine HCl entity1end was administered one hour after the initiation of entity2begin Cimetidine entity2end ( 300 mg four times a day ) , the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18 % ( compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine ) . 
false chemical chemical When a single 100 mg dose of entity1begin rimantadine HCl entity1end was administered one hour after the initiation of Cimetidine ( 300 mg four times a day ) , the apparent total entity2begin rimantadine entity2end clearance of this single dose in normal healthy adults was reduced by 18 % ( compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine ) . 
false chemical chemical When a single 100 mg dose of entity1begin rimantadine HCl entity1end was administered one hour after the initiation of Cimetidine ( 300 mg four times a day ) , the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18 % ( compared to the apparent total entity2begin rimantadine entity2end clearance in the same subjects in the absence of cimetidine ) . 
false chemical chemical When a single 100 mg dose of entity1begin rimantadine HCl entity1end was administered one hour after the initiation of Cimetidine ( 300 mg four times a day ) , the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18 % ( compared to the apparent total rimantadine clearance in the same subjects in the absence of entity2begin cimetidine entity2end ) . 
false chemical chemical When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of entity1begin Cimetidine entity1end ( 300 mg four times a day ) , the apparent total entity2begin rimantadine entity2end clearance of this single dose in normal healthy adults was reduced by 18 % ( compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine ) . 
false chemical chemical When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of entity1begin Cimetidine entity1end ( 300 mg four times a day ) , the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18 % ( compared to the apparent total entity2begin rimantadine entity2end clearance in the same subjects in the absence of cimetidine ) . 
false chemical chemical When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of entity1begin Cimetidine entity1end ( 300 mg four times a day ) , the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18 % ( compared to the apparent total rimantadine clearance in the same subjects in the absence of entity2begin cimetidine entity2end ) . 
false chemical chemical When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine ( 300 mg four times a day ) , the apparent total entity1begin rimantadine entity1end clearance of this single dose in normal healthy adults was reduced by 18 % ( compared to the apparent total entity2begin rimantadine entity2end clearance in the same subjects in the absence of cimetidine ) . 
false chemical chemical When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine ( 300 mg four times a day ) , the apparent total entity1begin rimantadine entity1end clearance of this single dose in normal healthy adults was reduced by 18 % ( compared to the apparent total rimantadine clearance in the same subjects in the absence of entity2begin cimetidine entity2end ) . 
false chemical chemical When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine ( 300 mg four times a day ) , the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18 % ( compared to the apparent total entity1begin rimantadine entity1end clearance in the same subjects in the absence of entity2begin cimetidine entity2end ) . 
false chemical chemical entity1begin Acetaminophen entity1end : entity2begin Rimantadine HCl entity2end , 100 mg , was given twice daily for 13 days to 12 healthy volunteers . 
true chemical chemical Coadministration with entity1begin acetaminophen entity1end reduced the peak concentration and AUC values for entity2begin rimantadine entity2end by approximately 11 % . 
false chemical chemical entity1begin Aspirin entity1end : entity2begin Rimantadine HCl entity2end , 100 mg , was given twice daily fro 13 days to 12 healthy volunteers . 
true chemical chemical Peak plasma concentrations and AUC of entity1begin rimantadine entity1end were reduced approximately 10 % in the presence of entity2begin aspirin entity2end . 
false chemical chemical Drug - Drug Interactions Effect of entity1begin Exelon entity1end ( entity2begin rivastigmine tartrate entity2end ) on the Metabolism of Other Drugs : Rivastigmine is primarily metabolized through hydrolysis by esterases . 
false chemical chemical Drug - Drug Interactions Effect of entity1begin Exelon entity1end ( rivastigmine tartrate ) on the Metabolism of Other Drugs : entity2begin Rivastigmine entity2end is primarily metabolized through hydrolysis by esterases . 
false chemical chemical Drug - Drug Interactions Effect of Exelon ( entity1begin rivastigmine tartrate entity1end ) on the Metabolism of Other Drugs : entity2begin Rivastigmine entity2end is primarily metabolized through hydrolysis by esterases . 
false chemical chemical No pharmacokinetic interaction was observed between entity1begin rivastigmine entity1end and entity2begin digoxin entity2end , warfarin , diazepam , or fluoxetine in studies in healthy volunteers . 
false chemical chemical No pharmacokinetic interaction was observed between entity1begin rivastigmine entity1end and digoxin , entity2begin warfarin entity2end , diazepam , or fluoxetine in studies in healthy volunteers . 
false chemical chemical No pharmacokinetic interaction was observed between entity1begin rivastigmine entity1end and digoxin , warfarin , entity2begin diazepam entity2end , or fluoxetine in studies in healthy volunteers . 
false chemical chemical No pharmacokinetic interaction was observed between entity1begin rivastigmine entity1end and digoxin , warfarin , diazepam , or entity2begin fluoxetine entity2end in studies in healthy volunteers . 
false chemical chemical No pharmacokinetic interaction was observed between rivastigmine and entity1begin digoxin entity1end , entity2begin warfarin entity2end , diazepam , or fluoxetine in studies in healthy volunteers . 
false chemical chemical No pharmacokinetic interaction was observed between rivastigmine and entity1begin digoxin entity1end , warfarin , entity2begin diazepam entity2end , or fluoxetine in studies in healthy volunteers . 
false chemical chemical No pharmacokinetic interaction was observed between rivastigmine and entity1begin digoxin entity1end , warfarin , diazepam , or entity2begin fluoxetine entity2end in studies in healthy volunteers . 
false chemical chemical No pharmacokinetic interaction was observed between rivastigmine and digoxin , entity1begin warfarin entity1end , entity2begin diazepam entity2end , or fluoxetine in studies in healthy volunteers . 
false chemical chemical No pharmacokinetic interaction was observed between rivastigmine and digoxin , entity1begin warfarin entity1end , diazepam , or entity2begin fluoxetine entity2end in studies in healthy volunteers . 
false chemical chemical No pharmacokinetic interaction was observed between rivastigmine and digoxin , warfarin , entity1begin diazepam entity1end , or entity2begin fluoxetine entity2end in studies in healthy volunteers . 
false chemical chemical The elevation of prothrombin time induced by entity1begin warfarin entity1end is not affected by administration of entity2begin Exelon entity2end . 
false chemical chemical Effect of Other Drugs on the Metabolism of entity1begin Exelon entity1end : Drugs that induce or inhibit CYP450 metabolism are not expected to alter the metabolism of entity2begin rivastigmine entity2end . 
false chemical chemical Single dose pharmacokinetic studies demonstrated that the metabolism of entity1begin rivastigmine entity1end is not significantly affected by concurrent administration of entity2begin digoxin entity2end , warfarin , diazepam , or fluoxetine . 
false chemical chemical Single dose pharmacokinetic studies demonstrated that the metabolism of entity1begin rivastigmine entity1end is not significantly affected by concurrent administration of digoxin , entity2begin warfarin entity2end , diazepam , or fluoxetine . 
false chemical chemical Single dose pharmacokinetic studies demonstrated that the metabolism of entity1begin rivastigmine entity1end is not significantly affected by concurrent administration of digoxin , warfarin , entity2begin diazepam entity2end , or fluoxetine . 
false chemical chemical Single dose pharmacokinetic studies demonstrated that the metabolism of entity1begin rivastigmine entity1end is not significantly affected by concurrent administration of digoxin , warfarin , diazepam , or entity2begin fluoxetine entity2end . 
false chemical chemical Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of entity1begin digoxin entity1end , entity2begin warfarin entity2end , diazepam , or fluoxetine . 
false chemical chemical Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of entity1begin digoxin entity1end , warfarin , entity2begin diazepam entity2end , or fluoxetine . 
false chemical chemical Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of entity1begin digoxin entity1end , warfarin , diazepam , or entity2begin fluoxetine entity2end . 
false chemical chemical Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin , entity1begin warfarin entity1end , entity2begin diazepam entity2end , or fluoxetine . 
false chemical chemical Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin , entity1begin warfarin entity1end , diazepam , or entity2begin fluoxetine entity2end . 
false chemical chemical Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin , warfarin , entity1begin diazepam entity1end , or entity2begin fluoxetine entity2end . 
false chemical chemical Population PK analysis with a database of 625 patients showed that the pharmacokinetics of entity1begin rivastigmine entity1end were not influenced by commonly prescribed medications such as entity2begin antacids entity2end ( n = 77 ) , antihypertensives ( n = 72 ) , calcium channel blockers ( n = 75 ) , antidiabetics ( n = 21 ) , nonsteroidal anti - inflammatory drugs ( n = 79 ) , estrogens ( n = 70 ) , salicylate analgesics ( n = 177 ) , antianginals ( n = 35 ) , and antihistamines ( n = 15 ) . 
false chemical chemical Population PK analysis with a database of 625 patients showed that the pharmacokinetics of entity1begin rivastigmine entity1end were not influenced by commonly prescribed medications such as antacids ( n = 77 ) , entity2begin antihypertensives entity2end ( n = 72 ) , calcium channel blockers ( n = 75 ) , antidiabetics ( n = 21 ) , nonsteroidal anti - inflammatory drugs ( n = 79 ) , estrogens ( n = 70 ) , salicylate analgesics ( n = 177 ) , antianginals ( n = 35 ) , and antihistamines ( n = 15 ) . 
false chemical chemical Population PK analysis with a database of 625 patients showed that the pharmacokinetics of entity1begin rivastigmine entity1end were not influenced by commonly prescribed medications such as antacids ( n = 77 ) , antihypertensives ( n = 72 ) , entity2begin calcium channel blockers entity2end ( n = 75 ) , antidiabetics ( n = 21 ) , nonsteroidal anti - inflammatory drugs ( n = 79 ) , estrogens ( n = 70 ) , salicylate analgesics ( n = 177 ) , antianginals ( n = 35 ) , and antihistamines ( n = 15 ) . 
false chemical chemical Population PK analysis with a database of 625 patients showed that the pharmacokinetics of entity1begin rivastigmine entity1end were not influenced by commonly prescribed medications such as antacids ( n = 77 ) , antihypertensives ( n = 72 ) , calcium channel blockers ( n = 75 ) , entity2begin antidiabetics entity2end ( n = 21 ) , nonsteroidal anti - inflammatory drugs ( n = 79 ) , estrogens ( n = 70 ) , salicylate analgesics ( n = 177 ) , antianginals ( n = 35 ) , and antihistamines ( n = 15 ) . 
false chemical chemical Population PK analysis with a database of 625 patients showed that the pharmacokinetics of entity1begin rivastigmine entity1end were not influenced by commonly prescribed medications such as antacids ( n = 77 ) , antihypertensives ( n = 72 ) , calcium channel blockers ( n = 75 ) , antidiabetics ( n = 21 ) , entity2begin nonsteroidal anti - inflammatory drugs entity2end ( n = 79 ) , estrogens ( n = 70 ) , salicylate analgesics ( n = 177 ) , antianginals ( n = 35 ) , and antihistamines ( n = 15 ) . 
false chemical chemical Population PK analysis with a database of 625 patients showed that the pharmacokinetics of entity1begin rivastigmine entity1end were not influenced by commonly prescribed medications such as antacids ( n = 77 ) , antihypertensives ( n = 72 ) , calcium channel blockers ( n = 75 ) , antidiabetics ( n = 21 ) , nonsteroidal anti - inflammatory drugs ( n = 79 ) , entity2begin estrogens entity2end ( n = 70 ) , salicylate analgesics ( n = 177 ) , antianginals ( n = 35 ) , and antihistamines ( n = 15 ) . 
false chemical chemical Population PK analysis with a database of 625 patients showed that the pharmacokinetics of entity1begin rivastigmine entity1end were not influenced by commonly prescribed medications such as antacids ( n = 77 ) , antihypertensives ( n = 72 ) , calcium channel blockers ( n = 75 ) , antidiabetics ( n = 21 ) , nonsteroidal anti - inflammatory drugs ( n = 79 ) , estrogens ( n = 70 ) , entity2begin salicylate analgesics entity2end ( n = 177 ) , antianginals ( n = 35 ) , and antihistamines ( n = 15 ) . 
false chemical chemical Population PK analysis with a database of 625 patients showed that the pharmacokinetics of entity1begin rivastigmine entity1end were not influenced by commonly prescribed medications such as antacids ( n = 77 ) , antihypertensives ( n = 72 ) , calcium channel blockers ( n = 75 ) , antidiabetics ( n = 21 ) , nonsteroidal anti - inflammatory drugs ( n = 79 ) , estrogens ( n = 70 ) , salicylate analgesics ( n = 177 ) , entity2begin antianginals entity2end ( n = 35 ) , and antihistamines ( n = 15 ) . 
false chemical chemical Population PK analysis with a database of 625 patients showed that the pharmacokinetics of entity1begin rivastigmine entity1end were not influenced by commonly prescribed medications such as antacids ( n = 77 ) , antihypertensives ( n = 72 ) , calcium channel blockers ( n = 75 ) , antidiabetics ( n = 21 ) , nonsteroidal anti - inflammatory drugs ( n = 79 ) , estrogens ( n = 70 ) , salicylate analgesics ( n = 177 ) , antianginals ( n = 35 ) , and entity2begin antihistamines entity2end ( n = 15 ) . 
false chemical chemical Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as entity1begin antacids entity1end ( n = 77 ) , entity2begin antihypertensives entity2end ( n = 72 ) , calcium channel blockers ( n = 75 ) , antidiabetics ( n = 21 ) , nonsteroidal anti - inflammatory drugs ( n = 79 ) , estrogens ( n = 70 ) , salicylate analgesics ( n = 177 ) , antianginals ( n = 35 ) , and antihistamines ( n = 15 ) . 
false chemical chemical Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as entity1begin antacids entity1end ( n = 77 ) , antihypertensives ( n = 72 ) , entity2begin calcium channel blockers entity2end ( n = 75 ) , antidiabetics ( n = 21 ) , nonsteroidal anti - inflammatory drugs ( n = 79 ) , estrogens ( n = 70 ) , salicylate analgesics ( n = 177 ) , antianginals ( n = 35 ) , and antihistamines ( n = 15 ) . 
false chemical chemical Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as entity1begin antacids entity1end ( n = 77 ) , antihypertensives ( n = 72 ) , calcium channel blockers ( n = 75 ) , entity2begin antidiabetics entity2end ( n = 21 ) , nonsteroidal anti - inflammatory drugs ( n = 79 ) , estrogens ( n = 70 ) , salicylate analgesics ( n = 177 ) , antianginals ( n = 35 ) , and antihistamines ( n = 15 ) . 
false chemical chemical Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as entity1begin antacids entity1end ( n = 77 ) , antihypertensives ( n = 72 ) , calcium channel blockers ( n = 75 ) , antidiabetics ( n = 21 ) , entity2begin nonsteroidal anti - inflammatory drugs entity2end ( n = 79 ) , estrogens ( n = 70 ) , salicylate analgesics ( n = 177 ) , antianginals ( n = 35 ) , and antihistamines ( n = 15 ) . 
false chemical chemical Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as entity1begin antacids entity1end ( n = 77 ) , antihypertensives ( n = 72 ) , calcium channel blockers ( n = 75 ) , antidiabetics ( n = 21 ) , nonsteroidal anti - inflammatory drugs ( n = 79 ) , entity2begin estrogens entity2end ( n = 70 ) , salicylate analgesics ( n = 177 ) , antianginals ( n = 35 ) , and antihistamines ( n = 15 ) . 
false chemical chemical Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as entity1begin antacids entity1end ( n = 77 ) , antihypertensives ( n = 72 ) , calcium channel blockers ( n = 75 ) , antidiabetics ( n = 21 ) , nonsteroidal anti - inflammatory drugs ( n = 79 ) , estrogens ( n = 70 ) , entity2begin salicylate analgesics entity2end ( n = 177 ) , antianginals ( n = 35 ) , and antihistamines ( n = 15 ) . 
false chemical chemical Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as entity1begin antacids entity1end ( n = 77 ) , antihypertensives ( n = 72 ) , calcium channel blockers ( n = 75 ) , antidiabetics ( n = 21 ) , nonsteroidal anti - inflammatory drugs ( n = 79 ) , estrogens ( n = 70 ) , salicylate analgesics ( n = 177 ) , entity2begin antianginals entity2end ( n = 35 ) , and antihistamines ( n = 15 ) . 
false chemical chemical Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as entity1begin antacids entity1end ( n = 77 ) , antihypertensives ( n = 72 ) , calcium channel blockers ( n = 75 ) , antidiabetics ( n = 21 ) , nonsteroidal anti - inflammatory drugs ( n = 79 ) , estrogens ( n = 70 ) , salicylate analgesics ( n = 177 ) , antianginals ( n = 35 ) , and entity2begin antihistamines entity2end ( n = 15 ) . 
false chemical chemical Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n = 77 ) , entity1begin antihypertensives entity1end ( n = 72 ) , entity2begin calcium channel blockers entity2end ( n = 75 ) , antidiabetics ( n = 21 ) , nonsteroidal anti - inflammatory drugs ( n = 79 ) , estrogens ( n = 70 ) , salicylate analgesics ( n = 177 ) , antianginals ( n = 35 ) , and antihistamines ( n = 15 ) . 
false chemical chemical Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n = 77 ) , entity1begin antihypertensives entity1end ( n = 72 ) , calcium channel blockers ( n = 75 ) , entity2begin antidiabetics entity2end ( n = 21 ) , nonsteroidal anti - inflammatory drugs ( n = 79 ) , estrogens ( n = 70 ) , salicylate analgesics ( n = 177 ) , antianginals ( n = 35 ) , and antihistamines ( n = 15 ) . 
false chemical chemical Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n = 77 ) , entity1begin antihypertensives entity1end ( n = 72 ) , calcium channel blockers ( n = 75 ) , antidiabetics ( n = 21 ) , entity2begin nonsteroidal anti - inflammatory drugs entity2end ( n = 79 ) , estrogens ( n = 70 ) , salicylate analgesics ( n = 177 ) , antianginals ( n = 35 ) , and antihistamines ( n = 15 ) . 
false chemical chemical Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n = 77 ) , entity1begin antihypertensives entity1end ( n = 72 ) , calcium channel blockers ( n = 75 ) , antidiabetics ( n = 21 ) , nonsteroidal anti - inflammatory drugs ( n = 79 ) , entity2begin estrogens entity2end ( n = 70 ) , salicylate analgesics ( n = 177 ) , antianginals ( n = 35 ) , and antihistamines ( n = 15 ) . 
false chemical chemical Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n = 77 ) , entity1begin antihypertensives entity1end ( n = 72 ) , calcium channel blockers ( n = 75 ) , antidiabetics ( n = 21 ) , nonsteroidal anti - inflammatory drugs ( n = 79 ) , estrogens ( n = 70 ) , entity2begin salicylate analgesics entity2end ( n = 177 ) , antianginals ( n = 35 ) , and antihistamines ( n = 15 ) . 
false chemical chemical Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n = 77 ) , entity1begin antihypertensives entity1end ( n = 72 ) , calcium channel blockers ( n = 75 ) , antidiabetics ( n = 21 ) , nonsteroidal anti - inflammatory drugs ( n = 79 ) , estrogens ( n = 70 ) , salicylate analgesics ( n = 177 ) , entity2begin antianginals entity2end ( n = 35 ) , and antihistamines ( n = 15 ) . 
false chemical chemical Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n = 77 ) , entity1begin antihypertensives entity1end ( n = 72 ) , calcium channel blockers ( n = 75 ) , antidiabetics ( n = 21 ) , nonsteroidal anti - inflammatory drugs ( n = 79 ) , estrogens ( n = 70 ) , salicylate analgesics ( n = 177 ) , antianginals ( n = 35 ) , and entity2begin antihistamines entity2end ( n = 15 ) . 
false chemical chemical Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n = 77 ) , antihypertensives ( n = 72 ) , entity1begin calcium channel blockers entity1end ( n = 75 ) , entity2begin antidiabetics entity2end ( n = 21 ) , nonsteroidal anti - inflammatory drugs ( n = 79 ) , estrogens ( n = 70 ) , salicylate analgesics ( n = 177 ) , antianginals ( n = 35 ) , and antihistamines ( n = 15 ) . 
false chemical chemical Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n = 77 ) , antihypertensives ( n = 72 ) , entity1begin calcium channel blockers entity1end ( n = 75 ) , antidiabetics ( n = 21 ) , entity2begin nonsteroidal anti - inflammatory drugs entity2end ( n = 79 ) , estrogens ( n = 70 ) , salicylate analgesics ( n = 177 ) , antianginals ( n = 35 ) , and antihistamines ( n = 15 ) . 
false chemical chemical Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n = 77 ) , antihypertensives ( n = 72 ) , entity1begin calcium channel blockers entity1end ( n = 75 ) , antidiabetics ( n = 21 ) , nonsteroidal anti - inflammatory drugs ( n = 79 ) , entity2begin estrogens entity2end ( n = 70 ) , salicylate analgesics ( n = 177 ) , antianginals ( n = 35 ) , and antihistamines ( n = 15 ) . 
false chemical chemical Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n = 77 ) , antihypertensives ( n = 72 ) , entity1begin calcium channel blockers entity1end ( n = 75 ) , antidiabetics ( n = 21 ) , nonsteroidal anti - inflammatory drugs ( n = 79 ) , estrogens ( n = 70 ) , entity2begin salicylate analgesics entity2end ( n = 177 ) , antianginals ( n = 35 ) , and antihistamines ( n = 15 ) . 
false chemical chemical Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n = 77 ) , antihypertensives ( n = 72 ) , entity1begin calcium channel blockers entity1end ( n = 75 ) , antidiabetics ( n = 21 ) , nonsteroidal anti - inflammatory drugs ( n = 79 ) , estrogens ( n = 70 ) , salicylate analgesics ( n = 177 ) , entity2begin antianginals entity2end ( n = 35 ) , and antihistamines ( n = 15 ) . 
false chemical chemical Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n = 77 ) , antihypertensives ( n = 72 ) , entity1begin calcium channel blockers entity1end ( n = 75 ) , antidiabetics ( n = 21 ) , nonsteroidal anti - inflammatory drugs ( n = 79 ) , estrogens ( n = 70 ) , salicylate analgesics ( n = 177 ) , antianginals ( n = 35 ) , and entity2begin antihistamines entity2end ( n = 15 ) . 
false chemical chemical Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n = 77 ) , antihypertensives ( n = 72 ) , calcium channel blockers ( n = 75 ) , entity1begin antidiabetics entity1end ( n = 21 ) , entity2begin nonsteroidal anti - inflammatory drugs entity2end ( n = 79 ) , estrogens ( n = 70 ) , salicylate analgesics ( n = 177 ) , antianginals ( n = 35 ) , and antihistamines ( n = 15 ) . 
false chemical chemical Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n = 77 ) , antihypertensives ( n = 72 ) , calcium channel blockers ( n = 75 ) , entity1begin antidiabetics entity1end ( n = 21 ) , nonsteroidal anti - inflammatory drugs ( n = 79 ) , entity2begin estrogens entity2end ( n = 70 ) , salicylate analgesics ( n = 177 ) , antianginals ( n = 35 ) , and antihistamines ( n = 15 ) . 
false chemical chemical Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n = 77 ) , antihypertensives ( n = 72 ) , calcium channel blockers ( n = 75 ) , entity1begin antidiabetics entity1end ( n = 21 ) , nonsteroidal anti - inflammatory drugs ( n = 79 ) , estrogens ( n = 70 ) , entity2begin salicylate analgesics entity2end ( n = 177 ) , antianginals ( n = 35 ) , and antihistamines ( n = 15 ) . 
false chemical chemical Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n = 77 ) , antihypertensives ( n = 72 ) , calcium channel blockers ( n = 75 ) , entity1begin antidiabetics entity1end ( n = 21 ) , nonsteroidal anti - inflammatory drugs ( n = 79 ) , estrogens ( n = 70 ) , salicylate analgesics ( n = 177 ) , entity2begin antianginals entity2end ( n = 35 ) , and antihistamines ( n = 15 ) . 
false chemical chemical Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n = 77 ) , antihypertensives ( n = 72 ) , calcium channel blockers ( n = 75 ) , entity1begin antidiabetics entity1end ( n = 21 ) , nonsteroidal anti - inflammatory drugs ( n = 79 ) , estrogens ( n = 70 ) , salicylate analgesics ( n = 177 ) , antianginals ( n = 35 ) , and entity2begin antihistamines entity2end ( n = 15 ) . 
false chemical chemical Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n = 77 ) , antihypertensives ( n = 72 ) , calcium channel blockers ( n = 75 ) , antidiabetics ( n = 21 ) , entity1begin nonsteroidal anti - inflammatory drugs entity1end ( n = 79 ) , entity2begin estrogens entity2end ( n = 70 ) , salicylate analgesics ( n = 177 ) , antianginals ( n = 35 ) , and antihistamines ( n = 15 ) . 
false chemical chemical Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n = 77 ) , antihypertensives ( n = 72 ) , calcium channel blockers ( n = 75 ) , antidiabetics ( n = 21 ) , entity1begin nonsteroidal anti - inflammatory drugs entity1end ( n = 79 ) , estrogens ( n = 70 ) , entity2begin salicylate analgesics entity2end ( n = 177 ) , antianginals ( n = 35 ) , and antihistamines ( n = 15 ) . 
false chemical chemical Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n = 77 ) , antihypertensives ( n = 72 ) , calcium channel blockers ( n = 75 ) , antidiabetics ( n = 21 ) , entity1begin nonsteroidal anti - inflammatory drugs entity1end ( n = 79 ) , estrogens ( n = 70 ) , salicylate analgesics ( n = 177 ) , entity2begin antianginals entity2end ( n = 35 ) , and antihistamines ( n = 15 ) . 
false chemical chemical Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n = 77 ) , antihypertensives ( n = 72 ) , calcium channel blockers ( n = 75 ) , antidiabetics ( n = 21 ) , entity1begin nonsteroidal anti - inflammatory drugs entity1end ( n = 79 ) , estrogens ( n = 70 ) , salicylate analgesics ( n = 177 ) , antianginals ( n = 35 ) , and entity2begin antihistamines entity2end ( n = 15 ) . 
false chemical chemical Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n = 77 ) , antihypertensives ( n = 72 ) , calcium channel blockers ( n = 75 ) , antidiabetics ( n = 21 ) , nonsteroidal anti - inflammatory drugs ( n = 79 ) , entity1begin estrogens entity1end ( n = 70 ) , entity2begin salicylate analgesics entity2end ( n = 177 ) , antianginals ( n = 35 ) , and antihistamines ( n = 15 ) . 
false chemical chemical Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n = 77 ) , antihypertensives ( n = 72 ) , calcium channel blockers ( n = 75 ) , antidiabetics ( n = 21 ) , nonsteroidal anti - inflammatory drugs ( n = 79 ) , entity1begin estrogens entity1end ( n = 70 ) , salicylate analgesics ( n = 177 ) , entity2begin antianginals entity2end ( n = 35 ) , and antihistamines ( n = 15 ) . 
false chemical chemical Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n = 77 ) , antihypertensives ( n = 72 ) , calcium channel blockers ( n = 75 ) , antidiabetics ( n = 21 ) , nonsteroidal anti - inflammatory drugs ( n = 79 ) , entity1begin estrogens entity1end ( n = 70 ) , salicylate analgesics ( n = 177 ) , antianginals ( n = 35 ) , and entity2begin antihistamines entity2end ( n = 15 ) . 
false chemical chemical Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n = 77 ) , antihypertensives ( n = 72 ) , calcium channel blockers ( n = 75 ) , antidiabetics ( n = 21 ) , nonsteroidal anti - inflammatory drugs ( n = 79 ) , estrogens ( n = 70 ) , entity1begin salicylate analgesics entity1end ( n = 177 ) , entity2begin antianginals entity2end ( n = 35 ) , and antihistamines ( n = 15 ) . 
false chemical chemical Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n = 77 ) , antihypertensives ( n = 72 ) , calcium channel blockers ( n = 75 ) , antidiabetics ( n = 21 ) , nonsteroidal anti - inflammatory drugs ( n = 79 ) , estrogens ( n = 70 ) , entity1begin salicylate analgesics entity1end ( n = 177 ) , antianginals ( n = 35 ) , and entity2begin antihistamines entity2end ( n = 15 ) . 
false chemical chemical Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n = 77 ) , antihypertensives ( n = 72 ) , calcium channel blockers ( n = 75 ) , antidiabetics ( n = 21 ) , nonsteroidal anti - inflammatory drugs ( n = 79 ) , estrogens ( n = 70 ) , salicylate analgesics ( n = 177 ) , entity1begin antianginals entity1end ( n = 35 ) , and entity2begin antihistamines entity2end ( n = 15 ) . 
false chemical chemical Use with entity1begin Anticholinergics entity1end : Because of their mechanism of action , entity2begin cholinesterase inhibitors entity2end have the potential to interfere with the activity of anticholinergic medications . 
false chemical chemical Use with entity1begin Anticholinergics entity1end : Because of their mechanism of action , cholinesterase inhibitors have the potential to interfere with the activity of entity2begin anticholinergic medications entity2end . 
true chemical chemical Use with Anticholinergics : Because of their mechanism of action , entity1begin cholinesterase inhibitors entity1end have the potential to interfere with the activity of entity2begin anticholinergic medications entity2end . 
false chemical chemical Use with entity1begin Cholinomimetics entity1end and Other entity2begin Cholinesterase Inhibitors entity2end : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol . 
false chemical chemical Use with entity1begin Cholinomimetics entity1end and Other Cholinesterase Inhibitors : A synergistic effect may be expected when entity2begin cholinesterase inhibitors entity2end are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol . 
false chemical chemical Use with entity1begin Cholinomimetics entity1end and Other Cholinesterase Inhibitors : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with entity2begin succinylcholine entity2end , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol . 
false chemical chemical Use with entity1begin Cholinomimetics entity1end and Other Cholinesterase Inhibitors : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar entity2begin neuromuscular blocking agents entity2end or cholinergic agonists such as bethanechol . 
false chemical chemical Use with entity1begin Cholinomimetics entity1end and Other Cholinesterase Inhibitors : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or entity2begin cholinergic agonists entity2end such as bethanechol . 
false chemical chemical Use with entity1begin Cholinomimetics entity1end and Other Cholinesterase Inhibitors : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as entity2begin bethanechol entity2end . 
false chemical chemical Use with Cholinomimetics and Other entity1begin Cholinesterase Inhibitors entity1end : A synergistic effect may be expected when entity2begin cholinesterase inhibitors entity2end are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol . 
false chemical chemical Use with Cholinomimetics and Other entity1begin Cholinesterase Inhibitors entity1end : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with entity2begin succinylcholine entity2end , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol . 
false chemical chemical Use with Cholinomimetics and Other entity1begin Cholinesterase Inhibitors entity1end : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar entity2begin neuromuscular blocking agents entity2end or cholinergic agonists such as bethanechol . 
false chemical chemical Use with Cholinomimetics and Other entity1begin Cholinesterase Inhibitors entity1end : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or entity2begin cholinergic agonists entity2end such as bethanechol . 
false chemical chemical Use with Cholinomimetics and Other entity1begin Cholinesterase Inhibitors entity1end : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as entity2begin bethanechol entity2end . 
true chemical chemical Use with Cholinomimetics and Other Cholinesterase Inhibitors : A synergistic effect may be expected when entity1begin cholinesterase inhibitors entity1end are given concurrently with entity2begin succinylcholine entity2end , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol . 
true chemical chemical Use with Cholinomimetics and Other Cholinesterase Inhibitors : A synergistic effect may be expected when entity1begin cholinesterase inhibitors entity1end are given concurrently with succinylcholine , similar entity2begin neuromuscular blocking agents entity2end or cholinergic agonists such as bethanechol . 
true chemical chemical Use with Cholinomimetics and Other Cholinesterase Inhibitors : A synergistic effect may be expected when entity1begin cholinesterase inhibitors entity1end are given concurrently with succinylcholine , similar neuromuscular blocking agents or entity2begin cholinergic agonists entity2end such as bethanechol . 
true chemical chemical Use with Cholinomimetics and Other Cholinesterase Inhibitors : A synergistic effect may be expected when entity1begin cholinesterase inhibitors entity1end are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as entity2begin bethanechol entity2end . 
false chemical chemical Use with Cholinomimetics and Other Cholinesterase Inhibitors : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with entity1begin succinylcholine entity1end , similar entity2begin neuromuscular blocking agents entity2end or cholinergic agonists such as bethanechol . 
false chemical chemical Use with Cholinomimetics and Other Cholinesterase Inhibitors : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with entity1begin succinylcholine entity1end , similar neuromuscular blocking agents or entity2begin cholinergic agonists entity2end such as bethanechol . 
false chemical chemical Use with Cholinomimetics and Other Cholinesterase Inhibitors : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with entity1begin succinylcholine entity1end , similar neuromuscular blocking agents or cholinergic agonists such as entity2begin bethanechol entity2end . 
false chemical chemical Use with Cholinomimetics and Other Cholinesterase Inhibitors : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar entity1begin neuromuscular blocking agents entity1end or entity2begin cholinergic agonists entity2end such as bethanechol . 
false chemical chemical Use with Cholinomimetics and Other Cholinesterase Inhibitors : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar entity1begin neuromuscular blocking agents entity1end or cholinergic agonists such as entity2begin bethanechol entity2end . 
false chemical chemical Use with Cholinomimetics and Other Cholinesterase Inhibitors : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or entity1begin cholinergic agonists entity1end such as entity2begin bethanechol entity2end . 
false chemical chemical Drug Interactions : The use of entity1begin ZEMURON entity1end ( entity2begin rocuronium bromide entity2end ) Injection before succinylcholine , for the purpose of attenuating some of the side effects of succinylcholine , has not been studied . 
false chemical chemical Drug Interactions : The use of entity1begin ZEMURON entity1end ( rocuronium bromide ) Injection before entity2begin succinylcholine entity2end , for the purpose of attenuating some of the side effects of succinylcholine , has not been studied . 
false chemical chemical Drug Interactions : The use of entity1begin ZEMURON entity1end ( rocuronium bromide ) Injection before succinylcholine , for the purpose of attenuating some of the side effects of entity2begin succinylcholine entity2end , has not been studied . 
false chemical chemical Drug Interactions : The use of ZEMURON ( entity1begin rocuronium bromide entity1end ) Injection before entity2begin succinylcholine entity2end , for the purpose of attenuating some of the side effects of succinylcholine , has not been studied . 
false chemical chemical Drug Interactions : The use of ZEMURON ( entity1begin rocuronium bromide entity1end ) Injection before succinylcholine , for the purpose of attenuating some of the side effects of entity2begin succinylcholine entity2end , has not been studied . 
false chemical chemical Drug Interactions : The use of ZEMURON ( rocuronium bromide ) Injection before entity1begin succinylcholine entity1end , for the purpose of attenuating some of the side effects of entity2begin succinylcholine entity2end , has not been studied . 
true chemical chemical If entity1begin ZEMURON entity1end is administered following administration of entity2begin succinylcholine entity2end , it should not be given until recovery from succinylcholine has been observed . 
false chemical chemical If entity1begin ZEMURON entity1end is administered following administration of succinylcholine , it should not be given until recovery from entity2begin succinylcholine entity2end has been observed . 
false chemical chemical If ZEMURON is administered following administration of entity1begin succinylcholine entity1end , it should not be given until recovery from entity2begin succinylcholine entity2end has been observed . 
false chemical chemical The median duration of action of entity1begin ZEMURON entity1end 0.6 mg / kg administered after a 1 mg / kg dose of entity2begin succinylcholine entity2end when T 1 returned to 75 % of control was 36 minutes ( range 14 - 57 , n = 12 ) vs . 
false chemical chemical There are no controlled studies documenting the use of entity1begin ZEMURON entity1end before or after other entity2begin nondepolarizing muscle relaxants entity2end . 
true chemical chemical entity1begin Ropivacaine entity1end should be used with caution in patients receiving other local entity2begin anesthetics entity2end or agents structurally related to amide - type local anesthetics , since the toxic effects of these drugs are additive . 
false chemical chemical entity1begin Ropivacaine entity1end should be used with caution in patients receiving other local anesthetics or agents structurally related to entity2begin amide - type local anesthetics entity2end , since the toxic effects of these drugs are additive . 
false chemical chemical Ropivacaine should be used with caution in patients receiving other local entity1begin anesthetics entity1end or agents structurally related to entity2begin amide - type local anesthetics entity2end , since the toxic effects of these drugs are additive . 
true chemical chemical In vivo , the plasma clearance of entity1begin ropivacaine entity1end was reduced by 70 % during coadministration of entity2begin fluvoxamine entity2end ( 25 mg bid for 2 days ) , a selective and potent CYP1A2 inhibitor . 
true chemical chemical Thus strong inhibitors of cytochrome P4501A2 , such as entity1begin fluvoxamine entity1end , given concomitantly during administration of entity2begin Ropivacaine entity2end , can interact with Ropivacaine leading to increased ropivacaine plasma levels . 
false chemical chemical Thus strong inhibitors of cytochrome P4501A2 , such as entity1begin fluvoxamine entity1end , given concomitantly during administration of Ropivacaine , can interact with entity2begin Ropivacaine entity2end leading to increased ropivacaine plasma levels . 
false chemical chemical Thus strong inhibitors of cytochrome P4501A2 , such as entity1begin fluvoxamine entity1end , given concomitantly during administration of Ropivacaine , can interact with Ropivacaine leading to increased entity2begin ropivacaine entity2end plasma levels . 
false chemical chemical Thus strong inhibitors of cytochrome P4501A2 , such as fluvoxamine , given concomitantly during administration of entity1begin Ropivacaine entity1end , can interact with entity2begin Ropivacaine entity2end leading to increased ropivacaine plasma levels . 
false chemical chemical Thus strong inhibitors of cytochrome P4501A2 , such as fluvoxamine , given concomitantly during administration of entity1begin Ropivacaine entity1end , can interact with Ropivacaine leading to increased entity2begin ropivacaine entity2end plasma levels . 
false chemical chemical Thus strong inhibitors of cytochrome P4501A2 , such as fluvoxamine , given concomitantly during administration of Ropivacaine , can interact with entity1begin Ropivacaine entity1end leading to increased entity2begin ropivacaine entity2end plasma levels . 
false chemical chemical Possible interactions with drugs known to be metabolized by CYP1A2 via competitive inhibition such as entity1begin theophylline entity1end and entity2begin imipramine entity2end may also occur . 
false chemical chemical Coadministration of a selective and potent inhibitor of CYP3A4 , entity1begin ketoconazole entity1end ( 100 mg bid for 2 days with entity2begin ropivacaine entity2end infusion administered 1 hour after ketoconazole ) caused a 15 % reduction in in - vivo plasma clearance of ropivacaine . 
false chemical chemical Coadministration of a selective and potent inhibitor of CYP3A4 , entity1begin ketoconazole entity1end ( 100 mg bid for 2 days with ropivacaine infusion administered 1 hour after entity2begin ketoconazole entity2end ) caused a 15 % reduction in in - vivo plasma clearance of ropivacaine . 
true chemical chemical Coadministration of a selective and potent inhibitor of CYP3A4 , entity1begin ketoconazole entity1end ( 100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole ) caused a 15 % reduction in in - vivo plasma clearance of entity2begin ropivacaine entity2end . 
false chemical chemical Coadministration of a selective and potent inhibitor of CYP3A4 , ketoconazole ( 100 mg bid for 2 days with entity1begin ropivacaine entity1end infusion administered 1 hour after entity2begin ketoconazole entity2end ) caused a 15 % reduction in in - vivo plasma clearance of ropivacaine . 
false chemical chemical Coadministration of a selective and potent inhibitor of CYP3A4 , ketoconazole ( 100 mg bid for 2 days with entity1begin ropivacaine entity1end infusion administered 1 hour after ketoconazole ) caused a 15 % reduction in in - vivo plasma clearance of entity2begin ropivacaine entity2end . 
false chemical chemical Coadministration of a selective and potent inhibitor of CYP3A4 , ketoconazole ( 100 mg bid for 2 days with ropivacaine infusion administered 1 hour after entity1begin ketoconazole entity1end ) caused a 15 % reduction in in - vivo plasma clearance of entity2begin ropivacaine entity2end . 
true chemical chemical An inhibitor of CYP2C8 ( such as entity1begin gemfibrozil entity1end ) may increase the AUC of entity2begin rosiglitazone entity2end and an inducer of CYP2C8 ( such as rifampin ) may decrease the AUC of rosiglitazone . 
false chemical chemical An inhibitor of CYP2C8 ( such as entity1begin gemfibrozil entity1end ) may increase the AUC of rosiglitazone and an inducer of CYP2C8 ( such as entity2begin rifampin entity2end ) may decrease the AUC of rosiglitazone . 
false chemical chemical An inhibitor of CYP2C8 ( such as entity1begin gemfibrozil entity1end ) may increase the AUC of rosiglitazone and an inducer of CYP2C8 ( such as rifampin ) may decrease the AUC of entity2begin rosiglitazone entity2end . 
false chemical chemical An inhibitor of CYP2C8 ( such as gemfibrozil ) may increase the AUC of entity1begin rosiglitazone entity1end and an inducer of CYP2C8 ( such as entity2begin rifampin entity2end ) may decrease the AUC of rosiglitazone . 
false chemical chemical An inhibitor of CYP2C8 ( such as gemfibrozil ) may increase the AUC of entity1begin rosiglitazone entity1end and an inducer of CYP2C8 ( such as rifampin ) may decrease the AUC of entity2begin rosiglitazone entity2end . 
true chemical chemical An inhibitor of CYP2C8 ( such as gemfibrozil ) may increase the AUC of rosiglitazone and an inducer of CYP2C8 ( such as entity1begin rifampin entity1end ) may decrease the AUC of entity2begin rosiglitazone entity2end . 
false chemical chemical Concomitant administrations not recommended : - entity1begin Terfenadine entity1end and entity2begin astemizole entity2end : Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter . 
false chemical chemical Concomitant administrations not recommended : - entity1begin Terfenadine entity1end and astemizole : Certain entity2begin macrolides entity2end interact with terfenadine and astemizole leading to increased serum concentrations of the latter . 
false chemical chemical Concomitant administrations not recommended : - entity1begin Terfenadine entity1end and astemizole : Certain macrolides interact with entity2begin terfenadine entity2end and astemizole leading to increased serum concentrations of the latter . 
false chemical chemical Concomitant administrations not recommended : - entity1begin Terfenadine entity1end and astemizole : Certain macrolides interact with terfenadine and entity2begin astemizole entity2end leading to increased serum concentrations of the latter . 
false chemical chemical Concomitant administrations not recommended : - Terfenadine and entity1begin astemizole entity1end : Certain entity2begin macrolides entity2end interact with terfenadine and astemizole leading to increased serum concentrations of the latter . 
false chemical chemical Concomitant administrations not recommended : - Terfenadine and entity1begin astemizole entity1end : Certain macrolides interact with entity2begin terfenadine entity2end and astemizole leading to increased serum concentrations of the latter . 
false chemical chemical Concomitant administrations not recommended : - Terfenadine and entity1begin astemizole entity1end : Certain macrolides interact with terfenadine and entity2begin astemizole entity2end leading to increased serum concentrations of the latter . 
true chemical chemical Concomitant administrations not recommended : - Terfenadine and astemizole : Certain entity1begin macrolides entity1end interact with entity2begin terfenadine entity2end and astemizole leading to increased serum concentrations of the latter . 
true chemical chemical Concomitant administrations not recommended : - Terfenadine and astemizole : Certain entity1begin macrolides entity1end interact with terfenadine and entity2begin astemizole entity2end leading to increased serum concentrations of the latter . 
false chemical chemical Concomitant administrations not recommended : - Terfenadine and astemizole : Certain macrolides interact with entity1begin terfenadine entity1end and entity2begin astemizole entity2end leading to increased serum concentrations of the latter . 
false chemical chemical Although such a reaction has not been demonstrated with entity1begin roxithromycin entity1end , concomitant administration of entity2begin roxithromycin entity2end with terfenadine or astemizole is not recommended . 
false chemical chemical Although such a reaction has not been demonstrated with entity1begin roxithromycin entity1end , concomitant administration of roxithromycin with entity2begin terfenadine entity2end or astemizole is not recommended . 
false chemical chemical Although such a reaction has not been demonstrated with entity1begin roxithromycin entity1end , concomitant administration of roxithromycin with terfenadine or entity2begin astemizole entity2end is not recommended . 
true chemical chemical Although such a reaction has not been demonstrated with roxithromycin , concomitant administration of entity1begin roxithromycin entity1end with entity2begin terfenadine entity2end or astemizole is not recommended . 
true chemical chemical Although such a reaction has not been demonstrated with roxithromycin , concomitant administration of entity1begin roxithromycin entity1end with terfenadine or entity2begin astemizole entity2end is not recommended . 
false chemical chemical Although such a reaction has not been demonstrated with roxithromycin , concomitant administration of roxithromycin with entity1begin terfenadine entity1end or entity2begin astemizole entity2end is not recommended . 
false chemical chemical - entity1begin Cisapride entity1end , entity2begin pimozide entity2end : Other drugs such as cisapride or pimozide , which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and / or cardiac arrythmias ( typically torsades de pointe ) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some macrolide antibacterials . 
false chemical chemical - entity1begin Cisapride entity1end , pimozide : Other drugs such as entity2begin cisapride entity2end or pimozide , which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and / or cardiac arrythmias ( typically torsades de pointe ) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some macrolide antibacterials . 
false chemical chemical - entity1begin Cisapride entity1end , pimozide : Other drugs such as cisapride or entity2begin pimozide entity2end , which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and / or cardiac arrythmias ( typically torsades de pointe ) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some macrolide antibacterials . 
false chemical chemical - entity1begin Cisapride entity1end , pimozide : Other drugs such as cisapride or pimozide , which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and / or cardiac arrythmias ( typically torsades de pointe ) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some entity2begin macrolide antibacterials entity2end . 
false chemical chemical - Cisapride , entity1begin pimozide entity1end : Other drugs such as entity2begin cisapride entity2end or pimozide , which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and / or cardiac arrythmias ( typically torsades de pointe ) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some macrolide antibacterials . 
false chemical chemical - Cisapride , entity1begin pimozide entity1end : Other drugs such as cisapride or entity2begin pimozide entity2end , which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and / or cardiac arrythmias ( typically torsades de pointe ) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some macrolide antibacterials . 
true chemical chemical - Cisapride , entity1begin pimozide entity1end : Other drugs such as cisapride or pimozide , which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and / or cardiac arrythmias ( typically torsades de pointe ) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some entity2begin macrolide antibacterials entity2end . 
false chemical chemical - Cisapride , pimozide : Other drugs such as entity1begin cisapride entity1end or entity2begin pimozide entity2end , which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and / or cardiac arrythmias ( typically torsades de pointe ) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some macrolide antibacterials . 
true chemical chemical - Cisapride , pimozide : Other drugs such as entity1begin cisapride entity1end or pimozide , which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and / or cardiac arrythmias ( typically torsades de pointe ) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some entity2begin macrolide antibacterials entity2end . 
false chemical chemical - Cisapride , pimozide : Other drugs such as cisapride or entity1begin pimozide entity1end , which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and / or cardiac arrythmias ( typically torsades de pointe ) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some entity2begin macrolide antibacterials entity2end . 
false chemical chemical Although such a risk is not verified for entity1begin roxithromycin entity1end , combination of entity2begin roxithromycin entity2end with such drugs is not recommended . 
true chemical chemical however , in patients with Paget 's Disease prior entity1begin diphosphonate entity1end use appears to reduce the anti - resorptive response to entity2begin Calcitonin ( salmon ) entity2end nasal spray . 
false chemical chemical entity1begin ASPIRIN entity1end AND OTHER entity2begin SALICYLATE DRUGS entity2end WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS . 
true chemical chemical entity1begin ASPIRIN entity1end AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO entity2begin DISALCID entity2end AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS . 
false chemical chemical entity1begin ASPIRIN entity1end AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF entity2begin SALICYLIC ACID entity2end TO TOXIC LEVELS . 
true chemical chemical ASPIRIN AND OTHER entity1begin SALICYLATE DRUGS entity1end WILL BE ADDITIVE TO entity2begin DISALCID entity2end AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS . 
false chemical chemical ASPIRIN AND OTHER entity1begin SALICYLATE DRUGS entity1end WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF entity2begin SALICYLIC ACID entity2end TO TOXIC LEVELS . 
false chemical chemical ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO entity1begin DISALCID entity1end AND MAY INCREASE PLASMA CONCENTRATIONS OF entity2begin SALICYLIC ACID entity2end TO TOXIC LEVELS . 
true chemical chemical entity1begin Salicylates entity1end given concomitantly with entity2begin anticoagulant drugs entity2end may predispose to systemic bleeding . 
true chemical chemical entity1begin Salicylates entity1end may enhance the hypoglycemic effect of oral entity2begin antidiabetic drugs entity2end of the sulfonylurea class . 
true chemical chemical entity1begin Salicylate entity1end competes with a number of drugs for protein binding sites , notably entity2begin penicillin entity2end , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
true chemical chemical entity1begin Salicylate entity1end competes with a number of drugs for protein binding sites , notably penicillin , entity2begin thiopental entity2end , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
true chemical chemical entity1begin Salicylate entity1end competes with a number of drugs for protein binding sites , notably penicillin , thiopental , entity2begin thyroxine entity2end , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
true chemical chemical entity1begin Salicylate entity1end competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , entity2begin triiodothyronine entity2end , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
true chemical chemical entity1begin Salicylate entity1end competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , entity2begin phenytoin entity2end , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
true chemical chemical entity1begin Salicylate entity1end competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , entity2begin sulfinpyrazone entity2end , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
true chemical chemical entity1begin Salicylate entity1end competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , entity2begin naproxen entity2end , warfarin , methotrexate , and possibly corticosteroids . 
true chemical chemical entity1begin Salicylate entity1end competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , entity2begin warfarin entity2end , methotrexate , and possibly corticosteroids . 
true chemical chemical entity1begin Salicylate entity1end competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , entity2begin methotrexate entity2end , and possibly corticosteroids . 
true chemical chemical entity1begin Salicylate entity1end competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly entity2begin corticosteroids entity2end . 
false chemical chemical Salicylate competes with a number of drugs for protein binding sites , notably entity1begin penicillin entity1end , entity2begin thiopental entity2end , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
false chemical chemical Salicylate competes with a number of drugs for protein binding sites , notably entity1begin penicillin entity1end , thiopental , entity2begin thyroxine entity2end , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
false chemical chemical Salicylate competes with a number of drugs for protein binding sites , notably entity1begin penicillin entity1end , thiopental , thyroxine , entity2begin triiodothyronine entity2end , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
false chemical chemical Salicylate competes with a number of drugs for protein binding sites , notably entity1begin penicillin entity1end , thiopental , thyroxine , triiodothyronine , entity2begin phenytoin entity2end , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
false chemical chemical Salicylate competes with a number of drugs for protein binding sites , notably entity1begin penicillin entity1end , thiopental , thyroxine , triiodothyronine , phenytoin , entity2begin sulfinpyrazone entity2end , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
false chemical chemical Salicylate competes with a number of drugs for protein binding sites , notably entity1begin penicillin entity1end , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , entity2begin naproxen entity2end , warfarin , methotrexate , and possibly corticosteroids . 
false chemical chemical Salicylate competes with a number of drugs for protein binding sites , notably entity1begin penicillin entity1end , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , entity2begin warfarin entity2end , methotrexate , and possibly corticosteroids . 
false chemical chemical Salicylate competes with a number of drugs for protein binding sites , notably entity1begin penicillin entity1end , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , entity2begin methotrexate entity2end , and possibly corticosteroids . 
false chemical chemical Salicylate competes with a number of drugs for protein binding sites , notably entity1begin penicillin entity1end , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly entity2begin corticosteroids entity2end . 
false chemical chemical Salicylate competes with a number of drugs for protein binding sites , notably penicillin , entity1begin thiopental entity1end , entity2begin thyroxine entity2end , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
false chemical chemical Salicylate competes with a number of drugs for protein binding sites , notably penicillin , entity1begin thiopental entity1end , thyroxine , entity2begin triiodothyronine entity2end , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
false chemical chemical Salicylate competes with a number of drugs for protein binding sites , notably penicillin , entity1begin thiopental entity1end , thyroxine , triiodothyronine , entity2begin phenytoin entity2end , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
false chemical chemical Salicylate competes with a number of drugs for protein binding sites , notably penicillin , entity1begin thiopental entity1end , thyroxine , triiodothyronine , phenytoin , entity2begin sulfinpyrazone entity2end , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
false chemical chemical Salicylate competes with a number of drugs for protein binding sites , notably penicillin , entity1begin thiopental entity1end , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , entity2begin naproxen entity2end , warfarin , methotrexate , and possibly corticosteroids . 
false chemical chemical Salicylate competes with a number of drugs for protein binding sites , notably penicillin , entity1begin thiopental entity1end , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , entity2begin warfarin entity2end , methotrexate , and possibly corticosteroids . 
false chemical chemical Salicylate competes with a number of drugs for protein binding sites , notably penicillin , entity1begin thiopental entity1end , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , entity2begin methotrexate entity2end , and possibly corticosteroids . 
false chemical chemical Salicylate competes with a number of drugs for protein binding sites , notably penicillin , entity1begin thiopental entity1end , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly entity2begin corticosteroids entity2end . 
false chemical chemical Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , entity1begin thyroxine entity1end , entity2begin triiodothyronine entity2end , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
false chemical chemical Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , entity1begin thyroxine entity1end , triiodothyronine , entity2begin phenytoin entity2end , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
false chemical chemical Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , entity1begin thyroxine entity1end , triiodothyronine , phenytoin , entity2begin sulfinpyrazone entity2end , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
false chemical chemical Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , entity1begin thyroxine entity1end , triiodothyronine , phenytoin , sulfinpyrazone , entity2begin naproxen entity2end , warfarin , methotrexate , and possibly corticosteroids . 
false chemical chemical Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , entity1begin thyroxine entity1end , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , entity2begin warfarin entity2end , methotrexate , and possibly corticosteroids . 
false chemical chemical Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , entity1begin thyroxine entity1end , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , entity2begin methotrexate entity2end , and possibly corticosteroids . 
false chemical chemical Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , entity1begin thyroxine entity1end , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly entity2begin corticosteroids entity2end . 
false chemical chemical Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , entity1begin triiodothyronine entity1end , entity2begin phenytoin entity2end , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
false chemical chemical Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , entity1begin triiodothyronine entity1end , phenytoin , entity2begin sulfinpyrazone entity2end , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
false chemical chemical Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , entity1begin triiodothyronine entity1end , phenytoin , sulfinpyrazone , entity2begin naproxen entity2end , warfarin , methotrexate , and possibly corticosteroids . 
false chemical chemical Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , entity1begin triiodothyronine entity1end , phenytoin , sulfinpyrazone , naproxen , entity2begin warfarin entity2end , methotrexate , and possibly corticosteroids . 
false chemical chemical Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , entity1begin triiodothyronine entity1end , phenytoin , sulfinpyrazone , naproxen , warfarin , entity2begin methotrexate entity2end , and possibly corticosteroids . 
false chemical chemical Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , entity1begin triiodothyronine entity1end , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly entity2begin corticosteroids entity2end . 
false chemical chemical Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , entity1begin phenytoin entity1end , entity2begin sulfinpyrazone entity2end , naproxen , warfarin , methotrexate , and possibly corticosteroids . 
false chemical chemical Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , entity1begin phenytoin entity1end , sulfinpyrazone , entity2begin naproxen entity2end , warfarin , methotrexate , and possibly corticosteroids . 
false chemical chemical Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , entity1begin phenytoin entity1end , sulfinpyrazone , naproxen , entity2begin warfarin entity2end , methotrexate , and possibly corticosteroids . 
false chemical chemical Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , entity1begin phenytoin entity1end , sulfinpyrazone , naproxen , warfarin , entity2begin methotrexate entity2end , and possibly corticosteroids . 
false chemical chemical Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , entity1begin phenytoin entity1end , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly entity2begin corticosteroids entity2end . 
false chemical chemical Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , entity1begin sulfinpyrazone entity1end , entity2begin naproxen entity2end , warfarin , methotrexate , and possibly corticosteroids . 
false chemical chemical Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , entity1begin sulfinpyrazone entity1end , naproxen , entity2begin warfarin entity2end , methotrexate , and possibly corticosteroids . 
false chemical chemical Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , entity1begin sulfinpyrazone entity1end , naproxen , warfarin , entity2begin methotrexate entity2end , and possibly corticosteroids . 
false chemical chemical Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , entity1begin sulfinpyrazone entity1end , naproxen , warfarin , methotrexate , and possibly entity2begin corticosteroids entity2end . 
false chemical chemical Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , entity1begin naproxen entity1end , entity2begin warfarin entity2end , methotrexate , and possibly corticosteroids . 
false chemical chemical Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , entity1begin naproxen entity1end , warfarin , entity2begin methotrexate entity2end , and possibly corticosteroids . 
false chemical chemical Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , entity1begin naproxen entity1end , warfarin , methotrexate , and possibly entity2begin corticosteroids entity2end . 
false chemical chemical Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , entity1begin warfarin entity1end , entity2begin methotrexate entity2end , and possibly corticosteroids . 
false chemical chemical Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , entity1begin warfarin entity1end , methotrexate , and possibly entity2begin corticosteroids entity2end . 
false chemical chemical Salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , entity1begin methotrexate entity1end , and possibly entity2begin corticosteroids entity2end . 
true chemical chemical Drugs which may potentiate the myeloproliferative effects of entity1begin Leukine entity1end , such as entity2begin lithium entity2end and corticosteroids , should be used with caution . 
true chemical chemical Drugs which may potentiate the myeloproliferative effects of entity1begin Leukine entity1end , such as lithium and entity2begin corticosteroids entity2end , should be used with caution . 
false chemical chemical Drugs which may potentiate the myeloproliferative effects of Leukine , such as entity1begin lithium entity1end and entity2begin corticosteroids entity2end , should be used with caution . 
true chemical chemical entity1begin Scopolamine entity1end should be used with care in patients taking other drugs that are capable of causing CNS effects such as entity2begin sedatives entity2end , tranquilizers , or alcohol . 
true chemical chemical entity1begin Scopolamine entity1end should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives , entity2begin tranquilizers entity2end , or alcohol . 
true chemical chemical entity1begin Scopolamine entity1end should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives , tranquilizers , or entity2begin alcohol entity2end . 
false chemical chemical Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as entity1begin sedatives entity1end , entity2begin tranquilizers entity2end , or alcohol . 
false chemical chemical Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as entity1begin sedatives entity1end , tranquilizers , or entity2begin alcohol entity2end . 
false chemical chemical Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives , entity1begin tranquilizers entity1end , or entity2begin alcohol entity2end . 
false chemical chemical e.g. , other entity1begin belladonna alkaloids entity1end , entity2begin antihistamines entity2end ( including meclizine ) , tricyclic antidepressants , and muscle relaxants . 
false chemical chemical e.g. , other entity1begin belladonna alkaloids entity1end , antihistamines ( including entity2begin meclizine entity2end ) , tricyclic antidepressants , and muscle relaxants . 
false chemical chemical e.g. , other entity1begin belladonna alkaloids entity1end , antihistamines ( including meclizine ) , entity2begin tricyclic antidepressants entity2end , and muscle relaxants . 
false chemical chemical e.g. , other entity1begin belladonna alkaloids entity1end , antihistamines ( including meclizine ) , tricyclic antidepressants , and entity2begin muscle relaxants entity2end . 
false chemical chemical e.g. , other belladonna alkaloids , entity1begin antihistamines entity1end ( including entity2begin meclizine entity2end ) , tricyclic antidepressants , and muscle relaxants . 
false chemical chemical e.g. , other belladonna alkaloids , entity1begin antihistamines entity1end ( including meclizine ) , entity2begin tricyclic antidepressants entity2end , and muscle relaxants . 
false chemical chemical e.g. , other belladonna alkaloids , entity1begin antihistamines entity1end ( including meclizine ) , tricyclic antidepressants , and entity2begin muscle relaxants entity2end . 
false chemical chemical e.g. , other belladonna alkaloids , antihistamines ( including entity1begin meclizine entity1end ) , entity2begin tricyclic antidepressants entity2end , and muscle relaxants . 
false chemical chemical e.g. , other belladonna alkaloids , antihistamines ( including entity1begin meclizine entity1end ) , tricyclic antidepressants , and entity2begin muscle relaxants entity2end . 
false chemical chemical e.g. , other belladonna alkaloids , antihistamines ( including meclizine ) , entity1begin tricyclic antidepressants entity1end , and entity2begin muscle relaxants entity2end . 
true chemical chemical entity1begin Barbiturates entity1end may decrease the effectiveness of oral entity2begin contraceptives entity2end , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers . 
true chemical chemical entity1begin Barbiturates entity1end may decrease the effectiveness of oral contraceptives , certain entity2begin antibiotics entity2end , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers . 
true chemical chemical entity1begin Barbiturates entity1end may decrease the effectiveness of oral contraceptives , certain antibiotics , entity2begin quinidine entity2end , theophylline , corticosteroids , anticoagulants , and beta blockers . 
true chemical chemical entity1begin Barbiturates entity1end may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , entity2begin theophylline entity2end , corticosteroids , anticoagulants , and beta blockers . 
true chemical chemical entity1begin Barbiturates entity1end may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , entity2begin corticosteroids entity2end , anticoagulants , and beta blockers . 
true chemical chemical entity1begin Barbiturates entity1end may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , entity2begin anticoagulants entity2end , and beta blockers . 
true chemical chemical entity1begin Barbiturates entity1end may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and entity2begin beta blockers entity2end . 
false chemical chemical Barbiturates may decrease the effectiveness of oral entity1begin contraceptives entity1end , certain entity2begin antibiotics entity2end , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers . 
false chemical chemical Barbiturates may decrease the effectiveness of oral entity1begin contraceptives entity1end , certain antibiotics , entity2begin quinidine entity2end , theophylline , corticosteroids , anticoagulants , and beta blockers . 
false chemical chemical Barbiturates may decrease the effectiveness of oral entity1begin contraceptives entity1end , certain antibiotics , quinidine , entity2begin theophylline entity2end , corticosteroids , anticoagulants , and beta blockers . 
false chemical chemical Barbiturates may decrease the effectiveness of oral entity1begin contraceptives entity1end , certain antibiotics , quinidine , theophylline , entity2begin corticosteroids entity2end , anticoagulants , and beta blockers . 
false chemical chemical Barbiturates may decrease the effectiveness of oral entity1begin contraceptives entity1end , certain antibiotics , quinidine , theophylline , corticosteroids , entity2begin anticoagulants entity2end , and beta blockers . 
false chemical chemical Barbiturates may decrease the effectiveness of oral entity1begin contraceptives entity1end , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and entity2begin beta blockers entity2end . 
false chemical chemical Barbiturates may decrease the effectiveness of oral contraceptives , certain entity1begin antibiotics entity1end , entity2begin quinidine entity2end , theophylline , corticosteroids , anticoagulants , and beta blockers . 
false chemical chemical Barbiturates may decrease the effectiveness of oral contraceptives , certain entity1begin antibiotics entity1end , quinidine , entity2begin theophylline entity2end , corticosteroids , anticoagulants , and beta blockers . 
false chemical chemical Barbiturates may decrease the effectiveness of oral contraceptives , certain entity1begin antibiotics entity1end , quinidine , theophylline , entity2begin corticosteroids entity2end , anticoagulants , and beta blockers . 
false chemical chemical Barbiturates may decrease the effectiveness of oral contraceptives , certain entity1begin antibiotics entity1end , quinidine , theophylline , corticosteroids , entity2begin anticoagulants entity2end , and beta blockers . 
false chemical chemical Barbiturates may decrease the effectiveness of oral contraceptives , certain entity1begin antibiotics entity1end , quinidine , theophylline , corticosteroids , anticoagulants , and entity2begin beta blockers entity2end . 
false chemical chemical Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , entity1begin quinidine entity1end , entity2begin theophylline entity2end , corticosteroids , anticoagulants , and beta blockers . 
false chemical chemical Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , entity1begin quinidine entity1end , theophylline , entity2begin corticosteroids entity2end , anticoagulants , and beta blockers . 
false chemical chemical Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , entity1begin quinidine entity1end , theophylline , corticosteroids , entity2begin anticoagulants entity2end , and beta blockers . 
false chemical chemical Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , entity1begin quinidine entity1end , theophylline , corticosteroids , anticoagulants , and entity2begin beta blockers entity2end . 
false chemical chemical Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , entity1begin theophylline entity1end , entity2begin corticosteroids entity2end , anticoagulants , and beta blockers . 
false chemical chemical Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , entity1begin theophylline entity1end , corticosteroids , entity2begin anticoagulants entity2end , and beta blockers . 
false chemical chemical Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , entity1begin theophylline entity1end , corticosteroids , anticoagulants , and entity2begin beta blockers entity2end . 
false chemical chemical Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , entity1begin corticosteroids entity1end , entity2begin anticoagulants entity2end , and beta blockers . 
false chemical chemical Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , entity1begin corticosteroids entity1end , anticoagulants , and entity2begin beta blockers entity2end . 
false chemical chemical Barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , entity1begin anticoagulants entity1end , and entity2begin beta blockers entity2end . 
true chemical chemical The occurrence of stupor , muscular rigidity , severe agitation , and elevated temperature has been reported in some patients receiving the combination of entity1begin selegiline entity1end and entity2begin meperidine entity2end . 
true chemical chemical This is typical of the interaction of entity1begin meperidine entity1end and entity2begin MAOIs entity2end . 
true chemical chemical Severe toxicity has also been reported in patients receiving the combination of entity1begin tricyclic antidepressants entity1end and entity2begin ELDEPRYL entity2end and selective serotonin reuptake inhibitors and ELDEPRYL . 
false chemical chemical Severe toxicity has also been reported in patients receiving the combination of entity1begin tricyclic antidepressants entity1end and ELDEPRYL and entity2begin selective serotonin reuptake inhibitors entity2end and ELDEPRYL . 
false chemical chemical Severe toxicity has also been reported in patients receiving the combination of entity1begin tricyclic antidepressants entity1end and ELDEPRYL and selective serotonin reuptake inhibitors and entity2begin ELDEPRYL entity2end . 
false chemical chemical Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and entity1begin ELDEPRYL entity1end and entity2begin selective serotonin reuptake inhibitors entity2end and ELDEPRYL . 
false chemical chemical Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and entity1begin ELDEPRYL entity1end and selective serotonin reuptake inhibitors and entity2begin ELDEPRYL entity2end . 
true chemical chemical Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and ELDEPRYL and entity1begin selective serotonin reuptake inhibitors entity1end and entity2begin ELDEPRYL entity2end . 
true chemical chemical One case of hypertensive crisis has been reported in a patient taking the recommended doses of entity1begin selegiline entity1end and a entity2begin sympathomimetic medication entity2end ( ephedrine ) . 
true chemical chemical One case of hypertensive crisis has been reported in a patient taking the recommended doses of entity1begin selegiline entity1end and a sympathomimetic medication ( entity2begin ephedrine entity2end ) . 
false chemical chemical One case of hypertensive crisis has been reported in a patient taking the recommended doses of selegiline and a entity1begin sympathomimetic medication entity1end ( entity2begin ephedrine entity2end ) . 
false chemical chemical entity1begin Digoxin entity1end : There was a slight increase in the area under the curve ( AUC , 11 % ) and mean peak drug concentration ( Cmax , 18 % ) of entity2begin digoxin entity2end with the co - administration of 100 mg sitagliptin for 10 days . 
false chemical chemical entity1begin Digoxin entity1end : There was a slight increase in the area under the curve ( AUC , 11 % ) and mean peak drug concentration ( Cmax , 18 % ) of digoxin with the co - administration of 100 mg entity2begin sitagliptin entity2end for 10 days . 
true chemical chemical Digoxin : There was a slight increase in the area under the curve ( AUC , 11 % ) and mean peak drug concentration ( Cmax , 18 % ) of entity1begin digoxin entity1end with the co - administration of 100 mg entity2begin sitagliptin entity2end for 10 days . 
false chemical chemical No dosage adjustment of entity1begin digoxin entity1end or entity2begin JANUVIA entity2end is recommended . 
false chemical chemical entity1begin norepinephrine entity1end and entity2begin dobutamine entity2end are incompatible with sodium bicarbonate solution . 
true chemical chemical entity1begin norepinephrine entity1end and dobutamine are incompatible with entity2begin sodium bicarbonate entity2end solution . 
true chemical chemical norepinephrine and entity1begin dobutamine entity1end are incompatible with entity2begin sodium bicarbonate entity2end solution . 
false chemical chemical The addition of entity1begin sodium bicarbonate entity1end to parenteral solutions containing entity2begin calcium entity2end should be avoided , except where compatibility has been previously established . 
true chemical chemical Do not exceed a 5 mg daily dose of entity1begin VESIcare entity1end when administered with therapeutic doses of entity2begin ketoconazole entity2end or other potent CYP3A4 inhibitors . 
false chemical chemical Patients with Congenital or Acquired QT Prolongation In a study of the effect of entity1begin solifenacin entity1end on the QT interval in 76 healthy women , the QT prolonging effect appeared less with entity2begin solifenacin entity2end 10 mg than with 30 mg ( three times the maximum recommended dose ) , and the effect of solifenacin 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose . 
false chemical chemical Patients with Congenital or Acquired QT Prolongation In a study of the effect of entity1begin solifenacin entity1end on the QT interval in 76 healthy women , the QT prolonging effect appeared less with solifenacin 10 mg than with 30 mg ( three times the maximum recommended dose ) , and the effect of entity2begin solifenacin entity2end 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose . 
false chemical chemical Patients with Congenital or Acquired QT Prolongation In a study of the effect of entity1begin solifenacin entity1end on the QT interval in 76 healthy women , the QT prolonging effect appeared less with solifenacin 10 mg than with 30 mg ( three times the maximum recommended dose ) , and the effect of solifenacin 30 mg did not appear as large as that of the positive control entity2begin moxifloxacin entity2end at its therapeutic dose . 
false chemical chemical Patients with Congenital or Acquired QT Prolongation In a study of the effect of solifenacin on the QT interval in 76 healthy women , the QT prolonging effect appeared less with entity1begin solifenacin entity1end 10 mg than with 30 mg ( three times the maximum recommended dose ) , and the effect of entity2begin solifenacin entity2end 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose . 
false chemical chemical Patients with Congenital or Acquired QT Prolongation In a study of the effect of solifenacin on the QT interval in 76 healthy women , the QT prolonging effect appeared less with entity1begin solifenacin entity1end 10 mg than with 30 mg ( three times the maximum recommended dose ) , and the effect of solifenacin 30 mg did not appear as large as that of the positive control entity2begin moxifloxacin entity2end at its therapeutic dose . 
false chemical chemical Patients with Congenital or Acquired QT Prolongation In a study of the effect of solifenacin on the QT interval in 76 healthy women , the QT prolonging effect appeared less with solifenacin 10 mg than with 30 mg ( three times the maximum recommended dose ) , and the effect of entity1begin solifenacin entity1end 30 mg did not appear as large as that of the positive control entity2begin moxifloxacin entity2end at its therapeutic dose . 
false chemical chemical If entity1begin glucocorticoid entity1end replacement is required , the entity2begin glucocorticoid entity2end dose should be carefully adjusted . 
true chemical chemical Limited published data indicate that entity1begin GH entity1end treatment increases cytochrome P450 ( CP450 ) mediated entity2begin antipyrine entity2end clearance in man . 
true chemical chemical These data suggest that entity1begin GH entity1end administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes ( e.g. , entity2begin corticosteroids entity2end , sex steroids , anticonvulsants , cyclosporin ) . 
true chemical chemical These data suggest that entity1begin GH entity1end administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes ( e.g. , corticosteroids , entity2begin sex steroids entity2end , anticonvulsants , cyclosporin ) . 
true chemical chemical These data suggest that entity1begin GH entity1end administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes ( e.g. , corticosteroids , sex steroids , entity2begin anticonvulsants entity2end , cyclosporin ) . 
true chemical chemical These data suggest that entity1begin GH entity1end administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes ( e.g. , corticosteroids , sex steroids , anticonvulsants , entity2begin cyclosporin entity2end ) . 
false chemical chemical These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes ( e.g. , entity1begin corticosteroids entity1end , entity2begin sex steroids entity2end , anticonvulsants , cyclosporin ) . 
false chemical chemical These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes ( e.g. , entity1begin corticosteroids entity1end , sex steroids , entity2begin anticonvulsants entity2end , cyclosporin ) . 
false chemical chemical These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes ( e.g. , entity1begin corticosteroids entity1end , sex steroids , anticonvulsants , entity2begin cyclosporin entity2end ) . 
false chemical chemical These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes ( e.g. , corticosteroids , entity1begin sex steroids entity1end , entity2begin anticonvulsants entity2end , cyclosporin ) . 
false chemical chemical These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes ( e.g. , corticosteroids , entity1begin sex steroids entity1end , anticonvulsants , entity2begin cyclosporin entity2end ) . 
false chemical chemical These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes ( e.g. , corticosteroids , sex steroids , entity1begin anticonvulsants entity1end , entity2begin cyclosporin entity2end ) . 
true chemical chemical Caution is recommended when administering entity1begin NEXAVAR entity1end with compounds that are metabolized / eliminated predominantly by the UGT1A1 pathway ( e.g. entity2begin irinotecan entity2end ) . 
true chemical chemical Concomitant treatment with entity1begin NEXAVAR entity1end resulted in a 21 % increase in the AUC of entity2begin doxorubicin entity2end . 
true chemical chemical Caution is recommended when administering entity1begin doxorubicin entity1end with entity2begin NEXAVAR entity2end . 
true chemical chemical entity1begin Zidovudine entity1end competitively inhibits the intracellular phosphorylation of entity2begin stavudine entity2end . 
true chemical chemical Therefore , use of entity1begin zidovudine entity1end in combination with entity2begin ZERIT entity2end should be avoided . 
true chemical chemical In vitro data indicate that the phosphorylation of entity1begin stavudine entity1end is also inhibited at relevant concentrations by entity2begin doxorubicin entity2end and ribavirin . 
true chemical chemical In vitro data indicate that the phosphorylation of entity1begin stavudine entity1end is also inhibited at relevant concentrations by doxorubicin and entity2begin ribavirin entity2end . 
false chemical chemical In vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by entity1begin doxorubicin entity1end and entity2begin ribavirin entity2end . 
false chemical chemical The interaction of entity1begin Streptase entity1end , entity2begin Streptokinase entity2end , with other drugs has not been well studied . 
false chemical chemical Use of entity1begin Anticoagulants entity1end and entity2begin Antiplatelet Agents entity2end - - Streptase , Streptokinase , alone or in combination with antiplatelet agents and anticoagulants , may cause bleeding complications . 
false chemical chemical Use of entity1begin Anticoagulants entity1end and Antiplatelet Agents - - entity2begin Streptase entity2end , Streptokinase , alone or in combination with antiplatelet agents and anticoagulants , may cause bleeding complications . 
false chemical chemical Use of entity1begin Anticoagulants entity1end and Antiplatelet Agents - - Streptase , entity2begin Streptokinase entity2end , alone or in combination with antiplatelet agents and anticoagulants , may cause bleeding complications . 
false chemical chemical Use of entity1begin Anticoagulants entity1end and Antiplatelet Agents - - Streptase , Streptokinase , alone or in combination with entity2begin antiplatelet agents entity2end and anticoagulants , may cause bleeding complications . 
false chemical chemical Use of entity1begin Anticoagulants entity1end and Antiplatelet Agents - - Streptase , Streptokinase , alone or in combination with antiplatelet agents and entity2begin anticoagulants entity2end , may cause bleeding complications . 
false chemical chemical Use of Anticoagulants and entity1begin Antiplatelet Agents entity1end - - entity2begin Streptase entity2end , Streptokinase , alone or in combination with antiplatelet agents and anticoagulants , may cause bleeding complications . 
false chemical chemical Use of Anticoagulants and entity1begin Antiplatelet Agents entity1end - - Streptase , entity2begin Streptokinase entity2end , alone or in combination with antiplatelet agents and anticoagulants , may cause bleeding complications . 
false chemical chemical Use of Anticoagulants and entity1begin Antiplatelet Agents entity1end - - Streptase , Streptokinase , alone or in combination with entity2begin antiplatelet agents entity2end and anticoagulants , may cause bleeding complications . 
false chemical chemical Use of Anticoagulants and entity1begin Antiplatelet Agents entity1end - - Streptase , Streptokinase , alone or in combination with antiplatelet agents and entity2begin anticoagulants entity2end , may cause bleeding complications . 
false chemical chemical Use of Anticoagulants and Antiplatelet Agents - - entity1begin Streptase entity1end , entity2begin Streptokinase entity2end , alone or in combination with antiplatelet agents and anticoagulants , may cause bleeding complications . 
true chemical chemical Use of Anticoagulants and Antiplatelet Agents - - entity1begin Streptase entity1end , Streptokinase , alone or in combination with entity2begin antiplatelet agents entity2end and anticoagulants , may cause bleeding complications . 
true chemical chemical Use of Anticoagulants and Antiplatelet Agents - - entity1begin Streptase entity1end , Streptokinase , alone or in combination with antiplatelet agents and entity2begin anticoagulants entity2end , may cause bleeding complications . 
true chemical chemical Use of Anticoagulants and Antiplatelet Agents - - Streptase , entity1begin Streptokinase entity1end , alone or in combination with entity2begin antiplatelet agents entity2end and anticoagulants , may cause bleeding complications . 
true chemical chemical Use of Anticoagulants and Antiplatelet Agents - - Streptase , entity1begin Streptokinase entity1end , alone or in combination with antiplatelet agents and entity2begin anticoagulants entity2end , may cause bleeding complications . 
false chemical chemical Use of Anticoagulants and Antiplatelet Agents - - Streptase , Streptokinase , alone or in combination with entity1begin antiplatelet agents entity1end and entity2begin anticoagulants entity2end , may cause bleeding complications . 
false chemical chemical In the treatment of acute MI , entity1begin aspirin entity1end , when not otherwise contraindicated , should be administered with entity2begin Streptokinase entity2end ( see below ) . 
false chemical chemical Anticoagulation and entity1begin Antiplatelets entity1end After Treatment for Myocardial Infarction - - In the treatment of acute myocardial infarction , the use of entity2begin aspirin entity2end has been shown to reduce the incidence of reinfarction and stroke . 
true chemical chemical The addition of entity1begin aspirin entity1end to entity2begin Streptokinase entity2end causes a minimal increase in the risk of minor bleeding ( 3.9 % vs. 3.1 % ) , but does not appear to increase the incidence of major bleeding ( see 
true chemical chemical entity1begin Streptozocin entity1end has been reported to prolong the elimination half - life of entity2begin doxorubicin entity2end and may lead to severe bone marrow suppression ; 
true chemical chemical a reduction of the entity1begin doxorubicin entity1end dosage should be considered in patients receiving entity2begin ZANOSAR entity2end concurrently . 
true chemical chemical The concurrent use of entity1begin streptozocin entity1end and entity2begin phenytoin entity2end has been reported in one case to result in reduced streptozocin cytotoxicity . 
false chemical chemical The concurrent use of entity1begin streptozocin entity1end and phenytoin has been reported in one case to result in reduced entity2begin streptozocin entity2end cytotoxicity . 
false chemical chemical The concurrent use of streptozocin and entity1begin phenytoin entity1end has been reported in one case to result in reduced entity2begin streptozocin entity2end cytotoxicity . 
false chemical chemical entity1begin CHEMET entity1end is not known to interact with other drugs including entity2begin iron entity2end supplements ; 
true chemical chemical Concomitant administration of entity1begin CHEMET entity1end with other chelation therapy , such as entity2begin CaNa 2 EDTA entity2end is not recommended . 
true chemical chemical entity1begin Sulfamethizole entity1end may increase the effects of entity2begin barbiturates entity2end , tolbutamide , and uricosurics . 
true chemical chemical entity1begin Sulfamethizole entity1end may increase the effects of barbiturates , entity2begin tolbutamide entity2end , and uricosurics . 
true chemical chemical entity1begin Sulfamethizole entity1end may increase the effects of barbiturates , tolbutamide , and entity2begin uricosurics entity2end . 
false chemical chemical Sulfamethizole may increase the effects of entity1begin barbiturates entity1end , entity2begin tolbutamide entity2end , and uricosurics . 
false chemical chemical Sulfamethizole may increase the effects of entity1begin barbiturates entity1end , tolbutamide , and entity2begin uricosurics entity2end . 
false chemical chemical Sulfamethizole may increase the effects of barbiturates , entity1begin tolbutamide entity1end , and entity2begin uricosurics entity2end . 
false chemical chemical It may also interact with entity1begin thiazides entity1end ( increased thrombocytopenia ) , entity2begin cyclosporine entity2end ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) . 
false chemical chemical It may also interact with entity1begin thiazides entity1end ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , entity2begin sulfonylurea agents entity2end ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) . 
false chemical chemical It may also interact with entity1begin thiazides entity1end ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , entity2begin warfarin entity2end ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) . 
false chemical chemical It may also interact with entity1begin thiazides entity1end ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , entity2begin methotrexate entity2end ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) . 
false chemical chemical It may also interact with entity1begin thiazides entity1end ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of entity2begin methotrexate entity2end ) , phenytoin ( decreased hepatic clearance of phenytoin ) . 
false chemical chemical It may also interact with entity1begin thiazides entity1end ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , entity2begin phenytoin entity2end ( decreased hepatic clearance of phenytoin ) . 
false chemical chemical It may also interact with entity1begin thiazides entity1end ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of entity2begin phenytoin entity2end ) . 
false chemical chemical It may also interact with thiazides ( increased thrombocytopenia ) , entity1begin cyclosporine entity1end ( increased nephrotoxicity ) , entity2begin sulfonylurea agents entity2end ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) . 
false chemical chemical It may also interact with thiazides ( increased thrombocytopenia ) , entity1begin cyclosporine entity1end ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , entity2begin warfarin entity2end ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) . 
false chemical chemical It may also interact with thiazides ( increased thrombocytopenia ) , entity1begin cyclosporine entity1end ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , entity2begin methotrexate entity2end ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) . 
false chemical chemical It may also interact with thiazides ( increased thrombocytopenia ) , entity1begin cyclosporine entity1end ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of entity2begin methotrexate entity2end ) , phenytoin ( decreased hepatic clearance of phenytoin ) . 
false chemical chemical It may also interact with thiazides ( increased thrombocytopenia ) , entity1begin cyclosporine entity1end ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , entity2begin phenytoin entity2end ( decreased hepatic clearance of phenytoin ) . 
false chemical chemical It may also interact with thiazides ( increased thrombocytopenia ) , entity1begin cyclosporine entity1end ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of entity2begin phenytoin entity2end ) . 
false chemical chemical It may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , entity1begin sulfonylurea agents entity1end ( increased hypoglycemic response ) , entity2begin warfarin entity2end ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) . 
false chemical chemical It may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , entity1begin sulfonylurea agents entity1end ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , entity2begin methotrexate entity2end ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) . 
false chemical chemical It may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , entity1begin sulfonylurea agents entity1end ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of entity2begin methotrexate entity2end ) , phenytoin ( decreased hepatic clearance of phenytoin ) . 
false chemical chemical It may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , entity1begin sulfonylurea agents entity1end ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , entity2begin phenytoin entity2end ( decreased hepatic clearance of phenytoin ) . 
false chemical chemical It may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , entity1begin sulfonylurea agents entity1end ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of entity2begin phenytoin entity2end ) . 
false chemical chemical It may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , entity1begin warfarin entity1end ( increased anticoagulant effect ) , entity2begin methotrexate entity2end ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) . 
false chemical chemical It may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , entity1begin warfarin entity1end ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of entity2begin methotrexate entity2end ) , phenytoin ( decreased hepatic clearance of phenytoin ) . 
false chemical chemical It may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , entity1begin warfarin entity1end ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , entity2begin phenytoin entity2end ( decreased hepatic clearance of phenytoin ) . 
false chemical chemical It may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , entity1begin warfarin entity1end ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of entity2begin phenytoin entity2end ) . 
false chemical chemical It may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , entity1begin methotrexate entity1end ( decreased renal excretion of entity2begin methotrexate entity2end ) , phenytoin ( decreased hepatic clearance of phenytoin ) . 
false chemical chemical It may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , entity1begin methotrexate entity1end ( decreased renal excretion of methotrexate ) , entity2begin phenytoin entity2end ( decreased hepatic clearance of phenytoin ) . 
false chemical chemical It may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , entity1begin methotrexate entity1end ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of entity2begin phenytoin entity2end ) . 
false chemical chemical It may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of entity1begin methotrexate entity1end ) , entity2begin phenytoin entity2end ( decreased hepatic clearance of phenytoin ) . 
false chemical chemical It may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of entity1begin methotrexate entity1end ) , phenytoin ( decreased hepatic clearance of entity2begin phenytoin entity2end ) . 
false chemical chemical It may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , entity1begin phenytoin entity1end ( decreased hepatic clearance of entity2begin phenytoin entity2end ) . 
false chemical chemical In elderly patients concurrently receiving certain entity1begin diuretics entity1end , primarily entity2begin thiazides entity2end , an increased incidence of thrombopenia with purpura has been reported . 
false chemical chemical It has been reported that entity1begin sulfamethoxazole entity1end may prolong the prothrombin time in patients who are receiving the entity2begin anticoagulant entity2end warfarin . 
true chemical chemical It has been reported that entity1begin sulfamethoxazole entity1end may prolong the prothrombin time in patients who are receiving the anticoagulant entity2begin warfarin entity2end . 
false chemical chemical It has been reported that sulfamethoxazole may prolong the prothrombin time in patients who are receiving the entity1begin anticoagulant entity1end entity2begin warfarin entity2end . 
true chemical chemical entity1begin Sulfamethoxazole entity1end may inhibit the hepatic metabolism of entity2begin phenytoin entity2end . 
true chemical chemical At a 1.6 - g dose , entity1begin sulfamethoxazole entity1end produced a slight but significant increase in the half - life of entity2begin phenytoin entity2end but did not produce a corresponding decrease in the metabolic clearance rate . 
true chemical chemical entity1begin Sulfonamides entity1end can also displace entity2begin methotrexate entity2end from plasma protein - binding sites , thus increasing free methotrexate concentrations . 
false chemical chemical entity1begin Sulfonamides entity1end can also displace methotrexate from plasma protein - binding sites , thus increasing free entity2begin methotrexate entity2end concentrations . 
false chemical chemical Sulfonamides can also displace entity1begin methotrexate entity1end from plasma protein - binding sites , thus increasing free entity2begin methotrexate entity2end concentrations . 
false chemical chemical Reduced absorption of entity1begin folic acid entity1end and entity2begin digoxin entity2end have been reported when those agents were administered concomitantly with sulfasalazine . 
true chemical chemical Reduced absorption of entity1begin folic acid entity1end and digoxin have been reported when those agents were administered concomitantly with entity2begin sulfasalazine entity2end . 
true chemical chemical Reduced absorption of folic acid and entity1begin digoxin entity1end have been reported when those agents were administered concomitantly with entity2begin sulfasalazine entity2end . 
false chemical chemical When daily doses of entity1begin sulfasalazine entity1end 2 g and weekly doses of entity2begin methotrexate entity2end 7.5 mg were coadministered to 15 rheumatoid arthritis patients in a drug - drug interaction study , the pharmacokinetic disposition of the drugs was not altered . 
false chemical chemical Daily doses of entity1begin sulfasalazine entity1end 2 g ( maximum 3 g ) and weekly doses of entity2begin methotrexate entity2end 7.5 mg ( maximum 15 mg ) were administered alone or in combination to 310 rheumatoid arthritis patients in two controlled 52 - week clinical studies . 
true chemical chemical entity1begin Sulfoxone entity1end may increase the effects of entity2begin barbiturates entity2end , tolbutamide , and uricosurics . 
true chemical chemical entity1begin Sulfoxone entity1end may increase the effects of barbiturates , entity2begin tolbutamide entity2end , and uricosurics . 
true chemical chemical entity1begin Sulfoxone entity1end may increase the effects of barbiturates , tolbutamide , and entity2begin uricosurics entity2end . 
false chemical chemical Sulfoxone may increase the effects of entity1begin barbiturates entity1end , entity2begin tolbutamide entity2end , and uricosurics . 
false chemical chemical Sulfoxone may increase the effects of entity1begin barbiturates entity1end , tolbutamide , and entity2begin uricosurics entity2end . 
false chemical chemical Sulfoxone may increase the effects of barbiturates , entity1begin tolbutamide entity1end , and entity2begin uricosurics entity2end . 
false chemical chemical It may also interact with entity1begin thiazides entity1end ( increased thrombocytopenia ) , entity2begin cyclosporine entity2end ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) . 
false chemical chemical It may also interact with entity1begin thiazides entity1end ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , entity2begin sulfonylurea agents entity2end ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) . 
false chemical chemical It may also interact with entity1begin thiazides entity1end ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , entity2begin warfarin entity2end ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) . 
false chemical chemical It may also interact with entity1begin thiazides entity1end ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , entity2begin methotrexate entity2end ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) . 
false chemical chemical It may also interact with entity1begin thiazides entity1end ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of entity2begin methotrexate entity2end ) , phenytoin ( decreased hepatic clearance of phenytoin ) . 
false chemical chemical It may also interact with entity1begin thiazides entity1end ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , entity2begin phenytoin entity2end ( decreased hepatic clearance of phenytoin ) . 
false chemical chemical It may also interact with entity1begin thiazides entity1end ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of entity2begin phenytoin entity2end ) . 
false chemical chemical It may also interact with thiazides ( increased thrombocytopenia ) , entity1begin cyclosporine entity1end ( increased nephrotoxicity ) , entity2begin sulfonylurea agents entity2end ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) . 
false chemical chemical It may also interact with thiazides ( increased thrombocytopenia ) , entity1begin cyclosporine entity1end ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , entity2begin warfarin entity2end ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) . 
false chemical chemical It may also interact with thiazides ( increased thrombocytopenia ) , entity1begin cyclosporine entity1end ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , entity2begin methotrexate entity2end ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) . 
false chemical chemical It may also interact with thiazides ( increased thrombocytopenia ) , entity1begin cyclosporine entity1end ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of entity2begin methotrexate entity2end ) , phenytoin ( decreased hepatic clearance of phenytoin ) . 
false chemical chemical It may also interact with thiazides ( increased thrombocytopenia ) , entity1begin cyclosporine entity1end ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , entity2begin phenytoin entity2end ( decreased hepatic clearance of phenytoin ) . 
false chemical chemical It may also interact with thiazides ( increased thrombocytopenia ) , entity1begin cyclosporine entity1end ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of entity2begin phenytoin entity2end ) . 
false chemical chemical It may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , entity1begin sulfonylurea agents entity1end ( increased hypoglycemic response ) , entity2begin warfarin entity2end ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) . 
false chemical chemical It may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , entity1begin sulfonylurea agents entity1end ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , entity2begin methotrexate entity2end ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) . 
false chemical chemical It may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , entity1begin sulfonylurea agents entity1end ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of entity2begin methotrexate entity2end ) , phenytoin ( decreased hepatic clearance of phenytoin ) . 
false chemical chemical It may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , entity1begin sulfonylurea agents entity1end ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , entity2begin phenytoin entity2end ( decreased hepatic clearance of phenytoin ) . 
false chemical chemical It may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , entity1begin sulfonylurea agents entity1end ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of entity2begin phenytoin entity2end ) . 
false chemical chemical It may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , entity1begin warfarin entity1end ( increased anticoagulant effect ) , entity2begin methotrexate entity2end ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) . 
false chemical chemical It may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , entity1begin warfarin entity1end ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of entity2begin methotrexate entity2end ) , phenytoin ( decreased hepatic clearance of phenytoin ) . 
false chemical chemical It may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , entity1begin warfarin entity1end ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , entity2begin phenytoin entity2end ( decreased hepatic clearance of phenytoin ) . 
false chemical chemical It may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , entity1begin warfarin entity1end ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of entity2begin phenytoin entity2end ) . 
false chemical chemical It may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , entity1begin methotrexate entity1end ( decreased renal excretion of entity2begin methotrexate entity2end ) , phenytoin ( decreased hepatic clearance of phenytoin ) . 
false chemical chemical It may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , entity1begin methotrexate entity1end ( decreased renal excretion of methotrexate ) , entity2begin phenytoin entity2end ( decreased hepatic clearance of phenytoin ) . 
false chemical chemical It may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , entity1begin methotrexate entity1end ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of entity2begin phenytoin entity2end ) . 
false chemical chemical It may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of entity1begin methotrexate entity1end ) , entity2begin phenytoin entity2end ( decreased hepatic clearance of phenytoin ) . 
false chemical chemical It may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of entity1begin methotrexate entity1end ) , phenytoin ( decreased hepatic clearance of entity2begin phenytoin entity2end ) . 
false chemical chemical It may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , entity1begin phenytoin entity1end ( decreased hepatic clearance of entity2begin phenytoin entity2end ) . 
false chemical chemical Because there is a theoretical basis that these effects may be additive , use of entity1begin ergotamine entity1end - containing or entity2begin ergot - type medications entity2end ( like dihydroergotamine or methysergide ) and sumatriptan within 24 hours of each other should be avoided . 
false chemical chemical Because there is a theoretical basis that these effects may be additive , use of entity1begin ergotamine entity1end - containing or ergot - type medications ( like entity2begin dihydroergotamine entity2end or methysergide ) and sumatriptan within 24 hours of each other should be avoided . 
false chemical chemical Because there is a theoretical basis that these effects may be additive , use of entity1begin ergotamine entity1end - containing or ergot - type medications ( like dihydroergotamine or entity2begin methysergide entity2end ) and sumatriptan within 24 hours of each other should be avoided . 
true chemical chemical Because there is a theoretical basis that these effects may be additive , use of entity1begin ergotamine entity1end - containing or ergot - type medications ( like dihydroergotamine or methysergide ) and entity2begin sumatriptan entity2end within 24 hours of each other should be avoided . 
false chemical chemical Because there is a theoretical basis that these effects may be additive , use of ergotamine - containing or entity1begin ergot - type medications entity1end ( like entity2begin dihydroergotamine entity2end or methysergide ) and sumatriptan within 24 hours of each other should be avoided . 
false chemical chemical Because there is a theoretical basis that these effects may be additive , use of ergotamine - containing or entity1begin ergot - type medications entity1end ( like dihydroergotamine or entity2begin methysergide entity2end ) and sumatriptan within 24 hours of each other should be avoided . 
true chemical chemical Because there is a theoretical basis that these effects may be additive , use of ergotamine - containing or entity1begin ergot - type medications entity1end ( like dihydroergotamine or methysergide ) and entity2begin sumatriptan entity2end within 24 hours of each other should be avoided . 
false chemical chemical Because there is a theoretical basis that these effects may be additive , use of ergotamine - containing or ergot - type medications ( like entity1begin dihydroergotamine entity1end or entity2begin methysergide entity2end ) and sumatriptan within 24 hours of each other should be avoided . 
true chemical chemical Because there is a theoretical basis that these effects may be additive , use of ergotamine - containing or ergot - type medications ( like entity1begin dihydroergotamine entity1end or methysergide ) and entity2begin sumatriptan entity2end within 24 hours of each other should be avoided . 
true chemical chemical Because there is a theoretical basis that these effects may be additive , use of ergotamine - containing or ergot - type medications ( like dihydroergotamine or entity1begin methysergide entity1end ) and entity2begin sumatriptan entity2end within 24 hours of each other should be avoided . 
true chemical chemical entity1begin MAO - A inhibitors entity1end reduce entity2begin sumatriptan entity2end clearance , significantly increasing systemic exposure . 
true chemical chemical Therefore , the use of entity1begin sumatriptan succinate entity1end tablets in patients receiving entity2begin MAO - A inhibitors entity2end is contraindicated . Selective serotonin reuptake inhibitors ( SSRIs ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
false chemical chemical Therefore , the use of entity1begin sumatriptan succinate entity1end tablets in patients receiving MAO - A inhibitors is contraindicated . entity2begin Selective serotonin reuptake inhibitors entity2end ( SSRIs ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
false chemical chemical Therefore , the use of entity1begin sumatriptan succinate entity1end tablets in patients receiving MAO - A inhibitors is contraindicated . Selective serotonin reuptake inhibitors ( entity2begin SSRIs entity2end ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
false chemical chemical Therefore , the use of entity1begin sumatriptan succinate entity1end tablets in patients receiving MAO - A inhibitors is contraindicated . Selective serotonin reuptake inhibitors ( SSRIs ) ( e.g. , entity2begin fluoxetine entity2end , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
false chemical chemical Therefore , the use of entity1begin sumatriptan succinate entity1end tablets in patients receiving MAO - A inhibitors is contraindicated . Selective serotonin reuptake inhibitors ( SSRIs ) ( e.g. , fluoxetine , entity2begin fluvoxamine entity2end , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
false chemical chemical Therefore , the use of entity1begin sumatriptan succinate entity1end tablets in patients receiving MAO - A inhibitors is contraindicated . Selective serotonin reuptake inhibitors ( SSRIs ) ( e.g. , fluoxetine , fluvoxamine , entity2begin paroxetine entity2end , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
false chemical chemical Therefore , the use of entity1begin sumatriptan succinate entity1end tablets in patients receiving MAO - A inhibitors is contraindicated . Selective serotonin reuptake inhibitors ( SSRIs ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , entity2begin sertraline entity2end ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
false chemical chemical Therefore , the use of entity1begin sumatriptan succinate entity1end tablets in patients receiving MAO - A inhibitors is contraindicated . Selective serotonin reuptake inhibitors ( SSRIs ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with entity2begin sumatriptan entity2end . 
false chemical chemical Therefore , the use of sumatriptan succinate tablets in patients receiving entity1begin MAO - A inhibitors entity1end is contraindicated . entity2begin Selective serotonin reuptake inhibitors entity2end ( SSRIs ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
false chemical chemical Therefore , the use of sumatriptan succinate tablets in patients receiving entity1begin MAO - A inhibitors entity1end is contraindicated . Selective serotonin reuptake inhibitors ( entity2begin SSRIs entity2end ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
false chemical chemical Therefore , the use of sumatriptan succinate tablets in patients receiving entity1begin MAO - A inhibitors entity1end is contraindicated . Selective serotonin reuptake inhibitors ( SSRIs ) ( e.g. , entity2begin fluoxetine entity2end , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
false chemical chemical Therefore , the use of sumatriptan succinate tablets in patients receiving entity1begin MAO - A inhibitors entity1end is contraindicated . Selective serotonin reuptake inhibitors ( SSRIs ) ( e.g. , fluoxetine , entity2begin fluvoxamine entity2end , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
false chemical chemical Therefore , the use of sumatriptan succinate tablets in patients receiving entity1begin MAO - A inhibitors entity1end is contraindicated . Selective serotonin reuptake inhibitors ( SSRIs ) ( e.g. , fluoxetine , fluvoxamine , entity2begin paroxetine entity2end , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
false chemical chemical Therefore , the use of sumatriptan succinate tablets in patients receiving entity1begin MAO - A inhibitors entity1end is contraindicated . Selective serotonin reuptake inhibitors ( SSRIs ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , entity2begin sertraline entity2end ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
false chemical chemical Therefore , the use of sumatriptan succinate tablets in patients receiving entity1begin MAO - A inhibitors entity1end is contraindicated . Selective serotonin reuptake inhibitors ( SSRIs ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with entity2begin sumatriptan entity2end . 
false chemical chemical Therefore , the use of sumatriptan succinate tablets in patients receiving MAO - A inhibitors is contraindicated . entity1begin Selective serotonin reuptake inhibitors entity1end ( entity2begin SSRIs entity2end ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
false chemical chemical Therefore , the use of sumatriptan succinate tablets in patients receiving MAO - A inhibitors is contraindicated . entity1begin Selective serotonin reuptake inhibitors entity1end ( SSRIs ) ( e.g. , entity2begin fluoxetine entity2end , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
false chemical chemical Therefore , the use of sumatriptan succinate tablets in patients receiving MAO - A inhibitors is contraindicated . entity1begin Selective serotonin reuptake inhibitors entity1end ( SSRIs ) ( e.g. , fluoxetine , entity2begin fluvoxamine entity2end , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
false chemical chemical Therefore , the use of sumatriptan succinate tablets in patients receiving MAO - A inhibitors is contraindicated . entity1begin Selective serotonin reuptake inhibitors entity1end ( SSRIs ) ( e.g. , fluoxetine , fluvoxamine , entity2begin paroxetine entity2end , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
false chemical chemical Therefore , the use of sumatriptan succinate tablets in patients receiving MAO - A inhibitors is contraindicated . entity1begin Selective serotonin reuptake inhibitors entity1end ( SSRIs ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , entity2begin sertraline entity2end ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
true chemical chemical Therefore , the use of sumatriptan succinate tablets in patients receiving MAO - A inhibitors is contraindicated . entity1begin Selective serotonin reuptake inhibitors entity1end ( SSRIs ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with entity2begin sumatriptan entity2end . 
false chemical chemical Therefore , the use of sumatriptan succinate tablets in patients receiving MAO - A inhibitors is contraindicated . Selective serotonin reuptake inhibitors ( entity1begin SSRIs entity1end ) ( e.g. , entity2begin fluoxetine entity2end , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
false chemical chemical Therefore , the use of sumatriptan succinate tablets in patients receiving MAO - A inhibitors is contraindicated . Selective serotonin reuptake inhibitors ( entity1begin SSRIs entity1end ) ( e.g. , fluoxetine , entity2begin fluvoxamine entity2end , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
false chemical chemical Therefore , the use of sumatriptan succinate tablets in patients receiving MAO - A inhibitors is contraindicated . Selective serotonin reuptake inhibitors ( entity1begin SSRIs entity1end ) ( e.g. , fluoxetine , fluvoxamine , entity2begin paroxetine entity2end , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
false chemical chemical Therefore , the use of sumatriptan succinate tablets in patients receiving MAO - A inhibitors is contraindicated . Selective serotonin reuptake inhibitors ( entity1begin SSRIs entity1end ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , entity2begin sertraline entity2end ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
true chemical chemical Therefore , the use of sumatriptan succinate tablets in patients receiving MAO - A inhibitors is contraindicated . Selective serotonin reuptake inhibitors ( entity1begin SSRIs entity1end ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with entity2begin sumatriptan entity2end . 
false chemical chemical Therefore , the use of sumatriptan succinate tablets in patients receiving MAO - A inhibitors is contraindicated . Selective serotonin reuptake inhibitors ( SSRIs ) ( e.g. , entity1begin fluoxetine entity1end , entity2begin fluvoxamine entity2end , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
false chemical chemical Therefore , the use of sumatriptan succinate tablets in patients receiving MAO - A inhibitors is contraindicated . Selective serotonin reuptake inhibitors ( SSRIs ) ( e.g. , entity1begin fluoxetine entity1end , fluvoxamine , entity2begin paroxetine entity2end , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
false chemical chemical Therefore , the use of sumatriptan succinate tablets in patients receiving MAO - A inhibitors is contraindicated . Selective serotonin reuptake inhibitors ( SSRIs ) ( e.g. , entity1begin fluoxetine entity1end , fluvoxamine , paroxetine , entity2begin sertraline entity2end ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
true chemical chemical Therefore , the use of sumatriptan succinate tablets in patients receiving MAO - A inhibitors is contraindicated . Selective serotonin reuptake inhibitors ( SSRIs ) ( e.g. , entity1begin fluoxetine entity1end , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with entity2begin sumatriptan entity2end . 
false chemical chemical Therefore , the use of sumatriptan succinate tablets in patients receiving MAO - A inhibitors is contraindicated . Selective serotonin reuptake inhibitors ( SSRIs ) ( e.g. , fluoxetine , entity1begin fluvoxamine entity1end , entity2begin paroxetine entity2end , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
false chemical chemical Therefore , the use of sumatriptan succinate tablets in patients receiving MAO - A inhibitors is contraindicated . Selective serotonin reuptake inhibitors ( SSRIs ) ( e.g. , fluoxetine , entity1begin fluvoxamine entity1end , paroxetine , entity2begin sertraline entity2end ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
true chemical chemical Therefore , the use of sumatriptan succinate tablets in patients receiving MAO - A inhibitors is contraindicated . Selective serotonin reuptake inhibitors ( SSRIs ) ( e.g. , fluoxetine , entity1begin fluvoxamine entity1end , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with entity2begin sumatriptan entity2end . 
false chemical chemical Therefore , the use of sumatriptan succinate tablets in patients receiving MAO - A inhibitors is contraindicated . Selective serotonin reuptake inhibitors ( SSRIs ) ( e.g. , fluoxetine , fluvoxamine , entity1begin paroxetine entity1end , entity2begin sertraline entity2end ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan . 
true chemical chemical Therefore , the use of sumatriptan succinate tablets in patients receiving MAO - A inhibitors is contraindicated . Selective serotonin reuptake inhibitors ( SSRIs ) ( e.g. , fluoxetine , fluvoxamine , entity1begin paroxetine entity1end , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with entity2begin sumatriptan entity2end . 
true chemical chemical Therefore , the use of sumatriptan succinate tablets in patients receiving MAO - A inhibitors is contraindicated . Selective serotonin reuptake inhibitors ( SSRIs ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , entity1begin sertraline entity1end ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with entity2begin sumatriptan entity2end . 
true chemical chemical If concomitant treatment with entity1begin sumatriptan entity1end and an entity2begin SSRI entity2end is clinically warranted , appropriate observation of the patient is advised . 
true chemical chemical Co - administration of entity1begin SUTENT entity1end with strong inhibitors of the CYP3A4 family ( e.g. , entity2begin ketoconazole entity2end , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 
true chemical chemical Co - administration of entity1begin SUTENT entity1end with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , entity2begin itraconazole entity2end , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 
true chemical chemical Co - administration of entity1begin SUTENT entity1end with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , entity2begin clarithromycin entity2end , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 
true chemical chemical Co - administration of entity1begin SUTENT entity1end with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , entity2begin atazanavir entity2end , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 
true chemical chemical Co - administration of entity1begin SUTENT entity1end with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , entity2begin indinavir entity2end , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 
true chemical chemical Co - administration of entity1begin SUTENT entity1end with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , entity2begin nefazodone entity2end , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 
true chemical chemical Co - administration of entity1begin SUTENT entity1end with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , entity2begin nelfinavir entity2end , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 
true chemical chemical Co - administration of entity1begin SUTENT entity1end with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , entity2begin ritonavir entity2end , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 
true chemical chemical Co - administration of entity1begin SUTENT entity1end with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , entity2begin saquinavir entity2end , telithromycin , voriconizole ) may increases sunitinib concentrations . 
true chemical chemical Co - administration of entity1begin SUTENT entity1end with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , entity2begin telithromycin entity2end , voriconizole ) may increases sunitinib concentrations . 
true chemical chemical Co - administration of entity1begin SUTENT entity1end with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , entity2begin voriconizole entity2end ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of entity1begin SUTENT entity1end with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases entity2begin sunitinib entity2end concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , entity1begin ketoconazole entity1end , entity2begin itraconazole entity2end , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , entity1begin ketoconazole entity1end , itraconazole , entity2begin clarithromycin entity2end , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , entity1begin ketoconazole entity1end , itraconazole , clarithromycin , entity2begin atazanavir entity2end , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , entity1begin ketoconazole entity1end , itraconazole , clarithromycin , atazanavir , entity2begin indinavir entity2end , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , entity1begin ketoconazole entity1end , itraconazole , clarithromycin , atazanavir , indinavir , entity2begin nefazodone entity2end , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , entity1begin ketoconazole entity1end , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , entity2begin nelfinavir entity2end , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , entity1begin ketoconazole entity1end , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , entity2begin ritonavir entity2end , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , entity1begin ketoconazole entity1end , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , entity2begin saquinavir entity2end , telithromycin , voriconizole ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , entity1begin ketoconazole entity1end , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , entity2begin telithromycin entity2end , voriconizole ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , entity1begin ketoconazole entity1end , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , entity2begin voriconizole entity2end ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , entity1begin ketoconazole entity1end , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases entity2begin sunitinib entity2end concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , entity1begin itraconazole entity1end , entity2begin clarithromycin entity2end , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , entity1begin itraconazole entity1end , clarithromycin , entity2begin atazanavir entity2end , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , entity1begin itraconazole entity1end , clarithromycin , atazanavir , entity2begin indinavir entity2end , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , entity1begin itraconazole entity1end , clarithromycin , atazanavir , indinavir , entity2begin nefazodone entity2end , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , entity1begin itraconazole entity1end , clarithromycin , atazanavir , indinavir , nefazodone , entity2begin nelfinavir entity2end , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , entity1begin itraconazole entity1end , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , entity2begin ritonavir entity2end , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , entity1begin itraconazole entity1end , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , entity2begin saquinavir entity2end , telithromycin , voriconizole ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , entity1begin itraconazole entity1end , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , entity2begin telithromycin entity2end , voriconizole ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , entity1begin itraconazole entity1end , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , entity2begin voriconizole entity2end ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , entity1begin itraconazole entity1end , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases entity2begin sunitinib entity2end concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , entity1begin clarithromycin entity1end , entity2begin atazanavir entity2end , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , entity1begin clarithromycin entity1end , atazanavir , entity2begin indinavir entity2end , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , entity1begin clarithromycin entity1end , atazanavir , indinavir , entity2begin nefazodone entity2end , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , entity1begin clarithromycin entity1end , atazanavir , indinavir , nefazodone , entity2begin nelfinavir entity2end , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , entity1begin clarithromycin entity1end , atazanavir , indinavir , nefazodone , nelfinavir , entity2begin ritonavir entity2end , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , entity1begin clarithromycin entity1end , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , entity2begin saquinavir entity2end , telithromycin , voriconizole ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , entity1begin clarithromycin entity1end , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , entity2begin telithromycin entity2end , voriconizole ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , entity1begin clarithromycin entity1end , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , entity2begin voriconizole entity2end ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , entity1begin clarithromycin entity1end , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases entity2begin sunitinib entity2end concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , entity1begin atazanavir entity1end , entity2begin indinavir entity2end , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , entity1begin atazanavir entity1end , indinavir , entity2begin nefazodone entity2end , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , entity1begin atazanavir entity1end , indinavir , nefazodone , entity2begin nelfinavir entity2end , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , entity1begin atazanavir entity1end , indinavir , nefazodone , nelfinavir , entity2begin ritonavir entity2end , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , entity1begin atazanavir entity1end , indinavir , nefazodone , nelfinavir , ritonavir , entity2begin saquinavir entity2end , telithromycin , voriconizole ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , entity1begin atazanavir entity1end , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , entity2begin telithromycin entity2end , voriconizole ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , entity1begin atazanavir entity1end , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , entity2begin voriconizole entity2end ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , entity1begin atazanavir entity1end , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases entity2begin sunitinib entity2end concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , entity1begin indinavir entity1end , entity2begin nefazodone entity2end , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , entity1begin indinavir entity1end , nefazodone , entity2begin nelfinavir entity2end , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , entity1begin indinavir entity1end , nefazodone , nelfinavir , entity2begin ritonavir entity2end , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , entity1begin indinavir entity1end , nefazodone , nelfinavir , ritonavir , entity2begin saquinavir entity2end , telithromycin , voriconizole ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , entity1begin indinavir entity1end , nefazodone , nelfinavir , ritonavir , saquinavir , entity2begin telithromycin entity2end , voriconizole ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , entity1begin indinavir entity1end , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , entity2begin voriconizole entity2end ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , entity1begin indinavir entity1end , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases entity2begin sunitinib entity2end concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , entity1begin nefazodone entity1end , entity2begin nelfinavir entity2end , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , entity1begin nefazodone entity1end , nelfinavir , entity2begin ritonavir entity2end , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , entity1begin nefazodone entity1end , nelfinavir , ritonavir , entity2begin saquinavir entity2end , telithromycin , voriconizole ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , entity1begin nefazodone entity1end , nelfinavir , ritonavir , saquinavir , entity2begin telithromycin entity2end , voriconizole ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , entity1begin nefazodone entity1end , nelfinavir , ritonavir , saquinavir , telithromycin , entity2begin voriconizole entity2end ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , entity1begin nefazodone entity1end , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases entity2begin sunitinib entity2end concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , entity1begin nelfinavir entity1end , entity2begin ritonavir entity2end , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , entity1begin nelfinavir entity1end , ritonavir , entity2begin saquinavir entity2end , telithromycin , voriconizole ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , entity1begin nelfinavir entity1end , ritonavir , saquinavir , entity2begin telithromycin entity2end , voriconizole ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , entity1begin nelfinavir entity1end , ritonavir , saquinavir , telithromycin , entity2begin voriconizole entity2end ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , entity1begin nelfinavir entity1end , ritonavir , saquinavir , telithromycin , voriconizole ) may increases entity2begin sunitinib entity2end concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , entity1begin ritonavir entity1end , entity2begin saquinavir entity2end , telithromycin , voriconizole ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , entity1begin ritonavir entity1end , saquinavir , entity2begin telithromycin entity2end , voriconizole ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , entity1begin ritonavir entity1end , saquinavir , telithromycin , entity2begin voriconizole entity2end ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , entity1begin ritonavir entity1end , saquinavir , telithromycin , voriconizole ) may increases entity2begin sunitinib entity2end concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , entity1begin saquinavir entity1end , entity2begin telithromycin entity2end , voriconizole ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , entity1begin saquinavir entity1end , telithromycin , entity2begin voriconizole entity2end ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , entity1begin saquinavir entity1end , telithromycin , voriconizole ) may increases entity2begin sunitinib entity2end concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , entity1begin telithromycin entity1end , entity2begin voriconizole entity2end ) may increases sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , entity1begin telithromycin entity1end , voriconizole ) may increases entity2begin sunitinib entity2end concentrations . 
false chemical chemical Co - administration of SUTENT with strong inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , entity1begin voriconizole entity1end ) may increases entity2begin sunitinib entity2end concentrations . 
true chemical chemical Co - administration of entity1begin SUTENT entity1end with inducers of the CYP3A4 family ( e.g. , entity2begin dexamethasone entity2end , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St. Johns Wort ) may decrease sunitinib concentrations . 
true chemical chemical Co - administration of entity1begin SUTENT entity1end with inducers of the CYP3A4 family ( e.g. , dexamethasone , entity2begin phenytoin entity2end , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St. Johns Wort ) may decrease sunitinib concentrations . 
true chemical chemical Co - administration of entity1begin SUTENT entity1end with inducers of the CYP3A4 family ( e.g. , dexamethasone , phenytoin , entity2begin carbamazepine entity2end , rifampin , rifabutin , rifapentin , phenobarbital , St. Johns Wort ) may decrease sunitinib concentrations . 
true chemical chemical Co - administration of entity1begin SUTENT entity1end with inducers of the CYP3A4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , entity2begin rifampin entity2end , rifabutin , rifapentin , phenobarbital , St. Johns Wort ) may decrease sunitinib concentrations . 
true chemical chemical Co - administration of entity1begin SUTENT entity1end with inducers of the CYP3A4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , entity2begin rifabutin entity2end , rifapentin , phenobarbital , St. Johns Wort ) may decrease sunitinib concentrations . 
true chemical chemical Co - administration of entity1begin SUTENT entity1end with inducers of the CYP3A4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , entity2begin rifapentin entity2end , phenobarbital , St. Johns Wort ) may decrease sunitinib concentrations . 
true chemical chemical Co - administration of entity1begin SUTENT entity1end with inducers of the CYP3A4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , entity2begin phenobarbital entity2end , St. Johns Wort ) may decrease sunitinib concentrations . 
false chemical chemical Co - administration of entity1begin SUTENT entity1end with inducers of the CYP3A4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St. Johns Wort ) may decrease entity2begin sunitinib entity2end concentrations . 
false chemical chemical Co - administration of SUTENT with inducers of the CYP3A4 family ( e.g. , entity1begin dexamethasone entity1end , entity2begin phenytoin entity2end , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St. Johns Wort ) may decrease sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with inducers of the CYP3A4 family ( e.g. , entity1begin dexamethasone entity1end , phenytoin , entity2begin carbamazepine entity2end , rifampin , rifabutin , rifapentin , phenobarbital , St. Johns Wort ) may decrease sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with inducers of the CYP3A4 family ( e.g. , entity1begin dexamethasone entity1end , phenytoin , carbamazepine , entity2begin rifampin entity2end , rifabutin , rifapentin , phenobarbital , St. Johns Wort ) may decrease sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with inducers of the CYP3A4 family ( e.g. , entity1begin dexamethasone entity1end , phenytoin , carbamazepine , rifampin , entity2begin rifabutin entity2end , rifapentin , phenobarbital , St. Johns Wort ) may decrease sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with inducers of the CYP3A4 family ( e.g. , entity1begin dexamethasone entity1end , phenytoin , carbamazepine , rifampin , rifabutin , entity2begin rifapentin entity2end , phenobarbital , St. Johns Wort ) may decrease sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with inducers of the CYP3A4 family ( e.g. , entity1begin dexamethasone entity1end , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , entity2begin phenobarbital entity2end , St. Johns Wort ) may decrease sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with inducers of the CYP3A4 family ( e.g. , entity1begin dexamethasone entity1end , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St. Johns Wort ) may decrease entity2begin sunitinib entity2end concentrations . 
false chemical chemical Co - administration of SUTENT with inducers of the CYP3A4 family ( e.g. , dexamethasone , entity1begin phenytoin entity1end , entity2begin carbamazepine entity2end , rifampin , rifabutin , rifapentin , phenobarbital , St. Johns Wort ) may decrease sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with inducers of the CYP3A4 family ( e.g. , dexamethasone , entity1begin phenytoin entity1end , carbamazepine , entity2begin rifampin entity2end , rifabutin , rifapentin , phenobarbital , St. Johns Wort ) may decrease sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with inducers of the CYP3A4 family ( e.g. , dexamethasone , entity1begin phenytoin entity1end , carbamazepine , rifampin , entity2begin rifabutin entity2end , rifapentin , phenobarbital , St. Johns Wort ) may decrease sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with inducers of the CYP3A4 family ( e.g. , dexamethasone , entity1begin phenytoin entity1end , carbamazepine , rifampin , rifabutin , entity2begin rifapentin entity2end , phenobarbital , St. Johns Wort ) may decrease sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with inducers of the CYP3A4 family ( e.g. , dexamethasone , entity1begin phenytoin entity1end , carbamazepine , rifampin , rifabutin , rifapentin , entity2begin phenobarbital entity2end , St. Johns Wort ) may decrease sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with inducers of the CYP3A4 family ( e.g. , dexamethasone , entity1begin phenytoin entity1end , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St. Johns Wort ) may decrease entity2begin sunitinib entity2end concentrations . 
false chemical chemical Co - administration of SUTENT with inducers of the CYP3A4 family ( e.g. , dexamethasone , phenytoin , entity1begin carbamazepine entity1end , entity2begin rifampin entity2end , rifabutin , rifapentin , phenobarbital , St. Johns Wort ) may decrease sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with inducers of the CYP3A4 family ( e.g. , dexamethasone , phenytoin , entity1begin carbamazepine entity1end , rifampin , entity2begin rifabutin entity2end , rifapentin , phenobarbital , St. Johns Wort ) may decrease sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with inducers of the CYP3A4 family ( e.g. , dexamethasone , phenytoin , entity1begin carbamazepine entity1end , rifampin , rifabutin , entity2begin rifapentin entity2end , phenobarbital , St. Johns Wort ) may decrease sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with inducers of the CYP3A4 family ( e.g. , dexamethasone , phenytoin , entity1begin carbamazepine entity1end , rifampin , rifabutin , rifapentin , entity2begin phenobarbital entity2end , St. Johns Wort ) may decrease sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with inducers of the CYP3A4 family ( e.g. , dexamethasone , phenytoin , entity1begin carbamazepine entity1end , rifampin , rifabutin , rifapentin , phenobarbital , St. Johns Wort ) may decrease entity2begin sunitinib entity2end concentrations . 
false chemical chemical Co - administration of SUTENT with inducers of the CYP3A4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , entity1begin rifampin entity1end , entity2begin rifabutin entity2end , rifapentin , phenobarbital , St. Johns Wort ) may decrease sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with inducers of the CYP3A4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , entity1begin rifampin entity1end , rifabutin , entity2begin rifapentin entity2end , phenobarbital , St. Johns Wort ) may decrease sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with inducers of the CYP3A4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , entity1begin rifampin entity1end , rifabutin , rifapentin , entity2begin phenobarbital entity2end , St. Johns Wort ) may decrease sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with inducers of the CYP3A4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , entity1begin rifampin entity1end , rifabutin , rifapentin , phenobarbital , St. Johns Wort ) may decrease entity2begin sunitinib entity2end concentrations . 
false chemical chemical Co - administration of SUTENT with inducers of the CYP3A4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , entity1begin rifabutin entity1end , entity2begin rifapentin entity2end , phenobarbital , St. Johns Wort ) may decrease sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with inducers of the CYP3A4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , entity1begin rifabutin entity1end , rifapentin , entity2begin phenobarbital entity2end , St. Johns Wort ) may decrease sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with inducers of the CYP3A4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , entity1begin rifabutin entity1end , rifapentin , phenobarbital , St. Johns Wort ) may decrease entity2begin sunitinib entity2end concentrations . 
false chemical chemical Co - administration of SUTENT with inducers of the CYP3A4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , entity1begin rifapentin entity1end , entity2begin phenobarbital entity2end , St. Johns Wort ) may decrease sunitinib concentrations . 
false chemical chemical Co - administration of SUTENT with inducers of the CYP3A4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , entity1begin rifapentin entity1end , phenobarbital , St. Johns Wort ) may decrease entity2begin sunitinib entity2end concentrations . 
false chemical chemical Co - administration of SUTENT with inducers of the CYP3A4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , entity1begin phenobarbital entity1end , St. Johns Wort ) may decrease entity2begin sunitinib entity2end concentrations . 
false chemical chemical Other eye drops or medications such as entity1begin acetylcholine chloride entity1end ( entity2begin Miochol entity2end ) and carbachol ( Carboptic , Isopto Carbachol ) may decrease the effects of suprofen ophthalmic . 
false chemical chemical Other eye drops or medications such as entity1begin acetylcholine chloride entity1end ( Miochol ) and entity2begin carbachol entity2end ( Carboptic , Isopto Carbachol ) may decrease the effects of suprofen ophthalmic . 
false chemical chemical Other eye drops or medications such as entity1begin acetylcholine chloride entity1end ( Miochol ) and carbachol ( entity2begin Carboptic entity2end , Isopto Carbachol ) may decrease the effects of suprofen ophthalmic . 
false chemical chemical Other eye drops or medications such as entity1begin acetylcholine chloride entity1end ( Miochol ) and carbachol ( Carboptic , entity2begin Isopto Carbachol entity2end ) may decrease the effects of suprofen ophthalmic . 
true chemical chemical Other eye drops or medications such as entity1begin acetylcholine chloride entity1end ( Miochol ) and carbachol ( Carboptic , Isopto Carbachol ) may decrease the effects of entity2begin suprofen entity2end ophthalmic . 
false chemical chemical Other eye drops or medications such as acetylcholine chloride ( entity1begin Miochol entity1end ) and entity2begin carbachol entity2end ( Carboptic , Isopto Carbachol ) may decrease the effects of suprofen ophthalmic . 
false chemical chemical Other eye drops or medications such as acetylcholine chloride ( entity1begin Miochol entity1end ) and carbachol ( entity2begin Carboptic entity2end , Isopto Carbachol ) may decrease the effects of suprofen ophthalmic . 
false chemical chemical Other eye drops or medications such as acetylcholine chloride ( entity1begin Miochol entity1end ) and carbachol ( Carboptic , entity2begin Isopto Carbachol entity2end ) may decrease the effects of suprofen ophthalmic . 
true chemical chemical Other eye drops or medications such as acetylcholine chloride ( entity1begin Miochol entity1end ) and carbachol ( Carboptic , Isopto Carbachol ) may decrease the effects of entity2begin suprofen entity2end ophthalmic . 
false chemical chemical Other eye drops or medications such as acetylcholine chloride ( Miochol ) and entity1begin carbachol entity1end ( entity2begin Carboptic entity2end , Isopto Carbachol ) may decrease the effects of suprofen ophthalmic . 
false chemical chemical Other eye drops or medications such as acetylcholine chloride ( Miochol ) and entity1begin carbachol entity1end ( Carboptic , entity2begin Isopto Carbachol entity2end ) may decrease the effects of suprofen ophthalmic . 
true chemical chemical Other eye drops or medications such as acetylcholine chloride ( Miochol ) and entity1begin carbachol entity1end ( Carboptic , Isopto Carbachol ) may decrease the effects of entity2begin suprofen entity2end ophthalmic . 
false chemical chemical Other eye drops or medications such as acetylcholine chloride ( Miochol ) and carbachol ( entity1begin Carboptic entity1end , entity2begin Isopto Carbachol entity2end ) may decrease the effects of suprofen ophthalmic . 
true chemical chemical Other eye drops or medications such as acetylcholine chloride ( Miochol ) and carbachol ( entity1begin Carboptic entity1end , Isopto Carbachol ) may decrease the effects of entity2begin suprofen entity2end ophthalmic . 
true chemical chemical Other eye drops or medications such as acetylcholine chloride ( Miochol ) and carbachol ( Carboptic , entity1begin Isopto Carbachol entity1end ) may decrease the effects of entity2begin suprofen entity2end ophthalmic . 
false chemical chemical Drug - Drug Interactions : The pharmacokinetic and pharmacodynamic interactions between entity1begin FLOMAX entity1end capsules and other entity2begin alpha - adrenergic blocking agents entity2end have not been determined . 
true chemical chemical However , interactions may be expected and entity1begin FLOMAX entity1end capsules should NOT be used in combination with other entity2begin alpha - adrenergic blocking agents entity2end . 
false chemical chemical The pharmacokinetic interaction between entity1begin cimetidine entity1end and entity2begin FLOMAX entity2end capsules was investigated . 
true chemical chemical Therefore , entity1begin FLOMAX entity1end capsules should be used with caution in combination with entity2begin cimetidine entity2end , particularly at doses higher than 0.4 mg . 
false chemical chemical Results from limited in vitro and in vivo drug - drug interaction studies between entity1begin tamsulosin HCI entity1end and entity2begin warfarin entity2end are inconclusive . 
true chemical chemical Therefore , caution should be exercised with concomitant administration of entity1begin warfarin entity1end and entity2begin FLOMAX entity2end capsules . 
true chemical chemical Administration of entity1begin valproic acid entity1end decreases oral clearance of entity2begin temozolomide entity2end by about 5 % . 
false chemical chemical Patients studied in clinical trials of entity1begin TNKase entity1end were routinely treated with entity2begin heparin entity2end and aspirin . 
false chemical chemical Patients studied in clinical trials of entity1begin TNKase entity1end were routinely treated with heparin and entity2begin aspirin entity2end . 
false chemical chemical Patients studied in clinical trials of TNKase were routinely treated with entity1begin heparin entity1end and entity2begin aspirin entity2end . 
false chemical chemical entity1begin Anticoagulants entity1end ( such as entity2begin heparin entity2end and vitamin K antagonists ) and drugs that alter platelet function ( such as acetylsalicylic acid , dipyridamole , and GP IIb / IIIa inhibitors ) may increase the risk of bleeding if administered prior to , during , or after TNKase therapy . 
false chemical chemical entity1begin Anticoagulants entity1end ( such as heparin and entity2begin vitamin K antagonists entity2end ) and drugs that alter platelet function ( such as acetylsalicylic acid , dipyridamole , and GP IIb / IIIa inhibitors ) may increase the risk of bleeding if administered prior to , during , or after TNKase therapy . 
false chemical chemical entity1begin Anticoagulants entity1end ( such as heparin and vitamin K antagonists ) and drugs that alter platelet function ( such as entity2begin acetylsalicylic acid entity2end , dipyridamole , and GP IIb / IIIa inhibitors ) may increase the risk of bleeding if administered prior to , during , or after TNKase therapy . 
false chemical chemical entity1begin Anticoagulants entity1end ( such as heparin and vitamin K antagonists ) and drugs that alter platelet function ( such as acetylsalicylic acid , entity2begin dipyridamole entity2end , and GP IIb / IIIa inhibitors ) may increase the risk of bleeding if administered prior to , during , or after TNKase therapy . 
true chemical chemical entity1begin Anticoagulants entity1end ( such as heparin and vitamin K antagonists ) and drugs that alter platelet function ( such as acetylsalicylic acid , dipyridamole , and GP IIb / IIIa inhibitors ) may increase the risk of bleeding if administered prior to , during , or after entity2begin TNKase entity2end therapy . 
false chemical chemical Anticoagulants ( such as entity1begin heparin entity1end and entity2begin vitamin K antagonists entity2end ) and drugs that alter platelet function ( such as acetylsalicylic acid , dipyridamole , and GP IIb / IIIa inhibitors ) may increase the risk of bleeding if administered prior to , during , or after TNKase therapy . 
false chemical chemical Anticoagulants ( such as entity1begin heparin entity1end and vitamin K antagonists ) and drugs that alter platelet function ( such as entity2begin acetylsalicylic acid entity2end , dipyridamole , and GP IIb / IIIa inhibitors ) may increase the risk of bleeding if administered prior to , during , or after TNKase therapy . 
false chemical chemical Anticoagulants ( such as entity1begin heparin entity1end and vitamin K antagonists ) and drugs that alter platelet function ( such as acetylsalicylic acid , entity2begin dipyridamole entity2end , and GP IIb / IIIa inhibitors ) may increase the risk of bleeding if administered prior to , during , or after TNKase therapy . 
true chemical chemical Anticoagulants ( such as entity1begin heparin entity1end and vitamin K antagonists ) and drugs that alter platelet function ( such as acetylsalicylic acid , dipyridamole , and GP IIb / IIIa inhibitors ) may increase the risk of bleeding if administered prior to , during , or after entity2begin TNKase entity2end therapy . 
false chemical chemical Anticoagulants ( such as heparin and entity1begin vitamin K antagonists entity1end ) and drugs that alter platelet function ( such as entity2begin acetylsalicylic acid entity2end , dipyridamole , and GP IIb / IIIa inhibitors ) may increase the risk of bleeding if administered prior to , during , or after TNKase therapy . 
false chemical chemical Anticoagulants ( such as heparin and entity1begin vitamin K antagonists entity1end ) and drugs that alter platelet function ( such as acetylsalicylic acid , entity2begin dipyridamole entity2end , and GP IIb / IIIa inhibitors ) may increase the risk of bleeding if administered prior to , during , or after TNKase therapy . 
true chemical chemical Anticoagulants ( such as heparin and entity1begin vitamin K antagonists entity1end ) and drugs that alter platelet function ( such as acetylsalicylic acid , dipyridamole , and GP IIb / IIIa inhibitors ) may increase the risk of bleeding if administered prior to , during , or after entity2begin TNKase entity2end therapy . 
false chemical chemical Anticoagulants ( such as heparin and vitamin K antagonists ) and drugs that alter platelet function ( such as entity1begin acetylsalicylic acid entity1end , entity2begin dipyridamole entity2end , and GP IIb / IIIa inhibitors ) may increase the risk of bleeding if administered prior to , during , or after TNKase therapy . 
true chemical chemical Anticoagulants ( such as heparin and vitamin K antagonists ) and drugs that alter platelet function ( such as entity1begin acetylsalicylic acid entity1end , dipyridamole , and GP IIb / IIIa inhibitors ) may increase the risk of bleeding if administered prior to , during , or after entity2begin TNKase entity2end therapy . 
true chemical chemical Anticoagulants ( such as heparin and vitamin K antagonists ) and drugs that alter platelet function ( such as acetylsalicylic acid , entity1begin dipyridamole entity1end , and GP IIb / IIIa inhibitors ) may increase the risk of bleeding if administered prior to , during , or after entity2begin TNKase entity2end therapy . 
false chemical chemical In a study in which 34 different drugs were tested , therapeutically relevant concentrations of entity1begin tolbutamide entity1end , entity2begin sodium salicylate entity2end and sulfamethizole displaced protein - bound teniposide in fresh human serum to a small but significant extent . 
false chemical chemical In a study in which 34 different drugs were tested , therapeutically relevant concentrations of entity1begin tolbutamide entity1end , sodium salicylate and entity2begin sulfamethizole entity2end displaced protein - bound teniposide in fresh human serum to a small but significant extent . 
true chemical chemical In a study in which 34 different drugs were tested , therapeutically relevant concentrations of entity1begin tolbutamide entity1end , sodium salicylate and sulfamethizole displaced protein - bound entity2begin teniposide entity2end in fresh human serum to a small but significant extent . 
false chemical chemical In a study in which 34 different drugs were tested , therapeutically relevant concentrations of tolbutamide , entity1begin sodium salicylate entity1end and entity2begin sulfamethizole entity2end displaced protein - bound teniposide in fresh human serum to a small but significant extent . 
true chemical chemical In a study in which 34 different drugs were tested , therapeutically relevant concentrations of tolbutamide , entity1begin sodium salicylate entity1end and sulfamethizole displaced protein - bound entity2begin teniposide entity2end in fresh human serum to a small but significant extent . 
true chemical chemical In a study in which 34 different drugs were tested , therapeutically relevant concentrations of tolbutamide , sodium salicylate and entity1begin sulfamethizole entity1end displaced protein - bound entity2begin teniposide entity2end in fresh human serum to a small but significant extent . 
false chemical chemical Therefore , caution should be used in administering entity1begin VUMON entity1end ( entity2begin teniposide entity2end injection ) to patients receiving these other agents . 
false chemical chemical There was no change in the plasma kinetics of entity1begin teniposide entity1end when coadministered with entity2begin methotrexate entity2end . 
true chemical chemical An increase in intracellular levels of entity1begin methotrexate entity1end was observed in vitro in the presence of entity2begin teniposide entity2end . 
false chemical chemical In vitro studies with human liver microsomes showed that entity1begin terbinafine entity1end does not inhibit the metabolism of entity2begin tolbutamide entity2end , ethinylestradiol , ethoxycoumarin , and cyclosporine . 
false chemical chemical In vitro studies with human liver microsomes showed that entity1begin terbinafine entity1end does not inhibit the metabolism of tolbutamide , entity2begin ethinylestradiol entity2end , ethoxycoumarin , and cyclosporine . 
false chemical chemical In vitro studies with human liver microsomes showed that entity1begin terbinafine entity1end does not inhibit the metabolism of tolbutamide , ethinylestradiol , entity2begin ethoxycoumarin entity2end , and cyclosporine . 
false chemical chemical In vitro studies with human liver microsomes showed that entity1begin terbinafine entity1end does not inhibit the metabolism of tolbutamide , ethinylestradiol , ethoxycoumarin , and entity2begin cyclosporine entity2end . 
false chemical chemical In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of entity1begin tolbutamide entity1end , entity2begin ethinylestradiol entity2end , ethoxycoumarin , and cyclosporine . 
false chemical chemical In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of entity1begin tolbutamide entity1end , ethinylestradiol , entity2begin ethoxycoumarin entity2end , and cyclosporine . 
false chemical chemical In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of entity1begin tolbutamide entity1end , ethinylestradiol , ethoxycoumarin , and entity2begin cyclosporine entity2end . 
false chemical chemical In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide , entity1begin ethinylestradiol entity1end , entity2begin ethoxycoumarin entity2end , and cyclosporine . 
false chemical chemical In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide , entity1begin ethinylestradiol entity1end , ethoxycoumarin , and entity2begin cyclosporine entity2end . 
false chemical chemical In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide , ethinylestradiol , entity1begin ethoxycoumarin entity1end , and entity2begin cyclosporine entity2end . 
false chemical chemical This may be of clinical relevance for compounds predominantly metabolized by this enzyme , such as entity1begin tricyclic antidepressants entity1end , - blockers , entity2begin selective serotonin reuptake inhibitors entity2end ( SSRIs ) , and monoamine oxidase inhibitors ( MAO - Is ) Type B , if they have a narrow therapeutic window . 
false chemical chemical This may be of clinical relevance for compounds predominantly metabolized by this enzyme , such as entity1begin tricyclic antidepressants entity1end , - blockers , selective serotonin reuptake inhibitors ( entity2begin SSRIs entity2end ) , and monoamine oxidase inhibitors ( MAO - Is ) Type B , if they have a narrow therapeutic window . 
false chemical chemical This may be of clinical relevance for compounds predominantly metabolized by this enzyme , such as entity1begin tricyclic antidepressants entity1end , - blockers , selective serotonin reuptake inhibitors ( SSRIs ) , and entity2begin monoamine oxidase inhibitors ( MAO - Is ) Type B entity2end , if they have a narrow therapeutic window . 
false chemical chemical This may be of clinical relevance for compounds predominantly metabolized by this enzyme , such as tricyclic antidepressants , - blockers , entity1begin selective serotonin reuptake inhibitors entity1end ( entity2begin SSRIs entity2end ) , and monoamine oxidase inhibitors ( MAO - Is ) Type B , if they have a narrow therapeutic window . 
false chemical chemical This may be of clinical relevance for compounds predominantly metabolized by this enzyme , such as tricyclic antidepressants , - blockers , entity1begin selective serotonin reuptake inhibitors entity1end ( SSRIs ) , and entity2begin monoamine oxidase inhibitors ( MAO - Is ) Type B entity2end , if they have a narrow therapeutic window . 
false chemical chemical This may be of clinical relevance for compounds predominantly metabolized by this enzyme , such as tricyclic antidepressants , - blockers , selective serotonin reuptake inhibitors ( entity1begin SSRIs entity1end ) , and entity2begin monoamine oxidase inhibitors ( MAO - Is ) Type B entity2end , if they have a narrow therapeutic window . 
false chemical chemical In vivo drug - drug interaction studies conducted in normal volunteer subjects showed that entity1begin terbinafine entity1end does not affect the clearance of entity2begin antipyrine entity2end or digoxin . 
false chemical chemical In vivo drug - drug interaction studies conducted in normal volunteer subjects showed that entity1begin terbinafine entity1end does not affect the clearance of antipyrine or entity2begin digoxin entity2end . 
false chemical chemical In vivo drug - drug interaction studies conducted in normal volunteer subjects showed that terbinafine does not affect the clearance of entity1begin antipyrine entity1end or entity2begin digoxin entity2end . 
true chemical chemical entity1begin Terbinafine entity1end decreases the clearance of entity2begin caffeine entity2end by 19 % . 
true chemical chemical entity1begin Terbinafine entity1end increases the clearance of entity2begin cyclosporine entity2end by 15 % . 
true chemical chemical There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral entity1begin terbinafine entity1end and entity2begin warfarin entity2end , however , a causal relationship between LAMISIL Tablets and these changes has not been established . 
false chemical chemical There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral entity1begin terbinafine entity1end and warfarin , however , a causal relationship between entity2begin LAMISIL entity2end Tablets and these changes has not been established . 
false chemical chemical There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral terbinafine and entity1begin warfarin entity1end , however , a causal relationship between entity2begin LAMISIL entity2end Tablets and these changes has not been established . 
true chemical chemical entity1begin Terbinafine entity1end clearance is increased 100 % by entity2begin rifampin entity2end , a CyP450 enzyme inducer , and decreased 33 % by cimetidine , a CyP450 enzyme inhibitor . 
true chemical chemical entity1begin Terbinafine entity1end clearance is increased 100 % by rifampin , a CyP450 enzyme inducer , and decreased 33 % by entity2begin cimetidine entity2end , a CyP450 enzyme inhibitor . 
false chemical chemical Terbinafine clearance is increased 100 % by entity1begin rifampin entity1end , a CyP450 enzyme inducer , and decreased 33 % by entity2begin cimetidine entity2end , a CyP450 enzyme inhibitor . 
false chemical chemical entity1begin Terbinafine entity1end clearance is unaffected by entity2begin cyclosporine entity2end . 
false chemical chemical There is no information available from adequate drug - drug interaction studies with the following classes of drugs : oral entity1begin contraceptives entity1end , hormone replacement therapies , entity2begin hypoglycemics entity2end , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers . 
false chemical chemical There is no information available from adequate drug - drug interaction studies with the following classes of drugs : oral entity1begin contraceptives entity1end , hormone replacement therapies , hypoglycemics , entity2begin theophyllines entity2end , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers . 
false chemical chemical There is no information available from adequate drug - drug interaction studies with the following classes of drugs : oral entity1begin contraceptives entity1end , hormone replacement therapies , hypoglycemics , theophyllines , entity2begin phenytoins entity2end , thiazide diuretics , beta blockers , and calcium channel blockers . 
false chemical chemical There is no information available from adequate drug - drug interaction studies with the following classes of drugs : oral entity1begin contraceptives entity1end , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , entity2begin thiazide diuretics entity2end , beta blockers , and calcium channel blockers . 
false chemical chemical There is no information available from adequate drug - drug interaction studies with the following classes of drugs : oral entity1begin contraceptives entity1end , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , entity2begin beta blockers entity2end , and calcium channel blockers . 
false chemical chemical There is no information available from adequate drug - drug interaction studies with the following classes of drugs : oral entity1begin contraceptives entity1end , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and entity2begin calcium channel blockers entity2end . 
false chemical chemical There is no information available from adequate drug - drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , entity1begin hypoglycemics entity1end , entity2begin theophyllines entity2end , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers . 
false chemical chemical There is no information available from adequate drug - drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , entity1begin hypoglycemics entity1end , theophyllines , entity2begin phenytoins entity2end , thiazide diuretics , beta blockers , and calcium channel blockers . 
false chemical chemical There is no information available from adequate drug - drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , entity1begin hypoglycemics entity1end , theophyllines , phenytoins , entity2begin thiazide diuretics entity2end , beta blockers , and calcium channel blockers . 
false chemical chemical There is no information available from adequate drug - drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , entity1begin hypoglycemics entity1end , theophyllines , phenytoins , thiazide diuretics , entity2begin beta blockers entity2end , and calcium channel blockers . 
false chemical chemical There is no information available from adequate drug - drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , entity1begin hypoglycemics entity1end , theophyllines , phenytoins , thiazide diuretics , beta blockers , and entity2begin calcium channel blockers entity2end . 
false chemical chemical There is no information available from adequate drug - drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , entity1begin theophyllines entity1end , entity2begin phenytoins entity2end , thiazide diuretics , beta blockers , and calcium channel blockers . 
false chemical chemical There is no information available from adequate drug - drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , entity1begin theophyllines entity1end , phenytoins , entity2begin thiazide diuretics entity2end , beta blockers , and calcium channel blockers . 
false chemical chemical There is no information available from adequate drug - drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , entity1begin theophyllines entity1end , phenytoins , thiazide diuretics , entity2begin beta blockers entity2end , and calcium channel blockers . 
false chemical chemical There is no information available from adequate drug - drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , entity1begin theophyllines entity1end , phenytoins , thiazide diuretics , beta blockers , and entity2begin calcium channel blockers entity2end . 
false chemical chemical There is no information available from adequate drug - drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , entity1begin phenytoins entity1end , entity2begin thiazide diuretics entity2end , beta blockers , and calcium channel blockers . 
false chemical chemical There is no information available from adequate drug - drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , entity1begin phenytoins entity1end , thiazide diuretics , entity2begin beta blockers entity2end , and calcium channel blockers . 
false chemical chemical There is no information available from adequate drug - drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , entity1begin phenytoins entity1end , thiazide diuretics , beta blockers , and entity2begin calcium channel blockers entity2end . 
false chemical chemical There is no information available from adequate drug - drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , entity1begin thiazide diuretics entity1end , entity2begin beta blockers entity2end , and calcium channel blockers . 
false chemical chemical There is no information available from adequate drug - drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , entity1begin thiazide diuretics entity1end , beta blockers , and entity2begin calcium channel blockers entity2end . 
false chemical chemical There is no information available from adequate drug - drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , entity1begin beta blockers entity1end , and entity2begin calcium channel blockers entity2end . 
false chemical chemical entity1begin Ketoconazole entity1end : Spontaneous adverse reaction reports of patients taking concomitant entity2begin ketoconazole entity2end with recommended doses of terfenadine demonstrate QT interval prolongation and rare serious cardiac events , e.g . 
false chemical chemical entity1begin Ketoconazole entity1end : Spontaneous adverse reaction reports of patients taking concomitant ketoconazole with recommended doses of entity2begin terfenadine entity2end demonstrate QT interval prolongation and rare serious cardiac events , e.g . 
true chemical chemical Ketoconazole : Spontaneous adverse reaction reports of patients taking concomitant entity1begin ketoconazole entity1end with recommended doses of entity2begin terfenadine entity2end demonstrate QT interval prolongation and rare serious cardiac events , e.g . 
true chemical chemical Pharmacokinetic data indicate that entity1begin ketoconazole entity1end markedly inhibits the metabolism of entity2begin terfenadine entity2end , resulting in elevated plasma terfenadine levels . 
false chemical chemical Pharmacokinetic data indicate that entity1begin ketoconazole entity1end markedly inhibits the metabolism of terfenadine , resulting in elevated plasma entity2begin terfenadine entity2end levels . 
false chemical chemical Pharmacokinetic data indicate that ketoconazole markedly inhibits the metabolism of entity1begin terfenadine entity1end , resulting in elevated plasma entity2begin terfenadine entity2end levels . 
true chemical chemical Concomitant administration of entity1begin ketoconazole entity1end and entity2begin terfenadine entity2end is contraindicated . 
false chemical chemical entity1begin Itraconazole entity1end : Torsades de pointes and elevated parent entity2begin terfenadine entity2end levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post - marketing sources . 
false chemical chemical entity1begin Itraconazole entity1end : Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of entity2begin terfenadine entity2end and itraconazole in clinical trials of itraconazole and from foreign post - marketing sources . 
false chemical chemical entity1begin Itraconazole entity1end : Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and entity2begin itraconazole entity2end in clinical trials of itraconazole and from foreign post - marketing sources . 
false chemical chemical entity1begin Itraconazole entity1end : Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of entity2begin itraconazole entity2end and from foreign post - marketing sources . 
false chemical chemical Itraconazole : Torsades de pointes and elevated parent entity1begin terfenadine entity1end levels have been reported during concomitant use of entity2begin terfenadine entity2end and itraconazole in clinical trials of itraconazole and from foreign post - marketing sources . 
false chemical chemical Itraconazole : Torsades de pointes and elevated parent entity1begin terfenadine entity1end levels have been reported during concomitant use of terfenadine and entity2begin itraconazole entity2end in clinical trials of itraconazole and from foreign post - marketing sources . 
false chemical chemical Itraconazole : Torsades de pointes and elevated parent entity1begin terfenadine entity1end levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of entity2begin itraconazole entity2end and from foreign post - marketing sources . 
true chemical chemical Itraconazole : Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of entity1begin terfenadine entity1end and entity2begin itraconazole entity2end in clinical trials of itraconazole and from foreign post - marketing sources . 
false chemical chemical Itraconazole : Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of entity1begin terfenadine entity1end and itraconazole in clinical trials of entity2begin itraconazole entity2end and from foreign post - marketing sources . 
false chemical chemical Itraconazole : Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and entity1begin itraconazole entity1end in clinical trials of entity2begin itraconazole entity2end and from foreign post - marketing sources . 
true chemical chemical Concomitant administration of entity1begin itraconazole entity1end and entity2begin terfenadine entity2end is contraindicated . 
false chemical chemical Due to the chemical similarity of other entity1begin azole - type antifungal agents entity1end ( including entity2begin fluconazole entity2end , metronidazole , and miconazole ) to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . 
false chemical chemical Due to the chemical similarity of other entity1begin azole - type antifungal agents entity1end ( including fluconazole , entity2begin metronidazole entity2end , and miconazole ) to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . 
false chemical chemical Due to the chemical similarity of other entity1begin azole - type antifungal agents entity1end ( including fluconazole , metronidazole , and entity2begin miconazole entity2end ) to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . 
false chemical chemical Due to the chemical similarity of other entity1begin azole - type antifungal agents entity1end ( including fluconazole , metronidazole , and miconazole ) to entity2begin ketoconazole entity2end , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . 
false chemical chemical Due to the chemical similarity of other entity1begin azole - type antifungal agents entity1end ( including fluconazole , metronidazole , and miconazole ) to ketoconazole , and entity2begin itraconazole entity2end , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . 
true chemical chemical Due to the chemical similarity of other entity1begin azole - type antifungal agents entity1end ( including fluconazole , metronidazole , and miconazole ) to ketoconazole , and itraconazole , concomitant use of these products with entity2begin terfenadine entity2end is not recommended pending full examination of potential interactions . 
false chemical chemical Due to the chemical similarity of other azole - type antifungal agents ( including entity1begin fluconazole entity1end , entity2begin metronidazole entity2end , and miconazole ) to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . 
false chemical chemical Due to the chemical similarity of other azole - type antifungal agents ( including entity1begin fluconazole entity1end , metronidazole , and entity2begin miconazole entity2end ) to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . 
false chemical chemical Due to the chemical similarity of other azole - type antifungal agents ( including entity1begin fluconazole entity1end , metronidazole , and miconazole ) to entity2begin ketoconazole entity2end , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . 
false chemical chemical Due to the chemical similarity of other azole - type antifungal agents ( including entity1begin fluconazole entity1end , metronidazole , and miconazole ) to ketoconazole , and entity2begin itraconazole entity2end , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . 
true chemical chemical Due to the chemical similarity of other azole - type antifungal agents ( including entity1begin fluconazole entity1end , metronidazole , and miconazole ) to ketoconazole , and itraconazole , concomitant use of these products with entity2begin terfenadine entity2end is not recommended pending full examination of potential interactions . 
false chemical chemical Due to the chemical similarity of other azole - type antifungal agents ( including fluconazole , entity1begin metronidazole entity1end , and entity2begin miconazole entity2end ) to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . 
false chemical chemical Due to the chemical similarity of other azole - type antifungal agents ( including fluconazole , entity1begin metronidazole entity1end , and miconazole ) to entity2begin ketoconazole entity2end , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . 
false chemical chemical Due to the chemical similarity of other azole - type antifungal agents ( including fluconazole , entity1begin metronidazole entity1end , and miconazole ) to ketoconazole , and entity2begin itraconazole entity2end , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . 
true chemical chemical Due to the chemical similarity of other azole - type antifungal agents ( including fluconazole , entity1begin metronidazole entity1end , and miconazole ) to ketoconazole , and itraconazole , concomitant use of these products with entity2begin terfenadine entity2end is not recommended pending full examination of potential interactions . 
false chemical chemical Due to the chemical similarity of other azole - type antifungal agents ( including fluconazole , metronidazole , and entity1begin miconazole entity1end ) to entity2begin ketoconazole entity2end , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . 
false chemical chemical Due to the chemical similarity of other azole - type antifungal agents ( including fluconazole , metronidazole , and entity1begin miconazole entity1end ) to ketoconazole , and entity2begin itraconazole entity2end , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . 
true chemical chemical Due to the chemical similarity of other azole - type antifungal agents ( including fluconazole , metronidazole , and entity1begin miconazole entity1end ) to ketoconazole , and itraconazole , concomitant use of these products with entity2begin terfenadine entity2end is not recommended pending full examination of potential interactions . 
false chemical chemical Due to the chemical similarity of other azole - type antifungal agents ( including fluconazole , metronidazole , and miconazole ) to entity1begin ketoconazole entity1end , and entity2begin itraconazole entity2end , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions . 
false chemical chemical Due to the chemical similarity of other azole - type antifungal agents ( including fluconazole , metronidazole , and miconazole ) to entity1begin ketoconazole entity1end , and itraconazole , concomitant use of these products with entity2begin terfenadine entity2end is not recommended pending full examination of potential interactions . 
false chemical chemical Due to the chemical similarity of other azole - type antifungal agents ( including fluconazole , metronidazole , and miconazole ) to ketoconazole , and entity1begin itraconazole entity1end , concomitant use of these products with entity2begin terfenadine entity2end is not recommended pending full examination of potential interactions . 
false chemical chemical entity1begin Macrolides entity1end : Clinical drug interaction studies indicate that entity2begin erythromycin entity2end and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole , but to a lesser extent . 
false chemical chemical entity1begin Macrolides entity1end : Clinical drug interaction studies indicate that erythromycin and entity2begin clarithromycin entity2end can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole , but to a lesser extent . 
false chemical chemical entity1begin Macrolides entity1end : Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on entity2begin terfenadine entity2end metabolism by a mechanism which may be similar to that of ketoconazole , but to a lesser extent . 
false chemical chemical entity1begin Macrolides entity1end : Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of entity2begin ketoconazole entity2end , but to a lesser extent . 
false chemical chemical Macrolides : Clinical drug interaction studies indicate that entity1begin erythromycin entity1end and entity2begin clarithromycin entity2end can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole , but to a lesser extent . 
true chemical chemical Macrolides : Clinical drug interaction studies indicate that entity1begin erythromycin entity1end and clarithromycin can exert an effect on entity2begin terfenadine entity2end metabolism by a mechanism which may be similar to that of ketoconazole , but to a lesser extent . 
false chemical chemical Macrolides : Clinical drug interaction studies indicate that entity1begin erythromycin entity1end and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of entity2begin ketoconazole entity2end , but to a lesser extent . 
true chemical chemical Macrolides : Clinical drug interaction studies indicate that erythromycin and entity1begin clarithromycin entity1end can exert an effect on entity2begin terfenadine entity2end metabolism by a mechanism which may be similar to that of ketoconazole , but to a lesser extent . 
false chemical chemical Macrolides : Clinical drug interaction studies indicate that erythromycin and entity1begin clarithromycin entity1end can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of entity2begin ketoconazole entity2end , but to a lesser extent . 
false chemical chemical Macrolides : Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on entity1begin terfenadine entity1end metabolism by a mechanism which may be similar to that of entity2begin ketoconazole entity2end , but to a lesser extent . 
false chemical chemical A few spontaneous accounts of QT interval prolongation with ventricular arrhythmia including torsades de pointes , have been reported in patients receiving entity1begin erythromycin entity1end or entity2begin troleandomycin entity2end . 
true chemical chemical Concomitant administration of entity1begin terfenadine entity1end with entity2begin clarithromycin entity2end , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended . 
true chemical chemical Concomitant administration of entity1begin terfenadine entity1end with clarithromycin , entity2begin erythromycin entity2end , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended . 
true chemical chemical Concomitant administration of entity1begin terfenadine entity1end with clarithromycin , erythromycin , or entity2begin troleandomycin entity2end is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended . 
false chemical chemical Concomitant administration of entity1begin terfenadine entity1end with clarithromycin , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of entity2begin terfenadine entity2end with other macrolide antibiotics , including azithromycin , is not recommended . 
false chemical chemical Concomitant administration of entity1begin terfenadine entity1end with clarithromycin , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other entity2begin macrolide antibiotics entity2end , including azithromycin , is not recommended . 
false chemical chemical Concomitant administration of entity1begin terfenadine entity1end with clarithromycin , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including entity2begin azithromycin entity2end , is not recommended . 
false chemical chemical Concomitant administration of terfenadine with entity1begin clarithromycin entity1end , entity2begin erythromycin entity2end , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended . 
false chemical chemical Concomitant administration of terfenadine with entity1begin clarithromycin entity1end , erythromycin , or entity2begin troleandomycin entity2end is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended . 
false chemical chemical Concomitant administration of terfenadine with entity1begin clarithromycin entity1end , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of entity2begin terfenadine entity2end with other macrolide antibiotics , including azithromycin , is not recommended . 
false chemical chemical Concomitant administration of terfenadine with entity1begin clarithromycin entity1end , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other entity2begin macrolide antibiotics entity2end , including azithromycin , is not recommended . 
false chemical chemical Concomitant administration of terfenadine with entity1begin clarithromycin entity1end , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including entity2begin azithromycin entity2end , is not recommended . 
false chemical chemical Concomitant administration of terfenadine with clarithromycin , entity1begin erythromycin entity1end , or entity2begin troleandomycin entity2end is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended . 
false chemical chemical Concomitant administration of terfenadine with clarithromycin , entity1begin erythromycin entity1end , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of entity2begin terfenadine entity2end with other macrolide antibiotics , including azithromycin , is not recommended . 
false chemical chemical Concomitant administration of terfenadine with clarithromycin , entity1begin erythromycin entity1end , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other entity2begin macrolide antibiotics entity2end , including azithromycin , is not recommended . 
false chemical chemical Concomitant administration of terfenadine with clarithromycin , entity1begin erythromycin entity1end , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including entity2begin azithromycin entity2end , is not recommended . 
false chemical chemical Concomitant administration of terfenadine with clarithromycin , erythromycin , or entity1begin troleandomycin entity1end is contraindicated : Pending full characterization of potential interactions , concomitant administration of entity2begin terfenadine entity2end with other macrolide antibiotics , including azithromycin , is not recommended . 
false chemical chemical Concomitant administration of terfenadine with clarithromycin , erythromycin , or entity1begin troleandomycin entity1end is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other entity2begin macrolide antibiotics entity2end , including azithromycin , is not recommended . 
false chemical chemical Concomitant administration of terfenadine with clarithromycin , erythromycin , or entity1begin troleandomycin entity1end is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including entity2begin azithromycin entity2end , is not recommended . 
true chemical chemical Concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of entity1begin terfenadine entity1end with other entity2begin macrolide antibiotics entity2end , including azithromycin , is not recommended . 
true chemical chemical Concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of entity1begin terfenadine entity1end with other macrolide antibiotics , including entity2begin azithromycin entity2end , is not recommended . 
false chemical chemical Concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other entity1begin macrolide antibiotics entity1end , including entity2begin azithromycin entity2end , is not recommended . 
false chemical chemical Studies to evaluate potential interactions of entity1begin terfenadine entity1end with entity2begin azithromycin entity2end are in progress . 
true chemical chemical When administered concurrently , entity1begin testolactone entity1end may increase the effects of oral entity2begin anticoagulants entity2end ; 
true chemical chemical entity1begin Thalidomide entity1end has been reported to enhance the sedative activity of entity2begin barbiturates entity2end , alcohol , chlorpromazine , and reserpine . 
false chemical chemical entity1begin Thalidomide entity1end has been reported to enhance the sedative activity of barbiturates , entity2begin alcohol entity2end , chlorpromazine , and reserpine . 
false chemical chemical entity1begin Thalidomide entity1end has been reported to enhance the sedative activity of barbiturates , alcohol , entity2begin chlorpromazine entity2end , and reserpine . 
false chemical chemical entity1begin Thalidomide entity1end has been reported to enhance the sedative activity of barbiturates , alcohol , chlorpromazine , and entity2begin reserpine entity2end . 
false chemical chemical Thalidomide has been reported to enhance the sedative activity of entity1begin barbiturates entity1end , entity2begin alcohol entity2end , chlorpromazine , and reserpine . 
false chemical chemical Thalidomide has been reported to enhance the sedative activity of entity1begin barbiturates entity1end , alcohol , entity2begin chlorpromazine entity2end , and reserpine . 
false chemical chemical Thalidomide has been reported to enhance the sedative activity of entity1begin barbiturates entity1end , alcohol , chlorpromazine , and entity2begin reserpine entity2end . 
false chemical chemical Thalidomide has been reported to enhance the sedative activity of barbiturates , entity1begin alcohol entity1end , entity2begin chlorpromazine entity2end , and reserpine . 
false chemical chemical Thalidomide has been reported to enhance the sedative activity of barbiturates , entity1begin alcohol entity1end , chlorpromazine , and entity2begin reserpine entity2end . 
false chemical chemical Thalidomide has been reported to enhance the sedative activity of barbiturates , alcohol , entity1begin chlorpromazine entity1end , and entity2begin reserpine entity2end . 
false chemical chemical Oral entity1begin Contraceptives entity1end : In 10 healthy women , the pharmacokinetic profiles of entity2begin norethindrone entity2end and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75 g of ethinyl estradiol were studied . 
false chemical chemical Oral entity1begin Contraceptives entity1end : In 10 healthy women , the pharmacokinetic profiles of norethindrone and entity2begin ethinyl estradiol entity2end following administration of a single dose containing 1.0 mg of norethindrone acetate and 75 g of ethinyl estradiol were studied . 
false chemical chemical Oral entity1begin Contraceptives entity1end : In 10 healthy women , the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of entity2begin norethindrone acetate entity2end and 75 g of ethinyl estradiol were studied . 
false chemical chemical Oral entity1begin Contraceptives entity1end : In 10 healthy women , the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75 g of entity2begin ethinyl estradiol entity2end were studied . 
false chemical chemical Oral Contraceptives : In 10 healthy women , the pharmacokinetic profiles of entity1begin norethindrone entity1end and entity2begin ethinyl estradiol entity2end following administration of a single dose containing 1.0 mg of norethindrone acetate and 75 g of ethinyl estradiol were studied . 
false chemical chemical Oral Contraceptives : In 10 healthy women , the pharmacokinetic profiles of entity1begin norethindrone entity1end and ethinyl estradiol following administration of a single dose containing 1.0 mg of entity2begin norethindrone acetate entity2end and 75 g of ethinyl estradiol were studied . 
false chemical chemical Oral Contraceptives : In 10 healthy women , the pharmacokinetic profiles of entity1begin norethindrone entity1end and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75 g of entity2begin ethinyl estradiol entity2end were studied . 
false chemical chemical Oral Contraceptives : In 10 healthy women , the pharmacokinetic profiles of norethindrone and entity1begin ethinyl estradiol entity1end following administration of a single dose containing 1.0 mg of entity2begin norethindrone acetate entity2end and 75 g of ethinyl estradiol were studied . 
false chemical chemical Oral Contraceptives : In 10 healthy women , the pharmacokinetic profiles of norethindrone and entity1begin ethinyl estradiol entity1end following administration of a single dose containing 1.0 mg of norethindrone acetate and 75 g of entity2begin ethinyl estradiol entity2end were studied . 
false chemical chemical Oral Contraceptives : In 10 healthy women , the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of entity1begin norethindrone acetate entity1end and 75 g of entity2begin ethinyl estradiol entity2end were studied . 
false chemical chemical Important Non - entity1begin Thalidomide entity1end Drug Interactions Drugs That Interfere with entity2begin Hormonal Contraceptives entity2end : Concomitant use of HIV - protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St . 
false chemical chemical Important Non - entity1begin Thalidomide entity1end Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of entity2begin HIV - protease inhibitors entity2end , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St . 
false chemical chemical Important Non - entity1begin Thalidomide entity1end Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV - protease inhibitors , entity2begin griseofulvin entity2end , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St . 
false chemical chemical Important Non - entity1begin Thalidomide entity1end Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV - protease inhibitors , griseofulvin , entity2begin modafinil entity2end , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St . 
false chemical chemical Important Non - entity1begin Thalidomide entity1end Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV - protease inhibitors , griseofulvin , modafinil , entity2begin penicillins entity2end , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St . 
false chemical chemical Important Non - entity1begin Thalidomide entity1end Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV - protease inhibitors , griseofulvin , modafinil , penicillins , entity2begin rifampin entity2end , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St . 
false chemical chemical Important Non - entity1begin Thalidomide entity1end Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV - protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , entity2begin rifabutin entity2end , phenytoin , carbamazepine , or certain herbal supplements such as St . 
false chemical chemical Important Non - entity1begin Thalidomide entity1end Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV - protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , entity2begin phenytoin entity2end , carbamazepine , or certain herbal supplements such as St . 
false chemical chemical Important Non - entity1begin Thalidomide entity1end Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV - protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , entity2begin carbamazepine entity2end , or certain herbal supplements such as St . 
false chemical chemical Important Non - Thalidomide Drug Interactions Drugs That Interfere with entity1begin Hormonal Contraceptives entity1end : Concomitant use of entity2begin HIV - protease inhibitors entity2end , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St . 
false chemical chemical Important Non - Thalidomide Drug Interactions Drugs That Interfere with entity1begin Hormonal Contraceptives entity1end : Concomitant use of HIV - protease inhibitors , entity2begin griseofulvin entity2end , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St . 
false chemical chemical Important Non - Thalidomide Drug Interactions Drugs That Interfere with entity1begin Hormonal Contraceptives entity1end : Concomitant use of HIV - protease inhibitors , griseofulvin , entity2begin modafinil entity2end , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St . 
false chemical chemical Important Non - Thalidomide Drug Interactions Drugs That Interfere with entity1begin Hormonal Contraceptives entity1end : Concomitant use of HIV - protease inhibitors , griseofulvin , modafinil , entity2begin penicillins entity2end , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St . 
false chemical chemical Important Non - Thalidomide Drug Interactions Drugs That Interfere with entity1begin Hormonal Contraceptives entity1end : Concomitant use of HIV - protease inhibitors , griseofulvin , modafinil , penicillins , entity2begin rifampin entity2end , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St . 
false chemical chemical Important Non - Thalidomide Drug Interactions Drugs That Interfere with entity1begin Hormonal Contraceptives entity1end : Concomitant use of HIV - protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , entity2begin rifabutin entity2end , phenytoin , carbamazepine , or certain herbal supplements such as St . 
false chemical chemical Important Non - Thalidomide Drug Interactions Drugs That Interfere with entity1begin Hormonal Contraceptives entity1end : Concomitant use of HIV - protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , entity2begin phenytoin entity2end , carbamazepine , or certain herbal supplements such as St . 
false chemical chemical Important Non - Thalidomide Drug Interactions Drugs That Interfere with entity1begin Hormonal Contraceptives entity1end : Concomitant use of HIV - protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , entity2begin carbamazepine entity2end , or certain herbal supplements such as St . 
false chemical chemical Important Non - Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of entity1begin HIV - protease inhibitors entity1end , entity2begin griseofulvin entity2end , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St . 
false chemical chemical Important Non - Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of entity1begin HIV - protease inhibitors entity1end , griseofulvin , entity2begin modafinil entity2end , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St . 
false chemical chemical Important Non - Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of entity1begin HIV - protease inhibitors entity1end , griseofulvin , modafinil , entity2begin penicillins entity2end , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St . 
false chemical chemical Important Non - Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of entity1begin HIV - protease inhibitors entity1end , griseofulvin , modafinil , penicillins , entity2begin rifampin entity2end , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St . 
false chemical chemical Important Non - Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of entity1begin HIV - protease inhibitors entity1end , griseofulvin , modafinil , penicillins , rifampin , entity2begin rifabutin entity2end , phenytoin , carbamazepine , or certain herbal supplements such as St . 
false chemical chemical Important Non - Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of entity1begin HIV - protease inhibitors entity1end , griseofulvin , modafinil , penicillins , rifampin , rifabutin , entity2begin phenytoin entity2end , carbamazepine , or certain herbal supplements such as St . 
false chemical chemical Important Non - Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of entity1begin HIV - protease inhibitors entity1end , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , entity2begin carbamazepine entity2end , or certain herbal supplements such as St . 
false chemical chemical Important Non - Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV - protease inhibitors , entity1begin griseofulvin entity1end , entity2begin modafinil entity2end , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St . 
false chemical chemical Important Non - Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV - protease inhibitors , entity1begin griseofulvin entity1end , modafinil , entity2begin penicillins entity2end , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St . 
false chemical chemical Important Non - Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV - protease inhibitors , entity1begin griseofulvin entity1end , modafinil , penicillins , entity2begin rifampin entity2end , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St . 
false chemical chemical Important Non - Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV - protease inhibitors , entity1begin griseofulvin entity1end , modafinil , penicillins , rifampin , entity2begin rifabutin entity2end , phenytoin , carbamazepine , or certain herbal supplements such as St . 
false chemical chemical Important Non - Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV - protease inhibitors , entity1begin griseofulvin entity1end , modafinil , penicillins , rifampin , rifabutin , entity2begin phenytoin entity2end , carbamazepine , or certain herbal supplements such as St . 
false chemical chemical Important Non - Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV - protease inhibitors , entity1begin griseofulvin entity1end , modafinil , penicillins , rifampin , rifabutin , phenytoin , entity2begin carbamazepine entity2end , or certain herbal supplements such as St . 
false chemical chemical Important Non - Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV - protease inhibitors , griseofulvin , entity1begin modafinil entity1end , entity2begin penicillins entity2end , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St . 
false chemical chemical Important Non - Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV - protease inhibitors , griseofulvin , entity1begin modafinil entity1end , penicillins , entity2begin rifampin entity2end , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St . 
false chemical chemical Important Non - Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV - protease inhibitors , griseofulvin , entity1begin modafinil entity1end , penicillins , rifampin , entity2begin rifabutin entity2end , phenytoin , carbamazepine , or certain herbal supplements such as St . 
false chemical chemical Important Non - Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV - protease inhibitors , griseofulvin , entity1begin modafinil entity1end , penicillins , rifampin , rifabutin , entity2begin phenytoin entity2end , carbamazepine , or certain herbal supplements such as St . 
false chemical chemical Important Non - Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV - protease inhibitors , griseofulvin , entity1begin modafinil entity1end , penicillins , rifampin , rifabutin , phenytoin , entity2begin carbamazepine entity2end , or certain herbal supplements such as St . 
false chemical chemical Important Non - Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV - protease inhibitors , griseofulvin , modafinil , entity1begin penicillins entity1end , entity2begin rifampin entity2end , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as St . 
false chemical chemical Important Non - Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV - protease inhibitors , griseofulvin , modafinil , entity1begin penicillins entity1end , rifampin , entity2begin rifabutin entity2end , phenytoin , carbamazepine , or certain herbal supplements such as St . 
false chemical chemical Important Non - Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV - protease inhibitors , griseofulvin , modafinil , entity1begin penicillins entity1end , rifampin , rifabutin , entity2begin phenytoin entity2end , carbamazepine , or certain herbal supplements such as St . 
false chemical chemical Important Non - Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV - protease inhibitors , griseofulvin , modafinil , entity1begin penicillins entity1end , rifampin , rifabutin , phenytoin , entity2begin carbamazepine entity2end , or certain herbal supplements such as St . 
false chemical chemical Important Non - Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV - protease inhibitors , griseofulvin , modafinil , penicillins , entity1begin rifampin entity1end , entity2begin rifabutin entity2end , phenytoin , carbamazepine , or certain herbal supplements such as St . 
false chemical chemical Important Non - Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV - protease inhibitors , griseofulvin , modafinil , penicillins , entity1begin rifampin entity1end , rifabutin , entity2begin phenytoin entity2end , carbamazepine , or certain herbal supplements such as St . 
false chemical chemical Important Non - Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV - protease inhibitors , griseofulvin , modafinil , penicillins , entity1begin rifampin entity1end , rifabutin , phenytoin , entity2begin carbamazepine entity2end , or certain herbal supplements such as St . 
false chemical chemical Important Non - Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV - protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , entity1begin rifabutin entity1end , entity2begin phenytoin entity2end , carbamazepine , or certain herbal supplements such as St . 
false chemical chemical Important Non - Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV - protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , entity1begin rifabutin entity1end , phenytoin , entity2begin carbamazepine entity2end , or certain herbal supplements such as St . 
false chemical chemical Important Non - Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives : Concomitant use of HIV - protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , entity1begin phenytoin entity1end , entity2begin carbamazepine entity2end , or certain herbal supplements such as St . 
true chemical chemical entity1begin John 's Wort entity1end with entity2begin hormonal contraceptive agents entity2end may reduce the effectiveness of the contraception and up to one month after discontinuation of these concomitant therapies . 
true chemical chemical entity1begin Thiabendazole entity1end may compete with other drugs , such as entity2begin theophylline entity2end , for sites of metabolism in the liver , thus elevating the serum levels of such compounds to potentially toxic levels . 
true chemical chemical Therefore , when concomitant use of entity1begin thiabendazole entity1end and entity2begin xanthine derivatives entity2end is anticipated , it may be necessary to monitor blood levels and / or reduce the dosage of such compounds . 
false chemical chemical Interactions for entity1begin Vitamin B1 entity1end ( entity2begin Thiamine entity2end ) : Loop Diuretics , Oral Contraceptives , Stavudine , Tricyclic Antidepressants 
true chemical chemical Interactions for entity1begin Vitamin B1 entity1end ( Thiamine ) : entity2begin Loop Diuretics entity2end , Oral Contraceptives , Stavudine , Tricyclic Antidepressants 
true chemical chemical Interactions for entity1begin Vitamin B1 entity1end ( Thiamine ) : Loop Diuretics , Oral entity2begin Contraceptives entity2end , Stavudine , Tricyclic Antidepressants 
true chemical chemical Interactions for entity1begin Vitamin B1 entity1end ( Thiamine ) : Loop Diuretics , Oral Contraceptives , entity2begin Stavudine entity2end , Tricyclic Antidepressants 
true chemical chemical Interactions for entity1begin Vitamin B1 entity1end ( Thiamine ) : Loop Diuretics , Oral Contraceptives , Stavudine , entity2begin Tricyclic Antidepressants entity2end 
true chemical chemical Interactions for Vitamin B1 ( entity1begin Thiamine entity1end ) : entity2begin Loop Diuretics entity2end , Oral Contraceptives , Stavudine , Tricyclic Antidepressants 
true chemical chemical Interactions for Vitamin B1 ( entity1begin Thiamine entity1end ) : Loop Diuretics , Oral entity2begin Contraceptives entity2end , Stavudine , Tricyclic Antidepressants 
true chemical chemical Interactions for Vitamin B1 ( entity1begin Thiamine entity1end ) : Loop Diuretics , Oral Contraceptives , entity2begin Stavudine entity2end , Tricyclic Antidepressants 
true chemical chemical Interactions for Vitamin B1 ( entity1begin Thiamine entity1end ) : Loop Diuretics , Oral Contraceptives , Stavudine , entity2begin Tricyclic Antidepressants entity2end 
false chemical chemical Interactions for Vitamin B1 ( Thiamine ) : entity1begin Loop Diuretics entity1end , Oral entity2begin Contraceptives entity2end , Stavudine , Tricyclic Antidepressants 
false chemical chemical Interactions for Vitamin B1 ( Thiamine ) : entity1begin Loop Diuretics entity1end , Oral Contraceptives , entity2begin Stavudine entity2end , Tricyclic Antidepressants 
false chemical chemical Interactions for Vitamin B1 ( Thiamine ) : entity1begin Loop Diuretics entity1end , Oral Contraceptives , Stavudine , entity2begin Tricyclic Antidepressants entity2end 
false chemical chemical Interactions for Vitamin B1 ( Thiamine ) : Loop Diuretics , Oral entity1begin Contraceptives entity1end , entity2begin Stavudine entity2end , Tricyclic Antidepressants 
false chemical chemical Interactions for Vitamin B1 ( Thiamine ) : Loop Diuretics , Oral entity1begin Contraceptives entity1end , Stavudine , entity2begin Tricyclic Antidepressants entity2end 
false chemical chemical Interactions for Vitamin B1 ( Thiamine ) : Loop Diuretics , Oral Contraceptives , entity1begin Stavudine entity1end , entity2begin Tricyclic Antidepressants entity2end 
true chemical chemical entity1begin Phenothiazines entity1end are capable of potentiating entity2begin CNS depressants entity2end ( e.g. , barbiturates , anesthetics , opiates , alcohol , etc. ) 
true chemical chemical entity1begin Phenothiazines entity1end are capable of potentiating CNS depressants ( e.g. , entity2begin barbiturates entity2end , anesthetics , opiates , alcohol , etc. ) 
true chemical chemical entity1begin Phenothiazines entity1end are capable of potentiating CNS depressants ( e.g. , barbiturates , entity2begin anesthetics entity2end , opiates , alcohol , etc. ) 
true chemical chemical entity1begin Phenothiazines entity1end are capable of potentiating CNS depressants ( e.g. , barbiturates , anesthetics , entity2begin opiates entity2end , alcohol , etc. ) 
true chemical chemical entity1begin Phenothiazines entity1end are capable of potentiating CNS depressants ( e.g. , barbiturates , anesthetics , opiates , entity2begin alcohol entity2end , etc. ) 
false chemical chemical Phenothiazines are capable of potentiating entity1begin CNS depressants entity1end ( e.g. , entity2begin barbiturates entity2end , anesthetics , opiates , alcohol , etc. ) 
false chemical chemical Phenothiazines are capable of potentiating entity1begin CNS depressants entity1end ( e.g. , barbiturates , entity2begin anesthetics entity2end , opiates , alcohol , etc. ) 
false chemical chemical Phenothiazines are capable of potentiating entity1begin CNS depressants entity1end ( e.g. , barbiturates , anesthetics , entity2begin opiates entity2end , alcohol , etc. ) 
false chemical chemical Phenothiazines are capable of potentiating entity1begin CNS depressants entity1end ( e.g. , barbiturates , anesthetics , opiates , entity2begin alcohol entity2end , etc. ) 
false chemical chemical Phenothiazines are capable of potentiating CNS depressants ( e.g. , entity1begin barbiturates entity1end , entity2begin anesthetics entity2end , opiates , alcohol , etc. ) 
false chemical chemical Phenothiazines are capable of potentiating CNS depressants ( e.g. , entity1begin barbiturates entity1end , anesthetics , entity2begin opiates entity2end , alcohol , etc. ) 
false chemical chemical Phenothiazines are capable of potentiating CNS depressants ( e.g. , entity1begin barbiturates entity1end , anesthetics , opiates , entity2begin alcohol entity2end , etc. ) 
false chemical chemical Phenothiazines are capable of potentiating CNS depressants ( e.g. , barbiturates , entity1begin anesthetics entity1end , entity2begin opiates entity2end , alcohol , etc. ) 
false chemical chemical Phenothiazines are capable of potentiating CNS depressants ( e.g. , barbiturates , entity1begin anesthetics entity1end , opiates , entity2begin alcohol entity2end , etc. ) 
false chemical chemical Phenothiazines are capable of potentiating CNS depressants ( e.g. , barbiturates , anesthetics , entity1begin opiates entity1end , entity2begin alcohol entity2end , etc. ) 
false chemical chemical as well as entity1begin atropine entity1end and entity2begin phosphorous insecticides entity2end . 
false chemical chemical There is usually complete cross - resistance between entity1begin PURINETHOL entity1end ( entity2begin mercaptopurine entity2end ) and TABLOID brand Thioguanine . 
true chemical chemical There is usually complete cross - resistance between entity1begin PURINETHOL entity1end ( mercaptopurine ) and entity2begin TABLOID entity2end brand Thioguanine . 
true chemical chemical There is usually complete cross - resistance between entity1begin PURINETHOL entity1end ( mercaptopurine ) and TABLOID brand entity2begin Thioguanine entity2end . 
true chemical chemical There is usually complete cross - resistance between PURINETHOL ( entity1begin mercaptopurine entity1end ) and entity2begin TABLOID entity2end brand Thioguanine . 
true chemical chemical There is usually complete cross - resistance between PURINETHOL ( entity1begin mercaptopurine entity1end ) and TABLOID brand entity2begin Thioguanine entity2end . 
false chemical chemical There is usually complete cross - resistance between PURINETHOL ( mercaptopurine ) and entity1begin TABLOID entity1end brand entity2begin Thioguanine entity2end . 
false chemical chemical As there is in vitro evidence that entity1begin aminosalicylate derivatives entity1end ( e.g. , entity2begin olsalazine entity2end , mesalazine , or sulphasalazine ) inhibit the TPMT enzyme , they should be administered with caution to patients receiving concurrent thioguanine therapy . 
false chemical chemical As there is in vitro evidence that entity1begin aminosalicylate derivatives entity1end ( e.g. , olsalazine , entity2begin mesalazine entity2end , or sulphasalazine ) inhibit the TPMT enzyme , they should be administered with caution to patients receiving concurrent thioguanine therapy . 
false chemical chemical As there is in vitro evidence that entity1begin aminosalicylate derivatives entity1end ( e.g. , olsalazine , mesalazine , or entity2begin sulphasalazine entity2end ) inhibit the TPMT enzyme , they should be administered with caution to patients receiving concurrent thioguanine therapy . 
true chemical chemical As there is in vitro evidence that entity1begin aminosalicylate derivatives entity1end ( e.g. , olsalazine , mesalazine , or sulphasalazine ) inhibit the TPMT enzyme , they should be administered with caution to patients receiving concurrent entity2begin thioguanine entity2end therapy . 
false chemical chemical As there is in vitro evidence that aminosalicylate derivatives ( e.g. , entity1begin olsalazine entity1end , entity2begin mesalazine entity2end , or sulphasalazine ) inhibit the TPMT enzyme , they should be administered with caution to patients receiving concurrent thioguanine therapy . 
false chemical chemical As there is in vitro evidence that aminosalicylate derivatives ( e.g. , entity1begin olsalazine entity1end , mesalazine , or entity2begin sulphasalazine entity2end ) inhibit the TPMT enzyme , they should be administered with caution to patients receiving concurrent thioguanine therapy . 
true chemical chemical As there is in vitro evidence that aminosalicylate derivatives ( e.g. , entity1begin olsalazine entity1end , mesalazine , or sulphasalazine ) inhibit the TPMT enzyme , they should be administered with caution to patients receiving concurrent entity2begin thioguanine entity2end therapy . 
false chemical chemical As there is in vitro evidence that aminosalicylate derivatives ( e.g. , olsalazine , entity1begin mesalazine entity1end , or entity2begin sulphasalazine entity2end ) inhibit the TPMT enzyme , they should be administered with caution to patients receiving concurrent thioguanine therapy . 
true chemical chemical As there is in vitro evidence that aminosalicylate derivatives ( e.g. , olsalazine , entity1begin mesalazine entity1end , or sulphasalazine ) inhibit the TPMT enzyme , they should be administered with caution to patients receiving concurrent entity2begin thioguanine entity2end therapy . 
true chemical chemical As there is in vitro evidence that aminosalicylate derivatives ( e.g. , olsalazine , mesalazine , or entity1begin sulphasalazine entity1end ) inhibit the TPMT enzyme , they should be administered with caution to patients receiving concurrent entity2begin thioguanine entity2end therapy . 
true chemical chemical Caution should be exercised when administering entity1begin ZADAXIN entity1end therapy in combination with other entity2begin immunomodulating drugs entity2end . 
true chemical chemical Prothrombin time or other suitable anticoagulation test should be monitored if entity1begin tigecycline entity1end is administered with entity2begin warfarin entity2end . 
true chemical chemical Concurrent use of entity1begin antibacterial drugs entity1end with oral entity2begin contraceptives entity2end may render oral contraceptives less effective . 
false chemical chemical Concurrent use of entity1begin antibacterial drugs entity1end with oral contraceptives may render oral entity2begin contraceptives entity2end less effective . 
false chemical chemical Concurrent use of antibacterial drugs with oral entity1begin contraceptives entity1end may render oral entity2begin contraceptives entity2end less effective . 
true chemical chemical The bioavailability of entity1begin SKELID entity1end is decreased 80 % by entity2begin calcium entity2end , when calcium and SKELID are administered at the same time , and 60 % by some aluminum - or magnesium - containing antacids , when administered 1 hour before SKELID . 
false chemical chemical The bioavailability of entity1begin SKELID entity1end is decreased 80 % by calcium , when entity2begin calcium entity2end and SKELID are administered at the same time , and 60 % by some aluminum - or magnesium - containing antacids , when administered 1 hour before SKELID . 
false chemical chemical The bioavailability of entity1begin SKELID entity1end is decreased 80 % by calcium , when calcium and entity2begin SKELID entity2end are administered at the same time , and 60 % by some aluminum - or magnesium - containing antacids , when administered 1 hour before SKELID . 
false chemical chemical The bioavailability of entity1begin SKELID entity1end is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some entity2begin aluminum entity2end - or magnesium - containing antacids , when administered 1 hour before SKELID . 
false chemical chemical The bioavailability of entity1begin SKELID entity1end is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some aluminum - or entity2begin magnesium entity2end - containing antacids , when administered 1 hour before SKELID . 
false chemical chemical The bioavailability of entity1begin SKELID entity1end is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some aluminum - or magnesium - containing entity2begin antacids entity2end , when administered 1 hour before SKELID . 
false chemical chemical The bioavailability of entity1begin SKELID entity1end is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some aluminum - or magnesium - containing antacids , when administered 1 hour before entity2begin SKELID entity2end . 
false chemical chemical The bioavailability of SKELID is decreased 80 % by entity1begin calcium entity1end , when entity2begin calcium entity2end and SKELID are administered at the same time , and 60 % by some aluminum - or magnesium - containing antacids , when administered 1 hour before SKELID . 
false chemical chemical The bioavailability of SKELID is decreased 80 % by entity1begin calcium entity1end , when calcium and entity2begin SKELID entity2end are administered at the same time , and 60 % by some aluminum - or magnesium - containing antacids , when administered 1 hour before SKELID . 
false chemical chemical The bioavailability of SKELID is decreased 80 % by entity1begin calcium entity1end , when calcium and SKELID are administered at the same time , and 60 % by some entity2begin aluminum entity2end - or magnesium - containing antacids , when administered 1 hour before SKELID . 
false chemical chemical The bioavailability of SKELID is decreased 80 % by entity1begin calcium entity1end , when calcium and SKELID are administered at the same time , and 60 % by some aluminum - or entity2begin magnesium entity2end - containing antacids , when administered 1 hour before SKELID . 
false chemical chemical The bioavailability of SKELID is decreased 80 % by entity1begin calcium entity1end , when calcium and SKELID are administered at the same time , and 60 % by some aluminum - or magnesium - containing entity2begin antacids entity2end , when administered 1 hour before SKELID . 
false chemical chemical The bioavailability of SKELID is decreased 80 % by entity1begin calcium entity1end , when calcium and SKELID are administered at the same time , and 60 % by some aluminum - or magnesium - containing antacids , when administered 1 hour before entity2begin SKELID entity2end . 
false chemical chemical The bioavailability of SKELID is decreased 80 % by calcium , when entity1begin calcium entity1end and entity2begin SKELID entity2end are administered at the same time , and 60 % by some aluminum - or magnesium - containing antacids , when administered 1 hour before SKELID . 
false chemical chemical The bioavailability of SKELID is decreased 80 % by calcium , when entity1begin calcium entity1end and SKELID are administered at the same time , and 60 % by some entity2begin aluminum entity2end - or magnesium - containing antacids , when administered 1 hour before SKELID . 
false chemical chemical The bioavailability of SKELID is decreased 80 % by calcium , when entity1begin calcium entity1end and SKELID are administered at the same time , and 60 % by some aluminum - or entity2begin magnesium entity2end - containing antacids , when administered 1 hour before SKELID . 
false chemical chemical The bioavailability of SKELID is decreased 80 % by calcium , when entity1begin calcium entity1end and SKELID are administered at the same time , and 60 % by some aluminum - or magnesium - containing entity2begin antacids entity2end , when administered 1 hour before SKELID . 
false chemical chemical The bioavailability of SKELID is decreased 80 % by calcium , when entity1begin calcium entity1end and SKELID are administered at the same time , and 60 % by some aluminum - or magnesium - containing antacids , when administered 1 hour before entity2begin SKELID entity2end . 
false chemical chemical The bioavailability of SKELID is decreased 80 % by calcium , when calcium and entity1begin SKELID entity1end are administered at the same time , and 60 % by some entity2begin aluminum entity2end - or magnesium - containing antacids , when administered 1 hour before SKELID . 
false chemical chemical The bioavailability of SKELID is decreased 80 % by calcium , when calcium and entity1begin SKELID entity1end are administered at the same time , and 60 % by some aluminum - or entity2begin magnesium entity2end - containing antacids , when administered 1 hour before SKELID . 
false chemical chemical The bioavailability of SKELID is decreased 80 % by calcium , when calcium and entity1begin SKELID entity1end are administered at the same time , and 60 % by some aluminum - or magnesium - containing entity2begin antacids entity2end , when administered 1 hour before SKELID . 
false chemical chemical The bioavailability of SKELID is decreased 80 % by calcium , when calcium and entity1begin SKELID entity1end are administered at the same time , and 60 % by some aluminum - or magnesium - containing antacids , when administered 1 hour before entity2begin SKELID entity2end . 
false chemical chemical The bioavailability of SKELID is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some entity1begin aluminum entity1end - or entity2begin magnesium entity2end - containing antacids , when administered 1 hour before SKELID . 
false chemical chemical The bioavailability of SKELID is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some entity1begin aluminum entity1end - or magnesium - containing entity2begin antacids entity2end , when administered 1 hour before SKELID . 
true chemical chemical The bioavailability of SKELID is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some entity1begin aluminum entity1end - or magnesium - containing antacids , when administered 1 hour before entity2begin SKELID entity2end . 
false chemical chemical The bioavailability of SKELID is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some aluminum - or entity1begin magnesium entity1end - containing entity2begin antacids entity2end , when administered 1 hour before SKELID . 
true chemical chemical The bioavailability of SKELID is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some aluminum - or entity1begin magnesium entity1end - containing antacids , when administered 1 hour before entity2begin SKELID entity2end . 
false chemical chemical The bioavailability of SKELID is decreased 80 % by calcium , when calcium and SKELID are administered at the same time , and 60 % by some aluminum - or magnesium - containing entity1begin antacids entity1end , when administered 1 hour before entity2begin SKELID entity2end . 
true chemical chemical entity1begin Aspirin entity1end may decrease bioavailability of entity2begin SKELID entity2end by up to 50 % when taken 2 hours after SKELID . 
false chemical chemical entity1begin Aspirin entity1end may decrease bioavailability of SKELID by up to 50 % when taken 2 hours after entity2begin SKELID entity2end . 
false chemical chemical Aspirin may decrease bioavailability of entity1begin SKELID entity1end by up to 50 % when taken 2 hours after entity2begin SKELID entity2end . 
true chemical chemical The bioavailability of entity1begin SKELID entity1end is increased 2 - 4 fold by entity2begin indomethacin entity2end but is not significantly altered by coadministration of diclofenac . 
false chemical chemical The bioavailability of entity1begin SKELID entity1end is increased 2 - 4 fold by indomethacin but is not significantly altered by coadministration of entity2begin diclofenac entity2end . 
false chemical chemical The bioavailability of SKELID is increased 2 - 4 fold by entity1begin indomethacin entity1end but is not significantly altered by coadministration of entity2begin diclofenac entity2end . 
false chemical chemical The pharmacokinetic parameters of entity1begin digoxin entity1end are not significantly modified by entity2begin SKELID entity2end coadministration . 
false chemical chemical In vitro studies show that entity1begin tiludronate entity1end does not displace entity2begin warfarin entity2end from its binding site on protein . 
false chemical chemical These include entity1begin sympathomimetic bronchodilators entity1end , entity2begin methylxanthines entity2end , and oral and inhaled steroids . 
false chemical chemical These include entity1begin sympathomimetic bronchodilators entity1end , methylxanthines , and oral and inhaled entity2begin steroids entity2end . 
false chemical chemical These include sympathomimetic bronchodilators , entity1begin methylxanthines entity1end , and oral and inhaled entity2begin steroids entity2end . 
true chemical chemical However , the co administration of entity1begin SPIRIVA entity1end with other entity2begin anticholinergic entity2end containing drugs ( e.g. , ipratropium ) has not been studied and is therefore not recommended . 
true chemical chemical However , the co administration of entity1begin SPIRIVA entity1end with other anticholinergic containing drugs ( e.g. , entity2begin ipratropium entity2end ) has not been studied and is therefore not recommended . 
false chemical chemical However , the co administration of SPIRIVA with other entity1begin anticholinergic entity1end containing drugs ( e.g. , entity2begin ipratropium entity2end ) has not been studied and is therefore not recommended . 
false chemical chemical entity1begin AGGRASTAT entity1end has been studied on a background of entity2begin aspirin entity2end and heparin . 
false chemical chemical entity1begin AGGRASTAT entity1end has been studied on a background of aspirin and entity2begin heparin entity2end . 
false chemical chemical AGGRASTAT has been studied on a background of entity1begin aspirin entity1end and entity2begin heparin entity2end . 
true chemical chemical The use of entity1begin AGGRASTAT entity1end , in combination with entity2begin heparin entity2end and aspirin , has been associated with an increase in bleeding compared to heparin and aspirin alone ( see 
true chemical chemical The use of entity1begin AGGRASTAT entity1end , in combination with heparin and entity2begin aspirin entity2end , has been associated with an increase in bleeding compared to heparin and aspirin alone ( see 
false chemical chemical The use of entity1begin AGGRASTAT entity1end , in combination with heparin and aspirin , has been associated with an increase in bleeding compared to entity2begin heparin entity2end and aspirin alone ( see 
false chemical chemical The use of entity1begin AGGRASTAT entity1end , in combination with heparin and aspirin , has been associated with an increase in bleeding compared to heparin and entity2begin aspirin entity2end alone ( see 
false chemical chemical The use of AGGRASTAT , in combination with entity1begin heparin entity1end and entity2begin aspirin entity2end , has been associated with an increase in bleeding compared to heparin and aspirin alone ( see 
false chemical chemical The use of AGGRASTAT , in combination with entity1begin heparin entity1end and aspirin , has been associated with an increase in bleeding compared to entity2begin heparin entity2end and aspirin alone ( see 
false chemical chemical The use of AGGRASTAT , in combination with entity1begin heparin entity1end and aspirin , has been associated with an increase in bleeding compared to heparin and entity2begin aspirin entity2end alone ( see 
false chemical chemical The use of AGGRASTAT , in combination with heparin and entity1begin aspirin entity1end , has been associated with an increase in bleeding compared to entity2begin heparin entity2end and aspirin alone ( see 
false chemical chemical The use of AGGRASTAT , in combination with heparin and entity1begin aspirin entity1end , has been associated with an increase in bleeding compared to heparin and entity2begin aspirin entity2end alone ( see 
false chemical chemical The use of AGGRASTAT , in combination with heparin and aspirin , has been associated with an increase in bleeding compared to entity1begin heparin entity1end and entity2begin aspirin entity2end alone ( see 
false chemical chemical In clinical studies of entity1begin TOBI entity1end , patients taking entity2begin TOBI entity2end concomitantly with dornase alfa ( PULMOZYME , Genentech ) , ( beta ) - agonists , inhaled corticosteroids , other anti - pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
false chemical chemical In clinical studies of entity1begin TOBI entity1end , patients taking TOBI concomitantly with entity2begin dornase alfa entity2end ( PULMOZYME , Genentech ) , ( beta ) - agonists , inhaled corticosteroids , other anti - pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
false chemical chemical In clinical studies of entity1begin TOBI entity1end , patients taking TOBI concomitantly with dornase alfa ( entity2begin PULMOZYME entity2end , Genentech ) , ( beta ) - agonists , inhaled corticosteroids , other anti - pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
false chemical chemical In clinical studies of entity1begin TOBI entity1end , patients taking TOBI concomitantly with dornase alfa ( PULMOZYME , Genentech ) , entity2begin ( beta ) - agonists entity2end , inhaled corticosteroids , other anti - pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
false chemical chemical In clinical studies of entity1begin TOBI entity1end , patients taking TOBI concomitantly with dornase alfa ( PULMOZYME , Genentech ) , ( beta ) - agonists , inhaled entity2begin corticosteroids entity2end , other anti - pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
false chemical chemical In clinical studies of entity1begin TOBI entity1end , patients taking TOBI concomitantly with dornase alfa ( PULMOZYME , Genentech ) , ( beta ) - agonists , inhaled corticosteroids , other entity2begin anti - pseudomonal antibiotics entity2end , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
false chemical chemical In clinical studies of entity1begin TOBI entity1end , patients taking TOBI concomitantly with dornase alfa ( PULMOZYME , Genentech ) , ( beta ) - agonists , inhaled corticosteroids , other anti - pseudomonal antibiotics , or parenteral entity2begin aminoglycosides entity2end demonstrated adverse experience profiles similar to the study population as a whole . 
true chemical chemical In clinical studies of TOBI , patients taking entity1begin TOBI entity1end concomitantly with entity2begin dornase alfa entity2end ( PULMOZYME , Genentech ) , ( beta ) - agonists , inhaled corticosteroids , other anti - pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
true chemical chemical In clinical studies of TOBI , patients taking entity1begin TOBI entity1end concomitantly with dornase alfa ( entity2begin PULMOZYME entity2end , Genentech ) , ( beta ) - agonists , inhaled corticosteroids , other anti - pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
true chemical chemical In clinical studies of TOBI , patients taking entity1begin TOBI entity1end concomitantly with dornase alfa ( PULMOZYME , Genentech ) , entity2begin ( beta ) - agonists entity2end , inhaled corticosteroids , other anti - pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
true chemical chemical In clinical studies of TOBI , patients taking entity1begin TOBI entity1end concomitantly with dornase alfa ( PULMOZYME , Genentech ) , ( beta ) - agonists , inhaled entity2begin corticosteroids entity2end , other anti - pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
true chemical chemical In clinical studies of TOBI , patients taking entity1begin TOBI entity1end concomitantly with dornase alfa ( PULMOZYME , Genentech ) , ( beta ) - agonists , inhaled corticosteroids , other entity2begin anti - pseudomonal antibiotics entity2end , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
true chemical chemical In clinical studies of TOBI , patients taking entity1begin TOBI entity1end concomitantly with dornase alfa ( PULMOZYME , Genentech ) , ( beta ) - agonists , inhaled corticosteroids , other anti - pseudomonal antibiotics , or parenteral entity2begin aminoglycosides entity2end demonstrated adverse experience profiles similar to the study population as a whole . 
false chemical chemical In clinical studies of TOBI , patients taking TOBI concomitantly with entity1begin dornase alfa entity1end ( entity2begin PULMOZYME entity2end , Genentech ) , ( beta ) - agonists , inhaled corticosteroids , other anti - pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
false chemical chemical In clinical studies of TOBI , patients taking TOBI concomitantly with entity1begin dornase alfa entity1end ( PULMOZYME , Genentech ) , entity2begin ( beta ) - agonists entity2end , inhaled corticosteroids , other anti - pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
false chemical chemical In clinical studies of TOBI , patients taking TOBI concomitantly with entity1begin dornase alfa entity1end ( PULMOZYME , Genentech ) , ( beta ) - agonists , inhaled entity2begin corticosteroids entity2end , other anti - pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
false chemical chemical In clinical studies of TOBI , patients taking TOBI concomitantly with entity1begin dornase alfa entity1end ( PULMOZYME , Genentech ) , ( beta ) - agonists , inhaled corticosteroids , other entity2begin anti - pseudomonal antibiotics entity2end , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
false chemical chemical In clinical studies of TOBI , patients taking TOBI concomitantly with entity1begin dornase alfa entity1end ( PULMOZYME , Genentech ) , ( beta ) - agonists , inhaled corticosteroids , other anti - pseudomonal antibiotics , or parenteral entity2begin aminoglycosides entity2end demonstrated adverse experience profiles similar to the study population as a whole . 
false chemical chemical In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa ( entity1begin PULMOZYME entity1end , Genentech ) , entity2begin ( beta ) - agonists entity2end , inhaled corticosteroids , other anti - pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
false chemical chemical In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa ( entity1begin PULMOZYME entity1end , Genentech ) , ( beta ) - agonists , inhaled entity2begin corticosteroids entity2end , other anti - pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
false chemical chemical In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa ( entity1begin PULMOZYME entity1end , Genentech ) , ( beta ) - agonists , inhaled corticosteroids , other entity2begin anti - pseudomonal antibiotics entity2end , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
false chemical chemical In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa ( entity1begin PULMOZYME entity1end , Genentech ) , ( beta ) - agonists , inhaled corticosteroids , other anti - pseudomonal antibiotics , or parenteral entity2begin aminoglycosides entity2end demonstrated adverse experience profiles similar to the study population as a whole . 
false chemical chemical In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa ( PULMOZYME , Genentech ) , entity1begin ( beta ) - agonists entity1end , inhaled entity2begin corticosteroids entity2end , other anti - pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
false chemical chemical In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa ( PULMOZYME , Genentech ) , entity1begin ( beta ) - agonists entity1end , inhaled corticosteroids , other entity2begin anti - pseudomonal antibiotics entity2end , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
false chemical chemical In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa ( PULMOZYME , Genentech ) , entity1begin ( beta ) - agonists entity1end , inhaled corticosteroids , other anti - pseudomonal antibiotics , or parenteral entity2begin aminoglycosides entity2end demonstrated adverse experience profiles similar to the study population as a whole . 
false chemical chemical In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa ( PULMOZYME , Genentech ) , ( beta ) - agonists , inhaled entity1begin corticosteroids entity1end , other entity2begin anti - pseudomonal antibiotics entity2end , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . 
false chemical chemical In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa ( PULMOZYME , Genentech ) , ( beta ) - agonists , inhaled entity1begin corticosteroids entity1end , other anti - pseudomonal antibiotics , or parenteral entity2begin aminoglycosides entity2end demonstrated adverse experience profiles similar to the study population as a whole . 
false chemical chemical In clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa ( PULMOZYME , Genentech ) , ( beta ) - agonists , inhaled corticosteroids , other entity1begin anti - pseudomonal antibiotics entity1end , or parenteral entity2begin aminoglycosides entity2end demonstrated adverse experience profiles similar to the study population as a whole . 
true chemical chemical Some entity1begin diuretics entity1end can enhance entity2begin aminoglycoside entity2end toxicity by altering antibiotic concentrations in serum and tissue . 
false chemical chemical Some entity1begin diuretics entity1end can enhance aminoglycoside toxicity by altering entity2begin antibiotic entity2end concentrations in serum and tissue . 
false chemical chemical Some diuretics can enhance entity1begin aminoglycoside entity1end toxicity by altering entity2begin antibiotic entity2end concentrations in serum and tissue . 
true chemical chemical entity1begin TOBI entity1end should not be administered concomitantly with entity2begin ethacrynic acid entity2end , furosemide , urea , or mannitol . 
true chemical chemical entity1begin TOBI entity1end should not be administered concomitantly with ethacrynic acid , entity2begin furosemide entity2end , urea , or mannitol . 
true chemical chemical entity1begin TOBI entity1end should not be administered concomitantly with ethacrynic acid , furosemide , entity2begin urea entity2end , or mannitol . 
true chemical chemical entity1begin TOBI entity1end should not be administered concomitantly with ethacrynic acid , furosemide , urea , or entity2begin mannitol entity2end . 
false chemical chemical TOBI should not be administered concomitantly with entity1begin ethacrynic acid entity1end , entity2begin furosemide entity2end , urea , or mannitol . 
false chemical chemical TOBI should not be administered concomitantly with entity1begin ethacrynic acid entity1end , furosemide , entity2begin urea entity2end , or mannitol . 
false chemical chemical TOBI should not be administered concomitantly with entity1begin ethacrynic acid entity1end , furosemide , urea , or entity2begin mannitol entity2end . 
false chemical chemical TOBI should not be administered concomitantly with ethacrynic acid , entity1begin furosemide entity1end , entity2begin urea entity2end , or mannitol . 
false chemical chemical TOBI should not be administered concomitantly with ethacrynic acid , entity1begin furosemide entity1end , urea , or entity2begin mannitol entity2end . 
false chemical chemical TOBI should not be administered concomitantly with ethacrynic acid , furosemide , entity1begin urea entity1end , or entity2begin mannitol entity2end . 
false chemical chemical The in vitro binding of entity1begin warfarin entity1end to human plasma proteins is unaffected by entity2begin tolmetin entity2end , and tolmetin does not alter the prothrombin time of normal volunteers . 
false chemical chemical The in vitro binding of entity1begin warfarin entity1end to human plasma proteins is unaffected by tolmetin , and entity2begin tolmetin entity2end does not alter the prothrombin time of normal volunteers . 
false chemical chemical The in vitro binding of warfarin to human plasma proteins is unaffected by entity1begin tolmetin entity1end , and entity2begin tolmetin entity2end does not alter the prothrombin time of normal volunteers . 
true chemical chemical However , increased prothrombin time and bleeding have been reported in patients on concomitant entity1begin TOLECTIN entity1end and entity2begin warfarin entity2end therapy . 
true chemical chemical Therefore , caution should be exercised when administering entity1begin TOLECTIN entity1end to patients on entity2begin anticoagulants entity2end . 
false chemical chemical In adult diabetic patients under treatment with either entity1begin sulfonylureas entity1end or entity2begin insulin entity2end there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents . 
false chemical chemical In adult diabetic patients under treatment with either entity1begin sulfonylureas entity1end or insulin there is no change in the clinical effects of either entity2begin TOLECTIN entity2end or the hypoglycemic agents . 
false chemical chemical In adult diabetic patients under treatment with either entity1begin sulfonylureas entity1end or insulin there is no change in the clinical effects of either TOLECTIN or the entity2begin hypoglycemic agents entity2end . 
false chemical chemical In adult diabetic patients under treatment with either sulfonylureas or entity1begin insulin entity1end there is no change in the clinical effects of either entity2begin TOLECTIN entity2end or the hypoglycemic agents . 
false chemical chemical In adult diabetic patients under treatment with either sulfonylureas or entity1begin insulin entity1end there is no change in the clinical effects of either TOLECTIN or the entity2begin hypoglycemic agents entity2end . 
false chemical chemical In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either entity1begin TOLECTIN entity1end or the entity2begin hypoglycemic agents entity2end . 
true chemical chemical Caution should be used if entity1begin TOLECTIN entity1end is administered concomitantly with entity2begin methotrexate entity2end . 
false chemical chemical entity1begin TOLECTIN entity1end and other entity2begin nonsteroidal anti - inflammatory drugs entity2end have been reported to reduce the tubular secretion of methotrexate in an animal model , possibly enhancing the toxicity of methotrexate . 
true chemical chemical entity1begin TOLECTIN entity1end and other nonsteroidal anti - inflammatory drugs have been reported to reduce the tubular secretion of entity2begin methotrexate entity2end in an animal model , possibly enhancing the toxicity of methotrexate . 
false chemical chemical entity1begin TOLECTIN entity1end and other nonsteroidal anti - inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model , possibly enhancing the toxicity of entity2begin methotrexate entity2end . 
true chemical chemical TOLECTIN and other entity1begin nonsteroidal anti - inflammatory drugs entity1end have been reported to reduce the tubular secretion of entity2begin methotrexate entity2end in an animal model , possibly enhancing the toxicity of methotrexate . 
false chemical chemical TOLECTIN and other entity1begin nonsteroidal anti - inflammatory drugs entity1end have been reported to reduce the tubular secretion of methotrexate in an animal model , possibly enhancing the toxicity of entity2begin methotrexate entity2end . 
false chemical chemical TOLECTIN and other nonsteroidal anti - inflammatory drugs have been reported to reduce the tubular secretion of entity1begin methotrexate entity1end in an animal model , possibly enhancing the toxicity of entity2begin methotrexate entity2end . 
true chemical chemical CYP3A4 Inhibitors : entity1begin Ketoconazole entity1end , an inhibitor of the drug metabolizing enzyme CYP3A4 , significantly increased plasma concentrations of entity2begin tolterodine entity2end when coadministered to subjects who were poor metabolizers ( see CLINICAL PHARMACOLOGY , Variability in Metabolism and Drug - Drug Interactions ) . 
false chemical chemical For patients receiving entity1begin ketoconazole entity1end or other potent CYP3A4 inhibitors such as other entity2begin azole antifungals entity2end ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
false chemical chemical For patients receiving entity1begin ketoconazole entity1end or other potent CYP3A4 inhibitors such as other azole antifungals ( eg , entity2begin itraconazole entity2end , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
false chemical chemical For patients receiving entity1begin ketoconazole entity1end or other potent CYP3A4 inhibitors such as other azole antifungals ( eg , itraconazole , entity2begin miconazole entity2end ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
false chemical chemical For patients receiving entity1begin ketoconazole entity1end or other potent CYP3A4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or entity2begin macrolide antibiotics entity2end ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
false chemical chemical For patients receiving entity1begin ketoconazole entity1end or other potent CYP3A4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , entity2begin erythromycin entity2end , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
false chemical chemical For patients receiving entity1begin ketoconazole entity1end or other potent CYP3A4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , entity2begin clarithromycin entity2end ) or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
false chemical chemical For patients receiving entity1begin ketoconazole entity1end or other potent CYP3A4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or entity2begin cyclosporine entity2end or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
false chemical chemical For patients receiving entity1begin ketoconazole entity1end or other potent CYP3A4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or entity2begin vinblastine entity2end , the recommended dose of DETROL LA is 2 mg daily . 
true chemical chemical For patients receiving entity1begin ketoconazole entity1end or other potent CYP3A4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of entity2begin DETROL LA entity2end is 2 mg daily . 
false chemical chemical For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other entity1begin azole antifungals entity1end ( eg , entity2begin itraconazole entity2end , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
false chemical chemical For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other entity1begin azole antifungals entity1end ( eg , itraconazole , entity2begin miconazole entity2end ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
false chemical chemical For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other entity1begin azole antifungals entity1end ( eg , itraconazole , miconazole ) or entity2begin macrolide antibiotics entity2end ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
false chemical chemical For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other entity1begin azole antifungals entity1end ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , entity2begin erythromycin entity2end , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
false chemical chemical For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other entity1begin azole antifungals entity1end ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , entity2begin clarithromycin entity2end ) or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
false chemical chemical For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other entity1begin azole antifungals entity1end ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or entity2begin cyclosporine entity2end or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
false chemical chemical For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other entity1begin azole antifungals entity1end ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or entity2begin vinblastine entity2end , the recommended dose of DETROL LA is 2 mg daily . 
true chemical chemical For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other entity1begin azole antifungals entity1end ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of entity2begin DETROL LA entity2end is 2 mg daily . 
false chemical chemical For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals ( eg , entity1begin itraconazole entity1end , entity2begin miconazole entity2end ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
false chemical chemical For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals ( eg , entity1begin itraconazole entity1end , miconazole ) or entity2begin macrolide antibiotics entity2end ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
false chemical chemical For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals ( eg , entity1begin itraconazole entity1end , miconazole ) or macrolide antibiotics ( eg , entity2begin erythromycin entity2end , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
false chemical chemical For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals ( eg , entity1begin itraconazole entity1end , miconazole ) or macrolide antibiotics ( eg , erythromycin , entity2begin clarithromycin entity2end ) or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
false chemical chemical For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals ( eg , entity1begin itraconazole entity1end , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or entity2begin cyclosporine entity2end or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
false chemical chemical For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals ( eg , entity1begin itraconazole entity1end , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or entity2begin vinblastine entity2end , the recommended dose of DETROL LA is 2 mg daily . 
true chemical chemical For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals ( eg , entity1begin itraconazole entity1end , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of entity2begin DETROL LA entity2end is 2 mg daily . 
false chemical chemical For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals ( eg , itraconazole , entity1begin miconazole entity1end ) or entity2begin macrolide antibiotics entity2end ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
false chemical chemical For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals ( eg , itraconazole , entity1begin miconazole entity1end ) or macrolide antibiotics ( eg , entity2begin erythromycin entity2end , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
false chemical chemical For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals ( eg , itraconazole , entity1begin miconazole entity1end ) or macrolide antibiotics ( eg , erythromycin , entity2begin clarithromycin entity2end ) or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
false chemical chemical For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals ( eg , itraconazole , entity1begin miconazole entity1end ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or entity2begin cyclosporine entity2end or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
false chemical chemical For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals ( eg , itraconazole , entity1begin miconazole entity1end ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or entity2begin vinblastine entity2end , the recommended dose of DETROL LA is 2 mg daily . 
true chemical chemical For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals ( eg , itraconazole , entity1begin miconazole entity1end ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of entity2begin DETROL LA entity2end is 2 mg daily . 
false chemical chemical For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or entity1begin macrolide antibiotics entity1end ( eg , entity2begin erythromycin entity2end , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
false chemical chemical For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or entity1begin macrolide antibiotics entity1end ( eg , erythromycin , entity2begin clarithromycin entity2end ) or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
false chemical chemical For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or entity1begin macrolide antibiotics entity1end ( eg , erythromycin , clarithromycin ) or entity2begin cyclosporine entity2end or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
false chemical chemical For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or entity1begin macrolide antibiotics entity1end ( eg , erythromycin , clarithromycin ) or cyclosporine or entity2begin vinblastine entity2end , the recommended dose of DETROL LA is 2 mg daily . 
true chemical chemical For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or entity1begin macrolide antibiotics entity1end ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of entity2begin DETROL LA entity2end is 2 mg daily . 
false chemical chemical For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , entity1begin erythromycin entity1end , entity2begin clarithromycin entity2end ) or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
false chemical chemical For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , entity1begin erythromycin entity1end , clarithromycin ) or entity2begin cyclosporine entity2end or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
false chemical chemical For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , entity1begin erythromycin entity1end , clarithromycin ) or cyclosporine or entity2begin vinblastine entity2end , the recommended dose of DETROL LA is 2 mg daily . 
true chemical chemical For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , entity1begin erythromycin entity1end , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of entity2begin DETROL LA entity2end is 2 mg daily . 
false chemical chemical For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , entity1begin clarithromycin entity1end ) or entity2begin cyclosporine entity2end or vinblastine , the recommended dose of DETROL LA is 2 mg daily . 
false chemical chemical For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , entity1begin clarithromycin entity1end ) or cyclosporine or entity2begin vinblastine entity2end , the recommended dose of DETROL LA is 2 mg daily . 
true chemical chemical For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , entity1begin clarithromycin entity1end ) or cyclosporine or vinblastine , the recommended dose of entity2begin DETROL LA entity2end is 2 mg daily . 
false chemical chemical For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or entity1begin cyclosporine entity1end or entity2begin vinblastine entity2end , the recommended dose of DETROL LA is 2 mg daily . 
true chemical chemical For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or entity1begin cyclosporine entity1end or vinblastine , the recommended dose of entity2begin DETROL LA entity2end is 2 mg daily . 
true chemical chemical For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or entity1begin vinblastine entity1end , the recommended dose of entity2begin DETROL LA entity2end is 2 mg daily . 
true chemical chemical Administration of entity1begin paclitaxel entity1end in combination with entity2begin HERCEPTIN entity2end resulted in a two - fold decrease in HERCEPTIN clearance in a non - human primate study and in a 1.5 - fold increase in HERCEPTIN serum levels in clinical studies . 
false chemical chemical Administration of entity1begin paclitaxel entity1end in combination with HERCEPTIN resulted in a two - fold decrease in entity2begin HERCEPTIN entity2end clearance in a non - human primate study and in a 1.5 - fold increase in HERCEPTIN serum levels in clinical studies . 
false chemical chemical Administration of entity1begin paclitaxel entity1end in combination with HERCEPTIN resulted in a two - fold decrease in HERCEPTIN clearance in a non - human primate study and in a 1.5 - fold increase in entity2begin HERCEPTIN entity2end serum levels in clinical studies . 
false chemical chemical Administration of paclitaxel in combination with entity1begin HERCEPTIN entity1end resulted in a two - fold decrease in entity2begin HERCEPTIN entity2end clearance in a non - human primate study and in a 1.5 - fold increase in HERCEPTIN serum levels in clinical studies . 
false chemical chemical Administration of paclitaxel in combination with entity1begin HERCEPTIN entity1end resulted in a two - fold decrease in HERCEPTIN clearance in a non - human primate study and in a 1.5 - fold increase in entity2begin HERCEPTIN entity2end serum levels in clinical studies . 
false chemical chemical Administration of paclitaxel in combination with HERCEPTIN resulted in a two - fold decrease in entity1begin HERCEPTIN entity1end clearance in a non - human primate study and in a 1.5 - fold increase in entity2begin HERCEPTIN entity2end serum levels in clinical studies . 
true chemical chemical entity1begin Trilostane entity1end may interact with entity2begin aminoglutethimide entity2end or mitotane ( causing too great a decrease in adrenal function ) . 
true chemical chemical entity1begin Trilostane entity1end may interact with aminoglutethimide or entity2begin mitotane entity2end ( causing too great a decrease in adrenal function ) . 
false chemical chemical Trilostane may interact with entity1begin aminoglutethimide entity1end or entity2begin mitotane entity2end ( causing too great a decrease in adrenal function ) . 
true chemical chemical entity1begin Trimethoprim entity1end may inhibit the hepatic metabolism of entity2begin phenytoin entity2end . 
true chemical chemical entity1begin Trimethoprim entity1end , given at a common clinical dosage , increased the entity2begin phenytoin entity2end half - life by 51 % and decreased the phenytoin metabolic clearance rate by 30 % . 
true chemical chemical entity1begin Trimethoprim entity1end , given at a common clinical dosage , increased the phenytoin half - life by 51 % and decreased the entity2begin phenytoin entity2end metabolic clearance rate by 30 % . 
false chemical chemical Trimethoprim , given at a common clinical dosage , increased the entity1begin phenytoin entity1end half - life by 51 % and decreased the entity2begin phenytoin entity2end metabolic clearance rate by 30 % . 
false chemical chemical Since entity1begin trimetrexate entity1end is metabolized by a P450 enzyme system , drugs that induce or inhibit this drug metabolizing enzyme system may elicit important drug - drug interactions that may alter entity2begin trimetrexate entity2end plasma concentrations . 
true chemical chemical Agents that might be coadministered with entity1begin trimetrexate entity1end in AIDS patients for other indications that could elicit this activity include entity2begin erythromycin entity2end , rifampin , rifabutin , ketoconazole , and fluconazole . 
true chemical chemical Agents that might be coadministered with entity1begin trimetrexate entity1end in AIDS patients for other indications that could elicit this activity include erythromycin , entity2begin rifampin entity2end , rifabutin , ketoconazole , and fluconazole . 
true chemical chemical Agents that might be coadministered with entity1begin trimetrexate entity1end in AIDS patients for other indications that could elicit this activity include erythromycin , rifampin , entity2begin rifabutin entity2end , ketoconazole , and fluconazole . 
true chemical chemical Agents that might be coadministered with entity1begin trimetrexate entity1end in AIDS patients for other indications that could elicit this activity include erythromycin , rifampin , rifabutin , entity2begin ketoconazole entity2end , and fluconazole . 
true chemical chemical Agents that might be coadministered with entity1begin trimetrexate entity1end in AIDS patients for other indications that could elicit this activity include erythromycin , rifampin , rifabutin , ketoconazole , and entity2begin fluconazole entity2end . 
false chemical chemical Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include entity1begin erythromycin entity1end , entity2begin rifampin entity2end , rifabutin , ketoconazole , and fluconazole . 
false chemical chemical Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include entity1begin erythromycin entity1end , rifampin , entity2begin rifabutin entity2end , ketoconazole , and fluconazole . 
false chemical chemical Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include entity1begin erythromycin entity1end , rifampin , rifabutin , entity2begin ketoconazole entity2end , and fluconazole . 
false chemical chemical Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include entity1begin erythromycin entity1end , rifampin , rifabutin , ketoconazole , and entity2begin fluconazole entity2end . 
false chemical chemical Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin , entity1begin rifampin entity1end , entity2begin rifabutin entity2end , ketoconazole , and fluconazole . 
false chemical chemical Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin , entity1begin rifampin entity1end , rifabutin , entity2begin ketoconazole entity2end , and fluconazole . 
false chemical chemical Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin , entity1begin rifampin entity1end , rifabutin , ketoconazole , and entity2begin fluconazole entity2end . 
false chemical chemical Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin , rifampin , entity1begin rifabutin entity1end , entity2begin ketoconazole entity2end , and fluconazole . 
false chemical chemical Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin , rifampin , entity1begin rifabutin entity1end , ketoconazole , and entity2begin fluconazole entity2end . 
false chemical chemical Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin , rifampin , rifabutin , entity1begin ketoconazole entity1end , and entity2begin fluconazole entity2end . 
true chemical chemical In vitro perfusion of isolated rat liver has shown that entity1begin cimetidine entity1end caused a significant reduction in entity2begin trimetrexate entity2end metabolism and that acetaminophen altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites . 
false chemical chemical In vitro perfusion of isolated rat liver has shown that entity1begin cimetidine entity1end caused a significant reduction in trimetrexate metabolism and that entity2begin acetaminophen entity2end altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites . 
false chemical chemical In vitro perfusion of isolated rat liver has shown that cimetidine caused a significant reduction in entity1begin trimetrexate entity1end metabolism and that entity2begin acetaminophen entity2end altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites . 
false chemical chemical Based on an in vitro rat liver model , nitrogen substituted entity1begin imidazole drugs entity1end ( entity2begin clotrimazole entity2end , ketoconazole , miconazole ) were potent , non - competitive inhibitors of trimetrexate metabolism . 
false chemical chemical Based on an in vitro rat liver model , nitrogen substituted entity1begin imidazole drugs entity1end ( clotrimazole , entity2begin ketoconazole entity2end , miconazole ) were potent , non - competitive inhibitors of trimetrexate metabolism . 
false chemical chemical Based on an in vitro rat liver model , nitrogen substituted entity1begin imidazole drugs entity1end ( clotrimazole , ketoconazole , entity2begin miconazole entity2end ) were potent , non - competitive inhibitors of trimetrexate metabolism . 
true chemical chemical Based on an in vitro rat liver model , nitrogen substituted entity1begin imidazole drugs entity1end ( clotrimazole , ketoconazole , miconazole ) were potent , non - competitive inhibitors of entity2begin trimetrexate entity2end metabolism . 
false chemical chemical Based on an in vitro rat liver model , nitrogen substituted imidazole drugs ( entity1begin clotrimazole entity1end , entity2begin ketoconazole entity2end , miconazole ) were potent , non - competitive inhibitors of trimetrexate metabolism . 
false chemical chemical Based on an in vitro rat liver model , nitrogen substituted imidazole drugs ( entity1begin clotrimazole entity1end , ketoconazole , entity2begin miconazole entity2end ) were potent , non - competitive inhibitors of trimetrexate metabolism . 
true chemical chemical Based on an in vitro rat liver model , nitrogen substituted imidazole drugs ( entity1begin clotrimazole entity1end , ketoconazole , miconazole ) were potent , non - competitive inhibitors of entity2begin trimetrexate entity2end metabolism . 
false chemical chemical Based on an in vitro rat liver model , nitrogen substituted imidazole drugs ( clotrimazole , entity1begin ketoconazole entity1end , entity2begin miconazole entity2end ) were potent , non - competitive inhibitors of trimetrexate metabolism . 
true chemical chemical Based on an in vitro rat liver model , nitrogen substituted imidazole drugs ( clotrimazole , entity1begin ketoconazole entity1end , miconazole ) were potent , non - competitive inhibitors of entity2begin trimetrexate entity2end metabolism . 
true chemical chemical Based on an in vitro rat liver model , nitrogen substituted imidazole drugs ( clotrimazole , ketoconazole , entity1begin miconazole entity1end ) were potent , non - competitive inhibitors of entity2begin trimetrexate entity2end metabolism . 
true chemical chemical entity1begin Triprolidine entity1end may enhance the sedative effects of entity2begin central nervous system depressants entity2end including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers . 
true chemical chemical entity1begin Triprolidine entity1end may enhance the sedative effects of central nervous system depressants including entity2begin alcohol entity2end , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers . 
true chemical chemical entity1begin Triprolidine entity1end may enhance the sedative effects of central nervous system depressants including alcohol , entity2begin barbiturates entity2end , hypnotics , narcotic analgesics , sedatives , and tranquillisers . 
true chemical chemical entity1begin Triprolidine entity1end may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , entity2begin hypnotics entity2end , narcotic analgesics , sedatives , and tranquillisers . 
true chemical chemical entity1begin Triprolidine entity1end may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , entity2begin narcotic analgesics entity2end , sedatives , and tranquillisers . 
true chemical chemical entity1begin Triprolidine entity1end may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , entity2begin sedatives entity2end , and tranquillisers . 
true chemical chemical entity1begin Triprolidine entity1end may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and entity2begin tranquillisers entity2end . 
false chemical chemical Triprolidine may enhance the sedative effects of entity1begin central nervous system depressants entity1end including entity2begin alcohol entity2end , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers . 
false chemical chemical Triprolidine may enhance the sedative effects of entity1begin central nervous system depressants entity1end including alcohol , entity2begin barbiturates entity2end , hypnotics , narcotic analgesics , sedatives , and tranquillisers . 
false chemical chemical Triprolidine may enhance the sedative effects of entity1begin central nervous system depressants entity1end including alcohol , barbiturates , entity2begin hypnotics entity2end , narcotic analgesics , sedatives , and tranquillisers . 
false chemical chemical Triprolidine may enhance the sedative effects of entity1begin central nervous system depressants entity1end including alcohol , barbiturates , hypnotics , entity2begin narcotic analgesics entity2end , sedatives , and tranquillisers . 
false chemical chemical Triprolidine may enhance the sedative effects of entity1begin central nervous system depressants entity1end including alcohol , barbiturates , hypnotics , narcotic analgesics , entity2begin sedatives entity2end , and tranquillisers . 
false chemical chemical Triprolidine may enhance the sedative effects of entity1begin central nervous system depressants entity1end including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and entity2begin tranquillisers entity2end . 
false chemical chemical Triprolidine may enhance the sedative effects of central nervous system depressants including entity1begin alcohol entity1end , entity2begin barbiturates entity2end , hypnotics , narcotic analgesics , sedatives , and tranquillisers . 
false chemical chemical Triprolidine may enhance the sedative effects of central nervous system depressants including entity1begin alcohol entity1end , barbiturates , entity2begin hypnotics entity2end , narcotic analgesics , sedatives , and tranquillisers . 
false chemical chemical Triprolidine may enhance the sedative effects of central nervous system depressants including entity1begin alcohol entity1end , barbiturates , hypnotics , entity2begin narcotic analgesics entity2end , sedatives , and tranquillisers . 
false chemical chemical Triprolidine may enhance the sedative effects of central nervous system depressants including entity1begin alcohol entity1end , barbiturates , hypnotics , narcotic analgesics , entity2begin sedatives entity2end , and tranquillisers . 
false chemical chemical Triprolidine may enhance the sedative effects of central nervous system depressants including entity1begin alcohol entity1end , barbiturates , hypnotics , narcotic analgesics , sedatives , and entity2begin tranquillisers entity2end . 
false chemical chemical Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , entity1begin barbiturates entity1end , entity2begin hypnotics entity2end , narcotic analgesics , sedatives , and tranquillisers . 
false chemical chemical Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , entity1begin barbiturates entity1end , hypnotics , entity2begin narcotic analgesics entity2end , sedatives , and tranquillisers . 
false chemical chemical Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , entity1begin barbiturates entity1end , hypnotics , narcotic analgesics , entity2begin sedatives entity2end , and tranquillisers . 
false chemical chemical Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , entity1begin barbiturates entity1end , hypnotics , narcotic analgesics , sedatives , and entity2begin tranquillisers entity2end . 
false chemical chemical Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , entity1begin hypnotics entity1end , entity2begin narcotic analgesics entity2end , sedatives , and tranquillisers . 
false chemical chemical Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , entity1begin hypnotics entity1end , narcotic analgesics , entity2begin sedatives entity2end , and tranquillisers . 
false chemical chemical Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , entity1begin hypnotics entity1end , narcotic analgesics , sedatives , and entity2begin tranquillisers entity2end . 
false chemical chemical Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , entity1begin narcotic analgesics entity1end , entity2begin sedatives entity2end , and tranquillisers . 
false chemical chemical Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , entity1begin narcotic analgesics entity1end , sedatives , and entity2begin tranquillisers entity2end . 
false chemical chemical Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , entity1begin sedatives entity1end , and entity2begin tranquillisers entity2end . 
false chemical chemical The effects of entity1begin anticholinergic drugs entity1end , such as entity2begin atropine entity2end and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine . 
false chemical chemical The effects of entity1begin anticholinergic drugs entity1end , such as atropine and entity2begin tricyclic antidepressants entity2end may be enhanced by the concomitant administration of triprolidine . 
true chemical chemical The effects of entity1begin anticholinergic drugs entity1end , such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of entity2begin triprolidine entity2end . 
false chemical chemical The effects of anticholinergic drugs , such as entity1begin atropine entity1end and entity2begin tricyclic antidepressants entity2end may be enhanced by the concomitant administration of triprolidine . 
true chemical chemical The effects of anticholinergic drugs , such as entity1begin atropine entity1end and tricyclic antidepressants may be enhanced by the concomitant administration of entity2begin triprolidine entity2end . 
true chemical chemical The effects of anticholinergic drugs , such as atropine and entity1begin tricyclic antidepressants entity1end may be enhanced by the concomitant administration of entity2begin triprolidine entity2end . 
true chemical chemical The concomitant use of entity1begin Sanctura entity1end with other entity2begin anticholinergic agents entity2end that produce dry mouth , constipation , and other anticholinergic pharmacological effects may increase the frequency and / or severity of such effects . 
false chemical chemical Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug - drug interactions with entity1begin Sanctura entity1end have not been conducted , entity2begin Sanctura entity2end has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ) . 
false chemical chemical Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug - drug interactions with entity1begin Sanctura entity1end have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. entity2begin digoxin entity2end , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ) . 
false chemical chemical Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug - drug interactions with entity1begin Sanctura entity1end have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , entity2begin procainamide entity2end , pancuronium , morphine , vancomycin , metformin and tenofovir ) . 
false chemical chemical Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug - drug interactions with entity1begin Sanctura entity1end have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , entity2begin pancuronium entity2end , morphine , vancomycin , metformin and tenofovir ) . 
false chemical chemical Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug - drug interactions with entity1begin Sanctura entity1end have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , entity2begin morphine entity2end , vancomycin , metformin and tenofovir ) . 
false chemical chemical Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug - drug interactions with entity1begin Sanctura entity1end have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , entity2begin vancomycin entity2end , metformin and tenofovir ) . 
false chemical chemical Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug - drug interactions with entity1begin Sanctura entity1end have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , entity2begin metformin entity2end and tenofovir ) . 
false chemical chemical Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug - drug interactions with entity1begin Sanctura entity1end have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and entity2begin tenofovir entity2end ) . 
true chemical chemical Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug - drug interactions with Sanctura have not been conducted , entity1begin Sanctura entity1end has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. entity2begin digoxin entity2end , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ) . 
true chemical chemical Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug - drug interactions with Sanctura have not been conducted , entity1begin Sanctura entity1end has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , entity2begin procainamide entity2end , pancuronium , morphine , vancomycin , metformin and tenofovir ) . 
true chemical chemical Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug - drug interactions with Sanctura have not been conducted , entity1begin Sanctura entity1end has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , entity2begin pancuronium entity2end , morphine , vancomycin , metformin and tenofovir ) . 
true chemical chemical Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug - drug interactions with Sanctura have not been conducted , entity1begin Sanctura entity1end has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , entity2begin morphine entity2end , vancomycin , metformin and tenofovir ) . 
true chemical chemical Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug - drug interactions with Sanctura have not been conducted , entity1begin Sanctura entity1end has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , entity2begin vancomycin entity2end , metformin and tenofovir ) . 
true chemical chemical Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug - drug interactions with Sanctura have not been conducted , entity1begin Sanctura entity1end has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , entity2begin metformin entity2end and tenofovir ) . 
true chemical chemical Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug - drug interactions with Sanctura have not been conducted , entity1begin Sanctura entity1end has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and entity2begin tenofovir entity2end ) . 
false chemical chemical Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug - drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. entity1begin digoxin entity1end , entity2begin procainamide entity2end , pancuronium , morphine , vancomycin , metformin and tenofovir ) . 
false chemical chemical Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug - drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. entity1begin digoxin entity1end , procainamide , entity2begin pancuronium entity2end , morphine , vancomycin , metformin and tenofovir ) . 
false chemical chemical Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug - drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. entity1begin digoxin entity1end , procainamide , pancuronium , entity2begin morphine entity2end , vancomycin , metformin and tenofovir ) . 
false chemical chemical Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug - drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. entity1begin digoxin entity1end , procainamide , pancuronium , morphine , entity2begin vancomycin entity2end , metformin and tenofovir ) . 
false chemical chemical Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug - drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. entity1begin digoxin entity1end , procainamide , pancuronium , morphine , vancomycin , entity2begin metformin entity2end and tenofovir ) . 
false chemical chemical Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug - drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. entity1begin digoxin entity1end , procainamide , pancuronium , morphine , vancomycin , metformin and entity2begin tenofovir entity2end ) . 
false chemical chemical Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug - drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , entity1begin procainamide entity1end , entity2begin pancuronium entity2end , morphine , vancomycin , metformin and tenofovir ) . 
false chemical chemical Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug - drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , entity1begin procainamide entity1end , pancuronium , entity2begin morphine entity2end , vancomycin , metformin and tenofovir ) . 
false chemical chemical Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug - drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , entity1begin procainamide entity1end , pancuronium , morphine , entity2begin vancomycin entity2end , metformin and tenofovir ) . 
false chemical chemical Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug - drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , entity1begin procainamide entity1end , pancuronium , morphine , vancomycin , entity2begin metformin entity2end and tenofovir ) . 
false chemical chemical Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug - drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , entity1begin procainamide entity1end , pancuronium , morphine , vancomycin , metformin and entity2begin tenofovir entity2end ) . 
false chemical chemical Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug - drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , entity1begin pancuronium entity1end , entity2begin morphine entity2end , vancomycin , metformin and tenofovir ) . 
false chemical chemical Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug - drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , entity1begin pancuronium entity1end , morphine , entity2begin vancomycin entity2end , metformin and tenofovir ) . 
false chemical chemical Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug - drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , entity1begin pancuronium entity1end , morphine , vancomycin , entity2begin metformin entity2end and tenofovir ) . 
false chemical chemical Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug - drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , entity1begin pancuronium entity1end , morphine , vancomycin , metformin and entity2begin tenofovir entity2end ) . 
false chemical chemical Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug - drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , entity1begin morphine entity1end , entity2begin vancomycin entity2end , metformin and tenofovir ) . 
false chemical chemical Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug - drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , entity1begin morphine entity1end , vancomycin , entity2begin metformin entity2end and tenofovir ) . 
false chemical chemical Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug - drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , entity1begin morphine entity1end , vancomycin , metformin and entity2begin tenofovir entity2end ) . 
false chemical chemical Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug - drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , entity1begin vancomycin entity1end , entity2begin metformin entity2end and tenofovir ) . 
false chemical chemical Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug - drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , entity1begin vancomycin entity1end , metformin and entity2begin tenofovir entity2end ) . 
false chemical chemical Drugs Eliminated by Active Tubular Secretion : Although studies to assess drug - drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , entity1begin metformin entity1end and entity2begin tenofovir entity2end ) . 
false chemical chemical Coadministration of entity1begin Sanctura entity1end with drugs that are eliminated by active renal tubular secretion may increase the serum concentration of entity2begin Sanctura entity2end and / or the coadministered drug due to competition for this elimination pathway . 
true chemical chemical Concomitant administration of entity1begin vancomycin entity1end and entity2begin anesthetic agents entity2end has been associated with erythema and histamine - like flushing and anaphylactoid reactions . 
false chemical chemical Concurrent and / or sequential systemic or topical use of other potentially neurotoxic and / or nephrotoxic drugs , such as entity1begin amphotericin B entity1end , entity2begin aminoglycosides entity2end , bacitracin , polymyxin B , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring . 
false chemical chemical Concurrent and / or sequential systemic or topical use of other potentially neurotoxic and / or nephrotoxic drugs , such as entity1begin amphotericin B entity1end , aminoglycosides , entity2begin bacitracin entity2end , polymyxin B , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring . 
false chemical chemical Concurrent and / or sequential systemic or topical use of other potentially neurotoxic and / or nephrotoxic drugs , such as entity1begin amphotericin B entity1end , aminoglycosides , bacitracin , entity2begin polymyxin B entity2end , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring . 
false chemical chemical Concurrent and / or sequential systemic or topical use of other potentially neurotoxic and / or nephrotoxic drugs , such as entity1begin amphotericin B entity1end , aminoglycosides , bacitracin , polymyxin B , entity2begin colistin entity2end , viomycin , or cisplatin , when indicated , requires careful monitoring . 
false chemical chemical Concurrent and / or sequential systemic or topical use of other potentially neurotoxic and / or nephrotoxic drugs , such as entity1begin amphotericin B entity1end , aminoglycosides , bacitracin , polymyxin B , colistin , entity2begin viomycin entity2end , or cisplatin , when indicated , requires careful monitoring . 
false chemical chemical Concurrent and / or sequential systemic or topical use of other potentially neurotoxic and / or nephrotoxic drugs , such as entity1begin amphotericin B entity1end , aminoglycosides , bacitracin , polymyxin B , colistin , viomycin , or entity2begin cisplatin entity2end , when indicated , requires careful monitoring . 
false chemical chemical Concurrent and / or sequential systemic or topical use of other potentially neurotoxic and / or nephrotoxic drugs , such as amphotericin B , entity1begin aminoglycosides entity1end , entity2begin bacitracin entity2end , polymyxin B , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring . 
false chemical chemical Concurrent and / or sequential systemic or topical use of other potentially neurotoxic and / or nephrotoxic drugs , such as amphotericin B , entity1begin aminoglycosides entity1end , bacitracin , entity2begin polymyxin B entity2end , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring . 
false chemical chemical Concurrent and / or sequential systemic or topical use of other potentially neurotoxic and / or nephrotoxic drugs , such as amphotericin B , entity1begin aminoglycosides entity1end , bacitracin , polymyxin B , entity2begin colistin entity2end , viomycin , or cisplatin , when indicated , requires careful monitoring . 
false chemical chemical Concurrent and / or sequential systemic or topical use of other potentially neurotoxic and / or nephrotoxic drugs , such as amphotericin B , entity1begin aminoglycosides entity1end , bacitracin , polymyxin B , colistin , entity2begin viomycin entity2end , or cisplatin , when indicated , requires careful monitoring . 
false chemical chemical Concurrent and / or sequential systemic or topical use of other potentially neurotoxic and / or nephrotoxic drugs , such as amphotericin B , entity1begin aminoglycosides entity1end , bacitracin , polymyxin B , colistin , viomycin , or entity2begin cisplatin entity2end , when indicated , requires careful monitoring . 
false chemical chemical Concurrent and / or sequential systemic or topical use of other potentially neurotoxic and / or nephrotoxic drugs , such as amphotericin B , aminoglycosides , entity1begin bacitracin entity1end , entity2begin polymyxin B entity2end , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring . 
false chemical chemical Concurrent and / or sequential systemic or topical use of other potentially neurotoxic and / or nephrotoxic drugs , such as amphotericin B , aminoglycosides , entity1begin bacitracin entity1end , polymyxin B , entity2begin colistin entity2end , viomycin , or cisplatin , when indicated , requires careful monitoring . 
false chemical chemical Concurrent and / or sequential systemic or topical use of other potentially neurotoxic and / or nephrotoxic drugs , such as amphotericin B , aminoglycosides , entity1begin bacitracin entity1end , polymyxin B , colistin , entity2begin viomycin entity2end , or cisplatin , when indicated , requires careful monitoring . 
false chemical chemical Concurrent and / or sequential systemic or topical use of other potentially neurotoxic and / or nephrotoxic drugs , such as amphotericin B , aminoglycosides , entity1begin bacitracin entity1end , polymyxin B , colistin , viomycin , or entity2begin cisplatin entity2end , when indicated , requires careful monitoring . 
false chemical chemical Concurrent and / or sequential systemic or topical use of other potentially neurotoxic and / or nephrotoxic drugs , such as amphotericin B , aminoglycosides , bacitracin , entity1begin polymyxin B entity1end , entity2begin colistin entity2end , viomycin , or cisplatin , when indicated , requires careful monitoring . 
false chemical chemical Concurrent and / or sequential systemic or topical use of other potentially neurotoxic and / or nephrotoxic drugs , such as amphotericin B , aminoglycosides , bacitracin , entity1begin polymyxin B entity1end , colistin , entity2begin viomycin entity2end , or cisplatin , when indicated , requires careful monitoring . 
false chemical chemical Concurrent and / or sequential systemic or topical use of other potentially neurotoxic and / or nephrotoxic drugs , such as amphotericin B , aminoglycosides , bacitracin , entity1begin polymyxin B entity1end , colistin , viomycin , or entity2begin cisplatin entity2end , when indicated , requires careful monitoring . 
false chemical chemical Concurrent and / or sequential systemic or topical use of other potentially neurotoxic and / or nephrotoxic drugs , such as amphotericin B , aminoglycosides , bacitracin , polymyxin B , entity1begin colistin entity1end , entity2begin viomycin entity2end , or cisplatin , when indicated , requires careful monitoring . 
false chemical chemical Concurrent and / or sequential systemic or topical use of other potentially neurotoxic and / or nephrotoxic drugs , such as amphotericin B , aminoglycosides , bacitracin , polymyxin B , entity1begin colistin entity1end , viomycin , or entity2begin cisplatin entity2end , when indicated , requires careful monitoring . 
false chemical chemical Concurrent and / or sequential systemic or topical use of other potentially neurotoxic and / or nephrotoxic drugs , such as amphotericin B , aminoglycosides , bacitracin , polymyxin B , colistin , entity1begin viomycin entity1end , or entity2begin cisplatin entity2end , when indicated , requires careful monitoring . 
true chemical chemical A study published in 2002 found that entity1begin vigabatrin entity1end causes a statistically significant increase in plasma clearance of entity2begin carbamazepine entity2end . 
true chemical chemical In 1984 , Drs Rimmer and Richens at the University of Wales reported that administering entity1begin vigabatrin entity1end with entity2begin phenytoin entity2end lowered the serum phenytoin concentration in patients with treatment - resistant epilepsy . 
false chemical chemical In 1984 , Drs Rimmer and Richens at the University of Wales reported that administering entity1begin vigabatrin entity1end with phenytoin lowered the serum entity2begin phenytoin entity2end concentration in patients with treatment - resistant epilepsy . 
false chemical chemical In 1984 , Drs Rimmer and Richens at the University of Wales reported that administering vigabatrin with entity1begin phenytoin entity1end lowered the serum entity2begin phenytoin entity2end concentration in patients with treatment - resistant epilepsy . 
true chemical chemical entity1begin Vindesine entity1end can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose - related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - entity2begin Phenytoin entity2end : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - Mitomycin - C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient 's response to the vaccine 
true chemical chemical entity1begin Vindesine entity1end can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose - related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - entity2begin Live virus vaccines entity2end : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - Mitomycin - C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient 's response to the vaccine 
false chemical chemical entity1begin Vindesine entity1end can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose - related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the entity2begin vaccine entity2end virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - Mitomycin - C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient 's response to the vaccine 
true chemical chemical entity1begin Vindesine entity1end can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose - related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - entity2begin Mitomycin - C entity2end : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient 's response to the vaccine 
true chemical chemical entity1begin Vindesine entity1end can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose - related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - Mitomycin - C : may cause shortness of breath and bronchospasm - entity2begin Killed virus vaccines entity2end : may decrease patient 's response to the vaccine 
false chemical chemical entity1begin Vindesine entity1end can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose - related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - Mitomycin - C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient 's response to the entity2begin vaccine entity2end 
false chemical chemical Vindesine can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose - related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - entity1begin Phenytoin entity1end : can increase seizure activity - entity2begin Live virus vaccines entity2end : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - Mitomycin - C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient 's response to the vaccine 
false chemical chemical Vindesine can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose - related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - entity1begin Phenytoin entity1end : can increase seizure activity - Live virus vaccines : may potentiate the replication of the entity2begin vaccine entity2end virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - Mitomycin - C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient 's response to the vaccine 
false chemical chemical Vindesine can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose - related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - entity1begin Phenytoin entity1end : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - entity2begin Mitomycin - C entity2end : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient 's response to the vaccine 
false chemical chemical Vindesine can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose - related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - entity1begin Phenytoin entity1end : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - Mitomycin - C : may cause shortness of breath and bronchospasm - entity2begin Killed virus vaccines entity2end : may decrease patient 's response to the vaccine 
false chemical chemical Vindesine can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose - related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - entity1begin Phenytoin entity1end : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - Mitomycin - C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient 's response to the entity2begin vaccine entity2end 
false chemical chemical Vindesine can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose - related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - entity1begin Live virus vaccines entity1end : may potentiate the replication of the entity2begin vaccine entity2end virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - Mitomycin - C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient 's response to the vaccine 
false chemical chemical Vindesine can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose - related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - entity1begin Live virus vaccines entity1end : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - entity2begin Mitomycin - C entity2end : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient 's response to the vaccine 
false chemical chemical Vindesine can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose - related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - entity1begin Live virus vaccines entity1end : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - Mitomycin - C : may cause shortness of breath and bronchospasm - entity2begin Killed virus vaccines entity2end : may decrease patient 's response to the vaccine 
false chemical chemical Vindesine can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose - related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - entity1begin Live virus vaccines entity1end : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - Mitomycin - C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient 's response to the entity2begin vaccine entity2end 
false chemical chemical Vindesine can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose - related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the entity1begin vaccine entity1end virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - entity2begin Mitomycin - C entity2end : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient 's response to the vaccine 
false chemical chemical Vindesine can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose - related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the entity1begin vaccine entity1end virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - Mitomycin - C : may cause shortness of breath and bronchospasm - entity2begin Killed virus vaccines entity2end : may decrease patient 's response to the vaccine 
false chemical chemical Vindesine can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose - related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the entity1begin vaccine entity1end virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - Mitomycin - C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient 's response to the entity2begin vaccine entity2end 
false chemical chemical Vindesine can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose - related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - entity1begin Mitomycin - C entity1end : may cause shortness of breath and bronchospasm - entity2begin Killed virus vaccines entity2end : may decrease patient 's response to the vaccine 
false chemical chemical Vindesine can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose - related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - entity1begin Mitomycin - C entity1end : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient 's response to the entity2begin vaccine entity2end 
false chemical chemical Vindesine can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose - related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - Mitomycin - C : may cause shortness of breath and bronchospasm - entity1begin Killed virus vaccines entity1end : may decrease patient 's response to the entity2begin vaccine entity2end 
true chemical chemical Drug Interactions : Women on oral entity1begin contraceptives entity1end have shown a significant increase in plasma entity2begin vitamin A entity2end levels . 
true chemical chemical Limited evidence suggests that entity1begin ascorbic acid entity1end may influence the intensity and duration of action of entity2begin bishydroxycoumarin entity2end . 
false chemical chemical entity1begin Coumarin - Derivative Anticoagulants entity1end : Prolongation of prothrombin time ( PT ) and International Normalized Ratio ( INR ) were observed in patients receiving entity2begin ZOLINZA entity2end concomitantly with coumarin - derivative anticoagulants . 
false chemical chemical entity1begin Coumarin - Derivative Anticoagulants entity1end : Prolongation of prothrombin time ( PT ) and International Normalized Ratio ( INR ) were observed in patients receiving ZOLINZA concomitantly with entity2begin coumarin - derivative anticoagulants entity2end . 
true chemical chemical Coumarin - Derivative Anticoagulants : Prolongation of prothrombin time ( PT ) and International Normalized Ratio ( INR ) were observed in patients receiving entity1begin ZOLINZA entity1end concomitantly with entity2begin coumarin - derivative anticoagulants entity2end . 
true chemical chemical Physicians should carefully monitor PT and INR in patients concurrently administered entity1begin ZOLINZA entity1end and entity2begin coumarin derivatives entity2end . 
false chemical chemical Other entity1begin HDAC Inhibitors entity1end Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of entity2begin ZOLINZA entity2end and other HDAC inhibitors ( e.g. , valproic acid ) . 
false chemical chemical Other entity1begin HDAC Inhibitors entity1end Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other entity2begin HDAC inhibitors entity2end ( e.g. , valproic acid ) . 
false chemical chemical Other entity1begin HDAC Inhibitors entity1end Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other HDAC inhibitors ( e.g. , entity2begin valproic acid entity2end ) . 
true chemical chemical Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of entity1begin ZOLINZA entity1end and other entity2begin HDAC inhibitors entity2end ( e.g. , valproic acid ) . 
true chemical chemical Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of entity1begin ZOLINZA entity1end and other HDAC inhibitors ( e.g. , entity2begin valproic acid entity2end ) . 
false chemical chemical Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other entity1begin HDAC inhibitors entity1end ( e.g. , entity2begin valproic acid entity2end ) . 
